'cyclopeptide'
(id=1831310 ; fe=cyclopeptide ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=1364 creation date=2015-07-30 touchdate=2025-10-08 15:17:06.000)

≈ 9793 relations sortantes cyclopeptide -- r_associated #0: 46 / 1 -> chimie n1=cyclopeptide | n2=chimie | rel=r_associated | relid=0 | w=46 cyclopeptide -- r_associated #0: 35 / 0.761 -> en:cyclic peptides n1=cyclopeptide | n2=en:cyclic peptides | rel=r_associated | relid=0 | w=35 cyclopeptide -- r_associated #0: 31 / 0.674 -> en:cyclopeptide n1=cyclopeptide | n2=en:cyclopeptide | rel=r_associated | relid=0 | w=31 cyclopeptide -- r_associated #0: 30 / 0.652 -> médecine n1=cyclopeptide | n2=médecine | rel=r_associated | relid=0 | w=30 cyclopeptide -- r_associated #0: 29 / 0.63 -> pathologie n1=cyclopeptide | n2=pathologie | rel=r_associated | relid=0 | w=29 cyclopeptide -- r_associated #0: 28 / 0.609 -> peptides cycliques n1=cyclopeptide | n2=peptides cycliques | rel=r_associated | relid=0 | w=28 cyclopeptide -- r_associated #0: 27 / 0.587 -> peptide cyclique n1=cyclopeptide | n2=peptide cyclique | rel=r_associated | relid=0 | w=27 cyclopeptide -- r_associated #0: 26 / 0.565 -> pharmacie n1=cyclopeptide | n2=pharmacie | rel=r_associated | relid=0 | w=26 cyclopeptide -- r_associated #0: 20 / 0.435 -> en:cyclic peptide n1=cyclopeptide | n2=en:cyclic peptide | rel=r_associated | relid=0 | w=20 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclope n1=cyclopeptide | n2=cyclope | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclope (oeil) n1=cyclopeptide | n2=cyclope (oeil) | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclophiline n1=cyclopeptide | n2=cyclophiline | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclophorie n1=cyclopeptide | n2=cyclophorie | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclophosphamide n1=cyclopeptide | n2=cyclophosphamide | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclophotocoagulation endoscopique n1=cyclopeptide | n2=cyclophotocoagulation endoscopique | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclophrénie n1=cyclopeptide | n2=cyclophrénie | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclophyllidés n1=cyclopeptide | n2=cyclophyllidés | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclopie n1=cyclopeptide | n2=cyclopie | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclopie-arhinencéphalie n1=cyclopeptide | n2=cyclopie-arhinencéphalie | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cycloplégie n1=cyclopeptide | n2=cycloplégie | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cycloplégique n1=cyclopeptide | n2=cycloplégique | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclopropane n1=cyclopeptide | n2=cyclopropane | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> Cyclops n1=cyclopeptide | n2=Cyclops | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclorrhaphes n1=cyclopeptide | n2=cyclorrhaphes | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> cyclosérine n1=cyclopeptide | n2=cyclosérine | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> en:cyclops eye n1=cyclopeptide | n2=en:cyclops eye | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> maladie n1=cyclopeptide | n2=maladie | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> médicament n1=cyclopeptide | n2=médicament | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> oeil n1=cyclopeptide | n2=oeil | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 15 / 0.326 -> processus pathologique n1=cyclopeptide | n2=processus pathologique | rel=r_associated | relid=0 | w=15 cyclopeptide -- r_associated #0: 10 / 0.217 -> biologie n1=cyclopeptide | n2=biologie | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> cyclopia n1=cyclopeptide | n2=cyclopia | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:anisocoria n1=cyclopeptide | n2=en:anisocoria | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:blepharospasm n1=cyclopeptide | n2=en:blepharospasm | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:chronic progressive external ophthalmoplegia n1=cyclopeptide | n2=en:chronic progressive external ophthalmoplegia | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:congenital anomaly of pupil n1=cyclopeptide | n2=en:congenital anomaly of pupil | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:cycloserine n1=cyclopeptide | n2=en:cycloserine | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:lid lag n1=cyclopeptide | n2=en:lid lag | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:medication n1=cyclopeptide | n2=en:medication | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:miosis disorder n1=cyclopeptide | n2=en:miosis disorder | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:ophthalmoplegia n1=cyclopeptide | n2=en:ophthalmoplegia | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:palsy of conjugate gaze n1=cyclopeptide | n2=en:palsy of conjugate gaze | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:papilledema n1=cyclopeptide | n2=en:papilledema | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:persistent pupillary membranes n1=cyclopeptide | n2=en:persistent pupillary membranes | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:photophobia n1=cyclopeptide | n2=en:photophobia | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:polycoria n1=cyclopeptide | n2=en:polycoria | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:pseudopapilledema n1=cyclopeptide | n2=en:pseudopapilledema | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:ptosis n1=cyclopeptide | n2=en:ptosis | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:reaction absents, pupil n1=cyclopeptide | n2=en:reaction absents, pupil | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:refractive error n1=cyclopeptide | n2=en:refractive error | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:supranuclear paralysis n1=cyclopeptide | n2=en:supranuclear paralysis | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> en:tonic pupil n1=cyclopeptide | n2=en:tonic pupil | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> maladies n1=cyclopeptide | n2=maladies | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> médicaments n1=cyclopeptide | n2=médicaments | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> synophtalmie n1=cyclopeptide | n2=synophtalmie | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 10 / 0.217 -> toxicologie n1=cyclopeptide | n2=toxicologie | rel=r_associated | relid=0 | w=10 cyclopeptide -- r_associated #0: 5 / 0.109 -> 2-H-1,3,2-oxazaphosphorinane n1=cyclopeptide | n2=2-H-1,3,2-oxazaphosphorinane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> accommodation (réserve d') n1=cyclopeptide | n2=accommodation (réserve d') | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> acrocéphalopolysyndactylie n1=cyclopeptide | n2=acrocéphalopolysyndactylie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> ADN n1=cyclopeptide | n2=ADN | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> agent alkylant n1=cyclopeptide | n2=agent alkylant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> agoniste n1=cyclopeptide | n2=agoniste | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> agoniste (molécule) n1=cyclopeptide | n2=agoniste (molécule) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> anatomie n1=cyclopeptide | n2=anatomie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> anomalie n1=cyclopeptide | n2=anomalie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> antibiogramme n1=cyclopeptide | n2=antibiogramme | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> antibiotique n1=cyclopeptide | n2=antibiotique | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> anticancéreux n1=cyclopeptide | n2=anticancéreux | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> arhinencéphalie n1=cyclopeptide | n2=arhinencéphalie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> autres malformations congénitales de la face et du cou n1=cyclopeptide | n2=autres malformations congénitales de la face et du cou | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> biochimie n1=cyclopeptide | n2=biochimie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> C3H6N2O2 n1=cyclopeptide | n2=C3H6N2O2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cancer n1=cyclopeptide | n2=cancer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cancer du poumon n1=cyclopeptide | n2=cancer du poumon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cancer (maladie) n1=cyclopeptide | n2=cancer (maladie) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cancérologie n1=cyclopeptide | n2=cancérologie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> carcinologie n1=cyclopeptide | n2=carcinologie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> chimio n1=cyclopeptide | n2=chimio | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> chimiothérapie n1=cyclopeptide | n2=chimiothérapie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cpm n1=cyclopeptide | n2=cpm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> ctx n1=cyclopeptide | n2=ctx | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cyclocéphalie n1=cyclopeptide | n2=cyclocéphalie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cyclodéviation n1=cyclopeptide | n2=cyclodéviation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cyclophilines n1=cyclopeptide | n2=cyclophilines | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cyclophosphamides n1=cyclopeptide | n2=cyclophosphamides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cyclophotocoagulation n1=cyclopeptide | n2=cyclophotocoagulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cyclorraphes n1=cyclopeptide | n2=cyclorraphes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cyclorrhaphe n1=cyclopeptide | n2=cyclorrhaphe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> Cyclorrhaphes n1=cyclopeptide | n2=Cyclorrhaphes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> cyt n1=cyclopeptide | n2=cyt | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> diagnostic n1=cyclopeptide | n2=diagnostic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> dysmorphie des freins buccaux n1=cyclopeptide | n2=dysmorphie des freins buccaux | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> dysmorphie orodactyle, type 1 n1=cyclopeptide | n2=dysmorphie orodactyle, type 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> dysmorphies des freins buccaux n1=cyclopeptide | n2=dysmorphies des freins buccaux | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> dysostose oro-digito-faciale de type 1 n1=cyclopeptide | n2=dysostose oro-digito-faciale de type 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> effets secondaires n1=cyclopeptide | n2=effets secondaires | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:'empty' vitreous with fibrillary condensations (childhood) n1=cyclopeptide | n2=en:'empty' vitreous with fibrillary condensations (childhood) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:'key-hole' iris, retina, choroid coloboma n1=cyclopeptide | n2=en:'key-hole' iris, retina, choroid coloboma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:'moth-eaten' pattern of peripupillary atrophy n1=cyclopeptide | n2=en:'moth-eaten' pattern of peripupillary atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:'sunflower' cataract (in some patients) n1=cyclopeptide | n2=en:'sunflower' cataract (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:(61)cu-atsm n1=cyclopeptide | n2=en:(61)cu-atsm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:(compadri)-iii protocol n1=cyclopeptide | n2=en:(compadri)-iii protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:[18f]-labeled substance p antagonist receptor quantifier n1=cyclopeptide | n2=en:[18f]-labeled substance p antagonist receptor quantifier | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:[18f]l-fac n1=cyclopeptide | n2=en:[18f]l-fac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:[18f]l-fmac n1=cyclopeptide | n2=en:[18f]l-fmac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:0.5 ml ustekinumab 90 mg/ml prefilled syringe n1=cyclopeptide | n2=en:0.5 ml ustekinumab 90 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:1 ml ustekinumab 90 mg/ml injection n1=cyclopeptide | n2=en:1 ml ustekinumab 90 mg/ml injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:1,2-carbon c 13-labeled glucose n1=cyclopeptide | n2=en:1,2-carbon c 13-labeled glucose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:11c topotecan n1=cyclopeptide | n2=en:11c topotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:13-deoxydoxorubicin n1=cyclopeptide | n2=en:13-deoxydoxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:14c bms-275183 n1=cyclopeptide | n2=en:14c bms-275183 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:16,16-dimethyl prostaglandin e2 n1=cyclopeptide | n2=en:16,16-dimethyl prostaglandin e2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:18-f-fluoroacetate n1=cyclopeptide | n2=en:18-f-fluoroacetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:18f-fhbg n1=cyclopeptide | n2=en:18f-fhbg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:18f-fluoroazomycin arabinoside n1=cyclopeptide | n2=en:18f-fluoroazomycin arabinoside | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:18f-fluoromisonidazole n1=cyclopeptide | n2=en:18f-fluoromisonidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:18f-labeled mini-peg spacered rgd dimer n1=cyclopeptide | n2=en:18f-labeled mini-peg spacered rgd dimer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2-0, 3-0 desulfated heparin n1=cyclopeptide | n2=en:2-0, 3-0 desulfated heparin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2-dechloroethylcyclophosphamide n1=cyclopeptide | n2=en:2-dechloroethylcyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2-deoxy-d-glucose n1=cyclopeptide | n2=en:2-deoxy-d-glucose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2-fluoropropionyl-labeled pegylated dimeric rgd peptide n1=cyclopeptide | n2=en:2-fluoropropionyl-labeled pegylated dimeric rgd peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2-hydroxyflutamide depot n1=cyclopeptide | n2=en:2-hydroxyflutamide depot | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2-hydroxyoleic acid n1=cyclopeptide | n2=en:2-hydroxyoleic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2-methoxyestradiol n1=cyclopeptide | n2=en:2-methoxyestradiol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2-methoxyestradiol nanocrystal colloidal dispersion n1=cyclopeptide | n2=en:2-methoxyestradiol nanocrystal colloidal dispersion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2'-f-ara-deoxyuridine n1=cyclopeptide | n2=en:2'-f-ara-deoxyuridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:24 hr tacrolimus 0.5 mg extended release oral capsule [astagraf] n1=cyclopeptide | n2=en:24 hr tacrolimus 0.5 mg extended release oral capsule [astagraf] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:24 hr tacrolimus 0.75 mg extended release oral tablet [envarsus] n1=cyclopeptide | n2=en:24 hr tacrolimus 0.75 mg extended release oral tablet [envarsus] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:24 hr tacrolimus 1 mg extended release oral capsule [astagraf] n1=cyclopeptide | n2=en:24 hr tacrolimus 1 mg extended release oral capsule [astagraf] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:24 hr tacrolimus 1 mg extended release oral tablet [envarsus] n1=cyclopeptide | n2=en:24 hr tacrolimus 1 mg extended release oral tablet [envarsus] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:24 hr tacrolimus 4 mg extended release oral tablet [envarsus] n1=cyclopeptide | n2=en:24 hr tacrolimus 4 mg extended release oral tablet [envarsus] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:24 hr tacrolimus 5 mg extended release oral capsule [astagraf] n1=cyclopeptide | n2=en:24 hr tacrolimus 5 mg extended release oral capsule [astagraf] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:2g-1 tcr retroviral vector-transduced lymphocytes n1=cyclopeptide | n2=en:2g-1 tcr retroviral vector-transduced lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:3-(1-oxy-2,2,6,6-tetramethyl-4-piperidinyl)cyclophosphamide n1=cyclopeptide | n2=en:3-(1-oxy-2,2,6,6-tetramethyl-4-piperidinyl)cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:3-deazauridine n1=cyclopeptide | n2=en:3-deazauridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:3-hydroxycyclophosphamide n1=cyclopeptide | n2=en:3-hydroxycyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:3-methoxy-1,3,5(10)-estratriene-17(r)-spiro-6'-(2'-(bis-(2-chloroethyl)amino)-2'-oxo-1'-oxa-3'-aza-2'-phosphorane) n1=cyclopeptide | n2=en:3-methoxy-1,3,5(10)-estratriene-17(r)-spiro-6'-(2'-(bis-(2-chloroethyl)amino)-2'-oxo-1'-oxa-3'-aza-2'-phosphorane) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:3-methyl-9-(2-oxa-2lambda(5)-2h-1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro(5.5)undecane n1=cyclopeptide | n2=en:3-methyl-9-(2-oxa-2lambda(5)-2h-1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro(5.5)undecane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:3,4-methylenedioxymethamphetamine n1=cyclopeptide | n2=en:3,4-methylenedioxymethamphetamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:3'-aminomethyl nicotine-p. aeruginosa r-exoprotein a conjugate vaccine n1=cyclopeptide | n2=en:3'-aminomethyl nicotine-p. aeruginosa r-exoprotein a conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:3'-c-ethynylcytidine n1=cyclopeptide | n2=en:3'-c-ethynylcytidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-(n-(s-glutathionylacetyl)amino)phenylarsenoxide n1=cyclopeptide | n2=en:4-(n-(s-glutathionylacetyl)amino)phenylarsenoxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-1bb agonist monoclonal antibody pf-05082566 n1=cyclopeptide | n2=en:4-1bb agonist monoclonal antibody pf-05082566 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-glutathionylcyclophosphamide n1=cyclopeptide | n2=en:4-glutathionylcyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-hydroperoxydechlorocyclophosphamide n1=cyclopeptide | n2=en:4-hydroperoxydechlorocyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-hydroperoxydidechlorocloclophosphamide n1=cyclopeptide | n2=en:4-hydroperoxydidechlorocloclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-hydroxycyclophosphamide n1=cyclopeptide | n2=en:4-hydroxycyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-hydroxyperoxycyclophosphamide n1=cyclopeptide | n2=en:4-hydroxyperoxycyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-ketocyclophosphamide n1=cyclopeptide | n2=en:4-ketocyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-methylcyclophosphamide n1=cyclopeptide | n2=en:4-methylcyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-nitroestrone 3-methyl ether n1=cyclopeptide | n2=en:4-nitroestrone 3-methyl ether | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-peptide melanoma vaccine n1=cyclopeptide | n2=en:4-peptide melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-peroxycyclophosphamide n1=cyclopeptide | n2=en:4-peroxycyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-phenylcyclophosphamide n1=cyclopeptide | n2=en:4-phenylcyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-s-(hexane-6-ol)sulfidocyclophosphamide n1=cyclopeptide | n2=en:4-s-(hexane-6-ol)sulfidocyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-s-(propionic acid)sulfidocyclophosphamide n1=cyclopeptide | n2=en:4-s-(propionic acid)sulfidocyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-s-ethanolsulfido-cyclophosphamide n1=cyclopeptide | n2=en:4-s-ethanolsulfido-cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-thio-2-deoxycytidine n1=cyclopeptide | n2=en:4-thio-2-deoxycytidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4-ureidooxycyclophosphamide n1=cyclopeptide | n2=en:4-ureidooxycyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4,6-diphenylcyclophosphamide n1=cyclopeptide | n2=en:4,6-diphenylcyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:4'-iodo-4'-deoxydoxorubicin n1=cyclopeptide | n2=en:4'-iodo-4'-deoxydoxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-[18f]fluorouracil n1=cyclopeptide | n2=en:5-[18f]fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-chlorocyclophosphamide n1=cyclopeptide | n2=en:5-chlorocyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-fitc-labeled colon-heptapeptide n1=cyclopeptide | n2=en:5-fitc-labeled colon-heptapeptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-fitc-labeled gi-heptapeptide n1=cyclopeptide | n2=en:5-fitc-labeled gi-heptapeptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-fluoro-2-deoxycytidine n1=cyclopeptide | n2=en:5-fluoro-2-deoxycytidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-fluorocyclophosphamide n1=cyclopeptide | n2=en:5-fluorocyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-fluoropyrimidinone n1=cyclopeptide | n2=en:5-fluoropyrimidinone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-fluorouracil/salicylic acid topical solution n1=cyclopeptide | n2=en:5-fluorouracil/salicylic acid topical solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5-ht3 receptor antagonist n1=cyclopeptide | n2=en:5-ht3 receptor antagonist | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:5,5-dimethylcyclophosphamide n1=cyclopeptide | n2=en:5,5-dimethylcyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:50% oxygen/50% nitrous oxide premix n1=cyclopeptide | n2=en:50% oxygen/50% nitrous oxide premix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:6-azauridine n1=cyclopeptide | n2=en:6-azauridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases isoform 3 inhibitor act-pfk-158 n1=cyclopeptide | n2=en:6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases isoform 3 inhibitor act-pfk-158 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:6,8-bis(benzylthio)octanoic acid n1=cyclopeptide | n2=en:6,8-bis(benzylthio)octanoic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:7-cyanoquinocarcinol n1=cyclopeptide | n2=en:7-cyanoquinocarcinol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:7-hydroxystaurosporine n1=cyclopeptide | n2=en:7-hydroxystaurosporine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:7+3 protocol n1=cyclopeptide | n2=en:7+3 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:714-x n1=cyclopeptide | n2=en:714-x | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:8-hydroxyquinoline sulfate ointment n1=cyclopeptide | n2=en:8-hydroxyquinoline sulfate ointment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:851b gel n1=cyclopeptide | n2=en:851b gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:a-cmf regimen n1=cyclopeptide | n2=en:a-cmf regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:a-t-c regimen n1=cyclopeptide | n2=en:a-t-c regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aaabc protocol n1=cyclopeptide | n2=en:aaabc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abacavir sulfate n1=cyclopeptide | n2=en:abacavir sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abagovomab n1=cyclopeptide | n2=en:abagovomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abarelix n1=cyclopeptide | n2=en:abarelix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abatacept n1=cyclopeptide | n2=en:abatacept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abbv-221 n1=cyclopeptide | n2=en:abbv-221 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abc protocol n1=cyclopeptide | n2=en:abc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abcdv protocol n1=cyclopeptide | n2=en:abcdv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abducens nerve disorder n1=cyclopeptide | n2=en:abducens nerve disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abducens palsy n1=cyclopeptide | n2=en:abducens palsy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abduction deficits (about half of patients) n1=cyclopeptide | n2=en:abduction deficits (about half of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abduction palsy, usually bilateral n1=cyclopeptide | n2=en:abduction palsy, usually bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abemaciclib n1=cyclopeptide | n2=en:abemaciclib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abetimus sodium n1=cyclopeptide | n2=en:abetimus sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abexinostat n1=cyclopeptide | n2=en:abexinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abi-007/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:abi-007/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abiraterone acetate n1=cyclopeptide | n2=en:abiraterone acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal accumulation of lipofuscin within and beneath the retinal pigment epithelium (rpe) on optical coherence tomography (oct) n1=cyclopeptide | n2=en:abnormal accumulation of lipofuscin within and beneath the retinal pigment epithelium (rpe) on optical coherence tomography (oct) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal appearance of eyes n1=cyclopeptide | n2=en:abnormal appearance of eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal color vision n1=cyclopeptide | n2=en:abnormal color vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal conjugate eye movement n1=cyclopeptide | n2=en:abnormal conjugate eye movement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal dark-adaptation, midperipheral scotoma n1=cyclopeptide | n2=en:abnormal dark-adaptation, midperipheral scotoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal deposit of pigment in perifoveal retinal pigment epithelium n1=cyclopeptide | n2=en:abnormal deposit of pigment in perifoveal retinal pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal distribution of retinal arterioles and venules n1=cyclopeptide | n2=en:abnormal distribution of retinal arterioles and venules | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal electrooculogram (eog) n1=cyclopeptide | n2=en:abnormal electrooculogram (eog) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal electroretinogram (in some patients) n1=cyclopeptide | n2=en:abnormal electroretinogram (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal electroretinograms in heterozygotes n1=cyclopeptide | n2=en:abnormal electroretinograms in heterozygotes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal eye morphology n1=cyclopeptide | n2=en:abnormal eye morphology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal eye movements (in some patients) n1=cyclopeptide | n2=en:abnormal eye movements (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal eye physiology n1=cyclopeptide | n2=en:abnormal eye physiology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal eyebrows n1=cyclopeptide | n2=en:abnormal eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal fetal duplication n1=cyclopeptide | n2=en:abnormal fetal duplication | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal fibrillar extracellular material in anterior segment tissues n1=cyclopeptide | n2=en:abnormal fibrillar extracellular material in anterior segment tissues | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal fibrils in stroma on electron microscopy n1=cyclopeptide | n2=en:abnormal fibrils in stroma on electron microscopy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal flash visual evoked potentials (vep) n1=cyclopeptide | n2=en:abnormal flash visual evoked potentials (vep) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal iris pigmentation n1=cyclopeptide | n2=en:abnormal iris pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal iris vasculature n1=cyclopeptide | n2=en:abnormal iris vasculature | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal lens suspensory ligament n1=cyclopeptide | n2=en:abnormal lens suspensory ligament | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal light- and dark-adapted electroretinogram n1=cyclopeptide | n2=en:abnormal light- and dark-adapted electroretinogram | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal ocular motility n1=cyclopeptide | n2=en:abnormal ocular motility | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal ocular movements (in some patients) n1=cyclopeptide | n2=en:abnormal ocular movements (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal pupillary light reflex n1=cyclopeptide | n2=en:abnormal pupillary light reflex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal pursuit n1=cyclopeptide | n2=en:abnormal pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal retinal pigment epithelium n1=cyclopeptide | n2=en:abnormal retinal pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal retinal vessels n1=cyclopeptide | n2=en:abnormal retinal vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal saccades n1=cyclopeptide | n2=en:abnormal saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal saccadic eye movement n1=cyclopeptide | n2=en:abnormal saccadic eye movement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal sensation in eye n1=cyclopeptide | n2=en:abnormal sensation in eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal vascularization of the iris on indocyanine green angiography (in some patients) n1=cyclopeptide | n2=en:abnormal vascularization of the iris on indocyanine green angiography (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal vestibuloocular reflex (vor) n1=cyclopeptide | n2=en:abnormal vestibuloocular reflex (vor) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal visual evoked potential n1=cyclopeptide | n2=en:abnormal visual evoked potential | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal visual evoked potential (vep) n1=cyclopeptide | n2=en:abnormal visual evoked potential (vep) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal visual evoked potentials (1 patient) n1=cyclopeptide | n2=en:abnormal visual evoked potentials (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal visual evoked responses (vep) n1=cyclopeptide | n2=en:abnormal visual evoked responses (vep) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal visual pursuit n1=cyclopeptide | n2=en:abnormal visual pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal, jerky eye movements n1=cyclopeptide | n2=en:abnormal, jerky eye movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormal/absent meibomian glands n1=cyclopeptide | n2=en:abnormal/absent meibomian glands | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormalities, drug-induced n1=cyclopeptide | n2=en:abnormalities, drug-induced | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality of ocular smooth pursuit n1=cyclopeptide | n2=en:abnormality of ocular smooth pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality of retinal pigmentation n1=cyclopeptide | n2=en:abnormality of retinal pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality of the cornea n1=cyclopeptide | n2=en:abnormality of the cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality of the eyebrow n1=cyclopeptide | n2=en:abnormality of the eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality of the eyelashes n1=cyclopeptide | n2=en:abnormality of the eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality of the lacrimal duct n1=cyclopeptide | n2=en:abnormality of the lacrimal duct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality of the optic disc n1=cyclopeptide | n2=en:abnormality of the optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality of the optic nerve n1=cyclopeptide | n2=en:abnormality of the optic nerve | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormality, severe teratoid n1=cyclopeptide | n2=en:abnormality, severe teratoid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abnormally prominent line of schwalbe n1=cyclopeptide | n2=en:abnormally prominent line of schwalbe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abolished electroretinogram (erg) (76%) n1=cyclopeptide | n2=en:abolished electroretinogram (erg) (76%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abortifacient agents n1=cyclopeptide | n2=en:abortifacient agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abp 215 n1=cyclopeptide | n2=en:abp 215 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abr-217620 n1=cyclopeptide | n2=en:abr-217620 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of central fovea of macula on optical coherence tomography n1=cyclopeptide | n2=en:absence of central fovea of macula on optical coherence tomography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of exophthalmos n1=cyclopeptide | n2=en:absence of exophthalmos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of eyebrows n1=cyclopeptide | n2=en:absence of eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of flash-evoked visual responses (ver) n1=cyclopeptide | n2=en:absence of flash-evoked visual responses (ver) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of foveal and macular reflexes n1=cyclopeptide | n2=en:absence of foveal and macular reflexes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of foveal avascularity n1=cyclopeptide | n2=en:absence of foveal avascularity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of foveal hyperpigmentation n1=cyclopeptide | n2=en:absence of foveal hyperpigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of foveal pit n1=cyclopeptide | n2=en:absence of foveal pit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of foveal pit on optical coherence tomography n1=cyclopeptide | n2=en:absence of foveal pit on optical coherence tomography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of ophthalmoparesis n1=cyclopeptide | n2=en:absence of ophthalmoparesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of ptosis n1=cyclopeptide | n2=en:absence of ptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absence of sulcus orbitopalpebralis superior (upper eyelid crease) n1=cyclopeptide | n2=en:absence of sulcus orbitopalpebralis superior (upper eyelid crease) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent a- and b-waves under scotopic conditions n1=cyclopeptide | n2=en:absent a- and b-waves under scotopic conditions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent abducens nerve on the affected side of synergistic divergence n1=cyclopeptide | n2=en:absent abducens nerve on the affected side of synergistic divergence | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent anterior chamber of eye n1=cyclopeptide | n2=en:absent anterior chamber of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent canaliculi n1=cyclopeptide | n2=en:absent canaliculi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent cone responses on electroretinography (erg) n1=cyclopeptide | n2=en:absent cone responses on electroretinography (erg) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent corneal reflex response n1=cyclopeptide | n2=en:absent corneal reflex response | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent corneal reflexes (reported in older children) n1=cyclopeptide | n2=en:absent corneal reflexes (reported in older children) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent eyebrow n1=cyclopeptide | n2=en:absent eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent eyebrows (in some patients) n1=cyclopeptide | n2=en:absent eyebrows (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent eyebrows and eyelashes n1=cyclopeptide | n2=en:absent eyebrows and eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent eyelashes n1=cyclopeptide | n2=en:absent eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent eyelashes (in some patients) n1=cyclopeptide | n2=en:absent eyelashes (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent foveal reflex (in some patients) n1=cyclopeptide | n2=en:absent foveal reflex (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent iris pigment n1=cyclopeptide | n2=en:absent iris pigment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent iris stromal pattern n1=cyclopeptide | n2=en:absent iris stromal pattern | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent lateral one-third of eyebrow n1=cyclopeptide | n2=en:absent lateral one-third of eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent macular reflex n1=cyclopeptide | n2=en:absent macular reflex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent miebomian glands n1=cyclopeptide | n2=en:absent miebomian glands | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent night vision n1=cyclopeptide | n2=en:absent night vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent ocular muscles n1=cyclopeptide | n2=en:absent ocular muscles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent optic nerve head n1=cyclopeptide | n2=en:absent optic nerve head | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent or abnormal eyelids n1=cyclopeptide | n2=en:absent or abnormal eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent or malformed lacrimal ducts n1=cyclopeptide | n2=en:absent or malformed lacrimal ducts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent or reduced b-wave on electroretinography n1=cyclopeptide | n2=en:absent or reduced b-wave on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent peripapillary choriocapillaris n1=cyclopeptide | n2=en:absent peripapillary choriocapillaris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent puncta n1=cyclopeptide | n2=en:absent puncta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent pupillary reaction n1=cyclopeptide | n2=en:absent pupillary reaction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent pupillary reflexes during blindness episodes n1=cyclopeptide | n2=en:absent pupillary reflexes during blindness episodes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent retinal pigment n1=cyclopeptide | n2=en:absent retinal pigment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent retinal pigment epithelium n1=cyclopeptide | n2=en:absent retinal pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent rod responses and small residual cone response on electroretinography n1=cyclopeptide | n2=en:absent rod responses and small residual cone response on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent rod-and cone-mediated responses on erg (late) n1=cyclopeptide | n2=en:absent rod-and cone-mediated responses on erg (late) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent stereopsis due to anomalous decussation at the optic chiasm n1=cyclopeptide | n2=en:absent stereopsis due to anomalous decussation at the optic chiasm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent tears n1=cyclopeptide | n2=en:absent tears | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent upper-lid skin crease n1=cyclopeptide | n2=en:absent upper-lid skin crease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absent visual evoked potentials n1=cyclopeptide | n2=en:absent visual evoked potentials | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absorbable adhesion barrier gel n1=cyclopeptide | n2=en:absorbable adhesion barrier gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absorbable fibrin sealant patch n1=cyclopeptide | n2=en:absorbable fibrin sealant patch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absorbable gelatin sponge n1=cyclopeptide | n2=en:absorbable gelatin sponge | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:absorbable modified polymer hemostatic powder n1=cyclopeptide | n2=en:absorbable modified polymer hemostatic powder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abt-510 n1=cyclopeptide | n2=en:abt-510 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abt-751 n1=cyclopeptide | n2=en:abt-751 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abvd regimen n1=cyclopeptide | n2=en:abvd regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:abve regimen n1=cyclopeptide | n2=en:abve regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ac regimen n1=cyclopeptide | n2=en:ac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ac-t regimen n1=cyclopeptide | n2=en:ac-t regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ac-t-t regimen n1=cyclopeptide | n2=en:ac-t-t regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acadesine n1=cyclopeptide | n2=en:acadesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acai berry juice n1=cyclopeptide | n2=en:acai berry juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acalabrutinib n1=cyclopeptide | n2=en:acalabrutinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acanthosis n1=cyclopeptide | n2=en:acanthosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acarbose n1=cyclopeptide | n2=en:acarbose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acaricides n1=cyclopeptide | n2=en:acaricides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:accessory eyelashes n1=cyclopeptide | n2=en:accessory eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ace inhibitor n1=cyclopeptide | n2=en:ace inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ace protocol 1 n1=cyclopeptide | n2=en:ace protocol 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acellular cadaveric dermal matrix n1=cyclopeptide | n2=en:acellular cadaveric dermal matrix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acenocoumarol n1=cyclopeptide | n2=en:acenocoumarol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acentric or irregular corneal video keratography shapes n1=cyclopeptide | n2=en:acentric or irregular corneal video keratography shapes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acephalostomia n1=cyclopeptide | n2=en:acephalostomia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acetaminophen n1=cyclopeptide | n2=en:acetaminophen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acetazolamide sodium n1=cyclopeptide | n2=en:acetazolamide sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acetic acid n1=cyclopeptide | n2=en:acetic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acetohexamide n1=cyclopeptide | n2=en:acetohexamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acetyl-l-carnitine hydrochloride n1=cyclopeptide | n2=en:acetyl-l-carnitine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acetylcysteine n1=cyclopeptide | n2=en:acetylcysteine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acf protocol n1=cyclopeptide | n2=en:acf protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acfm protocol n1=cyclopeptide | n2=en:acfm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acft protocol n1=cyclopeptide | n2=en:acft protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:achromatic retinal patches n1=cyclopeptide | n2=en:achromatic retinal patches | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:achromatopsia n1=cyclopeptide | n2=en:achromatopsia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:achromatopsia 1 n1=cyclopeptide | n2=en:achromatopsia 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:achromatopsia, complete or incomplete n1=cyclopeptide | n2=en:achromatopsia, complete or incomplete | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acitretin n1=cyclopeptide | n2=en:acitretin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acivicin n1=cyclopeptide | n2=en:acivicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aclarubicin n1=cyclopeptide | n2=en:aclarubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acm protocol n1=cyclopeptide | n2=en:acm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acmfvp protocol n1=cyclopeptide | n2=en:acmfvp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acob regimen n1=cyclopeptide | n2=en:acob regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acodazole n1=cyclopeptide | n2=en:acodazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acolbifene hydrochloride n1=cyclopeptide | n2=en:acolbifene hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acomla protocol n1=cyclopeptide | n2=en:acomla protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acop protocol 2 n1=cyclopeptide | n2=en:acop protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acop-e protocol n1=cyclopeptide | n2=en:acop-e protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acopa ii protocol n1=cyclopeptide | n2=en:acopa ii protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acoustic coupling fluid n1=cyclopeptide | n2=en:acoustic coupling fluid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acridine carboxamide n1=cyclopeptide | n2=en:acridine carboxamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:act regimen n1=cyclopeptide | n2=en:act regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:actinium ac 225 lintuzumab n1=cyclopeptide | n2=en:actinium ac 225 lintuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:activated marrow infiltrating lymphocytes n1=cyclopeptide | n2=en:activated marrow infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:activin type 2b receptor fc fusion protein stm 434 n1=cyclopeptide | n2=en:activin type 2b receptor fc fusion protein stm 434 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acute intraocular hypertension (rare) n1=cyclopeptide | n2=en:acute intraocular hypertension (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acute vision loss due to optic nerve infarction (rare) n1=cyclopeptide | n2=en:acute vision loss due to optic nerve infarction (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acvb protocol n1=cyclopeptide | n2=en:acvb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acvbp regimen n1=cyclopeptide | n2=en:acvbp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acyclovir n1=cyclopeptide | n2=en:acyclovir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:acyclovir sodium n1=cyclopeptide | n2=en:acyclovir sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad-hcmv-flt3l n1=cyclopeptide | n2=en:ad-hcmv-flt3l | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad-hcmv-tk n1=cyclopeptide | n2=en:ad-hcmv-tk | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad-isf35 n1=cyclopeptide | n2=en:ad-isf35 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad-reic/dkk3 vaccine n1=cyclopeptide | n2=en:ad-reic/dkk3 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad-sig-hmuc-1/ecdcd40l vaccine n1=cyclopeptide | n2=en:ad-sig-hmuc-1/ecdcd40l vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad5-cmv-nis n1=cyclopeptide | n2=en:ad5-cmv-nis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad5-ycd/muttk(sr39)rep-adp n1=cyclopeptide | n2=en:ad5-ycd/muttk(sr39)rep-adp | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad5-ycd/muttksr39rep-hil12 n1=cyclopeptide | n2=en:ad5-ycd/muttksr39rep-hil12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad5.sstr/tk.rgd n1=cyclopeptide | n2=en:ad5.sstr/tk.rgd | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad5cmv-p53 gene n1=cyclopeptide | n2=en:ad5cmv-p53 gene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ad5f35-lmp1/lmp2-transduced autologous dendritic cells n1=cyclopeptide | n2=en:ad5f35-lmp1/lmp2-transduced autologous dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adalimumab n1=cyclopeptide | n2=en:adalimumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:additional sex chromosome n1=cyclopeptide | n2=en:additional sex chromosome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adduction palsy, usually bilateral n1=cyclopeptide | n2=en:adduction palsy, usually bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ade regimen n1=cyclopeptide | n2=en:ade regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adecatumumab n1=cyclopeptide | n2=en:adecatumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adefovir dipivoxil n1=cyclopeptide | n2=en:adefovir dipivoxil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenosine a2 receptor agonists n1=cyclopeptide | n2=en:adenosine a2 receptor agonists | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenosine a2a receptor antagonist pbf-509 n1=cyclopeptide | n2=en:adenosine a2a receptor antagonist pbf-509 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenosine a3 receptor agonist cf102 n1=cyclopeptide | n2=en:adenosine a3 receptor agonist cf102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenosine triphosphate n1=cyclopeptide | n2=en:adenosine triphosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenosine-a2a receptor antagonist cpi-444 n1=cyclopeptide | n2=en:adenosine-a2a receptor antagonist cpi-444 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovector encoding mda7 n1=cyclopeptide | n2=en:adenovector encoding mda7 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovector-transduced ap1903-inducible myd88/cd40-expressing autologous psma-specific prostate cancer vaccine bpx-201 n1=cyclopeptide | n2=en:adenovector-transduced ap1903-inducible myd88/cd40-expressing autologous psma-specific prostate cancer vaccine bpx-201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenoviral transduced hil-12-expressing autologous dendritic cells inxn-3001 plus activator ligand inxn-1001 n1=cyclopeptide | n2=en:adenoviral transduced hil-12-expressing autologous dendritic cells inxn-3001 plus activator ligand inxn-1001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenoviral vector ad5-cea(6d) vaccine n1=cyclopeptide | n2=en:adenoviral vector ad5-cea(6d) vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus 5-cd40 ligand n1=cyclopeptide | n2=en:adenovirus 5-cd40 ligand | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus 5-human guanylyl cyclase c-padre vaccine n1=cyclopeptide | n2=en:adenovirus 5-human guanylyl cyclase c-padre vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus b7-1 n1=cyclopeptide | n2=en:adenovirus b7-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus encoding human aquaporin-1 n1=cyclopeptide | n2=en:adenovirus encoding human aquaporin-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus encoding rat her-2/neu n1=cyclopeptide | n2=en:adenovirus encoding rat her-2/neu | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus encoding recombinant human endostatin n1=cyclopeptide | n2=en:adenovirus encoding recombinant human endostatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus encoding tyrosinase/mart-1/magea6-transduced autologous dendritic cell vaccine n1=cyclopeptide | n2=en:adenovirus encoding tyrosinase/mart-1/magea6-transduced autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus her2-transduced autologous dendritic cell vaccine n1=cyclopeptide | n2=en:adenovirus her2-transduced autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus rsv-tk n1=cyclopeptide | n2=en:adenovirus rsv-tk | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus vector n1=cyclopeptide | n2=en:adenovirus vector | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus-encoding e.coli pnp n1=cyclopeptide | n2=en:adenovirus-encoding e.coli pnp | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus-mediated human interleukin-12 n1=cyclopeptide | n2=en:adenovirus-mediated human interleukin-12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus-mediated human interleukin-12 inxn-2001 plus activator ligand inxn-1001 n1=cyclopeptide | n2=en:adenovirus-mediated human interleukin-12 inxn-2001 plus activator ligand inxn-1001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus-p53 transduced dendritic cell vaccine n1=cyclopeptide | n2=en:adenovirus-p53 transduced dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus-psa prostate cancer vaccine n1=cyclopeptide | n2=en:adenovirus-psa prostate cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adenovirus/cytomegalovirus/epstein-barr virus-specific allogeneic cytotoxic t lymphocytes n1=cyclopeptide | n2=en:adenovirus/cytomegalovirus/epstein-barr virus-specific allogeneic cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adgmcaix-transduced autologous dendritic cells n1=cyclopeptide | n2=en:adgmcaix-transduced autologous dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adh-1 n1=cyclopeptide | n2=en:adh-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adhesions of iris n1=cyclopeptide | n2=en:adhesions of iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adipose-derived regenerative cells n1=cyclopeptide | n2=en:adipose-derived regenerative cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adipose-derived stromal vascular fraction cells n1=cyclopeptide | n2=en:adipose-derived stromal vascular fraction cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adoc protocol n1=cyclopeptide | n2=en:adoc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adozelesin n1=cyclopeptide | n2=en:adozelesin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:adrtvp-1-transduced prostate cancer cell-based vaccine n1=cyclopeptide | n2=en:adrtvp-1-transduced prostate cancer cell-based vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ae37 peptide/gm-csf vaccine n1=cyclopeptide | n2=en:ae37 peptide/gm-csf vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aee788 n1=cyclopeptide | n2=en:aee788 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aeg35156 n1=cyclopeptide | n2=en:aeg35156 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aerosol sargramostim n1=cyclopeptide | n2=en:aerosol sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aerosolized aldesleukin n1=cyclopeptide | n2=en:aerosolized aldesleukin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aerosolized liposomal rubitecan n1=cyclopeptide | n2=en:aerosolized liposomal rubitecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:afamelanotide n1=cyclopeptide | n2=en:afamelanotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:afatinib dimaleate n1=cyclopeptide | n2=en:afatinib dimaleate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:afferent pupillary defect n1=cyclopeptide | n2=en:afferent pupillary defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:afimoxifene n1=cyclopeptide | n2=en:afimoxifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:afp gene hepatocellular carcinoma vaccine n1=cyclopeptide | n2=en:afp gene hepatocellular carcinoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:afp464 n1=cyclopeptide | n2=en:afp464 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:afuresertib n1=cyclopeptide | n2=en:afuresertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ag-024322 n1=cyclopeptide | n2=en:ag-024322 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agaricus blazei murill extract n1=cyclopeptide | n2=en:agaricus blazei murill extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agatolimod sodium n1=cyclopeptide | n2=en:agatolimod sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:age-related macular degeneration n1=cyclopeptide | n2=en:age-related macular degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agenesis n1=cyclopeptide | n2=en:agenesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agent affecting cardiovascular system n1=cyclopeptide | n2=en:agent affecting cardiovascular system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aglatimagene besadenovec n1=cyclopeptide | n2=en:aglatimagene besadenovec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agnathia-holoprosencephaly n1=cyclopeptide | n2=en:agnathia-holoprosencephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agonistic anti-cd40 monoclonal antibody adc-1013 n1=cyclopeptide | n2=en:agonistic anti-cd40 monoclonal antibody adc-1013 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agonistic anti-ox40 monoclonal antibody medi6383 n1=cyclopeptide | n2=en:agonistic anti-ox40 monoclonal antibody medi6383 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agonistic anti-ox40 monoclonal antibody medi6469 n1=cyclopeptide | n2=en:agonistic anti-ox40 monoclonal antibody medi6469 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:agonists n1=cyclopeptide | n2=en:agonists | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aicardi syndrome n1=cyclopeptide | n2=en:aicardi syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aieop acute lymphoblastic leukemia protocol n1=cyclopeptide | n2=en:aieop acute lymphoblastic leukemia protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aim2(-1)/ht001(-1)/taf1b(-1) frameshift peptide vaccine n1=cyclopeptide | n2=en:aim2(-1)/ht001(-1)/taf1b(-1) frameshift peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ak 3012 n1=cyclopeptide | n2=en:ak 3012 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt 1/2 inhibitor bay1125976 n1=cyclopeptide | n2=en:akt 1/2 inhibitor bay1125976 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt inhibitor arq 092 n1=cyclopeptide | n2=en:akt inhibitor arq 092 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt inhibitor azd5363 n1=cyclopeptide | n2=en:akt inhibitor azd5363 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt inhibitor gsk2141795 n1=cyclopeptide | n2=en:akt inhibitor gsk2141795 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt inhibitor ly2780301 n1=cyclopeptide | n2=en:akt inhibitor ly2780301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt inhibitor mk2206 n1=cyclopeptide | n2=en:akt inhibitor mk2206 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt inhibitor sr13668 n1=cyclopeptide | n2=en:akt inhibitor sr13668 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt-1/2 inhibitor-treated tumor infiltrating lymphocytes n1=cyclopeptide | n2=en:akt-1/2 inhibitor-treated tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:akt/erk inhibitor onc201 n1=cyclopeptide | n2=en:akt/erk inhibitor onc201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:al721 n1=cyclopeptide | n2=en:al721 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alacrima n1=cyclopeptide | n2=en:alacrima | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alacrima - hypolacrimation n1=cyclopeptide | n2=en:alacrima - hypolacrimation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alacrima - hypolacrimation, severe n1=cyclopeptide | n2=en:alacrima - hypolacrimation, severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alacrima (dry eye syndrome) n1=cyclopeptide | n2=en:alacrima (dry eye syndrome) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alanosine n1=cyclopeptide | n2=en:alanosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:albinism n1=cyclopeptide | n2=en:albinism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:albinism, ocular n1=cyclopeptide | n2=en:albinism, ocular | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:albinoid fundi n1=cyclopeptide | n2=en:albinoid fundi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:albinotic fundus n1=cyclopeptide | n2=en:albinotic fundus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:albinotic optic disc n1=cyclopeptide | n2=en:albinotic optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:albumin n1=cyclopeptide | n2=en:albumin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:albuterol sulfate n1=cyclopeptide | n2=en:albuterol sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alcohol n1=cyclopeptide | n2=en:alcohol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alcohol deterrents n1=cyclopeptide | n2=en:alcohol deterrents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alcohol products n1=cyclopeptide | n2=en:alcohol products | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alcophosphamide n1=cyclopeptide | n2=en:alcophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aldesleukin n1=cyclopeptide | n2=en:aldesleukin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aldoxorubicin n1=cyclopeptide | n2=en:aldoxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alectinib n1=cyclopeptide | n2=en:alectinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alefacept n1=cyclopeptide | n2=en:alefacept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alemtuzumab n1=cyclopeptide | n2=en:alemtuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alemtuzumab/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine n1=cyclopeptide | n2=en:alemtuzumab/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alemtuzumab/cyclophosphamide/fludarabine n1=cyclopeptide | n2=en:alemtuzumab/cyclophosphamide/fludarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alemtuzumab/cyclophosphamide/fludarabine/rituximab n1=cyclopeptide | n2=en:alemtuzumab/cyclophosphamide/fludarabine/rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alendronate sodium n1=cyclopeptide | n2=en:alendronate sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alestramustine n1=cyclopeptide | n2=en:alestramustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alfentanil hydrochloride n1=cyclopeptide | n2=en:alfentanil hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alfuzosin hydrochloride n1=cyclopeptide | n2=en:alfuzosin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:algenpantucel-l n1=cyclopeptide | n2=en:algenpantucel-l | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alisertib n1=cyclopeptide | n2=en:alisertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alitretinoin n1=cyclopeptide | n2=en:alitretinoin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alizapride n1=cyclopeptide | n2=en:alizapride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alk inhibitor asp3026 n1=cyclopeptide | n2=en:alk inhibitor asp3026 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alk inhibitor ro5424802 n1=cyclopeptide | n2=en:alk inhibitor ro5424802 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alk inhibitor x-396 n1=cyclopeptide | n2=en:alk inhibitor x-396 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alk-fak inhibitor cep-37440 n1=cyclopeptide | n2=en:alk-fak inhibitor cep-37440 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alk/fak/pyk2 inhibitor ct-707 n1=cyclopeptide | n2=en:alk/fak/pyk2 inhibitor ct-707 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alk/ros1 inhibitor pf-06463922 n1=cyclopeptide | n2=en:alk/ros1 inhibitor pf-06463922 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alk/trk inhibitor tsr-011 n1=cyclopeptide | n2=en:alk/trk inhibitor tsr-011 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alk5 inhibitor tew-7197 n1=cyclopeptide | n2=en:alk5 inhibitor tew-7197 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alkaline water n1=cyclopeptide | n2=en:alkaline water | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alkalinizing agent (substance) n1=cyclopeptide | n2=en:alkalinizing agent (substance) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alkyl sulfonate antineoplastic n1=cyclopeptide | n2=en:alkyl sulfonate antineoplastic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alkylating activity [moa] n1=cyclopeptide | n2=en:alkylating activity [moa] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alkylating agent n1=cyclopeptide | n2=en:alkylating agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alkylating drug [epc] n1=cyclopeptide | n2=en:alkylating drug [epc] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alkylating function n1=cyclopeptide | n2=en:alkylating function | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:all-1 protocol n1=cyclopeptide | n2=en:all-1 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:all-bfm-95 protocol n1=cyclopeptide | n2=en:all-bfm-95 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allergen product n1=cyclopeptide | n2=en:allergen product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allergenic extract n1=cyclopeptide | n2=en:allergenic extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allodepleted haploidentical t cells-expressing inducible caspase 9 n1=cyclopeptide | n2=en:allodepleted haploidentical t cells-expressing inducible caspase 9 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allodepleted t cell immunotherapeutic atir101 n1=cyclopeptide | n2=en:allodepleted t cell immunotherapeutic atir101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic adenovirus-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:allogeneic adenovirus-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic aml antigen-expressing dendritic cell vaccine n1=cyclopeptide | n2=en:allogeneic aml antigen-expressing dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic b7.1/hla-a1 transfected tumor cell vaccine n1=cyclopeptide | n2=en:allogeneic b7.1/hla-a1 transfected tumor cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic cd19-specific car-modified cd8 plus central memory-derived virus-specific t cells n1=cyclopeptide | n2=en:allogeneic cd19-specific car-modified cd8 plus central memory-derived virus-specific t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic cd4+ memory th1-like t cells/microparticle-bound anti-cd3/anti-cd28 n1=cyclopeptide | n2=en:allogeneic cd4+ memory th1-like t cells/microparticle-bound anti-cd3/anti-cd28 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic cd56-positive cd3-negative natural killer cells n1=cyclopeptide | n2=en:allogeneic cd56-positive cd3-negative natural killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic cmv/adv-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:allogeneic cmv/adv-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic cytomegalovirus-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:allogeneic cytomegalovirus-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic dendritic cell vaccine combig-dc n1=cyclopeptide | n2=en:allogeneic dendritic cell vaccine combig-dc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic dendritic cell-myeloma idiotype vaccine n1=cyclopeptide | n2=en:allogeneic dendritic cell-myeloma idiotype vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic epstein-barr virus-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:allogeneic epstein-barr virus-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic gm-csf-based myeloma cell vaccine n1=cyclopeptide | n2=en:allogeneic gm-csf-based myeloma cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic gm-csf-secreting breast cancer vaccine n1=cyclopeptide | n2=en:allogeneic gm-csf-secreting breast cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic gm-csf-secreting breast cancer vaccine/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:allogeneic gm-csf-secreting breast cancer vaccine/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic gm-csf-secreting breast cancer vaccine/cyclophosphamide/interferon alfa n1=cyclopeptide | n2=en:allogeneic gm-csf-secreting breast cancer vaccine/cyclophosphamide/interferon alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic gm-csf-secreting lethally irradiated whole melanoma cell vaccine n1=cyclopeptide | n2=en:allogeneic gm-csf-secreting lethally irradiated whole melanoma cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic gm-csf-secreting tumor vaccine panc 10.05 pcdna-1/gm-neo n1=cyclopeptide | n2=en:allogeneic gm-csf-secreting tumor vaccine panc 10.05 pcdna-1/gm-neo | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic gm-csf-secreting tumor vaccine panc 6.03 pcdna-1/gm-neo n1=cyclopeptide | n2=en:allogeneic gm-csf-secreting tumor vaccine panc 6.03 pcdna-1/gm-neo | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic hla-a2/4-1bb ligand-expressing melanoma vaccine n1=cyclopeptide | n2=en:allogeneic hla-a2/4-1bb ligand-expressing melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic il13-zetakine/hytk-expressing-glucocorticoid resistant cytotoxic t lymphocytes grm13z40-2 n1=cyclopeptide | n2=en:allogeneic il13-zetakine/hytk-expressing-glucocorticoid resistant cytotoxic t lymphocytes grm13z40-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic irradiated melanoma cell vaccine csf470 n1=cyclopeptide | n2=en:allogeneic irradiated melanoma cell vaccine csf470 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic large multivalent immunogen breast cancer vaccine n1=cyclopeptide | n2=en:allogeneic large multivalent immunogen breast cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic large multivalent immunogen melanoma vaccine lp2307 n1=cyclopeptide | n2=en:allogeneic large multivalent immunogen melanoma vaccine lp2307 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic lmp1/lmp2-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:allogeneic lmp1/lmp2-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic melanoma vaccine agi-101h n1=cyclopeptide | n2=en:allogeneic melanoma vaccine agi-101h | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:allogeneic mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic multipotent adult progenitor cells n1=cyclopeptide | n2=en:allogeneic multipotent adult progenitor cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic multivirus-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:allogeneic multivirus-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic natural killer cell line mg4101 n1=cyclopeptide | n2=en:allogeneic natural killer cell line mg4101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic natural killer cell line nk-92 n1=cyclopeptide | n2=en:allogeneic natural killer cell line nk-92 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic renal cell carcinoma vaccine mgn1601 n1=cyclopeptide | n2=en:allogeneic renal cell carcinoma vaccine mgn1601 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic t-lymphocytes bpx-501 n1=cyclopeptide | n2=en:allogeneic t-lymphocytes bpx-501 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allogeneic tumor cell vaccine n1=cyclopeptide | n2=en:allogeneic tumor cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allopurinol n1=cyclopeptide | n2=en:allopurinol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allosteric bcr-abl tyrosine kinase inhibitor abl001 n1=cyclopeptide | n2=en:allosteric bcr-abl tyrosine kinase inhibitor abl001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:allovectin-7 n1=cyclopeptide | n2=en:allovectin-7 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alloxan n1=cyclopeptide | n2=en:alloxan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:almond-shaped eyes n1=cyclopeptide | n2=en:almond-shaped eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:almond-shaped eyes (1 patient) n1=cyclopeptide | n2=en:almond-shaped eyes (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:almond-shaped eyes (2p21del) n1=cyclopeptide | n2=en:almond-shaped eyes (2p21del) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:almond-shaped eyes (rare) n1=cyclopeptide | n2=en:almond-shaped eyes (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:almurtide n1=cyclopeptide | n2=en:almurtide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aloe vera gel n1=cyclopeptide | n2=en:aloe vera gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aloe/anise/ascorbic acid/clove/peppermint/spearmint/thyme-based mouthwash n1=cyclopeptide | n2=en:aloe/anise/ascorbic acid/clove/peppermint/spearmint/thyme-based mouthwash | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alogliptin n1=cyclopeptide | n2=en:alogliptin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alopecia preparation n1=cyclopeptide | n2=en:alopecia preparation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpelisib n1=cyclopeptide | n2=en:alpelisib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha fetoprotein adenoviral vector vaccine n1=cyclopeptide | n2=en:alpha fetoprotein adenoviral vector vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha fetoprotein plasmid dna vaccine n1=cyclopeptide | n2=en:alpha fetoprotein plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha galactosylceramide n1=cyclopeptide | n2=en:alpha galactosylceramide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-1-proteinase inhibitor human n1=cyclopeptide | n2=en:alpha-1-proteinase inhibitor human | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma vaccine n1=cyclopeptide | n2=en:alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-fetoprotein peptide-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:alpha-fetoprotein peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-folate receptor-targeting thymidylate synthase inhibitor onx-0801 n1=cyclopeptide | n2=en:alpha-folate receptor-targeting thymidylate synthase inhibitor onx-0801 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-gal glycosphingolipids n1=cyclopeptide | n2=en:alpha-gal glycosphingolipids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-galactosylceramide-pulsed autologous dendritic cells n1=cyclopeptide | n2=en:alpha-galactosylceramide-pulsed autologous dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-lipoic acid n1=cyclopeptide | n2=en:alpha-lipoic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-lipoic acid-palladium/vitamin/mineral supplement n1=cyclopeptide | n2=en:alpha-lipoic acid-palladium/vitamin/mineral supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-tocopheryloxyacetic acid n1=cyclopeptide | n2=en:alpha-tocopheryloxyacetic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alpha-type-1 polarized dendritic cells n1=cyclopeptide | n2=en:alpha-type-1 polarized dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alprazolam n1=cyclopeptide | n2=en:alprazolam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alprostadil n1=cyclopeptide | n2=en:alprostadil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alteplase n1=cyclopeptide | n2=en:alteplase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altered horizontal eye movements n1=cyclopeptide | n2=en:altered horizontal eye movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altered retinal vascular permeability with lipid exudation n1=cyclopeptide | n2=en:altered retinal vascular permeability with lipid exudation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altered vertical eye movements n1=cyclopeptide | n2=en:altered vertical eye movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altered visual acuity n1=cyclopeptide | n2=en:altered visual acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altered visual evoked potentials (1/4 patients) n1=cyclopeptide | n2=en:altered visual evoked potentials (1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alternating esotropia (in some patients) n1=cyclopeptide | n2=en:alternating esotropia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altiratinib n1=cyclopeptide | n2=en:altiratinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine n1=cyclopeptide | n2=en:altretamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/carboplatin/cyclophosphamide n1=cyclopeptide | n2=en:altretamine/carboplatin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/carboplatin/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:altretamine/carboplatin/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cisplatin/cyclophosphamide n1=cyclopeptide | n2=en:altretamine/cisplatin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cisplatin/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:altretamine/cisplatin/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cisplatin/cyclophosphamide/fluorouracil n1=cyclopeptide | n2=en:altretamine/cisplatin/cyclophosphamide/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cisplatin/cyclophosphamide/misonidazole n1=cyclopeptide | n2=en:altretamine/cisplatin/cyclophosphamide/misonidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:altretamine/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/methotrexate/prednisone/tamoxifen/vinblastine n1=cyclopeptide | n2=en:altretamine/cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/methotrexate/prednisone/tamoxifen/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cyclophosphamide/doxorubicin/prednisone/vincristine n1=cyclopeptide | n2=en:altretamine/cyclophosphamide/doxorubicin/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cyclophosphamide/doxorubicin/vincristine n1=cyclopeptide | n2=en:altretamine/cyclophosphamide/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cyclophosphamide/fluorouracil/methotrexate n1=cyclopeptide | n2=en:altretamine/cyclophosphamide/fluorouracil/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:altretamine/cyclophosphamide/methotrexate n1=cyclopeptide | n2=en:altretamine/cyclophosphamide/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aluminum hydroxide/magnesium hydroxide n1=cyclopeptide | n2=en:aluminum hydroxide/magnesium hydroxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aluminum sulfate n1=cyclopeptide | n2=en:aluminum sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvac-cea b7.1 vaccine n1=cyclopeptide | n2=en:alvac-cea b7.1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvac-cea vaccine n1=cyclopeptide | n2=en:alvac-cea vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvac-eso-1 vaccine n1=cyclopeptide | n2=en:alvac-eso-1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvac-hb7.1 n1=cyclopeptide | n2=en:alvac-hb7.1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvac-mart-1 vaccine n1=cyclopeptide | n2=en:alvac-mart-1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvac(2) melanoma multi-antigen therapeutic vaccine n1=cyclopeptide | n2=en:alvac(2) melanoma multi-antigen therapeutic vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvac(2)-ny-eso-1 (m)/tricom vaccine n1=cyclopeptide | n2=en:alvac(2)-ny-eso-1 (m)/tricom vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvelestat n1=cyclopeptide | n2=en:alvelestat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvespimycin hydrochloride n1=cyclopeptide | n2=en:alvespimycin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvimopan n1=cyclopeptide | n2=en:alvimopan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:alvocidib hydrochloride n1=cyclopeptide | n2=en:alvocidib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amantadine hydrochloride n1=cyclopeptide | n2=en:amantadine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amastia n1=cyclopeptide | n2=en:amastia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amatuximab n1=cyclopeptide | n2=en:amatuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amauroses n1=cyclopeptide | n2=en:amauroses | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ambamustine n1=cyclopeptide | n2=en:ambamustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ambazone n1=cyclopeptide | n2=en:ambazone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amblyopia n1=cyclopeptide | n2=en:amblyopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amblyopia (1 patient) n1=cyclopeptide | n2=en:amblyopia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amblyopia (reported in 1 family) n1=cyclopeptide | n2=en:amblyopia (reported in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amegakaryocytic thrombocytopenia with congenital malformation n1=cyclopeptide | n2=en:amegakaryocytic thrombocytopenia with congenital malformation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:american ginseng n1=cyclopeptide | n2=en:american ginseng | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ametantrone n1=cyclopeptide | n2=en:ametantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amg 224 n1=cyclopeptide | n2=en:amg 224 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amidino tic n1=cyclopeptide | n2=en:amidino tic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifampridine n1=cyclopeptide | n2=en:amifampridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifostine n1=cyclopeptide | n2=en:amifostine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifostine/carboplatin/cyclophosphamide n1=cyclopeptide | n2=en:amifostine/carboplatin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifostine/carboplatin/cyclophosphamide/thiotepa n1=cyclopeptide | n2=en:amifostine/carboplatin/cyclophosphamide/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifostine/carmustine/cyclophosphamide/cytarabine/etoposide n1=cyclopeptide | n2=en:amifostine/carmustine/cyclophosphamide/cytarabine/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifostine/cisplatin/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:amifostine/cisplatin/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifostine/cyclophosphamide n1=cyclopeptide | n2=en:amifostine/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifostine/cyclophosphamide/doxorubicin/paclitaxel n1=cyclopeptide | n2=en:amifostine/cyclophosphamide/doxorubicin/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amifostine/cyclophosphamide/mitoxantrone/thiotepa n1=cyclopeptide | n2=en:amifostine/cyclophosphamide/mitoxantrone/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amikacin sulfate n1=cyclopeptide | n2=en:amikacin sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amilomer n1=cyclopeptide | n2=en:amilomer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amino acid injection n1=cyclopeptide | n2=en:amino acid injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminobenzoate potassium n1=cyclopeptide | n2=en:aminobenzoate potassium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminocamptothecin n1=cyclopeptide | n2=en:aminocamptothecin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminocamptothecin colloidal dispersion n1=cyclopeptide | n2=en:aminocamptothecin colloidal dispersion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminocaproic acid n1=cyclopeptide | n2=en:aminocaproic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminoglutethimide n1=cyclopeptide | n2=en:aminoglutethimide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminolevulinic acid n1=cyclopeptide | n2=en:aminolevulinic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminolevulinic acid hydrochloride n1=cyclopeptide | n2=en:aminolevulinic acid hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminophylline n1=cyclopeptide | n2=en:aminophylline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminopterin n1=cyclopeptide | n2=en:aminopterin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminosyn n1=cyclopeptide | n2=en:aminosyn | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aminothiadiazole n1=cyclopeptide | n2=en:aminothiadiazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amiodarone hydrochloride n1=cyclopeptide | n2=en:amiodarone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amitriptyline hydrochloride n1=cyclopeptide | n2=en:amitriptyline hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aml mrna positive lysate loaded autologous dendritic cell vaccine n1=cyclopeptide | n2=en:aml mrna positive lysate loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ammonia n-13 n1=cyclopeptide | n2=en:ammonia n-13 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ammonium glycyrrhizate n1=cyclopeptide | n2=en:ammonium glycyrrhizate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amnion-derived cellular cytokine solution n1=cyclopeptide | n2=en:amnion-derived cellular cytokine solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amniotic band syndrome n1=cyclopeptide | n2=en:amniotic band syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amolimogene bepiplasmid n1=cyclopeptide | n2=en:amolimogene bepiplasmid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amonafide dihydrochloride n1=cyclopeptide | n2=en:amonafide dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amonafide l-malate n1=cyclopeptide | n2=en:amonafide l-malate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amoxicillin n1=cyclopeptide | n2=en:amoxicillin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amoxicillin-clavulanate potassium n1=cyclopeptide | n2=en:amoxicillin-clavulanate potassium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amphotericin b deoxycholate n1=cyclopeptide | n2=en:amphotericin b deoxycholate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ampicillin sodium/sulbactam sodium n1=cyclopeptide | n2=en:ampicillin sodium/sulbactam sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amrubicin hydrochloride n1=cyclopeptide | n2=en:amrubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amsacrine n1=cyclopeptide | n2=en:amsacrine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amsacrine/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:amsacrine/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amsacrine/cyclophosphamide/hydroxyurea n1=cyclopeptide | n2=en:amsacrine/cyclophosphamide/hydroxyurea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amsilarotene n1=cyclopeptide | n2=en:amsilarotene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amt2003 n1=cyclopeptide | n2=en:amt2003 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amuvatinib n1=cyclopeptide | n2=en:amuvatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amylin analog n1=cyclopeptide | n2=en:amylin analog | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amyloid deposition in the vitreous humor (variable expression) n1=cyclopeptide | n2=en:amyloid deposition in the vitreous humor (variable expression) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:amyloid deposits in corneal stroma n1=cyclopeptide | n2=en:amyloid deposits in corneal stroma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anagrelide hydrochloride n1=cyclopeptide | n2=en:anagrelide hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anagrelide prolonged-release formulation n1=cyclopeptide | n2=en:anagrelide prolonged-release formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anakinra n1=cyclopeptide | n2=en:anakinra | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:analgesic agent n1=cyclopeptide | n2=en:analgesic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:analysis aspect n1=cyclopeptide | n2=en:analysis aspect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anamorelin hydrochloride n1=cyclopeptide | n2=en:anamorelin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anastrozole n1=cyclopeptide | n2=en:anastrozole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anaxirone n1=cyclopeptide | n2=en:anaxirone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ancestim n1=cyclopeptide | n2=en:ancestim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ancitabine hydrochloride n1=cyclopeptide | n2=en:ancitabine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:androgen antagonist apc-100 n1=cyclopeptide | n2=en:androgen antagonist apc-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:androgen receptor antagonist arn-509 n1=cyclopeptide | n2=en:androgen receptor antagonist arn-509 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:androgen receptor antagonist shr3680 n1=cyclopeptide | n2=en:androgen receptor antagonist shr3680 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:androgen receptor antisense oligonucleotide azd5312 n1=cyclopeptide | n2=en:androgen receptor antisense oligonucleotide azd5312 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:androgen receptor antisense oligonucleotide ezn-4176 n1=cyclopeptide | n2=en:androgen receptor antisense oligonucleotide ezn-4176 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:androgen receptor inhibitor epi-506 n1=cyclopeptide | n2=en:androgen receptor inhibitor epi-506 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:androgen receptor ligand-binding domain-encoding plasmid dna vaccine mvi-118 n1=cyclopeptide | n2=en:androgen receptor ligand-binding domain-encoding plasmid dna vaccine mvi-118 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:andrographolide n1=cyclopeptide | n2=en:andrographolide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:androstane steroid he3235 n1=cyclopeptide | n2=en:androstane steroid he3235 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anencephalus and similar anomalies n1=cyclopeptide | n2=en:anencephalus and similar anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anesthetic agent n1=cyclopeptide | n2=en:anesthetic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anetholtrithion n1=cyclopeptide | n2=en:anetholtrithion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anetumab ravtansine n1=cyclopeptide | n2=en:anetumab ravtansine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ang2/vegf-binding peptides-antibody fusion protein cvx-241 n1=cyclopeptide | n2=en:ang2/vegf-binding peptides-antibody fusion protein cvx-241 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angelica sinensis root extract n1=cyclopeptide | n2=en:angelica sinensis root extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angiogenesis inhibitor n1=cyclopeptide | n2=en:angiogenesis inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angiogenesis inhibitor gt-111 n1=cyclopeptide | n2=en:angiogenesis inhibitor gt-111 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angiogenesis inhibitor ji-101 n1=cyclopeptide | n2=en:angiogenesis inhibitor ji-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angiogenesis/heparanase inhibitor pg545 n1=cyclopeptide | n2=en:angiogenesis/heparanase inhibitor pg545 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angioid retinal streaks (in some patients) n1=cyclopeptide | n2=en:angioid retinal streaks (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angioid streaks n1=cyclopeptide | n2=en:angioid streaks | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angioid streaks of the retina (85% of patients) n1=cyclopeptide | n2=en:angioid streaks of the retina (85% of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angiopoietin-2-specific fusion protein pf-04856884 n1=cyclopeptide | n2=en:angiopoietin-2-specific fusion protein pf-04856884 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angiostatin n1=cyclopeptide | n2=en:angiostatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:angle-closure glaucoma (in some patients) n1=cyclopeptide | n2=en:angle-closure glaucoma (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anguidine n1=cyclopeptide | n2=en:anguidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anhydrovinblastine n1=cyclopeptide | n2=en:anhydrovinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anidulafungin n1=cyclopeptide | n2=en:anidulafungin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aniline mustard n1=cyclopeptide | n2=en:aniline mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aniridia n1=cyclopeptide | n2=en:aniridia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aniridia (3%) n1=cyclopeptide | n2=en:aniridia (3%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anisocoria (in 1 patient) n1=cyclopeptide | n2=en:anisocoria (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anisocoria (in some patients) n1=cyclopeptide | n2=en:anisocoria (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anisocoria (unequal pupal size) n1=cyclopeptide | n2=en:anisocoria (unequal pupal size) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anisocoria due to autonomic dysfunction n1=cyclopeptide | n2=en:anisocoria due to autonomic dysfunction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anisometropia n1=cyclopeptide | n2=en:anisometropia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anisperimus n1=cyclopeptide | n2=en:anisperimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ankyloblepharon filiform n1=cyclopeptide | n2=en:ankyloblepharon filiform | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ankyloblepharon filiforme n1=cyclopeptide | n2=en:ankyloblepharon filiforme | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ankyloblepharon filiforme adnatum n1=cyclopeptide | n2=en:ankyloblepharon filiforme adnatum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ankyloglossia n1=cyclopeptide | n2=en:ankyloglossia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anlotinib hydrochloride n1=cyclopeptide | n2=en:anlotinib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:annamycin liposomal n1=cyclopeptide | n2=en:annamycin liposomal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:annonaceous acetogenins n1=cyclopeptide | n2=en:annonaceous acetogenins | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anomalous discs n1=cyclopeptide | n2=en:anomalous discs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anomalous extraocular muscles n1=cyclopeptide | n2=en:anomalous extraocular muscles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anomalous optic disc n1=cyclopeptide | n2=en:anomalous optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anomaly congenital special senses n1=cyclopeptide | n2=en:anomaly congenital special senses | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anophthalmia (1 family) n1=cyclopeptide | n2=en:anophthalmia (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anophthalmia, clinical, unilateral or bilateral n1=cyclopeptide | n2=en:anophthalmia, clinical, unilateral or bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anophthalmos n1=cyclopeptide | n2=en:anophthalmos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anophthalmos of left eye n1=cyclopeptide | n2=en:anophthalmos of left eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anophthalmos of right eye n1=cyclopeptide | n2=en:anophthalmos of right eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior and posterior chamber disorders congenital n1=cyclopeptide | n2=en:anterior and posterior chamber disorders congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior capsule of the lens n1=cyclopeptide | n2=en:anterior capsule of the lens | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior chamber angle open with grade iii-iv gonioscopy n1=cyclopeptide | n2=en:anterior chamber angle open with grade iii-iv gonioscopy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior chamber anomalies n1=cyclopeptide | n2=en:anterior chamber anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior chamber depth increased n1=cyclopeptide | n2=en:anterior chamber depth increased | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior chamber dysgenesis n1=cyclopeptide | n2=en:anterior chamber dysgenesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior chamber malformation (wws) n1=cyclopeptide | n2=en:anterior chamber malformation (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior chamber of the eye n1=cyclopeptide | n2=en:anterior chamber of the eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior corneal lens opacities n1=cyclopeptide | n2=en:anterior corneal lens opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior cortical cataract n1=cyclopeptide | n2=en:anterior cortical cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior eye defects n1=cyclopeptide | n2=en:anterior eye defects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior eye segment n1=cyclopeptide | n2=en:anterior eye segment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior iris surface and stromal abnormalities n1=cyclopeptide | n2=en:anterior iris surface and stromal abnormalities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior lenticonus n1=cyclopeptide | n2=en:anterior lenticonus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior segment dysgenesis (in some patients) n1=cyclopeptide | n2=en:anterior segment dysgenesis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior segment mesenchymal dysgenesis (in some patients) n1=cyclopeptide | n2=en:anterior segment mesenchymal dysgenesis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior segment of eye aplasia n1=cyclopeptide | n2=en:anterior segment of eye aplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior stromal haziness n1=cyclopeptide | n2=en:anterior stromal haziness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior subcapsular cataract n1=cyclopeptide | n2=en:anterior subcapsular cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior uveitis n1=cyclopeptide | n2=en:anterior uveitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anterior uveitis (predominant) n1=cyclopeptide | n2=en:anterior uveitis (predominant) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anteriorly displaced eyes n1=cyclopeptide | n2=en:anteriorly displaced eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anthocyanin-rich corn extract n1=cyclopeptide | n2=en:anthocyanin-rich corn extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anthracycline analogue gpx-150 n1=cyclopeptide | n2=en:anthracycline analogue gpx-150 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti c-kit antibody-drug conjugate lop628 n1=cyclopeptide | n2=en:anti c-kit antibody-drug conjugate lop628 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti glaucoma preparation n1=cyclopeptide | n2=en:anti glaucoma preparation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-5t4 antibody-drug conjugate pf-06263507 n1=cyclopeptide | n2=en:anti-5t4 antibody-drug conjugate pf-06263507 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-a33 monoclonal antibody krn330 n1=cyclopeptide | n2=en:anti-a33 monoclonal antibody krn330 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-a5b1 integrin monoclonal antibody pf-04605412 n1=cyclopeptide | n2=en:anti-a5b1 integrin monoclonal antibody pf-04605412 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ags-16 monoclonal antibody ags-16m18 n1=cyclopeptide | n2=en:anti-ags-16 monoclonal antibody ags-16m18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ags-5 antibody-drug conjugate asg-5me n1=cyclopeptide | n2=en:anti-ags-5 antibody-drug conjugate asg-5me | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ags-8 monoclonal antibody ags-8m4 n1=cyclopeptide | n2=en:anti-ags-8 monoclonal antibody ags-8m4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-alk-1 monoclonal antibody pf-03446962 n1=cyclopeptide | n2=en:anti-alk-1 monoclonal antibody pf-03446962 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-allergic agents n1=cyclopeptide | n2=en:anti-allergic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-alpha5beta1 integrin antibody mint1526a n1=cyclopeptide | n2=en:anti-alpha5beta1 integrin antibody mint1526a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-alphavbeta3 monoclonal antibody emd 525797 n1=cyclopeptide | n2=en:anti-alphavbeta3 monoclonal antibody emd 525797 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-amyloid monoclonal antibody neod001 n1=cyclopeptide | n2=en:anti-amyloid monoclonal antibody neod001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-androgen n1=cyclopeptide | n2=en:anti-androgen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ang2 monoclonal antibody medi-3617 n1=cyclopeptide | n2=en:anti-ang2 monoclonal antibody medi-3617 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-angiopoietin monoclonal antibody amg 780 n1=cyclopeptide | n2=en:anti-angiopoietin monoclonal antibody amg 780 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-b4 blocked ricin immunotoxin n1=cyclopeptide | n2=en:anti-b4 blocked ricin immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-b7-h3 antibody ds-5573a n1=cyclopeptide | n2=en:anti-b7-h3 antibody ds-5573a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-bcma antibody-drug conjugate gsk2857916 n1=cyclopeptide | n2=en:anti-bcma antibody-drug conjugate gsk2857916 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-c-fms monoclonal antibody amg 820 n1=cyclopeptide | n2=en:anti-c-fms monoclonal antibody amg 820 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-c-kit monoclonal antibody ktn0158 n1=cyclopeptide | n2=en:anti-c-kit monoclonal antibody ktn0158 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-c-met monoclonal antibody abt-700 n1=cyclopeptide | n2=en:anti-c-met monoclonal antibody abt-700 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-c-met monoclonal antibody argx-111 n1=cyclopeptide | n2=en:anti-c-met monoclonal antibody argx-111 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-c-met monoclonal antibody ly2875358 n1=cyclopeptide | n2=en:anti-c-met monoclonal antibody ly2875358 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-c-met monoclonal antibody sait301 n1=cyclopeptide | n2=en:anti-c-met monoclonal antibody sait301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-c4.4a antibody-drug conjugate bay1129980 n1=cyclopeptide | n2=en:anti-c4.4a antibody-drug conjugate bay1129980 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ca19-9 monoclonal antibody 5b1 n1=cyclopeptide | n2=en:anti-ca19-9 monoclonal antibody 5b1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ca6-dm4 immunoconjugate sar566658 n1=cyclopeptide | n2=en:anti-ca6-dm4 immunoconjugate sar566658 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd123 monoclonal antibody csl360 n1=cyclopeptide | n2=en:anti-cd123 monoclonal antibody csl360 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd123 monoclonal antibody csl362 n1=cyclopeptide | n2=en:anti-cd123 monoclonal antibody csl362 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd123 monoclonal antibody khk2823 n1=cyclopeptide | n2=en:anti-cd123 monoclonal antibody khk2823 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd123 x anti-cd3 bispecific antibody xmab1404 n1=cyclopeptide | n2=en:anti-cd123 x anti-cd3 bispecific antibody xmab1404 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd123/cd3 bispecific antibody jnj-63709178 n1=cyclopeptide | n2=en:anti-cd123/cd3 bispecific antibody jnj-63709178 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd123/cd3 monoclonal antibody mgd006 n1=cyclopeptide | n2=en:anti-cd123/cd3 monoclonal antibody mgd006 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd133-car vector-transduced allogeneic t lymphocytes n1=cyclopeptide | n2=en:anti-cd133-car vector-transduced allogeneic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd157 monoclonal antibody men1112 n1=cyclopeptide | n2=en:anti-cd157 monoclonal antibody men1112 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19 antibody-drug conjugate sgn-cd19b n1=cyclopeptide | n2=en:anti-cd19 antibody-drug conjugate sgn-cd19b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19 monoclonal antibody di-b4 n1=cyclopeptide | n2=en:anti-cd19 monoclonal antibody di-b4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19 monoclonal antibody mdx-1342 n1=cyclopeptide | n2=en:anti-cd19 monoclonal antibody mdx-1342 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19 monoclonal antibody medi-551 n1=cyclopeptide | n2=en:anti-cd19 monoclonal antibody medi-551 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19 monoclonal antibody xmab5574 n1=cyclopeptide | n2=en:anti-cd19 monoclonal antibody xmab5574 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19-car fmc63-28z retroviral vector-transduced allogeneic t-lymphocytes n1=cyclopeptide | n2=en:anti-cd19-car fmc63-28z retroviral vector-transduced allogeneic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19-car retroviral vector-transduced autologous t cells n1=cyclopeptide | n2=en:anti-cd19-car retroviral vector-transduced autologous t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19-car-cd3zeta-4-1bb-expressing allogenic natural killer cells n1=cyclopeptide | n2=en:anti-cd19-car-cd3zeta-4-1bb-expressing allogenic natural killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19-dm4 immunoconjugate sar3419 n1=cyclopeptide | n2=en:anti-cd19-dm4 immunoconjugate sar3419 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19/anti-cd22 bispecific immunotoxin dt2219arl n1=cyclopeptide | n2=en:anti-cd19/anti-cd22 bispecific immunotoxin dt2219arl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19/cd28/cd3zeta car gammaretroviral vector-transduced autologous t lymphocytes kte-c19 n1=cyclopeptide | n2=en:anti-cd19/cd28/cd3zeta car gammaretroviral vector-transduced autologous t lymphocytes kte-c19 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd19/cd3 tetravalent antibody afm11 n1=cyclopeptide | n2=en:anti-cd19/cd3 tetravalent antibody afm11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd20 b9e9 scfv-streptavidin fusion protein n1=cyclopeptide | n2=en:anti-cd20 b9e9 scfv-streptavidin fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd20 monoclonal antibody pro131921 n1=cyclopeptide | n2=en:anti-cd20 monoclonal antibody pro131921 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd20 monoclonal antibody sct400 n1=cyclopeptide | n2=en:anti-cd20 monoclonal antibody sct400 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd20 monoclonal antibody tl011 n1=cyclopeptide | n2=en:anti-cd20 monoclonal antibody tl011 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd20 monoclonal antibody-interferon-alpha fusion protein ign002 n1=cyclopeptide | n2=en:anti-cd20 monoclonal antibody-interferon-alpha fusion protein ign002 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd20-car-cd3zeta-4-1bb-expressing autologous t-lymphocyte cells n1=cyclopeptide | n2=en:anti-cd20-car-cd3zeta-4-1bb-expressing autologous t-lymphocyte cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd20-engineered toxin body mt-3724 n1=cyclopeptide | n2=en:anti-cd20-engineered toxin body mt-3724 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd20/cd3 monoclonal antibody regn1979 n1=cyclopeptide | n2=en:anti-cd20/cd3 monoclonal antibody regn1979 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd200 monoclonal antibody alxn6000 n1=cyclopeptide | n2=en:anti-cd200 monoclonal antibody alxn6000 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd22 car-expressing t lymphocytes n1=cyclopeptide | n2=en:anti-cd22 car-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd22 monoclonal antibody-mmae conjugate dcdt2980s n1=cyclopeptide | n2=en:anti-cd22 monoclonal antibody-mmae conjugate dcdt2980s | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd22 scfv tcrz:41bb-car lentiviral vector-transduced autologous t-lymphocytes n1=cyclopeptide | n2=en:anti-cd22 scfv tcrz:41bb-car lentiviral vector-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd22-car m971-bbz lentiviral vector-transduced autologous t lymphocytes n1=cyclopeptide | n2=en:anti-cd22-car m971-bbz lentiviral vector-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd25-pbd antibody-drug conjugate adct-301 n1=cyclopeptide | n2=en:anti-cd25-pbd antibody-drug conjugate adct-301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd27l antibody-drug conjugate amg 172 n1=cyclopeptide | n2=en:anti-cd27l antibody-drug conjugate amg 172 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1) n1=cyclopeptide | n2=en:anti-cd3 immunotoxin a-dmdt390-bisfv(ucht1) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd3 okt3/humanized anti-gd2 3f8 bispecific antibody-activated t lymphocytes n1=cyclopeptide | n2=en:anti-cd3 okt3/humanized anti-gd2 3f8 bispecific antibody-activated t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd3 x anti-cd20 bispecific antibody-armed activated t cells n1=cyclopeptide | n2=en:anti-cd3 x anti-cd20 bispecific antibody-armed activated t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd3/anti-cd20 trifunctional bispecific monoclonal antibody fbta05 n1=cyclopeptide | n2=en:anti-cd3/anti-cd20 trifunctional bispecific monoclonal antibody fbta05 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd3/anti-egfr-bispecific monoclonal antibody-armed activated autologous t-lymphocytes n1=cyclopeptide | n2=en:anti-cd3/anti-egfr-bispecific monoclonal antibody-armed activated autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd30 monoclonal antibody mdx-1401 n1=cyclopeptide | n2=en:anti-cd30 monoclonal antibody mdx-1401 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd30 monoclonal antibody xmab2513 n1=cyclopeptide | n2=en:anti-cd30 monoclonal antibody xmab2513 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd30/cd16a monoclonal antibody afm13 n1=cyclopeptide | n2=en:anti-cd30/cd16a monoclonal antibody afm13 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd33 antibody-drug conjugate imgn779 n1=cyclopeptide | n2=en:anti-cd33 antibody-drug conjugate imgn779 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd33 monoclonal antibody bi 836858 n1=cyclopeptide | n2=en:anti-cd33 monoclonal antibody bi 836858 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd33 monoclonal antibody-dm4 conjugate ave9633 n1=cyclopeptide | n2=en:anti-cd33 monoclonal antibody-dm4 conjugate ave9633 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd33/cd3 bite antibody amg 330 n1=cyclopeptide | n2=en:anti-cd33/cd3 bite antibody amg 330 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd37 antibody-drug conjugate imgn529 n1=cyclopeptide | n2=en:anti-cd37 antibody-drug conjugate imgn529 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd37 mmae antibody-drug conjugate ags67e n1=cyclopeptide | n2=en:anti-cd37 mmae antibody-drug conjugate ags67e | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd37 monoclonal antibody bi 836826 n1=cyclopeptide | n2=en:anti-cd37 monoclonal antibody bi 836826 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd38 monoclonal antibody mor03087 n1=cyclopeptide | n2=en:anti-cd38 monoclonal antibody mor03087 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd38 monoclonal antibody sar650984 n1=cyclopeptide | n2=en:anti-cd38 monoclonal antibody sar650984 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd40 monoclonal antibody chi lob 7/4 n1=cyclopeptide | n2=en:anti-cd40 monoclonal antibody chi lob 7/4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd40 monoclonal antibody sea-cd40 n1=cyclopeptide | n2=en:anti-cd40 monoclonal antibody sea-cd40 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd40l fc-fusion protein bms-986004 n1=cyclopeptide | n2=en:anti-cd40l fc-fusion protein bms-986004 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd44 monoclonal antibody ro5429083 n1=cyclopeptide | n2=en:anti-cd44 monoclonal antibody ro5429083 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd45 bc8 monoclonal antibody-streptavidin conjugate n1=cyclopeptide | n2=en:anti-cd45 bc8 monoclonal antibody-streptavidin conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd45 monoclonal antibody n1=cyclopeptide | n2=en:anti-cd45 monoclonal antibody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd45 monoclonal antibody ahn-12 n1=cyclopeptide | n2=en:anti-cd45 monoclonal antibody ahn-12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd45 monoclonal antibody bc8 n1=cyclopeptide | n2=en:anti-cd45 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd47 monoclonal antibody cc-90002 n1=cyclopeptide | n2=en:anti-cd47 monoclonal antibody cc-90002 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd47 monoclonal antibody hu5f9-g4 n1=cyclopeptide | n2=en:anti-cd47 monoclonal antibody hu5f9-g4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd7 immunotoxin n1=cyclopeptide | n2=en:anti-cd7 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd70 antibody-drug conjugate mdx-1203 n1=cyclopeptide | n2=en:anti-cd70 antibody-drug conjugate mdx-1203 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd70 antibody-drug conjugate sgn-cd70a n1=cyclopeptide | n2=en:anti-cd70 antibody-drug conjugate sgn-cd70a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd70 monoclonal antibody argx-110 n1=cyclopeptide | n2=en:anti-cd70 monoclonal antibody argx-110 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd70 monoclonal antibody mdx-1411 n1=cyclopeptide | n2=en:anti-cd70 monoclonal antibody mdx-1411 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd73 monoclonal antibody medi9447 n1=cyclopeptide | n2=en:anti-cd73 monoclonal antibody medi9447 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd98 monoclonal antibody ign523 n1=cyclopeptide | n2=en:anti-cd98 monoclonal antibody ign523 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cd98 monoclonal antibody khk2898 n1=cyclopeptide | n2=en:anti-cd98 monoclonal antibody khk2898 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cea bite monoclonal antibody amg211 n1=cyclopeptide | n2=en:anti-cea bite monoclonal antibody amg211 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cea igcd28tcr-transduced autologous t cells n1=cyclopeptide | n2=en:anti-cea igcd28tcr-transduced autologous t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cea tcr retroviral vector-transduced autologous peripheral blood lymphocytes n1=cyclopeptide | n2=en:anti-cea tcr retroviral vector-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cea-car autologous t lymphocytes n1=cyclopeptide | n2=en:anti-cea-car autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cea/anti-dtpa-in (f6-734) bispecific antibody n1=cyclopeptide | n2=en:anti-cea/anti-dtpa-in (f6-734) bispecific antibody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cea/anti-hsg bispecific monoclonal antibody tf2 n1=cyclopeptide | n2=en:anti-cea/anti-hsg bispecific monoclonal antibody tf2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cea/cd3 bispecific antibody ro6958688 n1=cyclopeptide | n2=en:anti-cea/cd3 bispecific antibody ro6958688 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ceacam1 monoclonal antibody cm-24 n1=cyclopeptide | n2=en:anti-ceacam1 monoclonal antibody cm-24 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ceacam5 antibody-drug conjugate sar408701 n1=cyclopeptide | n2=en:anti-ceacam5 antibody-drug conjugate sar408701 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ceacam6 afaikl2 antibody fragment/jack bean urease immunoconjugate l-dos47 n1=cyclopeptide | n2=en:anti-ceacam6 afaikl2 antibody fragment/jack bean urease immunoconjugate l-dos47 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-cldn6 monoclonal antibody imab027 n1=cyclopeptide | n2=en:anti-cldn6 monoclonal antibody imab027 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-csf1r monoclonal antibody fpa008 n1=cyclopeptide | n2=en:anti-csf1r monoclonal antibody fpa008 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-csf1r monoclonal antibody imc-cs4 n1=cyclopeptide | n2=en:anti-csf1r monoclonal antibody imc-cs4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ctgf monoclonal antibody fg-3019 n1=cyclopeptide | n2=en:anti-ctgf monoclonal antibody fg-3019 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ctla-4 mab rna-transfected autologous dendritic cell vaccine n1=cyclopeptide | n2=en:anti-ctla-4 mab rna-transfected autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ctla-4 monoclonal antibody agen1884 n1=cyclopeptide | n2=en:anti-ctla-4 monoclonal antibody agen1884 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ctla4 moab rna/gitrl rna-transfected autologous dendritic cell vaccine n1=cyclopeptide | n2=en:anti-ctla4 moab rna/gitrl rna-transfected autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-denatured collagen monoclonal antibody trc093 n1=cyclopeptide | n2=en:anti-denatured collagen monoclonal antibody trc093 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-diabetic agent n1=cyclopeptide | n2=en:anti-diabetic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-dkk-1 monoclonal antibody ly2812176 n1=cyclopeptide | n2=en:anti-dkk-1 monoclonal antibody ly2812176 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-dkk1 monoclonal antibody bhq880 n1=cyclopeptide | n2=en:anti-dkk1 monoclonal antibody bhq880 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-dll4 monoclonal antibody medi0639 n1=cyclopeptide | n2=en:anti-dll4 monoclonal antibody medi0639 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-dll4 monoclonal antibody regn421 n1=cyclopeptide | n2=en:anti-dll4 monoclonal antibody regn421 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-dll4/vegf bispecific monoclonal antibody omp-305b83 n1=cyclopeptide | n2=en:anti-dll4/vegf bispecific monoclonal antibody omp-305b83 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-dr5 agonist monoclonal antibody tra-8 n1=cyclopeptide | n2=en:anti-dr5 agonist monoclonal antibody tra-8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-dr5 agonistic antibody ds-8273a n1=cyclopeptide | n2=en:anti-dr5 agonistic antibody ds-8273a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr monoclonal antibody gc1118 n1=cyclopeptide | n2=en:anti-egfr monoclonal antibody gc1118 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr monoclonal antibody gt-mab 5.2-gex n1=cyclopeptide | n2=en:anti-egfr monoclonal antibody gt-mab 5.2-gex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr monoclonal antibody mixture mm-151 n1=cyclopeptide | n2=en:anti-egfr monoclonal antibody mixture mm-151 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr monoclonal antibody mixture sym004 n1=cyclopeptide | n2=en:anti-egfr monoclonal antibody mixture sym004 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr monoclonal antibody ro5083945 n1=cyclopeptide | n2=en:anti-egfr monoclonal antibody ro5083945 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr monoclonal antibody sct200 n1=cyclopeptide | n2=en:anti-egfr monoclonal antibody sct200 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr monoclonal antibody syn004 n1=cyclopeptide | n2=en:anti-egfr monoclonal antibody syn004 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr tap antibody-drug conjugate imgn289 n1=cyclopeptide | n2=en:anti-egfr tap antibody-drug conjugate imgn289 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfr/c-met bispecific antibody jnj-61186372 n1=cyclopeptide | n2=en:anti-egfr/c-met bispecific antibody jnj-61186372 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfrviii antibody drug conjugate amg 595 n1=cyclopeptide | n2=en:anti-egfrviii antibody drug conjugate amg 595 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfrviii car-transduced allogeneic t-lymphocytes n1=cyclopeptide | n2=en:anti-egfrviii car-transduced allogeneic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egfrviii immunotoxin mr1-1 n1=cyclopeptide | n2=en:anti-egfrviii immunotoxin mr1-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-egp-2 immunotoxin moc31-pe n1=cyclopeptide | n2=en:anti-egp-2 immunotoxin moc31-pe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-endoglin chimeric monoclonal antibody trc105 n1=cyclopeptide | n2=en:anti-endoglin chimeric monoclonal antibody trc105 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-endosialin monoclonal antibody morab-004 n1=cyclopeptide | n2=en:anti-endosialin monoclonal antibody morab-004 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-enpp3 antibody-drug conjugate ags-16c3f n1=cyclopeptide | n2=en:anti-enpp3 antibody-drug conjugate ags-16c3f | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-enpp3/mmaf antibody-drug conjugate ags-16m8f n1=cyclopeptide | n2=en:anti-enpp3/mmaf antibody-drug conjugate ags-16m8f | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-epcam antibody fragment-pseudomonas-exotoxin fusion protein n1=cyclopeptide | n2=en:anti-epcam antibody fragment-pseudomonas-exotoxin fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-epha2 monoclonal antibody ds-8895a n1=cyclopeptide | n2=en:anti-epha2 monoclonal antibody ds-8895a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-epha2 monoclonal antibody-mmaf immunoconjugate medi-547 n1=cyclopeptide | n2=en:anti-epha2 monoclonal antibody-mmaf immunoconjugate medi-547 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-epha3 monoclonal antibody kb004 n1=cyclopeptide | n2=en:anti-epha3 monoclonal antibody kb004 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-epidermal growth factor receptor 2 antibody expressing pluripotent killer t-lymphocytes n1=cyclopeptide | n2=en:anti-epidermal growth factor receptor 2 antibody expressing pluripotent killer t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-erbb2/anti-erbb3 bispecific monoclonal antibody mm-111 n1=cyclopeptide | n2=en:anti-erbb2/anti-erbb3 bispecific monoclonal antibody mm-111 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-erbb3 monoclonal antibody av-203 n1=cyclopeptide | n2=en:anti-erbb3 monoclonal antibody av-203 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-erbb3 monoclonal antibody ktn3379 n1=cyclopeptide | n2=en:anti-erbb3 monoclonal antibody ktn3379 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-erbb3 monoclonal antibody regn1400 n1=cyclopeptide | n2=en:anti-erbb3 monoclonal antibody regn1400 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-erbb3/anti-igf-1r bispecific monoclonal antibody mm-141 n1=cyclopeptide | n2=en:anti-erbb3/anti-igf-1r bispecific monoclonal antibody mm-141 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-etbr/mmae antibody-drug conjugate dedn6526a n1=cyclopeptide | n2=en:anti-etbr/mmae antibody-drug conjugate dedn6526a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fgf23 igg1 monoclonal antibody krn23 n1=cyclopeptide | n2=en:anti-fgf23 igg1 monoclonal antibody krn23 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fgfr2 antibody bay1179470 n1=cyclopeptide | n2=en:anti-fgfr2 antibody bay1179470 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fgfr2 antibody-drug conjugate bay1187982 n1=cyclopeptide | n2=en:anti-fgfr2 antibody-drug conjugate bay1187982 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fgfr2 monoclonal antibody fpa144 n1=cyclopeptide | n2=en:anti-fgfr2 monoclonal antibody fpa144 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fgfr3 antibody-drug conjugate ly3076226 n1=cyclopeptide | n2=en:anti-fgfr3 antibody-drug conjugate ly3076226 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fgfr3 monoclonal antibody b-701 n1=cyclopeptide | n2=en:anti-fgfr3 monoclonal antibody b-701 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fgfr3 monoclonal antibody mfgr1877s n1=cyclopeptide | n2=en:anti-fgfr3 monoclonal antibody mfgr1877s | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fgfr4 monoclonal antibody u3-1784 n1=cyclopeptide | n2=en:anti-fgfr4 monoclonal antibody u3-1784 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-flt3 monoclonal antibody imc-eb10 n1=cyclopeptide | n2=en:anti-flt3 monoclonal antibody imc-eb10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-fucosyl-gm1 monoclonal antibody bms-986012 n1=cyclopeptide | n2=en:anti-fucosyl-gm1 monoclonal antibody bms-986012 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ganglioside gm2 monoclonal antibody biw-8962 n1=cyclopeptide | n2=en:anti-ganglioside gm2 monoclonal antibody biw-8962 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gcc antibody-drug conjugate mln0264 n1=cyclopeptide | n2=en:anti-gcc antibody-drug conjugate mln0264 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gd2 monoclonal antibody hu14.18k322a n1=cyclopeptide | n2=en:anti-gd2 monoclonal antibody hu14.18k322a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gd2 monoclonal antibody morab-028 n1=cyclopeptide | n2=en:anti-gd2 monoclonal antibody morab-028 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gitr agonistic monoclonal antibody incagn01876 n1=cyclopeptide | n2=en:anti-gitr agonistic monoclonal antibody incagn01876 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gitr monoclonal antibody gwn 323 n1=cyclopeptide | n2=en:anti-gitr monoclonal antibody gwn 323 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gitr monoclonal antibody mk-4166 n1=cyclopeptide | n2=en:anti-gitr monoclonal antibody mk-4166 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gnrh vaccine pep223 n1=cyclopeptide | n2=en:anti-gnrh vaccine pep223 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gpa33/cd3 monoclonal antibody mgd007 n1=cyclopeptide | n2=en:anti-gpa33/cd3 monoclonal antibody mgd007 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gpc3 monoclonal antibody gc33 n1=cyclopeptide | n2=en:anti-gpc3 monoclonal antibody gc33 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-gpc3-car autologous t lymphocytes n1=cyclopeptide | n2=en:anti-gpc3-car autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-grp78 monoclonal antibody pat-sm6 n1=cyclopeptide | n2=en:anti-grp78 monoclonal antibody pat-sm6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-hb-egf monoclonal antibody khk2866 n1=cyclopeptide | n2=en:anti-hb-egf monoclonal antibody khk2866 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-hbegf monoclonal antibody u3-1565 n1=cyclopeptide | n2=en:anti-hbegf monoclonal antibody u3-1565 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-hcv e2 monoclonal antibody mbl-hcv1 n1=cyclopeptide | n2=en:anti-hcv e2 monoclonal antibody mbl-hcv1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-hepcidin monoclonal antibody ly2787106 n1=cyclopeptide | n2=en:anti-hepcidin monoclonal antibody ly2787106 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-her-2-car retroviral vector-transduced autologous peripheral blood lymphocytes n1=cyclopeptide | n2=en:anti-her-2-car retroviral vector-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-her2 antibody-drug conjugate arx788 n1=cyclopeptide | n2=en:anti-her2 antibody-drug conjugate arx788 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-her2 antibody-drug conjugate medi4276 n1=cyclopeptide | n2=en:anti-her2 antibody-drug conjugate medi4276 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-her2 monoclonal antibody ct-p6 n1=cyclopeptide | n2=en:anti-her2 monoclonal antibody ct-p6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-her2-car autologous cmv-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:anti-her2-car autologous cmv-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-her3 monoclonal antibody gsk2849330 n1=cyclopeptide | n2=en:anti-her3 monoclonal antibody gsk2849330 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-her3 monoclonal antibody ljm716 n1=cyclopeptide | n2=en:anti-her3 monoclonal antibody ljm716 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-hgf monoclonal antibody tak-701 n1=cyclopeptide | n2=en:anti-hgf monoclonal antibody tak-701 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-hif-1alpha lna antisense oligonucleotide ezn-2968 n1=cyclopeptide | n2=en:anti-hif-1alpha lna antisense oligonucleotide ezn-2968 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-hla-a2/ny-eso-1 tcr-transduced autologous t lymphocytes n1=cyclopeptide | n2=en:anti-hla-a2/ny-eso-1 tcr-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-hla-dr monoclonal antibody immu-114 n1=cyclopeptide | n2=en:anti-hla-dr monoclonal antibody immu-114 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-human chorionic gonadotropin vaccine n1=cyclopeptide | n2=en:anti-human chorionic gonadotropin vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-human gitr monoclonal antibody trx518 n1=cyclopeptide | n2=en:anti-human gitr monoclonal antibody trx518 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-icam-1 monoclonal antibody bi-505 n1=cyclopeptide | n2=en:anti-icam-1 monoclonal antibody bi-505 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-icos agonist antibody gsk3359609 n1=cyclopeptide | n2=en:anti-icos agonist antibody gsk3359609 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-icos monoclonal antibody medi-570 n1=cyclopeptide | n2=en:anti-icos monoclonal antibody medi-570 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-idiotypic monoclonal antibody bec2 n1=cyclopeptide | n2=en:anti-idiotypic monoclonal antibody bec2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-igf-1r monoclonal antibody ave1642 n1=cyclopeptide | n2=en:anti-igf-1r monoclonal antibody ave1642 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-igf-1r recombinant monoclonal antibody biib022 n1=cyclopeptide | n2=en:anti-igf-1r recombinant monoclonal antibody biib022 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-igf1/2 monoclonal antibody medi-573 n1=cyclopeptide | n2=en:anti-igf1/2 monoclonal antibody medi-573 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-il-1 alpha monoclonal antibody ca-18c3 n1=cyclopeptide | n2=en:anti-il-1 alpha monoclonal antibody ca-18c3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-il-1 alpha monoclonal antibody mabp1 n1=cyclopeptide | n2=en:anti-il-1 alpha monoclonal antibody mabp1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-il-13 humanized monoclonal antibody tnx-650 n1=cyclopeptide | n2=en:anti-il-13 humanized monoclonal antibody tnx-650 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-il-15 monoclonal antibody amg 714 n1=cyclopeptide | n2=en:anti-il-15 monoclonal antibody amg 714 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-il-4/il-13 combination agent qbx258 n1=cyclopeptide | n2=en:anti-il-4/il-13 combination agent qbx258 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-il-8 monoclonal antibody humax-il8 n1=cyclopeptide | n2=en:anti-il-8 monoclonal antibody humax-il8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-infective agent n1=cyclopeptide | n2=en:anti-infective agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-inflammatory agents n1=cyclopeptide | n2=en:anti-inflammatory agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-inflammatory antibody alxn1007 n1=cyclopeptide | n2=en:anti-inflammatory antibody alxn1007 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-inhibitor coagulant complex feiba nf n1=cyclopeptide | n2=en:anti-inhibitor coagulant complex feiba nf | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-integrin monoclonal antibody-dm4 immunoconjugate imgn388 n1=cyclopeptide | n2=en:anti-integrin monoclonal antibody-dm4 immunoconjugate imgn388 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-interferon gamma monoclonal antibody ni-0501 n1=cyclopeptide | n2=en:anti-interferon gamma monoclonal antibody ni-0501 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-interleukin 6 monoclonal antibody ald518 n1=cyclopeptide | n2=en:anti-interleukin 6 monoclonal antibody ald518 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-kir monoclonal antibody iph 2101 n1=cyclopeptide | n2=en:anti-kir monoclonal antibody iph 2101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-kir3dl2 monoclonal antibody iph4102 n1=cyclopeptide | n2=en:anti-kir3dl2 monoclonal antibody iph4102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ksp/anti-vegf sirnas aln-vsp02 n1=cyclopeptide | n2=en:anti-ksp/anti-vegf sirnas aln-vsp02 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-lag-3 monoclonal antibody bms-986016 n1=cyclopeptide | n2=en:anti-lag-3 monoclonal antibody bms-986016 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-lag-3 monoclonal antibody lag525 n1=cyclopeptide | n2=en:anti-lag-3 monoclonal antibody lag525 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-lamp1 antibody-drug conjugate sar428926 n1=cyclopeptide | n2=en:anti-lamp1 antibody-drug conjugate sar428926 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-lgr5 monoclonal antibody bnc101 n1=cyclopeptide | n2=en:anti-lgr5 monoclonal antibody bnc101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-liv-1 monoclonal antibody-mmae conjugate sgn-liv1a n1=cyclopeptide | n2=en:anti-liv-1 monoclonal antibody-mmae conjugate sgn-liv1a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ly6e antibody-drug conjugate dlye5953a n1=cyclopeptide | n2=en:anti-ly6e antibody-drug conjugate dlye5953a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-m-csf monoclonal antibody mcs110 n1=cyclopeptide | n2=en:anti-m-csf monoclonal antibody mcs110 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-masp-2 monoclonal antibody oms721 n1=cyclopeptide | n2=en:anti-masp-2 monoclonal antibody oms721 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-melanin monoclonal antibody pti-6d2 n1=cyclopeptide | n2=en:anti-melanin monoclonal antibody pti-6d2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-mesothelin antibody-drug conjugate bms-986148 n1=cyclopeptide | n2=en:anti-mesothelin antibody-drug conjugate bms-986148 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-mesothelin car vector-transduced autologous t-lymphocytes n1=cyclopeptide | n2=en:anti-mesothelin car vector-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-mesothelin cir mrna-electroporated autologous t cells n1=cyclopeptide | n2=en:anti-mesothelin cir mrna-electroporated autologous t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-mesothelin icasp9m28z car-transduced autologous t lymphocytes n1=cyclopeptide | n2=en:anti-mesothelin icasp9m28z car-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein lmb-100 n1=cyclopeptide | n2=en:anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein lmb-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-mesothelin/mmae antibody-drug conjugate dmot4039a n1=cyclopeptide | n2=en:anti-mesothelin/mmae antibody-drug conjugate dmot4039a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-met monoclonal antibody mixture sym015 n1=cyclopeptide | n2=en:anti-met monoclonal antibody mixture sym015 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-met/egfr monoclonal antibody ly3164530 n1=cyclopeptide | n2=en:anti-met/egfr monoclonal antibody ly3164530 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-mmp-9 monoclonal antibody gs-5745 n1=cyclopeptide | n2=en:anti-mmp-9 monoclonal antibody gs-5745 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-muc1 car-transduced autologous t-lymphocytes n1=cyclopeptide | n2=en:anti-muc1 car-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-muc1 monoclonal antibody bth1704 n1=cyclopeptide | n2=en:anti-muc1 monoclonal antibody bth1704 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-myeloma monoclonal antibody-dm4 immunoconjugate bt-062 n1=cyclopeptide | n2=en:anti-myeloma monoclonal antibody-dm4 immunoconjugate bt-062 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-myostatin monoclonal antibody ly2495655 n1=cyclopeptide | n2=en:anti-myostatin monoclonal antibody ly2495655 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-napi2b/mmae antibody-drug conjugate dnib0600a n1=cyclopeptide | n2=en:anti-napi2b/mmae antibody-drug conjugate dnib0600a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-nectin 4 antibody-drug conjugate asg-22ce n1=cyclopeptide | n2=en:anti-nectin 4 antibody-drug conjugate asg-22ce | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-nectin-4 monoclonal antibody-drug conjugate ags-22m6e n1=cyclopeptide | n2=en:anti-nectin-4 monoclonal antibody-drug conjugate ags-22m6e | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-neuropilin-1 monoclonal antibody mnrp1685a n1=cyclopeptide | n2=en:anti-neuropilin-1 monoclonal antibody mnrp1685a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-nf-p2x7 antibody ointment bil-010t n1=cyclopeptide | n2=en:anti-nf-p2x7 antibody ointment bil-010t | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-nucleolin aptamer as1411 n1=cyclopeptide | n2=en:anti-nucleolin aptamer as1411 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ny-eso-1 immunotherapeutic gsk-2241658a n1=cyclopeptide | n2=en:anti-ny-eso-1 immunotherapeutic gsk-2241658a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ny-eso1 tcr-transduced autologous cd62l+-derived t-lymphocytes n1=cyclopeptide | n2=en:anti-ny-eso1 tcr-transduced autologous cd62l+-derived t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ofa immunotherapeutic bb-mpi-03 n1=cyclopeptide | n2=en:anti-ofa immunotherapeutic bb-mpi-03 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ox40 antibody bms 986178 n1=cyclopeptide | n2=en:anti-ox40 antibody bms 986178 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ox40 antibody pf-04518600 n1=cyclopeptide | n2=en:anti-ox40 antibody pf-04518600 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ox40 monoclonal antibody n1=cyclopeptide | n2=en:anti-ox40 monoclonal antibody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ox40 monoclonal antibody gsk3174998 n1=cyclopeptide | n2=en:anti-ox40 monoclonal antibody gsk3174998 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ox40 monoclonal antibody medi0562 n1=cyclopeptide | n2=en:anti-ox40 monoclonal antibody medi0562 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ox40 monoclonal antibody moxr0916 n1=cyclopeptide | n2=en:anti-ox40 monoclonal antibody moxr0916 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-p53 t-cell receptor-transduced peripheral blood lymphocytes n1=cyclopeptide | n2=en:anti-p53 t-cell receptor-transduced peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-1 checkpoint inhibitor pf-06801591 n1=cyclopeptide | n2=en:anti-pd-1 checkpoint inhibitor pf-06801591 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-1 fusion protein amp-224 n1=cyclopeptide | n2=en:anti-pd-1 fusion protein amp-224 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-1 monoclonal antibody bgb-a317 n1=cyclopeptide | n2=en:anti-pd-1 monoclonal antibody bgb-a317 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-1 monoclonal antibody medi0680 n1=cyclopeptide | n2=en:anti-pd-1 monoclonal antibody medi0680 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-1 monoclonal antibody pdr001 n1=cyclopeptide | n2=en:anti-pd-1 monoclonal antibody pdr001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-1 monoclonal antibody regn2810 n1=cyclopeptide | n2=en:anti-pd-1 monoclonal antibody regn2810 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-1 monoclonal antibody shr-1210 n1=cyclopeptide | n2=en:anti-pd-1 monoclonal antibody shr-1210 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-1 monoclonal antibody tsr-042 n1=cyclopeptide | n2=en:anti-pd-1 monoclonal antibody tsr-042 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-l1 monoclonal antibody ly3300054 n1=cyclopeptide | n2=en:anti-pd-l1 monoclonal antibody ly3300054 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-l1 monoclonal antibody mdx-1105 n1=cyclopeptide | n2=en:anti-pd-l1 monoclonal antibody mdx-1105 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pd-l1/tgfbetarii fusion protein msb0011359c n1=cyclopeptide | n2=en:anti-pd-l1/tgfbetarii fusion protein msb0011359c | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pdgfr alpha monoclonal antibody medi-575 n1=cyclopeptide | n2=en:anti-pdgfr alpha monoclonal antibody medi-575 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pgf monoclonal antibody ro5323441 n1=cyclopeptide | n2=en:anti-pgf monoclonal antibody ro5323441 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pkn3 sirna atu027 n1=cyclopeptide | n2=en:anti-pkn3 sirna atu027 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-plgf monoclonal antibody tb-403 n1=cyclopeptide | n2=en:anti-plgf monoclonal antibody tb-403 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-pr1/hla-a2 monoclonal antibody hu8f4 n1=cyclopeptide | n2=en:anti-pr1/hla-a2 monoclonal antibody hu8f4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-prame immunotherapeutic gsk2302032a n1=cyclopeptide | n2=en:anti-prame immunotherapeutic gsk2302032a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-programmed cell death protein 1 antibody expressing pluripotent killer t-lymphocytes n1=cyclopeptide | n2=en:anti-programmed cell death protein 1 antibody expressing pluripotent killer t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-prolactin receptor antibody lfa102 n1=cyclopeptide | n2=en:anti-prolactin receptor antibody lfa102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-psca fully human monoclonal antibody ags-1c4d4 n1=cyclopeptide | n2=en:anti-psca fully human monoclonal antibody ags-1c4d4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-psma monoclonal antibody mdx1201-a488 n1=cyclopeptide | n2=en:anti-psma monoclonal antibody mdx1201-a488 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-psma monoclonal antibody-mmae conjugate n1=cyclopeptide | n2=en:anti-psma monoclonal antibody-mmae conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-psma/cd3 bite monoclonal antibody mt112 n1=cyclopeptide | n2=en:anti-psma/cd3 bite monoclonal antibody mt112 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-psma/cd3 monoclonal antibody mor209/es414 n1=cyclopeptide | n2=en:anti-psma/cd3 monoclonal antibody mor209/es414 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-rspo3 monoclonal antibody omp-131r10 n1=cyclopeptide | n2=en:anti-rspo3 monoclonal antibody omp-131r10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-sclu monoclonal antibody ab-16b5 n1=cyclopeptide | n2=en:anti-sclu monoclonal antibody ab-16b5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-sema4d monoclonal antibody vx15/2503 n1=cyclopeptide | n2=en:anti-sema4d monoclonal antibody vx15/2503 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-slitrk6 monoclonal antibody-mmae conjugate ags15e n1=cyclopeptide | n2=en:anti-slitrk6 monoclonal antibody-mmae conjugate ags15e | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-ta-muc1 monoclonal antibody pankomab n1=cyclopeptide | n2=en:anti-ta-muc1 monoclonal antibody pankomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-tf monoclonal antibody alt-836 n1=cyclopeptide | n2=en:anti-tf monoclonal antibody alt-836 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-tf monoclonal antibody-mmae conjugate n1=cyclopeptide | n2=en:anti-tf monoclonal antibody-mmae conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-tgf-beta rii monoclonal antibody imc-tr1 n1=cyclopeptide | n2=en:anti-tgf-beta rii monoclonal antibody imc-tr1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-thymocyte globulin n1=cyclopeptide | n2=en:anti-thymocyte globulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-thymocyte globulin/busulfan/cyclophosphamide/methylprednisolone n1=cyclopeptide | n2=en:anti-thymocyte globulin/busulfan/cyclophosphamide/methylprednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-thymocyte globulin/cyclophosphamide n1=cyclopeptide | n2=en:anti-thymocyte globulin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-thymocyte globulin/cyclophosphamide/cytarabine n1=cyclopeptide | n2=en:anti-thymocyte globulin/cyclophosphamide/cytarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-thymocyte globulin/cyclophosphamide/fludarabine n1=cyclopeptide | n2=en:anti-thymocyte globulin/cyclophosphamide/fludarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-thymocyte globulin/cyclophosphamide/fludarabine/methylprednisolone n1=cyclopeptide | n2=en:anti-thymocyte globulin/cyclophosphamide/fludarabine/methylprednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-thymocyte globulin/cyclophosphamide/methylprednisolone n1=cyclopeptide | n2=en:anti-thymocyte globulin/cyclophosphamide/methylprednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-thyroglobulin mtcr-transduced autologous peripheral blood lymphocytes n1=cyclopeptide | n2=en:anti-thyroglobulin mtcr-transduced autologous peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-tim-3 monoclonal antibody mbg453 n1=cyclopeptide | n2=en:anti-tim-3 monoclonal antibody mbg453 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-tissue factor monoclonal antibody morab-066 n1=cyclopeptide | n2=en:anti-tissue factor monoclonal antibody morab-066 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-tlr2 monoclonal antibody opn-305 n1=cyclopeptide | n2=en:anti-tlr2 monoclonal antibody opn-305 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-transthyretin sirna aln-ttr02 n1=cyclopeptide | n2=en:anti-transthyretin sirna aln-ttr02 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-tumor necrosis factor alpha drug n1=cyclopeptide | n2=en:anti-tumor necrosis factor alpha drug | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-tweak monoclonal antibody ro5458640 n1=cyclopeptide | n2=en:anti-tweak monoclonal antibody ro5458640 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-vegf anticalin prs-050-peg40 n1=cyclopeptide | n2=en:anti-vegf anticalin prs-050-peg40 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-vegf/ang2 nanobody bi 836880 n1=cyclopeptide | n2=en:anti-vegf/ang2 nanobody bi 836880 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-vegfc monoclonal antibody vgx-100 n1=cyclopeptide | n2=en:anti-vegfc monoclonal antibody vgx-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-vegfr2-car retroviral vector-transduced autologous t-lymphocytes n1=cyclopeptide | n2=en:anti-vegfr2-car retroviral vector-transduced autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-vegfr3 monoclonal antibody imc-3c5 n1=cyclopeptide | n2=en:anti-vegfr3 monoclonal antibody imc-3c5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-vista monoclonal antibody jnj 61610588 n1=cyclopeptide | n2=en:anti-vista monoclonal antibody jnj 61610588 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anti-von willebrand factor nanobody n1=cyclopeptide | n2=en:anti-von willebrand factor nanobody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antiangiogenic drug combination tl-118 n1=cyclopeptide | n2=en:antiangiogenic drug combination tl-118 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antiarrhythmic agent n1=cyclopeptide | n2=en:antiarrhythmic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antiarthritic agent n1=cyclopeptide | n2=en:antiarthritic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibiotic n1=cyclopeptide | n2=en:antibiotic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibiotic sq109 n1=cyclopeptide | n2=en:antibiotic sq109 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate abbv-085 n1=cyclopeptide | n2=en:antibody-drug conjugate abbv-085 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate abbv-399 n1=cyclopeptide | n2=en:antibody-drug conjugate abbv-399 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate abbv-838 n1=cyclopeptide | n2=en:antibody-drug conjugate abbv-838 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate adct-402 n1=cyclopeptide | n2=en:antibody-drug conjugate adct-402 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate bay79-4620 n1=cyclopeptide | n2=en:antibody-drug conjugate bay79-4620 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate dfrf4539a n1=cyclopeptide | n2=en:antibody-drug conjugate dfrf4539a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate pf-06647020 n1=cyclopeptide | n2=en:antibody-drug conjugate pf-06647020 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate pf-06647263 n1=cyclopeptide | n2=en:antibody-drug conjugate pf-06647263 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate pf-06664178 n1=cyclopeptide | n2=en:antibody-drug conjugate pf-06664178 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate sc-002 n1=cyclopeptide | n2=en:antibody-drug conjugate sc-002 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate sc-003 n1=cyclopeptide | n2=en:antibody-drug conjugate sc-003 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antibody-drug conjugate sc16ld6.5 n1=cyclopeptide | n2=en:antibody-drug conjugate sc16ld6.5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anticachexia agent mt-102 n1=cyclopeptide | n2=en:anticachexia agent mt-102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anticancer drug role n1=cyclopeptide | n2=en:anticancer drug role | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:anticarcinogenic agents n1=cyclopeptide | n2=en:anticarcinogenic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antidiuretic n1=cyclopeptide | n2=en:antidiuretic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antidote n1=cyclopeptide | n2=en:antidote | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antiestrogen n1=cyclopeptide | n2=en:antiestrogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antifungal agent f901318 n1=cyclopeptide | n2=en:antifungal agent f901318 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antigen-targeted personalized breast cancer vaccine n1=cyclopeptide | n2=en:antigen-targeted personalized breast cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antihemophilic factor, human recombinant n1=cyclopeptide | n2=en:antihemophilic factor, human recombinant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antihistamines n1=cyclopeptide | n2=en:antihistamines | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antihypertensive agent n1=cyclopeptide | n2=en:antihypertensive agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antileukemic agent n1=cyclopeptide | n2=en:antileukemic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antilipemic agent n1=cyclopeptide | n2=en:antilipemic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antilymphocyte immunoglobulins n1=cyclopeptide | n2=en:antilymphocyte immunoglobulins | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antimetabolite n1=cyclopeptide | n2=en:antimetabolite | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antimetabolite chemotherapy n1=cyclopeptide | n2=en:antimetabolite chemotherapy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antimetabolite ff-10502 n1=cyclopeptide | n2=en:antimetabolite ff-10502 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antimetastatic agent n1=cyclopeptide | n2=en:antimetastatic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antimitotic agent n1=cyclopeptide | n2=en:antimitotic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antimongoloid slant (in some patients) n1=cyclopeptide | n2=en:antimongoloid slant (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antimoniotungstate n1=cyclopeptide | n2=en:antimoniotungstate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antimony n1=cyclopeptide | n2=en:antimony | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic adjuvants n1=cyclopeptide | n2=en:antineoplastic adjuvants | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic agent n1=cyclopeptide | n2=en:antineoplastic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic agent combination sm-88 n1=cyclopeptide | n2=en:antineoplastic agent combination sm-88 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic agent trx-818 n1=cyclopeptide | n2=en:antineoplastic agent trx-818 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic agents, hormonal n1=cyclopeptide | n2=en:antineoplastic agents, hormonal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic agents, phytogenic n1=cyclopeptide | n2=en:antineoplastic agents, phytogenic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic alkaloid n1=cyclopeptide | n2=en:antineoplastic alkaloid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic alkylating agent n1=cyclopeptide | n2=en:antineoplastic alkylating agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic anthraquinone n1=cyclopeptide | n2=en:antineoplastic anthraquinone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic antibiotic n1=cyclopeptide | n2=en:antineoplastic antibiotic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic hormones n1=cyclopeptide | n2=en:antineoplastic hormones | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic metal complex agent n1=cyclopeptide | n2=en:antineoplastic metal complex agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic metal complex preparation n1=cyclopeptide | n2=en:antineoplastic metal complex preparation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic radiopharmaceuticals n1=cyclopeptide | n2=en:antineoplastic radiopharmaceuticals | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastic vinca alkaloid n1=cyclopeptide | n2=en:antineoplastic vinca alkaloid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplastics, other n1=cyclopeptide | n2=en:antineoplastics, other | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplaston a10 n1=cyclopeptide | n2=en:antineoplaston a10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antineoplaston as2-1 n1=cyclopeptide | n2=en:antineoplaston as2-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antiperspirant cream f511 n1=cyclopeptide | n2=en:antiperspirant cream f511 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antiplatelet agent n1=cyclopeptide | n2=en:antiplatelet agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antirheumatic agents n1=cyclopeptide | n2=en:antirheumatic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antispasmodic agent n1=cyclopeptide | n2=en:antispasmodic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antitumor b n1=cyclopeptide | n2=en:antitumor b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antivaricose agent n1=cyclopeptide | n2=en:antivaricose agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antiviral agent csj148 n1=cyclopeptide | n2=en:antiviral agent csj148 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antrodia cinnamomea supplement n1=cyclopeptide | n2=en:antrodia cinnamomea supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:antroquinonol capsule n1=cyclopeptide | n2=en:antroquinonol capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apatinib n1=cyclopeptide | n2=en:apatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apatorsen n1=cyclopeptide | n2=en:apatorsen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apaziquone n1=cyclopeptide | n2=en:apaziquone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apc8015f n1=cyclopeptide | n2=en:apc8015f | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apf530 n1=cyclopeptide | n2=en:apf530 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aphakia, congenital primary n1=cyclopeptide | n2=en:aphakia, congenital primary | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aphakic glaucoma n1=cyclopeptide | n2=en:aphakic glaucoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:api 31510 topical cream n1=cyclopeptide | n2=en:api 31510 topical cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apilimod dimesylate capsule n1=cyclopeptide | n2=en:apilimod dimesylate capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apixaban n1=cyclopeptide | n2=en:apixaban | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aplasia or atrophy of the dilatator pupillae muscle n1=cyclopeptide | n2=en:aplasia or atrophy of the dilatator pupillae muscle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aplasia, nos n1=cyclopeptide | n2=en:aplasia, nos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aplastic/hypoplastic lacrimal glands n1=cyclopeptide | n2=en:aplastic/hypoplastic lacrimal glands | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aplastic/hypoplastic lacrimal puncta n1=cyclopeptide | n2=en:aplastic/hypoplastic lacrimal puncta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apolizumab n1=cyclopeptide | n2=en:apolizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apomab n1=cyclopeptide | n2=en:apomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apomine n1=cyclopeptide | n2=en:apomine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apoptosis inducer bzl101 n1=cyclopeptide | n2=en:apoptosis inducer bzl101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apoptosis inducer gcs-100 n1=cyclopeptide | n2=en:apoptosis inducer gcs-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apoptosis inducer mpc-2130 n1=cyclopeptide | n2=en:apoptosis inducer mpc-2130 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apoptotic autologous tumor cells-pulsed alpha-type-1 polarized dendritic cells n1=cyclopeptide | n2=en:apoptotic autologous tumor cells-pulsed alpha-type-1 polarized dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apparent hypertelorism n1=cyclopeptide | n2=en:apparent hypertelorism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apraxia of eyelid n1=cyclopeptide | n2=en:apraxia of eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apraxia of eyelid opening n1=cyclopeptide | n2=en:apraxia of eyelid opening | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apremilast n1=cyclopeptide | n2=en:apremilast | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aprepitant n1=cyclopeptide | n2=en:aprepitant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:apricoxib n1=cyclopeptide | n2=en:apricoxib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aprotinin n1=cyclopeptide | n2=en:aprotinin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ar antagonist bms-641988 n1=cyclopeptide | n2=en:ar antagonist bms-641988 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ar antagonist odm-201 n1=cyclopeptide | n2=en:ar antagonist odm-201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ar ligand binding domain-targeting agent azd3514 n1=cyclopeptide | n2=en:ar ligand binding domain-targeting agent azd3514 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ara-cop protocol n1=cyclopeptide | n2=en:ara-cop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arched eyebrows (1/4 patients) n1=cyclopeptide | n2=en:arched eyebrows (1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arched eyebrows (in some patients) n1=cyclopeptide | n2=en:arched eyebrows (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arched eyebrows with inverted v-shape laterally n1=cyclopeptide | n2=en:arched eyebrows with inverted v-shape laterally | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arched, sparse eyebrows n1=cyclopeptide | n2=en:arched, sparse eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:archexin n1=cyclopeptide | n2=en:archexin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arcitumomab n1=cyclopeptide | n2=en:arcitumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arcus juvenilis n1=cyclopeptide | n2=en:arcus juvenilis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arcus senilis n1=cyclopeptide | n2=en:arcus senilis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arginine butyrate n1=cyclopeptide | n2=en:arginine butyrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arginine/omega-3 fatty acids/nucleotides oral supplement n1=cyclopeptide | n2=en:arginine/omega-3 fatty acids/nucleotides oral supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:argipressin n1=cyclopeptide | n2=en:argipressin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arhinencephalia-cyclopia n1=cyclopeptide | n2=en:arhinencephalia-cyclopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:armodafinil n1=cyclopeptide | n2=en:armodafinil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arnebia indigo jade pearl topical cream n1=cyclopeptide | n2=en:arnebia indigo jade pearl topical cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aromatase inhibitor n1=cyclopeptide | n2=en:aromatase inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aromatase inhibitors, 3rd generation n1=cyclopeptide | n2=en:aromatase inhibitors, 3rd generation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arrested retinal development n1=cyclopeptide | n2=en:arrested retinal development | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arsanilic acid n1=cyclopeptide | n2=en:arsanilic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arsenic n1=cyclopeptide | n2=en:arsenic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arsenic trioxide n1=cyclopeptide | n2=en:arsenic trioxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:artemether sublingual spray n1=cyclopeptide | n2=en:artemether sublingual spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:artemisia vulgaris n1=cyclopeptide | n2=en:artemisia vulgaris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arterial attenuation n1=cyclopeptide | n2=en:arterial attenuation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arteriolar attenuation n1=cyclopeptide | n2=en:arteriolar attenuation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arteriolar attenuation (in some patients) n1=cyclopeptide | n2=en:arteriolar attenuation (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:artesunate n1=cyclopeptide | n2=en:artesunate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:artichoke whole phytocomplex concentrate n1=cyclopeptide | n2=en:artichoke whole phytocomplex concentrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:arzoxifene hydrochloride n1=cyclopeptide | n2=en:arzoxifene hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:as03-adjuvanted h1n1 pandemic influenza vaccine n1=cyclopeptide | n2=en:as03-adjuvanted h1n1 pandemic influenza vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asaley n1=cyclopeptide | n2=en:asaley | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ascorbic acid n1=cyclopeptide | n2=en:ascorbic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asfotase alfa n1=cyclopeptide | n2=en:asfotase alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ashwagandha root powder extract n1=cyclopeptide | n2=en:ashwagandha root powder extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asian ginseng n1=cyclopeptide | n2=en:asian ginseng | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ask1 inhibitor gs-4997 n1=cyclopeptide | n2=en:ask1 inhibitor gs-4997 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asp4132 n1=cyclopeptide | n2=en:asp4132 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asp9521 n1=cyclopeptide | n2=en:asp9521 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asp9853 n1=cyclopeptide | n2=en:asp9853 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase n1=cyclopeptide | n2=en:asparaginase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase erwinia chrysanthemi n1=cyclopeptide | n2=en:asparaginase erwinia chrysanthemi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/mercaptopurine/methotrexate/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/mercaptopurine/methotrexate/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/mercaptopurine/methotrexate/thioguanine/vincristine/vindesine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/mercaptopurine/methotrexate/thioguanine/vincristine/vindesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/methotrexate/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/methotrexate/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/doxorubicin/mercaptopurine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/doxorubicin/mercaptopurine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/mercaptopurine/methotrexate/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/mercaptopurine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/thioguanine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/daunorubicin/thioguanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/mercaptopurine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/mercaptopurine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/epirubicin/etoposide/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/epirubicin/etoposide/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/mercaptopurine/methotrexate/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/dexamethasone/mercaptopurine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/doxorubicin/methotrexate/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/doxorubicin/methotrexate/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/filgrastim n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/filgrastim/mercaptopurine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/filgrastim/mercaptopurine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/idarubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/idarubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/mercaptopurine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/mercaptopurine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/mercaptopurine/methotrexate n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/mercaptopurine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/mercaptopurine/methotrexate/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/mercaptopurine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/mercaptopurine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/mercaptopurine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/methotrexate n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/methotrexate/prednisone/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/methotrexate/prednisone/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/methotrexate/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/methotrexate/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/methotrexate/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/cytarabine/thioguanine/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/cytarabine/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/daunorubicin/dexamethasone/leucovorin calcium/methotrexate/thioguanine/vindesine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/daunorubicin/dexamethasone/leucovorin calcium/methotrexate/thioguanine/vindesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/daunorubicin/dexamethasone/methotrexate/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/daunorubicin/dexamethasone/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/daunorubicin/dexamethasone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/daunorubicin/dexamethasone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/daunorubicin/filgrastim/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/daunorubicin/filgrastim/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/daunorubicin/methotrexate/prednisolone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/daunorubicin/methotrexate/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/daunorubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/daunorubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/daunorubicin/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/daunorubicin/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/doxorubicin/prednisolone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/doxorubicin/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/doxorubicin/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/doxorubicin/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/filgrastim n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/mercaptopurine/methotrexate n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/mercaptopurine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/methotrexate/prednisone/vincristine/zorubicin n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/methotrexate/prednisone/vincristine/zorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asparaginase/cyclophosphamide/prednisone/vincristine n1=cyclopeptide | n2=en:asparaginase/cyclophosphamide/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aspects of adverse effects n1=cyclopeptide | n2=en:aspects of adverse effects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aspects of radiation effects n1=cyclopeptide | n2=en:aspects of radiation effects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aspergillin n1=cyclopeptide | n2=en:aspergillin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aspirin n1=cyclopeptide | n2=en:aspirin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aspirin/simvastatin/atenolol/ramipril/thiazide capsule n1=cyclopeptide | n2=en:aspirin/simvastatin/atenolol/ramipril/thiazide capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asta z 7557 n1=cyclopeptide | n2=en:asta z 7557 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asteroid hyalosis n1=cyclopeptide | n2=en:asteroid hyalosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astigmatic refractive errors n1=cyclopeptide | n2=en:astigmatic refractive errors | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astigmatism n1=cyclopeptide | n2=en:astigmatism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astigmatism (1 family) n1=cyclopeptide | n2=en:astigmatism (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astigmatism (1 patient) n1=cyclopeptide | n2=en:astigmatism (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astigmatism (in some patients) n1=cyclopeptide | n2=en:astigmatism (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astigmatism (rare) n1=cyclopeptide | n2=en:astigmatism (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astigmatism, variable n1=cyclopeptide | n2=en:astigmatism, variable | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astragalus-based formulation qing shu yi qi tang n1=cyclopeptide | n2=en:astragalus-based formulation qing shu yi qi tang | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astringent n1=cyclopeptide | n2=en:astringent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:astuprotimut-r n1=cyclopeptide | n2=en:astuprotimut-r | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asulacrine isethionate n1=cyclopeptide | n2=en:asulacrine isethionate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asunaprevir n1=cyclopeptide | n2=en:asunaprevir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asymmetric palpebral fissure n1=cyclopeptide | n2=en:asymmetric palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asymmetric pendular movements n1=cyclopeptide | n2=en:asymmetric pendular movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asymmetric pupils (rare) n1=cyclopeptide | n2=en:asymmetric pupils (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asymmetric visual evoked potentials n1=cyclopeptide | n2=en:asymmetric visual evoked potentials | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:asymmetry of intraocular pressure n1=cyclopeptide | n2=en:asymmetry of intraocular pressure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:at 211 monoclonal antibody 81c6 n1=cyclopeptide | n2=en:at 211 monoclonal antibody 81c6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atacicept n1=cyclopeptide | n2=en:atacicept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atamestane n1=cyclopeptide | n2=en:atamestane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atenolol n1=cyclopeptide | n2=en:atenolol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atezolizumab n1=cyclopeptide | n2=en:atezolizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atiprimod n1=cyclopeptide | n2=en:atiprimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atm kinase inhibitor azd0156 n1=cyclopeptide | n2=en:atm kinase inhibitor azd0156 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atn-161 n1=cyclopeptide | n2=en:atn-161 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atomoxetine hydrochloride n1=cyclopeptide | n2=en:atomoxetine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atonic pupil n1=cyclopeptide | n2=en:atonic pupil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atopic conjunctivitis n1=cyclopeptide | n2=en:atopic conjunctivitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atorvastatin calcium n1=cyclopeptide | n2=en:atorvastatin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atr kinase inhibitor azd6738 n1=cyclopeptide | n2=en:atr kinase inhibitor azd6738 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atr kinase inhibitor vx-970 n1=cyclopeptide | n2=en:atr kinase inhibitor vx-970 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atr-101 n1=cyclopeptide | n2=en:atr-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrasentan hydrochloride n1=cyclopeptide | n2=en:atrasentan hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atresia n1=cyclopeptide | n2=en:atresia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atresia of nasolacrimal duct n1=cyclopeptide | n2=en:atresia of nasolacrimal duct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atretic lacrimal punctum n1=cyclopeptide | n2=en:atretic lacrimal punctum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrial septal defect n1=cyclopeptide | n2=en:atrial septal defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrimustine n1=cyclopeptide | n2=en:atrimustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrophic changes of central macula (in some patients) n1=cyclopeptide | n2=en:atrophic changes of central macula (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrophic iris n1=cyclopeptide | n2=en:atrophic iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrophic macular change n1=cyclopeptide | n2=en:atrophic macular change | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrophic macular disease n1=cyclopeptide | n2=en:atrophic macular disease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrophic optic fundi n1=cyclopeptide | n2=en:atrophic optic fundi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrophic retina n1=cyclopeptide | n2=en:atrophic retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atrophy around the optic disc (in carrier females) n1=cyclopeptide | n2=en:atrophy around the optic disc (in carrier females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atropine sulfate n1=cyclopeptide | n2=en:atropine sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated arteries n1=cyclopeptide | n2=en:attenuated arteries | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated blood vessels in periphery n1=cyclopeptide | n2=en:attenuated blood vessels in periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated chimpanzee adenovirus 5t4 vaccine n1=cyclopeptide | n2=en:attenuated chimpanzee adenovirus 5t4 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated corynebacterium parvum n1=cyclopeptide | n2=en:attenuated corynebacterium parvum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated listeria monocytogenes crs-100 n1=cyclopeptide | n2=en:attenuated listeria monocytogenes crs-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated live listeria encoding hpv 16 e7 vaccine adxs11-001 n1=cyclopeptide | n2=en:attenuated live listeria encoding hpv 16 e7 vaccine adxs11-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated retinal blood vessels n1=cyclopeptide | n2=en:attenuated retinal blood vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated retinal vessels n1=cyclopeptide | n2=en:attenuated retinal vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuated vessels n1=cyclopeptide | n2=en:attenuated vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuation of retinal arterioles n1=cyclopeptide | n2=en:attenuation of retinal arterioles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuation of retinal arterioles (in some patients) n1=cyclopeptide | n2=en:attenuation of retinal arterioles (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuation of retinal blood vessels n1=cyclopeptide | n2=en:attenuation of retinal blood vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:attenuation of retinal vessels n1=cyclopeptide | n2=en:attenuation of retinal vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:atypical cornea guttata n1=cyclopeptide | n2=en:atypical cornea guttata | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:auranofin n1=cyclopeptide | n2=en:auranofin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora a kinase inhibitor mk5108 n1=cyclopeptide | n2=en:aurora a kinase inhibitor mk5108 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora a kinase inhibitor tas-119 n1=cyclopeptide | n2=en:aurora a kinase inhibitor tas-119 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora a kinase/tyrosine kinase inhibitor enmd-2076 n1=cyclopeptide | n2=en:aurora a kinase/tyrosine kinase inhibitor enmd-2076 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora b serine/threonine kinase inhibitor tak-901 n1=cyclopeptide | n2=en:aurora b serine/threonine kinase inhibitor tak-901 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora b/c kinase inhibitor gsk1070916a n1=cyclopeptide | n2=en:aurora b/c kinase inhibitor gsk1070916a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora kinase inhibitor amg 900 n1=cyclopeptide | n2=en:aurora kinase inhibitor amg 900 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora kinase inhibitor bi 811283 n1=cyclopeptide | n2=en:aurora kinase inhibitor bi 811283 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora kinase inhibitor mln8054 n1=cyclopeptide | n2=en:aurora kinase inhibitor mln8054 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora kinase inhibitor pf-03814735 n1=cyclopeptide | n2=en:aurora kinase inhibitor pf-03814735 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora kinase inhibitor sns-314 n1=cyclopeptide | n2=en:aurora kinase inhibitor sns-314 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora kinase inhibitor ttp607 n1=cyclopeptide | n2=en:aurora kinase inhibitor ttp607 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurora kinase/vegfr2 inhibitor cyc116 n1=cyclopeptide | n2=en:aurora kinase/vegfr2 inhibitor cyc116 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aurothioglucose n1=cyclopeptide | n2=en:aurothioglucose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autofluorescent dots in posterior pole n1=cyclopeptide | n2=en:autofluorescent dots in posterior pole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous ad-cd154-transduced cll b cells n1=cyclopeptide | n2=en:autologous ad-cd154-transduced cll b cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous anti-cd123 car tcr/4-1bb-expressing t-lymphocytes n1=cyclopeptide | n2=en:autologous anti-cd123 car tcr/4-1bb-expressing t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous anti-cd19 car-expressing t lymphocytes n1=cyclopeptide | n2=en:autologous anti-cd19 car-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014 n1=cyclopeptide | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ t-lymphocytes jcar017 n1=cyclopeptide | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ t-lymphocytes jcar017 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes n1=cyclopeptide | n2=en:autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous anti-gp100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes n1=cyclopeptide | n2=en:autologous anti-gp100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes n1=cyclopeptide | n2=en:autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous anti-psma gene-modified t-lymphocytes n1=cyclopeptide | n2=en:autologous anti-psma gene-modified t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous beta-a(t87q)-globin gene-transduced cd34-positive cells n1=cyclopeptide | n2=en:autologous beta-a(t87q)-globin gene-transduced cd34-positive cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous bone marrow-derived cd34/cxcr4-positive stem cells amr-001 n1=cyclopeptide | n2=en:autologous bone marrow-derived cd34/cxcr4-positive stem cells amr-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes n1=cyclopeptide | n2=en:autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cd133-positive btsc mrna-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:autologous cd133-positive btsc mrna-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cd171-specific car-cd28 zeta-4-1-bb-egfrt-expressing t lymphocytes n1=cyclopeptide | n2=en:autologous cd171-specific car-cd28 zeta-4-1-bb-egfrt-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cd19-28z chimeric antigen receptor-expressing t-lymphocytes n1=cyclopeptide | n2=en:autologous cd19-28z chimeric antigen receptor-expressing t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells n1=cyclopeptide | n2=en:autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cd34-positive hematopoietic progenitor cells n1=cyclopeptide | n2=en:autologous cd34-positive hematopoietic progenitor cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cd8 positive pbl sensitized to drosophila cell-presented melanoma peptides n1=cyclopeptide | n2=en:autologous cd8 positive pbl sensitized to drosophila cell-presented melanoma peptides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cd8+ melanoma specific t cells n1=cyclopeptide | n2=en:autologous cd8+ melanoma specific t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cea-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:autologous cea-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous colon cancer cell vaccine n1=cyclopeptide | n2=en:autologous colon cancer cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous colorectal tumor antigen-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:autologous colorectal tumor antigen-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous ct7/mage-a3/wt1 mrna-electroporated langerhans-type dendritic cells n1=cyclopeptide | n2=en:autologous ct7/mage-a3/wt1 mrna-electroporated langerhans-type dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cultured acute myeloid leukemia-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:autologous cultured acute myeloid leukemia-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cytomegalovirus-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:autologous cytomegalovirus-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cytotoxic t-lymphocytes induced with muc1 gene-transfected dendritic cells n1=cyclopeptide | n2=en:autologous cytotoxic t-lymphocytes induced with muc1 gene-transfected dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous cytotoxic t-lymphocytes induced with muc1 peptide-pulsed dendritic cells n1=cyclopeptide | n2=en:autologous cytotoxic t-lymphocytes induced with muc1 peptide-pulsed dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dendritic cell vaccine act2001 n1=cyclopeptide | n2=en:autologous dendritic cell vaccine act2001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dendritic cell-adenovirus ccl21 vaccine n1=cyclopeptide | n2=en:autologous dendritic cell-adenovirus ccl21 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dendritic cell-adenovirus p53 vaccine n1=cyclopeptide | n2=en:autologous dendritic cell-adenovirus p53 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine n1=cyclopeptide | n2=en:autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dendritic cell-autologous tumor mrna-human cd40l vaccine n1=cyclopeptide | n2=en:autologous dendritic cell-autologous tumor mrna-human cd40l vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dendritic cell-based immunotherapeutic av0113 n1=cyclopeptide | n2=en:autologous dendritic cell-based immunotherapeutic av0113 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dendritic cell-tumor fusion vaccine n1=cyclopeptide | n2=en:autologous dendritic cell-tumor fusion vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dendritic cells/cmv pp65 peptide n1=cyclopeptide | n2=en:autologous dendritic cells/cmv pp65 peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous dinitrophenyl-modified ovarian cancer vaccine n1=cyclopeptide | n2=en:autologous dinitrophenyl-modified ovarian cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous ebv-ctl cd19car zeta n1=cyclopeptide | n2=en:autologous ebv-ctl cd19car zeta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous ebv-transformed b lymphoblastoid-tumor fusion cell vaccine n1=cyclopeptide | n2=en:autologous ebv-transformed b lymphoblastoid-tumor fusion cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine n1=cyclopeptide | n2=en:autologous epstein-barr virus-transformed b-lymphoblastoid cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous expanded mesenchymal stem cells oti-010 n1=cyclopeptide | n2=en:autologous expanded mesenchymal stem cells oti-010 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous glioma cell lysate n1=cyclopeptide | n2=en:autologous glioma cell lysate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous gm-csf-secreting breast cancer vaccine n1=cyclopeptide | n2=en:autologous gm-csf-secreting breast cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous gm-csf-secreting lethally irradiated colorectal cancer cell vaccine n1=cyclopeptide | n2=en:autologous gm-csf-secreting lethally irradiated colorectal cancer cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous gm-csf-secreting lethally irradiated leukemia cell vaccine n1=cyclopeptide | n2=en:autologous gm-csf-secreting lethally irradiated leukemia cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous gm-csf-secreting melanoma vaccine n1=cyclopeptide | n2=en:autologous gm-csf-secreting melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous hbv-specific tcr-redirected t-lymphocytes n1=cyclopeptide | n2=en:autologous hbv-specific tcr-redirected t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous heat-shock protein 70 peptide vaccine ag-858 n1=cyclopeptide | n2=en:autologous heat-shock protein 70 peptide vaccine ag-858 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous her2 chimeric receptor/tgfbeta dominant negative receptor-expressing ebv-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:autologous her2 chimeric receptor/tgfbeta dominant negative receptor-expressing ebv-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous hnscc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine n1=cyclopeptide | n2=en:autologous hnscc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous hpv-16/18 e6/e7-specific tgf-beta-resistant t lymphocytes n1=cyclopeptide | n2=en:autologous hpv-16/18 e6/e7-specific tgf-beta-resistant t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous ic9-gd2-car-expressing vzv-specific t lymphocytes n1=cyclopeptide | n2=en:autologous ic9-gd2-car-expressing vzv-specific t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous il-21-modulated cd8+ mart1-specific t cells n1=cyclopeptide | n2=en:autologous il-21-modulated cd8+ mart1-specific t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous immunoglobulin idiotype-klh conjugate vaccine n1=cyclopeptide | n2=en:autologous immunoglobulin idiotype-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous interferon-producing killer dendritic cells n1=cyclopeptide | n2=en:autologous interferon-producing killer dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous lmp1-/lmp2- specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:autologous lmp1-/lmp2- specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous lymphoid effector cells specific against tumor cells n1=cyclopeptide | n2=en:autologous lymphoid effector cells specific against tumor cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine n1=cyclopeptide | n2=en:autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine n1=cyclopeptide | n2=en:autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine n1=cyclopeptide | n2=en:autologous lymphoma immunoglobulin-derived scfv-chemokine dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous mage-a3-specific hla-a*01-restricted t cell receptor gene engineered lymphocytes n1=cyclopeptide | n2=en:autologous mage-a3-specific hla-a*01-restricted t cell receptor gene engineered lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous melanoma lysate-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:autologous melanoma lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous melanoma lysate/ny-eso-1-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:autologous melanoma lysate/ny-eso-1-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous mesenchymal stem cells apceth_101 n1=cyclopeptide | n2=en:autologous mesenchymal stem cells apceth_101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous muc1-mannan fusion protein pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:autologous muc1-mannan fusion protein pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous neuroblastoma lysate/klh-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:autologous neuroblastoma lysate/klh-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous nsclc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine n1=cyclopeptide | n2=en:autologous nsclc dna-transfected semi-allogeneic fibroblasts mrc-5 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous nsclc peptide-specific dendritic cell vaccine n1=cyclopeptide | n2=en:autologous nsclc peptide-specific dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous ny-eso-1-melanoma-specific cd8+ t-lymphocytes n1=cyclopeptide | n2=en:autologous ny-eso-1-melanoma-specific cd8+ t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous ofa-ilrp rna-transfected dendritic cell vaccine n1=cyclopeptide | n2=en:autologous ofa-ilrp rna-transfected dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:autologous ovarian tumor cell lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous oxidized ovarian tumor cell lysate vaccine n1=cyclopeptide | n2=en:autologous oxidized ovarian tumor cell lysate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous peripheral blood lymphocytes cotransduced with retroviral vectors encoding inducible il-12 and anti-ny-eso-1 tcr n1=cyclopeptide | n2=en:autologous peripheral blood lymphocytes cotransduced with retroviral vectors encoding inducible il-12 and anti-ny-eso-1 tcr | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous pluripotent aldhbr stem cells ald-451 n1=cyclopeptide | n2=en:autologous pluripotent aldhbr stem cells ald-451 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous prostate cancer antigen-expressing dendritic cell vaccine bpx-101 n1=cyclopeptide | n2=en:autologous prostate cancer antigen-expressing dendritic cell vaccine bpx-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous prostate stem cell antigen-specific car t cells bpx-601 n1=cyclopeptide | n2=en:autologous prostate stem cell antigen-specific car t cells bpx-601 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous renal cell carcinoma tumor lysate-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:autologous renal cell carcinoma tumor lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous sarcoma cell lysate n1=cyclopeptide | n2=en:autologous sarcoma cell lysate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous sarcoma lysate-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:autologous sarcoma lysate-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous t-lymphocytes-expressing ny-eso-1-c259-specific enhanced t-cell receptors n1=cyclopeptide | n2=en:autologous t-lymphocytes-expressing ny-eso-1-c259-specific enhanced t-cell receptors | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous tarp peptide-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:autologous tarp peptide-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous tns9.3.55-transduced cd34-positive cells n1=cyclopeptide | n2=en:autologous tns9.3.55-transduced cd34-positive cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous trimix-dc melanoma vaccine n1=cyclopeptide | n2=en:autologous trimix-dc melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous tumor cell proteoliposome chronic lymphocytic leukemia vaccine n1=cyclopeptide | n2=en:autologous tumor cell proteoliposome chronic lymphocytic leukemia vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous tumor cell vaccine n1=cyclopeptide | n2=en:autologous tumor cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous tumor infiltrating lymphocytes ln-144 n1=cyclopeptide | n2=en:autologous tumor infiltrating lymphocytes ln-144 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous tumor-associated peptide antigen-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:autologous tumor-associated peptide antigen-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes n1=cyclopeptide | n2=en:autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:autonomic agents n1=cyclopeptide | n2=en:autonomic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:av2-dm antiviral spray n1=cyclopeptide | n2=en:av2-dm antiviral spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avanafil n1=cyclopeptide | n2=en:avanafil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avascular conjunctival cystic elevations (filtering blebs) n1=cyclopeptide | n2=en:avascular conjunctival cystic elevations (filtering blebs) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avascular patches on conjunctiva and other eye regions n1=cyclopeptide | n2=en:avascular patches on conjunctiva and other eye regions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avascularity of peripheral retina n1=cyclopeptide | n2=en:avascularity of peripheral retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avct protocol n1=cyclopeptide | n2=en:avct protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avelumab n1=cyclopeptide | n2=en:avelumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avitinib maleate n1=cyclopeptide | n2=en:avitinib maleate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avlf protocol n1=cyclopeptide | n2=en:avlf protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:avn944 n1=cyclopeptide | n2=en:avn944 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axenfeld anomaly (disorder) n1=cyclopeptide | n2=en:axenfeld anomaly (disorder) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axenfeld anomaly (in some patients) n1=cyclopeptide | n2=en:axenfeld anomaly (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axenfeld-rieger anomalies (in some patients) n1=cyclopeptide | n2=en:axenfeld-rieger anomalies (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axenfeld-rieger syndrome n1=cyclopeptide | n2=en:axenfeld-rieger syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axial length, eye n1=cyclopeptide | n2=en:axial length, eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axial myopia n1=cyclopeptide | n2=en:axial myopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axitinib n1=cyclopeptide | n2=en:axitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axl inhibitor bgb324 n1=cyclopeptide | n2=en:axl inhibitor bgb324 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:axl inhibitor tp-0903 n1=cyclopeptide | n2=en:axl inhibitor tp-0903 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azacitidine n1=cyclopeptide | n2=en:azacitidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azacitidine/cyclophosphamide/cytarabine/thioguanine/vincristine n1=cyclopeptide | n2=en:azacitidine/cyclophosphamide/cytarabine/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azadirachta indica n1=cyclopeptide | n2=en:azadirachta indica | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azapicyl n1=cyclopeptide | n2=en:azapicyl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azaribine n1=cyclopeptide | n2=en:azaribine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azaserine n1=cyclopeptide | n2=en:azaserine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azathioprine n1=cyclopeptide | n2=en:azathioprine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azathioprine 50mg tablet n1=cyclopeptide | n2=en:azathioprine 50mg tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azathioprine 75mg tablet n1=cyclopeptide | n2=en:azathioprine 75mg tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azathioprine sodium n1=cyclopeptide | n2=en:azathioprine sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azd5438 n1=cyclopeptide | n2=en:azd5438 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azimexon n1=cyclopeptide | n2=en:azimexon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:aziridinylbenzoquinone rh1 n1=cyclopeptide | n2=en:aziridinylbenzoquinone rh1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azithromycin n1=cyclopeptide | n2=en:azithromycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azlocillin n1=cyclopeptide | n2=en:azlocillin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azp n1=cyclopeptide | n2=en:azp | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:azurin:50-77 cell penetrating peptide p28 n1=cyclopeptide | n2=en:azurin:50-77 cell penetrating peptide p28 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:b-8801 protocol n1=cyclopeptide | n2=en:b-8801 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:b-raf/vegfr-2 inhibitor raf265 n1=cyclopeptide | n2=en:b-raf/vegfr-2 inhibitor raf265 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:b-scan ultrasound shows echogenic, placoid calcified lesions at the level of the sclera and choroid n1=cyclopeptide | n2=en:b-scan ultrasound shows echogenic, placoid calcified lesions at the level of the sclera and choroid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:b16alphagal melanoma vaccine n1=cyclopeptide | n2=en:b16alphagal melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:b43-genistein immunoconjugate n1=cyclopeptide | n2=en:b43-genistein immunoconjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:b43-pap immunotoxin n1=cyclopeptide | n2=en:b43-pap immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:b7-dc crosslinking antibody rhigm12b7 n1=cyclopeptide | n2=en:b7-dc crosslinking antibody rhigm12b7 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bacitracin n1=cyclopeptide | n2=en:bacitracin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:baclofen n1=cyclopeptide | n2=en:baclofen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:baclofen/amitriptyline/ketamine gel n1=cyclopeptide | n2=en:baclofen/amitriptyline/ketamine gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bacod-vp16 protocol n1=cyclopeptide | n2=en:bacod-vp16 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bact protocol n1=cyclopeptide | n2=en:bact protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bacteriophage phi x 174 n1=cyclopeptide | n2=en:bacteriophage phi x 174 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bafetinib n1=cyclopeptide | n2=en:bafetinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bags under eyes n1=cyclopeptide | n2=en:bags under eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:balanced crystalloid solution n1=cyclopeptide | n2=en:balanced crystalloid solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:baminercept alfa n1=cyclopeptide | n2=en:baminercept alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:band keratopathy n1=cyclopeptide | n2=en:band keratopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:band-shaped spheroid corneal degeneration n1=cyclopeptide | n2=en:band-shaped spheroid corneal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:band-shaped, whorled microcystic dystrophy of the corneal epithelium n1=cyclopeptide | n2=en:band-shaped, whorled microcystic dystrophy of the corneal epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:banoxantrone n1=cyclopeptide | n2=en:banoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:barasertib n1=cyclopeptide | n2=en:barasertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bardoxolone n1=cyclopeptide | n2=en:bardoxolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bardoxolone methyl n1=cyclopeptide | n2=en:bardoxolone methyl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:baricitinib n1=cyclopeptide | n2=en:baricitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:barium sulfate n1=cyclopeptide | n2=en:barium sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:basiliximab n1=cyclopeptide | n2=en:basiliximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:basiliximab 10mg injection (pdr for recon)+solvent n1=cyclopeptide | n2=en:basiliximab 10mg injection (pdr for recon)+solvent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:batabulin sodium n1=cyclopeptide | n2=en:batabulin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:batanopride n1=cyclopeptide | n2=en:batanopride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bavituximab n1=cyclopeptide | n2=en:bavituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bay 56-3722 n1=cyclopeptide | n2=en:bay 56-3722 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bay 86-4367 n1=cyclopeptide | n2=en:bay 86-4367 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bay 87-2243 n1=cyclopeptide | n2=en:bay 87-2243 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bazedoxifene n1=cyclopeptide | n2=en:bazedoxifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bbr 3464 n1=cyclopeptide | n2=en:bbr 3464 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bc-819 plasmid/polyethylenimine complex n1=cyclopeptide | n2=en:bc-819 plasmid/polyethylenimine complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcg solution n1=cyclopeptide | n2=en:bcg solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcg vaccine n1=cyclopeptide | n2=en:bcg vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcg/cyclophosphamide/doxorubicin/tegafur n1=cyclopeptide | n2=en:bcg/cyclophosphamide/doxorubicin/tegafur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcg/cyclophosphamide/interleukin-2 n1=cyclopeptide | n2=en:bcg/cyclophosphamide/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcl-2 inhibitor bcl201 n1=cyclopeptide | n2=en:bcl-2 inhibitor bcl201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcma-specific car-expressing t lymphocytes n1=cyclopeptide | n2=en:bcma-specific car-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcomm protocol n1=cyclopeptide | n2=en:bcomm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcpe protocol n1=cyclopeptide | n2=en:bcpe protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcpp protocol n1=cyclopeptide | n2=en:bcpp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcr-abl (b2a2)-derived peptide vaccine n1=cyclopeptide | n2=en:bcr-abl (b2a2)-derived peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcr-abl (b3a2)-derived peptide vaccine n1=cyclopeptide | n2=en:bcr-abl (b3a2)-derived peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine n1=cyclopeptide | n2=en:bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bcr-abl peptide vaccine n1=cyclopeptide | n2=en:bcr-abl peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beacopp protocol n1=cyclopeptide | n2=en:beacopp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beacopp regimen n1=cyclopeptide | n2=en:beacopp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:becalm protocol n1=cyclopeptide | n2=en:becalm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:becatecarin n1=cyclopeptide | n2=en:becatecarin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beclomethasone dipropionate n1=cyclopeptide | n2=en:beclomethasone dipropionate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beetroot juice n1=cyclopeptide | n2=en:beetroot juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:begelomab n1=cyclopeptide | n2=en:begelomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:belagenpumatucel-l n1=cyclopeptide | n2=en:belagenpumatucel-l | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:belatacept n1=cyclopeptide | n2=en:belatacept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:belatacept 25 mg/ml injectable solution n1=cyclopeptide | n2=en:belatacept 25 mg/ml injectable solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:belimumab n1=cyclopeptide | n2=en:belimumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:belinostat n1=cyclopeptide | n2=en:belinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beloranib n1=cyclopeptide | n2=en:beloranib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:belotecan hydrochloride n1=cyclopeptide | n2=en:belotecan hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bemiparin sodium n1=cyclopeptide | n2=en:bemiparin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bemop-ca protocol n1=cyclopeptide | n2=en:bemop-ca protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:benaxibine n1=cyclopeptide | n2=en:benaxibine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:benazepril hydrochloride n1=cyclopeptide | n2=en:benazepril hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bendamustine n1=cyclopeptide | n2=en:bendamustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bendamustine hydrochloride n1=cyclopeptide | n2=en:bendamustine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bendamustine-containing nanoparticle-based formulation rxdx-107 n1=cyclopeptide | n2=en:bendamustine-containing nanoparticle-based formulation rxdx-107 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bendamustine-vorinostat fusion molecule edo-s101 n1=cyclopeptide | n2=en:bendamustine-vorinostat fusion molecule edo-s101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:benegrastim n1=cyclopeptide | n2=en:benegrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:benzaldehyde dimethane sulfonate n1=cyclopeptide | n2=en:benzaldehyde dimethane sulfonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:benznidazole n1=cyclopeptide | n2=en:benznidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:benzoylphenylurea n1=cyclopeptide | n2=en:benzoylphenylurea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:benzydamine hydrochloride n1=cyclopeptide | n2=en:benzydamine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bep regimen n1=cyclopeptide | n2=en:bep regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:berberine chloride n1=cyclopeptide | n2=en:berberine chloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:berlin-frankfurt-muenster protocol ii n1=cyclopeptide | n2=en:berlin-frankfurt-muenster protocol ii | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:berubicin hydrochloride n1=cyclopeptide | n2=en:berubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet bromodomain inhibitor zen-3694 n1=cyclopeptide | n2=en:bet bromodomain inhibitor zen-3694 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet bromodomains 2/3/4 inhibitor mk-8628 n1=cyclopeptide | n2=en:bet bromodomains 2/3/4 inhibitor mk-8628 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor n1=cyclopeptide | n2=en:bet inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor bay1238097 n1=cyclopeptide | n2=en:bet inhibitor bay1238097 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor bms-986158 n1=cyclopeptide | n2=en:bet inhibitor bms-986158 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor cpi-0610 n1=cyclopeptide | n2=en:bet inhibitor cpi-0610 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor ft-1101 n1=cyclopeptide | n2=en:bet inhibitor ft-1101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor gs-5829 n1=cyclopeptide | n2=en:bet inhibitor gs-5829 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor gsk2820151 n1=cyclopeptide | n2=en:bet inhibitor gsk2820151 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor gsk525762 n1=cyclopeptide | n2=en:bet inhibitor gsk525762 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor incb054329 n1=cyclopeptide | n2=en:bet inhibitor incb054329 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor incb057643 n1=cyclopeptide | n2=en:bet inhibitor incb057643 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bet inhibitor ten-010 n1=cyclopeptide | n2=en:bet inhibitor ten-010 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta alethine n1=cyclopeptide | n2=en:beta alethine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta endophorin n1=cyclopeptide | n2=en:beta endophorin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-carotene n1=cyclopeptide | n2=en:beta-carotene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-elemene n1=cyclopeptide | n2=en:beta-elemene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-glucan n1=cyclopeptide | n2=en:beta-glucan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-glucan mm-10-001 n1=cyclopeptide | n2=en:beta-glucan mm-10-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-glucan/alginate/hyaluronic acid/squalene/avocado oil-containing emulsion n1=cyclopeptide | n2=en:beta-glucan/alginate/hyaluronic acid/squalene/avocado oil-containing emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-glucan/lactobacillus casei/bifidobacterium lactis-based supplement n1=cyclopeptide | n2=en:beta-glucan/lactobacillus casei/bifidobacterium lactis-based supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-hydroxy-beta-methylbutyrate supplement n1=cyclopeptide | n2=en:beta-hydroxy-beta-methylbutyrate supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-lapachone prodrug arq 761 n1=cyclopeptide | n2=en:beta-lapachone prodrug arq 761 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:beta-thioguanine deoxyriboside n1=cyclopeptide | n2=en:beta-thioguanine deoxyriboside | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:betamethasone n1=cyclopeptide | n2=en:betamethasone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:betulinic acid n1=cyclopeptide | n2=en:betulinic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bevacizumab n1=cyclopeptide | n2=en:bevacizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bevacizumab-irdye 800cw n1=cyclopeptide | n2=en:bevacizumab-irdye 800cw | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bevacizumab/cyclophosphamide n1=cyclopeptide | n2=en:bevacizumab/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bevacizumab/cyclophosphamide/docetaxel/doxorubicin n1=cyclopeptide | n2=en:bevacizumab/cyclophosphamide/docetaxel/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bevacizumab/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:bevacizumab/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bevacizumab/cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:bevacizumab/cyclophosphamide/doxorubicin/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bevacizumab/cyclophosphamide/methotrexate n1=cyclopeptide | n2=en:bevacizumab/cyclophosphamide/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bexarotene n1=cyclopeptide | n2=en:bexarotene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bfm-86 protocol n1=cyclopeptide | n2=en:bfm-86 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bfm-all 81 protocol n1=cyclopeptide | n2=en:bfm-all 81 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bh3 mimetic abt-737 n1=cyclopeptide | n2=en:bh3 mimetic abt-737 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bi 2536 n1=cyclopeptide | n2=en:bi 2536 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bi 831266 n1=cyclopeptide | n2=en:bi 831266 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bi 894999 n1=cyclopeptide | n2=en:bi 894999 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bi-functional alkylating agent val-083 n1=cyclopeptide | n2=en:bi-functional alkylating agent val-083 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bi-shrna-furin/gm-csf-expressing autologous tumor cell vaccine n1=cyclopeptide | n2=en:bi-shrna-furin/gm-csf-expressing autologous tumor cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:biafine cream n1=cyclopeptide | n2=en:biafine cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bibx 1382 n1=cyclopeptide | n2=en:bibx 1382 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bicalutamide n1=cyclopeptide | n2=en:bicalutamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bifidobacterium lactis/lactobacillus acidophilus/l. plantarum/l. salivarius probiotic supplement n1=cyclopeptide | n2=en:bifidobacterium lactis/lactobacillus acidophilus/l. plantarum/l. salivarius probiotic supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex n1=cyclopeptide | n2=en:bifunctional expression vector plasmid dna-bi-shrna ews/fli1 type 1 lipoplex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral cataracts n1=cyclopeptide | n2=en:bilateral cataracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral chorioretinopathy n1=cyclopeptide | n2=en:bilateral chorioretinopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral congenital cataracts (males) n1=cyclopeptide | n2=en:bilateral congenital cataracts (males) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral decreased axial length n1=cyclopeptide | n2=en:bilateral decreased axial length | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral epicanthal folds n1=cyclopeptide | n2=en:bilateral epicanthal folds | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral hyperopia n1=cyclopeptide | n2=en:bilateral hyperopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral infraducted eye position (downward gaze) n1=cyclopeptide | n2=en:bilateral infraducted eye position (downward gaze) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral intraocular pressures greater than or equal to 22 mmhg n1=cyclopeptide | n2=en:bilateral intraocular pressures greater than or equal to 22 mmhg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral macular retinal pigment epithelial atrophy n1=cyclopeptide | n2=en:bilateral macular retinal pigment epithelial atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral macular retinal pigment epithelial mottling n1=cyclopeptide | n2=en:bilateral macular retinal pigment epithelial mottling | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral microphthalmos n1=cyclopeptide | n2=en:bilateral microphthalmos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral nuclear cataract, congenital n1=cyclopeptide | n2=en:bilateral nuclear cataract, congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral posterior subcapsular cataracts n1=cyclopeptide | n2=en:bilateral posterior subcapsular cataracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral ptosis n1=cyclopeptide | n2=en:bilateral ptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral red-speckled retinal pigment epithelium n1=cyclopeptide | n2=en:bilateral red-speckled retinal pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bilateral subretinal masses n1=cyclopeptide | n2=en:bilateral subretinal masses | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:biliary atresia n1=cyclopeptide | n2=en:biliary atresia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bimagrumab n1=cyclopeptide | n2=en:bimagrumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bimatoprost n1=cyclopeptide | n2=en:bimatoprost | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:binding function n1=cyclopeptide | n2=en:binding function | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:binetrakin n1=cyclopeptide | n2=en:binetrakin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:binimetinib n1=cyclopeptide | n2=en:binimetinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:biological agent n1=cyclopeptide | n2=en:biological agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:biological factors n1=cyclopeptide | n2=en:biological factors | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:biomed 101 n1=cyclopeptide | n2=en:biomed 101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:biricodar dicitrate n1=cyclopeptide | n2=en:biricodar dicitrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:birinapant n1=cyclopeptide | n2=en:birinapant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bis(choline)tetrathiomolybdate n1=cyclopeptide | n2=en:bis(choline)tetrathiomolybdate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bisacodyl n1=cyclopeptide | n2=en:bisacodyl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bisantrene hydrochloride n1=cyclopeptide | n2=en:bisantrene hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bismuth bi213 monoclonal antibody m195 n1=cyclopeptide | n2=en:bismuth bi213 monoclonal antibody m195 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bismuth compound n1=cyclopeptide | n2=en:bismuth compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bismuth subcitrate n1=cyclopeptide | n2=en:bismuth subcitrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bismuth subsalicylate n1=cyclopeptide | n2=en:bismuth subsalicylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bisoprolol fumarate n1=cyclopeptide | n2=en:bisoprolol fumarate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bispecific antibody 2b1 n1=cyclopeptide | n2=en:bispecific antibody 2b1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bispecific antibody 4g7xh22 n1=cyclopeptide | n2=en:bispecific antibody 4g7xh22 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bispecific antibody mdx-h210 n1=cyclopeptide | n2=en:bispecific antibody mdx-h210 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bispecific antibody mdx447 n1=cyclopeptide | n2=en:bispecific antibody mdx447 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bispecific human anti-ang-2/anti-vegf-a antibody ro5520985 n1=cyclopeptide | n2=en:bispecific human anti-ang-2/anti-vegf-a antibody ro5520985 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bivalent hpv16/18 therapeutic cervical cancer vaccine n1=cyclopeptide | n2=en:bivalent hpv16/18 therapeutic cervical cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bizelesin n1=cyclopeptide | n2=en:bizelesin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bl22 immunotoxin n1=cyclopeptide | n2=en:bl22 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:black cohosh n1=cyclopeptide | n2=en:black cohosh | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:black raspberry nectar n1=cyclopeptide | n2=en:black raspberry nectar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:black seed oil n1=cyclopeptide | n2=en:black seed oil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:black tea n1=cyclopeptide | n2=en:black tea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blackberry allergenic extract n1=cyclopeptide | n2=en:blackberry allergenic extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin sulfate n1=cyclopeptide | n2=en:bleomycin sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/chlorambucil/cisplatin/cyclophosphamide/dactinomycin/vinblastine n1=cyclopeptide | n2=en:bleomycin/chlorambucil/cisplatin/cyclophosphamide/dactinomycin/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cisplatin/cyclophosphamide/dactinomycin/vinblastine n1=cyclopeptide | n2=en:bleomycin/cisplatin/cyclophosphamide/dactinomycin/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cisplatin/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:bleomycin/cisplatin/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cisplatin/cyclophosphamide/doxorubicin/fluorouracil/vincristine n1=cyclopeptide | n2=en:bleomycin/cisplatin/cyclophosphamide/doxorubicin/fluorouracil/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cisplatin/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:bleomycin/cisplatin/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/filgrastim/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/filgrastim/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/sargramostim/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/sargramostim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/cytarabine/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/cytarabine/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/dactinomycin n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/dactinomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/dexamethasone/doxorubicin/methotrexate/sargramostim/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/dexamethasone/doxorubicin/methotrexate/sargramostim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/dexamethasone/doxorubicin/procarbazine/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/dexamethasone/doxorubicin/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/dexamethasone/doxorubicin/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/dexamethasone/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/dexamethasone/methotrexate/mitoxantrone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/dexamethasone/methotrexate/mitoxantrone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/dexrazoxane/doxorubicin/etoposide/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/dexrazoxane/doxorubicin/etoposide/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisolone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisone/vinblastine/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisone/vinblastine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/methotrexate/methylprednisolone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/methotrexate/methylprednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/methotrexate/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/methotrexate/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/mitomycin n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/mitomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/prednisolone/vindesine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/prednisolone/vindesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/prednisone/procarbazine/vinblastine/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/prednisone/procarbazine/vinblastine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/prednisone/procarbazine/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/prednisone/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/prednisone/teniposide/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/prednisone/teniposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/doxorubicin/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/doxorubicin/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/procarbazine/vinblastine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/procarbazine/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/rituximab/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/etoposide/mitoxantrone/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/etoposide/prednisone/procarbazine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/etoposide/prednisone/procarbazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/fluorouracil/methotrexate n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/fluorouracil/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/idarubicin/leucovorin calcium/methotrexate/methylprednisolone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/idarubicin/leucovorin calcium/methotrexate/methylprednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/idarubicin/methylprednisolone/methotrexate/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/idarubicin/methylprednisolone/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/lomustine/prednisone/procarbazine/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/lomustine/prednisone/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/methotrexate/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/prednisone/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bleomycin/cyclophosphamide/semustine/vincristine n1=cyclopeptide | n2=en:bleomycin/cyclophosphamide/semustine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharitis n1=cyclopeptide | n2=en:blepharitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharitis, recurrent, due to infection with staphylococcus aureus n1=cyclopeptide | n2=en:blepharitis, recurrent, due to infection with staphylococcus aureus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharitis/stye/chalazion n1=cyclopeptide | n2=en:blepharitis/stye/chalazion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharochalasis n1=cyclopeptide | n2=en:blepharochalasis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharophimosis n1=cyclopeptide | n2=en:blepharophimosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharophimosis (36%) n1=cyclopeptide | n2=en:blepharophimosis (36%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharophimosis (in 1 family) n1=cyclopeptide | n2=en:blepharophimosis (in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharophimosis (in some patients) n1=cyclopeptide | n2=en:blepharophimosis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharophimosis (uncommon) n1=cyclopeptide | n2=en:blepharophimosis (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharophimosis, mild n1=cyclopeptide | n2=en:blepharophimosis, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharoptosis (in some patients) n1=cyclopeptide | n2=en:blepharoptosis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharospasm (in some patients) n1=cyclopeptide | n2=en:blepharospasm (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blepharospasm may occur n1=cyclopeptide | n2=en:blepharospasm may occur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blex 404 n1=cyclopeptide | n2=en:blex 404 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blinatumomab n1=cyclopeptide | n2=en:blinatumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blind hypotensive eye n1=cyclopeptide | n2=en:blind hypotensive eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness n1=cyclopeptide | n2=en:blindness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness (6 to 14 years) n1=cyclopeptide | n2=en:blindness (6 to 14 years) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness (in some patients) n1=cyclopeptide | n2=en:blindness (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness (onset in 30s) n1=cyclopeptide | n2=en:blindness (onset in 30s) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness (onset in fourth or fifth decade) n1=cyclopeptide | n2=en:blindness (onset in fourth or fifth decade) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness (onset in infancy) n1=cyclopeptide | n2=en:blindness (onset in infancy) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness (rare) n1=cyclopeptide | n2=en:blindness (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness (wws) n1=cyclopeptide | n2=en:blindness (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness all degrees/types n1=cyclopeptide | n2=en:blindness all degrees/types | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness by age 2 n1=cyclopeptide | n2=en:blindness by age 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness by third decade n1=cyclopeptide | n2=en:blindness by third decade | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness in infancy or very early childhood n1=cyclopeptide | n2=en:blindness in infancy or very early childhood | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness may occur in affected infants n1=cyclopeptide | n2=en:blindness may occur in affected infants | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blindness, postretinal n1=cyclopeptide | n2=en:blindness, postretinal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blockage of the lacrimal ducts n1=cyclopeptide | n2=en:blockage of the lacrimal ducts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blocked lacrimal duct of infant n1=cyclopeptide | n2=en:blocked lacrimal duct of infant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue citrus-based herbal capsule n1=cyclopeptide | n2=en:blue citrus-based herbal capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue eyes (japanese patients) n1=cyclopeptide | n2=en:blue eyes (japanese patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue iris (physical finding) n1=cyclopeptide | n2=en:blue iris (physical finding) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue sclera n1=cyclopeptide | n2=en:blue sclera | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue sclera in infancy n1=cyclopeptide | n2=en:blue sclera in infancy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue sclerae (in some patients) n1=cyclopeptide | n2=en:blue sclerae (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue sclerae (rare) n1=cyclopeptide | n2=en:blue sclerae (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue sclerae at birth becoming normal with age n1=cyclopeptide | n2=en:blue sclerae at birth becoming normal with age | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue-gray irides (adult) n1=cyclopeptide | n2=en:blue-gray irides (adult) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue-green irides n1=cyclopeptide | n2=en:blue-green irides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue-white dots throughout lens, more numerous in cortex n1=cyclopeptide | n2=en:blue-white dots throughout lens, more numerous in cortex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blue/yellow color vision defect n1=cyclopeptide | n2=en:blue/yellow color vision defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blueberry powder supplement n1=cyclopeptide | n2=en:blueberry powder supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bluish sclerae (in 1 patient) n1=cyclopeptide | n2=en:bluish sclerae (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bluish sclerae in infancy (rare) n1=cyclopeptide | n2=en:bluish sclerae in infancy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blurred vision n1=cyclopeptide | n2=en:blurred vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blurred vision (early symptom) n1=cyclopeptide | n2=en:blurred vision (early symptom) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blurred vision, episodic n1=cyclopeptide | n2=en:blurred vision, episodic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:blurred/cloudy vision (acute phase) n1=cyclopeptide | n2=en:blurred/cloudy vision (acute phase) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bmf phase ii protocol n1=cyclopeptide | n2=en:bmf phase ii protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bmi1 inhibitor ptc596 n1=cyclopeptide | n2=en:bmi1 inhibitor ptc596 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bms-184476 n1=cyclopeptide | n2=en:bms-184476 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bms-188797 n1=cyclopeptide | n2=en:bms-188797 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bms-214662 n1=cyclopeptide | n2=en:bms-214662 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bms-275183 n1=cyclopeptide | n2=en:bms-275183 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bms-817378 n1=cyclopeptide | n2=en:bms-817378 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bms-986156 n1=cyclopeptide | n2=en:bms-986156 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bms-986205 n1=cyclopeptide | n2=en:bms-986205 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:boanmycin hydrochloride n1=cyclopeptide | n2=en:boanmycin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:boceprevir n1=cyclopeptide | n2=en:boceprevir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bofumustine n1=cyclopeptide | n2=en:bofumustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone cements n1=cyclopeptide | n2=en:bone cements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone corpuscle-like pigmentation in equatorial and peripheral areas n1=cyclopeptide | n2=en:bone corpuscle-like pigmentation in equatorial and peripheral areas | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone graft - material n1=cyclopeptide | n2=en:bone graft - material | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone metastasis targeting peptide-11 n1=cyclopeptide | n2=en:bone metastasis targeting peptide-11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone resorption inhibitor n1=cyclopeptide | n2=en:bone resorption inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone spicule pigment deposits in periphery and mid periphery n1=cyclopeptide | n2=en:bone spicule pigment deposits in periphery and mid periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone spicule pigment in periphery n1=cyclopeptide | n2=en:bone spicule pigment in periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone spicule pigmentation n1=cyclopeptide | n2=en:bone spicule pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone spicule pigmentation (rare) n1=cyclopeptide | n2=en:bone spicule pigmentation (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone spicule pigmentation of retina (in some patients) n1=cyclopeptide | n2=en:bone spicule pigmentation of retina (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone spicule-like pigmentation n1=cyclopeptide | n2=en:bone spicule-like pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone spicule-like pigmentation (in some patients) n1=cyclopeptide | n2=en:bone spicule-like pigmentation (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone spicules n1=cyclopeptide | n2=en:bone spicules | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone-spicule pigment clumping n1=cyclopeptide | n2=en:bone-spicule pigment clumping | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone-spicule pigment depositions (in some patients) n1=cyclopeptide | n2=en:bone-spicule pigment depositions (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone-spicule pigment deposits, retinal n1=cyclopeptide | n2=en:bone-spicule pigment deposits, retinal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone-spicule pigmentation in midperiphery of retina n1=cyclopeptide | n2=en:bone-spicule pigmentation in midperiphery of retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone-spicule pigmentation in peripheral retinal pigment epithelium (in some patients) n1=cyclopeptide | n2=en:bone-spicule pigmentation in peripheral retinal pigment epithelium (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone-spicule pigmentation in periphery n1=cyclopeptide | n2=en:bone-spicule pigmentation in periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bone-spicule-like pigmentation in midperiphery, mild-to-moderate n1=cyclopeptide | n2=en:bone-spicule-like pigmentation in midperiphery, mild-to-moderate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bop-cisca-pomb-ace regimen n1=cyclopeptide | n2=en:bop-cisca-pomb-ace regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:boron phenylalanine n1=cyclopeptide | n2=en:boron phenylalanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:boronophenylalanine-fructose complex n1=cyclopeptide | n2=en:boronophenylalanine-fructose complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bortezomib n1=cyclopeptide | n2=en:bortezomib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bortezomib/cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide/melphalan/thalidomide n1=cyclopeptide | n2=en:bortezomib/cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide/melphalan/thalidomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bortezomib/cyclophosphamide/dexamethasone regimen n1=cyclopeptide | n2=en:bortezomib/cyclophosphamide/dexamethasone regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bortezomib/cyclophosphamide/doxorubicin/etoposide/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:bortezomib/cyclophosphamide/doxorubicin/etoposide/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bortezomib/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine n1=cyclopeptide | n2=en:bortezomib/cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bosutinib n1=cyclopeptide | n2=en:bosutinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:boswellia serrata extract n1=cyclopeptide | n2=en:boswellia serrata extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:botanical extracts rinse izn-6n4 n1=cyclopeptide | n2=en:botanical extracts rinse izn-6n4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:botanical lotion cg428 n1=cyclopeptide | n2=en:botanical lotion cg428 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:both eyes n1=cyclopeptide | n2=en:both eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:botulinum toxin type a n1=cyclopeptide | n2=en:botulinum toxin type a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bovapec protocol n1=cyclopeptide | n2=en:bovapec protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bovine cartilage n1=cyclopeptide | n2=en:bovine cartilage | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bovine lactoferrin supplement n1=cyclopeptide | n2=en:bovine lactoferrin supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bowen-conradi syndrome n1=cyclopeptide | n2=en:bowen-conradi syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bowman membrane absent n1=cyclopeptide | n2=en:bowman membrane absent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bowman-birk inhibitor concentrate n1=cyclopeptide | n2=en:bowman-birk inhibitor concentrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bp-cx1-platinum complex bp-c1 n1=cyclopeptide | n2=en:bp-cx1-platinum complex bp-c1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:br96-doxorubicin immunoconjugate n1=cyclopeptide | n2=en:br96-doxorubicin immunoconjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brachyury-expressing modified vaccinia ankara-tricom vaccine n1=cyclopeptide | n2=en:brachyury-expressing modified vaccinia ankara-tricom vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brachyury-expressing yeast vaccine gi-6301 n1=cyclopeptide | n2=en:brachyury-expressing yeast vaccine gi-6301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:braf inhibitor n1=cyclopeptide | n2=en:braf inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:braf inhibitor arq 736 n1=cyclopeptide | n2=en:braf inhibitor arq 736 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:braf inhibitor plx8394 n1=cyclopeptide | n2=en:braf inhibitor plx8394 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:braf(v600e) inhibitor cep-32496 n1=cyclopeptide | n2=en:braf(v600e) inhibitor cep-32496 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:braf(v600e) kinase inhibitor ro5212054 n1=cyclopeptide | n2=en:braf(v600e) kinase inhibitor ro5212054 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:braf/egfr inhibitor bgb-283 n1=cyclopeptide | n2=en:braf/egfr inhibitor bgb-283 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brain tumor initiating cell vaccine n1=cyclopeptide | n2=en:brain tumor initiating cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:branched-chain amino acid supplement n1=cyclopeptide | n2=en:branched-chain amino acid supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:branchial cleft remnant n1=cyclopeptide | n2=en:branchial cleft remnant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:branchial cyst n1=cyclopeptide | n2=en:branchial cyst | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:branchiogenic syndrome n1=cyclopeptide | n2=en:branchiogenic syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brassica vegetable n1=cyclopeptide | n2=en:brassica vegetable | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brd4 inhibitor plx51107 n1=cyclopeptide | n2=en:brd4 inhibitor plx51107 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:breakdown of the blood retinal barrier with retinal neovascularization n1=cyclopeptide | n2=en:breakdown of the blood retinal barrier with retinal neovascularization | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:breflate n1=cyclopeptide | n2=en:breflate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brentuximab vedotin n1=cyclopeptide | n2=en:brentuximab vedotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brequinar n1=cyclopeptide | n2=en:brequinar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:briciclib sodium n1=cyclopeptide | n2=en:briciclib sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brigatinib n1=cyclopeptide | n2=en:brigatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bright blue eyes n1=cyclopeptide | n2=en:bright blue eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bright blue irides n1=cyclopeptide | n2=en:bright blue irides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brilacidin oral rinse n1=cyclopeptide | n2=en:brilacidin oral rinse | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brincidofovir n1=cyclopeptide | n2=en:brincidofovir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brittle and sparse eyebrows n1=cyclopeptide | n2=en:brittle and sparse eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brittle and sparse eyelashes n1=cyclopeptide | n2=en:brittle and sparse eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brittle cornea n1=cyclopeptide | n2=en:brittle cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brivanib n1=cyclopeptide | n2=en:brivanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brivanib alaninate n1=cyclopeptide | n2=en:brivanib alaninate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brivudine n1=cyclopeptide | n2=en:brivudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brivudine phosphoramidate n1=cyclopeptide | n2=en:brivudine phosphoramidate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brn01 n1=cyclopeptide | n2=en:brn01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broad bushy eyebrows n1=cyclopeptide | n2=en:broad bushy eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broad dense laterally descending eyebrows n1=cyclopeptide | n2=en:broad dense laterally descending eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broad lateral eyebrow n1=cyclopeptide | n2=en:broad lateral eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broad nasal tip n1=cyclopeptide | n2=en:broad nasal tip | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broad palpebral fissures (1 patient) n1=cyclopeptide | n2=en:broad palpebral fissures (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broad-spectrum human papillomavirus vaccine v505 n1=cyclopeptide | n2=en:broad-spectrum human papillomavirus vaccine v505 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broad, flared eyebrows n1=cyclopeptide | n2=en:broad, flared eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broccoli sprout extract n1=cyclopeptide | n2=en:broccoli sprout extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broccoli sprout/broccoli seed extract supplement n1=cyclopeptide | n2=en:broccoli sprout/broccoli seed extract supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bromacrylide n1=cyclopeptide | n2=en:bromacrylide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bromelains n1=cyclopeptide | n2=en:bromelains | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bromine compound agent n1=cyclopeptide | n2=en:bromine compound agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bromocriptine mesylate n1=cyclopeptide | n2=en:bromocriptine mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bromodomain inhibitor abbv-075 n1=cyclopeptide | n2=en:bromodomain inhibitor abbv-075 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brontictuzumab n1=cyclopeptide | n2=en:brontictuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bropirimine n1=cyclopeptide | n2=en:bropirimine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brostallicin n1=cyclopeptide | n2=en:brostallicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brown accumulation of gaucher cells at corneoscleral limbus n1=cyclopeptide | n2=en:brown accumulation of gaucher cells at corneoscleral limbus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:broxuridine n1=cyclopeptide | n2=en:broxuridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bruceantin n1=cyclopeptide | n2=en:bruceantin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:brushfield spots n1=cyclopeptide | n2=en:brushfield spots | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bryostatin 1 n1=cyclopeptide | n2=en:bryostatin 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:btct4465a n1=cyclopeptide | n2=en:btct4465a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:btk inhibitor bgb-3111 n1=cyclopeptide | n2=en:btk inhibitor bgb-3111 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:btk inhibitor gdc-0853 n1=cyclopeptide | n2=en:btk inhibitor gdc-0853 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:btk inhibitor ono-4059 n1=cyclopeptide | n2=en:btk inhibitor ono-4059 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bucet protocol n1=cyclopeptide | n2=en:bucet protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bucy-2 protocol n1=cyclopeptide | n2=en:bucy-2 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:budesonide n1=cyclopeptide | n2=en:budesonide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:budesonide/formoterol fumarate dihydrate inhalation aerosol n1=cyclopeptide | n2=en:budesonide/formoterol fumarate dihydrate inhalation aerosol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:budotitane n1=cyclopeptide | n2=en:budotitane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:buformin hydrochloride n1=cyclopeptide | n2=en:buformin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bulbar conjunctivitis n1=cyclopeptide | n2=en:bulbar conjunctivitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bulbus cordis anomalies and anomalies of cardiac septal closure n1=cyclopeptide | n2=en:bulbus cordis anomalies and anomalies of cardiac septal closure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bulging eyes (in some patients) n1=cyclopeptide | n2=en:bulging eyes (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bull's eye maculae n1=cyclopeptide | n2=en:bull's eye maculae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bull's eye macular lesion n1=cyclopeptide | n2=en:bull's eye macular lesion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bull's eye maculopathy (in some patients) n1=cyclopeptide | n2=en:bull's eye maculopathy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bull's-eye macular retinal pigment epithelium changes n1=cyclopeptide | n2=en:bull's-eye macular retinal pigment epithelium changes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:buparlisib n1=cyclopeptide | n2=en:buparlisib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:buphthalmos (in some patients) n1=cyclopeptide | n2=en:buphthalmos (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:buphthalmos (wws) n1=cyclopeptide | n2=en:buphthalmos (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bupivacaine hydrochloride n1=cyclopeptide | n2=en:bupivacaine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:buprenorphine transdermal matrix patch n1=cyclopeptide | n2=en:buprenorphine transdermal matrix patch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bupropion + naltrexone n1=cyclopeptide | n2=en:bupropion + naltrexone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bupropion hydrochloride n1=cyclopeptide | n2=en:bupropion hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:burixafor n1=cyclopeptide | n2=en:burixafor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:buserelin n1=cyclopeptide | n2=en:buserelin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:buspirone hydrochloride n1=cyclopeptide | n2=en:buspirone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan n1=cyclopeptide | n2=en:busulfan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/ciprofloxacin/cyclophosphamide/pentoxifylline n1=cyclopeptide | n2=en:busulfan/ciprofloxacin/cyclophosphamide/pentoxifylline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide n1=cyclopeptide | n2=en:busulfan/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/anti-thymocyte globulin n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/anti-thymocyte globulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/cytarabine n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/cytarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/cytarabine/sargramostim n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/cytarabine/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/decitabine n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/decitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/diaziquone n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/diaziquone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/interferon alfa/zidovudine n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/interferon alfa/zidovudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/methylprednisolone n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/methylprednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/mitoxantrone n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/cyclophosphamide/thiotepa n1=cyclopeptide | n2=en:busulfan/cyclophosphamide/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:busulfan/melphalan regimen n1=cyclopeptide | n2=en:busulfan/melphalan regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:buthionine sulfoximine n1=cyclopeptide | n2=en:buthionine sulfoximine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:butocin n1=cyclopeptide | n2=en:butocin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:butylscopolamine bromide n1=cyclopeptide | n2=en:butylscopolamine bromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bv-cap protocol n1=cyclopeptide | n2=en:bv-cap protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:bw a773u n1=cyclopeptide | n2=en:bw a773u | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c [preparations] n1=cyclopeptide | n2=en:c [preparations] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-kit inhibitor plx9486 n1=cyclopeptide | n2=en:c-kit inhibitor plx9486 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-met inhibitor amg 208 n1=cyclopeptide | n2=en:c-met inhibitor amg 208 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-met inhibitor amg 337 n1=cyclopeptide | n2=en:c-met inhibitor amg 337 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-met inhibitor jnj-38877605 n1=cyclopeptide | n2=en:c-met inhibitor jnj-38877605 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-met inhibitor mk2461 n1=cyclopeptide | n2=en:c-met inhibitor mk2461 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-met inhibitor mk8033 n1=cyclopeptide | n2=en:c-met inhibitor mk8033 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-met inhibitor msc2156119j n1=cyclopeptide | n2=en:c-met inhibitor msc2156119j | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-myb antisense oligonucleotide g4460 n1=cyclopeptide | n2=en:c-myb antisense oligonucleotide g4460 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-vamp protocol n1=cyclopeptide | n2=en:c-vamp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c-visa bikdd:liposome n1=cyclopeptide | n2=en:c-visa bikdd:liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:c3-targeted complement inhibitor apl-2 n1=cyclopeptide | n2=en:c3-targeted complement inhibitor apl-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cabazitaxel n1=cyclopeptide | n2=en:cabazitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cabergoline n1=cyclopeptide | n2=en:cabergoline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cabozantinib s-malate n1=cyclopeptide | n2=en:cabozantinib s-malate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cad protocol 3 n1=cyclopeptide | n2=en:cad protocol 3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cadazolid n1=cyclopeptide | n2=en:cadazolid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cadom protocol n1=cyclopeptide | n2=en:cadom protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cae regimen n1=cyclopeptide | n2=en:cae regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cae-p protocol n1=cyclopeptide | n2=en:cae-p protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caevm protocol n1=cyclopeptide | n2=en:caevm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caf protocol 2 n1=cyclopeptide | n2=en:caf protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caf regimen n1=cyclopeptide | n2=en:caf regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caf-ph protocol n1=cyclopeptide | n2=en:caf-ph protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caffeine n1=cyclopeptide | n2=en:caffeine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cafusertib hydrochloride n1=cyclopeptide | n2=en:cafusertib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caix inhibitor dtp348 n1=cyclopeptide | n2=en:caix inhibitor dtp348 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caix inhibitor slc-0111 n1=cyclopeptide | n2=en:caix inhibitor slc-0111 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calamine n1=cyclopeptide | n2=en:calamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calaspargase pegol n1=cyclopeptide | n2=en:calaspargase pegol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcineurin inhibitor n1=cyclopeptide | n2=en:calcineurin inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcipotriene n1=cyclopeptide | n2=en:calcipotriene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcitonin salmon n1=cyclopeptide | n2=en:calcitonin salmon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcitriol n1=cyclopeptide | n2=en:calcitriol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium aluminosilicate anti-diarrheal n1=cyclopeptide | n2=en:calcium aluminosilicate anti-diarrheal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium carbonate n1=cyclopeptide | n2=en:calcium carbonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium channel blocker n1=cyclopeptide | n2=en:calcium channel blocker | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium chloride n1=cyclopeptide | n2=en:calcium chloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium citrate n1=cyclopeptide | n2=en:calcium citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium gluconate n1=cyclopeptide | n2=en:calcium gluconate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium regulating agent n1=cyclopeptide | n2=en:calcium regulating agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium saccharate n1=cyclopeptide | n2=en:calcium saccharate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium-41 chloride aqueous solution n1=cyclopeptide | n2=en:calcium-41 chloride aqueous solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calcium-46 chloride aqueous solution n1=cyclopeptide | n2=en:calcium-46 chloride aqueous solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calculus bovis/moschus/olibanum/myrrha capsule n1=cyclopeptide | n2=en:calculus bovis/moschus/olibanum/myrrha capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calendula officinalis/plantago major/cochlearia armoracia/hamamelis virginiana herbal toothpaste n1=cyclopeptide | n2=en:calendula officinalis/plantago major/cochlearia armoracia/hamamelis virginiana herbal toothpaste | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calendula ointment n1=cyclopeptide | n2=en:calendula ointment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calf protocol n1=cyclopeptide | n2=en:calf protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calfactant n1=cyclopeptide | n2=en:calfactant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calgb 9251 regimen n1=cyclopeptide | n2=en:calgb 9251 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:calusterone n1=cyclopeptide | n2=en:calusterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cambo-vip protocol n1=cyclopeptide | n2=en:cambo-vip protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:camftp protocol n1=cyclopeptide | n2=en:camftp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:camp-l protocol n1=cyclopeptide | n2=en:camp-l protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:camptothecin n1=cyclopeptide | n2=en:camptothecin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:camptothecin analogue tlc388 n1=cyclopeptide | n2=en:camptothecin analogue tlc388 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:camptothecin-20(s)-o-propionate hydrate n1=cyclopeptide | n2=en:camptothecin-20(s)-o-propionate hydrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:campy cva agar n1=cyclopeptide | n2=en:campy cva agar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:canakinumab 150mg powder for injection solution n1=cyclopeptide | n2=en:canakinumab 150mg powder for injection solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:canal of schlemm n1=cyclopeptide | n2=en:canal of schlemm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:canarypox-hil-12 melanoma vaccine n1=cyclopeptide | n2=en:canarypox-hil-12 melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cancell n1=cyclopeptide | n2=en:cancell | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cancer peptide vaccine s-588410 n1=cyclopeptide | n2=en:cancer peptide vaccine s-588410 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cancer stemness kinase inhibitor bbi503 n1=cyclopeptide | n2=en:cancer stemness kinase inhibitor bbi503 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:candesartan cilexetil n1=cyclopeptide | n2=en:candesartan cilexetil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:candida albicans skin test reagent n1=cyclopeptide | n2=en:candida albicans skin test reagent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:canertinib dihydrochloride n1=cyclopeptide | n2=en:canertinib dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:canfosfamide hydrochloride n1=cyclopeptide | n2=en:canfosfamide hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cannabidiol n1=cyclopeptide | n2=en:cannabidiol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cannabinol n1=cyclopeptide | n2=en:cannabinol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cannabis extract oil sr capsule n1=cyclopeptide | n2=en:cannabis extract oil sr capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cantuzumab ravtansine n1=cyclopeptide | n2=en:cantuzumab ravtansine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caop protocol n1=cyclopeptide | n2=en:caop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cap protocol 2 n1=cyclopeptide | n2=en:cap protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cap regimen n1=cyclopeptide | n2=en:cap regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cap-1 protocol n1=cyclopeptide | n2=en:cap-1 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cap-m protocol n1=cyclopeptide | n2=en:cap-m protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capable protocol n1=cyclopeptide | n2=en:capable protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cape protocol n1=cyclopeptide | n2=en:cape protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cape-pale protocol n1=cyclopeptide | n2=en:cape-pale protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capecitabine n1=cyclopeptide | n2=en:capecitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capecitabine rapidly disintegrating tablet n1=cyclopeptide | n2=en:capecitabine rapidly disintegrating tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capecitabine/cyclophosphamide n1=cyclopeptide | n2=en:capecitabine/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capecitabine/cyclophosphamide/docetaxel/doxorubicin n1=cyclopeptide | n2=en:capecitabine/cyclophosphamide/docetaxel/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capecitabine/cyclophosphamide/epirubicin n1=cyclopeptide | n2=en:capecitabine/cyclophosphamide/epirubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capmatinib n1=cyclopeptide | n2=en:capmatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capox regimen n1=cyclopeptide | n2=en:capox regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capsaicin n1=cyclopeptide | n2=en:capsaicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:capt protocol n1=cyclopeptide | n2=en:capt protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:captopril n1=cyclopeptide | n2=en:captopril | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:car.cd30-expressing autologous epstein-barr virus-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:car.cd30-expressing autologous epstein-barr virus-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cara protocol n1=cyclopeptide | n2=en:cara protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caracemide n1=cyclopeptide | n2=en:caracemide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cararacts n1=cyclopeptide | n2=en:cararacts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbamazepine n1=cyclopeptide | n2=en:carbamazepine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbamide peroxide n1=cyclopeptide | n2=en:carbamide peroxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbendazim n1=cyclopeptide | n2=en:carbendazim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbenicillin n1=cyclopeptide | n2=en:carbenicillin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbetimer n1=cyclopeptide | n2=en:carbetimer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbidopa n1=cyclopeptide | n2=en:carbidopa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbogen n1=cyclopeptide | n2=en:carbogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbohydrate processing inhibitor n1=cyclopeptide | n2=en:carbohydrate processing inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbohydrate supplement drink n1=cyclopeptide | n2=en:carbohydrate supplement drink | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 11 alpha-methyltryptophan n1=cyclopeptide | n2=en:carbon c 11 alpha-methyltryptophan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 11 choline n1=cyclopeptide | n2=en:carbon c 11 choline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 11 erlotinib hydrochloride n1=cyclopeptide | n2=en:carbon c 11 erlotinib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 11 methylaminoisobutyrate n1=cyclopeptide | n2=en:carbon c 11 methylaminoisobutyrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 11 n-desmethyl-loperamide n1=cyclopeptide | n2=en:carbon c 11 n-desmethyl-loperamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 11 pbr-28 n1=cyclopeptide | n2=en:carbon c 11 pbr-28 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 11 sarcosine n1=cyclopeptide | n2=en:carbon c 11 sarcosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 11 sepantronium bromide n1=cyclopeptide | n2=en:carbon c 11 sepantronium bromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 13 acetate n1=cyclopeptide | n2=en:carbon c 13 acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 13 lycopene n1=cyclopeptide | n2=en:carbon c 13 lycopene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 13 octanoate n1=cyclopeptide | n2=en:carbon c 13 octanoate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 13 phytoene n1=cyclopeptide | n2=en:carbon c 13 phytoene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 13 phytofluene n1=cyclopeptide | n2=en:carbon c 13 phytofluene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 13/nitrogen n 15-labeled valine n1=cyclopeptide | n2=en:carbon c 13/nitrogen n 15-labeled valine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 anlotinib hydrochloride n1=cyclopeptide | n2=en:carbon c 14 anlotinib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 eribulin acetate n1=cyclopeptide | n2=en:carbon c 14 eribulin acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 gilteritinib n1=cyclopeptide | n2=en:carbon c 14 gilteritinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 ibrutinib n1=cyclopeptide | n2=en:carbon c 14 ibrutinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 lenvatinib mesylate n1=cyclopeptide | n2=en:carbon c 14 lenvatinib mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 ombrabulin n1=cyclopeptide | n2=en:carbon c 14 ombrabulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 oxaliplatin n1=cyclopeptide | n2=en:carbon c 14 oxaliplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 roniciclib n1=cyclopeptide | n2=en:carbon c 14 roniciclib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 selumetinib n1=cyclopeptide | n2=en:carbon c 14 selumetinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 telotristat etiprate n1=cyclopeptide | n2=en:carbon c 14 telotristat etiprate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14 vemurafenib n1=cyclopeptide | n2=en:carbon c 14 vemurafenib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c 14-labeled ixazomib n1=cyclopeptide | n2=en:carbon c 14-labeled ixazomib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c-13 dextromethorphan n1=cyclopeptide | n2=en:carbon c-13 dextromethorphan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c-14 dacomitinib n1=cyclopeptide | n2=en:carbon c-14 dacomitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon c11 temozolomide n1=cyclopeptide | n2=en:carbon c11 temozolomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon nanoparticle-based formulation n1=cyclopeptide | n2=en:carbon nanoparticle-based formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbon-11 acetate n1=cyclopeptide | n2=en:carbon-11 acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin n1=cyclopeptide | n2=en:carboplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin-taxol regimen n1=cyclopeptide | n2=en:carboplatin-taxol regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin-taxol-bevacizumab regimen n1=cyclopeptide | n2=en:carboplatin-taxol-bevacizumab regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cisplatin/cyclophosphamide n1=cyclopeptide | n2=en:carboplatin/cisplatin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cisplatin/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:carboplatin/cisplatin/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cisplatin/cyclophosphamide/etoposide/paclitaxel n1=cyclopeptide | n2=en:carboplatin/cisplatin/cyclophosphamide/etoposide/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cisplatin/cyclophosphamide/filgrastim n1=cyclopeptide | n2=en:carboplatin/cisplatin/cyclophosphamide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/cyclosporine/paclitaxel n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/cyclosporine/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/cytarabine/etoposide phosphate/rituximab/sodium thiosulfate n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/cytarabine/etoposide phosphate/rituximab/sodium thiosulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/cytarabine/etoposide/rituximab/sodium thiosulfate n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/cytarabine/etoposide/rituximab/sodium thiosulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/doxorubicin/etoposide n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/doxorubicin/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/etanidazole n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/etanidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/etoposide phosphate n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/etoposide phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/etoposide phosphate/sodium thiosulfate n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/etoposide phosphate/sodium thiosulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/etoposide/filgrastim/paclitaxel n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/etoposide/filgrastim/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/etoposide/melphalan n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/etoposide/melphalan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/etoposide/sodium thiosulfate n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/etoposide/sodium thiosulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/etoposide/vincristine n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/etoposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/filgrastim n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/filgrastim/paclitaxel n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/filgrastim/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/interleukin-1-beta n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/interleukin-1-beta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/milodistim/thiotepa n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/milodistim/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/mitoxantrone n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/paclitaxel n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/sargramostim n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/sargramostim/thiotepa n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/sargramostim/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/thiotepa n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/cyclophosphamide/vincristine n1=cyclopeptide | n2=en:carboplatin/cyclophosphamide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/etoposide/cyclophosphamide/thiotepa n1=cyclopeptide | n2=en:carboplatin/etoposide/cyclophosphamide/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboplatin/etoposide/melphalan regimen n1=cyclopeptide | n2=en:carboplatin/etoposide/melphalan regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboxyamidotriazole n1=cyclopeptide | n2=en:carboxyamidotriazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboxyamidotriazole orotate n1=cyclopeptide | n2=en:carboxyamidotriazole orotate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboxylesterase-expressing allogeneic neural stem cells n1=cyclopeptide | n2=en:carboxylesterase-expressing allogeneic neural stem cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboxymethylcellulose sodium n1=cyclopeptide | n2=en:carboxymethylcellulose sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carboxyphenyl retinamide n1=cyclopeptide | n2=en:carboxyphenyl retinamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carbutamide n1=cyclopeptide | n2=en:carbutamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carcinoembryonic antigen peptide 1 n1=cyclopeptide | n2=en:carcinoembryonic antigen peptide 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carcinoembryonic antigen peptide 1-6d n1=cyclopeptide | n2=en:carcinoembryonic antigen peptide 1-6d | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carcinoembryonic antigen peptide 1-6d virus-like replicon particles vaccine n1=cyclopeptide | n2=en:carcinoembryonic antigen peptide 1-6d virus-like replicon particles vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carcinoembryonic antigen peptide vaccine n1=cyclopeptide | n2=en:carcinoembryonic antigen peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carcinoembryonic antigen rna-pulsed dc cancer vaccine n1=cyclopeptide | n2=en:carcinoembryonic antigen rna-pulsed dc cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carcinoembryonic antigen-expressing measles virus n1=cyclopeptide | n2=en:carcinoembryonic antigen-expressing measles virus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carcinogen n1=cyclopeptide | n2=en:carcinogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cardiac and circulatory congenital anomalies n1=cyclopeptide | n2=en:cardiac and circulatory congenital anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cardiovascular abnormalities n1=cyclopeptide | n2=en:cardiovascular abnormalities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carfilzomib n1=cyclopeptide | n2=en:carfilzomib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caricotamide/tretazicar n1=cyclopeptide | n2=en:caricotamide/tretazicar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carlumab n1=cyclopeptide | n2=en:carlumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine n1=cyclopeptide | n2=en:carmustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine in ethanol n1=cyclopeptide | n2=en:carmustine in ethanol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine sustained-release implant wafer n1=cyclopeptide | n2=en:carmustine sustained-release implant wafer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cisplatin/cyclophosphamide n1=cyclopeptide | n2=en:carmustine/cisplatin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cisplatin/cyclophosphamide/cytarabine/hydroxyurea/methylprednisolone/procarbazine/vincristine n1=cyclopeptide | n2=en:carmustine/cisplatin/cyclophosphamide/cytarabine/hydroxyurea/methylprednisolone/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cisplatin/cyclophosphamide/filgrastim n1=cyclopeptide | n2=en:carmustine/cisplatin/cyclophosphamide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/cytarabine/daunorubicin/hydroxyurea/methotrexate/thioguanine/vincristine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/cytarabine/daunorubicin/hydroxyurea/methotrexate/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/cytarabine/etoposide n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/cytarabine/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/dactinomycin/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/dactinomycin/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/dactinomycin/mercaptopurine/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/dactinomycin/mercaptopurine/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/dexamethasone n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/dexamethasone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/doxorubicin/melphalan n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/doxorubicin/melphalan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/doxorubicin/melphalan/prednisone/vincristine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/doxorubicin/melphalan/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/etoposide/filgrastim n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/etoposide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/etoposide/hydroxyurea n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/etoposide/hydroxyurea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/etoposide/interferon alfa n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/etoposide/interferon alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/etoposide/melphalan n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/etoposide/melphalan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/etoposide/mesna n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/etoposide/mesna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/interferon alfa/melphalan/prednisone/vincristine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/interferon alfa/melphalan/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/melphalan/misonidazole/prednisone n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/melphalan/misonidazole/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/melphalan/prednisone n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/melphalan/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/melphalan/prednisone/vincristine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/melphalan/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/prednisone n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/prednisone/procarbazine/vinblastine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/prednisone/procarbazine/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/prednisone/vincristine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/thiotepa n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carmustine/cyclophosphamide/thiotepa/vincristine n1=cyclopeptide | n2=en:carmustine/cyclophosphamide/thiotepa/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caroli disease n1=cyclopeptide | n2=en:caroli disease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carrageenan-containing gel n1=cyclopeptide | n2=en:carrageenan-containing gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carrot juice n1=cyclopeptide | n2=en:carrot juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carrot/jilin ginseng/licorice root/tangerine peel/soy beverage n1=cyclopeptide | n2=en:carrot/jilin ginseng/licorice root/tangerine peel/soy beverage | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carubicin n1=cyclopeptide | n2=en:carubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carvedilol n1=cyclopeptide | n2=en:carvedilol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carvedilol phosphate extended-release capsule n1=cyclopeptide | n2=en:carvedilol phosphate extended-release capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:carzelesin n1=cyclopeptide | n2=en:carzelesin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:casein/whey protein/soy protein/pea protein/fat mix/epa/dha-based nutritional supplement n1=cyclopeptide | n2=en:casein/whey protein/soy protein/pea protein/fat mix/epa/dha-based nutritional supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caseinate protein isolate n1=cyclopeptide | n2=en:caseinate protein isolate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:casopitant mesylate n1=cyclopeptide | n2=en:casopitant mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caspofungin acetate n1=cyclopeptide | n2=en:caspofungin acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cat combination n1=cyclopeptide | n2=en:cat combination | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cat-g protocol n1=cyclopeptide | n2=en:cat-g protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract n1=cyclopeptide | n2=en:cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract (21%) n1=cyclopeptide | n2=en:cataract (21%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract (28%) n1=cyclopeptide | n2=en:cataract (28%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract (alport syndrome with macrothrombocytopenia) n1=cyclopeptide | n2=en:cataract (alport syndrome with macrothrombocytopenia) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract (in 2 brothers) n1=cyclopeptide | n2=en:cataract (in 2 brothers) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, adult-onset (punctate cortical) n1=cyclopeptide | n2=en:cataract, adult-onset (punctate cortical) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, anterior polar n1=cyclopeptide | n2=en:cataract, anterior polar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, anterior polar (in some patients) n1=cyclopeptide | n2=en:cataract, anterior polar (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, anterior polar, congenital or early-onset (in some patients) n1=cyclopeptide | n2=en:cataract, anterior polar, congenital or early-onset (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, anterior polar, nonprogressive n1=cyclopeptide | n2=en:cataract, anterior polar, nonprogressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, complete (in affected males) n1=cyclopeptide | n2=en:cataract, complete (in affected males) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, complete (in some patients) n1=cyclopeptide | n2=en:cataract, complete (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, congenital (nuclear, sutural, or stellate cortical) n1=cyclopeptide | n2=en:cataract, congenital (nuclear, sutural, or stellate cortical) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, congenital (rare) n1=cyclopeptide | n2=en:cataract, congenital (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, congenital, cerulean type 1 n1=cyclopeptide | n2=en:cataract, congenital, cerulean type 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, congenital, multiple types n1=cyclopeptide | n2=en:cataract, congenital, multiple types | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, coppock-like n1=cyclopeptide | n2=en:cataract, coppock-like | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, cortical (in some patients) n1=cyclopeptide | n2=en:cataract, cortical (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, fan-shaped n1=cyclopeptide | n2=en:cataract, fan-shaped | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, juvenile-onset (in some patients) n1=cyclopeptide | n2=en:cataract, juvenile-onset (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, lamellar (in some patients) n1=cyclopeptide | n2=en:cataract, lamellar (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, laminar n1=cyclopeptide | n2=en:cataract, laminar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, marner type n1=cyclopeptide | n2=en:cataract, marner type | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, nuclear (in some patients) n1=cyclopeptide | n2=en:cataract, nuclear (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, nuclear coralliform n1=cyclopeptide | n2=en:cataract, nuclear coralliform | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, nuclear sclerotic (in some patients) n1=cyclopeptide | n2=en:cataract, nuclear sclerotic (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, posterior polar (in some patients) n1=cyclopeptide | n2=en:cataract, posterior polar (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, posterior polar, congenital progressive n1=cyclopeptide | n2=en:cataract, posterior polar, congenital progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, posterior subcapsular (in some patients) n1=cyclopeptide | n2=en:cataract, posterior subcapsular (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, postnatal, bilateral dense nuclear n1=cyclopeptide | n2=en:cataract, postnatal, bilateral dense nuclear | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, progressive (in some patients) n1=cyclopeptide | n2=en:cataract, progressive (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, progressive, juvenile-onset (lamellar, cortical, nuclear embryonic, or y-sutural) n1=cyclopeptide | n2=en:cataract, progressive, juvenile-onset (lamellar, cortical, nuclear embryonic, or y-sutural) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, pulverulent n1=cyclopeptide | n2=en:cataract, pulverulent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, zonular central nuclear n1=cyclopeptide | n2=en:cataract, zonular central nuclear | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataract, zonular pulverulent 1 n1=cyclopeptide | n2=en:cataract, zonular pulverulent 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts (1 patient) n1=cyclopeptide | n2=en:cataracts (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts (e.g. 180380.0016) n1=cyclopeptide | n2=en:cataracts (e.g. 180380.0016) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts (in older patients) n1=cyclopeptide | n2=en:cataracts (in older patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts (in some patients) n1=cyclopeptide | n2=en:cataracts (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts (later onset) n1=cyclopeptide | n2=en:cataracts (later onset) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts (less common) n1=cyclopeptide | n2=en:cataracts (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts (rare) n1=cyclopeptide | n2=en:cataracts (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts (uncommon) n1=cyclopeptide | n2=en:cataracts (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts develop in second or third decade n1=cyclopeptide | n2=en:cataracts develop in second or third decade | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts, bilateral nuclear, present at birth or developing in infancy n1=cyclopeptide | n2=en:cataracts, bilateral nuclear, present at birth or developing in infancy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts, congenital (in some patients) n1=cyclopeptide | n2=en:cataracts, congenital (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts, cortical pulverulent, juvenile-onset n1=cyclopeptide | n2=en:cataracts, cortical pulverulent, juvenile-onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts, crenated n1=cyclopeptide | n2=en:cataracts, crenated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts, formation may be reversible with early dietary management n1=cyclopeptide | n2=en:cataracts, formation may be reversible with early dietary management | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts, postnatal n1=cyclopeptide | n2=en:cataracts, postnatal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts, rapid-onset n1=cyclopeptide | n2=en:cataracts, rapid-onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cataracts, usually congenital n1=cyclopeptide | n2=en:cataracts, usually congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cathelicidin ll-37 n1=cyclopeptide | n2=en:cathelicidin ll-37 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cathepsin-activatable cy5 fluorescent imaging probe lum015 n1=cyclopeptide | n2=en:cathepsin-activatable cy5 fluorescent imaging probe lum015 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cationic liposome-encapsulated paclitaxel n1=cyclopeptide | n2=en:cationic liposome-encapsulated paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:catumaxomab n1=cyclopeptide | n2=en:catumaxomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:caudal dysplasia n1=cyclopeptide | n2=en:caudal dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cav regimen n1=cyclopeptide | n2=en:cav regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cav-hem protocol n1=cyclopeptide | n2=en:cav-hem protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cav-t protocol n1=cyclopeptide | n2=en:cav-t protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cavb protocol n1=cyclopeptide | n2=en:cavb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cavity of eyeball n1=cyclopeptide | n2=en:cavity of eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cb10-277 n1=cyclopeptide | n2=en:cb10-277 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cbp-501 n1=cyclopeptide | n2=en:cbp-501 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cbp/beta-catenin antagonist pri-724 n1=cyclopeptide | n2=en:cbp/beta-catenin antagonist pri-724 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cbvpm protocol n1=cyclopeptide | n2=en:cbvpm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cc-1088 n1=cyclopeptide | n2=en:cc-1088 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cc-401 n1=cyclopeptide | n2=en:cc-401 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cc-8490 n1=cyclopeptide | n2=en:cc-8490 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cca protocol n1=cyclopeptide | n2=en:cca protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ccavp16 protocol n1=cyclopeptide | n2=en:ccavp16 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ccc protocol n1=cyclopeptide | n2=en:ccc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cce protocol n1=cyclopeptide | n2=en:cce protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ccl21-expressing h1944 cell vaccine n1=cyclopeptide | n2=en:ccl21-expressing h1944 cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ccp protocol n1=cyclopeptide | n2=en:ccp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ccr2 antagonist ccx872-b n1=cyclopeptide | n2=en:ccr2 antagonist ccx872-b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ccr2 antagonist pf-04136309 n1=cyclopeptide | n2=en:ccr2 antagonist pf-04136309 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ccvpp protocol n1=cyclopeptide | n2=en:ccvpp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd-expressing bifidobacterium aps001f n1=cyclopeptide | n2=en:cd-expressing bifidobacterium aps001f | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine n1=cyclopeptide | n2=en:cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd133 antigen peptide-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:cd133 antigen peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd138car-cd137/tcrzeta-expressing t lymphocytes n1=cyclopeptide | n2=en:cd138car-cd137/tcrzeta-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd19/cd3 dual-affinity retargeting protein jnj-64052781 n1=cyclopeptide | n2=en:cd19/cd3 dual-affinity retargeting protein jnj-64052781 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd19car-cd28zeta-4-1bb-expressing allogeneic t lymphocytes n1=cyclopeptide | n2=en:cd19car-cd28zeta-4-1bb-expressing allogeneic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd19car-cd3zeta-4-1bb-cd28-expressing autologous t-lymphocytes n1=cyclopeptide | n2=en:cd19car-cd3zeta-4-1bb-cd28-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd19car-cd3zeta-4-1bb-expressing allogeneic t-lymphocyte cells n1=cyclopeptide | n2=en:cd19car-cd3zeta-4-1bb-expressing allogeneic t-lymphocyte cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=cyclopeptide | n2=en:cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd19car-cd3zeta-expressing autologous t lymphocytes n1=cyclopeptide | n2=en:cd19car-cd3zeta-expressing autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd20-targeted polypeptide tru-015 n1=cyclopeptide | n2=en:cd20-targeted polypeptide tru-015 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc n1=cyclopeptide | n2=en:cd24 extracellular domain-igg1 fc domain recombinant fusion protein cd24fc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd28car/cd137car-expressing t-lymphocytes n1=cyclopeptide | n2=en:cd28car/cd137car-expressing t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd3/cd28 costimulated autologous t-cells n1=cyclopeptide | n2=en:cd3/cd28 costimulated autologous t-cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd30 car-expressing autologous t lymphocytes n1=cyclopeptide | n2=en:cd30 car-expressing autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd33car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=cyclopeptide | n2=en:cd33car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd34/tk75-transduced donor lymphocytes n1=cyclopeptide | n2=en:cd34/tk75-transduced donor lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd4+ cd25+ regulatory t cells n1=cyclopeptide | n2=en:cd4+ cd25+ regulatory t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd40 agonist monoclonal antibody cp-870,893 n1=cyclopeptide | n2=en:cd40 agonist monoclonal antibody cp-870,893 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd40 agonist monoclonal antibody ro7009789 n1=cyclopeptide | n2=en:cd40 agonist monoclonal antibody ro7009789 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd40 agonistic monoclonal antibody apx005m n1=cyclopeptide | n2=en:cd40 agonistic monoclonal antibody apx005m | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd5789 cream n1=cyclopeptide | n2=en:cd5789 cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd80 breast cancer vaccine n1=cyclopeptide | n2=en:cd80 breast cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cd95 ecd/igg-fc fusion protein apg101 n1=cyclopeptide | n2=en:cd95 ecd/igg-fc fusion protein apg101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cda inhibitor e7727/decitabine combination agent astx727 n1=cyclopeptide | n2=en:cda inhibitor e7727/decitabine combination agent astx727 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdc7 inhibitor tak-931 n1=cyclopeptide | n2=en:cdc7 inhibitor tak-931 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdc7 kinase inhibitor bms-863233 n1=cyclopeptide | n2=en:cdc7 kinase inhibitor bms-863233 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdc7 kinase inhibitor nms-1116354 n1=cyclopeptide | n2=en:cdc7 kinase inhibitor nms-1116354 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cde regimen n1=cyclopeptide | n2=en:cde regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdisc send fetal pathology findings result terminology n1=cyclopeptide | n2=en:cdisc send fetal pathology findings result terminology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdisc send terminology n1=cyclopeptide | n2=en:cdisc send terminology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdk inhibitor p276-00 n1=cyclopeptide | n2=en:cdk inhibitor p276-00 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdk inhibitor sns-032 n1=cyclopeptide | n2=en:cdk inhibitor sns-032 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdk/jak2/flt3 inhibitor tg02 citrate n1=cyclopeptide | n2=en:cdk/jak2/flt3 inhibitor tg02 citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdk2/5/9 inhibitor cyc065 n1=cyclopeptide | n2=en:cdk2/5/9 inhibitor cyc065 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdk2/trka inhibitor pha-848125 ac n1=cyclopeptide | n2=en:cdk2/trka inhibitor pha-848125 ac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdk4 inhibitor p1446a-05 n1=cyclopeptide | n2=en:cdk4 inhibitor p1446a-05 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdk4/6 inhibitor g1t28 n1=cyclopeptide | n2=en:cdk4/6 inhibitor g1t28 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdk4/6 inhibitor shr6390 n1=cyclopeptide | n2=en:cdk4/6 inhibitor shr6390 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdki at7519 n1=cyclopeptide | n2=en:cdki at7519 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdki r547 n1=cyclopeptide | n2=en:cdki r547 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdop protocol n1=cyclopeptide | n2=en:cdop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cdpth regimen n1=cyclopeptide | n2=en:cdpth regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ce protocol ii n1=cyclopeptide | n2=en:ce protocol ii | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ce-cap protocol n1=cyclopeptide | n2=en:ce-cap protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ce-pe childhood kidney cancer regimen n1=cyclopeptide | n2=en:ce-pe childhood kidney cancer regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cea/tetanus toxoid t helper epitope fusion protein-expressing dna plasmid vaccine n1=cyclopeptide | n2=en:cea/tetanus toxoid t helper epitope fusion protein-expressing dna plasmid vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cebocephaly n1=cyclopeptide | n2=en:cebocephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cebpa-targeting sarna mtl-cebpa liposome n1=cyclopeptide | n2=en:cebpa-targeting sarna mtl-cebpa liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cebranopadol n1=cyclopeptide | n2=en:cebranopadol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cec protocol n1=cyclopeptide | n2=en:cec protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceca protocol n1=cyclopeptide | n2=en:ceca protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cedefingol n1=cyclopeptide | n2=en:cedefingol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cediranib maleate n1=cyclopeptide | n2=en:cediranib maleate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cee protocol n1=cyclopeptide | n2=en:cee protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cef regimen n1=cyclopeptide | n2=en:cef regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cefamandole n1=cyclopeptide | n2=en:cefamandole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cefazolin sodium n1=cyclopeptide | n2=en:cefazolin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cefepime hydrochloride n1=cyclopeptide | n2=en:cefepime hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cefixime n1=cyclopeptide | n2=en:cefixime | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cefmetazole sodium n1=cyclopeptide | n2=en:cefmetazole sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cefotaxime n1=cyclopeptide | n2=en:cefotaxime | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cefpodoxime proxetil n1=cyclopeptide | n2=en:cefpodoxime proxetil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceft protocol n1=cyclopeptide | n2=en:ceft protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceftazidime sodium n1=cyclopeptide | n2=en:ceftazidime sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceftazidime/avibactam sodium n1=cyclopeptide | n2=en:ceftazidime/avibactam sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceftobiprole medocaril n1=cyclopeptide | n2=en:ceftobiprole medocaril | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceftriaxone sodium n1=cyclopeptide | n2=en:ceftriaxone sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:celecoxib n1=cyclopeptide | n2=en:celecoxib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:celecoxib/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:celecoxib/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:celecoxib/cyclophosphamide/doxorubicin/etoposide/ifosfamide/vinblastine/vincristine n1=cyclopeptide | n2=en:celecoxib/cyclophosphamide/doxorubicin/etoposide/ifosfamide/vinblastine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:celecoxib/cyclophosphamide/epirubicin/fluorouracil n1=cyclopeptide | n2=en:celecoxib/cyclophosphamide/epirubicin/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:celecoxib/cyclophosphamide/etoposide/thalidomide n1=cyclopeptide | n2=en:celecoxib/cyclophosphamide/etoposide/thalidomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cell cycle checkpoint/dna repair antagonist ic83 n1=cyclopeptide | n2=en:cell cycle checkpoint/dna repair antagonist ic83 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cell differentiating agent n1=cyclopeptide | n2=en:cell differentiating agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cellulose, oxidized n1=cyclopeptide | n2=en:cellulose, oxidized | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:celosomy n1=cyclopeptide | n2=en:celosomy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cemadotin hydrochloride n1=cyclopeptide | n2=en:cemadotin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cemp protocol n1=cyclopeptide | n2=en:cemp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cenersen n1=cyclopeptide | n2=en:cenersen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cenisertib n1=cyclopeptide | n2=en:cenisertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cenp-e inhibitor gsk-923295 n1=cyclopeptide | n2=en:cenp-e inhibitor gsk-923295 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central cataracts n1=cyclopeptide | n2=en:central cataracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central corneal thickness decreased n1=cyclopeptide | n2=en:central corneal thickness decreased | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central guttae, unilateral or bilateral n1=cyclopeptide | n2=en:central guttae, unilateral or bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central hypofluorescence or hyperfluorescence on fluorescein angiography n1=cyclopeptide | n2=en:central hypofluorescence or hyperfluorescence on fluorescein angiography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central islands of vision only (late) n1=cyclopeptide | n2=en:central islands of vision only (late) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central macular atrophy (in some patients) n1=cyclopeptide | n2=en:central macular atrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central nervous system agents n1=cyclopeptide | n2=en:central nervous system agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central pigmented spot in foveal area n1=cyclopeptide | n2=en:central pigmented spot in foveal area | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central retinal pigment epithelium changes n1=cyclopeptide | n2=en:central retinal pigment epithelium changes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central retinal vessel vascular tortuosity (acute phase) n1=cyclopeptide | n2=en:central retinal vessel vascular tortuosity (acute phase) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central retrocorneal fibrosis (in some patients) n1=cyclopeptide | n2=en:central retrocorneal fibrosis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central scotoma (in some patients) n1=cyclopeptide | n2=en:central scotoma (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central scotoma on goldmann visual field (in some patients) n1=cyclopeptide | n2=en:central scotoma on goldmann visual field (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central scotoma on visual field testing n1=cyclopeptide | n2=en:central scotoma on visual field testing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central scotoma, relative or absolute n1=cyclopeptide | n2=en:central scotoma, relative or absolute | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central scotomas n1=cyclopeptide | n2=en:central scotomas | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central scotomata on photopic and dark-adapted perimetry testing n1=cyclopeptide | n2=en:central scotomata on photopic and dark-adapted perimetry testing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central steepening of cornea n1=cyclopeptide | n2=en:central steepening of cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central tapetoretinal dystrophy n1=cyclopeptide | n2=en:central tapetoretinal dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:central/paracentral scotomata n1=cyclopeptide | n2=en:central/paracentral scotomata | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:centrocecal scotoma (acute phase) n1=cyclopeptide | n2=en:centrocecal scotoma (acute phase) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:centrocecal scotomas n1=cyclopeptide | n2=en:centrocecal scotomas | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceo-pe protocol n1=cyclopeptide | n2=en:ceo-pe protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceop protocol 1 n1=cyclopeptide | n2=en:ceop protocol 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceop protocol 2 n1=cyclopeptide | n2=en:ceop protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceop-imvp-dexa regimen n1=cyclopeptide | n2=en:ceop-imvp-dexa regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceop-mb protocol n1=cyclopeptide | n2=en:ceop-mb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cep regimen n1=cyclopeptide | n2=en:cep regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cep-2563 dihydrochloride n1=cyclopeptide | n2=en:cep-2563 dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cephalexin n1=cyclopeptide | n2=en:cephalexin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cephalostatin n1=cyclopeptide | n2=en:cephalostatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cephalothin sodium n1=cyclopeptide | n2=en:cephalothin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cepp protocol n1=cyclopeptide | n2=en:cepp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceramide n1=cyclopeptide | n2=en:ceramide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cerebral visual impairment n1=cyclopeptide | n2=en:cerebral visual impairment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceritinib n1=cyclopeptide | n2=en:ceritinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:certain congenital musculoskeletal deformities n1=cyclopeptide | n2=en:certain congenital musculoskeletal deformities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:certolizumab n1=cyclopeptide | n2=en:certolizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:certolizumab pegol n1=cyclopeptide | n2=en:certolizumab pegol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceruminolytic agent n1=cyclopeptide | n2=en:ceruminolytic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cervical auricle (disorder) n1=cyclopeptide | n2=en:cervical auricle (disorder) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cesium cs 137 n1=cyclopeptide | n2=en:cesium cs 137 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cesium cs-131 n1=cyclopeptide | n2=en:cesium cs-131 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ceteth-20 n1=cyclopeptide | n2=en:ceteth-20 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cetirizine n1=cyclopeptide | n2=en:cetirizine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cetrorelix n1=cyclopeptide | n2=en:cetrorelix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cetuximab n1=cyclopeptide | n2=en:cetuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cetuximab-ir700 conjugate rm-1929 n1=cyclopeptide | n2=en:cetuximab-ir700 conjugate rm-1929 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cetuximab-irdye 800cw n1=cyclopeptide | n2=en:cetuximab-irdye 800cw | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cevad protocol n1=cyclopeptide | n2=en:cevad protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cevbp protocol n1=cyclopeptide | n2=en:cevbp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cevimeline hydrochloride n1=cyclopeptide | n2=en:cevimeline hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cevp protocol n1=cyclopeptide | n2=en:cevp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cfmpv protocol n1=cyclopeptide | n2=en:cfmpv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cfms tyrosine kinase inhibitor arry-382 n1=cyclopeptide | n2=en:cfms tyrosine kinase inhibitor arry-382 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cg7870 n1=cyclopeptide | n2=en:cg7870 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cgp-6809 n1=cyclopeptide | n2=en:cgp-6809 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chac-1 protocol n1=cyclopeptide | n2=en:chac-1 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chamoca regimen n1=cyclopeptide | n2=en:chamoca regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chamoma protocol n1=cyclopeptide | n2=en:chamoma protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chamomile n1=cyclopeptide | n2=en:chamomile | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:champ-5 protocol n1=cyclopeptide | n2=en:champ-5 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:changchun marina n1=cyclopeptide | n2=en:changchun marina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chase protocol n1=cyclopeptide | n2=en:chase protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:checkpoint kinase inhibitor azd7762 n1=cyclopeptide | n2=en:checkpoint kinase inhibitor azd7762 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:checkpoint kinase inhibitor xl844 n1=cyclopeptide | n2=en:checkpoint kinase inhibitor xl844 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cheilognathopalatoschisis n1=cyclopeptide | n2=en:cheilognathopalatoschisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cheilognathoschisis n1=cyclopeptide | n2=en:cheilognathoschisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chelating agent n1=cyclopeptide | n2=en:chelating agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chelating agents and antidotes n1=cyclopeptide | n2=en:chelating agents and antidotes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chemical aspects n1=cyclopeptide | n2=en:chemical aspects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chemical synthesis n1=cyclopeptide | n2=en:chemical synthesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chemotherapeutic topical agent n1=cyclopeptide | n2=en:chemotherapeutic topical agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chep protocol n1=cyclopeptide | n2=en:chep protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cherry-red maculae (50%) n1=cyclopeptide | n2=en:cherry-red maculae (50%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cherry-red maculae (less common) n1=cyclopeptide | n2=en:cherry-red maculae (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cherry-red spot (type ii, infantile and juvenile and type i) n1=cyclopeptide | n2=en:cherry-red spot (type ii, infantile and juvenile and type i) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cherry-red spot in half the patients n1=cyclopeptide | n2=en:cherry-red spot in half the patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cherubism n1=cyclopeptide | n2=en:cherubism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chewing gum dosage form n1=cyclopeptide | n2=en:chewing gum dosage form | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chf protocol n1=cyclopeptide | n2=en:chf protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chiauranib n1=cyclopeptide | n2=en:chiauranib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chidamide n1=cyclopeptide | n2=en:chidamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chimeric fibril-reactive monoclonal antibody 111f4 n1=cyclopeptide | n2=en:chimeric fibril-reactive monoclonal antibody 111f4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chimeric humanized anti-cd47 antibody n1=cyclopeptide | n2=en:chimeric humanized anti-cd47 antibody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chinese herbal formulation changtai keli n1=cyclopeptide | n2=en:chinese herbal formulation changtai keli | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chinese herbal formulation phy906 n1=cyclopeptide | n2=en:chinese herbal formulation phy906 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chinese herbal medicine compound tpe-1 n1=cyclopeptide | n2=en:chinese herbal medicine compound tpe-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chinese herbs n1=cyclopeptide | n2=en:chinese herbs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chinese herbs/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:chinese herbs/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chining decoction n1=cyclopeptide | n2=en:chining decoction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chk1 inhibitor gdc-0425 n1=cyclopeptide | n2=en:chk1 inhibitor gdc-0425 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chk1 inhibitor gdc-0575 n1=cyclopeptide | n2=en:chk1 inhibitor gdc-0575 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chk1 inhibitor mk-8776 n1=cyclopeptide | n2=en:chk1 inhibitor mk-8776 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chk1 inhibitor pf-477736 n1=cyclopeptide | n2=en:chk1 inhibitor pf-477736 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorambucil n1=cyclopeptide | n2=en:chlorambucil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorambucil-prednisone regimen n1=cyclopeptide | n2=en:chlorambucil-prednisone regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorhexidine n1=cyclopeptide | n2=en:chlorhexidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorhexidine gluconate n1=cyclopeptide | n2=en:chlorhexidine gluconate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorhexidine/ethyl alcohol mouthwash n1=cyclopeptide | n2=en:chlorhexidine/ethyl alcohol mouthwash | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlornaphazine n1=cyclopeptide | n2=en:chlornaphazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorogenic acid n1=cyclopeptide | n2=en:chlorogenic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chloroquine n1=cyclopeptide | n2=en:chloroquine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chloroquinoxaline sulfonamide n1=cyclopeptide | n2=en:chloroquinoxaline sulfonamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorotoxin n1=cyclopeptide | n2=en:chlorotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorotoxin [131i] n1=cyclopeptide | n2=en:chlorotoxin [131i] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorotoxin-indocyanine green imaging agent blz-100 n1=cyclopeptide | n2=en:chlorotoxin-indocyanine green imaging agent blz-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorozotocin n1=cyclopeptide | n2=en:chlorozotocin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorpromazine n1=cyclopeptide | n2=en:chlorpromazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorpropamide n1=cyclopeptide | n2=en:chlorpropamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chlorzoxazone n1=cyclopeptide | n2=en:chlorzoxazone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choep protocol n1=cyclopeptide | n2=en:choep protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choioretinal atrophy n1=cyclopeptide | n2=en:choioretinal atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cholecalciferol n1=cyclopeptide | n2=en:cholecalciferol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cholecalciferol/whey protein isolate/epa/dha-based nutritional supplement n1=cyclopeptide | n2=en:cholecalciferol/whey protein isolate/epa/dha-based nutritional supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cholelitholytic and/or choleretic agent n1=cyclopeptide | n2=en:cholelitholytic and/or choleretic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choleretic agent n1=cyclopeptide | n2=en:choleretic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choline kinase alpha inhibitor tcd-717 n1=cyclopeptide | n2=en:choline kinase alpha inhibitor tcd-717 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choline magnesium trisalicylate n1=cyclopeptide | n2=en:choline magnesium trisalicylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choline salicylate n1=cyclopeptide | n2=en:choline salicylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chop protocol, modified n1=cyclopeptide | n2=en:chop protocol, modified | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chop regimen n1=cyclopeptide | n2=en:chop regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chop-v-mmv protocol n1=cyclopeptide | n2=en:chop-v-mmv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chop-vp16 protocol n1=cyclopeptide | n2=en:chop-vp16 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chope regimen n1=cyclopeptide | n2=en:chope regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorio-retinitis n1=cyclopeptide | n2=en:chorio-retinitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choriocapillaris atrophy n1=cyclopeptide | n2=en:choriocapillaris atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorioectopia n1=cyclopeptide | n2=en:chorioectopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorioretinal atrophic lacunae n1=cyclopeptide | n2=en:chorioretinal atrophic lacunae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorioretinal atrophy n1=cyclopeptide | n2=en:chorioretinal atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorioretinal coloboma (rare) n1=cyclopeptide | n2=en:chorioretinal coloboma (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorioretinal degeneration n1=cyclopeptide | n2=en:chorioretinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorioretinal dystrophy n1=cyclopeptide | n2=en:chorioretinal dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorioretinal lacunae n1=cyclopeptide | n2=en:chorioretinal lacunae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chorioretinopathy (in some patients) n1=cyclopeptide | n2=en:chorioretinopathy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroid atrophy (in some patients) n1=cyclopeptide | n2=en:choroid atrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroid atrophy (rare) n1=cyclopeptide | n2=en:choroid atrophy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroid hemangioma n1=cyclopeptide | n2=en:choroid hemangioma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal and/or chorioretinal disorder n1=cyclopeptide | n2=en:choroidal and/or chorioretinal disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal atrophy n1=cyclopeptide | n2=en:choroidal atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal atrophy (rare) n1=cyclopeptide | n2=en:choroidal atrophy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal dystrophy (in most patients) n1=cyclopeptide | n2=en:choroidal dystrophy (in most patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal fold n1=cyclopeptide | n2=en:choroidal fold | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal neovascularization n1=cyclopeptide | n2=en:choroidal neovascularization | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal neovascularization (in some patients) n1=cyclopeptide | n2=en:choroidal neovascularization (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal sclerosis n1=cyclopeptide | n2=en:choroidal sclerosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal sclerosis (in some patients) n1=cyclopeptide | n2=en:choroidal sclerosis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidal vessels visible n1=cyclopeptide | n2=en:choroidal vessels visible | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroideremia n1=cyclopeptide | n2=en:choroideremia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidoretinal degeneration (1 patient) n1=cyclopeptide | n2=en:choroidoretinal degeneration (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:choroidoretinal degeneration (starting in the midperiphery of the fundus and progressing centrally and peripherally) n1=cyclopeptide | n2=en:choroidoretinal degeneration (starting in the midperiphery of the fundus and progressing centrally and peripherally) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chp-her-2 peptide vaccine n1=cyclopeptide | n2=en:chp-her-2 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chp-ny-eso-1 peptide vaccine imf-001 n1=cyclopeptide | n2=en:chp-ny-eso-1 peptide vaccine imf-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chromomycin a3 n1=cyclopeptide | n2=en:chromomycin a3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chromosome disorder n1=cyclopeptide | n2=en:chromosome disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chronic blepharitis n1=cyclopeptide | n2=en:chronic blepharitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chronic keratitis n1=cyclopeptide | n2=en:chronic keratitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chronic tearing n1=cyclopeptide | n2=en:chronic tearing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:chvp regimen n1=cyclopeptide | n2=en:chvp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cicatricial ectropion n1=cyclopeptide | n2=en:cicatricial ectropion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ciclopirox olamine lotion n1=cyclopeptide | n2=en:ciclopirox olamine lotion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ciclopirox olamine oral n1=cyclopeptide | n2=en:ciclopirox olamine oral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cidan herbal capsule n1=cyclopeptide | n2=en:cidan herbal capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cidofovir n1=cyclopeptide | n2=en:cidofovir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cilengitide n1=cyclopeptide | n2=en:cilengitide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ciliary body n1=cyclopeptide | n2=en:ciliary body | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cimetidine n1=cyclopeptide | n2=en:cimetidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cimetidine/cyclophosphamide/indomethacin/interleukin-2 n1=cyclopeptide | n2=en:cimetidine/cyclophosphamide/indomethacin/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cinacalcet hydrochloride n1=cyclopeptide | n2=en:cinacalcet hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cinobufagin n1=cyclopeptide | n2=en:cinobufagin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cintredekin besudotox n1=cyclopeptide | n2=en:cintredekin besudotox | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ciod protocol n1=cyclopeptide | n2=en:ciod protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ciop protocol n1=cyclopeptide | n2=en:ciop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ciop-bleo protocol n1=cyclopeptide | n2=en:ciop-bleo protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cipatinib n1=cyclopeptide | n2=en:cipatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ciprofloxacin n1=cyclopeptide | n2=en:ciprofloxacin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ciprofloxacin/cisplatin/cyclophosphamide/etoposide/pentoxifylline n1=cyclopeptide | n2=en:ciprofloxacin/cisplatin/cyclophosphamide/etoposide/pentoxifylline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:circular patches of pigment epithelial atrophy at the macula and in peripheral retina (in some patients) n1=cyclopeptide | n2=en:circular patches of pigment epithelial atrophy at the macula and in peripheral retina (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:circumpapillary telangiectatic microangiopathy (acute phase) n1=cyclopeptide | n2=en:circumpapillary telangiectatic microangiopathy (acute phase) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cirmtuzumab n1=cyclopeptide | n2=en:cirmtuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cis-urocanic acid n1=cyclopeptide | n2=en:cis-urocanic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cis-vacd protocol n1=cyclopeptide | n2=en:cis-vacd protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisapride n1=cyclopeptide | n2=en:cisapride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisatracurium besylate n1=cyclopeptide | n2=en:cisatracurium besylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisca regimen n1=cyclopeptide | n2=en:cisca regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisca(ii)-vb(iv) protocol n1=cyclopeptide | n2=en:cisca(ii)-vb(iv) protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin n1=cyclopeptide | n2=en:cisplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin liposomal n1=cyclopeptide | n2=en:cisplatin liposomal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin-e therapeutic implant n1=cyclopeptide | n2=en:cisplatin-e therapeutic implant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/10-edam n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/10-edam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/cyclosporine/paclitaxel n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/cyclosporine/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/cytarabine/hydroxyurea/lomustine/methylprednisolone/procarbazine/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/cytarabine/hydroxyurea/lomustine/methylprednisolone/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/dacarbazine/doxorubicin/etoposide/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/dacarbazine/doxorubicin/etoposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/dacarbazine/doxorubicin/mechlorethamine/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/dacarbazine/doxorubicin/mechlorethamine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide/thalidomide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide/thalidomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/dexamethasone/etoposide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/dexamethasone/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/dexamethasone/etoposide/gemcitabine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/dexamethasone/etoposide/gemcitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/dexamethasone/etoposide/thalidomide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/dexamethasone/etoposide/thalidomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/diethyldithiocarbamate n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/diethyldithiocarbamate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide/filgrastim n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide/filgrastim/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide/filgrastim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide/fluorouracil/methotrexate/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide/fluorouracil/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide/fluorouracil/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide/fluorouracil/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine/vindesine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine/vindesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide/sargramostim n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/etoposide/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/etoposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/fluorouracil n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/lomustine/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/lomustine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/misonidazole n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/misonidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/prednisone n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/tegafur n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/tegafur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/teniposide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/teniposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/triazinate n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/triazinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/doxorubicin/vindesine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/doxorubicin/vindesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/epirubicin n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/epirubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/epirubicin/etoposide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/epirubicin/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/filgrastim n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/filgrastim/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/filgrastim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/interleukin-2 n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/interleukin-2/sargramostim n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/interleukin-2/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/leucovorin calcium/methotrexate/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/leucovorin calcium/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/lomustine/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/lomustine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/mafosfamide/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/mafosfamide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/methotrexate/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/sargramostim n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/thiotepa/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/thiotepa/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/etoposide/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/etoposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/filgrastim n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/filgrastim/paclitaxel n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/filgrastim/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/fluorouracil/methotrexate/prednisone n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/fluorouracil/methotrexate/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/fluorouracil/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/fluorouracil/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/interferon alfa n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/interferon alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/interleukin-2 n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/leuprolide n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/leuprolide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/melphalan n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/melphalan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/mitoxantrone n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/paclitaxel n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/thiotepa n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/vincristine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cisplatin/cyclophosphamide/vindesine n1=cyclopeptide | n2=en:cisplatin/cyclophosphamide/vindesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:citalopram hydrobromide n1=cyclopeptide | n2=en:citalopram hydrobromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:citatuzumab bogatox n1=cyclopeptide | n2=en:citatuzumab bogatox | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:citicoline n1=cyclopeptide | n2=en:citicoline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:citric acid + magnesium oxide + sodium picosulfate n1=cyclopeptide | n2=en:citric acid + magnesium oxide + sodium picosulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:citrulline n1=cyclopeptide | n2=en:citrulline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cixutumumab n1=cyclopeptide | n2=en:cixutumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ck2-targeting synthetic peptide cigb-300 n1=cyclopeptide | n2=en:ck2-targeting synthetic peptide cigb-300 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cl 246738 n1=cyclopeptide | n2=en:cl 246738 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cladribine n1=cyclopeptide | n2=en:cladribine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cladribine/cyclophosphamide/prednisone n1=cyclopeptide | n2=en:cladribine/cyclophosphamide/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clanfenur n1=cyclopeptide | n2=en:clanfenur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clarithromycin n1=cyclopeptide | n2=en:clarithromycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:classical phenylketonuria n1=cyclopeptide | n2=en:classical phenylketonuria | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:claudiximab n1=cyclopeptide | n2=en:claudiximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clear cornea n1=cyclopeptide | n2=en:clear cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clear corneas n1=cyclopeptide | n2=en:clear corneas | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clear gelatinous pterygia-like plaques of the nasal and temporal perilimbal bulbar conjunctiva n1=cyclopeptide | n2=en:clear gelatinous pterygia-like plaques of the nasal and temporal perilimbal bulbar conjunctiva | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clear to faintly hazy corneas n1=cyclopeptide | n2=en:clear to faintly hazy corneas | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cleft jaw n1=cyclopeptide | n2=en:cleft jaw | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cleft lip n1=cyclopeptide | n2=en:cleft lip | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cleft maxilla n1=cyclopeptide | n2=en:cleft maxilla | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cleft palate n1=cyclopeptide | n2=en:cleft palate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cleft palate with cleft lip n1=cyclopeptide | n2=en:cleft palate with cleft lip | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cleidocranial dysplasia n1=cyclopeptide | n2=en:cleidocranial dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clevidipine n1=cyclopeptide | n2=en:clevidipine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clevudine n1=cyclopeptide | n2=en:clevudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clindamycin n1=cyclopeptide | n2=en:clindamycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clindamycin phosphate n1=cyclopeptide | n2=en:clindamycin phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clindamycin/hydrocortisone lotion n1=cyclopeptide | n2=en:clindamycin/hydrocortisone lotion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clinical anophthalmia, unilateral/bilateral (87%) n1=cyclopeptide | n2=en:clinical anophthalmia, unilateral/bilateral (87%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clinical data interchange standards consortium terminology n1=cyclopeptide | n2=en:clinical data interchange standards consortium terminology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clinically 'silent' nystagmus evident on eye movement recording in carrier females n1=cyclopeptide | n2=en:clinically 'silent' nystagmus evident on eye movement recording in carrier females | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clino-san vaginal lubricant n1=cyclopeptide | n2=en:clino-san vaginal lubricant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clioquinol n1=cyclopeptide | n2=en:clioquinol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clobetasol propionate n1=cyclopeptide | n2=en:clobetasol propionate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clodronate disodium n1=cyclopeptide | n2=en:clodronate disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clofarabine n1=cyclopeptide | n2=en:clofarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clofibrate n1=cyclopeptide | n2=en:clofibrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clomiphene citrate n1=cyclopeptide | n2=en:clomiphene citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clonidine hydrochloride n1=cyclopeptide | n2=en:clonidine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clonidine-containing mucoadhesive buccal tablet n1=cyclopeptide | n2=en:clonidine-containing mucoadhesive buccal tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clopidogrel bisulfate n1=cyclopeptide | n2=en:clopidogrel bisulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clostridium butyricum-containing probiotic n1=cyclopeptide | n2=en:clostridium butyricum-containing probiotic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clostridium novyi-nt spores n1=cyclopeptide | n2=en:clostridium novyi-nt spores | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clotrimazole n1=cyclopeptide | n2=en:clotrimazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cloudy corneas n1=cyclopeptide | n2=en:cloudy corneas | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cloudy corneas (in some patients) n1=cyclopeptide | n2=en:cloudy corneas (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:clubfoot n1=cyclopeptide | n2=en:clubfoot | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmb protocol n1=cyclopeptide | n2=en:cmb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmc protocol 2 n1=cyclopeptide | n2=en:cmc protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmcf protocol n1=cyclopeptide | n2=en:cmcf protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmcp protocol n1=cyclopeptide | n2=en:cmcp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmed protocol n1=cyclopeptide | n2=en:cmed protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmet car-mrna electroporated autologous t lymphocytes n1=cyclopeptide | n2=en:cmet car-mrna electroporated autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmf regimen n1=cyclopeptide | n2=en:cmf regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmfpth regimen n1=cyclopeptide | n2=en:cmfpth regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmopp protocol n1=cyclopeptide | n2=en:cmopp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmu protocol n1=cyclopeptide | n2=en:cmu protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmv n495 peptide n1=cyclopeptide | n2=en:cmv n495 peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmv pp65 peptide-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:cmv pp65 peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmvp regimen n1=cyclopeptide | n2=en:cmvp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmvpp65-a*0201 peptide vaccine n1=cyclopeptide | n2=en:cmvpp65-a*0201 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmvpp65/gb plasmid vaccine asp0113 n1=cyclopeptide | n2=en:cmvpp65/gb plasmid vaccine asp0113 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cmxmf regimen n1=cyclopeptide | n2=en:cmxmf regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cn3op regimen n1=cyclopeptide | n2=en:cn3op regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cndo-109-activated allogeneic natural killer cells n1=cyclopeptide | n2=en:cndo-109-activated allogeneic natural killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cngrc peptide-tnf alpha conjugate n1=cyclopeptide | n2=en:cngrc peptide-tnf alpha conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cnop regimen n1=cyclopeptide | n2=en:cnop regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cnv protocol n1=cyclopeptide | n2=en:cnv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coarctation n1=cyclopeptide | n2=en:coarctation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coarse retinal pigmentation (rare) n1=cyclopeptide | n2=en:coarse retinal pigmentation (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coata protocol n1=cyclopeptide | n2=en:coata protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cobalamin n1=cyclopeptide | n2=en:cobalamin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cobdp regimen n1=cyclopeptide | n2=en:cobdp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cobimetinib n1=cyclopeptide | n2=en:cobimetinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cobiprostone n1=cyclopeptide | n2=en:cobiprostone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cocculus/nux vomica/tabacum/petroleum extract n1=cyclopeptide | n2=en:cocculus/nux vomica/tabacum/petroleum extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cockayne syndrome n1=cyclopeptide | n2=en:cockayne syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cocoa extract n1=cyclopeptide | n2=en:cocoa extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:codblam iv protocol n1=cyclopeptide | n2=en:codblam iv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:codeine phosphate n1=cyclopeptide | n2=en:codeine phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:codox-m regimen n1=cyclopeptide | n2=en:codox-m regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:codox-m/ivac regimen n1=cyclopeptide | n2=en:codox-m/ivac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coenzyme q10 n1=cyclopeptide | n2=en:coenzyme q10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cofb protocol n1=cyclopeptide | n2=en:cofb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coffee dietary supplement n1=cyclopeptide | n2=en:coffee dietary supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cofp protocol 1 n1=cyclopeptide | n2=en:cofp protocol 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cofp protocol 2 n1=cyclopeptide | n2=en:cofp protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cogwheel ocular pursuit n1=cyclopeptide | n2=en:cogwheel ocular pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colchicine n1=cyclopeptide | n2=en:colchicine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cold contaminant-free iobenguane i-131 n1=cyclopeptide | n2=en:cold contaminant-free iobenguane i-131 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colesevelam hydrochloride n1=cyclopeptide | n2=en:colesevelam hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colistin sulfate n1=cyclopeptide | n2=en:colistin sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:collagen n1=cyclopeptide | n2=en:collagen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:collagen/aloe vera/vitamin e/lidocaine topical hydrogel n1=cyclopeptide | n2=en:collagen/aloe vera/vitamin e/lidocaine topical hydrogel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colloidal gold-bound tumor necrosis factor n1=cyclopeptide | n2=en:colloidal gold-bound tumor necrosis factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colloidal oatmeal cream n1=cyclopeptide | n2=en:colloidal oatmeal cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma (1 patient) n1=cyclopeptide | n2=en:coloboma (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma (in some patients with larger microdeletion) n1=cyclopeptide | n2=en:coloboma (in some patients with larger microdeletion) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma (in some patients) n1=cyclopeptide | n2=en:coloboma (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma (iris or optic nerve) n1=cyclopeptide | n2=en:coloboma (iris or optic nerve) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma (iris, optic nerve) n1=cyclopeptide | n2=en:coloboma (iris, optic nerve) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma (wws) n1=cyclopeptide | n2=en:coloboma (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma and other anomalies of anterior segment n1=cyclopeptide | n2=en:coloboma and other anomalies of anterior segment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of choroid n1=cyclopeptide | n2=en:coloboma of choroid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of eyelids, iris, and choroid n1=cyclopeptide | n2=en:coloboma of eyelids, iris, and choroid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of iris (1 of 5 patients) n1=cyclopeptide | n2=en:coloboma of iris (1 of 5 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of optic disc n1=cyclopeptide | n2=en:coloboma of optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of optic nerve (rare) n1=cyclopeptide | n2=en:coloboma of optic nerve (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the eye n1=cyclopeptide | n2=en:coloboma of the eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the eyelid n1=cyclopeptide | n2=en:coloboma of the eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the iris n1=cyclopeptide | n2=en:coloboma of the iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the iris (in some patients) n1=cyclopeptide | n2=en:coloboma of the iris (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the iris (rare) n1=cyclopeptide | n2=en:coloboma of the iris (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the iris, inferior n1=cyclopeptide | n2=en:coloboma of the iris, inferior | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the lower eyelids (rare) n1=cyclopeptide | n2=en:coloboma of the lower eyelids (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the retina n1=cyclopeptide | n2=en:coloboma of the retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma of the right optic disc n1=cyclopeptide | n2=en:coloboma of the right optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma, choreoretinal n1=cyclopeptide | n2=en:coloboma, choreoretinal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma, choroid (rare) n1=cyclopeptide | n2=en:coloboma, choroid (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma, isolated (in some patients) n1=cyclopeptide | n2=en:coloboma, isolated (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coloboma, retinochoroidal (rare) n1=cyclopeptide | n2=en:coloboma, retinochoroidal (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colobomas (iris, choroid, retina, disc, and optic nerve) n1=cyclopeptide | n2=en:colobomas (iris, choroid, retina, disc, and optic nerve) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colobomas of optic disk, choroid, ciliary body, and iris n1=cyclopeptide | n2=en:colobomas of optic disk, choroid, ciliary body, and iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color blindness, blue n1=cyclopeptide | n2=en:color blindness, blue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color blindness, red n1=cyclopeptide | n2=en:color blindness, red | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color blindness, red-green n1=cyclopeptide | n2=en:color blindness, red-green | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color vision abnormalities (in some patients) n1=cyclopeptide | n2=en:color vision abnormalities (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color vision defect n1=cyclopeptide | n2=en:color vision defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color vision defect, severe n1=cyclopeptide | n2=en:color vision defect, severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color vision deficit, green or red-green n1=cyclopeptide | n2=en:color vision deficit, green or red-green | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color vision deficits (in some patients) n1=cyclopeptide | n2=en:color vision deficits (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color vision disturbance in protan, deutan, and tritan axes n1=cyclopeptide | n2=en:color vision disturbance in protan, deutan, and tritan axes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:color vision disturbed n1=cyclopeptide | n2=en:color vision disturbed | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colorblindness, blue cone monochromacy type n1=cyclopeptide | n2=en:colorblindness, blue cone monochromacy type | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colorblindness, severe to complete n1=cyclopeptide | n2=en:colorblindness, severe to complete | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colorectal tumor-associated peptides vaccine ima910 n1=cyclopeptide | n2=en:colorectal tumor-associated peptides vaccine ima910 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:colors indistinguishable n1=cyclopeptide | n2=en:colors indistinguishable | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:comb protocol n1=cyclopeptide | n2=en:comb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:combined hamartoma of the retinal pigment epithelium and retina n1=cyclopeptide | n2=en:combined hamartoma of the retinal pigment epithelium and retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:combretastatin a1 diphosphate n1=cyclopeptide | n2=en:combretastatin a1 diphosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:comet-a protocol n1=cyclopeptide | n2=en:comet-a protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:comla protocol n1=cyclopeptide | n2=en:comla protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:common atrioventricular orifice in double inlet ventricle n1=cyclopeptide | n2=en:common atrioventricular orifice in double inlet ventricle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:comp-1 protocol n1=cyclopeptide | n2=en:comp-1 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:comp-van protocol n1=cyclopeptide | n2=en:comp-van protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:compa protocol n1=cyclopeptide | n2=en:compa protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:complement c5 inhibitor alxn1210 n1=cyclopeptide | n2=en:complement c5 inhibitor alxn1210 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:complement inactivating agents n1=cyclopeptide | n2=en:complement inactivating agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:complete blindness between ages 40-50 years n1=cyclopeptide | n2=en:complete blindness between ages 40-50 years | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:complete trisomy 13 syndrome n1=cyclopeptide | n2=en:complete trisomy 13 syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:complicated strabismus n1=cyclopeptide | n2=en:complicated strabismus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:compound kushen injection n1=cyclopeptide | n2=en:compound kushen injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:compound sodium lactate solution n1=cyclopeptide | n2=en:compound sodium lactate solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:compression of optic nerve n1=cyclopeptide | n2=en:compression of optic nerve | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conatumumab n1=cyclopeptide | n2=en:conatumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:concentrated beet crystals n1=cyclopeptide | n2=en:concentrated beet crystals | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:concentrated fortified collagen protein hydrolysate liquid supplement n1=cyclopeptide | n2=en:concentrated fortified collagen protein hydrolysate liquid supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:concentric constriction of visual fields bilaterally n1=cyclopeptide | n2=en:concentric constriction of visual fields bilaterally | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conditionally replicative adenovirus 5/3-delta24 n1=cyclopeptide | n2=en:conditionally replicative adenovirus 5/3-delta24 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conductive hearing loss n1=cyclopeptide | n2=en:conductive hearing loss | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cone and rod responses borderline or nondetectable on electroretinography (erg) by the second decade of life n1=cyclopeptide | n2=en:cone and rod responses borderline or nondetectable on electroretinography (erg) by the second decade of life | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cone degeneration, stationary (in some patients) n1=cyclopeptide | n2=en:cone degeneration, stationary (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cone implicit times consistent with progressive disease n1=cyclopeptide | n2=en:cone implicit times consistent with progressive disease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cone responses decreased on erg n1=cyclopeptide | n2=en:cone responses decreased on erg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cone-driven 1-hz response with unusual waveform on electroretinography n1=cyclopeptide | n2=en:cone-driven 1-hz response with unusual waveform on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cone-driven 29-hz flicker erg with broadened trough and mildly delayed implicit time n1=cyclopeptide | n2=en:cone-driven 29-hz flicker erg with broadened trough and mildly delayed implicit time | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cone-first retinal dystrophy n1=cyclopeptide | n2=en:cone-first retinal dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cone-rod dystrophy (uncommon) n1=cyclopeptide | n2=en:cone-rod dystrophy (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital n1=cyclopeptide | n2=en:congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital abnormal communication n1=cyclopeptide | n2=en:congenital abnormal communication | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital abnormal fusion n1=cyclopeptide | n2=en:congenital abnormal fusion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital abnormality n1=cyclopeptide | n2=en:congenital abnormality | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital abnormality of lower limb and/or pelvic girdle n1=cyclopeptide | n2=en:congenital abnormality of lower limb and/or pelvic girdle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital absence of tears n1=cyclopeptide | n2=en:congenital absence of tears | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital ankyloblepharon n1=cyclopeptide | n2=en:congenital ankyloblepharon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital ankyloblepharon filiforme n1=cyclopeptide | n2=en:congenital ankyloblepharon filiforme | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomalies of eyelid, lacrimal system and orbit n1=cyclopeptide | n2=en:congenital anomalies of eyelid, lacrimal system and orbit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomalies of fetus n1=cyclopeptide | n2=en:congenital anomalies of fetus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of anterior segment of eye n1=cyclopeptide | n2=en:congenital anomaly of anterior segment of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of back n1=cyclopeptide | n2=en:congenital anomaly of back | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of body wall n1=cyclopeptide | n2=en:congenital anomaly of body wall | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of central nervous system n1=cyclopeptide | n2=en:congenital anomaly of central nervous system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of endocrine gland n1=cyclopeptide | n2=en:congenital anomaly of endocrine gland | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of face n1=cyclopeptide | n2=en:congenital anomaly of face | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of face bones n1=cyclopeptide | n2=en:congenital anomaly of face bones | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of gastrointestinal tract n1=cyclopeptide | n2=en:congenital anomaly of gastrointestinal tract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of head n1=cyclopeptide | n2=en:congenital anomaly of head | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of iris n1=cyclopeptide | n2=en:congenital anomaly of iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of jaw n1=cyclopeptide | n2=en:congenital anomaly of jaw | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of lacrimal gland n1=cyclopeptide | n2=en:congenital anomaly of lacrimal gland | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of neck n1=cyclopeptide | n2=en:congenital anomaly of neck | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of orbit n1=cyclopeptide | n2=en:congenital anomaly of orbit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of posterior segment of eye n1=cyclopeptide | n2=en:congenital anomaly of posterior segment of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of sclera n1=cyclopeptide | n2=en:congenital anomaly of sclera | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of skeletal bone n1=cyclopeptide | n2=en:congenital anomaly of skeletal bone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of skull n1=cyclopeptide | n2=en:congenital anomaly of skull | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of spine n1=cyclopeptide | n2=en:congenital anomaly of spine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of the hematopoietic system n1=cyclopeptide | n2=en:congenital anomaly of the hematopoietic system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of trunk n1=cyclopeptide | n2=en:congenital anomaly of trunk | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital anomaly of visual system n1=cyclopeptide | n2=en:congenital anomaly of visual system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital bilateral cataracts n1=cyclopeptide | n2=en:congenital bilateral cataracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital bilateral ptosis n1=cyclopeptide | n2=en:congenital bilateral ptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital blindness n1=cyclopeptide | n2=en:congenital blindness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cardiovascular abnormality n1=cyclopeptide | n2=en:congenital cardiovascular abnormality | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cardiovascular malformation n1=cyclopeptide | n2=en:congenital cardiovascular malformation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cataract n1=cyclopeptide | n2=en:congenital cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cataract (males) n1=cyclopeptide | n2=en:congenital cataract (males) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cataract and lens anomalies n1=cyclopeptide | n2=en:congenital cataract and lens anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cataracts (1 family) n1=cyclopeptide | n2=en:congenital cataracts (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cataracts (reported in 1 patient) n1=cyclopeptide | n2=en:congenital cataracts (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cataracts, facial dysmorphism, and neuropathy n1=cyclopeptide | n2=en:congenital cataracts, facial dysmorphism, and neuropathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cavitation n1=cyclopeptide | n2=en:congenital cavitation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital complete achromatopsia n1=cyclopeptide | n2=en:congenital complete achromatopsia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cyst of posterior segment of eye n1=cyclopeptide | n2=en:congenital cyst of posterior segment of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital cystic eyeball n1=cyclopeptide | n2=en:congenital cystic eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of ankle joint n1=cyclopeptide | n2=en:congenital deformity of ankle joint | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of chest wall n1=cyclopeptide | n2=en:congenital deformity of chest wall | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of clavicle n1=cyclopeptide | n2=en:congenital deformity of clavicle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of hip n1=cyclopeptide | n2=en:congenital deformity of hip | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of knee joint n1=cyclopeptide | n2=en:congenital deformity of knee joint | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of labyrinth n1=cyclopeptide | n2=en:congenital deformity of labyrinth | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of mitral valve annulus n1=cyclopeptide | n2=en:congenital deformity of mitral valve annulus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of pharynx n1=cyclopeptide | n2=en:congenital deformity of pharynx | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of pinna n1=cyclopeptide | n2=en:congenital deformity of pinna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital deformity of scapula n1=cyclopeptide | n2=en:congenital deformity of scapula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital diaphragmatic hernia n1=cyclopeptide | n2=en:congenital diaphragmatic hernia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital disorders of eye and eyelid movements n1=cyclopeptide | n2=en:congenital disorders of eye and eyelid movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital disruption n1=cyclopeptide | n2=en:congenital disruption | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital dysplasia n1=cyclopeptide | n2=en:congenital dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital ectopic lens n1=cyclopeptide | n2=en:congenital ectopic lens | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital ectopic pupil n1=cyclopeptide | n2=en:congenital ectopic pupil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital enlargement n1=cyclopeptide | n2=en:congenital enlargement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital epicanthus n1=cyclopeptide | n2=en:congenital epicanthus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital extension deformity n1=cyclopeptide | n2=en:congenital extension deformity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital eye disorder n1=cyclopeptide | n2=en:congenital eye disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital eye disorders nec n1=cyclopeptide | n2=en:congenital eye disorders nec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital eyelid malformation n1=cyclopeptide | n2=en:congenital eyelid malformation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital failure of fusion n1=cyclopeptide | n2=en:congenital failure of fusion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital fibrosis of the extraocular muscles n1=cyclopeptide | n2=en:congenital fibrosis of the extraocular muscles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital fibrosis of the extraocular muscles (1 family) n1=cyclopeptide | n2=en:congenital fibrosis of the extraocular muscles (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital fibrosis of the extraocular muscles (9%) n1=cyclopeptide | n2=en:congenital fibrosis of the extraocular muscles (9%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital fistula of lip n1=cyclopeptide | n2=en:congenital fistula of lip | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital flat back deformity n1=cyclopeptide | n2=en:congenital flat back deformity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital flexion deformity n1=cyclopeptide | n2=en:congenital flexion deformity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital foot deformity n1=cyclopeptide | n2=en:congenital foot deformity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital functional anomaly n1=cyclopeptide | n2=en:congenital functional anomaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital genitourinary abnormality n1=cyclopeptide | n2=en:congenital genitourinary abnormality | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital growth alteration n1=cyclopeptide | n2=en:congenital growth alteration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hallux valgus n1=cyclopeptide | n2=en:congenital hallux valgus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hamartoma n1=cyclopeptide | n2=en:congenital hamartoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hand and foot deformity n1=cyclopeptide | n2=en:congenital hand and foot deformity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hernia n1=cyclopeptide | n2=en:congenital hernia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hyperextension of limb n1=cyclopeptide | n2=en:congenital hyperextension of limb | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hyperflexion of limb n1=cyclopeptide | n2=en:congenital hyperflexion of limb | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hypertrophy of retinal pigment epithelium n1=cyclopeptide | n2=en:congenital hypertrophy of retinal pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hypoplasia of choroid n1=cyclopeptide | n2=en:congenital hypoplasia of choroid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hypoplasia of genital tubercle n1=cyclopeptide | n2=en:congenital hypoplasia of genital tubercle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital hypothyroidism n1=cyclopeptide | n2=en:congenital hypothyroidism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital infundibular stenosis n1=cyclopeptide | n2=en:congenital infundibular stenosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital keratoglobus n1=cyclopeptide | n2=en:congenital keratoglobus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital lens disorder n1=cyclopeptide | n2=en:congenital lens disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital macrocephaly n1=cyclopeptide | n2=en:congenital macrocephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital macrocheilia n1=cyclopeptide | n2=en:congenital macrocheilia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital malformation of genital organs n1=cyclopeptide | n2=en:congenital malformation of genital organs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital malformation syndrome n1=cyclopeptide | n2=en:congenital malformation syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital malformation syndrome related to known exogenous cause n1=cyclopeptide | n2=en:congenital malformation syndrome related to known exogenous cause | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital malformation syndromes affecting facial appearance n1=cyclopeptide | n2=en:congenital malformation syndromes affecting facial appearance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital malposition n1=cyclopeptide | n2=en:congenital malposition | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital malposition of eye n1=cyclopeptide | n2=en:congenital malposition of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital melanosis n1=cyclopeptide | n2=en:congenital melanosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital microcheilia n1=cyclopeptide | n2=en:congenital microcheilia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital microtia n1=cyclopeptide | n2=en:congenital microtia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital morphologic anomaly n1=cyclopeptide | n2=en:congenital morphologic anomaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital musculoskeletal defect n1=cyclopeptide | n2=en:congenital musculoskeletal defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital myopia n1=cyclopeptide | n2=en:congenital myopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital nasolacrimal duct obstruction n1=cyclopeptide | n2=en:congenital nasolacrimal duct obstruction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital nervous system disorder n1=cyclopeptide | n2=en:congenital nervous system disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital nuclear cataract (in some patients) n1=cyclopeptide | n2=en:congenital nuclear cataract (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital nystagmus n1=cyclopeptide | n2=en:congenital nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital opacity n1=cyclopeptide | n2=en:congenital opacity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital pigmentation n1=cyclopeptide | n2=en:congenital pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital porencephaly n1=cyclopeptide | n2=en:congenital porencephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital red cell hypoplasia n1=cyclopeptide | n2=en:congenital red cell hypoplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital respiratory system disorder n1=cyclopeptide | n2=en:congenital respiratory system disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital retinal fold n1=cyclopeptide | n2=en:congenital retinal fold | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital septation n1=cyclopeptide | n2=en:congenital septation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital sequestration n1=cyclopeptide | n2=en:congenital sequestration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital skin disorder n1=cyclopeptide | n2=en:congenital skin disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital stapes ankylosis n1=cyclopeptide | n2=en:congenital stapes ankylosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital stenosis n1=cyclopeptide | n2=en:congenital stenosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital strabismus n1=cyclopeptide | n2=en:congenital strabismus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital systemic disorder n1=cyclopeptide | n2=en:congenital systemic disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital urinary system abnormality n1=cyclopeptide | n2=en:congenital urinary system abnormality | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital vascular anomaly n1=cyclopeptide | n2=en:congenital vascular anomaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital vena cava abnormality n1=cyclopeptide | n2=en:congenital vena cava abnormality | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital visceral anomaly n1=cyclopeptide | n2=en:congenital visceral anomaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:congenital vision disorder n1=cyclopeptide | n2=en:congenital vision disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conical protrusion of cornea with curvature greater than 47 d on topography n1=cyclopeptide | n2=en:conical protrusion of cornea with curvature greater than 47 d on topography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjoined twins n1=cyclopeptide | n2=en:conjoined twins | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjugated estrogens/bazedoxifene n1=cyclopeptide | n2=en:conjugated estrogens/bazedoxifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjugated estrogens/cyclophosphamide/doxorubicin/fluorouracil/methotrexate/tamoxifen n1=cyclopeptide | n2=en:conjugated estrogens/cyclophosphamide/doxorubicin/fluorouracil/methotrexate/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjugated horizontal gaze palsy n1=cyclopeptide | n2=en:conjugated horizontal gaze palsy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjugated linoleic acid n1=cyclopeptide | n2=en:conjugated linoleic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctiva n1=cyclopeptide | n2=en:conjunctiva | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctiva shows dilated blood vessels n1=cyclopeptide | n2=en:conjunctiva shows dilated blood vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival and scleral pigmentation n1=cyclopeptide | n2=en:conjunctival and scleral pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival crystals n1=cyclopeptide | n2=en:conjunctival crystals | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival hyperemia n1=cyclopeptide | n2=en:conjunctival hyperemia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival injection, ipsilateral n1=cyclopeptide | n2=en:conjunctival injection, ipsilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival irritation n1=cyclopeptide | n2=en:conjunctival irritation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival leukoplakia n1=cyclopeptide | n2=en:conjunctival leukoplakia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival lipodermoid n1=cyclopeptide | n2=en:conjunctival lipodermoid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival sac n1=cyclopeptide | n2=en:conjunctival sac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival telangiectasia (reported in 1 family) n1=cyclopeptide | n2=en:conjunctival telangiectasia (reported in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival telangiectasis n1=cyclopeptide | n2=en:conjunctival telangiectasis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctival whitish salt-like deposits n1=cyclopeptide | n2=en:conjunctival whitish salt-like deposits | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctivitis n1=cyclopeptide | n2=en:conjunctivitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctivitis (in some patients) n1=cyclopeptide | n2=en:conjunctivitis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctivitis, episodic n1=cyclopeptide | n2=en:conjunctivitis, episodic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:conjunctivitis, recurrent n1=cyclopeptide | n2=en:conjunctivitis, recurrent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:connatal disorder n1=cyclopeptide | n2=en:connatal disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:constricted visual fields (occurs second) n1=cyclopeptide | n2=en:constricted visual fields (occurs second) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:constricted visual fields by age 20 years n1=cyclopeptide | n2=en:constricted visual fields by age 20 years | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:contraindications aspect n1=cyclopeptide | n2=en:contraindications aspect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:contralateral hemianopsia (1 family) n1=cyclopeptide | n2=en:contralateral hemianopsia (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:contrast agent cs-1000 n1=cyclopeptide | n2=en:contrast agent cs-1000 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:controlled substance n1=cyclopeptide | n2=en:controlled substance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:contusion/hemorrhage eye n1=cyclopeptide | n2=en:contusion/hemorrhage eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:convergence insufficiencies n1=cyclopeptide | n2=en:convergence insufficiencies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cop protocol 1 n1=cyclopeptide | n2=en:cop protocol 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cop-paf protocol n1=cyclopeptide | n2=en:cop-paf protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copadem protocol n1=cyclopeptide | n2=en:copadem protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copanlisib n1=cyclopeptide | n2=en:copanlisib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copdac regimen n1=cyclopeptide | n2=en:copdac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copep protocol n1=cyclopeptide | n2=en:copep protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copovithane n1=cyclopeptide | n2=en:copovithane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copp regimen n1=cyclopeptide | n2=en:copp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copp-abv regimen n1=cyclopeptide | n2=en:copp-abv regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copp-abvd protocol n1=cyclopeptide | n2=en:copp-abvd protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copp-abvd regimen n1=cyclopeptide | n2=en:copp-abvd regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 62 ethylglyoxal bis(thiosemicarbazone) n1=cyclopeptide | n2=en:copper cu 62 ethylglyoxal bis(thiosemicarbazone) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 62-atsm n1=cyclopeptide | n2=en:copper cu 62-atsm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 62-ptsm n1=cyclopeptide | n2=en:copper cu 62-ptsm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64 anti-cea monoclonal antibody m5a n1=cyclopeptide | n2=en:copper cu 64 anti-cea monoclonal antibody m5a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64 plerixafor n1=cyclopeptide | n2=en:copper cu 64 plerixafor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64 tp3805 n1=cyclopeptide | n2=en:copper cu 64 tp3805 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64 trastuzumab n1=cyclopeptide | n2=en:copper cu 64 trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64-atsm n1=cyclopeptide | n2=en:copper cu 64-atsm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64-dota b-fab n1=cyclopeptide | n2=en:copper cu 64-dota b-fab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64-dota-ae105 n1=cyclopeptide | n2=en:copper cu 64-dota-ae105 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64-dota-anti-her3 monoclonal antibody u3-1287 n1=cyclopeptide | n2=en:copper cu 64-dota-anti-her3 monoclonal antibody u3-1287 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64-dota-rituximab n1=cyclopeptide | n2=en:copper cu 64-dota-rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper cu 64-dota-trastuzumab n1=cyclopeptide | n2=en:copper cu 64-dota-trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper gluconate n1=cyclopeptide | n2=en:copper gluconate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copper supplement n1=cyclopeptide | n2=en:copper supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:copu protocol n1=cyclopeptide | n2=en:copu protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cord blood-derived expanded natural killer cell infusion pnk-007 n1=cyclopeptide | n2=en:cord blood-derived expanded natural killer cell infusion pnk-007 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cordycepin n1=cyclopeptide | n2=en:cordycepin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corectopia (in some patients) n1=cyclopeptide | n2=en:corectopia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corifollitropin alfa n1=cyclopeptide | n2=en:corifollitropin alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coriolus versicolor extract n1=cyclopeptide | n2=en:coriolus versicolor extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cornea n1=cyclopeptide | n2=en:cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cornea plana (in some patients) n1=cyclopeptide | n2=en:cornea plana (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal abrasion n1=cyclopeptide | n2=en:corneal abrasion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal and lenticular opacities n1=cyclopeptide | n2=en:corneal and lenticular opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal and retinal calcification n1=cyclopeptide | n2=en:corneal and retinal calcification | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal and scleral disorders congenital n1=cyclopeptide | n2=en:corneal and scleral disorders congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal anesthesia n1=cyclopeptide | n2=en:corneal anesthesia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal blisters (1 patient) n1=cyclopeptide | n2=en:corneal blisters (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal clouding (detroit type 107680.0011, apoa1 deficiency 107680.0014) n1=cyclopeptide | n2=en:corneal clouding (detroit type 107680.0011, apoa1 deficiency 107680.0014) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal clouding (in some) n1=cyclopeptide | n2=en:corneal clouding (in some) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal clouding (rare) n1=cyclopeptide | n2=en:corneal clouding (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal clouding (variable) n1=cyclopeptide | n2=en:corneal clouding (variable) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal clouding, congenital n1=cyclopeptide | n2=en:corneal clouding, congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal clouding, progressive n1=cyclopeptide | n2=en:corneal clouding, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal crystalline deposits n1=cyclopeptide | n2=en:corneal crystalline deposits | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal dermoid cyst (rare) n1=cyclopeptide | n2=en:corneal dermoid cyst (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal diameter increased n1=cyclopeptide | n2=en:corneal diameter increased | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal diameter, normal n1=cyclopeptide | n2=en:corneal diameter, normal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal drying n1=cyclopeptide | n2=en:corneal drying | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal dyskeratosis n1=cyclopeptide | n2=en:corneal dyskeratosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal dystrophy n1=cyclopeptide | n2=en:corneal dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal dystrophy (onset early in childhood) n1=cyclopeptide | n2=en:corneal dystrophy (onset early in childhood) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal endothelial dystrophy (guttata) n1=cyclopeptide | n2=en:corneal endothelial dystrophy (guttata) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal endothelial dystrophy (in some patients) n1=cyclopeptide | n2=en:corneal endothelial dystrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal endothelial guttata and folds n1=cyclopeptide | n2=en:corneal endothelial guttata and folds | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal endothelial vesicles n1=cyclopeptide | n2=en:corneal endothelial vesicles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal erosion n1=cyclopeptide | n2=en:corneal erosion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal erosions (1 patient) n1=cyclopeptide | n2=en:corneal erosions (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal flatness n1=cyclopeptide | n2=en:corneal flatness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal guttata n1=cyclopeptide | n2=en:corneal guttata | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal haze n1=cyclopeptide | n2=en:corneal haze | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal haze (rare) n1=cyclopeptide | n2=en:corneal haze (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal hypoesthesia n1=cyclopeptide | n2=en:corneal hypoesthesia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal irritation n1=cyclopeptide | n2=en:corneal irritation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal keloid n1=cyclopeptide | n2=en:corneal keloid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal lipid deposit n1=cyclopeptide | n2=en:corneal lipid deposit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal neovascularization n1=cyclopeptide | n2=en:corneal neovascularization | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal neovascularization (rare) n1=cyclopeptide | n2=en:corneal neovascularization (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal opacification, partial or total n1=cyclopeptide | n2=en:corneal opacification, partial or total | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal opacities (in some patients) n1=cyclopeptide | n2=en:corneal opacities (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal opacities on slit-lamp examination n1=cyclopeptide | n2=en:corneal opacities on slit-lamp examination | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal opacities, bilateral superior n1=cyclopeptide | n2=en:corneal opacities, bilateral superior | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal opacity (rare) n1=cyclopeptide | n2=en:corneal opacity (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal reflex absent n1=cyclopeptide | n2=en:corneal reflex absent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal reflex reduced n1=cyclopeptide | n2=en:corneal reflex reduced | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal rupture n1=cyclopeptide | n2=en:corneal rupture | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal scar n1=cyclopeptide | n2=en:corneal scar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal sensitivity impairment (hypesthesia) n1=cyclopeptide | n2=en:corneal sensitivity impairment (hypesthesia) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal stromal opacification, congenital progressive n1=cyclopeptide | n2=en:corneal stromal opacification, congenital progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal thinning n1=cyclopeptide | n2=en:corneal thinning | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal thinning and steepening n1=cyclopeptide | n2=en:corneal thinning and steepening | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal ulcer n1=cyclopeptide | n2=en:corneal ulcer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corneal vascularization extending to central cornea n1=cyclopeptide | n2=en:corneal vascularization extending to central cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cortical blindness n1=cyclopeptide | n2=en:cortical blindness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cortical blindness (1 patient) n1=cyclopeptide | n2=en:cortical blindness (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cortical blindness (in 1 moroccan patient) n1=cyclopeptide | n2=en:cortical blindness (in 1 moroccan patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cortical blindness (in one patient) n1=cyclopeptide | n2=en:cortical blindness (in one patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cortical blindness (patient a) n1=cyclopeptide | n2=en:cortical blindness (patient a) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cortical cataract n1=cyclopeptide | n2=en:cortical cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cortical punctate or pulverulent opacities (in carrier females) n1=cyclopeptide | n2=en:cortical punctate or pulverulent opacities (in carrier females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cortical visual impairment (in some patients) n1=cyclopeptide | n2=en:cortical visual impairment (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corticorelin acetate n1=cyclopeptide | n2=en:corticorelin acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corticotropin n1=cyclopeptide | n2=en:corticotropin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corticotropin releasing hormone n1=cyclopeptide | n2=en:corticotropin releasing hormone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corticotropin/cyclophosphamide n1=cyclopeptide | n2=en:corticotropin/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:corynebacterium granulosum p40 n1=cyclopeptide | n2=en:corynebacterium granulosum p40 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cositecan n1=cyclopeptide | n2=en:cositecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cosmeceuticals n1=cyclopeptide | n2=en:cosmeceuticals | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coumarin n1=cyclopeptide | n2=en:coumarin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:counterfeit drugs n1=cyclopeptide | n2=en:counterfeit drugs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:coxsackievirus a21 n1=cyclopeptide | n2=en:coxsackievirus a21 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cp 461 n1=cyclopeptide | n2=en:cp 461 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cp-547632 n1=cyclopeptide | n2=en:cp-547632 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cp-609,754 n1=cyclopeptide | n2=en:cp-609,754 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cp-724,714 n1=cyclopeptide | n2=en:cp-724,714 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cpdd protocol n1=cyclopeptide | n2=en:cpdd protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cpg oligodeoxynucleotide gnkg168 n1=cyclopeptide | n2=en:cpg oligodeoxynucleotide gnkg168 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cpg-28 oligodeoxynucleotide n1=cyclopeptide | n2=en:cpg-28 oligodeoxynucleotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cr2-fh fusion protein tt30 n1=cyclopeptide | n2=en:cr2-fh fusion protein tt30 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:craniofacial dysostosis n1=cyclopeptide | n2=en:craniofacial dysostosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:craniofenestria n1=cyclopeptide | n2=en:craniofenestria | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cranioschisis n1=cyclopeptide | n2=en:cranioschisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:craniosynostosis n1=cyclopeptide | n2=en:craniosynostosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:creatine monohydrate n1=cyclopeptide | n2=en:creatine monohydrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crenolanib n1=cyclopeptide | n2=en:crenolanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crenolanib besylate n1=cyclopeptide | n2=en:crenolanib besylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cri du chat syndrome n1=cyclopeptide | n2=en:cri du chat syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cridanimod sodium n1=cyclopeptide | n2=en:cridanimod sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crisnatol mesylate n1=cyclopeptide | n2=en:crisnatol mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crizotinib n1=cyclopeptide | n2=en:crizotinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crl 1005 n1=cyclopeptide | n2=en:crl 1005 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crolibulin n1=cyclopeptide | n2=en:crolibulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cromolyn sodium inhalant pa101 n1=cyclopeptide | n2=en:cromolyn sodium inhalant pa101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crossed asymmetry of cortical visual response on visual evoked potential testing n1=cyclopeptide | n2=en:crossed asymmetry of cortical visual response on visual evoked potential testing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crotoxin n1=cyclopeptide | n2=en:crotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cryoprotective agent n1=cyclopeptide | n2=en:cryoprotective agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cryptophthalmia n1=cyclopeptide | n2=en:cryptophthalmia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cryptophthalmos syndrome n1=cyclopeptide | n2=en:cryptophthalmos syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crystal-like lens opacity n1=cyclopeptide | n2=en:crystal-like lens opacity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crystalline genistein formulation axp107-11 n1=cyclopeptide | n2=en:crystalline genistein formulation axp107-11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:crystalline lens dislocation n1=cyclopeptide | n2=en:crystalline lens dislocation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:csf-1r inhibitor blz945 n1=cyclopeptide | n2=en:csf-1r inhibitor blz945 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ct2584 hms n1=cyclopeptide | n2=en:ct2584 hms | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ctec protocol n1=cyclopeptide | n2=en:ctec protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ctp-37-dt vaccine n1=cyclopeptide | n2=en:ctp-37-dt vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ctrp agent terminology n1=cyclopeptide | n2=en:ctrp agent terminology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ctrp terminology n1=cyclopeptide | n2=en:ctrp terminology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ctvp protocol n1=cyclopeptide | n2=en:ctvp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cuneiform opacities in lens periphery n1=cyclopeptide | n2=en:cuneiform opacities in lens periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cupping of optic nerve head n1=cyclopeptide | n2=en:cupping of optic nerve head | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:curcumin n1=cyclopeptide | n2=en:curcumin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:curcumin-based gel n1=cyclopeptide | n2=en:curcumin-based gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:curcumin/green tea extract/polygonum cuspidatum extract/soybean extract capsule n1=cyclopeptide | n2=en:curcumin/green tea extract/polygonum cuspidatum extract/soybean extract capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:curled eyelashes n1=cyclopeptide | n2=en:curled eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:curly eyebrows n1=cyclopeptide | n2=en:curly eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:curly eyelashes n1=cyclopeptide | n2=en:curly eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:custirsen sodium n1=cyclopeptide | n2=en:custirsen sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cutaneolacrimal fistulae n1=cyclopeptide | n2=en:cutaneolacrimal fistulae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cv protocol n1=cyclopeptide | n2=en:cv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cvad-v protocol n1=cyclopeptide | n2=en:cvad-v protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cvap-b protocol n1=cyclopeptide | n2=en:cvap-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cvp protocol 2 n1=cyclopeptide | n2=en:cvp protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cvp regimen n1=cyclopeptide | n2=en:cvp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cvpp regimen n1=cyclopeptide | n2=en:cvpp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cvppabo protocol n1=cyclopeptide | n2=en:cvppabo protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cwap regimen n1=cyclopeptide | n2=en:cwap regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cxc chemokine receptor 2 antagonist azd5069 n1=cyclopeptide | n2=en:cxc chemokine receptor 2 antagonist azd5069 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cxcr4 antagonist bl-8040 n1=cyclopeptide | n2=en:cxcr4 antagonist bl-8040 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cxcr4 inhibitor msx-122 n1=cyclopeptide | n2=en:cxcr4 inhibitor msx-122 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cxcr4 inhibitor pol6326 n1=cyclopeptide | n2=en:cxcr4 inhibitor pol6326 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cxcr4 inhibitor x4p-001 n1=cyclopeptide | n2=en:cxcr4 inhibitor x4p-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cxcr4 peptide antagonist ly2510924 n1=cyclopeptide | n2=en:cxcr4 peptide antagonist ly2510924 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyanocobalamin n1=cyclopeptide | n2=en:cyanocobalamin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyanocobalamin/dexamethasone/gentamicin/procaine formulation n1=cyclopeptide | n2=en:cyanocobalamin/dexamethasone/gentamicin/procaine formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cycle-phase nonspecific agent n1=cyclopeptide | n2=en:cycle-phase nonspecific agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cycle-phase specific agent n1=cyclopeptide | n2=en:cycle-phase specific agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclin b1 peptide-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:cyclin b1 peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclobenzaprine hydrochloride n1=cyclopeptide | n2=en:cyclobenzaprine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclodextrin-based polymer-camptothecin crlx101 n1=cyclopeptide | n2=en:cyclodextrin-based polymer-camptothecin crlx101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cycloleucine n1=cyclopeptide | n2=en:cycloleucine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclone protocol n1=cyclopeptide | n2=en:cyclone protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclopentenyl cytosine n1=cyclopeptide | n2=en:cyclopentenyl cytosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophilin n1=cyclopeptide | n2=en:cyclophilin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophilins n1=cyclopeptide | n2=en:cyclophilins | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophoria n1=cyclopeptide | n2=en:cyclophoria | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophorias n1=cyclopeptide | n2=en:cyclophorias | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide n1=cyclopeptide | n2=en:cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide 2000 mg injection n1=cyclopeptide | n2=en:cyclophosphamide 2000 mg injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide 25 mg oral capsule n1=cyclopeptide | n2=en:cyclophosphamide 25 mg oral capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide 25mg tablet n1=cyclopeptide | n2=en:cyclophosphamide 25mg tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide 50 mg oral capsule n1=cyclopeptide | n2=en:cyclophosphamide 50 mg oral capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide 50mg tablet n1=cyclopeptide | n2=en:cyclophosphamide 50mg tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide anhydrous n1=cyclopeptide | n2=en:cyclophosphamide anhydrous | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide lyophilized n1=cyclopeptide | n2=en:cyclophosphamide lyophilized | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide therapy n1=cyclopeptide | n2=en:cyclophosphamide therapy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide-etoposide-vincristine regimen n1=cyclopeptide | n2=en:cyclophosphamide-etoposide-vincristine regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide-topotecan regimen n1=cyclopeptide | n2=en:cyclophosphamide-topotecan regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide-vad regimen n1=cyclopeptide | n2=en:cyclophosphamide-vad regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide, (r)-isomer n1=cyclopeptide | n2=en:cyclophosphamide, (r)-isomer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide, (s)-isomer n1=cyclopeptide | n2=en:cyclophosphamide, (s)-isomer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide; oral, 25 mg n1=cyclopeptide | n2=en:cyclophosphamide; oral, 25 mg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide:mcnc:pt:ser/plas:qn n1=cyclopeptide | n2=en:cyclophosphamide:mcnc:pt:ser/plas:qn | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide:mcnc:pt:urine:qn n1=cyclopeptide | n2=en:cyclophosphamide:mcnc:pt:urine:qn | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/bleomycin/epirubicin/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/bleomycin/epirubicin/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cyclosporine/cytarabine/daunorubicin n1=cyclopeptide | n2=en:cyclophosphamide/cyclosporine/cytarabine/daunorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cyclosporine/fludarabine/methylprednisolone/thiotepa n1=cyclopeptide | n2=en:cyclophosphamide/cyclosporine/fludarabine/methylprednisolone/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/daunorubicin n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/daunorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/daunorubicin/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/pegaspargase/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/daunorubicin/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/pegaspargase/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/daunorubicin/dexamethasone/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/daunorubicin/dexamethasone/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/daunorubicin/dexamethasone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/daunorubicin/dexamethasone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/daunorubicin/thioguanine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/daunorubicin/thioguanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/filgrastim/leucovorin calcium/methotrexate/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/filgrastim/leucovorin calcium/methotrexate/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/pegaspargase/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/pegaspargase/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/pegaspargase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/methotrexate/pegaspargase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/pegaspargase/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/pegaspargase/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/dexamethasone/doxorubicin/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/dexamethasone/etoposide phosphate/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/dexamethasone/etoposide phosphate/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/dexamethasone/mercaptopurine/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/dexamethasone/mercaptopurine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/dexamethasone/mitoxantrone n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/dexamethasone/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/doxorubicin/etoposide/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/doxorubicin/hydroxyurea/lomustine/methotrexate/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/doxorubicin/hydroxyurea/lomustine/methotrexate/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/doxorubicin/methotrexate/prednisone/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/doxorubicin/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/doxorubicin/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/doxorubicin/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/doxorubicin/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/doxorubicin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate/pegaspargase n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate/pegaspargase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate/prednisolone/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/etoposide/mercaptopurine/methotrexate/prednisolone/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/etoposide/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/etoposide/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/fludarabine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/fludarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/hydrocortisone/leucovorin calcium n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/hydrocortisone/leucovorin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/mercaptopurine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/mercaptopurine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/mercaptopurine/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/mercaptopurine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/mercaptopurine/methotrexate/pegaspargase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/mercaptopurine/methotrexate/pegaspargase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/mercaptopurine/methotrexate/prednisolone n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/mercaptopurine/methotrexate/prednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/mercaptopurine/methotrexate/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/mercaptopurine/methotrexate/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/mercaptopurine/pegaspargase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/mercaptopurine/pegaspargase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/mercaptopurine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/mercaptopurine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/methotrexate/thioguanine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/methotrexate/thioguanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/methylprednisolone n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/methylprednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/monoclonal antibody bc8 n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/pegaspargase n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/pegaspargase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/prednisone/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/prednisone/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/teniposide n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/teniposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/thioguanine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/thioguanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/topotecan n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/topotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/cytarabine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/cytarabine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dacarbazine/dactinomycin/doxorubicin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dacarbazine/dactinomycin/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dacarbazine/doxorubicin n1=cyclopeptide | n2=en:cyclophosphamide/dacarbazine/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dacarbazine/doxorubicin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dacarbazine/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dacarbazine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dacarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/dexrazoxane/doxorubicin/filgrastim/temozolomide/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/dexrazoxane/doxorubicin/filgrastim/temozolomide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/doxorubicin/filgrastim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/doxorubicin/filgrastim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/doxorubicin/hydroxyurea/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/doxorubicin/hydroxyurea/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/doxorubicin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/filgrastim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/filgrastim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/fluorouracil n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/irinotecan/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/irinotecan/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/vinblastine n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dactinomycin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dactinomycin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin/dexamethasone/etoposide/methotrexate/thiotepa/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin/dexamethasone/etoposide/methotrexate/thiotepa/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin/dexamethasone/imatinib mesylate/methotrexate/pegaspargase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin/dexamethasone/imatinib mesylate/methotrexate/pegaspargase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin/dexamethasone/methotrexate/pegaspargase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin/dexamethasone/methotrexate/pegaspargase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin/dexamethasone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin/dexamethasone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin/etoposide/prednisone/teniposide/thioguanine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin/etoposide/prednisone/teniposide/thioguanine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin/pegaspargase/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin/pegaspargase/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/daunorubicin/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/daunorubicin/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/decitabine/doxorubicin n1=cyclopeptide | n2=en:cyclophosphamide/decitabine/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/detox-b adjuvant/interleukin-2 n1=cyclopeptide | n2=en:cyclophosphamide/detox-b adjuvant/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/detox/interleukin-2 n1=cyclopeptide | n2=en:cyclophosphamide/detox/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/etoposide n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/imatinib mesylate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/imatinib mesylate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/leucovorin calcium/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/leucovorin calcium/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vinblastine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/quinine/verapamil/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/quinine/verapamil/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/verapamil/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/verapamil/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/doxorubicin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/etoposide n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/etoposide/imatinib mesylate/mercaptopurine/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/etoposide/imatinib mesylate/mercaptopurine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/etoposide/mercaptopurine/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/etoposide/mercaptopurine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/filgrastim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/filgrastim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/idarubicin/pegaspargase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/idarubicin/pegaspargase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/mercaptopurine/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/mercaptopurine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/mitoxantrone n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexamethasone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexamethasone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexrazoxane/doxorubicin n1=cyclopeptide | n2=en:cyclophosphamide/dexrazoxane/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexrazoxane/doxorubicin/fluorouracil n1=cyclopeptide | n2=en:cyclophosphamide/dexrazoxane/doxorubicin/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexrazoxane/doxorubicin/oblimersen n1=cyclopeptide | n2=en:cyclophosphamide/dexrazoxane/doxorubicin/oblimersen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexrazoxane/doxorubicin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexrazoxane/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexverapamil/doxorubicin/etoposide/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexverapamil/doxorubicin/etoposide/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dexverapamil/doxorubicin/etoposide/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/dexverapamil/doxorubicin/etoposide/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/diaziquone n1=cyclopeptide | n2=en:cyclophosphamide/diaziquone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/didanosine/doxorubicin/etoposide n1=cyclopeptide | n2=en:cyclophosphamide/didanosine/doxorubicin/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/didanosine/doxorubicin/etoposide/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/didanosine/doxorubicin/etoposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/diethylstilbestrol/fluorouracil n1=cyclopeptide | n2=en:cyclophosphamide/diethylstilbestrol/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/diethylstilbestrol/fluorouracil/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/diethylstilbestrol/fluorouracil/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/docetaxel/doxorubicin n1=cyclopeptide | n2=en:cyclophosphamide/docetaxel/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/docetaxel/doxorubicin/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/docetaxel/doxorubicin/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin hcl liposome/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin hcl liposome/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/epratuzumab/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/epratuzumab/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/ethinyl estradiol/fluorouracil/leucovorin calcium n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/ethinyl estradiol/fluorouracil/leucovorin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/filgrastim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/filgrastim/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/filgrastim/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/fludarabine/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/fludarabine/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/fludarabine/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/fludarabine/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/fluorouracil n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/ifosfamide/pegfilgrastim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/ifosfamide/pegfilgrastim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/interleukin-2 n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/lomustine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/lomustine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/mechlorethamine/methotrexate/prednisone/procarbazine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/mechlorethamine/methotrexate/prednisone/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/medroxyprogesterone/quinine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/medroxyprogesterone/quinine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/methotrexate/pentamidine/sargramostim/vincristine/zidovudine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/methotrexate/pentamidine/sargramostim/vincristine/zidovudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/methotrexate/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/methotrexate/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/methotrexate/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/methotrexate/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/methotrexate/sargramostim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/methotrexate/sargramostim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine/r-verapamil n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine/r-verapamil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine/zidovudine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/prednisone/vincristine/zidovudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/etoposide/vincristine/zidovudine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/etoposide/vincristine/zidovudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/filgrastim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/filgrastim/fluorouracil/leucovorin calcium n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/filgrastim/fluorouracil/leucovorin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/filgrastim/paclitaxel n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/filgrastim/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/filgrastim/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/filgrastim/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/filgrastim/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/filgrastim/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/interferon alfa/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/interferon alfa/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/thiotepa/vinblastine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/fluoxymesterone/thiotepa/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/goserelin n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/goserelin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/goserelin/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/goserelin/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/interferon alfa n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/interferon alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/interleukin-3/leucovorin calcium n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/interleukin-3/leucovorin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/interleukin-3/leucovorin calcium/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/interleukin-3/leucovorin calcium/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium/milodistim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium/milodistim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/leucovorin calcium/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate/sargramostim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate/sargramostim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/streptozocin n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/streptozocin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/tegafur/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/tegafur/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/fluorouracil/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/fluorouracil/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/folic acid/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/folic acid/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/gemcitabine/paclitaxel n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/gemcitabine/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/gemcitabine/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/gemcitabine/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/goserelin/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/goserelin/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/interferon alfa/interleukin-2/lymphokine-activated killer cells n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/interferon alfa/interleukin-2/lymphokine-activated killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/interferon alfa/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/interferon alfa/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/interleukin-3/prednisone/vincristine/zidovudine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/interleukin-3/prednisone/vincristine/zidovudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/iodine i 131 tositumomab/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/iodine i 131 tositumomab/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/iodine i 131 tositumomab/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/iodine i 131 tositumomab/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/methylprednisolone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/methylprednisolone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/methylprednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/methylprednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/leucovorin calcium/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/leuprolide/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/leuprolide/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/lomustine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/lomustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/lomustine/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/lomustine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/lomustine/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/lomustine/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/lomustine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/lomustine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/marimastat n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/marimastat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/melphalan/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/melphalan/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/melphalan/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/melphalan/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/mercaptopurine/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methotrexate/methylprednisolone/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methotrexate/methylprednisolone/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methotrexate/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methotrexate/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methotrexate/procarbazine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methotrexate/procarbazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methotrexate/sargramostim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methotrexate/sargramostim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methotrexate/vinblastine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methotrexate/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methylprednisolone/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methylprednisolone/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/methylprednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/methylprednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/mitomycin n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/mitomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/monoclonal antibody her2 n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/monoclonal antibody her2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/oblimersen/prednisolone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/oblimersen/prednisolone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/oblimersen/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/oblimersen/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/octreotide pamoate/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/octreotide pamoate/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/paclitaxel n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/pegfilgrastim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/pegfilgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/prednisolone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/prednisolone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/prednisone/procarbazine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/prednisone/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/prednisone/sargramostim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/prednisone/sargramostim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/prednisone/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/prednisone/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/prednisone/teniposide n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/prednisone/teniposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/prednisone/teniposide/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/prednisone/teniposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/tipifarnib n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/tipifarnib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/tirapazamine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/tirapazamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/toremifene n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/toremifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/trastuzumab n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/uracil/tegafur/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/uracil/tegafur/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/vinblastine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/doxorubicin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/doxorubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/dppe n1=cyclopeptide | n2=en:cyclophosphamide/dppe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/filgrastim/fluorouracil n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/filgrastim/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/fluorouracil/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/fluorouracil/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/fluorouracil/paclitaxel/trastuzumab n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/fluorouracil/paclitaxel/trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/gemcitabine/paclitaxel n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/gemcitabine/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/monoclonal antibody her2 n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/monoclonal antibody her2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/paclitaxel n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/tesmilifene n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/tesmilifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/toremifene n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/toremifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/trastuzumab n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/epirubicin/vincristine/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/epirubicin/vincristine/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etanidazole n1=cyclopeptide | n2=en:cyclophosphamide/etanidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide n1=cyclopeptide | n2=en:cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/filgrastim n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/fludarabine n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/fludarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/imatinib mesylate n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/imatinib mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/imatinib mesylate/leucovorin calcium/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/imatinib mesylate/leucovorin calcium/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/iodine i 131 monoclonal antibody anti-b1 n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/iodine i 131 monoclonal antibody anti-b1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/iodine i 131 tositumomab n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/iodine i 131 tositumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/leucovorin calcium/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/leucovorin calcium/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/leuvocorin calcium/mercaptopurine/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/leuvocorin calcium/mercaptopurine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/lomustine/procarbazine n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/lomustine/procarbazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/lomustine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/lomustine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/mercaptopurine/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/mercaptopurine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/mitoxantrone n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/mitoxantrone/pegaspargase/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/mitoxantrone/pegaspargase/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/teniposide n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/teniposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/thiotepa n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/etoposide/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/etoposide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/filgrastim n1=cyclopeptide | n2=en:cyclophosphamide/filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/filgrastim/fludarabine n1=cyclopeptide | n2=en:cyclophosphamide/filgrastim/fludarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/filgrastim/interleukin-6 n1=cyclopeptide | n2=en:cyclophosphamide/filgrastim/interleukin-6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/filgrastim/paclitaxel n1=cyclopeptide | n2=en:cyclophosphamide/filgrastim/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/filgrastim/rituximab n1=cyclopeptide | n2=en:cyclophosphamide/filgrastim/rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/filgrastim/topotecan n1=cyclopeptide | n2=en:cyclophosphamide/filgrastim/topotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/filgrastim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/filgrastim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fludarabine n1=cyclopeptide | n2=en:cyclophosphamide/fludarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fludarabine/interleukin-2 n1=cyclopeptide | n2=en:cyclophosphamide/fludarabine/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fludarabine/lumiliximab/rituximab n1=cyclopeptide | n2=en:cyclophosphamide/fludarabine/lumiliximab/rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fludarabine/melphalan n1=cyclopeptide | n2=en:cyclophosphamide/fludarabine/melphalan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fludarabine/oblimersen n1=cyclopeptide | n2=en:cyclophosphamide/fludarabine/oblimersen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fludarabine/rituximab n1=cyclopeptide | n2=en:cyclophosphamide/fludarabine/rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fludarabine/siplizumab n1=cyclopeptide | n2=en:cyclophosphamide/fludarabine/siplizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fludarabine/yttrium y 90 ibritumomab tiuxetan n1=cyclopeptide | n2=en:cyclophosphamide/fludarabine/yttrium y 90 ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate/prednisone/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate/prednisone/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/fluoxymesterone/methotrexate/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/goserelin/methotrexate/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/goserelin/methotrexate/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/leucovorin calcium/mitoxantrone n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/leucovorin calcium/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/leuprolide/methotrexate/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/leuprolide/methotrexate/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/menogaril n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/menogaril | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/methotrexate/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/methotrexate/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/methotrexate/prednisone/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/methotrexate/prednisone/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/methotrexate/prednisone/tamoxifen/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/methotrexate/prednisone/tamoxifen/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/methotrexate/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/methotrexate/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/methotrexate/trastuzumab n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/methotrexate/trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/mitoxantrone n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/pirarubicin n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/pirarubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluorouracil/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/fluorouracil/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/fluoxymesterone/mitolactol/prednisone/tamoxifen n1=cyclopeptide | n2=en:cyclophosphamide/fluoxymesterone/mitolactol/prednisone/tamoxifen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/gvax lung cancer vaccine n1=cyclopeptide | n2=en:cyclophosphamide/gvax lung cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/idarubicin/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/idarubicin/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/indomethacin/interleukin-2/tumor infiltrating lymphocytes n1=cyclopeptide | n2=en:cyclophosphamide/indomethacin/interleukin-2/tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/indomethacin/zinc sulfate n1=cyclopeptide | n2=en:cyclophosphamide/indomethacin/zinc sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interferon alfa n1=cyclopeptide | n2=en:cyclophosphamide/interferon alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interferon alfa/interleukin-2 n1=cyclopeptide | n2=en:cyclophosphamide/interferon alfa/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interferon alfa/interleukin-2/tumor infiltrating lymphocytes n1=cyclopeptide | n2=en:cyclophosphamide/interferon alfa/interleukin-2/tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interferon alfa/melphalan/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/interferon alfa/melphalan/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interferon alfa/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/interferon alfa/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-1-alpha n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-1-alpha | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-2 n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-2/lymphokine-activated killer cells n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-2/lymphokine-activated killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-2/monoclonal antibody okt3 n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-2/monoclonal antibody okt3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-2/monoclonal antibody okt3/tumor necrosis factor n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-2/monoclonal antibody okt3/tumor necrosis factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-2/monoclonal antibody r24 n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-2/monoclonal antibody r24 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-2/tumor infiltrating lymphocytes n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-2/tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-2/tumor necrosis factor n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-2/tumor necrosis factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/interleukin-3/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/interleukin-3/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/lomustine/melphalan/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/lomustine/melphalan/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/lomustine/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/lomustine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/lomustine/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/lomustine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/lomustine/prednisone/procarbazine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/lomustine/prednisone/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/lomustine/procarbazine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/lomustine/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/lomustine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/lomustine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/losoxantrone n1=cyclopeptide | n2=en:cyclophosphamide/losoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mechlorethamine/prednisone/procarbazine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/mechlorethamine/prednisone/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/melanoma helper peptide vaccine/montanide isa-51/multi-epitope melanoma peptide vaccine n1=cyclopeptide | n2=en:cyclophosphamide/melanoma helper peptide vaccine/montanide isa-51/multi-epitope melanoma peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/melphalan n1=cyclopeptide | n2=en:cyclophosphamide/melphalan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/melphalan/methylprednisolone n1=cyclopeptide | n2=en:cyclophosphamide/melphalan/methylprednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/melphalan/mitoxantrone n1=cyclopeptide | n2=en:cyclophosphamide/melphalan/mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/melphalan/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/melphalan/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mercaptopurine/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/mercaptopurine/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mercaptopurine/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/mercaptopurine/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mercaptopurine/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/mercaptopurine/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mercaptopurine/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/mercaptopurine/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/methotrexate n1=cyclopeptide | n2=en:cyclophosphamide/methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/methotrexate/pegaspargase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/methotrexate/pegaspargase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/methotrexate/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/methotrexate/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/methotrexate/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/methylprednisolone n1=cyclopeptide | n2=en:cyclophosphamide/methylprednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/methylprednisolone/rasburicase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/methylprednisolone/rasburicase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/methylprednisolone/rituximab n1=cyclopeptide | n2=en:cyclophosphamide/methylprednisolone/rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/milodistim n1=cyclopeptide | n2=en:cyclophosphamide/milodistim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mitoxantrone/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/mitoxantrone/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mitoxantrone/prednisone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/mitoxantrone/prednisone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/montanide isa-51/multi-epitope melanoma peptide vaccine/tetanus toxoid helper peptide vaccine n1=cyclopeptide | n2=en:cyclophosphamide/montanide isa-51/multi-epitope melanoma peptide vaccine/tetanus toxoid helper peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mycophenolate mofetil n1=cyclopeptide | n2=en:cyclophosphamide/mycophenolate mofetil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/mycophenolate mofetil/tacrolimus n1=cyclopeptide | n2=en:cyclophosphamide/mycophenolate mofetil/tacrolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/oblimersen n1=cyclopeptide | n2=en:cyclophosphamide/oblimersen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/paclitaxel n1=cyclopeptide | n2=en:cyclophosphamide/paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/paclitaxel/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/paclitaxel/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/pegylated doxorubicin hcl liposome/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/pegylated doxorubicin hcl liposome/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/pentostatin n1=cyclopeptide | n2=en:cyclophosphamide/pentostatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/pentostatin/rituximab n1=cyclopeptide | n2=en:cyclophosphamide/pentostatin/rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/perflubron n1=cyclopeptide | n2=en:cyclophosphamide/perflubron | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisolone n1=cyclopeptide | n2=en:cyclophosphamide/prednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisolone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/prednisolone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisolone/teniposide n1=cyclopeptide | n2=en:cyclophosphamide/prednisolone/teniposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisolone/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/prednisolone/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisone n1=cyclopeptide | n2=en:cyclophosphamide/prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisone/procarbazine/vinblastine n1=cyclopeptide | n2=en:cyclophosphamide/prednisone/procarbazine/vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisone/rasburicase/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/prednisone/rasburicase/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisone/rituximab n1=cyclopeptide | n2=en:cyclophosphamide/prednisone/rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisone/rituximab/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/prednisone/rituximab/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisone/sargramostim/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/prednisone/sargramostim/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/prednisone/vincristine/zorubicin n1=cyclopeptide | n2=en:cyclophosphamide/prednisone/vincristine/zorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/procarbazine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/procarbazine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/rituximab n1=cyclopeptide | n2=en:cyclophosphamide/rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/sargramostim n1=cyclopeptide | n2=en:cyclophosphamide/sargramostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/semustine/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/semustine/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/thalidomide n1=cyclopeptide | n2=en:cyclophosphamide/thalidomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/theratope stn-klh vaccine n1=cyclopeptide | n2=en:cyclophosphamide/theratope stn-klh vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/thioguanine n1=cyclopeptide | n2=en:cyclophosphamide/thioguanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/thiotepa n1=cyclopeptide | n2=en:cyclophosphamide/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/tirapazamine n1=cyclopeptide | n2=en:cyclophosphamide/tirapazamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/topotecan n1=cyclopeptide | n2=en:cyclophosphamide/topotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/topotecan/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/topotecan/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophosphamide/vincristine n1=cyclopeptide | n2=en:cyclophosphamide/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclophrenia n1=cyclopeptide | n2=en:cyclophrenia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclopia n1=cyclopeptide | n2=en:cyclopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclopia (5%) n1=cyclopeptide | n2=en:cyclopia (5%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cycloplegia n1=cyclopeptide | n2=en:cycloplegia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cycloplegic n1=cyclopeptide | n2=en:cycloplegic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclorrhapha n1=cyclopeptide | n2=en:cyclorrhapha | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine n1=cyclopeptide | n2=en:cyclosporine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine 100 mg oral capsule n1=cyclopeptide | n2=en:cyclosporine 100 mg oral capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine 25 mg oral capsule n1=cyclopeptide | n2=en:cyclosporine 25 mg oral capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine 25 mg oral capsule [sandimmune] n1=cyclopeptide | n2=en:cyclosporine 25 mg oral capsule [sandimmune] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine 50 mg oral capsule n1=cyclopeptide | n2=en:cyclosporine 50 mg oral capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine 50 mg oral capsule [sandimmune] n1=cyclopeptide | n2=en:cyclosporine 50 mg oral capsule [sandimmune] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine 50 mg/ml oral solution n1=cyclopeptide | n2=en:cyclosporine 50 mg/ml oral solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine ophthalmic emulsion n1=cyclopeptide | n2=en:cyclosporine ophthalmic emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine, modified 100 mg oral capsule n1=cyclopeptide | n2=en:cyclosporine, modified 100 mg oral capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine, modified 100 mg oral capsule [gengraf] n1=cyclopeptide | n2=en:cyclosporine, modified 100 mg oral capsule [gengraf] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine, modified 100 mg oral capsule [neoral] n1=cyclopeptide | n2=en:cyclosporine, modified 100 mg oral capsule [neoral] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine, modified 25 mg oral capsule n1=cyclopeptide | n2=en:cyclosporine, modified 25 mg oral capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyclosporine, modified 25 mg oral capsule [gengraf] n1=cyclopeptide | n2=en:cyclosporine, modified 25 mg oral capsule [gengraf] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyl-02 plasmid dna n1=cyclopeptide | n2=en:cyl-02 plasmid dna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyomad protocol n1=cyclopeptide | n2=en:cyomad protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyp17 inhibitor cfg920 n1=cyclopeptide | n2=en:cyp17 inhibitor cfg920 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyp17 inhibitor vt-464 n1=cyclopeptide | n2=en:cyp17 inhibitor vt-464 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyp17 lyase inhibitor asn001 n1=cyclopeptide | n2=en:cyp17 lyase inhibitor asn001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyp17/androgen receptor inhibitor odm 204 n1=cyclopeptide | n2=en:cyp17/androgen receptor inhibitor odm 204 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyproheptadine hydrochloride n1=cyclopeptide | n2=en:cyproheptadine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyproterone n1=cyclopeptide | n2=en:cyproterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyproterone acetate n1=cyclopeptide | n2=en:cyproterone acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyst associated with dysplastic globe (in some patients) n1=cyclopeptide | n2=en:cyst associated with dysplastic globe (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cysteine-rich non-denatured whey protein isolate imn1207 n1=cyclopeptide | n2=en:cysteine-rich non-denatured whey protein isolate imn1207 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cystemustine n1=cyclopeptide | n2=en:cystemustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cystic degeneration of the macula (rare) n1=cyclopeptide | n2=en:cystic degeneration of the macula (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cystic maculopathy n1=cyclopeptide | n2=en:cystic maculopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cystic retinal degeneration n1=cyclopeptide | n2=en:cystic retinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cystoid macular edema n1=cyclopeptide | n2=en:cystoid macular edema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cystoid macular edema (in some patients) n1=cyclopeptide | n2=en:cystoid macular edema (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cystoid macular retinal degeneration n1=cyclopeptide | n2=en:cystoid macular retinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytarabine n1=cyclopeptide | n2=en:cytarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytarabine monophosphate prodrug mb07133 n1=cyclopeptide | n2=en:cytarabine monophosphate prodrug mb07133 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytarabine/cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vincristine n1=cyclopeptide | n2=en:cytarabine/cyclophosphamide/dexamethasone/doxorubicin/methotrexate/vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytembena n1=cyclopeptide | n2=en:cytembena | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytidine analog rx-3117 n1=cyclopeptide | n2=en:cytidine analog rx-3117 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytochlor n1=cyclopeptide | n2=en:cytochlor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytochrome p450 2b6 n1=cyclopeptide | n2=en:cytochrome p450 2b6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytochrome p450 2c19 n1=cyclopeptide | n2=en:cytochrome p450 2c19 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytochrome p450 2c9 n1=cyclopeptide | n2=en:cytochrome p450 2c9 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytochrome p450 3a4 n1=cyclopeptide | n2=en:cytochrome p450 3a4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytogenetic abnormality n1=cyclopeptide | n2=en:cytogenetic abnormality | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytokine agent n1=cyclopeptide | n2=en:cytokine agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytokine-induced killer cells n1=cyclopeptide | n2=en:cytokine-induced killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytomegalovirus ie-1-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:cytomegalovirus ie-1-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytomegalovirus pp65-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:cytomegalovirus pp65-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytoprotective agent n1=cyclopeptide | n2=en:cytoprotective agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytostatic agents n1=cyclopeptide | n2=en:cytostatic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytotoxic agent n1=cyclopeptide | n2=en:cytotoxic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cytoxan lyophilized n1=cyclopeptide | n2=en:cytoxan lyophilized | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyvadic regimen n1=cyclopeptide | n2=en:cyvadic regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:cyvedic protocol n1=cyclopeptide | n2=en:cyvedic protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:d vitamin n1=cyclopeptide | n2=en:d vitamin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:d-cecat regimen n1=cyclopeptide | n2=en:d-cecat regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:d-methionine formulation mrx-1024 n1=cyclopeptide | n2=en:d-methionine formulation mrx-1024 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:d1/3-mage-3-his fusion protein n1=cyclopeptide | n2=en:d1/3-mage-3-his fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:d4-cyclophosphamide n1=cyclopeptide | n2=en:d4-cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:d4064a n1=cyclopeptide | n2=en:d4064a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dab389 epidermal growth factor n1=cyclopeptide | n2=en:dab389 epidermal growth factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dabigatran etexilate mesylate n1=cyclopeptide | n2=en:dabigatran etexilate mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dabrafenib n1=cyclopeptide | n2=en:dabrafenib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dac protocol n1=cyclopeptide | n2=en:dac protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dac protocol 2 n1=cyclopeptide | n2=en:dac protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dacarbazine n1=cyclopeptide | n2=en:dacarbazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dacetuzumab n1=cyclopeptide | n2=en:dacetuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dach polymer platinate ap5346 n1=cyclopeptide | n2=en:dach polymer platinate ap5346 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dach-platin micelle nc-4016 n1=cyclopeptide | n2=en:dach-platin micelle nc-4016 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daclatasvir n1=cyclopeptide | n2=en:daclatasvir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daclizumab n1=cyclopeptide | n2=en:daclizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daclizumab 25mg/5ml infusion concentrate n1=cyclopeptide | n2=en:daclizumab 25mg/5ml infusion concentrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dacomitinib n1=cyclopeptide | n2=en:dacomitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dacryocystitis n1=cyclopeptide | n2=en:dacryocystitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dacryocystitis (in some patients) n1=cyclopeptide | n2=en:dacryocystitis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dactinomycin n1=cyclopeptide | n2=en:dactinomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daep protocol n1=cyclopeptide | n2=en:daep protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daflon 500 n1=cyclopeptide | n2=en:daflon 500 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dakins solution n1=cyclopeptide | n2=en:dakins solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dalantercept n1=cyclopeptide | n2=en:dalantercept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dalbavancin n1=cyclopeptide | n2=en:dalbavancin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dalotuzumab n1=cyclopeptide | n2=en:dalotuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dalteparin n1=cyclopeptide | n2=en:dalteparin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:danazol n1=cyclopeptide | n2=en:danazol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daniquidone n1=cyclopeptide | n2=en:daniquidone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:danusertib n1=cyclopeptide | n2=en:danusertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daporinad n1=cyclopeptide | n2=en:daporinad | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dapsone n1=cyclopeptide | n2=en:dapsone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dapsone gel n1=cyclopeptide | n2=en:dapsone gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daptomycin n1=cyclopeptide | n2=en:daptomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daratumumab n1=cyclopeptide | n2=en:daratumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:darbepoetin alfa n1=cyclopeptide | n2=en:darbepoetin alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:darinaparsin n1=cyclopeptide | n2=en:darinaparsin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dark choroid (rare) n1=cyclopeptide | n2=en:dark choroid (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dark iris color n1=cyclopeptide | n2=en:dark iris color | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dasabuvir n1=cyclopeptide | n2=en:dasabuvir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dasatinib n1=cyclopeptide | n2=en:dasatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dat-coap regimen n1=cyclopeptide | n2=en:dat-coap regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daunorubicin hydrochloride n1=cyclopeptide | n2=en:daunorubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:daunorubicin-dna complex n1=cyclopeptide | n2=en:daunorubicin-dna complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dbve-pc regimen n1=cyclopeptide | n2=en:dbve-pc regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dc-cholesterol liposome n1=cyclopeptide | n2=en:dc-cholesterol liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dc-ova vaccine n1=cyclopeptide | n2=en:dc-ova vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dcb-bo1202 n1=cyclopeptide | n2=en:dcb-bo1202 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dccm protocol n1=cyclopeptide | n2=en:dccm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dcds0780a n1=cyclopeptide | n2=en:dcds0780a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dcep protocol n1=cyclopeptide | n2=en:dcep protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dcr ligand-bearing liposome-encapsulated melanoma antigens vaccine n1=cyclopeptide | n2=en:dcr ligand-bearing liposome-encapsulated melanoma antigens vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dd1 protocol n1=cyclopeptide | n2=en:dd1 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dec-205/ny-eso-1 fusion protein cdx-1401 n1=cyclopeptide | n2=en:dec-205/ny-eso-1 fusion protein cdx-1401 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decav protocol n1=cyclopeptide | n2=en:decav protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dechloroethylcyclophosphamide n1=cyclopeptide | n2=en:dechloroethylcyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decitabine n1=cyclopeptide | n2=en:decitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:declopramide n1=cyclopeptide | n2=en:declopramide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased central vision (later in course of disease) n1=cyclopeptide | n2=en:decreased central vision (later in course of disease) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased corneal sensation due to peripheral neuropathy n1=cyclopeptide | n2=en:decreased corneal sensation due to peripheral neuropathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased electroretinogram (erg) n1=cyclopeptide | n2=en:decreased electroretinogram (erg) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased electroretinogram (erg) response n1=cyclopeptide | n2=en:decreased electroretinogram (erg) response | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased eye contact n1=cyclopeptide | n2=en:decreased eye contact | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased foveolar thickness n1=cyclopeptide | n2=en:decreased foveolar thickness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased iris pigment n1=cyclopeptide | n2=en:decreased iris pigment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased lacrimation n1=cyclopeptide | n2=en:decreased lacrimation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased light- and dark-adapted electroretinogram amplitude n1=cyclopeptide | n2=en:decreased light- and dark-adapted electroretinogram amplitude | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased night vision n1=cyclopeptide | n2=en:decreased night vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased night vision (early in course of disease) n1=cyclopeptide | n2=en:decreased night vision (early in course of disease) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased night vision, childhood-onset n1=cyclopeptide | n2=en:decreased night vision, childhood-onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased or absent corneal reflexes n1=cyclopeptide | n2=en:decreased or absent corneal reflexes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased or absent electroretinogram (erg) n1=cyclopeptide | n2=en:decreased or absent electroretinogram (erg) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased or absent electroretinogram (erg) responses n1=cyclopeptide | n2=en:decreased or absent electroretinogram (erg) responses | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased or absent laminin beta-2 immunoreactivity in tissues of the anterior eye n1=cyclopeptide | n2=en:decreased or absent laminin beta-2 immunoreactivity in tissues of the anterior eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased or undetectable rod responses on electroretinography n1=cyclopeptide | n2=en:decreased or undetectable rod responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased peripheral vision, childhood-onset n1=cyclopeptide | n2=en:decreased peripheral vision, childhood-onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased pupillary accommodation n1=cyclopeptide | n2=en:decreased pupillary accommodation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased retinal pigmentation with dispersion n1=cyclopeptide | n2=en:decreased retinal pigmentation with dispersion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased to undetectable oscillatory potentials n1=cyclopeptide | n2=en:decreased to undetectable oscillatory potentials | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity n1=cyclopeptide | n2=en:decreased visual acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity (in some patients) n1=cyclopeptide | n2=en:decreased visual acuity (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity (rare) n1=cyclopeptide | n2=en:decreased visual acuity (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity in early childhood n1=cyclopeptide | n2=en:decreased visual acuity in early childhood | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity in fourth decade of life n1=cyclopeptide | n2=en:decreased visual acuity in fourth decade of life | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity, adult-onset n1=cyclopeptide | n2=en:decreased visual acuity, adult-onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity, in some female carriers n1=cyclopeptide | n2=en:decreased visual acuity, in some female carriers | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity, nonprogressive n1=cyclopeptide | n2=en:decreased visual acuity, nonprogressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity, progressive n1=cyclopeptide | n2=en:decreased visual acuity, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity, rapidly progressive n1=cyclopeptide | n2=en:decreased visual acuity, rapidly progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:decreased visual acuity, slowly progressive n1=cyclopeptide | n2=en:decreased visual acuity, slowly progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep anterior chamber (in some patients) n1=cyclopeptide | n2=en:deep anterior chamber (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep-seated eyes n1=cyclopeptide | n2=en:deep-seated eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep-set eyes (1 patient) n1=cyclopeptide | n2=en:deep-set eyes (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep-set eyes (in 1/4 patients) n1=cyclopeptide | n2=en:deep-set eyes (in 1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep-set eyes (in 2 patients) n1=cyclopeptide | n2=en:deep-set eyes (in 2 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep-set eyes (in early childhood) n1=cyclopeptide | n2=en:deep-set eyes (in early childhood) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep-set eyes (in some patients) n1=cyclopeptide | n2=en:deep-set eyes (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep-set eyes (rare) n1=cyclopeptide | n2=en:deep-set eyes (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deep, sunken eyes n1=cyclopeptide | n2=en:deep, sunken eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deeper, fusiform lattice deposits develop later n1=cyclopeptide | n2=en:deeper, fusiform lattice deposits develop later | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:defactinib n1=cyclopeptide | n2=en:defactinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:defective color vision in some patients n1=cyclopeptide | n2=en:defective color vision in some patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:defects in all axes of color vision n1=cyclopeptide | n2=en:defects in all axes of color vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deferasirox n1=cyclopeptide | n2=en:deferasirox | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deferiprone n1=cyclopeptide | n2=en:deferiprone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deferoxamine mesylate n1=cyclopeptide | n2=en:deferoxamine mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:defibrotide sodium n1=cyclopeptide | n2=en:defibrotide sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:defined green tea catechin extract n1=cyclopeptide | n2=en:defined green tea catechin extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deformed pupils n1=cyclopeptide | n2=en:deformed pupils | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:defosfamide n1=cyclopeptide | n2=en:defosfamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:degarelix n1=cyclopeptide | n2=en:degarelix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:degeneration of retinal pigment epithelium (relatively less involvement of central retina) n1=cyclopeptide | n2=en:degeneration of retinal pigment epithelium (relatively less involvement of central retina) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:degenerative vitreoretinopathy n1=cyclopeptide | n2=en:degenerative vitreoretinopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins n1=cyclopeptide | n2=en:deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dehydrated human amnion/chorion membrane n1=cyclopeptide | n2=en:dehydrated human amnion/chorion membrane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dehydroemetine n1=cyclopeptide | n2=en:dehydroemetine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delanzomib n1=cyclopeptide | n2=en:delanzomib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delayed epiphyseal fusion n1=cyclopeptide | n2=en:delayed epiphyseal fusion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delayed eye opening as a neonate (up to 2 weeks) n1=cyclopeptide | n2=en:delayed eye opening as a neonate (up to 2 weeks) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delayed pupillary responses (in some patients) n1=cyclopeptide | n2=en:delayed pupillary responses (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delayed visual-evoked potential n1=cyclopeptide | n2=en:delayed visual-evoked potential | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delmitide n1=cyclopeptide | n2=en:delmitide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delmitide acetate n1=cyclopeptide | n2=en:delmitide acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delta-8-tetrahydrocannabinol n1=cyclopeptide | n2=en:delta-8-tetrahydrocannabinol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delta-tocopherol n1=cyclopeptide | n2=en:delta-tocopherol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:delta-tocotrienol n1=cyclopeptide | n2=en:delta-tocotrienol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:demcizumab n1=cyclopeptide | n2=en:demcizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:demeclocycline hydrochloride n1=cyclopeptide | n2=en:demeclocycline hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:demineralized bone matrix n1=cyclopeptide | n2=en:demineralized bone matrix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dendritic cell-autologous lung tumor vaccine n1=cyclopeptide | n2=en:dendritic cell-autologous lung tumor vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dendritic cell-cea peptide vaccine n1=cyclopeptide | n2=en:dendritic cell-cea peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dendritic cell-gp100-mart-1 antigen vaccine n1=cyclopeptide | n2=en:dendritic cell-gp100-mart-1 antigen vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dendritic cell-idiotype-keyhole limpet hemocyanin vaccine n1=cyclopeptide | n2=en:dendritic cell-idiotype-keyhole limpet hemocyanin vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dendritic cell-mart-1 peptide vaccine n1=cyclopeptide | n2=en:dendritic cell-mart-1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dendritic cell-precision multiple antigen t-lymphocytes n1=cyclopeptide | n2=en:dendritic cell-precision multiple antigen t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dendritic cell-recombinant prostate-specific membrane antigen vaccine n1=cyclopeptide | n2=en:dendritic cell-recombinant prostate-specific membrane antigen vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dendritic cell-targeting lentiviral vector id-lv305 n1=cyclopeptide | n2=en:dendritic cell-targeting lentiviral vector id-lv305 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:denenicokin n1=cyclopeptide | n2=en:denenicokin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:denibulin hydrochloride n1=cyclopeptide | n2=en:denibulin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:denileukin diftitox n1=cyclopeptide | n2=en:denileukin diftitox | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:denintuzumab mafodotin n1=cyclopeptide | n2=en:denintuzumab mafodotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:denosumab n1=cyclopeptide | n2=en:denosumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dense, posterior cortical cataract (carrier females) n1=cyclopeptide | n2=en:dense, posterior cortical cataract (carrier females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dental agent n1=cyclopeptide | n2=en:dental agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dental disclosing preparation n1=cyclopeptide | n2=en:dental disclosing preparation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dentofacial anomaly n1=cyclopeptide | n2=en:dentofacial anomaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deoxycytidine n1=cyclopeptide | n2=en:deoxycytidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deoxycytidine analogue tas-109 n1=cyclopeptide | n2=en:deoxycytidine analogue tas-109 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:depatuxizumab n1=cyclopeptide | n2=en:depatuxizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:depdc1/mphosh1 peptide vaccine n1=cyclopeptide | n2=en:depdc1/mphosh1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:depigmented iris n1=cyclopeptide | n2=en:depigmented iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:depigmented lesions of the retinal pigment epithelium n1=cyclopeptide | n2=en:depigmented lesions of the retinal pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deprecated visual acuity log mar.right: cmplx: pt: eye.left: qn: n1=cyclopeptide | n2=en:deprecated visual acuity log mar.right: cmplx: pt: eye.left: qn: | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deprecated visual acuity log mar.right: cmplx: pt: eye.right: qn: n1=cyclopeptide | n2=en:deprecated visual acuity log mar.right: cmplx: pt: eye.right: qn: | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:derma-membrane-structure topical cream n1=cyclopeptide | n2=en:derma-membrane-structure topical cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dermatologic agents n1=cyclopeptide | n2=en:dermatologic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dermoid choristoma of eye proper n1=cyclopeptide | n2=en:dermoid choristoma of eye proper | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dermoid cyst n1=cyclopeptide | n2=en:dermoid cyst | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dermoid cyst of conjunctiva n1=cyclopeptide | n2=en:dermoid cyst of conjunctiva | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dermoid cyst of cornea n1=cyclopeptide | n2=en:dermoid cyst of cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dermolipoma n1=cyclopeptide | n2=en:dermolipoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:desflurane n1=cyclopeptide | n2=en:desflurane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:designer drugs n1=cyclopeptide | n2=en:designer drugs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:desipramine hydrochloride n1=cyclopeptide | n2=en:desipramine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deslorelin n1=cyclopeptide | n2=en:deslorelin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:desmethylmisonidazole n1=cyclopeptide | n2=en:desmethylmisonidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:desmopressin acetate n1=cyclopeptide | n2=en:desmopressin acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:desogestrel n1=cyclopeptide | n2=en:desogestrel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:desvenlafaxine succinate n1=cyclopeptide | n2=en:desvenlafaxine succinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:detached retina (in some patients) n1=cyclopeptide | n2=en:detached retina (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:detorubicin n1=cyclopeptide | n2=en:detorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:detox-b adjuvant n1=cyclopeptide | n2=en:detox-b adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:detoxpc n1=cyclopeptide | n2=en:detoxpc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deuterated 3-methylhistidine n1=cyclopeptide | n2=en:deuterated 3-methylhistidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deuterated phenanthrene n1=cyclopeptide | n2=en:deuterated phenanthrene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:deuterium oxide n1=cyclopeptide | n2=en:deuterium oxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:developmental dislocation n1=cyclopeptide | n2=en:developmental dislocation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:developmental failure of fusion n1=cyclopeptide | n2=en:developmental failure of fusion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:developmental immaturity n1=cyclopeptide | n2=en:developmental immaturity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:developmental malformation of branchial arch n1=cyclopeptide | n2=en:developmental malformation of branchial arch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:developmental stricture n1=cyclopeptide | n2=en:developmental stricture | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexamethasone n1=cyclopeptide | n2=en:dexamethasone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexamethasone intravitreal implant n1=cyclopeptide | n2=en:dexamethasone intravitreal implant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexanabinol n1=cyclopeptide | n2=en:dexanabinol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexmedetomidine hydrochloride n1=cyclopeptide | n2=en:dexmedetomidine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexmethylphenidate n1=cyclopeptide | n2=en:dexmethylphenidate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexniguldipine n1=cyclopeptide | n2=en:dexniguldipine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexpanthenol n1=cyclopeptide | n2=en:dexpanthenol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexpanthenol mouthwash n1=cyclopeptide | n2=en:dexpanthenol mouthwash | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexrazoxane hydrochloride n1=cyclopeptide | n2=en:dexrazoxane hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dextran n1=cyclopeptide | n2=en:dextran | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dextran sulfate sodium n1=cyclopeptide | n2=en:dextran sulfate sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dextroamphetamine sulfate n1=cyclopeptide | n2=en:dextroamphetamine sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dextroamphetamine-amphetamine n1=cyclopeptide | n2=en:dextroamphetamine-amphetamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dextromethorphan hydrobromide n1=cyclopeptide | n2=en:dextromethorphan hydrobromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dextropropoxyphene hydrochloride n1=cyclopeptide | n2=en:dextropropoxyphene hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dexverapamil n1=cyclopeptide | n2=en:dexverapamil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dezaguanine n1=cyclopeptide | n2=en:dezaguanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dha-paclitaxel n1=cyclopeptide | n2=en:dha-paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dhap regimen n1=cyclopeptide | n2=en:dhap regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dhea mustard n1=cyclopeptide | n2=en:dhea mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dher2 vaccine+as15 adjuvant n1=cyclopeptide | n2=en:dher2 vaccine+as15 adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:di-dga-rfb4 immunotoxin n1=cyclopeptide | n2=en:di-dga-rfb4 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:di-leu16-il2 immunocytokine n1=cyclopeptide | n2=en:di-leu16-il2 immunocytokine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diacetylmorphine hydrochloride n1=cyclopeptide | n2=en:diacetylmorphine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diagnostic agents n1=cyclopeptide | n2=en:diagnostic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diammonium glycyrrhizinate n1=cyclopeptide | n2=en:diammonium glycyrrhizinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dianhydrogalactitol n1=cyclopeptide | n2=en:dianhydrogalactitol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dianicline n1=cyclopeptide | n2=en:dianicline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diarylsulfonylurea compound n1=cyclopeptide | n2=en:diarylsulfonylurea compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diazepinomicin n1=cyclopeptide | n2=en:diazepinomicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diaziquone n1=cyclopeptide | n2=en:diaziquone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diazooxonorleucine n1=cyclopeptide | n2=en:diazooxonorleucine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diazoxide n1=cyclopeptide | n2=en:diazoxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dichloromethotrexate n1=cyclopeptide | n2=en:dichloromethotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diclofenac epolamine patch n1=cyclopeptide | n2=en:diclofenac epolamine patch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diclofenac sodium gel n1=cyclopeptide | n2=en:diclofenac sodium gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dicumarol n1=cyclopeptide | n2=en:dicumarol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:didanosine n1=cyclopeptide | n2=en:didanosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:didemnin b n1=cyclopeptide | n2=en:didemnin b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dideoxyadenosine n1=cyclopeptide | n2=en:dideoxyadenosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:didox n1=cyclopeptide | n2=en:didox | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dienogest n1=cyclopeptide | n2=en:dienogest | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dietary product n1=cyclopeptide | n2=en:dietary product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diethylhomospermine n1=cyclopeptide | n2=en:diethylhomospermine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diethylnorspermine n1=cyclopeptide | n2=en:diethylnorspermine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diethylstilbestrol n1=cyclopeptide | n2=en:diethylstilbestrol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:difficulties with light adaptation n1=cyclopeptide | n2=en:difficulties with light adaptation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:difficulties with night vision (reported in 1 family) n1=cyclopeptide | n2=en:difficulties with night vision (reported in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:difficulty reading n1=cyclopeptide | n2=en:difficulty reading | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diffuse fine hard drusen in macula and paracentral area n1=cyclopeptide | n2=en:diffuse fine hard drusen in macula and paracentral area | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diffuse or localized pigmentary changes, with bone spicules in some patients n1=cyclopeptide | n2=en:diffuse or localized pigmentary changes, with bone spicules in some patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diffuse pigment epithelial disturbances n1=cyclopeptide | n2=en:diffuse pigment epithelial disturbances | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diffuse pigmentary stippling of peripheral retina n1=cyclopeptide | n2=en:diffuse pigmentary stippling of peripheral retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diflomotecan n1=cyclopeptide | n2=en:diflomotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diflunisal n1=cyclopeptide | n2=en:diflunisal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:digeorge syndrome n1=cyclopeptide | n2=en:digeorge syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:digitoxin n1=cyclopeptide | n2=en:digitoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:digoxin n1=cyclopeptide | n2=en:digoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dihydro-5-azacytidine n1=cyclopeptide | n2=en:dihydro-5-azacytidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dihydrolenperone n1=cyclopeptide | n2=en:dihydrolenperone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diindolylmethane n1=cyclopeptide | n2=en:diindolylmethane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diiodocyclophosphamide n1=cyclopeptide | n2=en:diiodocyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dilated superficial vessels give 'red eye' appearance n1=cyclopeptide | n2=en:dilated superficial vessels give 'red eye' appearance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diltiazem hydrochloride n1=cyclopeptide | n2=en:diltiazem hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dilution of color of iris n1=cyclopeptide | n2=en:dilution of color of iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dimesna n1=cyclopeptide | n2=en:dimesna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dimethicone-containing botanicals-based lotion n1=cyclopeptide | n2=en:dimethicone-containing botanicals-based lotion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dimethicone/polymer barrier cream n1=cyclopeptide | n2=en:dimethicone/polymer barrier cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dimethoate n1=cyclopeptide | n2=en:dimethoate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dimethyl fumarate n1=cyclopeptide | n2=en:dimethyl fumarate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dimethyl sulfone n1=cyclopeptide | n2=en:dimethyl sulfone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dimethyl sulfoxide n1=cyclopeptide | n2=en:dimethyl sulfoxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dimethylmyleran n1=cyclopeptide | n2=en:dimethylmyleran | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diminished amplitude on erg n1=cyclopeptide | n2=en:diminished amplitude on erg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diminished or extinguished responses on electroretinography n1=cyclopeptide | n2=en:diminished or extinguished responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diminished pupillary light responses n1=cyclopeptide | n2=en:diminished pupillary light responses | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diminished visual acuity (1 patient) n1=cyclopeptide | n2=en:diminished visual acuity (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dinaciclib n1=cyclopeptide | n2=en:dinaciclib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dinitrochlorobenzene n1=cyclopeptide | n2=en:dinitrochlorobenzene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dinitrofluorobenzene n1=cyclopeptide | n2=en:dinitrofluorobenzene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dinitrophenyl n1=cyclopeptide | n2=en:dinitrophenyl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dinitrophenyl-modified autologous renal cell carcinoma tumor cell vaccine n1=cyclopeptide | n2=en:dinitrophenyl-modified autologous renal cell carcinoma tumor cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dinoprost tromethamine n1=cyclopeptide | n2=en:dinoprost tromethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dinutuximab n1=cyclopeptide | n2=en:dinutuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dioscorea nipponica makino extract dne3 n1=cyclopeptide | n2=en:dioscorea nipponica makino extract dne3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphencyprone n1=cyclopeptide | n2=en:diphencyprone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphenhydramine hydrochloride n1=cyclopeptide | n2=en:diphenhydramine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphenhydramine hydrochloride/dexamethasone/nystatin magic mouthwash n1=cyclopeptide | n2=en:diphenhydramine hydrochloride/dexamethasone/nystatin magic mouthwash | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphenhydramine/lidocaine/antacid mouthwash n1=cyclopeptide | n2=en:diphenhydramine/lidocaine/antacid mouthwash | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphtheria toxin fragment-interleukin-2 fusion protein e7777 n1=cyclopeptide | n2=en:diphtheria toxin fragment-interleukin-2 fusion protein e7777 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphtheria toxoid/tetanus toxoid vaccine adsorbed n1=cyclopeptide | n2=en:diphtheria toxoid/tetanus toxoid vaccine adsorbed | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphtheria toxoid/tetanus toxoid/acellular pertussis adsorbed, recombinant hepatitis b/inactivated poliovirus vaccine combined n1=cyclopeptide | n2=en:diphtheria toxoid/tetanus toxoid/acellular pertussis adsorbed, recombinant hepatitis b/inactivated poliovirus vaccine combined | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed n1=cyclopeptide | n2=en:diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-haemophilus influenzae type b vaccine n1=cyclopeptide | n2=en:diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-haemophilus influenzae type b vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diplopia n1=cyclopeptide | n2=en:diplopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diplopias, intermittent n1=cyclopeptide | n2=en:diplopias, intermittent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dipyridamole n1=cyclopeptide | n2=en:dipyridamole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:directly observed therapy n1=cyclopeptide | n2=en:directly observed therapy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:disaccharide tripeptide glycerol dipalmitoyl n1=cyclopeptide | n2=en:disaccharide tripeptide glycerol dipalmitoyl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:disc hemorrhage n1=cyclopeptide | n2=en:disc hemorrhage | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:discontinuity and degeneration of the endothelial cell layer n1=cyclopeptide | n2=en:discontinuity and degeneration of the endothelial cell layer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dislocated lens (upward) n1=cyclopeptide | n2=en:dislocated lens (upward) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:disorder of macula of retina n1=cyclopeptide | n2=en:disorder of macula of retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:displaced pupils n1=cyclopeptide | n2=en:displaced pupils | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:displacement of pupil, inferior (in some patients) n1=cyclopeptide | n2=en:displacement of pupil, inferior (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:distichiasis n1=cyclopeptide | n2=en:distichiasis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:distichiasis (double row of eyelashes, 1 family) n1=cyclopeptide | n2=en:distichiasis (double row of eyelashes, 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:distilled water n1=cyclopeptide | n2=en:distilled water | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:distinctive electroretinogram - focal macular cone erg is well-preserved n1=cyclopeptide | n2=en:distinctive electroretinogram - focal macular cone erg is well-preserved | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:districhiasis n1=cyclopeptide | n2=en:districhiasis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:disulfiram n1=cyclopeptide | n2=en:disulfiram | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ditiocarb n1=cyclopeptide | n2=en:ditiocarb | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:diuretic n1=cyclopeptide | n2=en:diuretic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:divalproex sodium n1=cyclopeptide | n2=en:divalproex sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:divergent strabismus n1=cyclopeptide | n2=en:divergent strabismus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dkk1-neutralizing monoclonal antibody dkn-01 n1=cyclopeptide | n2=en:dkk1-neutralizing monoclonal antibody dkn-01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dl-selenomethionine n1=cyclopeptide | n2=en:dl-selenomethionine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dlk1/epha2/hbb/nrp1/rgs5/tem1 peptide-pulsed alpha-type-1 polarized dendritic cell vaccine n1=cyclopeptide | n2=en:dlk1/epha2/hbb/nrp1/rgs5/tem1 peptide-pulsed alpha-type-1 polarized dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dm-choc-pen n1=cyclopeptide | n2=en:dm-choc-pen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dm4-conjugated anti-cripto monoclonal antibody biib015 n1=cyclopeptide | n2=en:dm4-conjugated anti-cripto monoclonal antibody biib015 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dmuc4064a n1=cyclopeptide | n2=en:dmuc4064a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dn-101 n1=cyclopeptide | n2=en:dn-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna binding agent n1=cyclopeptide | n2=en:dna binding agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna interference oligonucleotide pnt2258 n1=cyclopeptide | n2=en:dna interference oligonucleotide pnt2258 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna minor groove binding agent pm060184 n1=cyclopeptide | n2=en:dna minor groove binding agent pm060184 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna minor groove binding agent sg2000 n1=cyclopeptide | n2=en:dna minor groove binding agent sg2000 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna plasmid encoding interleukin-12 ino-9012 n1=cyclopeptide | n2=en:dna plasmid encoding interleukin-12 ino-9012 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine ino-3112 n1=cyclopeptide | n2=en:dna plasmid-encoding interleukin-12/hpv dna plasmids therapeutic vaccine ino-3112 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna vaccine vb10.16 n1=cyclopeptide | n2=en:dna vaccine vb10.16 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna vector ppra-psm vaccine n1=cyclopeptide | n2=en:dna vector ppra-psm vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna-dependent protein kinase-targeting sidna dt01 n1=cyclopeptide | n2=en:dna-dependent protein kinase-targeting sidna dt01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna-pk inhibitor msc2490484a n1=cyclopeptide | n2=en:dna-pk inhibitor msc2490484a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna-pk/tor kinase inhibitor cc-115 n1=cyclopeptide | n2=en:dna-pk/tor kinase inhibitor cc-115 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dna-rna transcription regulator n1=cyclopeptide | n2=en:dna-rna transcription regulator | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dnr-expressing nasopharyngeal carcinoma-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:dnr-expressing nasopharyngeal carcinoma-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dobutamine n1=cyclopeptide | n2=en:dobutamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docetaxel n1=cyclopeptide | n2=en:docetaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docetaxel emulsion anx-514 n1=cyclopeptide | n2=en:docetaxel emulsion anx-514 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docetaxel formulation ckd-810 n1=cyclopeptide | n2=en:docetaxel formulation ckd-810 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docetaxel lipid microspheres n1=cyclopeptide | n2=en:docetaxel lipid microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docetaxel-loaded nanopharmaceutical crlx301 n1=cyclopeptide | n2=en:docetaxel-loaded nanopharmaceutical crlx301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docetaxel-pnp n1=cyclopeptide | n2=en:docetaxel-pnp | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docetaxel/cyclophosphamide n1=cyclopeptide | n2=en:docetaxel/cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doconexent n1=cyclopeptide | n2=en:doconexent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docosahexaenoic acid n1=cyclopeptide | n2=en:docosahexaenoic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:docusate n1=cyclopeptide | n2=en:docusate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dofequidar fumarate n1=cyclopeptide | n2=en:dofequidar fumarate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dolasetron mesylate n1=cyclopeptide | n2=en:dolasetron mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dolastatin 10 n1=cyclopeptide | n2=en:dolastatin 10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dolutegravir n1=cyclopeptide | n2=en:dolutegravir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dominance, ocular n1=cyclopeptide | n2=en:dominance, ocular | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:domperidone n1=cyclopeptide | n2=en:domperidone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:donafenib n1=cyclopeptide | n2=en:donafenib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:donepezil + memantine n1=cyclopeptide | n2=en:donepezil + memantine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:donepezil hydrochloride n1=cyclopeptide | n2=en:donepezil hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:donor lymphocytes n1=cyclopeptide | n2=en:donor lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:donor regulatory t-lymphocytes n1=cyclopeptide | n2=en:donor regulatory t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:donor-derived wt1/prame/ny-eso-1/survivin-specific t-lymphocytes n1=cyclopeptide | n2=en:donor-derived wt1/prame/ny-eso-1/survivin-specific t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dopamine-somatostatin chimeric molecule bim-23a760 n1=cyclopeptide | n2=en:dopamine-somatostatin chimeric molecule bim-23a760 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dornase alfa n1=cyclopeptide | n2=en:dornase alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dornase alfa inhalation solution n1=cyclopeptide | n2=en:dornase alfa inhalation solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dot1l inhibitor epz-5676 n1=cyclopeptide | n2=en:dot1l inhibitor epz-5676 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dotap:cholesterol-fus1 liposome complex n1=cyclopeptide | n2=en:dotap:cholesterol-fus1 liposome complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:double-ring sign of lens (in some patients) n1=cyclopeptide | n2=en:double-ring sign of lens (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dovitinib lactate n1=cyclopeptide | n2=en:dovitinib lactate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:down-slanting palpebral fissures (in some patients) n1=cyclopeptide | n2=en:down-slanting palpebral fissures (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downbeat nystagmus n1=cyclopeptide | n2=en:downbeat nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downslanting eyebrows n1=cyclopeptide | n2=en:downslanting eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downslanting palpebral fissure (male) n1=cyclopeptide | n2=en:downslanting palpebral fissure (male) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downslanting palpebral fissures (6 of 22) n1=cyclopeptide | n2=en:downslanting palpebral fissures (6 of 22) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downslanting palpebral fissures (in 1 of 2 patients) n1=cyclopeptide | n2=en:downslanting palpebral fissures (in 1 of 2 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downslanting palpebral fissures (in 2 patients) n1=cyclopeptide | n2=en:downslanting palpebral fissures (in 2 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downslanting palpebral fissures (in 2/4 patients) n1=cyclopeptide | n2=en:downslanting palpebral fissures (in 2/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downslanting palpebral fissures (in some patients) n1=cyclopeptide | n2=en:downslanting palpebral fissures (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downslanting palpebral fissures (rare) n1=cyclopeptide | n2=en:downslanting palpebral fissures (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downward gaze n1=cyclopeptide | n2=en:downward gaze | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:downward slant of palpebral fissure n1=cyclopeptide | n2=en:downward slant of palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxazosin mesylate n1=cyclopeptide | n2=en:doxazosin mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxepin hydrochloride n1=cyclopeptide | n2=en:doxepin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxercalciferol n1=cyclopeptide | n2=en:doxercalciferol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxifluridine n1=cyclopeptide | n2=en:doxifluridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxorubicin hcl inhalation solution n1=cyclopeptide | n2=en:doxorubicin hcl inhalation solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxorubicin hydrochloride n1=cyclopeptide | n2=en:doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxorubicin-dna complex n1=cyclopeptide | n2=en:doxorubicin-dna complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxorubicin-eluting beads n1=cyclopeptide | n2=en:doxorubicin-eluting beads | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxorubicin-hpma conjugate n1=cyclopeptide | n2=en:doxorubicin-hpma conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxorubicin-magnetic targeted carrier complex n1=cyclopeptide | n2=en:doxorubicin-magnetic targeted carrier complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxycycline n1=cyclopeptide | n2=en:doxycycline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxycycline hyclate n1=cyclopeptide | n2=en:doxycycline hyclate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxycycline hyclate foam n1=cyclopeptide | n2=en:doxycycline hyclate foam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:doxycycline hyclate injection n1=cyclopeptide | n2=en:doxycycline hyclate injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dpt/bcg/measles/serratia/pneumococcus vaccine n1=cyclopeptide | n2=en:dpt/bcg/measles/serratia/pneumococcus vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dpt/typhoid/staphylococcus aureus/paratyphoid a/paratyphoid b vaccine n1=cyclopeptide | n2=en:dpt/typhoid/staphylococcus aureus/paratyphoid a/paratyphoid b vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dr5-targeting tetrameric nanobody agonist tas266 n1=cyclopeptide | n2=en:dr5-targeting tetrameric nanobody agonist tas266 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dromostanolone propionate n1=cyclopeptide | n2=en:dromostanolone propionate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dronabinol n1=cyclopeptide | n2=en:dronabinol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:droperidol n1=cyclopeptide | n2=en:droperidol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drotrecogin alfa (activated) n1=cyclopeptide | n2=en:drotrecogin alfa (activated) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drug allergen n1=cyclopeptide | n2=en:drug allergen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drug combinations n1=cyclopeptide | n2=en:drug combinations | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drug groups primarily affecting the musculoskeletal system n1=cyclopeptide | n2=en:drug groups primarily affecting the musculoskeletal system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drug products by fda established pharmacologic class n1=cyclopeptide | n2=en:drug products by fda established pharmacologic class | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drug products by generic ingredient combinations n1=cyclopeptide | n2=en:drug products by generic ingredient combinations | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drug products by va class n1=cyclopeptide | n2=en:drug products by va class | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drug values n1=cyclopeptide | n2=en:drug values | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drug-device combination product n1=cyclopeptide | n2=en:drug-device combination product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drugs treating radiation contamination n1=cyclopeptide | n2=en:drugs treating radiation contamination | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drugs used in metabolic disorders n1=cyclopeptide | n2=en:drugs used in metabolic disorders | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drugs used to treat addiction n1=cyclopeptide | n2=en:drugs used to treat addiction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drugs, chinese herbal n1=cyclopeptide | n2=en:drugs, chinese herbal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drugs, essential n1=cyclopeptide | n2=en:drugs, essential | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:drusen (in some patients) n1=cyclopeptide | n2=en:drusen (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dry conjunctival mucosae n1=cyclopeptide | n2=en:dry conjunctival mucosae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dryness of eye n1=cyclopeptide | n2=en:dryness of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dt-pace protocol n1=cyclopeptide | n2=en:dt-pace protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dt-pace regimen n1=cyclopeptide | n2=en:dt-pace regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dt(388)il3 fusion protein sl-401 n1=cyclopeptide | n2=en:dt(388)il3 fusion protein sl-401 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dta-h19 plasmid n1=cyclopeptide | n2=en:dta-h19 plasmid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dtgm fusion protein n1=cyclopeptide | n2=en:dtgm fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dual igf-1r/insr inhibitor bms-754807 n1=cyclopeptide | n2=en:dual igf-1r/insr inhibitor bms-754807 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dual pi3 kinase/mtor inhibitor gdc-0980 n1=cyclopeptide | n2=en:dual pi3 kinase/mtor inhibitor gdc-0980 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dual variable domain immunoglobulin abt-165 n1=cyclopeptide | n2=en:dual variable domain immunoglobulin abt-165 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dual waveform jerk movements n1=cyclopeptide | n2=en:dual waveform jerk movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duane anomaly (less common) n1=cyclopeptide | n2=en:duane anomaly (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duane anomaly (rare) n1=cyclopeptide | n2=en:duane anomaly (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duane anomaly (reported in 1 female) n1=cyclopeptide | n2=en:duane anomaly (reported in 1 female) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duane retraction syndrome (34%) n1=cyclopeptide | n2=en:duane retraction syndrome (34%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duane syndrome n1=cyclopeptide | n2=en:duane syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duane syndrome (abducens palsy with retracted globe) n1=cyclopeptide | n2=en:duane syndrome (abducens palsy with retracted globe) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duborimycin n1=cyclopeptide | n2=en:duborimycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dulanermin n1=cyclopeptide | n2=en:dulanermin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duligotuzumab n1=cyclopeptide | n2=en:duligotuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dull-appearing central foveal reflex (rare) n1=cyclopeptide | n2=en:dull-appearing central foveal reflex (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:duloxetine hydrochloride n1=cyclopeptide | n2=en:duloxetine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:durvalumab n1=cyclopeptide | n2=en:durvalumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dutasteride n1=cyclopeptide | n2=en:dutasteride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dutpase/dpd inhibitor tas-114 n1=cyclopeptide | n2=en:dutpase/dpd inhibitor tas-114 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dvp-m-chop protocol n1=cyclopeptide | n2=en:dvp-m-chop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dwarfism n1=cyclopeptide | n2=en:dwarfism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dwj1319 n1=cyclopeptide | n2=en:dwj1319 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dyschromatopsia n1=cyclopeptide | n2=en:dyschromatopsia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dyschromatopsia (1 patient) n1=cyclopeptide | n2=en:dyschromatopsia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dyschromatopsia (some) n1=cyclopeptide | n2=en:dyschromatopsia (some) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dysconjugate gaze n1=cyclopeptide | n2=en:dysconjugate gaze | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dysgnathia n1=cyclopeptide | n2=en:dysgnathia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dysinnervation of various cranial nerves to ocular muscles n1=cyclopeptide | n2=en:dysinnervation of various cranial nerves to ocular muscles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dyskeratotic keratinization n1=cyclopeptide | n2=en:dyskeratotic keratinization | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dysmetric saccades n1=cyclopeptide | n2=en:dysmetric saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dysmorphism n1=cyclopeptide | n2=en:dysmorphism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dystopia canthorum absent n1=cyclopeptide | n2=en:dystopia canthorum absent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:dystrophy does not recur after penetrating keratoplasty n1=cyclopeptide | n2=en:dystrophy does not recur after penetrating keratoplasty | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e-101 solution n1=cyclopeptide | n2=en:e-101 solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e-cmf regimen n1=cyclopeptide | n2=en:e-cmf regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e-selectin antagonist gmi-1271 n1=cyclopeptide | n2=en:e-selectin antagonist gmi-1271 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e. coli cd-expressing genetically modified neural stem cells n1=cyclopeptide | n2=en:e. coli cd-expressing genetically modified neural stem cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e1a lipid complex n1=cyclopeptide | n2=en:e1a lipid complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e1m184v peptide vaccine n1=cyclopeptide | n2=en:e1m184v peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e2f1 pathway activator arq 171 n1=cyclopeptide | n2=en:e2f1 pathway activator arq 171 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e7046 n1=cyclopeptide | n2=en:e7046 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:e7820 n1=cyclopeptide | n2=en:e7820 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eacb protocol n1=cyclopeptide | n2=en:eacb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ear, face and neck congenital anomalies n1=cyclopeptide | n2=en:ear, face and neck congenital anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:early cataracts n1=cyclopeptide | n2=en:early cataracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:early glaucoma n1=cyclopeptide | n2=en:early glaucoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:early onset night blindness and abnormal fundus (e.g. 180380.0013) n1=cyclopeptide | n2=en:early onset night blindness and abnormal fundus (e.g. 180380.0013) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:early onset of decreased visual acuity: nonrecordable cone pattern on electroretinogram n1=cyclopeptide | n2=en:early onset of decreased visual acuity: nonrecordable cone pattern on electroretinogram | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:early onset open-angle glaucoma n1=cyclopeptide | n2=en:early onset open-angle glaucoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:early-onset cataracts (1 family) n1=cyclopeptide | n2=en:early-onset cataracts (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:early-onset corneal degeneration n1=cyclopeptide | n2=en:early-onset corneal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:east indian sandalwood oil mouth rinse n1=cyclopeptide | n2=en:east indian sandalwood oil mouth rinse | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ebselen-containing oral capsule spi-1005 n1=cyclopeptide | n2=en:ebselen-containing oral capsule spi-1005 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ebv-specific cytotoxic t-lymphocyte n1=cyclopeptide | n2=en:ebv-specific cytotoxic t-lymphocyte | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ec breast regimen n1=cyclopeptide | n2=en:ec breast regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ec regimen n1=cyclopeptide | n2=en:ec regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ecapp protocol n1=cyclopeptide | n2=en:ecapp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ecbc protocol n1=cyclopeptide | n2=en:ecbc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eccentric or ectopic pupils n1=cyclopeptide | n2=en:eccentric or ectopic pupils | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eccentric pupil (rare) n1=cyclopeptide | n2=en:eccentric pupil (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:echinomycin n1=cyclopeptide | n2=en:echinomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ecp regimen n1=cyclopeptide | n2=en:ecp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ecromeximab n1=cyclopeptide | n2=en:ecromeximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectodermal dysplasia n1=cyclopeptide | n2=en:ectodermal dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia n1=cyclopeptide | n2=en:ectopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia cordis n1=cyclopeptide | n2=en:ectopia cordis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia lentis (6%) n1=cyclopeptide | n2=en:ectopia lentis (6%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia lentis (64%) n1=cyclopeptide | n2=en:ectopia lentis (64%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia lentis (84%) n1=cyclopeptide | n2=en:ectopia lentis (84%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia lentis (in some patients) n1=cyclopeptide | n2=en:ectopia lentis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia lentis spherophakia (in some patients) n1=cyclopeptide | n2=en:ectopia lentis spherophakia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia lentis with ectopia of pupil n1=cyclopeptide | n2=en:ectopia lentis with ectopia of pupil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia lentis, isolated (congenital lens dislocation) n1=cyclopeptide | n2=en:ectopia lentis, isolated (congenital lens dislocation) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopia lentis, uncomplicated n1=cyclopeptide | n2=en:ectopia lentis, uncomplicated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectopic lens n1=cyclopeptide | n2=en:ectopic lens | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectromelia n1=cyclopeptide | n2=en:ectromelia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectropion n1=cyclopeptide | n2=en:ectropion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectropion (in some patients) n1=cyclopeptide | n2=en:ectropion (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ectropion, bilateral (in some patients) n1=cyclopeptide | n2=en:ectropion, bilateral (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eculizumab n1=cyclopeptide | n2=en:eculizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:edatrexate n1=cyclopeptide | n2=en:edatrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:edelfosine n1=cyclopeptide | n2=en:edelfosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:edema of eyelid n1=cyclopeptide | n2=en:edema of eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:edematous eyelids n1=cyclopeptide | n2=en:edematous eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:edetate calcium disodium n1=cyclopeptide | n2=en:edetate calcium disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:edotecarin n1=cyclopeptide | n2=en:edotecarin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:edoxaban tosylate n1=cyclopeptide | n2=en:edoxaban tosylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:edrecolomab n1=cyclopeptide | n2=en:edrecolomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ef5 n1=cyclopeptide | n2=en:ef5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:efalizumab n1=cyclopeptide | n2=en:efalizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:efaproxiral n1=cyclopeptide | n2=en:efaproxiral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:efatutazone dihydrochloride n1=cyclopeptide | n2=en:efatutazone dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:efavirenz n1=cyclopeptide | n2=en:efavirenz | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eflornithine n1=cyclopeptide | n2=en:eflornithine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eflornithine hydrochloride ointment n1=cyclopeptide | n2=en:eflornithine hydrochloride ointment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:efs-ada lentiviral vector-transduced cd34-positive autologous lymphocytes n1=cyclopeptide | n2=en:efs-ada lentiviral vector-transduced cd34-positive autologous lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:efungumab n1=cyclopeptide | n2=en:efungumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eg5 kinesin-related motor protein inhibitor 4sc-205 n1=cyclopeptide | n2=en:eg5 kinesin-related motor protein inhibitor 4sc-205 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eg5 kinesin-related motor protein inhibitor arq 621 n1=cyclopeptide | n2=en:eg5 kinesin-related motor protein inhibitor arq 621 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egb761 n1=cyclopeptide | n2=en:egb761 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr antagonist hemay022 n1=cyclopeptide | n2=en:egfr antagonist hemay022 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr antisense dna n1=cyclopeptide | n2=en:egfr antisense dna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=cyclopeptide | n2=en:egfr car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr inhibitor abt-414 n1=cyclopeptide | n2=en:egfr inhibitor abt-414 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr inhibitor asp8273 n1=cyclopeptide | n2=en:egfr inhibitor asp8273 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr inhibitor azd3759 n1=cyclopeptide | n2=en:egfr inhibitor azd3759 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr inhibitor co-1686 n1=cyclopeptide | n2=en:egfr inhibitor co-1686 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr inhibitor egf816 n1=cyclopeptide | n2=en:egfr inhibitor egf816 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr inhibitor hm61713 n1=cyclopeptide | n2=en:egfr inhibitor hm61713 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr mutation-selective inhibitor ac0010ma n1=cyclopeptide | n2=en:egfr mutation-selective inhibitor ac0010ma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr t790m inhibitor pf-06747775 n1=cyclopeptide | n2=en:egfr t790m inhibitor pf-06747775 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr/her2 inhibitor ap32788 n1=cyclopeptide | n2=en:egfr/her2 inhibitor ap32788 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr/her2 inhibitor av-412 n1=cyclopeptide | n2=en:egfr/her2 inhibitor av-412 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfr/her2 kinase inhibitor tak-285 n1=cyclopeptide | n2=en:egfr/her2 kinase inhibitor tak-285 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfrbi-armed autologous t cells n1=cyclopeptide | n2=en:egfrbi-armed autologous t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:egfrviii-specific car-transduced autologous t lymphocytes n1=cyclopeptide | n2=en:egfrviii-specific car-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eicosapentaenoic acid n1=cyclopeptide | n2=en:eicosapentaenoic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eicosapentaenoic acid-enriched nutritional supplement n1=cyclopeptide | n2=en:eicosapentaenoic acid-enriched nutritional supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eif4e antisense oligonucleotide isis 183750 n1=cyclopeptide | n2=en:eif4e antisense oligonucleotide isis 183750 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elacytarabine n1=cyclopeptide | n2=en:elacytarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electro-oculogram (eog), flash electroretinogram (erg) and pattern erg (perg) initially normal n1=cyclopeptide | n2=en:electro-oculogram (eog), flash electroretinogram (erg) and pattern erg (perg) initially normal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electrokinetically modified water n1=cyclopeptide | n2=en:electrokinetically modified water | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electrolyte-free parenteral nutrition emulsion n1=cyclopeptide | n2=en:electrolyte-free parenteral nutrition emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinogram (erg) shows a reduced b-wave in most cases n1=cyclopeptide | n2=en:electroretinogram (erg) shows a reduced b-wave in most cases | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinogram abnormal n1=cyclopeptide | n2=en:electroretinogram abnormal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinogram normal n1=cyclopeptide | n2=en:electroretinogram normal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinograms markedly reduced or completely extinct n1=cyclopeptide | n2=en:electroretinograms markedly reduced or completely extinct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinograms unrecordable at birth or in infancy n1=cyclopeptide | n2=en:electroretinograms unrecordable at birth or in infancy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinographic responses reduced or nonrecordable n1=cyclopeptide | n2=en:electroretinographic responses reduced or nonrecordable | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinography (erg) shows decreased amplitudes n1=cyclopeptide | n2=en:electroretinography (erg) shows decreased amplitudes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinography responses diminished or undetectable n1=cyclopeptide | n2=en:electroretinography responses diminished or undetectable | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:electroretinography responses nondetectable (in most patients) n1=cyclopeptide | n2=en:electroretinography responses nondetectable (in most patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elesclomol n1=cyclopeptide | n2=en:elesclomol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elesclomol sodium n1=cyclopeptide | n2=en:elesclomol sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elevated intraocular pressure (in some patients) n1=cyclopeptide | n2=en:elevated intraocular pressure (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elevated papillomacular retinal fold n1=cyclopeptide | n2=en:elevated papillomacular retinal fold | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elicited repetitive daily blindness (erdb) n1=cyclopeptide | n2=en:elicited repetitive daily blindness (erdb) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elinafide n1=cyclopeptide | n2=en:elinafide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elisidepsin n1=cyclopeptide | n2=en:elisidepsin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ellagic acid/annona muricata supplement n1=cyclopeptide | n2=en:ellagic acid/annona muricata supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elliptinium acetate n1=cyclopeptide | n2=en:elliptinium acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elongated palpebral fissures n1=cyclopeptide | n2=en:elongated palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elosulfase alfa n1=cyclopeptide | n2=en:elosulfase alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elotuzumab n1=cyclopeptide | n2=en:elotuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elsamitrucin n1=cyclopeptide | n2=en:elsamitrucin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:elsiglutide n1=cyclopeptide | n2=en:elsiglutide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eltrombopag olamine n1=cyclopeptide | n2=en:eltrombopag olamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ema-ce regimen n1=cyclopeptide | n2=en:ema-ce regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ema-co regimen n1=cyclopeptide | n2=en:ema-co regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:emactuzumab n1=cyclopeptide | n2=en:emactuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:embolic agent n1=cyclopeptide | n2=en:embolic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:embryological remnant n1=cyclopeptide | n2=en:embryological remnant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:embryonal nuclear cataract (disorder) n1=cyclopeptide | n2=en:embryonal nuclear cataract (disorder) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:embryonal rest and/or persistent embryonic structure n1=cyclopeptide | n2=en:embryonal rest and/or persistent embryonic structure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:embryonic cyst n1=cyclopeptide | n2=en:embryonic cyst | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:emepepimut-s n1=cyclopeptide | n2=en:emepepimut-s | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:emitefur n1=cyclopeptide | n2=en:emitefur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:emmetropia n1=cyclopeptide | n2=en:emmetropia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:emollients n1=cyclopeptide | n2=en:emollients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:emricasan n1=cyclopeptide | n2=en:emricasan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:emtricitabine n1=cyclopeptide | n2=en:emtricitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enadenotucirev n1=cyclopeptide | n2=en:enadenotucirev | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enalapril maleate n1=cyclopeptide | n2=en:enalapril maleate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enavatuzumab n1=cyclopeptide | n2=en:enavatuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:encephalocele n1=cyclopeptide | n2=en:encephalocele | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enclomiphene citrate n1=cyclopeptide | n2=en:enclomiphene citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:end-position nystagmus n1=cyclopeptide | n2=en:end-position nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:endoscopic cyclophotocoagulation n1=cyclopeptide | n2=en:endoscopic cyclophotocoagulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:endothelial cell death with hypertrophy and polymorphism of surviving cells n1=cyclopeptide | n2=en:endothelial cell death with hypertrophy and polymorphism of surviving cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:endothelial changes resembling lunar craters (in carrier females and some affected males) n1=cyclopeptide | n2=en:endothelial changes resembling lunar craters (in carrier females and some affected males) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:endothelin b receptor agonist spi-1620 n1=cyclopeptide | n2=en:endothelin b receptor agonist spi-1620 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eniluracil n1=cyclopeptide | n2=en:eniluracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enlarged corneal diameters (in some patients) n1=cyclopeptide | n2=en:enlarged corneal diameters (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enlarged globes n1=cyclopeptide | n2=en:enlarged globes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enlarged lacrimal glands n1=cyclopeptide | n2=en:enlarged lacrimal glands | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enobosarm n1=cyclopeptide | n2=en:enobosarm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enophthalmos n1=cyclopeptide | n2=en:enophthalmos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enoxaparin n1=cyclopeptide | n2=en:enoxaparin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enpromate n1=cyclopeptide | n2=en:enpromate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ensituximab n1=cyclopeptide | n2=en:ensituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:entecavir n1=cyclopeptide | n2=en:entecavir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enteric transport medium n1=cyclopeptide | n2=en:enteric transport medium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enteric-coated trpm8 agonist d-3263 hydrochloride n1=cyclopeptide | n2=en:enteric-coated trpm8 agonist d-3263 hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enteric-coated zoledronic acid tablet mer-101 n1=cyclopeptide | n2=en:enteric-coated zoledronic acid tablet mer-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:entinostat n1=cyclopeptide | n2=en:entinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:entire eye n1=cyclopeptide | n2=en:entire eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:entolimod n1=cyclopeptide | n2=en:entolimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:entospletinib n1=cyclopeptide | n2=en:entospletinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:entrectinib n1=cyclopeptide | n2=en:entrectinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:entropion n1=cyclopeptide | n2=en:entropion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:entropion, bilateral (in some patients) n1=cyclopeptide | n2=en:entropion, bilateral (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enzalutamide n1=cyclopeptide | n2=en:enzalutamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enzastaurin hydrochloride n1=cyclopeptide | n2=en:enzastaurin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enzymatically-hydrolyzed whey protein-based nutritional supplement n1=cyclopeptide | n2=en:enzymatically-hydrolyzed whey protein-based nutritional supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enzyme agent n1=cyclopeptide | n2=en:enzyme agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:enzyme inhibitor n1=cyclopeptide | n2=en:enzyme inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ep4 receptor antagonist aat-007 n1=cyclopeptide | n2=en:ep4 receptor antagonist aat-007 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epacadostat n1=cyclopeptide | n2=en:epacadostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epcam-specific car-expressing autologous t-lymphocytes n1=cyclopeptide | n2=en:epcam-specific car-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epha2-targeting dopc-encapsulated sirna n1=cyclopeptide | n2=en:epha2-targeting dopc-encapsulated sirna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthal folds (1 patient) n1=cyclopeptide | n2=en:epicanthal folds (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthal folds (3/4 patients) n1=cyclopeptide | n2=en:epicanthal folds (3/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthal folds (39%) n1=cyclopeptide | n2=en:epicanthal folds (39%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthal folds (68%) n1=cyclopeptide | n2=en:epicanthal folds (68%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthal folds (89%) n1=cyclopeptide | n2=en:epicanthal folds (89%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthal folds (in some patients) n1=cyclopeptide | n2=en:epicanthal folds (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthal folds (rare) n1=cyclopeptide | n2=en:epicanthal folds (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthal folds, mild n1=cyclopeptide | n2=en:epicanthal folds, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthic folds (in some patients) n1=cyclopeptide | n2=en:epicanthic folds (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthus (in one family) n1=cyclopeptide | n2=en:epicanthus (in one family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthus (in some patients) n1=cyclopeptide | n2=en:epicanthus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epicanthus inversus n1=cyclopeptide | n2=en:epicanthus inversus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epidermal growth factor ointment n1=cyclopeptide | n2=en:epidermal growth factor ointment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epidermal growth factor receptor tyrosine kinase inhibitor n1=cyclopeptide | n2=en:epidermal growth factor receptor tyrosine kinase inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epigallocatechin gallate n1=cyclopeptide | n2=en:epigallocatechin gallate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epiphora (classic feature) n1=cyclopeptide | n2=en:epiphora (classic feature) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epiphora, severe n1=cyclopeptide | n2=en:epiphora, severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epipropidine n1=cyclopeptide | n2=en:epipropidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epiretinal membrane n1=cyclopeptide | n2=en:epiretinal membrane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epiretinal membranes, with wrinkling of retina n1=cyclopeptide | n2=en:epiretinal membranes, with wrinkling of retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epirubicin hydrochloride n1=cyclopeptide | n2=en:epirubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:episodic loss of vision n1=cyclopeptide | n2=en:episodic loss of vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:episodic ptosis n1=cyclopeptide | n2=en:episodic ptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epithelial cell adhesion molecule n1=cyclopeptide | n2=en:epithelial cell adhesion molecule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eplerenone n1=cyclopeptide | n2=en:eplerenone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epoch regimen n1=cyclopeptide | n2=en:epoch regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epoetin alfa n1=cyclopeptide | n2=en:epoetin alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epoetin beta n1=cyclopeptide | n2=en:epoetin beta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epoetin zeta n1=cyclopeptide | n2=en:epoetin zeta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epothilone analog utd1 n1=cyclopeptide | n2=en:epothilone analog utd1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epothilone compound n1=cyclopeptide | n2=en:epothilone compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epothilone d n1=cyclopeptide | n2=en:epothilone d | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epothilone kos-1584 n1=cyclopeptide | n2=en:epothilone kos-1584 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:epratuzumab n1=cyclopeptide | n2=en:epratuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eprodisate disodium n1=cyclopeptide | n2=en:eprodisate disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:era36 modulator icaritin n1=cyclopeptide | n2=en:era36 modulator icaritin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erastin analogue prlx 93936 n1=cyclopeptide | n2=en:erastin analogue prlx 93936 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erb-38 immunotoxin n1=cyclopeptide | n2=en:erb-38 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erbb-2 inhibitor arry-380 n1=cyclopeptide | n2=en:erbb-2 inhibitor arry-380 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ergocalciferol n1=cyclopeptide | n2=en:ergocalciferol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ergoline n1=cyclopeptide | n2=en:ergoline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ergoline derivative n1=cyclopeptide | n2=en:ergoline derivative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eribulin mesylate n1=cyclopeptide | n2=en:eribulin mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eritoran tetrasodium n1=cyclopeptide | n2=en:eritoran tetrasodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erk inhibitor cc-90003 n1=cyclopeptide | n2=en:erk inhibitor cc-90003 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erk inhibitor gdc-0994 n1=cyclopeptide | n2=en:erk inhibitor gdc-0994 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erk inhibitor ltt462 n1=cyclopeptide | n2=en:erk inhibitor ltt462 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erk inhibitor mk-8353 n1=cyclopeptide | n2=en:erk inhibitor mk-8353 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erlotinib hydrochloride n1=cyclopeptide | n2=en:erlotinib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ertapenem sodium n1=cyclopeptide | n2=en:ertapenem sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ertumaxomab n1=cyclopeptide | n2=en:ertumaxomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erythrocyte-encapsulated l-asparaginase suspension n1=cyclopeptide | n2=en:erythrocyte-encapsulated l-asparaginase suspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erythromycin n1=cyclopeptide | n2=en:erythromycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:erythromycin topical cream n1=cyclopeptide | n2=en:erythromycin topical cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:escitalopram oxalate n1=cyclopeptide | n2=en:escitalopram oxalate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eslicarbazepine n1=cyclopeptide | n2=en:eslicarbazepine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esmolol n1=cyclopeptide | n2=en:esmolol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esomeprazole magnesium n1=cyclopeptide | n2=en:esomeprazole magnesium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esophoria n1=cyclopeptide | n2=en:esophoria | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esophoria (1 patient) n1=cyclopeptide | n2=en:esophoria (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esophoria (in some patients) n1=cyclopeptide | n2=en:esophoria (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esorubicin n1=cyclopeptide | n2=en:esorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esotropia (1 patient) n1=cyclopeptide | n2=en:esotropia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esotropia (about half of patients) n1=cyclopeptide | n2=en:esotropia (about half of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esotropia (in some patients) n1=cyclopeptide | n2=en:esotropia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esotropia with accommodative compensation n1=cyclopeptide | n2=en:esotropia with accommodative compensation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esotropia with hypermetropia and strabismus (rare) n1=cyclopeptide | n2=en:esotropia with hypermetropia and strabismus (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:esotropias, secondary n1=cyclopeptide | n2=en:esotropias, secondary | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:essiac n1=cyclopeptide | n2=en:essiac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estradiol mustard n1=cyclopeptide | n2=en:estradiol mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estradiol vaginal ring n1=cyclopeptide | n2=en:estradiol vaginal ring | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estradiol valerate n1=cyclopeptide | n2=en:estradiol valerate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estradiol/norethindrone acetate tablet n1=cyclopeptide | n2=en:estradiol/norethindrone acetate tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estramustine n1=cyclopeptide | n2=en:estramustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estramustine phosphate sodium n1=cyclopeptide | n2=en:estramustine phosphate sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estriol vaginal gel n1=cyclopeptide | n2=en:estriol vaginal gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estrogen receptor agonist gtx-758 n1=cyclopeptide | n2=en:estrogen receptor agonist gtx-758 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estrogens, conjugated n1=cyclopeptide | n2=en:estrogens, conjugated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:estrogens, esterified (usp) n1=cyclopeptide | n2=en:estrogens, esterified (usp) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eszopiclone n1=cyclopeptide | n2=en:eszopiclone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etalocib n1=cyclopeptide | n2=en:etalocib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etanercept n1=cyclopeptide | n2=en:etanercept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etanidazole n1=cyclopeptide | n2=en:etanidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etaracizumab n1=cyclopeptide | n2=en:etaracizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethacridine n1=cyclopeptide | n2=en:ethacridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethacrynic acid n1=cyclopeptide | n2=en:ethacrynic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethambutol n1=cyclopeptide | n2=en:ethambutol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethaselen n1=cyclopeptide | n2=en:ethaselen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethinyl estradiol n1=cyclopeptide | n2=en:ethinyl estradiol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethinyl estradiol/levonorgestrel n1=cyclopeptide | n2=en:ethinyl estradiol/levonorgestrel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethinyl estradiol/norethindrone n1=cyclopeptide | n2=en:ethinyl estradiol/norethindrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethiodized oil n1=cyclopeptide | n2=en:ethiodized oil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethmocephaly n1=cyclopeptide | n2=en:ethmocephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethosuximide n1=cyclopeptide | n2=en:ethosuximide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethyl alcohol mouthwash n1=cyclopeptide | n2=en:ethyl alcohol mouthwash | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethylchlorformate n1=cyclopeptide | n2=en:ethylchlorformate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethylchlorformate vaccine n1=cyclopeptide | n2=en:ethylchlorformate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ethyleneimine antineoplastic n1=cyclopeptide | n2=en:ethyleneimine antineoplastic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etidronate-cytarabine conjugate mbc-11 n1=cyclopeptide | n2=en:etidronate-cytarabine conjugate mbc-11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etidronic acid n1=cyclopeptide | n2=en:etidronic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etodolac n1=cyclopeptide | n2=en:etodolac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etoglucid n1=cyclopeptide | n2=en:etoglucid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etoposide n1=cyclopeptide | n2=en:etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etoposide phosphate n1=cyclopeptide | n2=en:etoposide phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etoposide prodrug cap7.1 n1=cyclopeptide | n2=en:etoposide prodrug cap7.1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:etoricoxib n1=cyclopeptide | n2=en:etoricoxib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ets-family transcription factor inhibitor tk216 n1=cyclopeptide | n2=en:ets-family transcription factor inhibitor tk216 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eucerin n1=cyclopeptide | n2=en:eucerin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eutectic mixture of local anesthetics n1=cyclopeptide | n2=en:eutectic mixture of local anesthetics | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:evac regimen n1=cyclopeptide | n2=en:evac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:evaux spring water-based cream n1=cyclopeptide | n2=en:evaux spring water-based cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:evaux spring water-based topical spray n1=cyclopeptide | n2=en:evaux spring water-based topical spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:evaux thermal spring water-based solution n1=cyclopeptide | n2=en:evaux thermal spring water-based solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:evdac regimen n1=cyclopeptide | n2=en:evdac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eventual loss of peripheral vision and night blindness n1=cyclopeptide | n2=en:eventual loss of peripheral vision and night blindness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:everolimus n1=cyclopeptide | n2=en:everolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:everolimus tablets for oral suspension n1=cyclopeptide | n2=en:everolimus tablets for oral suspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eversion of lateral third of lower eyelids n1=cyclopeptide | n2=en:eversion of lateral third of lower eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eversion of the lower eyelids n1=cyclopeptide | n2=en:eversion of the lower eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ex vivo-activated autologous lymph node lymphocytes n1=cyclopeptide | n2=en:ex vivo-activated autologous lymph node lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ex vivo-expanded her2-specific t cells n1=cyclopeptide | n2=en:ex vivo-expanded her2-specific t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exatecan mesylate n1=cyclopeptide | n2=en:exatecan mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:excavation of optic disc (pits) n1=cyclopeptide | n2=en:excavation of optic disc (pits) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:excessive lacrimation (in some patients) n1=cyclopeptide | n2=en:excessive lacrimation (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:excessive tearing n1=cyclopeptide | n2=en:excessive tearing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exemestane n1=cyclopeptide | n2=en:exemestane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exenatide n1=cyclopeptide | n2=en:exenatide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exencephaly n1=cyclopeptide | n2=en:exencephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exisulind n1=cyclopeptide | n2=en:exisulind | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exogenous intraocular fluid n1=cyclopeptide | n2=en:exogenous intraocular fluid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exophthalmia (wws) n1=cyclopeptide | n2=en:exophthalmia (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exophthalmos n1=cyclopeptide | n2=en:exophthalmos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exophthalmos due to hyperthyroidism n1=cyclopeptide | n2=en:exophthalmos due to hyperthyroidism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exophthalmos, bilateral n1=cyclopeptide | n2=en:exophthalmos, bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exophthalmos, mild n1=cyclopeptide | n2=en:exophthalmos, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exorbitism n1=cyclopeptide | n2=en:exorbitism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exorbitism (major feature) n1=cyclopeptide | n2=en:exorbitism (major feature) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exotropia (1 patient) n1=cyclopeptide | n2=en:exotropia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exotropia (females) n1=cyclopeptide | n2=en:exotropia (females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exotropia (in some patients) n1=cyclopeptide | n2=en:exotropia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exotropia (less common) n1=cyclopeptide | n2=en:exotropia (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exotropia (severe cases) n1=cyclopeptide | n2=en:exotropia (severe cases) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exotropia, secondary n1=cyclopeptide | n2=en:exotropia, secondary | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:expanded umbilical cord blood product hsc835 n1=cyclopeptide | n2=en:expanded umbilical cord blood product hsc835 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:expectorant/mucolytic n1=cyclopeptide | n2=en:expectorant/mucolytic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exposure as collected domain n1=cyclopeptide | n2=en:exposure as collected domain | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exposure conjunctivitis/keratitis n1=cyclopeptide | n2=en:exposure conjunctivitis/keratitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exposure keratoconjunctivitis n1=cyclopeptide | n2=en:exposure keratoconjunctivitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exstrophy n1=cyclopeptide | n2=en:exstrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extended release bupivacaine hydrochloride resorbable matrix formulation n1=cyclopeptide | n2=en:extended release bupivacaine hydrochloride resorbable matrix formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extended release flucytosine n1=cyclopeptide | n2=en:extended release flucytosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extended-release onapristone n1=cyclopeptide | n2=en:extended-release onapristone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extensive geographic retinal atrophy (butterfly pattern in some patients) n1=cyclopeptide | n2=en:extensive geographic retinal atrophy (butterfly pattern in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extensive lesions may impair vision (in some patients) n1=cyclopeptide | n2=en:extensive lesions may impair vision (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:external ophthalmoplegia n1=cyclopeptide | n2=en:external ophthalmoplegia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:external ophthalmoplegia (in some patients) n1=cyclopeptide | n2=en:external ophthalmoplegia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:external ophthalmoplegia (less common) n1=cyclopeptide | n2=en:external ophthalmoplegia (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:external ophthalmoplegia (uncommon) n1=cyclopeptide | n2=en:external ophthalmoplegia (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:external ophthalmoplegia affecting upward and lateral gaze n1=cyclopeptide | n2=en:external ophthalmoplegia affecting upward and lateral gaze | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:external ophthalmoplegia, progressive (rare) n1=cyclopeptide | n2=en:external ophthalmoplegia, progressive (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extinction of electroretinogram (before age 10) n1=cyclopeptide | n2=en:extinction of electroretinogram (before age 10) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extinguished electroretinograms in second or third decade n1=cyclopeptide | n2=en:extinguished electroretinograms in second or third decade | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extinguished responses on electroretinography n1=cyclopeptide | n2=en:extinguished responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extraocular movement difficulties n1=cyclopeptide | n2=en:extraocular movement difficulties | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extraocular movements may be mildly decreased n1=cyclopeptide | n2=en:extraocular movements may be mildly decreased | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extraocular muscle fibrosis n1=cyclopeptide | n2=en:extraocular muscle fibrosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extraocular muscle weakness (in some patients) n1=cyclopeptide | n2=en:extraocular muscle weakness (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extraocular muscle weakness, mild (1 patient) n1=cyclopeptide | n2=en:extraocular muscle weakness, mild (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:extraocular muscles are not involved n1=cyclopeptide | n2=en:extraocular muscles are not involved | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exudative maculopathy n1=cyclopeptide | n2=en:exudative maculopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exudative retinopathy n1=cyclopeptide | n2=en:exudative retinopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:exudative vitreoretinopathy (in some patients) n1=cyclopeptide | n2=en:exudative vitreoretinopathy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye n1=cyclopeptide | n2=en:eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye agent n1=cyclopeptide | n2=en:eye agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye anomalies, variable n1=cyclopeptide | n2=en:eye anomalies, variable | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye discharge n1=cyclopeptide | n2=en:eye discharge | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye inflammation (1 patient) n1=cyclopeptide | n2=en:eye inflammation (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye irritation n1=cyclopeptide | n2=en:eye irritation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye pain n1=cyclopeptide | n2=en:eye pain | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye part n1=cyclopeptide | n2=en:eye part | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eye poking n1=cyclopeptide | n2=en:eye poking | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyebrow n1=cyclopeptide | n2=en:eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyebrow hypoplasia (in some patients) n1=cyclopeptide | n2=en:eyebrow hypoplasia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyebrows slanted upward n1=cyclopeptide | n2=en:eyebrows slanted upward | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyebrows wiry and disorganized n1=cyclopeptide | n2=en:eyebrows wiry and disorganized | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelash absence n1=cyclopeptide | n2=en:eyelash absence | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelash thinning n1=cyclopeptide | n2=en:eyelash thinning | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelashes wiry and disorganized n1=cyclopeptide | n2=en:eyelashes wiry and disorganized | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid n1=cyclopeptide | n2=en:eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid and corneal neuromas n1=cyclopeptide | n2=en:eyelid and corneal neuromas | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid colobomata (in some patients) n1=cyclopeptide | n2=en:eyelid colobomata (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid edema (present at birth) n1=cyclopeptide | n2=en:eyelid edema (present at birth) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid edema, ipsilateral n1=cyclopeptide | n2=en:eyelid edema, ipsilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid hooding n1=cyclopeptide | n2=en:eyelid hooding | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid infiltrates n1=cyclopeptide | n2=en:eyelid infiltrates | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid margin cysts (hidrocystoma) n1=cyclopeptide | n2=en:eyelid margin cysts (hidrocystoma) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid myoclonus n1=cyclopeptide | n2=en:eyelid myoclonus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid myotonia n1=cyclopeptide | n2=en:eyelid myotonia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid myxoma n1=cyclopeptide | n2=en:eyelid myxoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelid thickening n1=cyclopeptide | n2=en:eyelid thickening | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyelids (symptom) n1=cyclopeptide | n2=en:eyelids (symptom) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyes fixed in extreme abduction (exotropia strabismus fixus) n1=cyclopeptide | n2=en:eyes fixed in extreme abduction (exotropia strabismus fixus) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:eyes fixed in hypotrophic eye position (severe cases) n1=cyclopeptide | n2=en:eyes fixed in hypotrophic eye position (severe cases) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ezatiostat hydrochloride n1=cyclopeptide | n2=en:ezatiostat hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ezetimibe n1=cyclopeptide | n2=en:ezetimibe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ezetimibe/simvastatin n1=cyclopeptide | n2=en:ezetimibe/simvastatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ezh1/2 inhibitor ds-3201 n1=cyclopeptide | n2=en:ezh1/2 inhibitor ds-3201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ezh2 inhibitor cpi-1205 n1=cyclopeptide | n2=en:ezh2 inhibitor cpi-1205 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:f-18 16 alpha-fluoroestradiol n1=cyclopeptide | n2=en:f-18 16 alpha-fluoroestradiol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:f-18 fluoroethyltyrosine n1=cyclopeptide | n2=en:f-18 fluoroethyltyrosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:f-machop protocol n1=cyclopeptide | n2=en:f-machop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:f-machop regimen n1=cyclopeptide | n2=en:f-machop regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:f16-il2 fusion protein n1=cyclopeptide | n2=en:f16-il2 fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fac-mv protocol n1=cyclopeptide | n2=en:fac-mv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:facial cleft n1=cyclopeptide | n2=en:facial cleft | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:faciodigitogenital dysplasia n1=cyclopeptide | n2=en:faciodigitogenital dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fact complex-targeting curaxin cbl0137 n1=cyclopeptide | n2=en:fact complex-targeting curaxin cbl0137 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:factor vii-targeting immunoconjugate protein icon-1 n1=cyclopeptide | n2=en:factor vii-targeting immunoconjugate protein icon-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:factor viia inhibitor pci-27483 n1=cyclopeptide | n2=en:factor viia inhibitor pci-27483 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fadrozole hydrochloride n1=cyclopeptide | n2=en:fadrozole hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:failure to fixate on objects n1=cyclopeptide | n2=en:failure to fixate on objects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:faint blue sclera (in some patients) n1=cyclopeptide | n2=en:faint blue sclera (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fak inhibitor gsk2256098 n1=cyclopeptide | n2=en:fak inhibitor gsk2256098 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fak inhibitor pf-00562271 n1=cyclopeptide | n2=en:fak inhibitor pf-00562271 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fak inhibitor vs-4718 n1=cyclopeptide | n2=en:fak inhibitor vs-4718 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:falimarev n1=cyclopeptide | n2=en:falimarev | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:familial amyloid polyneuropathy, type v n1=cyclopeptide | n2=en:familial amyloid polyneuropathy, type v | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:famitinib n1=cyclopeptide | n2=en:famitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:famotidine n1=cyclopeptide | n2=en:famotidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fap-specific cd8-positive t cells n1=cyclopeptide | n2=en:fap-specific cd8-positive t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:farletuzumab n1=cyclopeptide | n2=en:farletuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fas receptor agonist apo010 n1=cyclopeptide | n2=en:fas receptor agonist apo010 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fas-chimera transgene-expressing endothelial tumor cell-targeting adenovector vb-111 n1=cyclopeptide | n2=en:fas-chimera transgene-expressing endothelial tumor cell-targeting adenovector vb-111 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fasn inhibitor tvb-2640 n1=cyclopeptide | n2=en:fasn inhibitor tvb-2640 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fat emulsion n1=cyclopeptide | n2=en:fat emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fazarabine n1=cyclopeptide | n2=en:fazarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fc regimen n1=cyclopeptide | n2=en:fc regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fcc protocol n1=cyclopeptide | n2=en:fcc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fcr regimen n1=cyclopeptide | n2=en:fcr regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fda established names and unique ingredient identifier codes terminology n1=cyclopeptide | n2=en:fda established names and unique ingredient identifier codes terminology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fear of eye disease n1=cyclopeptide | n2=en:fear of eye disease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:febuxostat n1=cyclopeptide | n2=en:febuxostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fec regimen n1=cyclopeptide | n2=en:fec regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:femp protocol n1=cyclopeptide | n2=en:femp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fenofibrate n1=cyclopeptide | n2=en:fenofibrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fenretinide n1=cyclopeptide | n2=en:fenretinide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fenretinide lipid matrix n1=cyclopeptide | n2=en:fenretinide lipid matrix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fentanyl buccal soluble film n1=cyclopeptide | n2=en:fentanyl buccal soluble film | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fentanyl citrate n1=cyclopeptide | n2=en:fentanyl citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fentanyl citrate buccal tablet n1=cyclopeptide | n2=en:fentanyl citrate buccal tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fentanyl citrate pectin-based nasal spray n1=cyclopeptide | n2=en:fentanyl citrate pectin-based nasal spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fentanyl citrate-containing nasal spray n1=cyclopeptide | n2=en:fentanyl citrate-containing nasal spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fentanyl matrix transdermal patch n1=cyclopeptide | n2=en:fentanyl matrix transdermal patch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fentanyl sublingual spray n1=cyclopeptide | n2=en:fentanyl sublingual spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fermented soybean protein beverage n1=cyclopeptide | n2=en:fermented soybean protein beverage | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fermented wheat germ extract n1=cyclopeptide | n2=en:fermented wheat germ extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ferric carboxymaltose solution n1=cyclopeptide | n2=en:ferric carboxymaltose solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ferrosoferric oxide n1=cyclopeptide | n2=en:ferrosoferric oxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ferrous fumarate n1=cyclopeptide | n2=en:ferrous fumarate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ferrous sulfate n1=cyclopeptide | n2=en:ferrous sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fertility agents n1=cyclopeptide | n2=en:fertility agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ferumoxides injectable solution n1=cyclopeptide | n2=en:ferumoxides injectable solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ferumoxsil oral suspension n1=cyclopeptide | n2=en:ferumoxsil oral suspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ferumoxtran-10 n1=cyclopeptide | n2=en:ferumoxtran-10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fesoterodine fumarate n1=cyclopeptide | n2=en:fesoterodine fumarate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fetal postural deformity n1=cyclopeptide | n2=en:fetal postural deformity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fexofenadine hydrochloride n1=cyclopeptide | n2=en:fexofenadine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgf receptor antagonist hgs1036 n1=cyclopeptide | n2=en:fgf receptor antagonist hgs1036 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgf/fgfr pathway inhibitor e7090 n1=cyclopeptide | n2=en:fgf/fgfr pathway inhibitor e7090 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgf401 inhibitor fgf401 n1=cyclopeptide | n2=en:fgf401 inhibitor fgf401 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgfr inhibitor asp5878 n1=cyclopeptide | n2=en:fgfr inhibitor asp5878 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgfr inhibitor azd4547 n1=cyclopeptide | n2=en:fgfr inhibitor azd4547 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgfr inhibitor debio 1347 n1=cyclopeptide | n2=en:fgfr inhibitor debio 1347 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgfr inhibitor incb054828 n1=cyclopeptide | n2=en:fgfr inhibitor incb054828 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgfr inhibitor ly2874455 n1=cyclopeptide | n2=en:fgfr inhibitor ly2874455 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgfr inhibitor tas-120 n1=cyclopeptide | n2=en:fgfr inhibitor tas-120 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgfr/vegfr/pdgfr/flt3/src inhibitor xl999 n1=cyclopeptide | n2=en:fgfr/vegfr/pdgfr/flt3/src inhibitor xl999 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fgfr4 inhibitor blu-554 n1=cyclopeptide | n2=en:fgfr4 inhibitor blu-554 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fibrin sealant n1=cyclopeptide | n2=en:fibrin sealant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fibrous dysplasia of the cornea n1=cyclopeptide | n2=en:fibrous dysplasia of the cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ficlatuzumab n1=cyclopeptide | n2=en:ficlatuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fidaxomicin n1=cyclopeptide | n2=en:fidaxomicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:figitumumab n1=cyclopeptide | n2=en:figitumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:filgrastim n1=cyclopeptide | n2=en:filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:filgrastim-primed peripheral blood progenitor cells n1=cyclopeptide | n2=en:filgrastim-primed peripheral blood progenitor cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:finasteride n1=cyclopeptide | n2=en:finasteride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fine corneal opacities n1=cyclopeptide | n2=en:fine corneal opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fine horizontal nystagmus n1=cyclopeptide | n2=en:fine horizontal nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fine iris processes extending to schwalbe line for 360 degrees n1=cyclopeptide | n2=en:fine iris processes extending to schwalbe line for 360 degrees | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fine lamellar white opacities on slit lamp exam in carrier females n1=cyclopeptide | n2=en:fine lamellar white opacities on slit lamp exam in carrier females | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fine lens opacities (carrier females) n1=cyclopeptide | n2=en:fine lens opacities (carrier females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fine peripheral pigmentary mottling n1=cyclopeptide | n2=en:fine peripheral pigmentary mottling | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fine punctate lens opacities (in some patients) n1=cyclopeptide | n2=en:fine punctate lens opacities (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fingolimod n1=cyclopeptide | n2=en:fingolimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fingolimod 500microgram capsule n1=cyclopeptide | n2=en:fingolimod 500microgram capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fingolimod hydrochloride n1=cyclopeptide | n2=en:fingolimod hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:firategrast n1=cyclopeptide | n2=en:firategrast | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:firtecan pegol n1=cyclopeptide | n2=en:firtecan pegol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fish oil/glycerol/egg lecithin-based emulsion n1=cyclopeptide | n2=en:fish oil/glycerol/egg lecithin-based emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fixation nystagmus n1=cyclopeptide | n2=en:fixation nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flanvotumab n1=cyclopeptide | n2=en:flanvotumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flared eyebrows n1=cyclopeptide | n2=en:flared eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flat anterior chamber (in some patients) n1=cyclopeptide | n2=en:flat anterior chamber (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flat electroretinogram (erg) n1=cyclopeptide | n2=en:flat electroretinogram (erg) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flat-appearing iris n1=cyclopeptide | n2=en:flat-appearing iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flattened corneal topography n1=cyclopeptide | n2=en:flattened corneal topography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flattened or absent electroretinogram (erg) n1=cyclopeptide | n2=en:flattened or absent electroretinogram (erg) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flavonoid tablet n1=cyclopeptide | n2=en:flavonoid tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flaxseed n1=cyclopeptide | n2=en:flaxseed | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flecainide acetate n1=cyclopeptide | n2=en:flecainide acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:floaters, flashing lights, visual field cuts n1=cyclopeptide | n2=en:floaters, flashing lights, visual field cuts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:floxuridine n1=cyclopeptide | n2=en:floxuridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flp injection n1=cyclopeptide | n2=en:flp injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flt3/abl/aurora kinase inhibitor kw-2449 n1=cyclopeptide | n2=en:flt3/abl/aurora kinase inhibitor kw-2449 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flt3/cdk4/6 inhibitor flx925 n1=cyclopeptide | n2=en:flt3/cdk4/6 inhibitor flx925 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flt3/kit kinase inhibitor akn-028 n1=cyclopeptide | n2=en:flt3/kit kinase inhibitor akn-028 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flu matrix peptide p58-66 n1=cyclopeptide | n2=en:flu matrix peptide p58-66 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluciclatide f-18 n1=cyclopeptide | n2=en:fluciclatide f-18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluciclovine (18f) n1=cyclopeptide | n2=en:fluciclovine (18f) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluconazole n1=cyclopeptide | n2=en:fluconazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flucytosine n1=cyclopeptide | n2=en:flucytosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fludarabine n1=cyclopeptide | n2=en:fludarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fludarabine phosphate n1=cyclopeptide | n2=en:fludarabine phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fludeoxyglucose f-18 n1=cyclopeptide | n2=en:fludeoxyglucose f-18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fludrocortisone acetate n1=cyclopeptide | n2=en:fludrocortisone acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flumatinib mesylate n1=cyclopeptide | n2=en:flumatinib mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluocinonide n1=cyclopeptide | n2=en:fluocinonide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorescein sodium injection n1=cyclopeptide | n2=en:fluorescein sodium injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorescence imaging agent emi-137 n1=cyclopeptide | n2=en:fluorescence imaging agent emi-137 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorescent antibody sgm-101 n1=cyclopeptide | n2=en:fluorescent antibody sgm-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorescent crgdy peg-cy5.5 c dots n1=cyclopeptide | n2=en:fluorescent crgdy peg-cy5.5 c dots | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorescent imaging ligand otl38 n1=cyclopeptide | n2=en:fluorescent imaging ligand otl38 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorescent protease-activated peptide avb-620 n1=cyclopeptide | n2=en:fluorescent protease-activated peptide avb-620 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorides n1=cyclopeptide | n2=en:fluorides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine 18 f fludarabine n1=cyclopeptide | n2=en:fluorine 18 f fludarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 4-l-fluoroglutamine (2s,4r) n1=cyclopeptide | n2=en:fluorine f 18 4-l-fluoroglutamine (2s,4r) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 5-fluoro-2-deoxycytidine n1=cyclopeptide | n2=en:fluorine f 18 5-fluoro-2-deoxycytidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 alfatide ii n1=cyclopeptide | n2=en:fluorine f 18 alfatide ii | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 ara-g n1=cyclopeptide | n2=en:fluorine f 18 ara-g | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 bay 85-8050 n1=cyclopeptide | n2=en:fluorine f 18 bay 85-8050 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 bay 86-9596 n1=cyclopeptide | n2=en:fluorine f 18 bay 86-9596 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 bay1075553 n1=cyclopeptide | n2=en:fluorine f 18 bay1075553 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 choline n1=cyclopeptide | n2=en:fluorine f 18 choline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 cp18 peptide n1=cyclopeptide | n2=en:fluorine f 18 cp18 peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 d-fmau n1=cyclopeptide | n2=en:fluorine f 18 d-fmau | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 dabrafenib n1=cyclopeptide | n2=en:fluorine f 18 dabrafenib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 dcfbc n1=cyclopeptide | n2=en:fluorine f 18 dcfbc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 dcfpyl n1=cyclopeptide | n2=en:fluorine f 18 dcfpyl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 ef5 n1=cyclopeptide | n2=en:fluorine f 18 ef5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fdht n1=cyclopeptide | n2=en:fluorine f 18 fdht | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 feqa n1=cyclopeptide | n2=en:fluorine f 18 feqa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fluoro furanyl norprogesterone n1=cyclopeptide | n2=en:fluorine f 18 fluoro furanyl norprogesterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fluoro-peg6-ipqa n1=cyclopeptide | n2=en:fluorine f 18 fluoro-peg6-ipqa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fluorobenzyl triphenyl phosphonium n1=cyclopeptide | n2=en:fluorine f 18 fluorobenzyl triphenyl phosphonium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fluorodopa n1=cyclopeptide | n2=en:fluorine f 18 fluorodopa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fluoroethylcholine n1=cyclopeptide | n2=en:fluorine f 18 fluoroethylcholine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fluoromethylcholine n1=cyclopeptide | n2=en:fluorine f 18 fluoromethylcholine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fluorthanatrace n1=cyclopeptide | n2=en:fluorine f 18 fluorthanatrace | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fmdht n1=cyclopeptide | n2=en:fluorine f 18 fmdht | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 fp-r01-mg-f2 n1=cyclopeptide | n2=en:fluorine f 18 fp-r01-mg-f2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 galacto-rgd peptide n1=cyclopeptide | n2=en:fluorine f 18 galacto-rgd peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 iso-1 n1=cyclopeptide | n2=en:fluorine f 18 iso-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 l-glutamate derivative bay94-9392 n1=cyclopeptide | n2=en:fluorine f 18 l-glutamate derivative bay94-9392 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 rgd-k5 n1=cyclopeptide | n2=en:fluorine f 18 rgd-k5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 ski-249380 n1=cyclopeptide | n2=en:fluorine f 18 ski-249380 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18 sodium fluoride n1=cyclopeptide | n2=en:fluorine f 18 sodium fluoride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18-av-133 n1=cyclopeptide | n2=en:fluorine f 18-av-133 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18-labeled s-(3-fluoropropyl)homocysteine hydrochloride n1=cyclopeptide | n2=en:fluorine f 18-labeled s-(3-fluoropropyl)homocysteine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f 18-vm4-037 n1=cyclopeptide | n2=en:fluorine f 18-vm4-037 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f-18 6-fluorodopamine n1=cyclopeptide | n2=en:fluorine f-18 6-fluorodopamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f-18 fluoropaclitaxel n1=cyclopeptide | n2=en:fluorine f-18 fluoropaclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f-18 hx4 n1=cyclopeptide | n2=en:fluorine f-18 hx4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorine f-18 ml-10 n1=cyclopeptide | n2=en:fluorine f-18 ml-10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorodeoxygalactose f-18 n1=cyclopeptide | n2=en:fluorodeoxygalactose f-18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorometholone acetate ophthalmic suspension n1=cyclopeptide | n2=en:fluorometholone acetate ophthalmic suspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorothymidine f-18 n1=cyclopeptide | n2=en:fluorothymidine f-18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorouracil n1=cyclopeptide | n2=en:fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorouracil implant n1=cyclopeptide | n2=en:fluorouracil implant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluorouracil-e therapeutic implant n1=cyclopeptide | n2=en:fluorouracil-e therapeutic implant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluosol-da n1=cyclopeptide | n2=en:fluosol-da | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluoxetine n1=cyclopeptide | n2=en:fluoxetine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluoxymesterone n1=cyclopeptide | n2=en:fluoxymesterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluphenazine hydrochloride n1=cyclopeptide | n2=en:fluphenazine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flurbiprofen n1=cyclopeptide | n2=en:flurbiprofen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flurocitabine n1=cyclopeptide | n2=en:flurocitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flutamide n1=cyclopeptide | n2=en:flutamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:flutemetamol f 18 n1=cyclopeptide | n2=en:flutemetamol f 18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluticasone + vilanterol n1=cyclopeptide | n2=en:fluticasone + vilanterol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluticasone propionate n1=cyclopeptide | n2=en:fluticasone propionate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluvastatin sodium n1=cyclopeptide | n2=en:fluvastatin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluvoxamine maleate n1=cyclopeptide | n2=en:fluvoxamine maleate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fluzoparib n1=cyclopeptide | n2=en:fluzoparib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fms inhibitor jnj-40346527 n1=cyclopeptide | n2=en:fms inhibitor jnj-40346527 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fms/trk tyrosine kinase inhibitor plx7486 n1=cyclopeptide | n2=en:fms/trk tyrosine kinase inhibitor plx7486 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:focal atrophy of choroid n1=cyclopeptide | n2=en:focal atrophy of choroid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:focal retinal edema n1=cyclopeptide | n2=en:focal retinal edema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:focal retinal infarction n1=cyclopeptide | n2=en:focal retinal infarction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate binding protein e39 peptide vaccine n1=cyclopeptide | n2=en:folate binding protein e39 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate binding protein j65 peptide vaccine n1=cyclopeptide | n2=en:folate binding protein j65 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate receptor alpha-loaded dendritic cell vaccine n1=cyclopeptide | n2=en:folate receptor alpha-loaded dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate receptor targeted epothilone bms753493 n1=cyclopeptide | n2=en:folate receptor targeted epothilone bms753493 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate receptor-targeted technetium tc-99m ec20 n1=cyclopeptide | n2=en:folate receptor-targeted technetium tc-99m ec20 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate receptor-targeted tubulysin conjugate ec1456 n1=cyclopeptide | n2=en:folate receptor-targeted tubulysin conjugate ec1456 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate receptor-targeted vinca alkaloid ec0489 n1=cyclopeptide | n2=en:folate receptor-targeted vinca alkaloid ec0489 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 n1=cyclopeptide | n2=en:folate receptor-targeted vinca alkaloid/mitomycin c ec0225 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folate-fitc n1=cyclopeptide | n2=en:folate-fitc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folfiri regimen n1=cyclopeptide | n2=en:folfiri regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folfiri-bevacizumab regimen n1=cyclopeptide | n2=en:folfiri-bevacizumab regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folfiri-cetuximab regimen n1=cyclopeptide | n2=en:folfiri-cetuximab regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folfirinox regimen n1=cyclopeptide | n2=en:folfirinox regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folfox regimen n1=cyclopeptide | n2=en:folfox regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folic acid n1=cyclopeptide | n2=en:folic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:folitixorin n1=cyclopeptide | n2=en:folitixorin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fondaparinux sodium n1=cyclopeptide | n2=en:fondaparinux sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foreign body sensation if erosions occur n1=cyclopeptide | n2=en:foreign body sensation if erosions occur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foreign-body sensation (early symptom) n1=cyclopeptide | n2=en:foreign-body sensation (early symptom) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foreshortening of axial length of eyes (bilateral) n1=cyclopeptide | n2=en:foreshortening of axial length of eyes (bilateral) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foretinib n1=cyclopeptide | n2=en:foretinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:formation of mucosal pseudomembranes that progress to plaques n1=cyclopeptide | n2=en:formation of mucosal pseudomembranes that progress to plaques | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:formestane n1=cyclopeptide | n2=en:formestane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:formoterol fumarate oral n1=cyclopeptide | n2=en:formoterol fumarate oral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:formoterol fumarate/roxithromycin n1=cyclopeptide | n2=en:formoterol fumarate/roxithromycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:forodesine n1=cyclopeptide | n2=en:forodesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:forodesine hydrochloride n1=cyclopeptide | n2=en:forodesine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fosaprepitant dimeglumine n1=cyclopeptide | n2=en:fosaprepitant dimeglumine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fosbretabulin disodium n1=cyclopeptide | n2=en:fosbretabulin disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fosbretabulin tromethamine n1=cyclopeptide | n2=en:fosbretabulin tromethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foscarnet sodium n1=cyclopeptide | n2=en:foscarnet sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fosfestrol n1=cyclopeptide | n2=en:fosfestrol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fosfomycin tromethamine n1=cyclopeptide | n2=en:fosfomycin tromethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fosquidone n1=cyclopeptide | n2=en:fosquidone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fostamatinib disodium n1=cyclopeptide | n2=en:fostamatinib disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fostriecin n1=cyclopeptide | n2=en:fostriecin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fotemustine n1=cyclopeptide | n2=en:fotemustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foveal atrophy (in some patients) n1=cyclopeptide | n2=en:foveal atrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foveal hyperfluorescence n1=cyclopeptide | n2=en:foveal hyperfluorescence | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foveal hyperpigmentation n1=cyclopeptide | n2=en:foveal hyperpigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foveal hypoplasia (finding) n1=cyclopeptide | n2=en:foveal hypoplasia (finding) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foveal thinning (in some patients) n1=cyclopeptide | n2=en:foveal thinning (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foveolar reflex indistinct n1=cyclopeptide | n2=en:foveolar reflex indistinct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:foveoschisis n1=cyclopeptide | n2=en:foveoschisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fowlpox virus vaccine vector n1=cyclopeptide | n2=en:fowlpox virus vaccine vector | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fowlpox-ny-eso-1 vaccine n1=cyclopeptide | n2=en:fowlpox-ny-eso-1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fowlpox-psa-tricom vaccine n1=cyclopeptide | n2=en:fowlpox-psa-tricom vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fragmentation of bowman membrane n1=cyclopeptide | n2=en:fragmentation of bowman membrane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fraser syndrome n1=cyclopeptide | n2=en:fraser syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:freeze-dried black raspberry bioadhesive gel n1=cyclopeptide | n2=en:freeze-dried black raspberry bioadhesive gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:french maritime pine bark extract n1=cyclopeptide | n2=en:french maritime pine bark extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:frequent blinking n1=cyclopeptide | n2=en:frequent blinking | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fresolimumab n1=cyclopeptide | n2=en:fresolimumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:freund's adjuvant n1=cyclopeptide | n2=en:freund's adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:frontalis overaction, pronounced n1=cyclopeptide | n2=en:frontalis overaction, pronounced | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fronto-frontal dysostosis n1=cyclopeptide | n2=en:fronto-frontal dysostosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fronto-naso-ethmoidal dysostosis n1=cyclopeptide | n2=en:fronto-naso-ethmoidal dysostosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fructooligosaccharide supplement n1=cyclopeptide | n2=en:fructooligosaccharide supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fructooligosaccharide/lactobacillus paracasei/lactobacillus rhamnosus/lactobacillus acidophilus/bifidobacterium lactis probiotic supplement n1=cyclopeptide | n2=en:fructooligosaccharide/lactobacillus paracasei/lactobacillus rhamnosus/lactobacillus acidophilus/bifidobacterium lactis probiotic supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fruit and vegetable extract n1=cyclopeptide | n2=en:fruit and vegetable extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fruquintinib n1=cyclopeptide | n2=en:fruquintinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ft-2102 n1=cyclopeptide | n2=en:ft-2102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fu-lv regimen n1=cyclopeptide | n2=en:fu-lv regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:full eyebrows n1=cyclopeptide | n2=en:full eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fulranumab n1=cyclopeptide | n2=en:fulranumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fulvestrant n1=cyclopeptide | n2=en:fulvestrant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fumagillin-derived polymer conjugate xmt-1107 n1=cyclopeptide | n2=en:fumagillin-derived polymer conjugate xmt-1107 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fundi show dilated blood vessels with corkscrew-like tortuosity n1=cyclopeptide | n2=en:fundi show dilated blood vessels with corkscrew-like tortuosity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fundoscopy normal n1=cyclopeptide | n2=en:fundoscopy normal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fundus albipunctatus n1=cyclopeptide | n2=en:fundus albipunctatus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fundus atrophy n1=cyclopeptide | n2=en:fundus atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fundus dystrophy n1=cyclopeptide | n2=en:fundus dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fundus examination normal at birth n1=cyclopeptide | n2=en:fundus examination normal at birth | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fundus pigment lumps, bone-corpuscle/bone-spicule pattern n1=cyclopeptide | n2=en:fundus pigment lumps, bone-corpuscle/bone-spicule pattern | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:funduscopic examination normal n1=cyclopeptide | n2=en:funduscopic examination normal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:funnel-shaped papillomacular fold n1=cyclopeptide | n2=en:funnel-shaped papillomacular fold | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:furosemide n1=cyclopeptide | n2=en:furosemide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fursultiamine n1=cyclopeptide | n2=en:fursultiamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fused eyes (1 family) n1=cyclopeptide | n2=en:fused eyes (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:fusidic acid/betamethasone valerate topical cream n1=cyclopeptide | n2=en:fusidic acid/betamethasone valerate topical cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:g-quadruplex stabilizer bmvc n1=cyclopeptide | n2=en:g-quadruplex stabilizer bmvc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:g207 n1=cyclopeptide | n2=en:g207 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:g250 peptide vaccine n1=cyclopeptide | n2=en:g250 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ga-68-labeled f(ab') 2- trastuzumab n1=cyclopeptide | n2=en:ga-68-labeled f(ab') 2- trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gabapentin n1=cyclopeptide | n2=en:gabapentin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gabapentin enacarbil n1=cyclopeptide | n2=en:gabapentin enacarbil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadobenate dimeglumine n1=cyclopeptide | n2=en:gadobenate dimeglumine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadobutrol n1=cyclopeptide | n2=en:gadobutrol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadodiamide n1=cyclopeptide | n2=en:gadodiamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadofosveset trisodium n1=cyclopeptide | n2=en:gadofosveset trisodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadolinium-chelate n1=cyclopeptide | n2=en:gadolinium-chelate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadopentetate dimeglumine n1=cyclopeptide | n2=en:gadopentetate dimeglumine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadoterate meglumine n1=cyclopeptide | n2=en:gadoterate meglumine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadoteridol n1=cyclopeptide | n2=en:gadoteridol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gadoxetate disodium n1=cyclopeptide | n2=en:gadoxetate disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gag:267-274 peptide vaccine n1=cyclopeptide | n2=en:gag:267-274 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galactomannan derivative n1=cyclopeptide | n2=en:galactomannan derivative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galactose n1=cyclopeptide | n2=en:galactose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galamustine n1=cyclopeptide | n2=en:galamustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galantamine hydrobromide n1=cyclopeptide | n2=en:galantamine hydrobromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galectin inhibitor gr-md-02 n1=cyclopeptide | n2=en:galectin inhibitor gr-md-02 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galectin-1 inhibitor otx008 n1=cyclopeptide | n2=en:galectin-1 inhibitor otx008 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galeterone n1=cyclopeptide | n2=en:galeterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galiximab n1=cyclopeptide | n2=en:galiximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium citrate ga-67 n1=cyclopeptide | n2=en:gallium citrate ga-67 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68 citrate n1=cyclopeptide | n2=en:gallium ga 68 citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68 dota-jr11 n1=cyclopeptide | n2=en:gallium ga 68 dota-jr11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68 ops202 n1=cyclopeptide | n2=en:gallium ga 68 ops202 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-dota-exendin-4 n1=cyclopeptide | n2=en:gallium ga 68-dota-exendin-4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-dotanoc n1=cyclopeptide | n2=en:gallium ga 68-dotanoc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-dotatate n1=cyclopeptide | n2=en:gallium ga 68-dotatate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-edotreotide n1=cyclopeptide | n2=en:gallium ga 68-edotreotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-labeled affibody aby-025 n1=cyclopeptide | n2=en:gallium ga 68-labeled affibody aby-025 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-labeled bnota-prgd2 n1=cyclopeptide | n2=en:gallium ga 68-labeled bnota-prgd2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-labeled dota di-hsg peptide imp-288 n1=cyclopeptide | n2=en:gallium ga 68-labeled dota di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-labeled grpr antagonist bay86-7548 n1=cyclopeptide | n2=en:gallium ga 68-labeled grpr antagonist bay86-7548 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-labeled mln6907 n1=cyclopeptide | n2=en:gallium ga 68-labeled mln6907 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-labeled psma ligand glu-urea-lys(ahx)-hbed-cc n1=cyclopeptide | n2=en:gallium ga 68-labeled psma ligand glu-urea-lys(ahx)-hbed-cc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-labeled-nodaga-mj9 n1=cyclopeptide | n2=en:gallium ga 68-labeled-nodaga-mj9 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-neb n1=cyclopeptide | n2=en:gallium ga 68-neb | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-nota-aca-bbn(7-14) n1=cyclopeptide | n2=en:gallium ga 68-nota-aca-bbn(7-14) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-nota-ae105 n1=cyclopeptide | n2=en:gallium ga 68-nota-ae105 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-nota-bbn(7-14)-rgd n1=cyclopeptide | n2=en:gallium ga 68-nota-bbn(7-14)-rgd | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-nota-nfb n1=cyclopeptide | n2=en:gallium ga 68-nota-nfb | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium ga 68-rgd n1=cyclopeptide | n2=en:gallium ga 68-rgd | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium maltolate n1=cyclopeptide | n2=en:gallium maltolate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gallium nitrate n1=cyclopeptide | n2=en:gallium nitrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galnac-anti-c5 sirna aln-cc5 n1=cyclopeptide | n2=en:galnac-anti-c5 sirna aln-cc5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:galunisertib n1=cyclopeptide | n2=en:galunisertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gamboge resin extract tsb-9-w1 n1=cyclopeptide | n2=en:gamboge resin extract tsb-9-w1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gamma secretase inhibitor pf-03084014 n1=cyclopeptide | n2=en:gamma secretase inhibitor pf-03084014 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gamma-delta tocotrienol n1=cyclopeptide | n2=en:gamma-delta tocotrienol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gamma-secretase inhibitor ly3039478 n1=cyclopeptide | n2=en:gamma-secretase inhibitor ly3039478 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gamma-secretase inhibitor ro4929097 n1=cyclopeptide | n2=en:gamma-secretase inhibitor ro4929097 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ganciclovir n1=cyclopeptide | n2=en:ganciclovir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gandotinib n1=cyclopeptide | n2=en:gandotinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ganetespib n1=cyclopeptide | n2=en:ganetespib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ganglioside gd2 n1=cyclopeptide | n2=en:ganglioside gd2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ganglioside gm2 n1=cyclopeptide | n2=en:ganglioside gm2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ganitumab n1=cyclopeptide | n2=en:ganitumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ganoderma lucidum spores powder capsule n1=cyclopeptide | n2=en:ganoderma lucidum spores powder capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:garlic extract n1=cyclopeptide | n2=en:garlic extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gastrin immunotoxin n1=cyclopeptide | n2=en:gastrin immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gastroenteral dosage form product n1=cyclopeptide | n2=en:gastroenteral dosage form product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gastrointestinal agents n1=cyclopeptide | n2=en:gastrointestinal agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gastroschisis n1=cyclopeptide | n2=en:gastroschisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gataparsen sodium n1=cyclopeptide | n2=en:gataparsen sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gavilimomab n1=cyclopeptide | n2=en:gavilimomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gaze limitation n1=cyclopeptide | n2=en:gaze limitation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gaze-evoked horizontal nystagmus (not always present) n1=cyclopeptide | n2=en:gaze-evoked horizontal nystagmus (not always present) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gaze-evoked nystagmus (1 patient) n1=cyclopeptide | n2=en:gaze-evoked nystagmus (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gaze-evoked nystagmus (33%) n1=cyclopeptide | n2=en:gaze-evoked nystagmus (33%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gd2 lactone/gd3 lactone-klh conjugate bivalent vaccine n1=cyclopeptide | n2=en:gd2 lactone/gd3 lactone-klh conjugate bivalent vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gd2-car-expressing autologous t-lymphocytes n1=cyclopeptide | n2=en:gd2-car-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gd2-klh vaccine n1=cyclopeptide | n2=en:gd2-klh vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gdc-0349 n1=cyclopeptide | n2=en:gdc-0349 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gedatolisib n1=cyclopeptide | n2=en:gedatolisib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gefitinib n1=cyclopeptide | n2=en:gefitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gel protein, gelonium multiflorum n1=cyclopeptide | n2=en:gel protein, gelonium multiflorum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gelatin n1=cyclopeptide | n2=en:gelatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gem 231 n1=cyclopeptide | n2=en:gem 231 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine n1=cyclopeptide | n2=en:gemcitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine elaidate n1=cyclopeptide | n2=en:gemcitabine elaidate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine hydrochloride n1=cyclopeptide | n2=en:gemcitabine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine hydrochloride emulsion n1=cyclopeptide | n2=en:gemcitabine hydrochloride emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine prodrug ly2334737 n1=cyclopeptide | n2=en:gemcitabine prodrug ly2334737 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine-cisplatin regimen n1=cyclopeptide | n2=en:gemcitabine-cisplatin regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine-erlotinib regimen n1=cyclopeptide | n2=en:gemcitabine-erlotinib regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine-oxaliplatin regimen n1=cyclopeptide | n2=en:gemcitabine-oxaliplatin regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemcitabine-phosphoramidate hydrochloride nuc-1031 n1=cyclopeptide | n2=en:gemcitabine-phosphoramidate hydrochloride nuc-1031 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemfibrozil n1=cyclopeptide | n2=en:gemfibrozil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemigliptin n1=cyclopeptide | n2=en:gemigliptin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gemtuzumab ozogamicin n1=cyclopeptide | n2=en:gemtuzumab ozogamicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gene-modified hiv-protected hematopoietic stem cells n1=cyclopeptide | n2=en:gene-modified hiv-protected hematopoietic stem cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:generic drug n1=cyclopeptide | n2=en:generic drug | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:genetically engineered ny-eso-1-specific t lymphocytes n1=cyclopeptide | n2=en:genetically engineered ny-eso-1-specific t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:genetically-modified mage-a3-expressing mg1 maraba virus vaccine n1=cyclopeptide | n2=en:genetically-modified mage-a3-expressing mg1 maraba virus vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:genistein n1=cyclopeptide | n2=en:genistein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:genital system agent n1=cyclopeptide | n2=en:genital system agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gentamicin n1=cyclopeptide | n2=en:gentamicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:geranylgeranyltransferase i inhibitor n1=cyclopeptide | n2=en:geranylgeranyltransferase i inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ghrelin peptide analogue n1=cyclopeptide | n2=en:ghrelin peptide analogue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gi-4000 vaccine n1=cyclopeptide | n2=en:gi-4000 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gilteritinib n1=cyclopeptide | n2=en:gilteritinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gimatecan n1=cyclopeptide | n2=en:gimatecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gimeracil n1=cyclopeptide | n2=en:gimeracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ginger extract n1=cyclopeptide | n2=en:ginger extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ginseng compound n1=cyclopeptide | n2=en:ginseng compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ginsenoside rg3 capsule n1=cyclopeptide | n2=en:ginsenoside rg3 capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:giracodazole n1=cyclopeptide | n2=en:giracodazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:girentuximab n1=cyclopeptide | n2=en:girentuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gitr agonist medi1873 n1=cyclopeptide | n2=en:gitr agonist medi1873 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gitrl rna-transfected autologous dendritic cell vaccine n1=cyclopeptide | n2=en:gitrl rna-transfected autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:givinostat n1=cyclopeptide | n2=en:givinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gk567 n1=cyclopeptide | n2=en:gk567 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glare - eye symptom n1=cyclopeptide | n2=en:glare - eye symptom | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glatiramer n1=cyclopeptide | n2=en:glatiramer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma n1=cyclopeptide | n2=en:glaucoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma (50% of males) n1=cyclopeptide | n2=en:glaucoma (50% of males) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma (75%) n1=cyclopeptide | n2=en:glaucoma (75%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma (in 80% of patients) n1=cyclopeptide | n2=en:glaucoma (in 80% of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma (in some patients) n1=cyclopeptide | n2=en:glaucoma (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma (rare) n1=cyclopeptide | n2=en:glaucoma (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma (uncommon) n1=cyclopeptide | n2=en:glaucoma (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma may precede development of neuropathy n1=cyclopeptide | n2=en:glaucoma may precede development of neuropathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma of childhood n1=cyclopeptide | n2=en:glaucoma of childhood | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma secondary to lens subluxation or dislocation n1=cyclopeptide | n2=en:glaucoma secondary to lens subluxation or dislocation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma, chronic angle-closure, in older patients n1=cyclopeptide | n2=en:glaucoma, chronic angle-closure, in older patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glaucoma, open-angle, early-onset (occurs in patients with nonsense or truncating mutations in the sbf2 gene) n1=cyclopeptide | n2=en:glaucoma, open-angle, early-onset (occurs in patients with nonsense or truncating mutations in the sbf2 gene) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glembatumumab vedotin n1=cyclopeptide | n2=en:glembatumumab vedotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glibornuride n1=cyclopeptide | n2=en:glibornuride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gliclazide n1=cyclopeptide | n2=en:gliclazide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glimepiride n1=cyclopeptide | n2=en:glimepiride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glioblastoma cancer vaccine erc1671 n1=cyclopeptide | n2=en:glioblastoma cancer vaccine erc1671 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glioblastoma multiforme multipeptide vaccine ima950 n1=cyclopeptide | n2=en:glioblastoma multiforme multipeptide vaccine ima950 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glioma-associated peptide-loaded dendritic cell vaccine sl-701 n1=cyclopeptide | n2=en:glioma-associated peptide-loaded dendritic cell vaccine sl-701 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gliosis of optic nerve n1=cyclopeptide | n2=en:gliosis of optic nerve | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glipizide n1=cyclopeptide | n2=en:glipizide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gliquidone n1=cyclopeptide | n2=en:gliquidone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glisoxepide n1=cyclopeptide | n2=en:glisoxepide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glistening white dots in fundus n1=cyclopeptide | n2=en:glistening white dots in fundus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:globe retraction and deviation on adduction n1=cyclopeptide | n2=en:globe retraction and deviation on adduction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:globo h-dt vaccine obi-833 n1=cyclopeptide | n2=en:globo h-dt vaccine obi-833 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:globo h-gm2-lewis-y-muc1-32-mer-tf(c)-tn(c)-klh conjugate vaccine n1=cyclopeptide | n2=en:globo h-gm2-lewis-y-muc1-32-mer-tf(c)-tn(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:globo h-klh immunostimulant opt-822 n1=cyclopeptide | n2=en:globo h-klh immunostimulant opt-822 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine n1=cyclopeptide | n2=en:globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:globular deposits along major vascular arcades n1=cyclopeptide | n2=en:globular deposits along major vascular arcades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:globulin component macrophage-activating factor n1=cyclopeptide | n2=en:globulin component macrophage-activating factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glomeruloid vascular proliferation in the retina n1=cyclopeptide | n2=en:glomeruloid vascular proliferation in the retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glse compound n1=cyclopeptide | n2=en:glse compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glucagon n1=cyclopeptide | n2=en:glucagon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glucarpidase n1=cyclopeptide | n2=en:glucarpidase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glucocorticoid receptor antagonist cort125134 n1=cyclopeptide | n2=en:glucocorticoid receptor antagonist cort125134 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glucosamine sulfate/chondroitin sulfate tablet n1=cyclopeptide | n2=en:glucosamine sulfate/chondroitin sulfate tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glucuronic acid n1=cyclopeptide | n2=en:glucuronic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glufosfamide n1=cyclopeptide | n2=en:glufosfamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glutamic acid n1=cyclopeptide | n2=en:glutamic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glutaminase inhibitor cb-839 n1=cyclopeptide | n2=en:glutaminase inhibitor cb-839 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glutaminase-asparaginase n1=cyclopeptide | n2=en:glutaminase-asparaginase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glutamine n1=cyclopeptide | n2=en:glutamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glutathione n1=cyclopeptide | n2=en:glutathione | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glutathione disulfide nov-002 n1=cyclopeptide | n2=en:glutathione disulfide nov-002 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glutathione pegylated liposomal doxorubicin hydrochloride formulation 2b3-101 n1=cyclopeptide | n2=en:glutathione pegylated liposomal doxorubicin hydrochloride formulation 2b3-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gluten-free compact nutritional supplement drink n1=cyclopeptide | n2=en:gluten-free compact nutritional supplement drink | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gluten-free dha/epa/gla/antioxidant-rich nutritional liquid n1=cyclopeptide | n2=en:gluten-free dha/epa/gla/antioxidant-rich nutritional liquid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gluten-free/fiber-enriched compact nutritional supplement drink n1=cyclopeptide | n2=en:gluten-free/fiber-enriched compact nutritional supplement drink | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glyburide n1=cyclopeptide | n2=en:glyburide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycerin cream (10%) n1=cyclopeptide | n2=en:glycerin cream (10%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycerin enema n1=cyclopeptide | n2=en:glycerin enema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycine n1=cyclopeptide | n2=en:glycine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycooptimized trastuzumab-gex n1=cyclopeptide | n2=en:glycooptimized trastuzumab-gex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycopeptide antibiotic n1=cyclopeptide | n2=en:glycopeptide antibiotic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycopyrrolate n1=cyclopeptide | n2=en:glycopyrrolate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycosylated recombinant human g-csf avi-014 n1=cyclopeptide | n2=en:glycosylated recombinant human g-csf avi-014 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycosylated recombinant human interleukin-7 n1=cyclopeptide | n2=en:glycosylated recombinant human interleukin-7 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycyrrhiza glabra root n1=cyclopeptide | n2=en:glycyrrhiza glabra root | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glycyrrhizin n1=cyclopeptide | n2=en:glycyrrhizin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glymidine n1=cyclopeptide | n2=en:glymidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:glyt2/5ht2a antagonist vvz-149 n1=cyclopeptide | n2=en:glyt2/5ht2a antagonist vvz-149 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gm-csf-encoding oncolytic adenovirus cgtg-102 n1=cyclopeptide | n2=en:gm-csf-encoding oncolytic adenovirus cgtg-102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gm-k562 cell vaccine n1=cyclopeptide | n2=en:gm-k562 cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gm.cd40l cell vaccine n1=cyclopeptide | n2=en:gm.cd40l cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gm2-klh vaccine n1=cyclopeptide | n2=en:gm2-klh vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gm2/gd2/gd3 lactone-klh conjugate trivalent vaccine n1=cyclopeptide | n2=en:gm2/gd2/gd3 lactone-klh conjugate trivalent vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gnrh antagonist tak-385 n1=cyclopeptide | n2=en:gnrh antagonist tak-385 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gold sodium thiomalate n1=cyclopeptide | n2=en:gold sodium thiomalate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:goldenrod n1=cyclopeptide | n2=en:goldenrod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:golimumab n1=cyclopeptide | n2=en:golimumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:golnerminogene pradenovec n1=cyclopeptide | n2=en:golnerminogene pradenovec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:golotimod n1=cyclopeptide | n2=en:golotimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:golvatinib n1=cyclopeptide | n2=en:golvatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gomiliximab n1=cyclopeptide | n2=en:gomiliximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gonadal dysgenesis n1=cyclopeptide | n2=en:gonadal dysgenesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gonadotropin-releasing hormone analog n1=cyclopeptide | n2=en:gonadotropin-releasing hormone analog | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:goniodysgenesis n1=cyclopeptide | n2=en:goniodysgenesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:good visual acuity n1=cyclopeptide | n2=en:good visual acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:goserelin acetate n1=cyclopeptide | n2=en:goserelin acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gossypol n1=cyclopeptide | n2=en:gossypol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gout suppressants n1=cyclopeptide | n2=en:gout suppressants | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp100 antigen n1=cyclopeptide | n2=en:gp100 antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp100-fowlpox vaccine n1=cyclopeptide | n2=en:gp100-fowlpox vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp100:154-162 peptide vaccine n1=cyclopeptide | n2=en:gp100:154-162 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp100:209-217(210m) peptide vaccine n1=cyclopeptide | n2=en:gp100:209-217(210m) peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp100:280-288(288v) peptide vaccine n1=cyclopeptide | n2=en:gp100:280-288(288v) peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp2 peptide/gm-csf vaccine n1=cyclopeptide | n2=en:gp2 peptide/gm-csf vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp2013 n1=cyclopeptide | n2=en:gp2013 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp209-2m antigen n1=cyclopeptide | n2=en:gp209-2m antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gp96-secreting allogeneic bladder cancer cell vaccine hs-410 n1=cyclopeptide | n2=en:gp96-secreting allogeneic bladder cancer cell vaccine hs-410 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gpi 1485 n1=cyclopeptide | n2=en:gpi 1485 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gpi-0100 n1=cyclopeptide | n2=en:gpi-0100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gradual progressive loss of central visual acuity n1=cyclopeptide | n2=en:gradual progressive loss of central visual acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gradual visual impairment n1=cyclopeptide | n2=en:gradual visual impairment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:granisetron hydrochloride n1=cyclopeptide | n2=en:granisetron hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:granisetron hydrochloride nasal spray n1=cyclopeptide | n2=en:granisetron hydrochloride nasal spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:granisetron transdermal patch n1=cyclopeptide | n2=en:granisetron transdermal patch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:granular deposits replace epithelial basement membrane n1=cyclopeptide | n2=en:granular deposits replace epithelial basement membrane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:granular fundus n1=cyclopeptide | n2=en:granular fundus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:granular retinal pigmentation, mild (in 1 patient) n1=cyclopeptide | n2=en:granular retinal pigmentation, mild (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:granulomatous lymphangitis on eyelid biopsy n1=cyclopeptide | n2=en:granulomatous lymphangitis on eyelid biopsy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gray, crumb-like granular deposits in anterior third of stroma n1=cyclopeptide | n2=en:gray, crumb-like granular deposits in anterior third of stroma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gray, granular-appearing maculae n1=cyclopeptide | n2=en:gray, granular-appearing maculae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:greatly reduced light-adapted scotopic and photopic erg by 7th decade n1=cyclopeptide | n2=en:greatly reduced light-adapted scotopic and photopic erg by 7th decade | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:green tea n1=cyclopeptide | n2=en:green tea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:green tea extract n1=cyclopeptide | n2=en:green tea extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:green tea extract-based antioxidant supplement n1=cyclopeptide | n2=en:green tea extract-based antioxidant supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:green tea lozenge n1=cyclopeptide | n2=en:green tea lozenge | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gs/pan-notch inhibitor bms-906024 n1=cyclopeptide | n2=en:gs/pan-notch inhibitor bms-906024 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gs/pan-notch inhibitor bms-986115 n1=cyclopeptide | n2=en:gs/pan-notch inhibitor bms-986115 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gsk-3 inhibitor ly2090314 n1=cyclopeptide | n2=en:gsk-3 inhibitor ly2090314 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gti-2040 n1=cyclopeptide | n2=en:gti-2040 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:guadecitabine n1=cyclopeptide | n2=en:guadecitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:guanabenz acetate n1=cyclopeptide | n2=en:guanabenz acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:guanazole n1=cyclopeptide | n2=en:guanazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:guar gum n1=cyclopeptide | n2=en:guar gum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:guarana supplement n1=cyclopeptide | n2=en:guarana supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gusperimus n1=cyclopeptide | n2=en:gusperimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gusperimus trihydrochloride n1=cyclopeptide | n2=en:gusperimus trihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gvax lung cancer vaccine n1=cyclopeptide | n2=en:gvax lung cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gvax pancreatic cancer vaccine n1=cyclopeptide | n2=en:gvax pancreatic cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:gvax prostate cancer vaccine n1=cyclopeptide | n2=en:gvax prostate cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:h1299 tumor cell lysate vaccine n1=cyclopeptide | n2=en:h1299 tumor cell lysate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:haemophilus influenzae b vaccine n1=cyclopeptide | n2=en:haemophilus influenzae b vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hafnium oxide-containing nanoparticles nbtxr3 n1=cyclopeptide | n2=en:hafnium oxide-containing nanoparticles nbtxr3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hallucinations, visual, precipitated by infectious illness (in some patients) n1=cyclopeptide | n2=en:hallucinations, visual, precipitated by infectious illness (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:halofuginone hydrobromide n1=cyclopeptide | n2=en:halofuginone hydrobromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:halometasone n1=cyclopeptide | n2=en:halometasone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:haloperidol n1=cyclopeptide | n2=en:haloperidol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hamartoma n1=cyclopeptide | n2=en:hamartoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hamartoma of retina n1=cyclopeptide | n2=en:hamartoma of retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:harringtonines n1=cyclopeptide | n2=en:harringtonines | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:harrod doman keele syndrome n1=cyclopeptide | n2=en:harrod doman keele syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:haspeslagh fryns muelenaere syndrome n1=cyclopeptide | n2=en:haspeslagh fryns muelenaere syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hcomla protocol n1=cyclopeptide | n2=en:hcomla protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hcv antigen therapeutic bivalent vaccine v5 n1=cyclopeptide | n2=en:hcv antigen therapeutic bivalent vaccine v5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hcv dna vaccine ino-8000 n1=cyclopeptide | n2=en:hcv dna vaccine ino-8000 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hcvad protocol n1=cyclopeptide | n2=en:hcvad protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hd-cep regimen n1=cyclopeptide | n2=en:hd-cep regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hd-cnv protocol n1=cyclopeptide | n2=en:hd-cnv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor 4sc-202 n1=cyclopeptide | n2=en:hdac inhibitor 4sc-202 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor acy-241 n1=cyclopeptide | n2=en:hdac inhibitor acy-241 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor ar-42 n1=cyclopeptide | n2=en:hdac inhibitor ar-42 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor cg200745 n1=cyclopeptide | n2=en:hdac inhibitor cg200745 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor chr-2845 n1=cyclopeptide | n2=en:hdac inhibitor chr-2845 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor chr-3996 n1=cyclopeptide | n2=en:hdac inhibitor chr-3996 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor cxd101 n1=cyclopeptide | n2=en:hdac inhibitor cxd101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor mpt0e028 n1=cyclopeptide | n2=en:hdac inhibitor mpt0e028 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor obp-801 n1=cyclopeptide | n2=en:hdac inhibitor obp-801 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac inhibitor shp-141 n1=cyclopeptide | n2=en:hdac inhibitor shp-141 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdac/egfr/her2 inhibitor cudc-101 n1=cyclopeptide | n2=en:hdac/egfr/her2 inhibitor cudc-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdm2 antagonist jnj-26854165 n1=cyclopeptide | n2=en:hdm2 antagonist jnj-26854165 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdm2 inhibitor hdm201 n1=cyclopeptide | n2=en:hdm2 inhibitor hdm201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hdm2 inhibitor mk-8242 n1=cyclopeptide | n2=en:hdm2 inhibitor mk-8242 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:head-eye lag n1=cyclopeptide | n2=en:head-eye lag | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hearing loss, sensorineural, postlingual progressive, moderate to severe n1=cyclopeptide | n2=en:hearing loss, sensorineural, postlingual progressive, moderate to severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hearing loss, sensorineural, progressive post-lingual n1=cyclopeptide | n2=en:hearing loss, sensorineural, progressive post-lingual | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heart malformation n1=cyclopeptide | n2=en:heart malformation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heat shock protein inhibitor n1=cyclopeptide | n2=en:heat shock protein inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heat-killed mycobacterial product imm-101 n1=cyclopeptide | n2=en:heat-killed mycobacterial product imm-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heat-treated varicella-zoster virus vaccine v212 n1=cyclopeptide | n2=en:heat-treated varicella-zoster virus vaccine v212 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heavd protocol n1=cyclopeptide | n2=en:heavd protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heavy horizontal eyebrows n1=cyclopeptide | n2=en:heavy horizontal eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heavy, arched eyebrows n1=cyclopeptide | n2=en:heavy, arched eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hedgehog inhibitor pf-04449913 n1=cyclopeptide | n2=en:hedgehog inhibitor pf-04449913 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hematologic agents n1=cyclopeptide | n2=en:hematologic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hematoporphyrin derivative n1=cyclopeptide | n2=en:hematoporphyrin derivative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hemeralopia n1=cyclopeptide | n2=en:hemeralopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hemianopic blurring n1=cyclopeptide | n2=en:hemianopic blurring | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hemianopsia n1=cyclopeptide | n2=en:hemianopsia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hemiasterlin analog e7974 n1=cyclopeptide | n2=en:hemiasterlin analog e7974 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hemihypertrophy n1=cyclopeptide | n2=en:hemihypertrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hemivertebra n1=cyclopeptide | n2=en:hemivertebra | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hemorrhage beneath internal limiting membrane due to leaking macroaneurysms n1=cyclopeptide | n2=en:hemorrhage beneath internal limiting membrane due to leaking macroaneurysms | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hemorrhoid preparation n1=cyclopeptide | n2=en:hemorrhoid preparation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:henatinib maleate n1=cyclopeptide | n2=en:henatinib maleate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heparan sulfate glycosaminoglycan mimetic m402 n1=cyclopeptide | n2=en:heparan sulfate glycosaminoglycan mimetic m402 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heparan sulfate glycosaminoglycan mimetic nanopolymer mouthwash n1=cyclopeptide | n2=en:heparan sulfate glycosaminoglycan mimetic nanopolymer mouthwash | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heparin n1=cyclopeptide | n2=en:heparin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heparin derivative sst0001 n1=cyclopeptide | n2=en:heparin derivative sst0001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hepatitis a vaccine n1=cyclopeptide | n2=en:hepatitis a vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hepatitis b antigen vaccine n1=cyclopeptide | n2=en:hepatitis b antigen vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hepatitis b vaccine n1=cyclopeptide | n2=en:hepatitis b vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hepsulfam n1=cyclopeptide | n2=en:hepsulfam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her-2-neu, cea peptides, gm-csf, montanide isa-51 vaccine n1=cyclopeptide | n2=en:her-2-neu, cea peptides, gm-csf, montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her-2-positive b-cell peptide antigen p467-dt-crm197/montanide vaccine imu-131 n1=cyclopeptide | n2=en:her-2-positive b-cell peptide antigen p467-dt-crm197/montanide vaccine imu-131 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her-2/neu intracellular domain protein n1=cyclopeptide | n2=en:her-2/neu intracellular domain protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her-2/neu peptide vaccine n1=cyclopeptide | n2=en:her-2/neu peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her2 ecd+tm virus-like replicon particles vaccine avx901 n1=cyclopeptide | n2=en:her2 ecd+tm virus-like replicon particles vaccine avx901 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her2-pulsed autologous type-1 polarized dendritic cell vaccine n1=cyclopeptide | n2=en:her2-pulsed autologous type-1 polarized dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her2-targeted liposomal doxorubicin hydrochloride mm-302 n1=cyclopeptide | n2=en:her2-targeted liposomal doxorubicin hydrochloride mm-302 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her2-targeting antibody fc fragment fs102 n1=cyclopeptide | n2=en:her2-targeting antibody fc fragment fs102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:her2bi-armed activated t cells n1=cyclopeptide | n2=en:her2bi-armed activated t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:herba scutellaria barbata n1=cyclopeptide | n2=en:herba scutellaria barbata | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:herbal medicine (product) n1=cyclopeptide | n2=en:herbal medicine (product) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:herbal medicine agent n1=cyclopeptide | n2=en:herbal medicine agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:herbal polysaccharide saliva substitute n1=cyclopeptide | n2=en:herbal polysaccharide saliva substitute | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hereditary elliptocytosis n1=cyclopeptide | n2=en:hereditary elliptocytosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hereditary macular coloboma n1=cyclopeptide | n2=en:hereditary macular coloboma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hermansky-pudlak syndrome n1=cyclopeptide | n2=en:hermansky-pudlak syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hermaphrodite n1=cyclopeptide | n2=en:hermaphrodite | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:herpes zoster vaccine gsk1437173a n1=cyclopeptide | n2=en:herpes zoster vaccine gsk1437173a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hetastarch n1=cyclopeptide | n2=en:hetastarch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heterochromia iridis n1=cyclopeptide | n2=en:heterochromia iridis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heterochromia iridis (complete or partial) n1=cyclopeptide | n2=en:heterochromia iridis (complete or partial) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:heterodimeric interleukin-15 n1=cyclopeptide | n2=en:heterodimeric interleukin-15 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hexamethylene bisacetamide n1=cyclopeptide | n2=en:hexamethylene bisacetamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hexaminolevulinate n1=cyclopeptide | n2=en:hexaminolevulinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hexaminolevulinate hydrochloride n1=cyclopeptide | n2=en:hexaminolevulinate hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hif-1alpha inhibitor px-478 n1=cyclopeptide | n2=en:hif-1alpha inhibitor px-478 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hif-2alpha inhibitor pt2385 n1=cyclopeptide | n2=en:hif-2alpha inhibitor pt2385 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high arched eyebrows n1=cyclopeptide | n2=en:high arched eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high flash visual evoked potentials (vep) n1=cyclopeptide | n2=en:high flash visual evoked potentials (vep) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high intraocular pressure (reported in 1 family) n1=cyclopeptide | n2=en:high intraocular pressure (reported in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high lens-to-eye volume ratio n1=cyclopeptide | n2=en:high lens-to-eye volume ratio | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high myopia (1 patient) n1=cyclopeptide | n2=en:high myopia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high myopia (in some patients) n1=cyclopeptide | n2=en:high myopia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high myopia, severe n1=cyclopeptide | n2=en:high myopia, severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high reflectivity of fundus (in some patients) n1=cyclopeptide | n2=en:high reflectivity of fundus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high refractive errors (hyperopia, myopia, with-the-rule astigmatism) n1=cyclopeptide | n2=en:high refractive errors (hyperopia, myopia, with-the-rule astigmatism) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high-arched, dense eyebrows n1=cyclopeptide | n2=en:high-arched, dense eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high-density concentric perifoveal ring surrounding irregular foveal autofluorescence on autofluorescence imaging of fundus n1=cyclopeptide | n2=en:high-density concentric perifoveal ring surrounding irregular foveal autofluorescence on autofluorescence imaging of fundus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high-selenium baker's yeast n1=cyclopeptide | n2=en:high-selenium baker's yeast | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high-selenium brassica juncea n1=cyclopeptide | n2=en:high-selenium brassica juncea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:high-titer rsv immune globulin ri-001 n1=cyclopeptide | n2=en:high-titer rsv immune globulin ri-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:highly purified staphylococcal protein a prtx-100 n1=cyclopeptide | n2=en:highly purified staphylococcal protein a prtx-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:histamine dihydrochloride n1=cyclopeptide | n2=en:histamine dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:histiocytic deposits in eyelids n1=cyclopeptide | n2=en:histiocytic deposits in eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:histology shows degeneration of retinal ganglion cells n1=cyclopeptide | n2=en:histology shows degeneration of retinal ganglion cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:histone-lysine n-methyltransferase ezh2 inhibitor gsk2816126 n1=cyclopeptide | n2=en:histone-lysine n-methyltransferase ezh2 inhibitor gsk2816126 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:histopathology shows fusiform amyloid deposits in the deeper stroma as seen in lattice dystrophy n1=cyclopeptide | n2=en:histopathology shows fusiform amyloid deposits in the deeper stroma as seen in lattice dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:histopathology shows hyaline changes consistent with granular dystrophy in the anterior stroma n1=cyclopeptide | n2=en:histopathology shows hyaline changes consistent with granular dystrophy in the anterior stroma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:histopathology shows rosettes of immature retinal cells in vascular connective tissue n1=cyclopeptide | n2=en:histopathology shows rosettes of immature retinal cells in vascular connective tissue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:historical aspects qualifier n1=cyclopeptide | n2=en:historical aspects qualifier | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:histrelin acetate n1=cyclopeptide | n2=en:histrelin acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*0201 restricted tert(572y)/tert(572) peptides vaccine vx-001 n1=cyclopeptide | n2=en:hla-a*0201 restricted tert(572y)/tert(572) peptides vaccine vx-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*0201-restricted trp2-gp100-epha2-her2 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*0201-restricted trp2-gp100-epha2-her2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*0201-restricted urlc10-vegfr1-vegfr2 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*0201-restricted urlc10-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*0201-restricted vegfr1 peptide vaccine n1=cyclopeptide | n2=en:hla-a*0201-restricted vegfr1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*0201-restricted vegfr1-vegfr2 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*0201-restricted vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted cdca1-a24-56 peptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted cdca1-a24-56 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted cdca1-kif20a multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted cdca1-kif20a multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted koc1-ttk-co16-depdc1-mphosph1 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted koc1-ttk-co16-depdc1-mphosph1 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted multipeptide vaccine s-488410 n1=cyclopeptide | n2=en:hla-a*2402-restricted multipeptide vaccine s-488410 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted urlc10 peptides vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted urlc10 peptides vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted urlc10-cdca1-kif20a multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted urlc10-cdca1-kif20a multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted urlc10-cdca1-vegfr1-vegfr2 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted urlc10-cdca1-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted urlc10-koc1-vegfr1-vegfr2 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted urlc10-koc1-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted urlc10-ttk-koc1 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted urlc10-ttk-koc1 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted urlc10-ttk-vegfr1-vegfr2 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted urlc10-ttk-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted vegfr1 peptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted vegfr1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2402-restricted vegfr1/2 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2402-restricted vegfr1/2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a*2404-restricted rnf43-tomm34-vegfr1-vegfr2 multipeptide vaccine n1=cyclopeptide | n2=en:hla-a*2404-restricted rnf43-tomm34-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a1-binding mage-1/mage-3 multipeptide-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:hla-a1-binding mage-1/mage-3 multipeptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a1, a2, b35-restricted survivin peptides/montanide isa-51 vaccine n1=cyclopeptide | n2=en:hla-a1, a2, b35-restricted survivin peptides/montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a2-binding tyr/mart-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:hla-a2-binding tyr/mart-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a2-restricted synthetic glioma antigen peptides vaccine n1=cyclopeptide | n2=en:hla-a2-restricted synthetic glioma antigen peptides vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-a2, a3-restricted fgf-5 peptides/montanide isa-51 vaccine n1=cyclopeptide | n2=en:hla-a2, a3-restricted fgf-5 peptides/montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-dp0401/0402-restricted mage-a3-reactive t cell receptor-transduced autologous t cells n1=cyclopeptide | n2=en:hla-dp0401/0402-restricted mage-a3-reactive t cell receptor-transduced autologous t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hla-matched donor mononuclear cell-enriched leukocytes apocell n1=cyclopeptide | n2=en:hla-matched donor mononuclear cell-enriched leukocytes apocell | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hm 89 protocol n1=cyclopeptide | n2=en:hm 89 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hm 91 protocol n1=cyclopeptide | n2=en:hm 91 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hm89 regimen n1=cyclopeptide | n2=en:hm89 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hm91 regimen n1=cyclopeptide | n2=en:hm91 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ho 166 dotmp n1=cyclopeptide | n2=en:ho 166 dotmp | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ho/02/02 n1=cyclopeptide | n2=en:ho/02/02 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hodgkin's antigens-gm-csf-expressing cell vaccine n1=cyclopeptide | n2=en:hodgkin's antigens-gm-csf-expressing cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:holmium ho 166 poly(l-lactic acid) microspheres n1=cyclopeptide | n2=en:holmium ho 166 poly(l-lactic acid) microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:holoprosencephaly n1=cyclopeptide | n2=en:holoprosencephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:holoprosencephaly type 1 n1=cyclopeptide | n2=en:holoprosencephaly type 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:holoprosencephaly type 2 n1=cyclopeptide | n2=en:holoprosencephaly type 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:homeopathic remedies n1=cyclopeptide | n2=en:homeopathic remedies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:honey n1=cyclopeptide | n2=en:honey | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:honey-containing mouthwash n1=cyclopeptide | n2=en:honey-containing mouthwash | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hooded eyelids n1=cyclopeptide | n2=en:hooded eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal gaze nystagmus n1=cyclopeptide | n2=en:horizontal gaze nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal gaze palsy n1=cyclopeptide | n2=en:horizontal gaze palsy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal nystagmus (5%) n1=cyclopeptide | n2=en:horizontal nystagmus (5%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal nystagmus (about half of patients) n1=cyclopeptide | n2=en:horizontal nystagmus (about half of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal nystagmus (in 1 patient) n1=cyclopeptide | n2=en:horizontal nystagmus (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal nystagmus (in some patients) n1=cyclopeptide | n2=en:horizontal nystagmus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal or rotary nystagmus n1=cyclopeptide | n2=en:horizontal or rotary nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal oval-shaped fovea (in some patients) n1=cyclopeptide | n2=en:horizontal oval-shaped fovea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal pendular nystagmus n1=cyclopeptide | n2=en:horizontal pendular nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horizontal saccades n1=cyclopeptide | n2=en:horizontal saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hormone, hormone metabolite, hormone precursor, synthetic hormone substitute, and/or hormone antagonist n1=cyclopeptide | n2=en:hormone, hormone metabolite, hormone precursor, synthetic hormone substitute, and/or hormone antagonist | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hormones, synthetic substitutes and antagonists n1=cyclopeptide | n2=en:hormones, synthetic substitutes and antagonists | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horner syndrome n1=cyclopeptide | n2=en:horner syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:horse antihuman thymocyte gamma globulin n1=cyclopeptide | n2=en:horse antihuman thymocyte gamma globulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:host dendritic cell vaccine-001 mssm/biir n1=cyclopeptide | n2=en:host dendritic cell vaccine-001 mssm/biir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpe1 gene n1=cyclopeptide | n2=en:hpe1 gene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpph n1=cyclopeptide | n2=en:hpph | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv 16 e7 antigen-expressing lactobacillis casei vaccine bls-ilb-e710c n1=cyclopeptide | n2=en:hpv 16 e7 antigen-expressing lactobacillis casei vaccine bls-ilb-e710c | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv 16 e7:12-20 peptide vaccine n1=cyclopeptide | n2=en:hpv 16 e7:12-20 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv 16 e7:86-93 peptide vaccine n1=cyclopeptide | n2=en:hpv 16 e7:86-93 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv dna plasmids therapeutic vaccine vgx-3100 n1=cyclopeptide | n2=en:hpv dna plasmids therapeutic vaccine vgx-3100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv e1/e2 interaction inhibitor gel ap611074 n1=cyclopeptide | n2=en:hpv e1/e2 interaction inhibitor gel ap611074 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv e6/e7 dna vaccine gx-188e n1=cyclopeptide | n2=en:hpv e6/e7 dna vaccine gx-188e | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv-16 e6 peptides vaccine/candida albicans extract n1=cyclopeptide | n2=en:hpv-16 e6 peptides vaccine/candida albicans extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv-6-targeting immunotherapeutic vaccine ino-3106 n1=cyclopeptide | n2=en:hpv-6-targeting immunotherapeutic vaccine ino-3106 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hpv16 l2/e6/e7 fusion protein vaccine ta-cin n1=cyclopeptide | n2=en:hpv16 l2/e6/e7 fusion protein vaccine ta-cin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp70-peptide tkd/il-2-activated autologous natural killer cells n1=cyclopeptide | n2=en:hsp70-peptide tkd/il-2-activated autologous natural killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 antagonist kw-2478 n1=cyclopeptide | n2=en:hsp90 antagonist kw-2478 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor ab-010 n1=cyclopeptide | n2=en:hsp90 inhibitor ab-010 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor auy922 n1=cyclopeptide | n2=en:hsp90 inhibitor auy922 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor biib021 n1=cyclopeptide | n2=en:hsp90 inhibitor biib021 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor biib028 n1=cyclopeptide | n2=en:hsp90 inhibitor biib028 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor debio 0932 n1=cyclopeptide | n2=en:hsp90 inhibitor debio 0932 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor ds-2248 n1=cyclopeptide | n2=en:hsp90 inhibitor ds-2248 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor hsp990 n1=cyclopeptide | n2=en:hsp90 inhibitor hsp990 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor mpc-3100 n1=cyclopeptide | n2=en:hsp90 inhibitor mpc-3100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor pu-h71 n1=cyclopeptide | n2=en:hsp90 inhibitor pu-h71 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor snx-5542 mesylate n1=cyclopeptide | n2=en:hsp90 inhibitor snx-5542 mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsp90 inhibitor xl888 n1=cyclopeptide | n2=en:hsp90 inhibitor xl888 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsv-1 hf10 n1=cyclopeptide | n2=en:hsv-1 hf10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hsv-tk-transduced donor lymphocytes n1=cyclopeptide | n2=en:hsv-tk-transduced donor lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:htert i540/r572y/d988y multipeptide vaccine n1=cyclopeptide | n2=en:htert i540/r572y/d988y multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:htert mrna/survivin peptide-double-loaded autologous dendritic cell vaccine n1=cyclopeptide | n2=en:htert mrna/survivin peptide-double-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:htert multipeptide/montanide isa-51 vg/imiquimod gx 301 n1=cyclopeptide | n2=en:htert multipeptide/montanide isa-51 vg/imiquimod gx 301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:htert vaccine v934/v935 n1=cyclopeptide | n2=en:htert vaccine v934/v935 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:htert-encoding dna vaccine invac-1 n1=cyclopeptide | n2=en:htert-encoding dna vaccine invac-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:htert-lamp mrna-loaded autologous dendritic cell vaccine grnvac1 n1=cyclopeptide | n2=en:htert-lamp mrna-loaded autologous dendritic cell vaccine grnvac1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:htert/survivin/cmv multipeptide vaccine n1=cyclopeptide | n2=en:htert/survivin/cmv multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:htert/survivin/melanoma tumor cell-derived mrna-transfected dendritic cell vaccine n1=cyclopeptide | n2=en:htert/survivin/melanoma tumor cell-derived mrna-transfected dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hu14.18-il2 fusion protein n1=cyclopeptide | n2=en:hu14.18-il2 fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:huachansu n1=cyclopeptide | n2=en:huachansu | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:huaier extract granule n1=cyclopeptide | n2=en:huaier extract granule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:huang lian n1=cyclopeptide | n2=en:huang lian | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hubc1-huil12 fusion protein as1409 n1=cyclopeptide | n2=en:hubc1-huil12 fusion protein as1409 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human combinatorial antibody library-based monoclonal antibody vay736 n1=cyclopeptide | n2=en:human combinatorial antibody library-based monoclonal antibody vay736 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human gp100 plasmid dna vaccine n1=cyclopeptide | n2=en:human gp100 plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human lactoferrin peptide hlf1-11 n1=cyclopeptide | n2=en:human lactoferrin peptide hlf1-11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human menopausal gonadotropin n1=cyclopeptide | n2=en:human menopausal gonadotropin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human mhc non-restricted cytotoxic t-cell line tall-104 n1=cyclopeptide | n2=en:human mhc non-restricted cytotoxic t-cell line tall-104 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human monoclonal antibody 216 n1=cyclopeptide | n2=en:human monoclonal antibody 216 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human monoclonal antibody b11-hcg beta fusion protein cdx-1307 n1=cyclopeptide | n2=en:human monoclonal antibody b11-hcg beta fusion protein cdx-1307 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human monoclonal igm antibody n1=cyclopeptide | n2=en:human monoclonal igm antibody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human myeloid progenitor cells clt-008 n1=cyclopeptide | n2=en:human myeloid progenitor cells clt-008 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human papilloma virus l1 virus-like particle v504 vaccine n1=cyclopeptide | n2=en:human papilloma virus l1 virus-like particle v504 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human papillomavirus 16/18 l1 virus-like particle/as04 vaccine n1=cyclopeptide | n2=en:human papillomavirus 16/18 l1 virus-like particle/as04 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human papillomavirus tumor antigen vaccine n1=cyclopeptide | n2=en:human papillomavirus tumor antigen vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human papillomavirus vaccine v503 n1=cyclopeptide | n2=en:human papillomavirus vaccine v503 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human prostate-specific membrane antigen plasmid dna vaccine n1=cyclopeptide | n2=en:human prostate-specific membrane antigen plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human trefoil factor 1-secreting lactococcus lactis ag013 n1=cyclopeptide | n2=en:human trefoil factor 1-secreting lactococcus lactis ag013 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:human varicella zoster immune globulin n1=cyclopeptide | n2=en:human varicella zoster immune globulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:humanized monoclonal antibody 3f8 n1=cyclopeptide | n2=en:humanized monoclonal antibody 3f8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hvegf26-104/rfase peptide vaccine n1=cyclopeptide | n2=en:hvegf26-104/rfase peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyaline body n1=cyclopeptide | n2=en:hyaline body | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyaluronic acid n1=cyclopeptide | n2=en:hyaluronic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyaluronic acid-based hydrating vaginal gel n1=cyclopeptide | n2=en:hyaluronic acid-based hydrating vaginal gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyaluronic acid-containing topical cream n1=cyclopeptide | n2=en:hyaluronic acid-containing topical cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyb2055 n1=cyclopeptide | n2=en:hyb2055 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hycanthone n1=cyclopeptide | n2=en:hycanthone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydralazine hydrochloride n1=cyclopeptide | n2=en:hydralazine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydrated sodium calcium aluminosilicate n1=cyclopeptide | n2=en:hydrated sodium calcium aluminosilicate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydrazine sulfate n1=cyclopeptide | n2=en:hydrazine sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydrocephalus n1=cyclopeptide | n2=en:hydrocephalus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydrocodone/acetaminophen n1=cyclopeptide | n2=en:hydrocodone/acetaminophen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydrocortisone sodium succinate n1=cyclopeptide | n2=en:hydrocortisone sodium succinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydromorphone hydrochloride n1=cyclopeptide | n2=en:hydromorphone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydroxychloroquine n1=cyclopeptide | n2=en:hydroxychloroquine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydroxyprogesterone caproate n1=cyclopeptide | n2=en:hydroxyprogesterone caproate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydroxytyrosol n1=cyclopeptide | n2=en:hydroxytyrosol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hydroxyurea n1=cyclopeptide | n2=en:hydroxyurea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperbaric oxygen n1=cyclopeptide | n2=en:hyperbaric oxygen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypercdt protocol n1=cyclopeptide | n2=en:hypercdt protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypercvad regimen n1=cyclopeptide | n2=en:hypercvad regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypercvad/hd mtx arac regimen n1=cyclopeptide | n2=en:hypercvad/hd mtx arac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperfluorescent ring in area of macular lesions on fluorescein angiography n1=cyclopeptide | n2=en:hyperfluorescent ring in area of macular lesions on fluorescein angiography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperglycemic agent n1=cyclopeptide | n2=en:hyperglycemic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperimmune bovine colostrum n1=cyclopeptide | n2=en:hyperimmune bovine colostrum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypermetric saccades n1=cyclopeptide | n2=en:hypermetric saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypermetropia (1 patient) n1=cyclopeptide | n2=en:hypermetropia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypermetropia (36%) n1=cyclopeptide | n2=en:hypermetropia (36%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypermetropia (in some patients) n1=cyclopeptide | n2=en:hypermetropia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypermetropia (meb) n1=cyclopeptide | n2=en:hypermetropia (meb) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypermetropia (rare) n1=cyclopeptide | n2=en:hypermetropia (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypermetropic astigmatism (in some patients) n1=cyclopeptide | n2=en:hypermetropic astigmatism (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypermyelinated retinal nerve fibers n1=cyclopeptide | n2=en:hypermyelinated retinal nerve fibers | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperopia n1=cyclopeptide | n2=en:hyperopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperopia (in some patients) n1=cyclopeptide | n2=en:hyperopia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperopia, high n1=cyclopeptide | n2=en:hyperopia, high | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperopic astigmatism n1=cyclopeptide | n2=en:hyperopic astigmatism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperpigmentation of the macula (rare) n1=cyclopeptide | n2=en:hyperpigmentation of the macula (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperplastic primary vitreous (wws) n1=cyclopeptide | n2=en:hyperplastic primary vitreous (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperplastic vitreous n1=cyclopeptide | n2=en:hyperplastic vitreous | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperpolarized carbon c 13 pyruvate n1=cyclopeptide | n2=en:hyperpolarized carbon c 13 pyruvate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperpolarized helium 3 n1=cyclopeptide | n2=en:hyperpolarized helium 3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperpolarized xenon 129 n1=cyclopeptide | n2=en:hyperpolarized xenon 129 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperreflective bodies below the outer limiting membrane on oct n1=cyclopeptide | n2=en:hyperreflective bodies below the outer limiting membrane on oct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperreflectivity of ganglion cell layer n1=cyclopeptide | n2=en:hyperreflectivity of ganglion cell layer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hyperreflectivity of nerve cell layer n1=cyclopeptide | n2=en:hyperreflectivity of nerve cell layer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism n1=cyclopeptide | n2=en:hypertelorism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (100%) n1=cyclopeptide | n2=en:hypertelorism (100%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (12%) n1=cyclopeptide | n2=en:hypertelorism (12%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (2/4 patients) n1=cyclopeptide | n2=en:hypertelorism (2/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (25%) n1=cyclopeptide | n2=en:hypertelorism (25%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (in 1 family) n1=cyclopeptide | n2=en:hypertelorism (in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (in brother) n1=cyclopeptide | n2=en:hypertelorism (in brother) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (major feature) n1=cyclopeptide | n2=en:hypertelorism (major feature) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (males and females) n1=cyclopeptide | n2=en:hypertelorism (males and females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (rare) n1=cyclopeptide | n2=en:hypertelorism (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (reported in 1 patient) n1=cyclopeptide | n2=en:hypertelorism (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism (some) n1=cyclopeptide | n2=en:hypertelorism (some) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism or telecanthus n1=cyclopeptide | n2=en:hypertelorism or telecanthus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertelorism, mild n1=cyclopeptide | n2=en:hypertelorism, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertonic saline n1=cyclopeptide | n2=en:hypertonic saline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertrichosis of eyebrows, mild n1=cyclopeptide | n2=en:hypertrichosis of eyebrows, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertrichosis of the eyebrows n1=cyclopeptide | n2=en:hypertrichosis of the eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertrophic conjunctivae n1=cyclopeptide | n2=en:hypertrophic conjunctivae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertrophy of clitoris n1=cyclopeptide | n2=en:hypertrophy of clitoris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertropia n1=cyclopeptide | n2=en:hypertropia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypertropia (in some patients) n1=cyclopeptide | n2=en:hypertropia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypesthetic cornea n1=cyclopeptide | n2=en:hypesthetic cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoglycemic agents n1=cyclopeptide | n2=en:hypoglycemic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypometric horizontal saccades n1=cyclopeptide | n2=en:hypometric horizontal saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypometric saccades n1=cyclopeptide | n2=en:hypometric saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypometric saccades (1 patient) n1=cyclopeptide | n2=en:hypometric saccades (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypometric saccades (about half of patients) n1=cyclopeptide | n2=en:hypometric saccades (about half of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypometric saccades (in some patients) n1=cyclopeptide | n2=en:hypometric saccades (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypometric vertical saccades n1=cyclopeptide | n2=en:hypometric vertical saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypomyelination n1=cyclopeptide | n2=en:hypomyelination | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypopigmented and underdeveloped macula n1=cyclopeptide | n2=en:hypopigmented and underdeveloped macula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypopigmented iris n1=cyclopeptide | n2=en:hypopigmented iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypopigmented ocular fundus n1=cyclopeptide | n2=en:hypopigmented ocular fundus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplasia n1=cyclopeptide | n2=en:hypoplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplasia of iris n1=cyclopeptide | n2=en:hypoplasia of iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplasia of optic disc n1=cyclopeptide | n2=en:hypoplasia of optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplasia of the ciliary body n1=cyclopeptide | n2=en:hypoplasia of the ciliary body | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplasia of the ocular nerve n1=cyclopeptide | n2=en:hypoplasia of the ocular nerve | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplasia of the retina n1=cyclopeptide | n2=en:hypoplasia of the retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplasia or absence of optic nerve n1=cyclopeptide | n2=en:hypoplasia or absence of optic nerve | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplastic eyebrows n1=cyclopeptide | n2=en:hypoplastic eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplastic iris stroma n1=cyclopeptide | n2=en:hypoplastic iris stroma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplastic lacrimal duct n1=cyclopeptide | n2=en:hypoplastic lacrimal duct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplastic oculomotor nerves, bilateral n1=cyclopeptide | n2=en:hypoplastic oculomotor nerves, bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplastic optic chiasm n1=cyclopeptide | n2=en:hypoplastic optic chiasm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplastic orbital ridges n1=cyclopeptide | n2=en:hypoplastic orbital ridges | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoplastic supra-orbital ridges n1=cyclopeptide | n2=en:hypoplastic supra-orbital ridges | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypotelorism (1 patient) n1=cyclopeptide | n2=en:hypotelorism (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypotelorism (19%) n1=cyclopeptide | n2=en:hypotelorism (19%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypotelorism (in 2 patients) n1=cyclopeptide | n2=en:hypotelorism (in 2 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypotelorism (in some patients) n1=cyclopeptide | n2=en:hypotelorism (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypotelorism (rare) n1=cyclopeptide | n2=en:hypotelorism (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoxia-activated prodrug th-302 n1=cyclopeptide | n2=en:hypoxia-activated prodrug th-302 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:hypoxia-activated prodrug th-4000 n1=cyclopeptide | n2=en:hypoxia-activated prodrug th-4000 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:i 123 monoclonal antibody 81c6 n1=cyclopeptide | n2=en:i 123 monoclonal antibody 81c6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:i 131 antiferritin immunoglobulin n1=cyclopeptide | n2=en:i 131 antiferritin immunoglobulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:i 131 monoclonal antibody a33 n1=cyclopeptide | n2=en:i 131 monoclonal antibody a33 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:i 131 monoclonal antibody cc49 n1=cyclopeptide | n2=en:i 131 monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:i 131 monoclonal antibody f19 n1=cyclopeptide | n2=en:i 131 monoclonal antibody f19 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:i 131 monoclonal antibody lym-1 n1=cyclopeptide | n2=en:i 131 monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iap inhibitor at-406 n1=cyclopeptide | n2=en:iap inhibitor at-406 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iap inhibitor hgs1029 n1=cyclopeptide | n2=en:iap inhibitor hgs1029 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iapa-based dendritic cells/cytotoxic t lymphocytes n1=cyclopeptide | n2=en:iapa-based dendritic cells/cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ibandronate sodium n1=cyclopeptide | n2=en:ibandronate sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ibritumomab n1=cyclopeptide | n2=en:ibritumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ibritumomab tiuxetan n1=cyclopeptide | n2=en:ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ibrutinib n1=cyclopeptide | n2=en:ibrutinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ibuprofen n1=cyclopeptide | n2=en:ibuprofen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ibuprofen injection n1=cyclopeptide | n2=en:ibuprofen injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ic9-gd2-cd28-ox40-expressing t lymphocytes n1=cyclopeptide | n2=en:ic9-gd2-cd28-ox40-expressing t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:icatibant n1=cyclopeptide | n2=en:icatibant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:icbv regimen n1=cyclopeptide | n2=en:icbv regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ice regimen n1=cyclopeptide | n2=en:ice regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:icodextrin solution n1=cyclopeptide | n2=en:icodextrin solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:icotinib hydrochloride n1=cyclopeptide | n2=en:icotinib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:icrucumab n1=cyclopeptide | n2=en:icrucumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ictal and interictal diplopia n1=cyclopeptide | n2=en:ictal and interictal diplopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idarubicin hydrochloride n1=cyclopeptide | n2=en:idarubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idarubicin-eluting beads n1=cyclopeptide | n2=en:idarubicin-eluting beads | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idasanutlin n1=cyclopeptide | n2=en:idasanutlin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idelalisib n1=cyclopeptide | n2=en:idelalisib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idh1 inhibitor ag-120 n1=cyclopeptide | n2=en:idh1 inhibitor ag-120 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idh1(r132) inhibitor idh305 n1=cyclopeptide | n2=en:idh1(r132) inhibitor idh305 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idh1r132h mutation-targeting idh1 peptide vaccine n1=cyclopeptide | n2=en:idh1r132h mutation-targeting idh1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idh1r132h-specific peptide vaccine pepidh1m n1=cyclopeptide | n2=en:idh1r132h-specific peptide vaccine pepidh1m | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idh2 inhibitor ag-221 n1=cyclopeptide | n2=en:idh2 inhibitor ag-221 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idiotype-pulsed autologous dendritic cell vaccine apc8020 n1=cyclopeptide | n2=en:idiotype-pulsed autologous dendritic cell vaccine apc8020 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ido inhibitor nlg919 n1=cyclopeptide | n2=en:ido inhibitor nlg919 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idoxifene n1=cyclopeptide | n2=en:idoxifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idoxuridine n1=cyclopeptide | n2=en:idoxuridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:idronoxil n1=cyclopeptide | n2=en:idronoxil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iep-abvd-copp regimen n1=cyclopeptide | n2=en:iep-abvd-copp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ifosfamide n1=cyclopeptide | n2=en:ifosfamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ifosfamide/cyclophosphamide/etoposide n1=cyclopeptide | n2=en:ifosfamide/cyclophosphamide/etoposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:igf ligand neutralizing antibody bi 836845 n1=cyclopeptide | n2=en:igf ligand neutralizing antibody bi 836845 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:igf-1r antisense oligodeoxynucleotide-treated autologous glioma cells n1=cyclopeptide | n2=en:igf-1r antisense oligodeoxynucleotide-treated autologous glioma cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:igf-1r inhibitor pl225b n1=cyclopeptide | n2=en:igf-1r inhibitor pl225b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:igf-1r/ir inhibitor kw-2450 n1=cyclopeptide | n2=en:igf-1r/ir inhibitor kw-2450 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:igf-methotrexate conjugate n1=cyclopeptide | n2=en:igf-methotrexate conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ih636 grape seed proanthocyanidin extract n1=cyclopeptide | n2=en:ih636 grape seed proanthocyanidin extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:il-10 immunomodulator mk-1966 n1=cyclopeptide | n2=en:il-10 immunomodulator mk-1966 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:il-12-expressing hsv-1 n1=cyclopeptide | n2=en:il-12-expressing hsv-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:il-12-expressing mesenchymal stem cell vaccine gx-051 n1=cyclopeptide | n2=en:il-12-expressing mesenchymal stem cell vaccine gx-051 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:il-2 plasmid dna/lipid complex n1=cyclopeptide | n2=en:il-2 plasmid dna/lipid complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:il-2 recombinant fusion protein alt-801 n1=cyclopeptide | n2=en:il-2 recombinant fusion protein alt-801 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:il-2/lptn gene-modified allogeneic neuroblastoma tumor cell vaccine n1=cyclopeptide | n2=en:il-2/lptn gene-modified allogeneic neuroblastoma tumor cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes n1=cyclopeptide | n2=en:il13ralpha2-specific hinge-optimized 41bb-co-stimulatory car truncated cd19-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:il4-pseudomonas exotoxin fusion protein prx321 n1=cyclopeptide | n2=en:il4-pseudomonas exotoxin fusion protein prx321 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ilaprazole n1=cyclopeptide | n2=en:ilaprazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iloprost n1=cyclopeptide | n2=en:iloprost | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ilorasertib n1=cyclopeptide | n2=en:ilorasertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ilx-295501 n1=cyclopeptide | n2=en:ilx-295501 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ilx23-7553 n1=cyclopeptide | n2=en:ilx23-7553 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imalumab n1=cyclopeptide | n2=en:imalumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imatinib mesylate n1=cyclopeptide | n2=en:imatinib mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imetelstat sodium n1=cyclopeptide | n2=en:imetelstat sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imexon n1=cyclopeptide | n2=en:imexon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imidazole mustard n1=cyclopeptide | n2=en:imidazole mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imidazolyl ethanamide pentandioic acid n1=cyclopeptide | n2=en:imidazolyl ethanamide pentandioic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iminophosphamide n1=cyclopeptide | n2=en:iminophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imipenem n1=cyclopeptide | n2=en:imipenem | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imipenem-cilastatin sodium n1=cyclopeptide | n2=en:imipenem-cilastatin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imiquimod n1=cyclopeptide | n2=en:imiquimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imisopasem manganese n1=cyclopeptide | n2=en:imisopasem manganese | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immature eyes n1=cyclopeptide | n2=en:immature eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immediate-release onapristone n1=cyclopeptide | n2=en:immediate-release onapristone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immediate-release oral liquid formulation oxymorphone hydrochloride n1=cyclopeptide | n2=en:immediate-release oral liquid formulation oxymorphone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immediate-release tablet afuresertib n1=cyclopeptide | n2=en:immediate-release tablet afuresertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunoadjuvant qs-dg n1=cyclopeptide | n2=en:immunoadjuvant qs-dg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunoconjugate ro5479599 n1=cyclopeptide | n2=en:immunoconjugate ro5479599 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunocytokine nhs-il12 n1=cyclopeptide | n2=en:immunocytokine nhs-il12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunocytokine nhs-il2-lt n1=cyclopeptide | n2=en:immunocytokine nhs-il2-lt | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunology aspects n1=cyclopeptide | n2=en:immunology aspects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunomodulating agent n1=cyclopeptide | n2=en:immunomodulating agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunomodulator ohr/avr118 n1=cyclopeptide | n2=en:immunomodulator ohr/avr118 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunomodulators n1=cyclopeptide | n2=en:immunomodulators | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunomodulatory agent cc-11006 n1=cyclopeptide | n2=en:immunomodulatory agent cc-11006 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunosuppressant n1=cyclopeptide | n2=en:immunosuppressant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunosuppressive antileukocyte serum n1=cyclopeptide | n2=en:immunosuppressive antileukocyte serum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunotherapeutic agent n1=cyclopeptide | n2=en:immunotherapeutic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunotherapeutic combination product cmb305 n1=cyclopeptide | n2=en:immunotherapeutic combination product cmb305 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunotherapeutic gsk1572932a n1=cyclopeptide | n2=en:immunotherapeutic gsk1572932a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunotherapy regimen mkc-1106-mt n1=cyclopeptide | n2=en:immunotherapy regimen mkc-1106-mt | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunotoxin cmd-193 n1=cyclopeptide | n2=en:immunotoxin cmd-193 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:immunotoxin d2c7-(scdsfv)-pe38kdel n1=cyclopeptide | n2=en:immunotoxin d2c7-(scdsfv)-pe38kdel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imp321 n1=cyclopeptide | n2=en:imp321 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired central vision n1=cyclopeptide | n2=en:impaired central vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired corneal reflex n1=cyclopeptide | n2=en:impaired corneal reflex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired horizontal smooth pursuit n1=cyclopeptide | n2=en:impaired horizontal smooth pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired night vision n1=cyclopeptide | n2=en:impaired night vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired ocular abduction n1=cyclopeptide | n2=en:impaired ocular abduction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired ocular adduction n1=cyclopeptide | n2=en:impaired ocular adduction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired ocular movements n1=cyclopeptide | n2=en:impaired ocular movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired pupillary constriction to light n1=cyclopeptide | n2=en:impaired pupillary constriction to light | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired pupillary response to light n1=cyclopeptide | n2=en:impaired pupillary response to light | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired pursuit initiation and maintenance n1=cyclopeptide | n2=en:impaired pursuit initiation and maintenance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired retinal vasculogenesis n1=cyclopeptide | n2=en:impaired retinal vasculogenesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired saccades n1=cyclopeptide | n2=en:impaired saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired smooth pursuit n1=cyclopeptide | n2=en:impaired smooth pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired smooth pursuit in adult patients n1=cyclopeptide | n2=en:impaired smooth pursuit in adult patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired vestibuloocular reflex (vor) n1=cyclopeptide | n2=en:impaired vestibuloocular reflex (vor) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired vision (in some patients) n1=cyclopeptide | n2=en:impaired vision (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired visual fields n1=cyclopeptide | n2=en:impaired visual fields | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impaired visually enhanced vestibuloocular reflex (vvor) n1=cyclopeptide | n2=en:impaired visually enhanced vestibuloocular reflex (vvor) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impairment of compensatory eye movement reflexes n1=cyclopeptide | n2=en:impairment of compensatory eye movement reflexes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impairment of dark adaptation with age n1=cyclopeptide | n2=en:impairment of dark adaptation with age | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:impairment of extraocular movement (in some patients) n1=cyclopeptide | n2=en:impairment of extraocular movement (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imperforate anus n1=cyclopeptide | n2=en:imperforate anus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imreg-1 n1=cyclopeptide | n2=en:imreg-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imt-1012 immunotherapeutic vaccine n1=cyclopeptide | n2=en:imt-1012 immunotherapeutic vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:imuvert n1=cyclopeptide | n2=en:imuvert | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in 111 folic acid n1=cyclopeptide | n2=en:in 111 folic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in 111 monoclonal antibody b3 n1=cyclopeptide | n2=en:in 111 monoclonal antibody b3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in 111 monoclonal antibody hu3s193 n1=cyclopeptide | n2=en:in 111 monoclonal antibody hu3s193 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in 111 monoclonal antibody ll2 n1=cyclopeptide | n2=en:in 111 monoclonal antibody ll2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in 111 monoclonal antibody lym-1 n1=cyclopeptide | n2=en:in 111 monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in 111 monoclonal antibody m170 n1=cyclopeptide | n2=en:in 111 monoclonal antibody m170 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in 111 monoclonal antibody mn-14 n1=cyclopeptide | n2=en:in 111 monoclonal antibody mn-14 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in 111 satumomab pendetide n1=cyclopeptide | n2=en:in 111 satumomab pendetide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in blood n1=cyclopeptide | n2=en:in blood | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in cerebrospinal fluid n1=cyclopeptide | n2=en:in cerebrospinal fluid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:in urine n1=cyclopeptide | n2=en:in urine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inability to fully close eyes during sleep n1=cyclopeptide | n2=en:inability to fully close eyes during sleep | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inability to raise eyes above horizontal midline n1=cyclopeptide | n2=en:inability to raise eyes above horizontal midline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inability to raise eyes above midline n1=cyclopeptide | n2=en:inability to raise eyes above midline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inability to raise one or both eyes above midline n1=cyclopeptide | n2=en:inability to raise one or both eyes above midline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inability to suppress vestibuloocular reflex (vor) n1=cyclopeptide | n2=en:inability to suppress vestibuloocular reflex (vor) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inaccurate saccades n1=cyclopeptide | n2=en:inaccurate saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inactivated poliovirus vaccine n1=cyclopeptide | n2=en:inactivated poliovirus vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inalimarev n1=cyclopeptide | n2=en:inalimarev | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:incomplete anencephaly, hemicrania n1=cyclopeptide | n2=en:incomplete anencephaly, hemicrania | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:incomplete eyelid closure n1=cyclopeptide | n2=en:incomplete eyelid closure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:incomplete freund's adjuvant n1=cyclopeptide | n2=en:incomplete freund's adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:incontinentia pigmenti n1=cyclopeptide | n2=en:incontinentia pigmenti | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased axial globe length n1=cyclopeptide | n2=en:increased axial globe length | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased axial length n1=cyclopeptide | n2=en:increased axial length | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased corneal thickness n1=cyclopeptide | n2=en:increased corneal thickness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased cup-to-disc ratio n1=cyclopeptide | n2=en:increased cup-to-disc ratio | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased density of the upper eyelid eyelashes n1=cyclopeptide | n2=en:increased density of the upper eyelid eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased error rates of antisaccades (50%) n1=cyclopeptide | n2=en:increased error rates of antisaccades (50%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased error rates of memory-guided saccades (40%) n1=cyclopeptide | n2=en:increased error rates of memory-guided saccades (40%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased intercanthal distance n1=cyclopeptide | n2=en:increased intercanthal distance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased intraocular pressure (in some patients) n1=cyclopeptide | n2=en:increased intraocular pressure (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased ocular axial length (35 mm vs. 24 mm in normal non-myopes) n1=cyclopeptide | n2=en:increased ocular axial length (35 mm vs. 24 mm in normal non-myopes) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased retinal vascular permeability n1=cyclopeptide | n2=en:increased retinal vascular permeability | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased retinal vascularity n1=cyclopeptide | n2=en:increased retinal vascularity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased vascular tortuosity (in some patients) n1=cyclopeptide | n2=en:increased vascular tortuosity (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:increased velocity of larger saccades n1=cyclopeptide | n2=en:increased velocity of larger saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:incyclinide n1=cyclopeptide | n2=en:incyclinide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:index myopia n1=cyclopeptide | n2=en:index myopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indibulin n1=cyclopeptide | n2=en:indibulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indicine-n-oxide n1=cyclopeptide | n2=en:indicine-n-oxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indinavir sulfate n1=cyclopeptide | n2=en:indinavir sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indisulam n1=cyclopeptide | n2=en:indisulam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 anti-cd45 monoclonal antibody bc8 n1=cyclopeptide | n2=en:indium in 111 anti-cd45 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 anti-egfr monoclonal antibody abt-806 n1=cyclopeptide | n2=en:indium in 111 anti-egfr monoclonal antibody abt-806 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 bevacizumab n1=cyclopeptide | n2=en:indium in 111 bevacizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 capromab pendetide n1=cyclopeptide | n2=en:indium in 111 capromab pendetide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 chimeric monoclonal antibody 806 n1=cyclopeptide | n2=en:indium in 111 chimeric monoclonal antibody 806 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 chx-a dtpa trastuzumab n1=cyclopeptide | n2=en:indium in 111 chx-a dtpa trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 girentuximab n1=cyclopeptide | n2=en:indium in 111 girentuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 her2-specific high-affinity protein aby-025 n1=cyclopeptide | n2=en:indium in 111 her2-specific high-affinity protein aby-025 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 monoclonal antibody bre-3 n1=cyclopeptide | n2=en:indium in 111 monoclonal antibody bre-3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 monoclonal antibody hupam4 n1=cyclopeptide | n2=en:indium in 111 monoclonal antibody hupam4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 pentetate n1=cyclopeptide | n2=en:indium in 111 pentetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111 pertuzumab n1=cyclopeptide | n2=en:indium in 111 pertuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111-cmd-193 n1=cyclopeptide | n2=en:indium in 111-cmd-193 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111-dota-biotin n1=cyclopeptide | n2=en:indium in 111-dota-biotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111-dota-di-hsg peptide imp-288 n1=cyclopeptide | n2=en:indium in 111-dota-di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111-dota-exendin-4 n1=cyclopeptide | n2=en:indium in 111-dota-exendin-4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111-labeled autologous peripheral blood mononuclear cells n1=cyclopeptide | n2=en:indium in 111-labeled autologous peripheral blood mononuclear cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111-labeled autologous polymorphonuclear leukocytes n1=cyclopeptide | n2=en:indium in 111-labeled autologous polymorphonuclear leukocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111-labeled macroaggregated albumin n1=cyclopeptide | n2=en:indium in 111-labeled macroaggregated albumin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in 111/yttrium y90-dota-biotin n1=cyclopeptide | n2=en:indium in 111/yttrium y90-dota-biotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in-111 ibritumomab tiuxetan n1=cyclopeptide | n2=en:indium in-111 ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indium in-111 pentetreotide n1=cyclopeptide | n2=en:indium in-111 pentetreotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indocyanine green solution n1=cyclopeptide | n2=en:indocyanine green solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indocyanine green/albumin solution n1=cyclopeptide | n2=en:indocyanine green/albumin solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indole-3-carbinol n1=cyclopeptide | n2=en:indole-3-carbinol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indole-3-carbinol/calcium/schizandra/vitamin d3/milk thistle/stinging nettle/lignan-based nutritional capsule n1=cyclopeptide | n2=en:indole-3-carbinol/calcium/schizandra/vitamin d3/milk thistle/stinging nettle/lignan-based nutritional capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indoleamine 2,3-dioxygenase peptide vaccine n1=cyclopeptide | n2=en:indoleamine 2,3-dioxygenase peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indomethacin n1=cyclopeptide | n2=en:indomethacin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:indoximod n1=cyclopeptide | n2=en:indoximod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inducible cd4+cd25+ regulatory t cells n1=cyclopeptide | n2=en:inducible cd4+cd25+ regulatory t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inecalcitol n1=cyclopeptide | n2=en:inecalcitol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:infantile cataract n1=cyclopeptide | n2=en:infantile cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:infantile nystagmus n1=cyclopeptide | n2=en:infantile nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:infectious conjunctivitis n1=cyclopeptide | n2=en:infectious conjunctivitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inferior and inferonasal retinal pigmentation (e.g. 180380.0004 and 180380.0025) n1=cyclopeptide | n2=en:inferior and inferonasal retinal pigmentation (e.g. 180380.0004 and 180380.0025) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inferonasal iris coloboma n1=cyclopeptide | n2=en:inferonasal iris coloboma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:infliximab n1=cyclopeptide | n2=en:infliximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:infliximab 100 mg injection n1=cyclopeptide | n2=en:infliximab 100 mg injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:infra-orbital crease n1=cyclopeptide | n2=en:infra-orbital crease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:infra-orbital fold n1=cyclopeptide | n2=en:infra-orbital fold | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ingenol derivative leo 43204 gel n1=cyclopeptide | n2=en:ingenol derivative leo 43204 gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ingenol mebutate n1=cyclopeptide | n2=en:ingenol mebutate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ingenol mebutate gel n1=cyclopeptide | n2=en:ingenol mebutate gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iniparib n1=cyclopeptide | n2=en:iniparib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:initial disturbance of central vision n1=cyclopeptide | n2=en:initial disturbance of central vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:initial loss of central visual acuity and color vision n1=cyclopeptide | n2=en:initial loss of central visual acuity and color vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:injectable astragalus membranaceus polysaccharide n1=cyclopeptide | n2=en:injectable astragalus membranaceus polysaccharide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:injectable liposomal vinorelbine n1=cyclopeptide | n2=en:injectable liposomal vinorelbine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:innate defense regulator sgx942 n1=cyclopeptide | n2=en:innate defense regulator sgx942 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:innate immunostimulator rbbx-01 n1=cyclopeptide | n2=en:innate immunostimulator rbbx-01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ino-1001 n1=cyclopeptide | n2=en:ino-1001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inosine 5'-monophosphate dehydrogenase inhibitor ff-10501-01 n1=cyclopeptide | n2=en:inosine 5'-monophosphate dehydrogenase inhibitor ff-10501-01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inosine dialdehyde n1=cyclopeptide | n2=en:inosine dialdehyde | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inosine pranobex n1=cyclopeptide | n2=en:inosine pranobex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inositol n1=cyclopeptide | n2=en:inositol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inotropic agent n1=cyclopeptide | n2=en:inotropic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inotuzumab ozogamicin n1=cyclopeptide | n2=en:inotuzumab ozogamicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inproquone n1=cyclopeptide | n2=en:inproquone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ins316 n1=cyclopeptide | n2=en:ins316 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:insidious, painless, nonpitting eyelid edema n1=cyclopeptide | n2=en:insidious, painless, nonpitting eyelid edema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:insulin aspart n1=cyclopeptide | n2=en:insulin aspart | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:insulin degludec n1=cyclopeptide | n2=en:insulin degludec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:insulin glargine n1=cyclopeptide | n2=en:insulin glargine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:insulin lispro n1=cyclopeptide | n2=en:insulin lispro | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:insulin sensitizer s-707106 n1=cyclopeptide | n2=en:insulin sensitizer s-707106 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:insulin, nph n1=cyclopeptide | n2=en:insulin, nph | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:insulin, regular n1=cyclopeptide | n2=en:insulin, regular | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:integrin receptor antagonist glpg0187 n1=cyclopeptide | n2=en:integrin receptor antagonist glpg0187 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interferon alfacon-1 n1=cyclopeptide | n2=en:interferon alfacon-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interferon beta-secreting mesenchymal stem cells n1=cyclopeptide | n2=en:interferon beta-secreting mesenchymal stem cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interferon-gamma-expressing adenovirus vaccine asn-002 n1=cyclopeptide | n2=en:interferon-gamma-expressing adenovirus vaccine asn-002 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interictal downbeat nystagmus n1=cyclopeptide | n2=en:interictal downbeat nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interleukin-10 n1=cyclopeptide | n2=en:interleukin-10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interleukin-12 gene n1=cyclopeptide | n2=en:interleukin-12 gene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interleukin-2 fusion protein msb0010445 n1=cyclopeptide | n2=en:interleukin-2 fusion protein msb0010445 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interleukin-2 gene n1=cyclopeptide | n2=en:interleukin-2 gene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interleukin-2 liposome n1=cyclopeptide | n2=en:interleukin-2 liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interleukin-4 pe38kdel immunotoxin n1=cyclopeptide | n2=en:interleukin-4 pe38kdel immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interleukin-6 n1=cyclopeptide | n2=en:interleukin-6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intermediate-affinity interleukin-2 receptor agonist alks 4230 n1=cyclopeptide | n2=en:intermediate-affinity interleukin-2 receptor agonist alks 4230 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:internal strabismus n1=cyclopeptide | n2=en:internal strabismus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:interpupillary:len:pt:face:qn n1=cyclopeptide | n2=en:interpupillary:len:pt:face:qn | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intestinal malrotation n1=cyclopeptide | n2=en:intestinal malrotation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intetumumab n1=cyclopeptide | n2=en:intetumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intiquinatine n1=cyclopeptide | n2=en:intiquinatine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intoplicine n1=cyclopeptide | n2=en:intoplicine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intranasal ketamine n1=cyclopeptide | n2=en:intranasal ketamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraocular part of central retinal artery n1=cyclopeptide | n2=en:intraocular part of central retinal artery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraocular part of central retinal vein n1=cyclopeptide | n2=en:intraocular part of central retinal vein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraocular pressure rise n1=cyclopeptide | n2=en:intraocular pressure rise | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraocular retrolental masses, bilateral ('pseudoglioma') n1=cyclopeptide | n2=en:intraocular retrolental masses, bilateral ('pseudoglioma') | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraretinal and subretinal fluid in cystic spaces with splitting of retina on oct n1=cyclopeptide | n2=en:intraretinal and subretinal fluid in cystic spaces with splitting of retina on oct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraretinal bone spicule pigmentation n1=cyclopeptide | n2=en:intraretinal bone spicule pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraretinal bone-spicule pigment n1=cyclopeptide | n2=en:intraretinal bone-spicule pigment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraretinal pigment deposition extending to posterior pole (in some patients) n1=cyclopeptide | n2=en:intraretinal pigment deposition extending to posterior pole (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraretinal pigmentation n1=cyclopeptide | n2=en:intraretinal pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraretinal pigmentation in the midperiphery n1=cyclopeptide | n2=en:intraretinal pigmentation in the midperiphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intraretinal splitting n1=cyclopeptide | n2=en:intraretinal splitting | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:intravesical bcg n1=cyclopeptide | n2=en:intravesical bcg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:inulin n1=cyclopeptide | n2=en:inulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:investigational new drug n1=cyclopeptide | n2=en:investigational new drug | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:involuntary spasms of eyelid closure (blepharospasm) n1=cyclopeptide | n2=en:involuntary spasms of eyelid closure (blepharospasm) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iobenguane i-124 n1=cyclopeptide | n2=en:iobenguane i-124 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iobenguane i-131 n1=cyclopeptide | n2=en:iobenguane i-131 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iobenguane sulfate i-123 n1=cyclopeptide | n2=en:iobenguane sulfate i-123 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iobitridol n1=cyclopeptide | n2=en:iobitridol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodinated contrast agent n1=cyclopeptide | n2=en:iodinated contrast agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine 131-6-beta-iodomethyl-19-norcholesterol n1=cyclopeptide | n2=en:iodine 131-6-beta-iodomethyl-19-norcholesterol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine compounds n1=cyclopeptide | n2=en:iodine compounds | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 123 anti-cea recombinant diabody t84.66 n1=cyclopeptide | n2=en:iodine i 123 anti-cea recombinant diabody t84.66 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 123 iodobenzamide n1=cyclopeptide | n2=en:iodine i 123 iodobenzamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 n1=cyclopeptide | n2=en:iodine i 124 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 anti-phosphatidylserine monoclonal antibody pgn650 n1=cyclopeptide | n2=en:iodine i 124 anti-phosphatidylserine monoclonal antibody pgn650 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 cpd-1028 n1=cyclopeptide | n2=en:iodine i 124 cpd-1028 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 iododeoxyuridine n1=cyclopeptide | n2=en:iodine i 124 iododeoxyuridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 monoclonal antibody 3f8 n1=cyclopeptide | n2=en:iodine i 124 monoclonal antibody 3f8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 monoclonal antibody 8h9 n1=cyclopeptide | n2=en:iodine i 124 monoclonal antibody 8h9 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 monoclonal antibody a33 n1=cyclopeptide | n2=en:iodine i 124 monoclonal antibody a33 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 nm404 n1=cyclopeptide | n2=en:iodine i 124 nm404 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 phospholipid ether analogue clr1404 n1=cyclopeptide | n2=en:iodine i 124 phospholipid ether analogue clr1404 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124 pu-ad n1=cyclopeptide | n2=en:iodine i 124 pu-ad | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124-crgdy-peg-c dots n1=cyclopeptide | n2=en:iodine i 124-crgdy-peg-c dots | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124-iodo-azomycin galactopyranoside n1=cyclopeptide | n2=en:iodine i 124-iodo-azomycin galactopyranoside | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124-labeled anti-psca a11 minibody n1=cyclopeptide | n2=en:iodine i 124-labeled anti-psca a11 minibody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 124-labeled hsp90 inhibitor puh71 n1=cyclopeptide | n2=en:iodine i 124-labeled hsp90 inhibitor puh71 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 125-anti-egfr-425 monoclonal antibody n1=cyclopeptide | n2=en:iodine i 125-anti-egfr-425 monoclonal antibody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 anti-fibronectin antibody fragment l19-sip n1=cyclopeptide | n2=en:iodine i 131 anti-fibronectin antibody fragment l19-sip | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 ethiodized oil n1=cyclopeptide | n2=en:iodine i 131 ethiodized oil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody 3f8 n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody 3f8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody 81c6 n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody 81c6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody 8h9 n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody 8h9 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody bc8 n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody cc49-deltach2 n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody cc49-deltach2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody f16sip n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody f16sip | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody g-250 n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody g-250 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody muj591 n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody muj591 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 monoclonal antibody tnt-1/b n1=cyclopeptide | n2=en:iodine i 131 monoclonal antibody tnt-1/b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 nm404 n1=cyclopeptide | n2=en:iodine i 131 nm404 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 phospholipid ether analogue clr1404 n1=cyclopeptide | n2=en:iodine i 131 phospholipid ether analogue clr1404 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 rituximab n1=cyclopeptide | n2=en:iodine i 131 rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 sgmib-anti-her2 vhh1 n1=cyclopeptide | n2=en:iodine i 131 sgmib-anti-her2 vhh1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 tenatumomab n1=cyclopeptide | n2=en:iodine i 131 tenatumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 tm-601 n1=cyclopeptide | n2=en:iodine i 131 tm-601 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131 tositumomab n1=cyclopeptide | n2=en:iodine i 131 tositumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i 131-labeled anti-cea/anti-hsg bispecific monoclonal antibody tf2 n1=cyclopeptide | n2=en:iodine i 131-labeled anti-cea/anti-hsg bispecific monoclonal antibody tf2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i-123 n1=cyclopeptide | n2=en:iodine i-123 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i-123 adam n1=cyclopeptide | n2=en:iodine i-123 adam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i-123 iodometomidate n1=cyclopeptide | n2=en:iodine i-123 iodometomidate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i-123 mip-1095 n1=cyclopeptide | n2=en:iodine i-123 mip-1095 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i-124 fiau n1=cyclopeptide | n2=en:iodine i-124 fiau | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i-124 girentuximab n1=cyclopeptide | n2=en:iodine i-124 girentuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i-125 n1=cyclopeptide | n2=en:iodine i-125 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine i-131 n1=cyclopeptide | n2=en:iodine i-131 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodine norcholestenol n1=cyclopeptide | n2=en:iodine norcholestenol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodixanol n1=cyclopeptide | n2=en:iodixanol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodocholesterol i^131^ n1=cyclopeptide | n2=en:iodocholesterol i^131^ | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodocyclophosphamide n1=cyclopeptide | n2=en:iodocyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iodophore product n1=cyclopeptide | n2=en:iodophore product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ioflubenzamide i-131 n1=cyclopeptide | n2=en:ioflubenzamide i-131 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iofolastat i123 n1=cyclopeptide | n2=en:iofolastat i123 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iohexol n1=cyclopeptide | n2=en:iohexol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ionic silver-impregnated sodium carboxymethylcellulose antimicrobial dressing n1=cyclopeptide | n2=en:ionic silver-impregnated sodium carboxymethylcellulose antimicrobial dressing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ionomycin n1=cyclopeptide | n2=en:ionomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iopromide n1=cyclopeptide | n2=en:iopromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ipafricept n1=cyclopeptide | n2=en:ipafricept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ipamorelin n1=cyclopeptide | n2=en:ipamorelin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ipatasertib n1=cyclopeptide | n2=en:ipatasertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ipilimumab n1=cyclopeptide | n2=en:ipilimumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ipomeanol n1=cyclopeptide | n2=en:ipomeanol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ipp-204106n n1=cyclopeptide | n2=en:ipp-204106n | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iproplatin n1=cyclopeptide | n2=en:iproplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iratumumab n1=cyclopeptide | n2=en:iratumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irides blue-gray to light brown n1=cyclopeptide | n2=en:irides blue-gray to light brown | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridescent posterior subcapsular cataract n1=cyclopeptide | n2=en:iridescent posterior subcapsular cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridium ir 192 n1=cyclopeptide | n2=en:iridium ir 192 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irido-corneal dysgenesis n1=cyclopeptide | n2=en:irido-corneal dysgenesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irido-corneo-trabecular dysgenesis (disorder) n1=cyclopeptide | n2=en:irido-corneo-trabecular dysgenesis (disorder) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridocorneal adhesions n1=cyclopeptide | n2=en:iridocorneal adhesions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridocorneal adhesions with overlying corneal opacity (peters anomaly) n1=cyclopeptide | n2=en:iridocorneal adhesions with overlying corneal opacity (peters anomaly) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridocorneal angle maldevelopment n1=cyclopeptide | n2=en:iridocorneal angle maldevelopment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridocorneal dysgenesis (in some patients) n1=cyclopeptide | n2=en:iridocorneal dysgenesis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridocorneal synechiae (in some patients) prominent or irregular schwalbe line (in some patients) n1=cyclopeptide | n2=en:iridocorneal synechiae (in some patients) prominent or irregular schwalbe line (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridocyclitis n1=cyclopeptide | n2=en:iridocyclitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridodonesis n1=cyclopeptide | n2=en:iridodonesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridodonesis (in some patients) n1=cyclopeptide | n2=en:iridodonesis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridogoniodysgenesis (rare) n1=cyclopeptide | n2=en:iridogoniodysgenesis (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iridoretinal coloboma n1=cyclopeptide | n2=en:iridoretinal coloboma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irinotecan n1=cyclopeptide | n2=en:irinotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irinotecan hydrochloride n1=cyclopeptide | n2=en:irinotecan hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irinotecan-eluting beads n1=cyclopeptide | n2=en:irinotecan-eluting beads | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irinotecan/p-glycoprotein inhibitor hm30181ak combination tablet n1=cyclopeptide | n2=en:irinotecan/p-glycoprotein inhibitor hm30181ak combination tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris n1=cyclopeptide | n2=en:iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris and choroid disorders congenital n1=cyclopeptide | n2=en:iris and choroid disorders congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris color blue to brown n1=cyclopeptide | n2=en:iris color blue to brown | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris crypts and clefts underdeveloped n1=cyclopeptide | n2=en:iris crypts and clefts underdeveloped | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris discoloration n1=cyclopeptide | n2=en:iris discoloration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris dysplasia (goniodysgenesis) n1=cyclopeptide | n2=en:iris dysplasia (goniodysgenesis) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris hypoperfusion resulting from degenerated stromal vessels n1=cyclopeptide | n2=en:iris hypoperfusion resulting from degenerated stromal vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris hypopigmentation n1=cyclopeptide | n2=en:iris hypopigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris hypoplasia (in some patients) n1=cyclopeptide | n2=en:iris hypoplasia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris hypoplasia, partial n1=cyclopeptide | n2=en:iris hypoplasia, partial | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris malformation or hypoplasia (wws) n1=cyclopeptide | n2=en:iris malformation or hypoplasia (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris pigment epithelial cyst n1=cyclopeptide | n2=en:iris pigment epithelial cyst | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris rigidity n1=cyclopeptide | n2=en:iris rigidity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris strands attached to schwalbe line bridging the iridocorneal angle n1=cyclopeptide | n2=en:iris strands attached to schwalbe line bridging the iridocorneal angle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris stromal atrophy n1=cyclopeptide | n2=en:iris stromal atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris stromal atrophy (rare) n1=cyclopeptide | n2=en:iris stromal atrophy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris transillumination n1=cyclopeptide | n2=en:iris transillumination | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris transillumination (variable) n1=cyclopeptide | n2=en:iris transillumination (variable) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iris transillumination with pigment dispersion n1=cyclopeptide | n2=en:iris transillumination with pigment dispersion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iritis n1=cyclopeptide | n2=en:iritis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irofulven n1=cyclopeptide | n2=en:irofulven | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iron n1=cyclopeptide | n2=en:iron | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iron dextran complex n1=cyclopeptide | n2=en:iron dextran complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iron isomaltoside 1000 n1=cyclopeptide | n2=en:iron isomaltoside 1000 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iron sucrose injection n1=cyclopeptide | n2=en:iron sucrose injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irosustat n1=cyclopeptide | n2=en:irosustat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irregular eyebrows n1=cyclopeptide | n2=en:irregular eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irregular macular reflex (in some patients) n1=cyclopeptide | n2=en:irregular macular reflex (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irregular nystagmus n1=cyclopeptide | n2=en:irregular nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irregular pigmentation of fovea with atrophy of rpe (in some patients) n1=cyclopeptide | n2=en:irregular pigmentation of fovea with atrophy of rpe (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irregular pigmentation of fundus (in carrier females) n1=cyclopeptide | n2=en:irregular pigmentation of fundus (in carrier females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irregular pursuit n1=cyclopeptide | n2=en:irregular pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irregular white dots at the vitreoretinal interface n1=cyclopeptide | n2=en:irregular white dots at the vitreoretinal interface | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irritants n1=cyclopeptide | n2=en:irritants | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irritation of eye with itching (in some patients) n1=cyclopeptide | n2=en:irritation of eye with itching (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:irx-2 n1=cyclopeptide | n2=en:irx-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isavuconazole n1=cyclopeptide | n2=en:isavuconazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iseganan hydrochloride n1=cyclopeptide | n2=en:iseganan hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isis 2503 n1=cyclopeptide | n2=en:isis 2503 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isis 3521 n1=cyclopeptide | n2=en:isis 3521 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isis 5132 n1=cyclopeptide | n2=en:isis 5132 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iso-fludelone n1=cyclopeptide | n2=en:iso-fludelone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isoflurane n1=cyclopeptide | n2=en:isoflurane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isoniazid n1=cyclopeptide | n2=en:isoniazid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isoquercetin n1=cyclopeptide | n2=en:isoquercetin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isosulfan blue n1=cyclopeptide | n2=en:isosulfan blue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isotretinoin n1=cyclopeptide | n2=en:isotretinoin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:isoxazoles n1=cyclopeptide | n2=en:isoxazoles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ispinesib n1=cyclopeptide | n2=en:ispinesib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:iss 1018 cpg oligodeoxynucleotide n1=cyclopeptide | n2=en:iss 1018 cpg oligodeoxynucleotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:itraconazole n1=cyclopeptide | n2=en:itraconazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:itraconazole dispersion in polymer matrix n1=cyclopeptide | n2=en:itraconazole dispersion in polymer matrix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ivabradine n1=cyclopeptide | n2=en:ivabradine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ivac mutanome vaccine n1=cyclopeptide | n2=en:ivac mutanome vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ivad protocol n1=cyclopeptide | n2=en:ivad protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ixabepilone n1=cyclopeptide | n2=en:ixabepilone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ixazomib citrate n1=cyclopeptide | n2=en:ixazomib citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:j5 antiserum n1=cyclopeptide | n2=en:j5 antiserum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jac protocol n1=cyclopeptide | n2=en:jac protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak inhibitor incb047986 n1=cyclopeptide | n2=en:jak inhibitor incb047986 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak1 inhibitor incb039110 n1=cyclopeptide | n2=en:jak1 inhibitor incb039110 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak1 inhibitor incb052793 n1=cyclopeptide | n2=en:jak1 inhibitor incb052793 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak2 inhibitor azd1480 n1=cyclopeptide | n2=en:jak2 inhibitor azd1480 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak2 inhibitor bms-911543 n1=cyclopeptide | n2=en:jak2 inhibitor bms-911543 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak2 inhibitor tg101348 n1=cyclopeptide | n2=en:jak2 inhibitor tg101348 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak2 inhibitor wp1066 n1=cyclopeptide | n2=en:jak2 inhibitor wp1066 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak2 inhibitor xl019 n1=cyclopeptide | n2=en:jak2 inhibitor xl019 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jak2/src inhibitor ns-018 n1=cyclopeptide | n2=en:jak2/src inhibitor ns-018 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jaundice n1=cyclopeptide | n2=en:jaundice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jeb regimen n1=cyclopeptide | n2=en:jeb regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jerky ocular pursuit movements n1=cyclopeptide | n2=en:jerky ocular pursuit movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jerky saccades n1=cyclopeptide | n2=en:jerky saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jerky smooth pursuit (in some patients) n1=cyclopeptide | n2=en:jerky smooth pursuit (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:jin fu kang n1=cyclopeptide | n2=en:jin fu kang | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:juven n1=cyclopeptide | n2=en:juven | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:juvenile cataract n1=cyclopeptide | n2=en:juvenile cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:juvenile cortical cataract n1=cyclopeptide | n2=en:juvenile cortical cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:juvenile posterior subcapsular lenticular opacities n1=cyclopeptide | n2=en:juvenile posterior subcapsular lenticular opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:juvenile zonular cataracts n1=cyclopeptide | n2=en:juvenile zonular cataracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:kanamycin sulfate n1=cyclopeptide | n2=en:kanamycin sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:kanglaite n1=cyclopeptide | n2=en:kanglaite | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:kava-based supplement n1=cyclopeptide | n2=en:kava-based supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:kayser-fleischer ring n1=cyclopeptide | n2=en:kayser-fleischer ring | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:kbg syndrome n1=cyclopeptide | n2=en:kbg syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratitis n1=cyclopeptide | n2=en:keratitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratitis-ichthyosis-deafness syndrome n1=cyclopeptide | n2=en:keratitis-ichthyosis-deafness syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratoconjunctivitis n1=cyclopeptide | n2=en:keratoconjunctivitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratoconjunctivitis sicca n1=cyclopeptide | n2=en:keratoconjunctivitis sicca | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratoconus n1=cyclopeptide | n2=en:keratoconus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratoconus (in some patients) n1=cyclopeptide | n2=en:keratoconus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratoconus (less common) n1=cyclopeptide | n2=en:keratoconus (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratoconus, bilateral n1=cyclopeptide | n2=en:keratoconus, bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratoconus, severe anterior (in some patients) n1=cyclopeptide | n2=en:keratoconus, severe anterior (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratoglobus n1=cyclopeptide | n2=en:keratoglobus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keratopathy n1=cyclopeptide | n2=en:keratopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ketamine hydrochloride n1=cyclopeptide | n2=en:ketamine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ketamine/amitriptyline np-h cream n1=cyclopeptide | n2=en:ketamine/amitriptyline np-h cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ketoconazole n1=cyclopeptide | n2=en:ketoconazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ketoprofen n1=cyclopeptide | n2=en:ketoprofen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ketorolac n1=cyclopeptide | n2=en:ketorolac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ketorolac + phenylephrine n1=cyclopeptide | n2=en:ketorolac + phenylephrine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ketorolac tromethamine n1=cyclopeptide | n2=en:ketorolac tromethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:keyhole limpet hemocyanin n1=cyclopeptide | n2=en:keyhole limpet hemocyanin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:kit/pdgfr inhibitor dcc-2618 n1=cyclopeptide | n2=en:kit/pdgfr inhibitor dcc-2618 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:klebsiella pneumoniae glycoprotein n1=cyclopeptide | n2=en:klebsiella pneumoniae glycoprotein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:klh-fitc n1=cyclopeptide | n2=en:klh-fitc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:known or suspected fetal abnormality affecting management of mother n1=cyclopeptide | n2=en:known or suspected fetal abnormality affecting management of mother | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:krn5500 n1=cyclopeptide | n2=en:krn5500 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ksa-klh conjugate vaccine n1=cyclopeptide | n2=en:ksa-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ksp inhibitor arry-520 n1=cyclopeptide | n2=en:ksp inhibitor arry-520 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ksp inhibitor azd4877 n1=cyclopeptide | n2=en:ksp inhibitor azd4877 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:kunecatechins ointment n1=cyclopeptide | n2=en:kunecatechins ointment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:kw-2149 n1=cyclopeptide | n2=en:kw-2149 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-377,202 n1=cyclopeptide | n2=en:l-377,202 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-4-chlorokynurenine n1=cyclopeptide | n2=en:l-4-chlorokynurenine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-6 protocol n1=cyclopeptide | n2=en:l-6 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-778,123 n1=cyclopeptide | n2=en:l-778,123 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-arginine/korean ginseng/ginkgo biloba/damiana-based supplement n1=cyclopeptide | n2=en:l-arginine/korean ginseng/ginkgo biloba/damiana-based supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-carnitine l-tartrate n1=cyclopeptide | n2=en:l-carnitine l-tartrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-gossypol n1=cyclopeptide | n2=en:l-gossypol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-leucyl-l-leucine methyl ester n1=cyclopeptide | n2=en:l-leucyl-l-leucine methyl ester | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-lysine n1=cyclopeptide | n2=en:l-lysine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-menthol preparation npo-11 n1=cyclopeptide | n2=en:l-menthol preparation npo-11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-methylfolate n1=cyclopeptide | n2=en:l-methylfolate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-ornithine l-aspartate n1=cyclopeptide | n2=en:l-ornithine l-aspartate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l-tryptophan/thymine-based supplement n1=cyclopeptide | n2=en:l-tryptophan/thymine-based supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:l19-il2 monoclonal antibody-cytokine fusion protein n1=cyclopeptide | n2=en:l19-il2 monoclonal antibody-cytokine fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:labetuzumab-sn-38 immunoconjugate immu-130 n1=cyclopeptide | n2=en:labetuzumab-sn-38 immunoconjugate immu-130 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:labradimil n1=cyclopeptide | n2=en:labradimil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of blink reflex (in some patients) n1=cyclopeptide | n2=en:lack of blink reflex (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of fixation n1=cyclopeptide | n2=en:lack of fixation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of foveal reflex n1=cyclopeptide | n2=en:lack of foveal reflex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of ocular fixation (1 patient) n1=cyclopeptide | n2=en:lack of ocular fixation (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of photoreceptors in fovea by optical coherence tomography n1=cyclopeptide | n2=en:lack of photoreceptors in fovea by optical coherence tomography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of pupillary dilation in the dark n1=cyclopeptide | n2=en:lack of pupillary dilation in the dark | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of visual contact n1=cyclopeptide | n2=en:lack of visual contact | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of visual fixation n1=cyclopeptide | n2=en:lack of visual fixation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lack of visual tracking n1=cyclopeptide | n2=en:lack of visual tracking | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacosamide n1=cyclopeptide | n2=en:lacosamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal apparatus n1=cyclopeptide | n2=en:lacrimal apparatus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal duct n1=cyclopeptide | n2=en:lacrimal duct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal duct aplasia or stenosis (25% of patients) n1=cyclopeptide | n2=en:lacrimal duct aplasia or stenosis (25% of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal duct defect n1=cyclopeptide | n2=en:lacrimal duct defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal duct fistula (in some patients) n1=cyclopeptide | n2=en:lacrimal duct fistula (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal duct imperforation (rare) n1=cyclopeptide | n2=en:lacrimal duct imperforation (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal duct obstruction n1=cyclopeptide | n2=en:lacrimal duct obstruction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal duct obstruction (in some patients) n1=cyclopeptide | n2=en:lacrimal duct obstruction (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal gland n1=cyclopeptide | n2=en:lacrimal gland | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal gland aplasia/hypoplasia n1=cyclopeptide | n2=en:lacrimal gland aplasia/hypoplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal gland hypoplasia n1=cyclopeptide | n2=en:lacrimal gland hypoplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal mucocele n1=cyclopeptide | n2=en:lacrimal mucocele | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal puncta, absence of n1=cyclopeptide | n2=en:lacrimal puncta, absence of | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimal sac fistula n1=cyclopeptide | n2=en:lacrimal sac fistula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimation (early symptom) n1=cyclopeptide | n2=en:lacrimation (early symptom) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimation, episodic n1=cyclopeptide | n2=en:lacrimation, episodic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacrimation, ipsilateral n1=cyclopeptide | n2=en:lacrimation, ipsilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactated ringer solution n1=cyclopeptide | n2=en:lactated ringer solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus acidophilus n1=cyclopeptide | n2=en:lactobacillus acidophilus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus acidophilus/estriol vaginal tablet n1=cyclopeptide | n2=en:lactobacillus acidophilus/estriol vaginal tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus acidophilus/streptococcus thermophilus/bifidobacterium lactis/l. rhamnosus/b. longum/b. bifidum-based probiotic supplement n1=cyclopeptide | n2=en:lactobacillus acidophilus/streptococcus thermophilus/bifidobacterium lactis/l. rhamnosus/b. longum/b. bifidum-based probiotic supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus brevis cd2 lozenge n1=cyclopeptide | n2=en:lactobacillus brevis cd2 lozenge | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus fermented extract n1=cyclopeptide | n2=en:lactobacillus fermented extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus plantarum 299v/lactobacillus acidophilus/bifidobacterium lactis probiotic supplement n1=cyclopeptide | n2=en:lactobacillus plantarum 299v/lactobacillus acidophilus/bifidobacterium lactis probiotic supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus plantarum strain 299 n1=cyclopeptide | n2=en:lactobacillus plantarum strain 299 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus plantarum strain 299v n1=cyclopeptide | n2=en:lactobacillus plantarum strain 299v | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus rhamnosus gg n1=cyclopeptide | n2=en:lactobacillus rhamnosus gg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus rhamnosus/l. jensenii/l. crispatus/l. gasseri oral supplement n1=cyclopeptide | n2=en:lactobacillus rhamnosus/l. jensenii/l. crispatus/l. gasseri oral supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactobacillus-based probiotic capsule n1=cyclopeptide | n2=en:lactobacillus-based probiotic capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactoferrin-derived lytic peptide ltx-315 n1=cyclopeptide | n2=en:lactoferrin-derived lytic peptide ltx-315 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lactoperoxidase/lysozyme/lactoferrin-based prebiotic vaginal lubricant n1=cyclopeptide | n2=en:lactoperoxidase/lysozyme/lactoferrin-based prebiotic vaginal lubricant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lacunar retinal depigmentation (rare) n1=cyclopeptide | n2=en:lacunar retinal depigmentation (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laetrile n1=cyclopeptide | n2=en:laetrile | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laflunimus n1=cyclopeptide | n2=en:laflunimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lagophthalmos n1=cyclopeptide | n2=en:lagophthalmos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lagophthalmos (rare) n1=cyclopeptide | n2=en:lagophthalmos (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lala 87 protocol n1=cyclopeptide | n2=en:lala 87 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lamellar body mimetic mouth spray lms-611 n1=cyclopeptide | n2=en:lamellar body mimetic mouth spray lms-611 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lamivudine n1=cyclopeptide | n2=en:lamivudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lamotrigine n1=cyclopeptide | n2=en:lamotrigine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laniquidar n1=cyclopeptide | n2=en:laniquidar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lanreotide acetate n1=cyclopeptide | n2=en:lanreotide acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lanreotide acetate copolymer microparticles n1=cyclopeptide | n2=en:lanreotide acetate copolymer microparticles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lanreotide long-acting aqueous gel n1=cyclopeptide | n2=en:lanreotide long-acting aqueous gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lapachone n1=cyclopeptide | n2=en:lapachone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lapatinib ditosylate n1=cyclopeptide | n2=en:lapatinib ditosylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lapuleucel-t n1=cyclopeptide | n2=en:lapuleucel-t | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:large corneae n1=cyclopeptide | n2=en:large corneae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:large eyebrows n1=cyclopeptide | n2=en:large eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:large eyes n1=cyclopeptide | n2=en:large eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:large optic discs n1=cyclopeptide | n2=en:large optic discs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:large prominent eyes n1=cyclopeptide | n2=en:large prominent eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:large-appearing eyes n1=cyclopeptide | n2=en:large-appearing eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:large, prominent eyebrow n1=cyclopeptide | n2=en:large, prominent eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:largetrifoliolious bugbane rhizome supplement n1=cyclopeptide | n2=en:largetrifoliolious bugbane rhizome supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:larnygeotracheoesophageal cleft n1=cyclopeptide | n2=en:larnygeotracheoesophageal cleft | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laromustine n1=cyclopeptide | n2=en:laromustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laronidase n1=cyclopeptide | n2=en:laronidase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:larotaxel n1=cyclopeptide | n2=en:larotaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:larson regimen n1=cyclopeptide | n2=en:larson regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laryngeal atresia n1=cyclopeptide | n2=en:laryngeal atresia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laryngocele n1=cyclopeptide | n2=en:laryngocele | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:las41007 n1=cyclopeptide | n2=en:las41007 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lasw1510 n1=cyclopeptide | n2=en:lasw1510 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:late onset congenital glaucoma n1=cyclopeptide | n2=en:late onset congenital glaucoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:late subepithelial band keratopathy n1=cyclopeptide | n2=en:late subepithelial band keratopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:late-onset corneal degeneration n1=cyclopeptide | n2=en:late-onset corneal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lateral displacement of inner canthi n1=cyclopeptide | n2=en:lateral displacement of inner canthi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lateral displacement of medial canthi n1=cyclopeptide | n2=en:lateral displacement of medial canthi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lateral palpebral commissure n1=cyclopeptide | n2=en:lateral palpebral commissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laterally curved eyebrow n1=cyclopeptide | n2=en:laterally curved eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laterally displaced inner canthi (dystopia canthorum) (95 to 99%) n1=cyclopeptide | n2=en:laterally displaced inner canthi (dystopia canthorum) (95 to 99%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:laterally placed eyebrows n1=cyclopeptide | n2=en:laterally placed eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lawsone n1=cyclopeptide | n2=en:lawsone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lead pb 212 tcmc-trastuzumab n1=cyclopeptide | n2=en:lead pb 212 tcmc-trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leber congenital amaurosis n1=cyclopeptide | n2=en:leber congenital amaurosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leber congenital amaurosis (in some patients) n1=cyclopeptide | n2=en:leber congenital amaurosis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leflunomide n1=cyclopeptide | n2=en:leflunomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:left eye n1=cyclopeptide | n2=en:left eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:left eyeball n1=cyclopeptide | n2=en:left eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:legal blindness in early adulthood (in some patients) n1=cyclopeptide | n2=en:legal blindness in early adulthood (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lenalidomide n1=cyclopeptide | n2=en:lenalidomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lenapenem n1=cyclopeptide | n2=en:lenapenem | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lenograstim n1=cyclopeptide | n2=en:lenograstim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens n1=cyclopeptide | n2=en:lens | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens instability (in some patients) n1=cyclopeptide | n2=en:lens instability (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens opacities n1=cyclopeptide | n2=en:lens opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens opacities (type ii, infantile and juvenile) n1=cyclopeptide | n2=en:lens opacities (type ii, infantile and juvenile) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens opacity (rare) n1=cyclopeptide | n2=en:lens opacity (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens opacity, mild (in some patients) n1=cyclopeptide | n2=en:lens opacity, mild (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens subluxation n1=cyclopeptide | n2=en:lens subluxation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens subluxation (in some patients) n1=cyclopeptide | n2=en:lens subluxation (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lens subluxation or dislocation n1=cyclopeptide | n2=en:lens subluxation or dislocation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lenti-d/abcd1-transduced autologous hematopoietic stem cells n1=cyclopeptide | n2=en:lenti-d/abcd1-transduced autologous hematopoietic stem cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lenticular 'spoke-like' opacities n1=cyclopeptide | n2=en:lenticular 'spoke-like' opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lentivirus vector ccr5 shrna/trim5alpha/tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells n1=cyclopeptide | n2=en:lentivirus vector ccr5 shrna/trim5alpha/tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells n1=cyclopeptide | n2=en:lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lenvatinib mesylate n1=cyclopeptide | n2=en:lenvatinib mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lenzilumab n1=cyclopeptide | n2=en:lenzilumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lepirudin n1=cyclopeptide | n2=en:lepirudin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leridistim n1=cyclopeptide | n2=en:leridistim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lerisetron n1=cyclopeptide | n2=en:lerisetron | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lesinurad n1=cyclopeptide | n2=en:lesinurad | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lesions may involve cornea (in some patients) n1=cyclopeptide | n2=en:lesions may involve cornea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lestaurtinib n1=cyclopeptide | n2=en:lestaurtinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:letermovir n1=cyclopeptide | n2=en:letermovir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:letrozole n1=cyclopeptide | n2=en:letrozole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leucine-enhanced essential amino acid dietary supplement n1=cyclopeptide | n2=en:leucine-enhanced essential amino acid dietary supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leucovorin calcium n1=cyclopeptide | n2=en:leucovorin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leukemic apoptotic corpse-pulsed autologous dendritic cells n1=cyclopeptide | n2=en:leukemic apoptotic corpse-pulsed autologous dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leukocoria n1=cyclopeptide | n2=en:leukocoria | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leuprolide n1=cyclopeptide | n2=en:leuprolide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leuprolide acetate n1=cyclopeptide | n2=en:leuprolide acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:leuprolide mesylate injectable suspension n1=cyclopeptide | n2=en:leuprolide mesylate injectable suspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levamisole hydrochloride n1=cyclopeptide | n2=en:levamisole hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levetiracetam n1=cyclopeptide | n2=en:levetiracetam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levobupivacaine hydrochloride n1=cyclopeptide | n2=en:levobupivacaine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levocarnitine n1=cyclopeptide | n2=en:levocarnitine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levocetirizine dihydrochloride n1=cyclopeptide | n2=en:levocetirizine dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levodopa n1=cyclopeptide | n2=en:levodopa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levofloxacin n1=cyclopeptide | n2=en:levofloxacin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levoleucovorin n1=cyclopeptide | n2=en:levoleucovorin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levoleucovorin calcium n1=cyclopeptide | n2=en:levoleucovorin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levonantradol n1=cyclopeptide | n2=en:levonantradol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levonorgestrel n1=cyclopeptide | n2=en:levonorgestrel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levonorgestrel-releasing intrauterine system n1=cyclopeptide | n2=en:levonorgestrel-releasing intrauterine system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:levothyroxine sodium n1=cyclopeptide | n2=en:levothyroxine sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lexatumumab n1=cyclopeptide | n2=en:lexatumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lexibulin n1=cyclopeptide | n2=en:lexibulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liarozole fumarate n1=cyclopeptide | n2=en:liarozole fumarate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:licartin n1=cyclopeptide | n2=en:licartin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lid lipodermoid n1=cyclopeptide | n2=en:lid lipodermoid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lidocaine n1=cyclopeptide | n2=en:lidocaine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lidocaine patch n1=cyclopeptide | n2=en:lidocaine patch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lifelong reduced visual acuity, legal blindness to low vision n1=cyclopeptide | n2=en:lifelong reduced visual acuity, legal blindness to low vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:light blue irides n1=cyclopeptide | n2=en:light blue irides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:light-colored eyes n1=cyclopeptide | n2=en:light-colored eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:light-emitting oncolytic vaccinia virus gl-onc1 n1=cyclopeptide | n2=en:light-emitting oncolytic vaccinia virus gl-onc1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ligneous conjunctivitis n1=cyclopeptide | n2=en:ligneous conjunctivitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limb deformities, congenital n1=cyclopeptide | n2=en:limb deformities, congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limbal stem cell deficiency n1=cyclopeptide | n2=en:limbal stem cell deficiency | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limbal stem cell insufficiency n1=cyclopeptide | n2=en:limbal stem cell insufficiency | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limbitis n1=cyclopeptide | n2=en:limbitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limited extraocular movements n1=cyclopeptide | n2=en:limited extraocular movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limited extraocular movements (1 family) n1=cyclopeptide | n2=en:limited extraocular movements (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limited eyelid closure (1/4 patients) n1=cyclopeptide | n2=en:limited eyelid closure (1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limited ocular function n1=cyclopeptide | n2=en:limited ocular function | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limited vision n1=cyclopeptide | n2=en:limited vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:limonene n1=cyclopeptide | n2=en:limonene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:linaclotide acetate n1=cyclopeptide | n2=en:linaclotide acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:linagliptin + metformin n1=cyclopeptide | n2=en:linagliptin + metformin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:linear deposition of pale material in foveal area n1=cyclopeptide | n2=en:linear deposition of pale material in foveal area | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:linezolid n1=cyclopeptide | n2=en:linezolid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:linifanib n1=cyclopeptide | n2=en:linifanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:linoleyl carbonate-paclitaxel n1=cyclopeptide | n2=en:linoleyl carbonate-paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:linsitinib n1=cyclopeptide | n2=en:linsitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lintuzumab n1=cyclopeptide | n2=en:lintuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liothyronine n1=cyclopeptide | n2=en:liothyronine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liothyronine i-131 n1=cyclopeptide | n2=en:liothyronine i-131 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liothyronine sodium n1=cyclopeptide | n2=en:liothyronine sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lipegfilgrastim n1=cyclopeptide | n2=en:lipegfilgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lipemia retinalis (in severe cases) n1=cyclopeptide | n2=en:lipemia retinalis (in severe cases) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lipemia retinalis (in some patients) n1=cyclopeptide | n2=en:lipemia retinalis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lipid n1=cyclopeptide | n2=en:lipid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lipid encapsulated anti-plk1 sirna tkm-plk1 n1=cyclopeptide | n2=en:lipid encapsulated anti-plk1 sirna tkm-plk1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lipidemia retinalis n1=cyclopeptide | n2=en:lipidemia retinalis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lipodermoid n1=cyclopeptide | n2=en:lipodermoid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lipopolysaccharide n1=cyclopeptide | n2=en:lipopolysaccharide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal amphotericin b n1=cyclopeptide | n2=en:liposomal amphotericin b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal bupivacaine n1=cyclopeptide | n2=en:liposomal bupivacaine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal c-raf antisense oligonucleotide n1=cyclopeptide | n2=en:liposomal c-raf antisense oligonucleotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal curcumin n1=cyclopeptide | n2=en:liposomal curcumin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal cytarabine n1=cyclopeptide | n2=en:liposomal cytarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal cytarabine-daunorubicin cpx-351 n1=cyclopeptide | n2=en:liposomal cytarabine-daunorubicin cpx-351 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal daunorubicin citrate n1=cyclopeptide | n2=en:liposomal daunorubicin citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal docetaxel n1=cyclopeptide | n2=en:liposomal docetaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal eribulin mesylate n1=cyclopeptide | n2=en:liposomal eribulin mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal hpv-16 e6/e7 multipeptide vaccine pds0101 n1=cyclopeptide | n2=en:liposomal hpv-16 e6/e7 multipeptide vaccine pds0101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal irinotecan n1=cyclopeptide | n2=en:liposomal irinotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal mitoxantrone hydrochloride n1=cyclopeptide | n2=en:liposomal mitoxantrone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal mnsod plasmid n1=cyclopeptide | n2=en:liposomal mnsod plasmid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal muc1/pet-lipid a vaccine n1=cyclopeptide | n2=en:liposomal muc1/pet-lipid a vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal nddp n1=cyclopeptide | n2=en:liposomal nddp | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal oxaliplatin n1=cyclopeptide | n2=en:liposomal oxaliplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal rhenium re 186 n1=cyclopeptide | n2=en:liposomal rhenium re 186 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposomal sn-38 n1=cyclopeptide | n2=en:liposomal sn-38 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposome-encapsulated doxorubicin citrate n1=cyclopeptide | n2=en:liposome-encapsulated doxorubicin citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposome-encapsulated mir-34 mimic mrx34 n1=cyclopeptide | n2=en:liposome-encapsulated mir-34 mimic mrx34 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposome-encapsulated rb94 plasmid dna gene therapy agent sgt-94 n1=cyclopeptide | n2=en:liposome-encapsulated rb94 plasmid dna gene therapy agent sgt-94 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposome-encapsulated recombinant human cu/zn superoxide-dismutase n1=cyclopeptide | n2=en:liposome-encapsulated recombinant human cu/zn superoxide-dismutase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liposome-incorporated grb2 antisense oligodeoxynucleotide n1=cyclopeptide | n2=en:liposome-incorporated grb2 antisense oligodeoxynucleotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liraglutide n1=cyclopeptide | n2=en:liraglutide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lirilumab n1=cyclopeptide | n2=en:lirilumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lisch nodule n1=cyclopeptide | n2=en:lisch nodule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lisch nodules (iris hamartomas) n1=cyclopeptide | n2=en:lisch nodules (iris hamartomas) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lisch nodules (iris hamartomas) (93%) n1=cyclopeptide | n2=en:lisch nodules (iris hamartomas) (93%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lisch nodules (iris hamartomas) may or may not be present n1=cyclopeptide | n2=en:lisch nodules (iris hamartomas) may or may not be present | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lisdexamfetamine dimesylate n1=cyclopeptide | n2=en:lisdexamfetamine dimesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lisinopril n1=cyclopeptide | n2=en:lisinopril | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lisofylline n1=cyclopeptide | n2=en:lisofylline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lissencephaly syndrome, norman-roberts type n1=cyclopeptide | n2=en:lissencephaly syndrome, norman-roberts type | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:listeria monocytogenes-llo-psa vaccine adxs31-142 n1=cyclopeptide | n2=en:listeria monocytogenes-llo-psa vaccine adxs31-142 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lithium carbonate n1=cyclopeptide | n2=en:lithium carbonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lithium induced birth defect n1=cyclopeptide | n2=en:lithium induced birth defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:litronesib n1=cyclopeptide | n2=en:litronesib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:live attenuated measles virus vaccine n1=cyclopeptide | n2=en:live attenuated measles virus vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:live freeze-dried lactic acid bacteria probiotic n1=cyclopeptide | n2=en:live freeze-dried lactic acid bacteria probiotic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:live-attenuated double-deleted listeria monocytogenes bacteria jnj-64041809 n1=cyclopeptide | n2=en:live-attenuated double-deleted listeria monocytogenes bacteria jnj-64041809 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:live-attenuated listeria encoding human mesothelin vaccine crs-207 n1=cyclopeptide | n2=en:live-attenuated listeria encoding human mesothelin vaccine crs-207 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757 n1=cyclopeptide | n2=en:live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:live-attenuated listeria monocytogenes-encoding egfrviii-ny-eso-1 vaccine adu-623 n1=cyclopeptide | n2=en:live-attenuated listeria monocytogenes-encoding egfrviii-ny-eso-1 vaccine adu-623 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liver extract n1=cyclopeptide | n2=en:liver extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:liver metabolism n1=cyclopeptide | n2=en:liver metabolism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmb-1 immunotoxin n1=cyclopeptide | n2=en:lmb-1 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmb-2 immunotoxin n1=cyclopeptide | n2=en:lmb-2 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmb-7 immunotoxin n1=cyclopeptide | n2=en:lmb-7 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmb-84 regimen n1=cyclopeptide | n2=en:lmb-84 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmb-86 regimen n1=cyclopeptide | n2=en:lmb-86 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmb-89 regimen n1=cyclopeptide | n2=en:lmb-89 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmb-9 immunotoxin n1=cyclopeptide | n2=en:lmb-9 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmb89 protocol n1=cyclopeptide | n2=en:lmb89 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmdda-llo-chher2 fusion protein-secreting live-attenuated listeria cancer vaccine adxs31-164 n1=cyclopeptide | n2=en:lmdda-llo-chher2 fusion protein-secreting live-attenuated listeria cancer vaccine adxs31-164 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmp-2:340-349 peptide vaccine n1=cyclopeptide | n2=en:lmp-2:340-349 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmp-2:419-427 peptide vaccine n1=cyclopeptide | n2=en:lmp-2:419-427 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmp1/barf1/ebna1-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:lmp1/barf1/ebna1-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lmp2a-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:lmp2a-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lna-based antimir-155 mrg-106 n1=cyclopeptide | n2=en:lna-based antimir-155 mrg-106 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lnh 84 protocol n1=cyclopeptide | n2=en:lnh 84 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lnh 87 protocol n1=cyclopeptide | n2=en:lnh 87 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lnh-80 regimen n1=cyclopeptide | n2=en:lnh-80 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lnh-92 regimen n1=cyclopeptide | n2=en:lnh-92 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lnh87-2 protocol n1=cyclopeptide | n2=en:lnh87-2 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lobaplatin n1=cyclopeptide | n2=en:lobaplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lobar dysmorphism n1=cyclopeptide | n2=en:lobar dysmorphism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:localized congenital skull defect n1=cyclopeptide | n2=en:localized congenital skull defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lometrexol n1=cyclopeptide | n2=en:lometrexol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lomustine n1=cyclopeptide | n2=en:lomustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lonafarnib n1=cyclopeptide | n2=en:lonafarnib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lonaprisan n1=cyclopeptide | n2=en:lonaprisan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long curly eyelashes n1=cyclopeptide | n2=en:long curly eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long eyebrows n1=cyclopeptide | n2=en:long eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long eyelashes n1=cyclopeptide | n2=en:long eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long eyelashes (2p21del) n1=cyclopeptide | n2=en:long eyelashes (2p21del) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long eyelashes (54%) n1=cyclopeptide | n2=en:long eyelashes (54%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long eyelashes (59%) n1=cyclopeptide | n2=en:long eyelashes (59%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long eyelashes (in some patients) n1=cyclopeptide | n2=en:long eyelashes (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long eyelashes (trichomegaly) n1=cyclopeptide | n2=en:long eyelashes (trichomegaly) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long eyelashes in irregular rows n1=cyclopeptide | n2=en:long eyelashes in irregular rows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long narrow palpebral fissures (1 patient) n1=cyclopeptide | n2=en:long narrow palpebral fissures (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long palpebral fissure n1=cyclopeptide | n2=en:long palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long peptide vaccine 7 n1=cyclopeptide | n2=en:long peptide vaccine 7 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long upslanting palpebral fissures (1/4 patients) n1=cyclopeptide | n2=en:long upslanting palpebral fissures (1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long-acting granulocyte colony-stimulating factor analog spi-2012 n1=cyclopeptide | n2=en:long-acting granulocyte colony-stimulating factor analog spi-2012 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long-acting release pasireotide n1=cyclopeptide | n2=en:long-acting release pasireotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long, curly dark upper eyelashes (in some patients) n1=cyclopeptide | n2=en:long, curly dark upper eyelashes (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long, curved eyelashes n1=cyclopeptide | n2=en:long, curved eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long, prominent eyelashes n1=cyclopeptide | n2=en:long, prominent eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:long, straight eyelashes n1=cyclopeptide | n2=en:long, straight eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lonidamine n1=cyclopeptide | n2=en:lonidamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loperamide hydrochloride n1=cyclopeptide | n2=en:loperamide hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lopinavir n1=cyclopeptide | n2=en:lopinavir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loratadine n1=cyclopeptide | n2=en:loratadine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lorazepam n1=cyclopeptide | n2=en:lorazepam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lorvotuzumab mertansine n1=cyclopeptide | n2=en:lorvotuzumab mertansine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:losartan potassium n1=cyclopeptide | n2=en:losartan potassium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:losoxantrone n1=cyclopeptide | n2=en:losoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of central vision between ages 25-30 years n1=cyclopeptide | n2=en:loss of central vision between ages 25-30 years | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of color vision, progressive n1=cyclopeptide | n2=en:loss of color vision, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of eye contact n1=cyclopeptide | n2=en:loss of eye contact | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of inner segment/outer segment junction in the parafoveal area on ocular coherence tomography (in some patients) n1=cyclopeptide | n2=en:loss of inner segment/outer segment junction in the parafoveal area on ocular coherence tomography (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of periorbital fat n1=cyclopeptide | n2=en:loss of periorbital fat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of peripheral retinal tissue n1=cyclopeptide | n2=en:loss of peripheral retinal tissue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of peripheral vision in third and fourth decades of life n1=cyclopeptide | n2=en:loss of peripheral vision in third and fourth decades of life | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of peripheral visual fields (in some patients) n1=cyclopeptide | n2=en:loss of peripheral visual fields (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of vision n1=cyclopeptide | n2=en:loss of vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of vision (34%) n1=cyclopeptide | n2=en:loss of vision (34%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of vision (rare) n1=cyclopeptide | n2=en:loss of vision (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loss of visual acuity (late) n1=cyclopeptide | n2=en:loss of visual acuity (late) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lovastatin n1=cyclopeptide | n2=en:lovastatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:low arden ratio on electrooculography n1=cyclopeptide | n2=en:low arden ratio on electrooculography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:low intraocular pressure (in some patients) n1=cyclopeptide | n2=en:low intraocular pressure (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:low vision n1=cyclopeptide | n2=en:low vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lower eyelid n1=cyclopeptide | n2=en:lower eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lower eyelid coloboma n1=cyclopeptide | n2=en:lower eyelid coloboma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lower eyelid ectropion n1=cyclopeptide | n2=en:lower eyelid ectropion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lower eyelid epiblepharon n1=cyclopeptide | n2=en:lower eyelid epiblepharon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lower lacrimal dystopia n1=cyclopeptide | n2=en:lower lacrimal dystopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loxanast n1=cyclopeptide | n2=en:loxanast | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:loxoribine n1=cyclopeptide | n2=en:loxoribine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lps/cd40l-activated klh- and melanoma/hiv peptides-loaded autologous dendritic cell vaccine n1=cyclopeptide | n2=en:lps/cd40l-activated klh- and melanoma/hiv peptides-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lsa(2)l(2) protocol n1=cyclopeptide | n2=en:lsa(2)l(2) protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lsa2-l2 protocol n1=cyclopeptide | n2=en:lsa2-l2 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lsd1 inhibitor gsk2879552 n1=cyclopeptide | n2=en:lsd1 inhibitor gsk2879552 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lsg15 regimen n1=cyclopeptide | n2=en:lsg15 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lubiprostone n1=cyclopeptide | n2=en:lubiprostone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lucanthone n1=cyclopeptide | n2=en:lucanthone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lucatumumab n1=cyclopeptide | n2=en:lucatumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lucitanib n1=cyclopeptide | n2=en:lucitanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lugol's solution n1=cyclopeptide | n2=en:lugol's solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lung tumor associated antigen n1=cyclopeptide | n2=en:lung tumor associated antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lung-targeted immunomodulator qbkpn n1=cyclopeptide | n2=en:lung-targeted immunomodulator qbkpn | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lurasidone n1=cyclopeptide | n2=en:lurasidone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lurbinectedin n1=cyclopeptide | n2=en:lurbinectedin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lurtotecan n1=cyclopeptide | n2=en:lurtotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lurtotecan liposome n1=cyclopeptide | n2=en:lurtotecan liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:luspatercept n1=cyclopeptide | n2=en:luspatercept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177 dota-biotin n1=cyclopeptide | n2=en:lutetium lu 177 dota-biotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177 dota-jr11 n1=cyclopeptide | n2=en:lutetium lu 177 dota-jr11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177 dota-tetulomab n1=cyclopeptide | n2=en:lutetium lu 177 dota-tetulomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177 monoclonal antibody cc49 n1=cyclopeptide | n2=en:lutetium lu 177 monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177 monoclonal antibody j591 n1=cyclopeptide | n2=en:lutetium lu 177 monoclonal antibody j591 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177 peptide receptor radionuclide n1=cyclopeptide | n2=en:lutetium lu 177 peptide receptor radionuclide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177 pp-f11n n1=cyclopeptide | n2=en:lutetium lu 177 pp-f11n | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177-dota-di-hsg peptide imp-288 n1=cyclopeptide | n2=en:lutetium lu 177-dota-di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177-dota-octreotate n1=cyclopeptide | n2=en:lutetium lu 177-dota-octreotate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177-dota-tate n1=cyclopeptide | n2=en:lutetium lu 177-dota-tate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu 177-edotreotide n1=cyclopeptide | n2=en:lutetium lu 177-edotreotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu-177 capromab n1=cyclopeptide | n2=en:lutetium lu-177 capromab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lutetium lu-177 girentuximab n1=cyclopeptide | n2=en:lutetium lu-177 girentuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lv.il-2/b7.1-transduced aml blast vaccine n1=cyclopeptide | n2=en:lv.il-2/b7.1-transduced aml blast vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ly2624587 n1=cyclopeptide | n2=en:ly2624587 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ly2880070 n1=cyclopeptide | n2=en:ly2880070 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ly6k/vegfr1/vegfr2 multipeptide vaccine n1=cyclopeptide | n2=en:ly6k/vegfr1/vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lycopene n1=cyclopeptide | n2=en:lycopene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lymphatic abnormalities n1=cyclopeptide | n2=en:lymphatic abnormalities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lymphokine-activated killer cells n1=cyclopeptide | n2=en:lymphokine-activated killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lymphoma taa-specific cytotoxic t lymphocytes n1=cyclopeptide | n2=en:lymphoma taa-specific cytotoxic t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lyophilized black raspberry lozenge n1=cyclopeptide | n2=en:lyophilized black raspberry lozenge | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lyophilized black raspberry saliva substitute n1=cyclopeptide | n2=en:lyophilized black raspberry saliva substitute | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lysine-specific demethylase 1 inhibitor incb059872 n1=cyclopeptide | n2=en:lysine-specific demethylase 1 inhibitor incb059872 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:lyso-thermosensitive liposome doxorubicin n1=cyclopeptide | n2=en:lyso-thermosensitive liposome doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m-acod protocol n1=cyclopeptide | n2=en:m-acod protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m-azidopyrimethamine n1=cyclopeptide | n2=en:m-azidopyrimethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m-bacod protocol n1=cyclopeptide | n2=en:m-bacod protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m-bacod regimen n1=cyclopeptide | n2=en:m-bacod regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m-bacop protocol n1=cyclopeptide | n2=en:m-bacop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m-bacop regimen n1=cyclopeptide | n2=en:m-bacop regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m-bacos protocol n1=cyclopeptide | n2=en:m-bacos protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m-becod protocol n1=cyclopeptide | n2=en:m-becod protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:m87o-transduced cd34+ peripheral blood stem cells n1=cyclopeptide | n2=en:m87o-transduced cd34+ peripheral blood stem cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mac conditioning regimen n1=cyclopeptide | n2=en:mac conditioning regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mac iii protocol n1=cyclopeptide | n2=en:mac iii protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mac321 n1=cyclopeptide | n2=en:mac321 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macho protocol n1=cyclopeptide | n2=en:macho protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macimorelin n1=cyclopeptide | n2=en:macimorelin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macitentan n1=cyclopeptide | n2=en:macitentan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macop-b protocol n1=cyclopeptide | n2=en:macop-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macop-b regimen n1=cyclopeptide | n2=en:macop-b regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macroblepharon n1=cyclopeptide | n2=en:macroblepharon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macrogenia n1=cyclopeptide | n2=en:macrogenia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macrognathia n1=cyclopeptide | n2=en:macrognathia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macrogol 3350-based iso-osmotic laxative n1=cyclopeptide | n2=en:macrogol 3350-based iso-osmotic laxative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macrolide immunosuppressant n1=cyclopeptide | n2=en:macrolide immunosuppressant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macrophthalmia (in some patients) n1=cyclopeptide | n2=en:macrophthalmia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macrophthalmus n1=cyclopeptide | n2=en:macrophthalmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macrosaccadic oscillations n1=cyclopeptide | n2=en:macrosaccadic oscillations | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macrostomia n1=cyclopeptide | n2=en:macrostomia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macula clear in early stages n1=cyclopeptide | n2=en:macula clear in early stages | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular atrophy (1 patient) n1=cyclopeptide | n2=en:macular atrophy (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular atrophy (in some patients) n1=cyclopeptide | n2=en:macular atrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular atrophy, bull's eye pattern, in fourth decade of life n1=cyclopeptide | n2=en:macular atrophy, bull's eye pattern, in fourth decade of life | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular atrophy, marked n1=cyclopeptide | n2=en:macular atrophy, marked | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular atrophy, mild (in some patients) n1=cyclopeptide | n2=en:macular atrophy, mild (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular cherry-red spots (in some patients) n1=cyclopeptide | n2=en:macular cherry-red spots (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular corneal dystrophy n1=cyclopeptide | n2=en:macular corneal dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular degeneration n1=cyclopeptide | n2=en:macular degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular degeneration (in some patients) n1=cyclopeptide | n2=en:macular degeneration (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular degeneration (rare) n1=cyclopeptide | n2=en:macular degeneration (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular dysfunction, marked, on electroretinography n1=cyclopeptide | n2=en:macular dysfunction, marked, on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular dystrophy n1=cyclopeptide | n2=en:macular dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular ectopia n1=cyclopeptide | n2=en:macular ectopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular edema n1=cyclopeptide | n2=en:macular edema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular edema (in some patients) n1=cyclopeptide | n2=en:macular edema (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular exudates and hemorrhages n1=cyclopeptide | n2=en:macular exudates and hemorrhages | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular granularity (in some patients) n1=cyclopeptide | n2=en:macular granularity (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular hemorrhage and fuchs spots (rare) n1=cyclopeptide | n2=en:macular hemorrhage and fuchs spots (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular heterotopia n1=cyclopeptide | n2=en:macular heterotopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular hypoplasia n1=cyclopeptide | n2=en:macular hypoplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular hypoplasia (rare) n1=cyclopeptide | n2=en:macular hypoplasia (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular or extramacular punctate yellow lesions n1=cyclopeptide | n2=en:macular or extramacular punctate yellow lesions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular pallor with prominence of fovea centralis (cherry red spot) n1=cyclopeptide | n2=en:macular pallor with prominence of fovea centralis (cherry red spot) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular pattern dystrophy (in some patients) n1=cyclopeptide | n2=en:macular pattern dystrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular pigment migration n1=cyclopeptide | n2=en:macular pigment migration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular pigmentary changes n1=cyclopeptide | n2=en:macular pigmentary changes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular red spot n1=cyclopeptide | n2=en:macular red spot | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular retinal folds n1=cyclopeptide | n2=en:macular retinal folds | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular retinal pigment epithelial changes (in some patients) n1=cyclopeptide | n2=en:macular retinal pigment epithelial changes (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular striae n1=cyclopeptide | n2=en:macular striae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:macular translucency (variable) n1=cyclopeptide | n2=en:macular translucency (variable) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maculopathy (uncommon) n1=cyclopeptide | n2=en:maculopathy (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maculopathy, marked (in older patients) n1=cyclopeptide | n2=en:maculopathy, marked (in older patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:madarosis of eyebrow n1=cyclopeptide | n2=en:madarosis of eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mafosfamide n1=cyclopeptide | n2=en:mafosfamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mafosfamide-lysine n1=cyclopeptide | n2=en:mafosfamide-lysine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mag-tn3/as15 vaccine n1=cyclopeptide | n2=en:mag-tn3/as15 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-10.a2 n1=cyclopeptide | n2=en:mage-10.a2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-12 peptide vaccine n1=cyclopeptide | n2=en:mage-12 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-3.a1 peptide vaccine n1=cyclopeptide | n2=en:mage-3.a1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-a1, her-2/neu, fbp peptides cancer vaccine n1=cyclopeptide | n2=en:mage-a1, her-2/neu, fbp peptides cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-a1/mage-a3/ny-eso-1 peptides vaccine n1=cyclopeptide | n2=en:mage-a1/mage-a3/ny-eso-1 peptides vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-a3 peptide vaccine n1=cyclopeptide | n2=en:mage-a3 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-a3 reactive t cell receptor-transduced autologous t cells n1=cyclopeptide | n2=en:mage-a3 reactive t cell receptor-transduced autologous t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-a3-expressing adenovirus type 5 vaccine n1=cyclopeptide | n2=en:mage-a3-expressing adenovirus type 5 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-a3/12-specific tcr gene-transduced autologous pbls n1=cyclopeptide | n2=en:mage-a3/12-specific tcr gene-transduced autologous pbls | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-a3/hpv 16 peptide vaccine n1=cyclopeptide | n2=en:mage-a3/hpv 16 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 n1=cyclopeptide | n2=en:mage-a4-specific tcr gene-transduced autologous t lymphocytes tbi-1201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:magnesium citrate n1=cyclopeptide | n2=en:magnesium citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:magnesium hydroxide n1=cyclopeptide | n2=en:magnesium hydroxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:magnesium isoglycyrrhizinate n1=cyclopeptide | n2=en:magnesium isoglycyrrhizinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:magnesium l-threonate n1=cyclopeptide | n2=en:magnesium l-threonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:magnesium oxide n1=cyclopeptide | n2=en:magnesium oxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:magnesium sulfate n1=cyclopeptide | n2=en:magnesium sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:magnesium valproate n1=cyclopeptide | n2=en:magnesium valproate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:magrath regimen n1=cyclopeptide | n2=en:magrath regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maitake mushroom extract n1=cyclopeptide | n2=en:maitake mushroom extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:major congenital anomaly n1=cyclopeptide | n2=en:major congenital anomaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mallinson protocol n1=cyclopeptide | n2=en:mallinson protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:malmo protocol n1=cyclopeptide | n2=en:malmo protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maltodextrin n1=cyclopeptide | n2=en:maltodextrin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maltose n1=cyclopeptide | n2=en:maltose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maltose tetrapalmitate n1=cyclopeptide | n2=en:maltose tetrapalmitate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mammaglobin-a dna vaccine n1=cyclopeptide | n2=en:mammaglobin-a dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mandibular cleft n1=cyclopeptide | n2=en:mandibular cleft | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mangafodipir trisodium n1=cyclopeptide | n2=en:mangafodipir trisodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:manifest-latent nystagmus n1=cyclopeptide | n2=en:manifest-latent nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:manitimus n1=cyclopeptide | n2=en:manitimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mannitol n1=cyclopeptide | n2=en:mannitol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mannomustine n1=cyclopeptide | n2=en:mannomustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mannose-binding lectin n1=cyclopeptide | n2=en:mannose-binding lectin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:manuka honey n1=cyclopeptide | n2=en:manuka honey | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mapatumumab n1=cyclopeptide | n2=en:mapatumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maphosphamide n1=cyclopeptide | n2=en:maphosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maraviroc n1=cyclopeptide | n2=en:maraviroc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marcellomycin n1=cyclopeptide | n2=en:marcellomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marcus gunn jaw winking (in some patients) n1=cyclopeptide | n2=en:marcus gunn jaw winking (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:margetuximab n1=cyclopeptide | n2=en:margetuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maribavir n1=cyclopeptide | n2=en:maribavir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marijuana n1=cyclopeptide | n2=en:marijuana | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marimastat n1=cyclopeptide | n2=en:marimastat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marizomib n1=cyclopeptide | n2=en:marizomib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marked amplitude reduction and delay of a- and b-waves on electroretinography, more severe in scotopic than photopic system n1=cyclopeptide | n2=en:marked amplitude reduction and delay of a- and b-waves on electroretinography, more severe in scotopic than photopic system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marked hypertelorism n1=cyclopeptide | n2=en:marked hypertelorism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marked macular degeneration n1=cyclopeptide | n2=en:marked macular degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marked pallor of mucous membranes n1=cyclopeptide | n2=en:marked pallor of mucous membranes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:marked thickening of descemet membrane n1=cyclopeptide | n2=en:marked thickening of descemet membrane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:markedly constricted visual fields n1=cyclopeptide | n2=en:markedly constricted visual fields | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:markedly reduced or absent b-wave on scotopic electroretinography n1=cyclopeptide | n2=en:markedly reduced or absent b-wave on scotopic electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mart-1 reactive cd8+ lymphocytes n1=cyclopeptide | n2=en:mart-1 reactive cd8+ lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mart-1:26-35(27l) peptide vaccine n1=cyclopeptide | n2=en:mart-1:26-35(27l) peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mart-1:27-35 peptide vaccine n1=cyclopeptide | n2=en:mart-1:27-35 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mart-1/gp100/tyrosinase/mage-a3 peptides-loaded irradiated allogeneic plasmacytoid dendritic cells n1=cyclopeptide | n2=en:mart-1/gp100/tyrosinase/mage-a3 peptides-loaded irradiated allogeneic plasmacytoid dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:masitinib mesylate n1=cyclopeptide | n2=en:masitinib mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:masoprocol n1=cyclopeptide | n2=en:masoprocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mast cell stabilizer n1=cyclopeptide | n2=en:mast cell stabilizer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mast cell stabilizer tf002 n1=cyclopeptide | n2=en:mast cell stabilizer tf002 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:matcop regimen n1=cyclopeptide | n2=en:matcop regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:materia medica n1=cyclopeptide | n2=en:materia medica | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:matricaria recutita gel n1=cyclopeptide | n2=en:matricaria recutita gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:matricaria recutita topical infusion n1=cyclopeptide | n2=en:matricaria recutita topical infusion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mature cataract n1=cyclopeptide | n2=en:mature cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:matuzumab n1=cyclopeptide | n2=en:matuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maxillonasal dysplasia, binder type n1=cyclopeptide | n2=en:maxillonasal dysplasia, binder type | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maxzide n1=cyclopeptide | n2=en:maxzide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:maytansine n1=cyclopeptide | n2=en:maytansine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mchc protocol n1=cyclopeptide | n2=en:mchc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mchod protocol n1=cyclopeptide | n2=en:mchod protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mcl-1 inhibitor amg 176 n1=cyclopeptide | n2=en:mcl-1 inhibitor amg 176 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mcop protocol n1=cyclopeptide | n2=en:mcop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mcp 842 regimen n1=cyclopeptide | n2=en:mcp 842 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mcpd protocol n1=cyclopeptide | n2=en:mcpd protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mcpp protocol n1=cyclopeptide | n2=en:mcpp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mcpyv tag-specific polyclonal autologous cd8-positive t cells n1=cyclopeptide | n2=en:mcpyv tag-specific polyclonal autologous cd8-positive t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mcs-5 n1=cyclopeptide | n2=en:mcs-5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mct/lct lipid emulsion n1=cyclopeptide | n2=en:mct/lct lipid emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mct/lct/fish oil omega-3 fatty acid lipid emulsion n1=cyclopeptide | n2=en:mct/lct/fish oil omega-3 fatty acid lipid emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mdacc protocol n1=cyclopeptide | n2=en:mdacc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mdm2 antagonist ro5045337 n1=cyclopeptide | n2=en:mdm2 antagonist ro5045337 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mdm2 antagonist ro6839921 n1=cyclopeptide | n2=en:mdm2 antagonist ro6839921 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mdm2 inhibitor amg-232 n1=cyclopeptide | n2=en:mdm2 inhibitor amg-232 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mdm2 inhibitor ds-3032b n1=cyclopeptide | n2=en:mdm2 inhibitor ds-3032b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mdm2/mdmx inhibitor alrn-6924 n1=cyclopeptide | n2=en:mdm2/mdmx inhibitor alrn-6924 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mdr modulator cbt-1 n1=cyclopeptide | n2=en:mdr modulator cbt-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mdx-1379 melanoma vaccine n1=cyclopeptide | n2=en:mdx-1379 melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:me-143 n1=cyclopeptide | n2=en:me-143 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:measles/mumps/rubella vaccine n1=cyclopeptide | n2=en:measles/mumps/rubella vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mebendazole n1=cyclopeptide | n2=en:mebendazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mechanism of action qualifier n1=cyclopeptide | n2=en:mechanism of action qualifier | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mechlorethamine n1=cyclopeptide | n2=en:mechlorethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mechlorethamine hydrochloride n1=cyclopeptide | n2=en:mechlorethamine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mechlorethamine hydrochloride gel n1=cyclopeptide | n2=en:mechlorethamine hydrochloride gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mechlorethamine oxide hydrochloride n1=cyclopeptide | n2=en:mechlorethamine oxide hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mechop-bm protocol n1=cyclopeptide | n2=en:mechop-bm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:meclocycline sulfosalicylate n1=cyclopeptide | n2=en:meclocycline sulfosalicylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:meclofenamate sodium n1=cyclopeptide | n2=en:meclofenamate sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mecy protocol n1=cyclopeptide | n2=en:mecy protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:medial canthal webbing (in some patients) n1=cyclopeptide | n2=en:medial canthal webbing (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:medial flaring of the eyebrow n1=cyclopeptide | n2=en:medial flaring of the eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:medial palpebral commissure n1=cyclopeptide | n2=en:medial palpebral commissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:medially flared eyebrows n1=cyclopeptide | n2=en:medially flared eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:medical gases n1=cyclopeptide | n2=en:medical gases | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:medical marijuana n1=cyclopeptide | n2=en:medical marijuana | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:medroxyprogesterone n1=cyclopeptide | n2=en:medroxyprogesterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:medullated corneal nerve fibers n1=cyclopeptide | n2=en:medullated corneal nerve fibers | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mefloquine n1=cyclopeptide | n2=en:mefloquine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:megaloblepharon (large eyelids) n1=cyclopeptide | n2=en:megaloblepharon (large eyelids) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:megalocornea (corneal diameter of 13mm and greater in affected males) n1=cyclopeptide | n2=en:megalocornea (corneal diameter of 13mm and greater in affected males) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:megalocornea (diameter greater than 12 mm) n1=cyclopeptide | n2=en:megalocornea (diameter greater than 12 mm) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:megalocornea (in some patients) n1=cyclopeptide | n2=en:megalocornea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:megalocornea (wws) n1=cyclopeptide | n2=en:megalocornea (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:megestrol n1=cyclopeptide | n2=en:megestrol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:megestrol acetate n1=cyclopeptide | n2=en:megestrol acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:meglumine ioxithalamate n1=cyclopeptide | n2=en:meglumine ioxithalamate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:megophthalmos n1=cyclopeptide | n2=en:megophthalmos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:meibomian gland dysfunction n1=cyclopeptide | n2=en:meibomian gland dysfunction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek 1/2 inhibitor as703988/msc2015103b n1=cyclopeptide | n2=en:mek 1/2 inhibitor as703988/msc2015103b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek inhibitor azd8330 n1=cyclopeptide | n2=en:mek inhibitor azd8330 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek inhibitor ci-1040 n1=cyclopeptide | n2=en:mek inhibitor ci-1040 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek inhibitor gdc-0623 n1=cyclopeptide | n2=en:mek inhibitor gdc-0623 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek inhibitor ro4987655 n1=cyclopeptide | n2=en:mek inhibitor ro4987655 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek inhibitor tak-733 n1=cyclopeptide | n2=en:mek inhibitor tak-733 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek inhibitor wx-554 n1=cyclopeptide | n2=en:mek inhibitor wx-554 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek-1/mekk-1 inhibitor e6201 n1=cyclopeptide | n2=en:mek-1/mekk-1 inhibitor e6201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mek/aurora kinase inhibitor bi 847325 n1=cyclopeptide | n2=en:mek/aurora kinase inhibitor bi 847325 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melan-a vlp vaccine n1=cyclopeptide | n2=en:melan-a vlp vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melan-a/mage-3.dp4 peptide vaccine n1=cyclopeptide | n2=en:melan-a/mage-3.dp4 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melanin dispersion in iris n1=cyclopeptide | n2=en:melanin dispersion in iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melanoma antigen recognized by t-cells 1 n1=cyclopeptide | n2=en:melanoma antigen recognized by t-cells 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melanoma helper peptide vaccine n1=cyclopeptide | n2=en:melanoma helper peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melanoma trp2 ctl epitope vaccine scib1 n1=cyclopeptide | n2=en:melanoma trp2 ctl epitope vaccine scib1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melitac 12.1 peptide vaccine n1=cyclopeptide | n2=en:melitac 12.1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melk inhibitor ots167 n1=cyclopeptide | n2=en:melk inhibitor ots167 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mellaril n1=cyclopeptide | n2=en:mellaril | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:meloxicam n1=cyclopeptide | n2=en:meloxicam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melphalan n1=cyclopeptide | n2=en:melphalan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melphalan hydrochloride n1=cyclopeptide | n2=en:melphalan hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melphalan hydrochloride/sulfobutyl ether beta-cyclodextrin complex n1=cyclopeptide | n2=en:melphalan hydrochloride/sulfobutyl ether beta-cyclodextrin complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melphalan-flufenamide prodrug n1=cyclopeptide | n2=en:melphalan-flufenamide prodrug | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:melphalan/thiotepa n1=cyclopeptide | n2=en:melphalan/thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:memantine hydrochloride n1=cyclopeptide | n2=en:memantine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:membrane-disrupting peptide ep-100 n1=cyclopeptide | n2=en:membrane-disrupting peptide ep-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:membranous (type i) vitreous phenotype n1=cyclopeptide | n2=en:membranous (type i) vitreous phenotype | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:menadione topical lotion n1=cyclopeptide | n2=en:menadione topical lotion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:menatetrenone n1=cyclopeptide | n2=en:menatetrenone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:menogaril n1=cyclopeptide | n2=en:menogaril | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mental retardation n1=cyclopeptide | n2=en:mental retardation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:menthol n1=cyclopeptide | n2=en:menthol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:meperidine hydrochloride n1=cyclopeptide | n2=en:meperidine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mepivacaine hydrochloride n1=cyclopeptide | n2=en:mepivacaine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:merbarone n1=cyclopeptide | n2=en:merbarone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mercaptopurine n1=cyclopeptide | n2=en:mercaptopurine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mercaptopurine anhydrous n1=cyclopeptide | n2=en:mercaptopurine anhydrous | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mercaptopurine oral suspension n1=cyclopeptide | n2=en:mercaptopurine oral suspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mercuric cyanide n1=cyclopeptide | n2=en:mercuric cyanide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:merestinib n1=cyclopeptide | n2=en:merestinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:meropenem n1=cyclopeptide | n2=en:meropenem | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mesalamine n1=cyclopeptide | n2=en:mesalamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mesna n1=cyclopeptide | n2=en:mesna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mesodermal iris dysgenesis (in some patients) n1=cyclopeptide | n2=en:mesodermal iris dysgenesis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes n1=cyclopeptide | n2=en:mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mesulfen n1=cyclopeptide | n2=en:mesulfen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:met tyrosine kinase inhibitor bms-777607 n1=cyclopeptide | n2=en:met tyrosine kinase inhibitor bms-777607 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:met tyrosine kinase inhibitor emd 1204831 n1=cyclopeptide | n2=en:met tyrosine kinase inhibitor emd 1204831 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:met tyrosine kinase inhibitor pf-04217903 n1=cyclopeptide | n2=en:met tyrosine kinase inhibitor pf-04217903 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:met tyrosine kinase inhibitor sar125844 n1=cyclopeptide | n2=en:met tyrosine kinase inhibitor sar125844 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:met tyrosine kinase inhibitor sgx523 n1=cyclopeptide | n2=en:met tyrosine kinase inhibitor sgx523 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:meta-fluorine f 18 fluorobenzylguanidine n1=cyclopeptide | n2=en:meta-fluorine f 18 fluorobenzylguanidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metabolic aspects n1=cyclopeptide | n2=en:metabolic aspects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metahexamide n1=cyclopeptide | n2=en:metahexamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metaiodobenzylguanidine[131i] n1=cyclopeptide | n2=en:metaiodobenzylguanidine[131i] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metamelfalan n1=cyclopeptide | n2=en:metamelfalan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metamorphopsia (in some patients) n1=cyclopeptide | n2=en:metamorphopsia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metamorphopsias n1=cyclopeptide | n2=en:metamorphopsias | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metap2 inhibitor sdx-7320 n1=cyclopeptide | n2=en:metap2 inhibitor sdx-7320 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metatinib tromethamine n1=cyclopeptide | n2=en:metatinib tromethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metformin hydrochloride n1=cyclopeptide | n2=en:metformin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methadone hydrochloride n1=cyclopeptide | n2=en:methadone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methanol extraction residue of bcg n1=cyclopeptide | n2=en:methanol extraction residue of bcg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methazolamide n1=cyclopeptide | n2=en:methazolamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methimazole n1=cyclopeptide | n2=en:methimazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methionine c 11 n1=cyclopeptide | n2=en:methionine c 11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methotrexate n1=cyclopeptide | n2=en:methotrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methotrexate-e therapeutic implant n1=cyclopeptide | n2=en:methotrexate-e therapeutic implant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methotrexate-encapsulating autologous tumor-derived microparticles n1=cyclopeptide | n2=en:methotrexate-encapsulating autologous tumor-derived microparticles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methoxsalen n1=cyclopeptide | n2=en:methoxsalen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methoxy polyethylene glycol-epoetin beta n1=cyclopeptide | n2=en:methoxy polyethylene glycol-epoetin beta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methoxyamine n1=cyclopeptide | n2=en:methoxyamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methoxyamine hydrochloride n1=cyclopeptide | n2=en:methoxyamine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methoxyflurane n1=cyclopeptide | n2=en:methoxyflurane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methyl-5-aminolevulinate hydrochloride cream n1=cyclopeptide | n2=en:methyl-5-aminolevulinate hydrochloride cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methylcellulose n1=cyclopeptide | n2=en:methylcellulose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methylene blue n1=cyclopeptide | n2=en:methylene blue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methylene dimethane sulfonate n1=cyclopeptide | n2=en:methylene dimethane sulfonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methylmercaptopurine riboside n1=cyclopeptide | n2=en:methylmercaptopurine riboside | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methylnaltrexone n1=cyclopeptide | n2=en:methylnaltrexone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methylphenidate hydrochloride n1=cyclopeptide | n2=en:methylphenidate hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methylprednisolone n1=cyclopeptide | n2=en:methylprednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methylselenocysteine n1=cyclopeptide | n2=en:methylselenocysteine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:methyltestosterone n1=cyclopeptide | n2=en:methyltestosterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metoclopramide hydrochloride n1=cyclopeptide | n2=en:metoclopramide hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metoprine n1=cyclopeptide | n2=en:metoprine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metoprolol n1=cyclopeptide | n2=en:metoprolol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metreleptin n1=cyclopeptide | n2=en:metreleptin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metronidazole hydrochloride n1=cyclopeptide | n2=en:metronidazole hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:metyrosine n1=cyclopeptide | n2=en:metyrosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mev-ad protocol n1=cyclopeptide | n2=en:mev-ad protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mezlocillin n1=cyclopeptide | n2=en:mezlocillin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes n1=cyclopeptide | n2=en:mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mg 98 n1=cyclopeptide | n2=en:mg 98 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mgmtp140k-encoding retroviral vector n1=cyclopeptide | n2=en:mgmtp140k-encoding retroviral vector | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mibefradil dihydrochloride n1=cyclopeptide | n2=en:mibefradil dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:micafungin n1=cyclopeptide | n2=en:micafungin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:micafungin sodium n1=cyclopeptide | n2=en:micafungin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:micat protocol n1=cyclopeptide | n2=en:micat protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:micellar nanoparticle-encapsulated cisplatin nc-6004 n1=cyclopeptide | n2=en:micellar nanoparticle-encapsulated cisplatin nc-6004 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microaneurysm n1=cyclopeptide | n2=en:microaneurysm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microangiopathic telangiectasia n1=cyclopeptide | n2=en:microangiopathic telangiectasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microblepharon n1=cyclopeptide | n2=en:microblepharon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microcornea n1=cyclopeptide | n2=en:microcornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microcornea (2 of 5 patients) n1=cyclopeptide | n2=en:microcornea (2 of 5 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microcornea (in some patients) n1=cyclopeptide | n2=en:microcornea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microcystic epithelial edema n1=cyclopeptide | n2=en:microcystic epithelial edema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microgenia n1=cyclopeptide | n2=en:microgenia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:micrognathism n1=cyclopeptide | n2=en:micrognathism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:micronutrient-fortified probiotic yogurt n1=cyclopeptide | n2=en:micronutrient-fortified probiotic yogurt | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:micronystagmus (rare) n1=cyclopeptide | n2=en:micronystagmus (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphakia n1=cyclopeptide | n2=en:microphakia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia (1 patient) n1=cyclopeptide | n2=en:microphthalmia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia (15%) n1=cyclopeptide | n2=en:microphthalmia (15%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia (in some patients) n1=cyclopeptide | n2=en:microphthalmia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia (ipsilateral to facial hemangioma) n1=cyclopeptide | n2=en:microphthalmia (ipsilateral to facial hemangioma) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia (rare) n1=cyclopeptide | n2=en:microphthalmia (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia (some) n1=cyclopeptide | n2=en:microphthalmia (some) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia (wws) n1=cyclopeptide | n2=en:microphthalmia (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia, bilateral (isolated feature in some patients) n1=cyclopeptide | n2=en:microphthalmia, bilateral (isolated feature in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia, extreme n1=cyclopeptide | n2=en:microphthalmia, extreme | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia, mild n1=cyclopeptide | n2=en:microphthalmia, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia, mild (in some patients) n1=cyclopeptide | n2=en:microphthalmia, mild (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia, posterior (nanophthalmos) n1=cyclopeptide | n2=en:microphthalmia, posterior (nanophthalmos) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia, severe, bilateral n1=cyclopeptide | n2=en:microphthalmia, severe, bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia, syndromic 3 n1=cyclopeptide | n2=en:microphthalmia, syndromic 3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmia, unilateral or bilateral n1=cyclopeptide | n2=en:microphthalmia, unilateral or bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microphthalmos n1=cyclopeptide | n2=en:microphthalmos | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microsaccadic pursuit n1=cyclopeptide | n2=en:microsaccadic pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microsclerocornea n1=cyclopeptide | n2=en:microsclerocornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microspherophakia n1=cyclopeptide | n2=en:microspherophakia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microspherophakia (small, spherical lens) (74%) n1=cyclopeptide | n2=en:microspherophakia (small, spherical lens) (74%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microspherophakia (small, spherical lens) (94%) n1=cyclopeptide | n2=en:microspherophakia (small, spherical lens) (94%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microstomia n1=cyclopeptide | n2=en:microstomia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:microtubule-targeted agent bal101553 n1=cyclopeptide | n2=en:microtubule-targeted agent bal101553 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:midazolam hydrochloride n1=cyclopeptide | n2=en:midazolam hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:midazolam-containing buccal liquid n1=cyclopeptide | n2=en:midazolam-containing buccal liquid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:midostaurin n1=cyclopeptide | n2=en:midostaurin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mifamurtide n1=cyclopeptide | n2=en:mifamurtide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mifepristone n1=cyclopeptide | n2=en:mifepristone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:miglitol n1=cyclopeptide | n2=en:miglitol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:miglustat n1=cyclopeptide | n2=en:miglustat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:miha-loaded pd-l1/l2-silenced dendritic cell vaccine n1=cyclopeptide | n2=en:miha-loaded pd-l1/l2-silenced dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:milatuzumab n1=cyclopeptide | n2=en:milatuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:milatuzumab-doxorubicin antibody-drug conjugate n1=cyclopeptide | n2=en:milatuzumab-doxorubicin antibody-drug conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild depression and delay in both scotopic and photopic function on electroretinography n1=cyclopeptide | n2=en:mild depression and delay in both scotopic and photopic function on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild ocular nuclear density (uncommon) n1=cyclopeptide | n2=en:mild ocular nuclear density (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild palpebral ptosis n1=cyclopeptide | n2=en:mild palpebral ptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild peripheral retinal pigmentary changes n1=cyclopeptide | n2=en:mild peripheral retinal pigmentary changes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild photophobia n1=cyclopeptide | n2=en:mild photophobia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild proptosis n1=cyclopeptide | n2=en:mild proptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild retinal arteriolar constriction n1=cyclopeptide | n2=en:mild retinal arteriolar constriction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild retinopathy n1=cyclopeptide | n2=en:mild retinopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild temporal optic nerve pallor n1=cyclopeptide | n2=en:mild temporal optic nerve pallor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild temporal pallor of the optic disc (partial optic atrophy) n1=cyclopeptide | n2=en:mild temporal pallor of the optic disc (partial optic atrophy) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild transient cherry-red spot n1=cyclopeptide | n2=en:mild transient cherry-red spot | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mild vision impairment n1=cyclopeptide | n2=en:mild vision impairment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mildly abnormal cone function on erg (rare) n1=cyclopeptide | n2=en:mildly abnormal cone function on erg (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mildly downslanting palpebral fissures n1=cyclopeptide | n2=en:mildly downslanting palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mildly reduced visual acuity n1=cyclopeptide | n2=en:mildly reduced visual acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:milk protein-based energy drink n1=cyclopeptide | n2=en:milk protein-based energy drink | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:milk thistle n1=cyclopeptide | n2=en:milk thistle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:milodistim n1=cyclopeptide | n2=en:milodistim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:miltefosine n1=cyclopeptide | n2=en:miltefosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mimotope-p10s-padre peptide vaccine n1=cyclopeptide | n2=en:mimotope-p10s-padre peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mina protocol n1=cyclopeptide | n2=en:mina protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:minocycline hydrochloride n1=cyclopeptide | n2=en:minocycline hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:minocycline-edta n1=cyclopeptide | n2=en:minocycline-edta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:minor photophobia n1=cyclopeptide | n2=en:minor photophobia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:miosis due to decreased function of dilator muscle n1=cyclopeptide | n2=en:miosis due to decreased function of dilator muscle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:miosis, ipsilateral n1=cyclopeptide | n2=en:miosis, ipsilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:miotics n1=cyclopeptide | n2=en:miotics | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mipsagargin n1=cyclopeptide | n2=en:mipsagargin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mirabegron n1=cyclopeptide | n2=en:mirabegron | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:miracle mouthwash plus hydrocortisone n1=cyclopeptide | n2=en:miracle mouthwash plus hydrocortisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mirtazapine n1=cyclopeptide | n2=en:mirtazapine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mirvetuximab soravtansine n1=cyclopeptide | n2=en:mirvetuximab soravtansine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:misonidazole n1=cyclopeptide | n2=en:misonidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:misoprostol n1=cyclopeptide | n2=en:misoprostol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:misrouting of the optic nerves at the chiasm n1=cyclopeptide | n2=en:misrouting of the optic nerves at the chiasm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mistletoe extract n1=cyclopeptide | n2=en:mistletoe extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitobronitol n1=cyclopeptide | n2=en:mitobronitol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitoclomine n1=cyclopeptide | n2=en:mitoclomine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitoflaxone n1=cyclopeptide | n2=en:mitoflaxone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitogen n1=cyclopeptide | n2=en:mitogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitoguazone n1=cyclopeptide | n2=en:mitoguazone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitolactol n1=cyclopeptide | n2=en:mitolactol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitomycin n1=cyclopeptide | n2=en:mitomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitoquidone n1=cyclopeptide | n2=en:mitoquidone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitotane n1=cyclopeptide | n2=en:mitotane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitoxantrone n1=cyclopeptide | n2=en:mitoxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitoxantrone hydrochloride n1=cyclopeptide | n2=en:mitoxantrone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mitozolomide n1=cyclopeptide | n2=en:mitozolomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mivobulin isethionate n1=cyclopeptide | n2=en:mivobulin isethionate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mixed bacteria vaccine n1=cyclopeptide | n2=en:mixed bacteria vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mizoribine n1=cyclopeptide | n2=en:mizoribine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mizuo-nakamura phenomenon (fundus color changes from red in the dark-adapted state to golden after light exposure) n1=cyclopeptide | n2=en:mizuo-nakamura phenomenon (fundus color changes from red in the dark-adapted state to golden after light exposure) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mk-1248 n1=cyclopeptide | n2=en:mk-1248 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mk-4280 n1=cyclopeptide | n2=en:mk-4280 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mk-6592 n1=cyclopeptide | n2=en:mk-6592 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mk-8808 n1=cyclopeptide | n2=en:mk-8808 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mk0429 n1=cyclopeptide | n2=en:mk0429 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mk0731 n1=cyclopeptide | n2=en:mk0731 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mkc-1 n1=cyclopeptide | n2=en:mkc-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mknk1 inhibitor bay 1143269 n1=cyclopeptide | n2=en:mknk1 inhibitor bay 1143269 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ml-y1 protocol n1=cyclopeptide | n2=en:ml-y1 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mll-93 protocol n1=cyclopeptide | n2=en:mll-93 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mln2704 n1=cyclopeptide | n2=en:mln2704 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mmc protocol n1=cyclopeptide | n2=en:mmc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mncop-b protocol n1=cyclopeptide | n2=en:mncop-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mnk1/2 inhibitor eft508 n1=cyclopeptide | n2=en:mnk1/2 inhibitor eft508 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mnsod mimetic bmx-001 n1=cyclopeptide | n2=en:mnsod mimetic bmx-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mocca protocol n1=cyclopeptide | n2=en:mocca protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mocetinostat n1=cyclopeptide | n2=en:mocetinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:modafinil n1=cyclopeptide | n2=en:modafinil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:moderate atrophy of optic disc n1=cyclopeptide | n2=en:moderate atrophy of optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:moderate central loss of visual acuity in males (20/60) n1=cyclopeptide | n2=en:moderate central loss of visual acuity in males (20/60) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:modified citrus pectin supplement n1=cyclopeptide | n2=en:modified citrus pectin supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:modified vaccinia ankara (bavarian nordic)-her2 vaccine n1=cyclopeptide | n2=en:modified vaccinia ankara (bavarian nordic)-her2 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:modified vaccinia virus ankara vaccine expressing p53 n1=cyclopeptide | n2=en:modified vaccinia virus ankara vaccine expressing p53 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:modified-release calcifediol capsule n1=cyclopeptide | n2=en:modified-release calcifediol capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mogamulizumab n1=cyclopeptide | n2=en:mogamulizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:molecular target inhibitors n1=cyclopeptide | n2=en:molecular target inhibitors | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:molybdenum n1=cyclopeptide | n2=en:molybdenum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:momelotinib n1=cyclopeptide | n2=en:momelotinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mometasone furoate n1=cyclopeptide | n2=en:mometasone furoate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monalizumab n1=cyclopeptide | n2=en:monalizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoacetyldiglyceride ec-18 n1=cyclopeptide | n2=en:monoacetyldiglyceride ec-18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monobenzone n1=cyclopeptide | n2=en:monobenzone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monocarboxylate transporter 1 inhibitor azd3965 n1=cyclopeptide | n2=en:monocarboxylate transporter 1 inhibitor azd3965 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibodies, antineoplastic n1=cyclopeptide | n2=en:monoclonal antibodies, antineoplastic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody 105ad7 anti-idiotype vaccine n1=cyclopeptide | n2=en:monoclonal antibody 105ad7 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody 11d10 n1=cyclopeptide | n2=en:monoclonal antibody 11d10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody 11d10 anti-idiotype vaccine n1=cyclopeptide | n2=en:monoclonal antibody 11d10 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody 14g2a n1=cyclopeptide | n2=en:monoclonal antibody 14g2a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody 3622w94 n1=cyclopeptide | n2=en:monoclonal antibody 3622w94 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody 3f8 n1=cyclopeptide | n2=en:monoclonal antibody 3f8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody 3h1 anti-idiotype vaccine n1=cyclopeptide | n2=en:monoclonal antibody 3h1 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody 4b5 anti-idiotype vaccine n1=cyclopeptide | n2=en:monoclonal antibody 4b5 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody a1g4 anti-idiotype vaccine n1=cyclopeptide | n2=en:monoclonal antibody a1g4 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody a27.15 n1=cyclopeptide | n2=en:monoclonal antibody a27.15 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody a33 n1=cyclopeptide | n2=en:monoclonal antibody a33 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody abgn-7 n1=cyclopeptide | n2=en:monoclonal antibody abgn-7 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody agent n1=cyclopeptide | n2=en:monoclonal antibody agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody amg 228 n1=cyclopeptide | n2=en:monoclonal antibody amg 228 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody c-58 n1=cyclopeptide | n2=en:monoclonal antibody c-58 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody cal n1=cyclopeptide | n2=en:monoclonal antibody cal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody cbe-11 n1=cyclopeptide | n2=en:monoclonal antibody cbe-11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody cc49 n1=cyclopeptide | n2=en:monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody cc49-delta ch2 n1=cyclopeptide | n2=en:monoclonal antibody cc49-delta ch2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody cc49-streptavidin conjugate n1=cyclopeptide | n2=en:monoclonal antibody cc49-streptavidin conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody cd19 n1=cyclopeptide | n2=en:monoclonal antibody cd19 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody cep-37250/khk2804 n1=cyclopeptide | n2=en:monoclonal antibody cep-37250/khk2804 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody d6.12 n1=cyclopeptide | n2=en:monoclonal antibody d6.12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody e2.3 n1=cyclopeptide | n2=en:monoclonal antibody e2.3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody f19 n1=cyclopeptide | n2=en:monoclonal antibody f19 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody gd2 anti-idiotype vaccine n1=cyclopeptide | n2=en:monoclonal antibody gd2 anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody hefi-1 n1=cyclopeptide | n2=en:monoclonal antibody hefi-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody hu3s193 n1=cyclopeptide | n2=en:monoclonal antibody hu3s193 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody huafp31 n1=cyclopeptide | n2=en:monoclonal antibody huafp31 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody huhmfg1 n1=cyclopeptide | n2=en:monoclonal antibody huhmfg1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody huj591 n1=cyclopeptide | n2=en:monoclonal antibody huj591 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody hupam4 n1=cyclopeptide | n2=en:monoclonal antibody hupam4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody idec-159 n1=cyclopeptide | n2=en:monoclonal antibody idec-159 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody ing-1 n1=cyclopeptide | n2=en:monoclonal antibody ing-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody l6 n1=cyclopeptide | n2=en:monoclonal antibody l6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody lym-1 n1=cyclopeptide | n2=en:monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody m170 n1=cyclopeptide | n2=en:monoclonal antibody m170 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody me1-14 f(ab')2 n1=cyclopeptide | n2=en:monoclonal antibody me1-14 f(ab')2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody mga271 n1=cyclopeptide | n2=en:monoclonal antibody mga271 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody mik-beta-1 n1=cyclopeptide | n2=en:monoclonal antibody mik-beta-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody mono-dga-rfb4 n1=cyclopeptide | n2=en:monoclonal antibody mono-dga-rfb4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody muj591 n1=cyclopeptide | n2=en:monoclonal antibody muj591 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody mx35 f(ab')2 n1=cyclopeptide | n2=en:monoclonal antibody mx35 f(ab')2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody r24 n1=cyclopeptide | n2=en:monoclonal antibody r24 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody rav12 n1=cyclopeptide | n2=en:monoclonal antibody rav12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody sgn-30 n1=cyclopeptide | n2=en:monoclonal antibody sgn-30 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal antibody t101 n1=cyclopeptide | n2=en:monoclonal antibody t101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monoclonal t-cell receptor anti-cd3 scfv fusion protein imcgp100 n1=cyclopeptide | n2=en:monoclonal t-cell receptor anti-cd3 scfv fusion protein imcgp100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monophosphoryl lipid a n1=cyclopeptide | n2=en:monophosphoryl lipid a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monopia n1=cyclopeptide | n2=en:monopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monosialotetrahexosylganglioside n1=cyclopeptide | n2=en:monosialotetrahexosylganglioside | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:monster (disorder) n1=cyclopeptide | n2=en:monster (disorder) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:montanide isa 51 vg n1=cyclopeptide | n2=en:montanide isa 51 vg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:montanide isa 720 n1=cyclopeptide | n2=en:montanide isa 720 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:montelukast sodium n1=cyclopeptide | n2=en:montelukast sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mopidamol n1=cyclopeptide | n2=en:mopidamol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:moplace protocol n1=cyclopeptide | n2=en:moplace protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:moplec protocol n1=cyclopeptide | n2=en:moplec protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mopp regimen n1=cyclopeptide | n2=en:mopp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:morinda citrifolia fruit extract n1=cyclopeptide | n2=en:morinda citrifolia fruit extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:morning glory disc anomaly (1 family) n1=cyclopeptide | n2=en:morning glory disc anomaly (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:morning glory optic disc n1=cyclopeptide | n2=en:morning glory optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:morning glory-like dysplastic macropapillae n1=cyclopeptide | n2=en:morning glory-like dysplastic macropapillae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:morphine n1=cyclopeptide | n2=en:morphine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:morphine sulfate n1=cyclopeptide | n2=en:morphine sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:morphine sulfate sustained-release tablet n1=cyclopeptide | n2=en:morphine sulfate sustained-release tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mosaic corneal dystrophy ('shagreen') n1=cyclopeptide | n2=en:mosaic corneal dystrophy ('shagreen') | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mosapride n1=cyclopeptide | n2=en:mosapride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:motesanib diphosphate n1=cyclopeptide | n2=en:motesanib diphosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:motexafin gadolinium n1=cyclopeptide | n2=en:motexafin gadolinium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:motexafin lutetium n1=cyclopeptide | n2=en:motexafin lutetium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:moth-eaten appearance of fovea (in some patients) n1=cyclopeptide | n2=en:moth-eaten appearance of fovea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mottled pigmentation of retina n1=cyclopeptide | n2=en:mottled pigmentation of retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mouse gp100 plasmid dna vaccine n1=cyclopeptide | n2=en:mouse gp100 plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mouse prostate-specific membrane antigen plasmid dna vaccine n1=cyclopeptide | n2=en:mouse prostate-specific membrane antigen plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads n1=cyclopeptide | n2=en:mouse renal adenocarcinoma cell-encapsulated agarose-agarose macrobeads | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mov-gamma chimeric receptor gene n1=cyclopeptide | n2=en:mov-gamma chimeric receptor gene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:movement of visual image - finding n1=cyclopeptide | n2=en:movement of visual image - finding | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:moxalactam n1=cyclopeptide | n2=en:moxalactam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:moxetumomab pasudotox n1=cyclopeptide | n2=en:moxetumomab pasudotox | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:moxifloxacin hydrochloride n1=cyclopeptide | n2=en:moxifloxacin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mpccv protocol n1=cyclopeptide | n2=en:mpccv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mps1 inhibitor bay 1217389 n1=cyclopeptide | n2=en:mps1 inhibitor bay 1217389 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mps1 kinase inhibitor bay1161909 n1=cyclopeptide | n2=en:mps1 kinase inhibitor bay1161909 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mrna-derived lung cancer vaccine cv9202 n1=cyclopeptide | n2=en:mrna-derived lung cancer vaccine cv9202 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mrna-derived prostate cancer vaccine cv9103 n1=cyclopeptide | n2=en:mrna-derived prostate cancer vaccine cv9103 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mrna-derived prostate cancer vaccine cv9104 n1=cyclopeptide | n2=en:mrna-derived prostate cancer vaccine cv9104 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:msk-ny-ii protocol, modified n1=cyclopeptide | n2=en:msk-ny-ii protocol, modified | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtf-1 inhibitor apto-253 hcl n1=cyclopeptide | n2=en:mtf-1 inhibitor apto-253 hcl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtig7192a n1=cyclopeptide | n2=en:mtig7192a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtor kinase inhibitor azd8055 n1=cyclopeptide | n2=en:mtor kinase inhibitor azd8055 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtor kinase inhibitor cc-223 n1=cyclopeptide | n2=en:mtor kinase inhibitor cc-223 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtor kinase inhibitor osi-027 n1=cyclopeptide | n2=en:mtor kinase inhibitor osi-027 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtor1/2 kinase inhibitor me-344 n1=cyclopeptide | n2=en:mtor1/2 kinase inhibitor me-344 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtorc1/2 kinase inhibitor bi 860585 n1=cyclopeptide | n2=en:mtorc1/2 kinase inhibitor bi 860585 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtorc1/mtorc2/dhfr inhibitor abtl0812 n1=cyclopeptide | n2=en:mtorc1/mtorc2/dhfr inhibitor abtl0812 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mtx-chop protocol n1=cyclopeptide | n2=en:mtx-chop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc-1 antigen n1=cyclopeptide | n2=en:muc-1 antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc-1 peptide vaccine n1=cyclopeptide | n2=en:muc-1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc-2-globo h-klh conjugate vaccine n1=cyclopeptide | n2=en:muc-2-globo h-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc-2-klh vaccine n1=cyclopeptide | n2=en:muc-2-klh vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc1 antigen/sb as-2 n1=cyclopeptide | n2=en:muc1 antigen/sb as-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc1 peptide-poly-iclc adjuvant vaccine n1=cyclopeptide | n2=en:muc1 peptide-poly-iclc adjuvant vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc1-klh conjugate vaccine n1=cyclopeptide | n2=en:muc1-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc1-klh vaccine/qs21 n1=cyclopeptide | n2=en:muc1-klh vaccine/qs21 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc1-targeted peptide go-203-2c n1=cyclopeptide | n2=en:muc1-targeted peptide go-203-2c | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muc16-targeted antibody-drug conjugate dmuc5754a n1=cyclopeptide | n2=en:muc16-targeted antibody-drug conjugate dmuc5754a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mucoadhesive hydrogel gargle n1=cyclopeptide | n2=en:mucoadhesive hydrogel gargle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mucoadhesive oral wound rinse n1=cyclopeptide | n2=en:mucoadhesive oral wound rinse | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mucoadhesive paclitaxel formulation n1=cyclopeptide | n2=en:mucoadhesive paclitaxel formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mucoprotective agent xer2020 n1=cyclopeptide | n2=en:mucoprotective agent xer2020 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multi-agc kinase inhibitor at13148 n1=cyclopeptide | n2=en:multi-agc kinase inhibitor at13148 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multi-epitope folate receptor alpha peptide vaccine n1=cyclopeptide | n2=en:multi-epitope folate receptor alpha peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multi-epitope melanoma peptide vaccine n1=cyclopeptide | n2=en:multi-epitope melanoma peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multi-glioblastoma-peptide-targeting autologous dendritic cell vaccine ict-107 n1=cyclopeptide | n2=en:multi-glioblastoma-peptide-targeting autologous dendritic cell vaccine ict-107 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multi-peptide cmv-modified vaccinia ankara vaccine n1=cyclopeptide | n2=en:multi-peptide cmv-modified vaccinia ankara vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multi-subtype natural human leukocyte interferon alpha n1=cyclopeptide | n2=en:multi-subtype natural human leukocyte interferon alpha | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multi-targeted cyclin-dependent protein kinase inhibitor rgb-286638 n1=cyclopeptide | n2=en:multi-targeted cyclin-dependent protein kinase inhibitor rgb-286638 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multicarotenoid supplement mcs-8 n1=cyclopeptide | n2=en:multicarotenoid supplement mcs-8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multidrug resistance modulator n1=cyclopeptide | n2=en:multidrug resistance modulator | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multifocal choroiditis n1=cyclopeptide | n2=en:multifocal choroiditis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multifocal yellow-white geographic, solid, choriodal lesions along the retinal vascular arcades n1=cyclopeptide | n2=en:multifocal yellow-white geographic, solid, choriodal lesions along the retinal vascular arcades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multifunctional/multitargeted anticancer agent omn54 n1=cyclopeptide | n2=en:multifunctional/multitargeted anticancer agent omn54 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multikinase inhibitor 4sc-203 n1=cyclopeptide | n2=en:multikinase inhibitor 4sc-203 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multikinase inhibitor arry614 n1=cyclopeptide | n2=en:multikinase inhibitor arry614 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multikinase inhibitor at9283 n1=cyclopeptide | n2=en:multikinase inhibitor at9283 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multikinase inhibitor sar103168 n1=cyclopeptide | n2=en:multikinase inhibitor sar103168 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multilobulated central atrophic maculopathy (in some patients) n1=cyclopeptide | n2=en:multilobulated central atrophic maculopathy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multipeptide vaccine s-588210 n1=cyclopeptide | n2=en:multipeptide vaccine s-588210 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multiple anterior segment anomalies n1=cyclopeptide | n2=en:multiple anterior segment anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multiple congenital anomalies n1=cyclopeptide | n2=en:multiple congenital anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multiple retinal holes n1=cyclopeptide | n2=en:multiple retinal holes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multiple rows of eyelashes n1=cyclopeptide | n2=en:multiple rows of eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multitargeted kinase inhibitor mgcd516 n1=cyclopeptide | n2=en:multitargeted kinase inhibitor mgcd516 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multitargeted tyrosine kinase inhibitor jnj-26483327 n1=cyclopeptide | n2=en:multitargeted tyrosine kinase inhibitor jnj-26483327 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multitargeted tyrosine kinase inhibitor mgcd265 n1=cyclopeptide | n2=en:multitargeted tyrosine kinase inhibitor mgcd265 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:multivitamin n1=cyclopeptide | n2=en:multivitamin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mureletecan n1=cyclopeptide | n2=en:mureletecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:murine tyrp2 plasmid dna vaccine n1=cyclopeptide | n2=en:murine tyrp2 plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:murine-human monoclonal igg antibody n1=cyclopeptide | n2=en:murine-human monoclonal igg antibody | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muromonab-cd3 n1=cyclopeptide | n2=en:muromonab-cd3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muscadine grape skin extract n1=cyclopeptide | n2=en:muscadine grape skin extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muscarinic agonist apd515 n1=cyclopeptide | n2=en:muscarinic agonist apd515 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muscle relaxant n1=cyclopeptide | n2=en:muscle relaxant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:muscular dystrophy, oculopharyngeal n1=cyclopeptide | n2=en:muscular dystrophy, oculopharyngeal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:musculoskeletal and connective tissue disorders of face, neck and jaw congenital n1=cyclopeptide | n2=en:musculoskeletal and connective tissue disorders of face, neck and jaw congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mutagen n1=cyclopeptide | n2=en:mutagen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mutant p53 activator coti-2 n1=cyclopeptide | n2=en:mutant p53 activator coti-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mutant p53 peptide pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:mutant p53 peptide pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mutant-selective egfr inhibitor pf-06459988 n1=cyclopeptide | n2=en:mutant-selective egfr inhibitor pf-06459988 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mva-ebna1/lmp2 vaccine n1=cyclopeptide | n2=en:mva-ebna1/lmp2 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mva-fcu1 tg4023 n1=cyclopeptide | n2=en:mva-fcu1 tg4023 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mva-muc1-il2 vaccine n1=cyclopeptide | n2=en:mva-muc1-il2 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mva-psa/pap prostate cancer vaccine n1=cyclopeptide | n2=en:mva-psa/pap prostate cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mvf-her-2(597-626)/mvf-her-2 (266-296) peptide vaccine n1=cyclopeptide | n2=en:mvf-her-2(597-626)/mvf-her-2 (266-296) peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mvf-her-2(628-647)-crl 1005 vaccine n1=cyclopeptide | n2=en:mvf-her-2(628-647)-crl 1005 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mvp-cab protocol n1=cyclopeptide | n2=en:mvp-cab protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mvx-1-loaded macrocapsule/autologous tumor cell vaccine mvx-onco-1 n1=cyclopeptide | n2=en:mvx-1-loaded macrocapsule/autologous tumor cell vaccine mvx-onco-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myc-targeting sirna dcr-myc n1=cyclopeptide | n2=en:myc-targeting sirna dcr-myc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycobacterial cell wall-dna complex n1=cyclopeptide | n2=en:mycobacterial cell wall-dna complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycobacterium tuberculosis arabinomannan z-100 n1=cyclopeptide | n2=en:mycobacterium tuberculosis arabinomannan z-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycobacterium w n1=cyclopeptide | n2=en:mycobacterium w | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate n1=cyclopeptide | n2=en:mycophenolate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil n1=cyclopeptide | n2=en:mycophenolate mofetil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil 1g/5ml oral suspension n1=cyclopeptide | n2=en:mycophenolate mofetil 1g/5ml oral suspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil 200 mg/ml oral suspension [cellcept] n1=cyclopeptide | n2=en:mycophenolate mofetil 200 mg/ml oral suspension [cellcept] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil 250 mg oral capsule n1=cyclopeptide | n2=en:mycophenolate mofetil 250 mg oral capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil 250 mg oral capsule [cellcept] n1=cyclopeptide | n2=en:mycophenolate mofetil 250 mg oral capsule [cellcept] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil 500 mg oral tablet [cellcept] n1=cyclopeptide | n2=en:mycophenolate mofetil 500 mg oral tablet [cellcept] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil 500mg powder for infusion solution vial n1=cyclopeptide | n2=en:mycophenolate mofetil 500mg powder for infusion solution vial | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil 500mg tablet n1=cyclopeptide | n2=en:mycophenolate mofetil 500mg tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate mofetil hydrochloride n1=cyclopeptide | n2=en:mycophenolate mofetil hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolate sodium n1=cyclopeptide | n2=en:mycophenolate sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolic acid n1=cyclopeptide | n2=en:mycophenolic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolic acid 180mg gastro-resistant tablet n1=cyclopeptide | n2=en:mycophenolic acid 180mg gastro-resistant tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mycophenolic acid 360mg gastro-resistant tablet n1=cyclopeptide | n2=en:mycophenolic acid 360mg gastro-resistant tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:mydriasis, congenital n1=cyclopeptide | n2=en:mydriasis, congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myeloablative agonist n1=cyclopeptide | n2=en:myeloablative agonist | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myelomeningocele n1=cyclopeptide | n2=en:myelomeningocele | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia n1=cyclopeptide | n2=en:myopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (1 family) n1=cyclopeptide | n2=en:myopia (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (1/4 patients) n1=cyclopeptide | n2=en:myopia (1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (in 1 patient) n1=cyclopeptide | n2=en:myopia (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (in 2 of 3 siblings) n1=cyclopeptide | n2=en:myopia (in 2 of 3 siblings) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (in brother) n1=cyclopeptide | n2=en:myopia (in brother) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (in most patients) n1=cyclopeptide | n2=en:myopia (in most patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (in some patients) n1=cyclopeptide | n2=en:myopia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (less common) n1=cyclopeptide | n2=en:myopia (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (onset before 6 years) n1=cyclopeptide | n2=en:myopia (onset before 6 years) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (onset in first decade) n1=cyclopeptide | n2=en:myopia (onset in first decade) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (onset in teens) n1=cyclopeptide | n2=en:myopia (onset in teens) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (reported in 1 family) n1=cyclopeptide | n2=en:myopia (reported in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia (reported in 1 patient) n1=cyclopeptide | n2=en:myopia (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia of variable severity n1=cyclopeptide | n2=en:myopia of variable severity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, apparent with age n1=cyclopeptide | n2=en:myopia, apparent with age | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, high-grade (average refractive error -7.04 diopters) n1=cyclopeptide | n2=en:myopia, high-grade (average refractive error -7.04 diopters) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, high-grade (average spherical refractive error of -22.00d) n1=cyclopeptide | n2=en:myopia, high-grade (average spherical refractive error of -22.00d) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, high-grade bilateral (range -5.50 to -50 diopters, average adult refractive error -13.925 diopters) n1=cyclopeptide | n2=en:myopia, high-grade bilateral (range -5.50 to -50 diopters, average adult refractive error -13.925 diopters) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, infantile n1=cyclopeptide | n2=en:myopia, infantile | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, low to moderate (-12.12 d to +7.25 d) n1=cyclopeptide | n2=en:myopia, low to moderate (-12.12 d to +7.25 d) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, mild n1=cyclopeptide | n2=en:myopia, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, mild to severe n1=cyclopeptide | n2=en:myopia, mild to severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, moderate to high n1=cyclopeptide | n2=en:myopia, moderate to high | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, progressive severe n1=cyclopeptide | n2=en:myopia, progressive severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopia, progressive, early onset n1=cyclopeptide | n2=en:myopia, progressive, early onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopic chorioretinal atrophy n1=cyclopeptide | n2=en:myopic chorioretinal atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:myopic conus (in some patients) n1=cyclopeptide | n2=en:myopic conus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:n-methylformamide n1=cyclopeptide | n2=en:n-methylformamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:n,n-diethylcyclophosphamide n1=cyclopeptide | n2=en:n,n-diethylcyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:n(3)-methyl-4-(diethyldithiocarbamoyl)cyclophosphamide n1=cyclopeptide | n2=en:n(3)-methyl-4-(diethyldithiocarbamoyl)cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:n(3)-methyl-4-(propylthio)cyclophosphamide n1=cyclopeptide | n2=en:n(3)-methyl-4-(propylthio)cyclophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:n4se protocol n1=cyclopeptide | n2=en:n4se protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:na-17/mage-3.a2/ny-eso-1 peptide vaccine n1=cyclopeptide | n2=en:na-17/mage-3.a2/ny-eso-1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:na17-a antigen n1=cyclopeptide | n2=en:na17-a antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:na17.a2 peptide vaccine n1=cyclopeptide | n2=en:na17.a2 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nabilone n1=cyclopeptide | n2=en:nabilone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nabiximols n1=cyclopeptide | n2=en:nabiximols | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nadolol n1=cyclopeptide | n2=en:nadolol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nadroparin calcium n1=cyclopeptide | n2=en:nadroparin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nafarelin n1=cyclopeptide | n2=en:nafarelin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nafazatrom n1=cyclopeptide | n2=en:nafazatrom | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nafoxidine hydrochloride n1=cyclopeptide | n2=en:nafoxidine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:naloxegol n1=cyclopeptide | n2=en:naloxegol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:naloxone + oxycodone n1=cyclopeptide | n2=en:naloxone + oxycodone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:naloxone hydrochloride n1=cyclopeptide | n2=en:naloxone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:naltrexone hydrochloride n1=cyclopeptide | n2=en:naltrexone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nandrolone decanoate n1=cyclopeptide | n2=en:nandrolone decanoate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nanocell-encapsulated mir-16-based microrna mimic n1=cyclopeptide | n2=en:nanocell-encapsulated mir-16-based microrna mimic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nanoparticle albumin-bound docetaxel n1=cyclopeptide | n2=en:nanoparticle albumin-bound docetaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nanoparticle albumin-bound rapamycin n1=cyclopeptide | n2=en:nanoparticle albumin-bound rapamycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nanoparticle albumin-bound thiocolchicine dimer nab-5404 n1=cyclopeptide | n2=en:nanoparticle albumin-bound thiocolchicine dimer nab-5404 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nanoparticle-encapsulated docetaxel n1=cyclopeptide | n2=en:nanoparticle-encapsulated docetaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nanoparticle-encapsulated doxorubicin hydrochloride n1=cyclopeptide | n2=en:nanoparticle-encapsulated doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nanosomal docetaxel lipid suspension n1=cyclopeptide | n2=en:nanosomal docetaxel lipid suspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:napabucasin n1=cyclopeptide | n2=en:napabucasin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:naphthalimide analogue unbs5162 n1=cyclopeptide | n2=en:naphthalimide analogue unbs5162 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:napirimus n1=cyclopeptide | n2=en:napirimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:naproxen n1=cyclopeptide | n2=en:naproxen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:naptumomab n1=cyclopeptide | n2=en:naptumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:narnatumab n1=cyclopeptide | n2=en:narnatumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:narrow palpebral fissures (9 of 22) n1=cyclopeptide | n2=en:narrow palpebral fissures (9 of 22) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:narrow palpebral fissures (in some patients) n1=cyclopeptide | n2=en:narrow palpebral fissures (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:narrowed vasculature n1=cyclopeptide | n2=en:narrowed vasculature | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:narrowed vessels n1=cyclopeptide | n2=en:narrowed vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nasal dosage form product n1=cyclopeptide | n2=en:nasal dosage form product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nasal saline irrigation solution n1=cyclopeptide | n2=en:nasal saline irrigation solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nasally displaced pupils (in some patients) n1=cyclopeptide | n2=en:nasally displaced pupils (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nasolacrimal duct obstruction (classic feature) n1=cyclopeptide | n2=en:nasolacrimal duct obstruction (classic feature) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nasolacrimal duct obstruction due to ectropion of lower eyelids (rare) n1=cyclopeptide | n2=en:nasolacrimal duct obstruction due to ectropion of lower eyelids (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:natalizumab n1=cyclopeptide | n2=en:natalizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nateglinide n1=cyclopeptide | n2=en:nateglinide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:natural ifn-alpha opc-18 n1=cyclopeptide | n2=en:natural ifn-alpha opc-18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:natural killer cells zrx101 n1=cyclopeptide | n2=en:natural killer cells zrx101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:navitoclax n1=cyclopeptide | n2=en:navitoclax | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:navy bean powder n1=cyclopeptide | n2=en:navy bean powder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nci pb 93-c-207 protocol n1=cyclopeptide | n2=en:nci pb 93-c-207 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ncit antineoplastic agent terminology n1=cyclopeptide | n2=en:ncit antineoplastic agent terminology | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ncmtrna oligonucleotide andes-1537 n1=cyclopeptide | n2=en:ncmtrna oligonucleotide andes-1537 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ncvb protocol n1=cyclopeptide | n2=en:ncvb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nd-420 n1=cyclopeptide | n2=en:nd-420 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:near complete loss of peripheral retinal pigment in males n1=cyclopeptide | n2=en:near complete loss of peripheral retinal pigment in males | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:necitumumab n1=cyclopeptide | n2=en:necitumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nedaplatin n1=cyclopeptide | n2=en:nedaplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nefopam hydrochloride n1=cyclopeptide | n2=en:nefopam hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neihulizumab n1=cyclopeptide | n2=en:neihulizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nelarabine n1=cyclopeptide | n2=en:nelarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nelfinavir mesylate n1=cyclopeptide | n2=en:nelfinavir mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nelipepimut-s plus gm-csf vaccine n1=cyclopeptide | n2=en:nelipepimut-s plus gm-csf vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neo-macop-b protocol n1=cyclopeptide | n2=en:neo-macop-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neoantigen-based glioblastoma vaccine n1=cyclopeptide | n2=en:neoantigen-based glioblastoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neoantigen-based melanoma-poly-iclc vaccine n1=cyclopeptide | n2=en:neoantigen-based melanoma-poly-iclc vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neomycin n1=cyclopeptide | n2=en:neomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neonatal deformity n1=cyclopeptide | n2=en:neonatal deformity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neonatal hearing impairment n1=cyclopeptide | n2=en:neonatal hearing impairment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neonatal jaundice n1=cyclopeptide | n2=en:neonatal jaundice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neonatal vitreous hemorrhages n1=cyclopeptide | n2=en:neonatal vitreous hemorrhages | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neoplasm of ocular adnexa n1=cyclopeptide | n2=en:neoplasm of ocular adnexa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neovascularization n1=cyclopeptide | n2=en:neovascularization | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nepidermin n1=cyclopeptide | n2=en:nepidermin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neratinib n1=cyclopeptide | n2=en:neratinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nesiritide n1=cyclopeptide | n2=en:nesiritide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nesvacumab n1=cyclopeptide | n2=en:nesvacumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:netazepide n1=cyclopeptide | n2=en:netazepide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:netupitant n1=cyclopeptide | n2=en:netupitant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:netupitant/palonosetron hydrochloride n1=cyclopeptide | n2=en:netupitant/palonosetron hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neural tube defect n1=cyclopeptide | n2=en:neural tube defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neurodevelopmental anomaly n1=cyclopeptide | n2=en:neurodevelopmental anomaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neuromuscular blocking agents n1=cyclopeptide | n2=en:neuromuscular blocking agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neuropharmacologic agent n1=cyclopeptide | n2=en:neuropharmacologic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neurotrophic keratitis n1=cyclopeptide | n2=en:neurotrophic keratitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neutral palpebral fissures n1=cyclopeptide | n2=en:neutral palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:neutrophil activation probe imaging agent n1=cyclopeptide | n2=en:neutrophil activation probe imaging agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nevirapine n1=cyclopeptide | n2=en:nevirapine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nevoid basal cell carcinoma syndrome n1=cyclopeptide | n2=en:nevoid basal cell carcinoma syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nevus of ota n1=cyclopeptide | n2=en:nevus of ota | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:new york protocol n1=cyclopeptide | n2=en:new york protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ng-nitro-l-arginine n1=cyclopeptide | n2=en:ng-nitro-l-arginine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ngfr-transduced autologous t lymphocytes n1=cyclopeptide | n2=en:ngfr-transduced autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nhl-bfm-90 regimen n1=cyclopeptide | n2=en:nhl-bfm-90 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nhl-bfm-95 regimen n1=cyclopeptide | n2=en:nhl-bfm-95 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:niacin n1=cyclopeptide | n2=en:niacin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:niacinamide n1=cyclopeptide | n2=en:niacinamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nicardipine n1=cyclopeptide | n2=en:nicardipine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:niclosamide n1=cyclopeptide | n2=en:niclosamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nicolaides baraitser syndrome n1=cyclopeptide | n2=en:nicolaides baraitser syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nicotine n1=cyclopeptide | n2=en:nicotine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nicotine gum n1=cyclopeptide | n2=en:nicotine gum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nicotine lozenge n1=cyclopeptide | n2=en:nicotine lozenge | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nicotine nasal spray n1=cyclopeptide | n2=en:nicotine nasal spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nicotine patch n1=cyclopeptide | n2=en:nicotine patch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nifurtimox n1=cyclopeptide | n2=en:nifurtimox | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness n1=cyclopeptide | n2=en:night blindness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness (age of onset from <10 to >21 years of age) n1=cyclopeptide | n2=en:night blindness (age of onset from <10 to >21 years of age) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness (in some patients) n1=cyclopeptide | n2=en:night blindness (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness (infancy and early childhood) n1=cyclopeptide | n2=en:night blindness (infancy and early childhood) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness (occurs first) n1=cyclopeptide | n2=en:night blindness (occurs first) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness (onset in first decade) n1=cyclopeptide | n2=en:night blindness (onset in first decade) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness (onset in teens) n1=cyclopeptide | n2=en:night blindness (onset in teens) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness beginning in early childhood n1=cyclopeptide | n2=en:night blindness beginning in early childhood | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness beginning in the 6th decade n1=cyclopeptide | n2=en:night blindness beginning in the 6th decade | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness by age 20 years n1=cyclopeptide | n2=en:night blindness by age 20 years | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness followed by complete blindness n1=cyclopeptide | n2=en:night blindness followed by complete blindness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness onset during teen years n1=cyclopeptide | n2=en:night blindness onset during teen years | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness, congenital stationary n1=cyclopeptide | n2=en:night blindness, congenital stationary | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness, in some female carriers n1=cyclopeptide | n2=en:night blindness, in some female carriers | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness, severe n1=cyclopeptide | n2=en:night blindness, severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness, stationary n1=cyclopeptide | n2=en:night blindness, stationary | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:night blindness, with onset in first and second decades of life n1=cyclopeptide | n2=en:night blindness, with onset in first and second decades of life | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nijmegen breakage syndrome n1=cyclopeptide | n2=en:nijmegen breakage syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nilotinib n1=cyclopeptide | n2=en:nilotinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nilutamide n1=cyclopeptide | n2=en:nilutamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nimodipine n1=cyclopeptide | n2=en:nimodipine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nimorazole n1=cyclopeptide | n2=en:nimorazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nimotuzumab n1=cyclopeptide | n2=en:nimotuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nimustine n1=cyclopeptide | n2=en:nimustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nintedanib n1=cyclopeptide | n2=en:nintedanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:niraparib n1=cyclopeptide | n2=en:niraparib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nitazoxanide n1=cyclopeptide | n2=en:nitazoxanide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nitric oxide-releasing acetylsalicylic acid derivative n1=cyclopeptide | n2=en:nitric oxide-releasing acetylsalicylic acid derivative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nitrogen mustard n1=cyclopeptide | n2=en:nitrogen mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nitrogen mustard compound n1=cyclopeptide | n2=en:nitrogen mustard compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nitroglycerin n1=cyclopeptide | n2=en:nitroglycerin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nitroglycerin transdermal patch n1=cyclopeptide | n2=en:nitroglycerin transdermal patch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nitroglycerin/sodium citrate/ethanol solution n1=cyclopeptide | n2=en:nitroglycerin/sodium citrate/ethanol solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nitrosourea compound n1=cyclopeptide | n2=en:nitrosourea compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nivolumab n1=cyclopeptide | n2=en:nivolumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nm-3 n1=cyclopeptide | n2=en:nm-3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no cataract (epstein syndrome) n1=cyclopeptide | n2=en:no cataract (epstein syndrome) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no cataracts n1=cyclopeptide | n2=en:no cataracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no cherry red spots n1=cyclopeptide | n2=en:no cherry red spots | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no corneal erosions n1=cyclopeptide | n2=en:no corneal erosions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no corneal opacities n1=cyclopeptide | n2=en:no corneal opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no heterochromia irides n1=cyclopeptide | n2=en:no heterochromia irides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no light-evoked response on electroretinogram (erg) n1=cyclopeptide | n2=en:no light-evoked response on electroretinogram (erg) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no lisch nodules n1=cyclopeptide | n2=en:no lisch nodules | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no nystagmus n1=cyclopeptide | n2=en:no nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no ocular symptoms n1=cyclopeptide | n2=en:no ocular symptoms | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no other ocular defects n1=cyclopeptide | n2=en:no other ocular defects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no response to dim stimuli in dark-adapted state on electroretinography n1=cyclopeptide | n2=en:no response to dim stimuli in dark-adapted state on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no retinal degeneration n1=cyclopeptide | n2=en:no retinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no retinitis pigmentosa n1=cyclopeptide | n2=en:no retinitis pigmentosa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no retinopathy n1=cyclopeptide | n2=en:no retinopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no visual attention n1=cyclopeptide | n2=en:no visual attention | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:no visual tracking n1=cyclopeptide | n2=en:no visual tracking | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nolatrexed dihydrochloride n1=cyclopeptide | n2=en:nolatrexed dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:non-adjuvanted a(h1n1) influenza vaccine n1=cyclopeptide | n2=en:non-adjuvanted a(h1n1) influenza vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:non-small cell lung cancer mrna-derived vaccine cv9201 n1=cyclopeptide | n2=en:non-small cell lung cancer mrna-derived vaccine cv9201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nonarteritic anterior ischemic optic neuropathy (naion) n1=cyclopeptide | n2=en:nonarteritic anterior ischemic optic neuropathy (naion) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nonaxial myopia n1=cyclopeptide | n2=en:nonaxial myopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nondetectable electroretinogram, all components, in older individuals n1=cyclopeptide | n2=en:nondetectable electroretinogram, all components, in older individuals | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nondetectable photopic responses on electroretinography n1=cyclopeptide | n2=en:nondetectable photopic responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nondetectable responses on electroretinography n1=cyclopeptide | n2=en:nondetectable responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nondetectable scotopic electroretinogram with relative preservation of photopic and pattern elements in younger patients n1=cyclopeptide | n2=en:nondetectable scotopic electroretinogram with relative preservation of photopic and pattern elements in younger patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nonenzyme proteolytic agent n1=cyclopeptide | n2=en:nonenzyme proteolytic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nonprogressive restrictive ophthalmoplegia (superior rectus, inferior oblique, levator palpebralis dysfunction) n1=cyclopeptide | n2=en:nonprogressive restrictive ophthalmoplegia (superior rectus, inferior oblique, levator palpebralis dysfunction) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nonreactive, fixed narrowing of the pupil ('microcoria') n1=cyclopeptide | n2=en:nonreactive, fixed narrowing of the pupil ('microcoria') | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nonrecordable or severely reduced rod pattern on electroretinogram n1=cyclopeptide | n2=en:nonrecordable or severely reduced rod pattern on electroretinogram | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nonspecific changes on electroretinogram in carrier females n1=cyclopeptide | n2=en:nonspecific changes on electroretinogram in carrier females | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nonspecific granular appearance of retinal pigment epithelium n1=cyclopeptide | n2=en:nonspecific granular appearance of retinal pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:norepinephrine, dl- n1=cyclopeptide | n2=en:norepinephrine, dl- | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:norethindrone acetate n1=cyclopeptide | n2=en:norethindrone acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:norgestrel n1=cyclopeptide | n2=en:norgestrel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal color vision n1=cyclopeptide | n2=en:normal color vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal eyelashes n1=cyclopeptide | n2=en:normal eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal eyelashes, eyebrows n1=cyclopeptide | n2=en:normal eyelashes, eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal eyelid n1=cyclopeptide | n2=en:normal eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal full-field electroretinogram n1=cyclopeptide | n2=en:normal full-field electroretinogram | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal fundus on ophthalmoscopy n1=cyclopeptide | n2=en:normal fundus on ophthalmoscopy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal intraocular pressure n1=cyclopeptide | n2=en:normal intraocular pressure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal lacrimal puncta n1=cyclopeptide | n2=en:normal lacrimal puncta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal lacrimation n1=cyclopeptide | n2=en:normal lacrimation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal or decreased arden ratios on electrooculography n1=cyclopeptide | n2=en:normal or decreased arden ratios on electrooculography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal or decreased cone and rod responses on electroretinography n1=cyclopeptide | n2=en:normal or decreased cone and rod responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal or mildly reduced cone responses under photopic conditions n1=cyclopeptide | n2=en:normal or mildly reduced cone responses under photopic conditions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal or reduced electrooculographic (eog) results n1=cyclopeptide | n2=en:normal or reduced electrooculographic (eog) results | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal or reduced responses on electroretinography n1=cyclopeptide | n2=en:normal or reduced responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal palpebral fissures n1=cyclopeptide | n2=en:normal palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal photopic and scotopic responses on electroretinography (erg) n1=cyclopeptide | n2=en:normal photopic and scotopic responses on electroretinography (erg) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal retinal and pupillary reflexes between episodes n1=cyclopeptide | n2=en:normal retinal and pupillary reflexes between episodes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal rod function on erg n1=cyclopeptide | n2=en:normal rod function on erg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal sclerae n1=cyclopeptide | n2=en:normal sclerae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal scotopic responses on rod electroretinogram (in some patients) n1=cyclopeptide | n2=en:normal scotopic responses on rod electroretinogram (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal to near-normal visual acuity in carrier females (20/30-20/20) n1=cyclopeptide | n2=en:normal to near-normal visual acuity in carrier females (20/30-20/20) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal vision (females) n1=cyclopeptide | n2=en:normal vision (females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal visual acuity n1=cyclopeptide | n2=en:normal visual acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal vitreous n1=cyclopeptide | n2=en:normal vitreous | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:normal-greyish sclerae n1=cyclopeptide | n2=en:normal-greyish sclerae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:north american ginseng extract afx-2 n1=cyclopeptide | n2=en:north american ginseng extract afx-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nortriptyline hydrochloride n1=cyclopeptide | n2=en:nortriptyline hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:noscapine hydrochloride n1=cyclopeptide | n2=en:noscapine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nostrums n1=cyclopeptide | n2=en:nostrums | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:notch signaling inhibitor pf-06650808 n1=cyclopeptide | n2=en:notch signaling inhibitor pf-06650808 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:notch signaling pathway inhibitor mk0752 n1=cyclopeptide | n2=en:notch signaling pathway inhibitor mk0752 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:novembichin n1=cyclopeptide | n2=en:novembichin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:novobiocin n1=cyclopeptide | n2=en:novobiocin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nrf2 activator rta 408 n1=cyclopeptide | n2=en:nrf2 activator rta 408 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ns-9 n1=cyclopeptide | n2=en:ns-9 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ns5b polymerase inhibitor bms-791325 n1=cyclopeptide | n2=en:ns5b polymerase inhibitor bms-791325 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nsc 26271 n1=cyclopeptide | n2=en:nsc 26271 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nsclc antigen-loaded dendritic cell-derived exosomesnon-small cell lung cancer tumor antigen-loaded dendritic cell-derived exosomes n1=cyclopeptide | n2=en:nsclc antigen-loaded dendritic cell-derived exosomesnon-small cell lung cancer tumor antigen-loaded dendritic cell-derived exosomes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ntrk/ros1 inhibitor ds-6051b n1=cyclopeptide | n2=en:ntrk/ros1 inhibitor ds-6051b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nuclear cataract n1=cyclopeptide | n2=en:nuclear cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nuclear cataract (in some patients) retinal dystrophy (in some patients) n1=cyclopeptide | n2=en:nuclear cataract (in some patients) retinal dystrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nucleolin antagonist ipp-204106n n1=cyclopeptide | n2=en:nucleolin antagonist ipp-204106n | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nucleoside analog dfp-10917 n1=cyclopeptide | n2=en:nucleoside analog dfp-10917 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nucleotide analogue gs 9219 n1=cyclopeptide | n2=en:nucleotide analogue gs 9219 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:null point shifts every few seconds to minutes n1=cyclopeptide | n2=en:null point shifts every few seconds to minutes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nutlin-3a n1=cyclopeptide | n2=en:nutlin-3a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nutraceutical tbl-12 n1=cyclopeptide | n2=en:nutraceutical tbl-12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nutrient-rich whole wheat flour supplement n1=cyclopeptide | n2=en:nutrient-rich whole wheat flour supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nutritional supplement drink n1=cyclopeptide | n2=en:nutritional supplement drink | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nv1020 n1=cyclopeptide | n2=en:nv1020 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nwts regimen 1 n1=cyclopeptide | n2=en:nwts regimen 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nx-1207 n1=cyclopeptide | n2=en:nx-1207 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1 peptide vaccine n1=cyclopeptide | n2=en:ny-eso-1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1 plasmid dna cancer vaccine n1=cyclopeptide | n2=en:ny-eso-1 plasmid dna cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1 protein vaccine plus montanide isa-51 vg n1=cyclopeptide | n2=en:ny-eso-1 protein vaccine plus montanide isa-51 vg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1 reactive tcr retroviral vector transduced autologous pbl n1=cyclopeptide | n2=en:ny-eso-1 reactive tcr retroviral vector transduced autologous pbl | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1-specific cd4-positive t lymphocytes n1=cyclopeptide | n2=en:ny-eso-1-specific cd4-positive t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1-specific tcr gene-transduced t lymphocytes tbi-1301 n1=cyclopeptide | n2=en:ny-eso-1-specific tcr gene-transduced t lymphocytes tbi-1301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1/gla-se vaccine id-g305 n1=cyclopeptide | n2=en:ny-eso-1/gla-se vaccine id-g305 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1/lage-1 peptide vaccine n1=cyclopeptide | n2=en:ny-eso-1/lage-1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1/mage-a4/prame/survivin/ssx-specific autologous cytotoxic t lymphoyctes n1=cyclopeptide | n2=en:ny-eso-1/mage-a4/prame/survivin/ssx-specific autologous cytotoxic t lymphoyctes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1/mart-1 peptide-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:ny-eso-1/mart-1 peptide-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1/prame/mage-a3/wt-1 peptide vaccine n1=cyclopeptide | n2=en:ny-eso-1/prame/mage-a3/wt-1 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-1b peptide vaccine n1=cyclopeptide | n2=en:ny-eso-1b peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ny-eso-b n1=cyclopeptide | n2=en:ny-eso-b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nyctalopia (in some patients) n1=cyclopeptide | n2=en:nyctalopia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nyctalopia, congenital (in some patients) n1=cyclopeptide | n2=en:nyctalopia, congenital (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus n1=cyclopeptide | n2=en:nystagmus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (1 family) n1=cyclopeptide | n2=en:nystagmus (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (1 patient) n1=cyclopeptide | n2=en:nystagmus (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (females) n1=cyclopeptide | n2=en:nystagmus (females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (in some patients) n1=cyclopeptide | n2=en:nystagmus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (infancy) n1=cyclopeptide | n2=en:nystagmus (infancy) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (may be permanent in 50% of patients) n1=cyclopeptide | n2=en:nystagmus (may be permanent in 50% of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (patient a) n1=cyclopeptide | n2=en:nystagmus (patient a) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (rare) n1=cyclopeptide | n2=en:nystagmus (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (reported in 1 patient) n1=cyclopeptide | n2=en:nystagmus (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (type i) n1=cyclopeptide | n2=en:nystagmus (type i) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus (uncommon) n1=cyclopeptide | n2=en:nystagmus (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus in adult patients n1=cyclopeptide | n2=en:nystagmus in adult patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus on lateral gaze n1=cyclopeptide | n2=en:nystagmus on lateral gaze | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, congenital horizontal pendular n1=cyclopeptide | n2=en:nystagmus, congenital horizontal pendular | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, horizontal n1=cyclopeptide | n2=en:nystagmus, horizontal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, horizontal (rare) n1=cyclopeptide | n2=en:nystagmus, horizontal (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, horizontal gaze-evoked n1=cyclopeptide | n2=en:nystagmus, horizontal gaze-evoked | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, horizontal, mild n1=cyclopeptide | n2=en:nystagmus, horizontal, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, horizontal, mild (44%) n1=cyclopeptide | n2=en:nystagmus, horizontal, mild (44%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, intermittent (1 of 2 sibs) n1=cyclopeptide | n2=en:nystagmus, intermittent (1 of 2 sibs) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, jerk n1=cyclopeptide | n2=en:nystagmus, jerk | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, jerky n1=cyclopeptide | n2=en:nystagmus, jerky | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, jerky, horizontal, congenital n1=cyclopeptide | n2=en:nystagmus, jerky, horizontal, congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, mild n1=cyclopeptide | n2=en:nystagmus, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, minimal rotational (rare) n1=cyclopeptide | n2=en:nystagmus, minimal rotational (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, moderate n1=cyclopeptide | n2=en:nystagmus, moderate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, pendular n1=cyclopeptide | n2=en:nystagmus, pendular | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, pendular (primarily in childhood) n1=cyclopeptide | n2=en:nystagmus, pendular (primarily in childhood) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, rotary n1=cyclopeptide | n2=en:nystagmus, rotary | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, rotary (in some patients) n1=cyclopeptide | n2=en:nystagmus, rotary (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystagmus, vertical (rare) n1=cyclopeptide | n2=en:nystagmus, vertical (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:nystatin n1=cyclopeptide | n2=en:nystatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:o-chloroacetylcarbamoylfumagillol n1=cyclopeptide | n2=en:o-chloroacetylcarbamoylfumagillol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:o/e - lens normal n1=cyclopeptide | n2=en:o/e - lens normal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:o6-benzylguanine n1=cyclopeptide | n2=en:o6-benzylguanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oat biscuit n1=cyclopeptide | n2=en:oat biscuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:obatoclax n1=cyclopeptide | n2=en:obatoclax | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:obatoclax mesylate n1=cyclopeptide | n2=en:obatoclax mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:obinutuzumab n1=cyclopeptide | n2=en:obinutuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oblimersen n1=cyclopeptide | n2=en:oblimersen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oblimersen sodium n1=cyclopeptide | n2=en:oblimersen sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oblique palpebral fissures n1=cyclopeptide | n2=en:oblique palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:obliteration of peripheral retinal blood vessels (in some patients) n1=cyclopeptide | n2=en:obliteration of peripheral retinal blood vessels (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:observation of narrowing of palpebral fissure n1=cyclopeptide | n2=en:observation of narrowing of palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:obstruction of nasolacrimal duct n1=cyclopeptide | n2=en:obstruction of nasolacrimal duct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oc-hdp protocol n1=cyclopeptide | n2=en:oc-hdp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocaratuzumab n1=cyclopeptide | n2=en:ocaratuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:occasional cataracts n1=cyclopeptide | n2=en:occasional cataracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocrelizumab n1=cyclopeptide | n2=en:ocrelizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocriplasmin n1=cyclopeptide | n2=en:ocriplasmin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:octreotide acetate n1=cyclopeptide | n2=en:octreotide acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:octreotide pamoate n1=cyclopeptide | n2=en:octreotide pamoate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular abnormalities often persist between attacks n1=cyclopeptide | n2=en:ocular abnormalities often persist between attacks | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular albinism (reported in 1 patient) n1=cyclopeptide | n2=en:ocular albinism (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular albinism, tyrosinase-positive n1=cyclopeptide | n2=en:ocular albinism, tyrosinase-positive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular colobomas (rare) n1=cyclopeptide | n2=en:ocular colobomas (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular cyst, inferior n1=cyclopeptide | n2=en:ocular cyst, inferior | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular disorders congenital nec n1=cyclopeptide | n2=en:ocular disorders congenital nec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular disturbances, nonspecific n1=cyclopeptide | n2=en:ocular disturbances, nonspecific | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular dosage form product n1=cyclopeptide | n2=en:ocular dosage form product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular flutter n1=cyclopeptide | n2=en:ocular flutter | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular foreign body n1=cyclopeptide | n2=en:ocular foreign body | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular gaze palsies (onset in second decade) n1=cyclopeptide | n2=en:ocular gaze palsies (onset in second decade) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular globe large n1=cyclopeptide | n2=en:ocular globe large | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular hypopigmentation n1=cyclopeptide | n2=en:ocular hypopigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular hypoplasia (1 patient) n1=cyclopeptide | n2=en:ocular hypoplasia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular melanosis n1=cyclopeptide | n2=en:ocular melanosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular motility disorders n1=cyclopeptide | n2=en:ocular motility disorders | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular muscle n1=cyclopeptide | n2=en:ocular muscle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular muscle palsies n1=cyclopeptide | n2=en:ocular muscle palsies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular nystagmus, spontaneous n1=cyclopeptide | n2=en:ocular nystagmus, spontaneous | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular pain, episodic n1=cyclopeptide | n2=en:ocular pain, episodic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular paresis n1=cyclopeptide | n2=en:ocular paresis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular pursuit poor or absent n1=cyclopeptide | n2=en:ocular pursuit poor or absent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular rupture n1=cyclopeptide | n2=en:ocular rupture | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocular telangiectasia n1=cyclopeptide | n2=en:ocular telangiectasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculo-dento-digital syndrome n1=cyclopeptide | n2=en:oculo-dento-digital syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculocerebrorenal syndrome n1=cyclopeptide | n2=en:oculocerebrorenal syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculocutaneous albinism n1=cyclopeptide | n2=en:oculocutaneous albinism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculocutaneous hypopigmentation (in some patients) n1=cyclopeptide | n2=en:oculocutaneous hypopigmentation (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculodigital reflex (in some patients) n1=cyclopeptide | n2=en:oculodigital reflex (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculodigital sign of franceschetti n1=cyclopeptide | n2=en:oculodigital sign of franceschetti | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculogyric crisis n1=cyclopeptide | n2=en:oculogyric crisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculogyric dystonic spasms n1=cyclopeptide | n2=en:oculogyric dystonic spasms | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculogyric eye movements n1=cyclopeptide | n2=en:oculogyric eye movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculomotor apraxia n1=cyclopeptide | n2=en:oculomotor apraxia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculomotor apraxia (56% of patients) n1=cyclopeptide | n2=en:oculomotor apraxia (56% of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculomotor apraxia (in 86% of patients) n1=cyclopeptide | n2=en:oculomotor apraxia (in 86% of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculomotor apraxia (in some patients) n1=cyclopeptide | n2=en:oculomotor apraxia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculomotor apraxia (rare) n1=cyclopeptide | n2=en:oculomotor apraxia (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculomotor apraxia (variable) n1=cyclopeptide | n2=en:oculomotor apraxia (variable) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculomotor muscle n1=cyclopeptide | n2=en:oculomotor muscle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculomotor nerve paralysis n1=cyclopeptide | n2=en:oculomotor nerve paralysis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculopalpebral synechia n1=cyclopeptide | n2=en:oculopalpebral synechia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oculoskeletal dysplasia n1=cyclopeptide | n2=en:oculoskeletal dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocv-103 n1=cyclopeptide | n2=en:ocv-103 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ocv-104 n1=cyclopeptide | n2=en:ocv-104 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:odanacatib n1=cyclopeptide | n2=en:odanacatib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:odontogenic cyst n1=cyclopeptide | n2=en:odontogenic cyst | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oepa regimen n1=cyclopeptide | n2=en:oepa regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oepa-copp regimen n1=cyclopeptide | n2=en:oepa-copp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ofatumumab n1=cyclopeptide | n2=en:ofatumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:off regimen n1=cyclopeptide | n2=en:off regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ofloxacin n1=cyclopeptide | n2=en:ofloxacin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oglufanide disodium n1=cyclopeptide | n2=en:oglufanide disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:olanzapine n1=cyclopeptide | n2=en:olanzapine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:olaparib n1=cyclopeptide | n2=en:olaparib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:olaratumab n1=cyclopeptide | n2=en:olaratumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oleandrin n1=cyclopeptide | n2=en:oleandrin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oligofructose-enriched inulin n1=cyclopeptide | n2=en:oligofructose-enriched inulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oligonucleotide spc2996 n1=cyclopeptide | n2=en:oligonucleotide spc2996 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:olive oil extract/curcumin-based capsule n1=cyclopeptide | n2=en:olive oil extract/curcumin-based capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:olive oil/soya oil/egg lecithin-based emulsion n1=cyclopeptide | n2=en:olive oil/soya oil/egg lecithin-based emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:olive oil/soybean oil/multi-amino acid/glucose parenteral nutrition emulsion n1=cyclopeptide | n2=en:olive oil/soybean oil/multi-amino acid/glucose parenteral nutrition emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:olodaterol n1=cyclopeptide | n2=en:olodaterol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:olsalazine n1=cyclopeptide | n2=en:olsalazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oltipraz n1=cyclopeptide | n2=en:oltipraz | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omacetaxine mepesuccinate n1=cyclopeptide | n2=en:omacetaxine mepesuccinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omalizumab n1=cyclopeptide | n2=en:omalizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omalizumab 150 mg powder for injection 5 ml vial n1=cyclopeptide | n2=en:omalizumab 150 mg powder for injection 5 ml vial | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omalizumab 75mg/vil inj n1=cyclopeptide | n2=en:omalizumab 75mg/vil inj | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ombitasvir/paritaprevir/ritonavir n1=cyclopeptide | n2=en:ombitasvir/paritaprevir/ritonavir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ombrabulin n1=cyclopeptide | n2=en:ombrabulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omega 3-marine triglycerides n1=cyclopeptide | n2=en:omega 3-marine triglycerides | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omega-3 fatty acid n1=cyclopeptide | n2=en:omega-3 fatty acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omeprazole n1=cyclopeptide | n2=en:omeprazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omiganan pentahydrochloride n1=cyclopeptide | n2=en:omiganan pentahydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omphalocele n1=cyclopeptide | n2=en:omphalocele | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:omtriptolide n1=cyclopeptide | n2=en:omtriptolide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:onalespib n1=cyclopeptide | n2=en:onalespib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:onartuzumab n1=cyclopeptide | n2=en:onartuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oncolytic adenovirus ad5-dnx-2401 n1=cyclopeptide | n2=en:oncolytic adenovirus ad5-dnx-2401 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oncolytic adenovirus encoding gm-csf n1=cyclopeptide | n2=en:oncolytic adenovirus encoding gm-csf | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oncolytic adenovirus icovir5-infected autologous mesenchymal stem cells n1=cyclopeptide | n2=en:oncolytic adenovirus icovir5-infected autologous mesenchymal stem cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oncolytic herpes simplex virus-1-encoding gm-csf n1=cyclopeptide | n2=en:oncolytic herpes simplex virus-1-encoding gm-csf | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oncolytic hsv-1 rrp450 n1=cyclopeptide | n2=en:oncolytic hsv-1 rrp450 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oncolytic hsv1716 n1=cyclopeptide | n2=en:oncolytic hsv1716 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oncolytic measles virus encoding thyroidal sodium iodide symporter n1=cyclopeptide | n2=en:oncolytic measles virus encoding thyroidal sodium iodide symporter | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oncolytic newcastle disease virus n1=cyclopeptide | n2=en:oncolytic newcastle disease virus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ondansetron n1=cyclopeptide | n2=en:ondansetron | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ondansetron hydrochloride n1=cyclopeptide | n2=en:ondansetron hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:onercept n1=cyclopeptide | n2=en:onercept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:only upward-growing eyebrows (uncommon) n1=cyclopeptide | n2=en:only upward-growing eyebrows (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:onyx-015 n1=cyclopeptide | n2=en:onyx-015 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opacification of the corneal epithelium n1=cyclopeptide | n2=en:opacification of the corneal epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opacities in embryonal nuclei n1=cyclopeptide | n2=en:opacities in embryonal nuclei | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opacities in embryonic, fetal, and infantile nuclei n1=cyclopeptide | n2=en:opacities in embryonic, fetal, and infantile nuclei | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opb-111001 n1=cyclopeptide | n2=en:opb-111001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opcs/green tea/spirullina/curcumin/antrodia camphorate/fermented soymilk extract capsule n1=cyclopeptide | n2=en:opcs/green tea/spirullina/curcumin/antrodia camphorate/fermented soymilk extract capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opebacan n1=cyclopeptide | n2=en:opebacan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opec ojec protocol n1=cyclopeptide | n2=en:opec ojec protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opec protocol 1 n1=cyclopeptide | n2=en:opec protocol 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opec-d protocol n1=cyclopeptide | n2=en:opec-d protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:open angle glaucoma n1=cyclopeptide | n2=en:open angle glaucoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:open eye n1=cyclopeptide | n2=en:open eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:open-angle glaucoma due to pupillary and ciliary block n1=cyclopeptide | n2=en:open-angle glaucoma due to pupillary and ciliary block | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoparesis n1=cyclopeptide | n2=en:ophthalmoparesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoparesis (less common) n1=cyclopeptide | n2=en:ophthalmoparesis (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoparesis (with longer disease duration) n1=cyclopeptide | n2=en:ophthalmoparesis (with longer disease duration) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoparesis, progressive, external n1=cyclopeptide | n2=en:ophthalmoparesis, progressive, external | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoplegia (1 family) n1=cyclopeptide | n2=en:ophthalmoplegia (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoplegia (in 20%) n1=cyclopeptide | n2=en:ophthalmoplegia (in 20%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoplegia (in some patients) n1=cyclopeptide | n2=en:ophthalmoplegia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoplegia (in some) n1=cyclopeptide | n2=en:ophthalmoplegia (in some) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoplegia, mild n1=cyclopeptide | n2=en:ophthalmoplegia, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ophthalmoplegia, nonprogressive restrictive, bilateral or unilateral n1=cyclopeptide | n2=en:ophthalmoplegia, nonprogressive restrictive, bilateral or unilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opioid agonist gic-1001 n1=cyclopeptide | n2=en:opioid agonist gic-1001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opioid agonist gic-1002 n1=cyclopeptide | n2=en:opioid agonist gic-1002 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opioid growth factor n1=cyclopeptide | n2=en:opioid growth factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:opium tincture n1=cyclopeptide | n2=en:opium tincture | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oppa regimen n1=cyclopeptide | n2=en:oppa regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oppa-copp regimen n1=cyclopeptide | n2=en:oppa-copp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oprelvekin n1=cyclopeptide | n2=en:oprelvekin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oprozomib n1=cyclopeptide | n2=en:oprozomib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy n1=cyclopeptide | n2=en:optic atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (1 family) n1=cyclopeptide | n2=en:optic atrophy (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (1 patient) n1=cyclopeptide | n2=en:optic atrophy (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (67%) n1=cyclopeptide | n2=en:optic atrophy (67%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (chronic phase) n1=cyclopeptide | n2=en:optic atrophy (chronic phase) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (in 1 of 3 patients) n1=cyclopeptide | n2=en:optic atrophy (in 1 of 3 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (in some patients) n1=cyclopeptide | n2=en:optic atrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (may be asymptomatic in some patients) n1=cyclopeptide | n2=en:optic atrophy (may be asymptomatic in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (patient a) n1=cyclopeptide | n2=en:optic atrophy (patient a) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (rare) n1=cyclopeptide | n2=en:optic atrophy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (reported in 1 patient) n1=cyclopeptide | n2=en:optic atrophy (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (seen in patients older than 45 years) n1=cyclopeptide | n2=en:optic atrophy (seen in patients older than 45 years) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy (uncommon) n1=cyclopeptide | n2=en:optic atrophy (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy by 2 years of age n1=cyclopeptide | n2=en:optic atrophy by 2 years of age | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy, bilateral (in some patients) n1=cyclopeptide | n2=en:optic atrophy, bilateral (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy, congenital n1=cyclopeptide | n2=en:optic atrophy, congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy, isolated n1=cyclopeptide | n2=en:optic atrophy, isolated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic atrophy, mild (in 1 patient) n1=cyclopeptide | n2=en:optic atrophy, mild (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic cupping n1=cyclopeptide | n2=en:optic cupping | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic degeneration n1=cyclopeptide | n2=en:optic degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc n1=cyclopeptide | n2=en:optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc atrophy (in some older patients) n1=cyclopeptide | n2=en:optic disc atrophy (in some older patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc drusen (in some patients) n1=cyclopeptide | n2=en:optic disc drusen (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc dysplasia n1=cyclopeptide | n2=en:optic disc dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc edema n1=cyclopeptide | n2=en:optic disc edema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc hyperplasia n1=cyclopeptide | n2=en:optic disc hyperplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc pallor (in older patients) n1=cyclopeptide | n2=en:optic disc pallor (in older patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc pallor (in some patients) n1=cyclopeptide | n2=en:optic disc pallor (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc pallor (less common) n1=cyclopeptide | n2=en:optic disc pallor (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc pallor (rare) n1=cyclopeptide | n2=en:optic disc pallor (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc pallor in fourth decade of life n1=cyclopeptide | n2=en:optic disc pallor in fourth decade of life | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic disc small n1=cyclopeptide | n2=en:optic disc small | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic dysplasia n1=cyclopeptide | n2=en:optic dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic head drusen (yellowish-white irregularities of optic disc) n1=cyclopeptide | n2=en:optic head drusen (yellowish-white irregularities of optic disc) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve and optic disc disorders congenital n1=cyclopeptide | n2=en:optic nerve and optic disc disorders congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve atrophy (in some patients) n1=cyclopeptide | n2=en:optic nerve atrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve atrophy, bilateral n1=cyclopeptide | n2=en:optic nerve atrophy, bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve atrophy, progressive n1=cyclopeptide | n2=en:optic nerve atrophy, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve dysplasia n1=cyclopeptide | n2=en:optic nerve dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve excavation (rare) n1=cyclopeptide | n2=en:optic nerve excavation (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve glioma n1=cyclopeptide | n2=en:optic nerve glioma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve hypoplasia n1=cyclopeptide | n2=en:optic nerve hypoplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve hypoplasia (1 patient) n1=cyclopeptide | n2=en:optic nerve hypoplasia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve hypoplasia (in some patients) n1=cyclopeptide | n2=en:optic nerve hypoplasia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve hypoplasia (less common) n1=cyclopeptide | n2=en:optic nerve hypoplasia (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve hypoplasia (wws) n1=cyclopeptide | n2=en:optic nerve hypoplasia (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve hypoplasia or agenesis n1=cyclopeptide | n2=en:optic nerve hypoplasia or agenesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve hypoplasia, segmental (rare) n1=cyclopeptide | n2=en:optic nerve hypoplasia, segmental (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic nerve misrouting on visual evoked potential analysis n1=cyclopeptide | n2=en:optic nerve misrouting on visual evoked potential analysis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic neuropathy n1=cyclopeptide | n2=en:optic neuropathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic neuropathy (in some patients) n1=cyclopeptide | n2=en:optic neuropathy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optic pallor n1=cyclopeptide | n2=en:optic pallor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:optical coherence tomography shows normal retina and retinal pigment epithelium overlying the sclerochoroidal lesions n1=cyclopeptide | n2=en:optical coherence tomography shows normal retina and retinal pigment epithelium overlying the sclerochoroidal lesions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral aminolevulinic acid hydrochloride n1=cyclopeptide | n2=en:oral aminolevulinic acid hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral azacitidine n1=cyclopeptide | n2=en:oral azacitidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral dosage form product n1=cyclopeptide | n2=en:oral dosage form product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral fludarabine phosphate n1=cyclopeptide | n2=en:oral fludarabine phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral hsp90 inhibitor ipi-493 n1=cyclopeptide | n2=en:oral hsp90 inhibitor ipi-493 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral ixabepilone n1=cyclopeptide | n2=en:oral ixabepilone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral medication n1=cyclopeptide | n2=en:oral medication | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral microencapsulated diindolylmethane n1=cyclopeptide | n2=en:oral microencapsulated diindolylmethane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral milataxel n1=cyclopeptide | n2=en:oral milataxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral picoplatin n1=cyclopeptide | n2=en:oral picoplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral rehydration solution os-1 n1=cyclopeptide | n2=en:oral rehydration solution os-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral sodium phenylbutyrate n1=cyclopeptide | n2=en:oral sodium phenylbutyrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral topotecan hydrochloride n1=cyclopeptide | n2=en:oral topotecan hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oral-facial-digital syndrome n1=cyclopeptide | n2=en:oral-facial-digital syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orantinib n1=cyclopeptide | n2=en:orantinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oraxol n1=cyclopeptide | n2=en:oraxol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbicularis oculi n1=cyclopeptide | n2=en:orbicularis oculi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbit n1=cyclopeptide | n2=en:orbit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital clefts n1=cyclopeptide | n2=en:orbital clefts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital cyst n1=cyclopeptide | n2=en:orbital cyst | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital darkening n1=cyclopeptide | n2=en:orbital darkening | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital dermoid cyst n1=cyclopeptide | n2=en:orbital dermoid cyst | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital dystopia n1=cyclopeptide | n2=en:orbital dystopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital fat body n1=cyclopeptide | n2=en:orbital fat body | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital mass n1=cyclopeptide | n2=en:orbital mass | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital mass due to histiocytosis n1=cyclopeptide | n2=en:orbital mass due to histiocytosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbital separation diminished n1=cyclopeptide | n2=en:orbital separation diminished | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orbitalis muscle n1=cyclopeptide | n2=en:orbitalis muscle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oregovomab n1=cyclopeptide | n2=en:oregovomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:organic sulfone compound n1=cyclopeptide | n2=en:organic sulfone compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ormaplatin n1=cyclopeptide | n2=en:ormaplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orofaciodigital syndrome i n1=cyclopeptide | n2=en:orofaciodigital syndrome i | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orofaciodigital syndrome type 1 n1=cyclopeptide | n2=en:orofaciodigital syndrome type 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oropharyngeal dosage form product n1=cyclopeptide | n2=en:oropharyngeal dosage form product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ortataxel n1=cyclopeptide | n2=en:ortataxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:orteronel n1=cyclopeptide | n2=en:orteronel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ose 2101 n1=cyclopeptide | n2=en:ose 2101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oseltamivir phosphate n1=cyclopeptide | n2=en:oseltamivir phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oshadi d n1=cyclopeptide | n2=en:oshadi d | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oshadi r n1=cyclopeptide | n2=en:oshadi r | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:osi-7904l n1=cyclopeptide | n2=en:osi-7904l | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:osimertinib n1=cyclopeptide | n2=en:osimertinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:osteogenesis imperfecta with blue sclerae and normal teeth n1=cyclopeptide | n2=en:osteogenesis imperfecta with blue sclerae and normal teeth | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:osteogenesis imperfecta, type 1a n1=cyclopeptide | n2=en:osteogenesis imperfecta, type 1a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:osteoma of choroid n1=cyclopeptide | n2=en:osteoma of choroid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:otd70derm n1=cyclopeptide | n2=en:otd70derm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oteracil potassium n1=cyclopeptide | n2=en:oteracil potassium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other and unspecified congenital anomalies n1=cyclopeptide | n2=en:other and unspecified congenital anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital anomalies of eyelids, lacrimal system, and orbit n1=cyclopeptide | n2=en:other congenital anomalies of eyelids, lacrimal system, and orbit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital anomalies of limbs n1=cyclopeptide | n2=en:other congenital anomalies of limbs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital anomalies of nervous system n1=cyclopeptide | n2=en:other congenital anomalies of nervous system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital malformations of circulatory system n1=cyclopeptide | n2=en:other congenital malformations of circulatory system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital malformations of digestive system n1=cyclopeptide | n2=en:other congenital malformations of digestive system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital malformations of eye n1=cyclopeptide | n2=en:other congenital malformations of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital malformations of face and neck n1=cyclopeptide | n2=en:other congenital malformations of face and neck | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital malformations of heart n1=cyclopeptide | n2=en:other congenital malformations of heart | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital musculoskeletal deformities n1=cyclopeptide | n2=en:other congenital musculoskeletal deformities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other congenital upper alimentary tract anomalies n1=cyclopeptide | n2=en:other congenital upper alimentary tract anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other disorders of eye n1=cyclopeptide | n2=en:other disorders of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other infection/inflammation of eye (excluding herpes) n1=cyclopeptide | n2=en:other infection/inflammation of eye (excluding herpes) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other ocular injuries n1=cyclopeptide | n2=en:other ocular injuries | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other specified congenital malformations n1=cyclopeptide | n2=en:other specified congenital malformations | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other specified congenital malformations of eye n1=cyclopeptide | n2=en:other specified congenital malformations of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other symptom/complaint of eye n1=cyclopeptide | n2=en:other symptom/complaint of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:other visual disturbances n1=cyclopeptide | n2=en:other visual disturbances | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:otic preparation n1=cyclopeptide | n2=en:otic preparation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:otlertuzumab n1=cyclopeptide | n2=en:otlertuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:otocephaly n1=cyclopeptide | n2=en:otocephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:otsgc-a24 vaccine n1=cyclopeptide | n2=en:otsgc-a24 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ova bip peptide n1=cyclopeptide | n2=en:ova bip peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ovapuldencel-t n1=cyclopeptide | n2=en:ovapuldencel-t | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ovarian cancer peptide vaccine n1=cyclopeptide | n2=en:ovarian cancer peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ovarian cancer stem cell/htert/survivin mrnas-loaded autologous dendritic cell vaccine n1=cyclopeptide | n2=en:ovarian cancer stem cell/htert/survivin mrnas-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ovarian tumor antigen-activated autologous dendritic cell vaccine n1=cyclopeptide | n2=en:ovarian tumor antigen-activated autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:over the counter product n1=cyclopeptide | n2=en:over the counter product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:overshooting horizontal saccades n1=cyclopeptide | n2=en:overshooting horizontal saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ovine submaxillary mucin n1=cyclopeptide | n2=en:ovine submaxillary mucin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:owl's eyes (paired hyperpigmented spots) n1=cyclopeptide | n2=en:owl's eyes (paired hyperpigmented spots) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxac protocol n1=cyclopeptide | n2=en:oxac protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxacillin sodium n1=cyclopeptide | n2=en:oxacillin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxaliplatin n1=cyclopeptide | n2=en:oxaliplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxaliplatin-encapsulated transferrin-conjugated n-glutaryl phosphatidylethanolamine liposome n1=cyclopeptide | n2=en:oxaliplatin-encapsulated transferrin-conjugated n-glutaryl phosphatidylethanolamine liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxandrolone n1=cyclopeptide | n2=en:oxandrolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxcarbazepine n1=cyclopeptide | n2=en:oxcarbazepine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxidized avidin n1=cyclopeptide | n2=en:oxidized avidin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxidopamine n1=cyclopeptide | n2=en:oxidopamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxisuran n1=cyclopeptide | n2=en:oxisuran | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxitriptan n1=cyclopeptide | n2=en:oxitriptan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxphos inhibitor vlx600 n1=cyclopeptide | n2=en:oxphos inhibitor vlx600 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxycodone hydrochloride n1=cyclopeptide | n2=en:oxycodone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxycodone hydrochloride/naloxone hydrochloride prolonged-release tablet n1=cyclopeptide | n2=en:oxycodone hydrochloride/naloxone hydrochloride prolonged-release tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxycodone/acetaminophen n1=cyclopeptide | n2=en:oxycodone/acetaminophen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxymetholone n1=cyclopeptide | n2=en:oxymetholone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxymorphone hydrochloride n1=cyclopeptide | n2=en:oxymorphone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:oxytocics n1=cyclopeptide | n2=en:oxytocics | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ozarelix n1=cyclopeptide | n2=en:ozarelix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ozone-based agent n1=cyclopeptide | n2=en:ozone-based agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-cadherin antagonist pf-03732010 n1=cyclopeptide | n2=en:p-cadherin antagonist pf-03732010 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-cadherin inhibitor pca062 n1=cyclopeptide | n2=en:p-cadherin inhibitor pca062 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-cadherin-targeting agent pf-06671008 n1=cyclopeptide | n2=en:p-cadherin-targeting agent pf-06671008 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-comm-b protocol n1=cyclopeptide | n2=en:p-comm-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-doce protocol n1=cyclopeptide | n2=en:p-doce protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-glycoprotein inhibitor hm30181ak n1=cyclopeptide | n2=en:p-glycoprotein inhibitor hm30181ak | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-p68 inhibitor rx-5902 n1=cyclopeptide | n2=en:p-p68 inhibitor rx-5902 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-tefb inhibitor bay1143572 n1=cyclopeptide | n2=en:p-tefb inhibitor bay1143572 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p-vebec protocol n1=cyclopeptide | n2=en:p-vebec protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p.dom-wt1-126 dna vaccine n1=cyclopeptide | n2=en:p.dom-wt1-126 dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p.dom-wt1-37 dna vaccine n1=cyclopeptide | n2=en:p.dom-wt1-37 dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p110beta/delta pi3k inhibitor gs-9820 n1=cyclopeptide | n2=en:p110beta/delta pi3k inhibitor gs-9820 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p16_37-63 peptide vaccine n1=cyclopeptide | n2=en:p16_37-63 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p38 mapk inhibitor ly2228820 dimesylate n1=cyclopeptide | n2=en:p38 mapk inhibitor ly2228820 dimesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p38 mapk inhibitor ly3007113 n1=cyclopeptide | n2=en:p38 mapk inhibitor ly3007113 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p501-as15 vaccine n1=cyclopeptide | n2=en:p501-as15 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p53 peptide vaccine n1=cyclopeptide | n2=en:p53 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p53-hdm2 interaction inhibitor mi-773 n1=cyclopeptide | n2=en:p53-hdm2 interaction inhibitor mi-773 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p53-synthetic long peptides vaccine n1=cyclopeptide | n2=en:p53-synthetic long peptides vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p53/hdm2 interaction inhibitor cgm097 n1=cyclopeptide | n2=en:p53/hdm2 interaction inhibitor cgm097 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p70s6k inhibitor ly2584702 n1=cyclopeptide | n2=en:p70s6k inhibitor ly2584702 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p70s6k/akt inhibitor msc2363318a n1=cyclopeptide | n2=en:p70s6k/akt inhibitor msc2363318a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:p97 inhibitor cb-5083 n1=cyclopeptide | n2=en:p97 inhibitor cb-5083 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pa-1-stk ovarian carcinoma vaccine n1=cyclopeptide | n2=en:pa-1-stk ovarian carcinoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pace-bom protocol n1=cyclopeptide | n2=en:pace-bom protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pacebo protocol n1=cyclopeptide | n2=en:pacebo protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paclitaxel n1=cyclopeptide | n2=en:paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paclitaxel albumin-stabilized nanoparticle formulation n1=cyclopeptide | n2=en:paclitaxel albumin-stabilized nanoparticle formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paclitaxel injection concentrate for nanodispersion n1=cyclopeptide | n2=en:paclitaxel injection concentrate for nanodispersion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paclitaxel liposome n1=cyclopeptide | n2=en:paclitaxel liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paclitaxel poliglumex n1=cyclopeptide | n2=en:paclitaxel poliglumex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paclitaxel trevatide n1=cyclopeptide | n2=en:paclitaxel trevatide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paclitaxel vitamin e-based emulsion n1=cyclopeptide | n2=en:paclitaxel vitamin e-based emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paclitaxel-loaded polymeric micelle n1=cyclopeptide | n2=en:paclitaxel-loaded polymeric micelle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pacritinib n1=cyclopeptide | n2=en:pacritinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pad regimen n1=cyclopeptide | n2=en:pad regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:padeliporfin n1=cyclopeptide | n2=en:padeliporfin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:padre 965.10 n1=cyclopeptide | n2=en:padre 965.10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:padre-cmv fusion peptide vaccine n1=cyclopeptide | n2=en:padre-cmv fusion peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pak4 inhibitor pf-03758309 n1=cyclopeptide | n2=en:pak4 inhibitor pf-03758309 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pak4/nampt inhibitor kpt-9274 n1=cyclopeptide | n2=en:pak4/nampt inhibitor kpt-9274 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palbociclib n1=cyclopeptide | n2=en:palbociclib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale blue sclerae (10% of the cases) n1=cyclopeptide | n2=en:pale blue sclerae (10% of the cases) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale fundi n1=cyclopeptide | n2=en:pale fundi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale irides (45%) n1=cyclopeptide | n2=en:pale irides (45%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale optic discs (1 family) n1=cyclopeptide | n2=en:pale optic discs (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale optic discs (1 patient) n1=cyclopeptide | n2=en:pale optic discs (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale optic discs (1/4 patients) n1=cyclopeptide | n2=en:pale optic discs (1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale optic discs (in some patients) n1=cyclopeptide | n2=en:pale optic discs (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale optic nerves n1=cyclopeptide | n2=en:pale optic nerves | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale optic nerves (rare) n1=cyclopeptide | n2=en:pale optic nerves (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pale or atrophic peripapillary area n1=cyclopeptide | n2=en:pale or atrophic peripapillary area | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palifermin n1=cyclopeptide | n2=en:palifermin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palifosfamide n1=cyclopeptide | n2=en:palifosfamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palifosfamide tromethamine n1=cyclopeptide | n2=en:palifosfamide tromethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palivizumab n1=cyclopeptide | n2=en:palivizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palladium pd-103 n1=cyclopeptide | n2=en:palladium pd-103 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palladium-bacteriopheophorbide n1=cyclopeptide | n2=en:palladium-bacteriopheophorbide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pallid optic disc n1=cyclopeptide | n2=en:pallid optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pallor of optic disc n1=cyclopeptide | n2=en:pallor of optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palm extract phytonutrient supplement n1=cyclopeptide | n2=en:palm extract phytonutrient supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palonosetron hydrochloride n1=cyclopeptide | n2=en:palonosetron hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palpebral edema (in 1 family) n1=cyclopeptide | n2=en:palpebral edema (in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palpebral fissure narrowing on adduction n1=cyclopeptide | n2=en:palpebral fissure narrowing on adduction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:palpebronasal fold n1=cyclopeptide | n2=en:palpebronasal fold | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pamidronate disodium n1=cyclopeptide | n2=en:pamidronate disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan fgfr inhibitor arq 087 n1=cyclopeptide | n2=en:pan fgfr inhibitor arq 087 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan fgfr inhibitor prn1371 n1=cyclopeptide | n2=en:pan fgfr inhibitor prn1371 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan fgfr kinase inhibitor bgj398 n1=cyclopeptide | n2=en:pan fgfr kinase inhibitor bgj398 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan her/vegfr2 receptor tyrosine kinase inhibitor bms-690514 n1=cyclopeptide | n2=en:pan her/vegfr2 receptor tyrosine kinase inhibitor bms-690514 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-akt inhibitor arq751 n1=cyclopeptide | n2=en:pan-akt inhibitor arq751 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-akt kinase inhibitor gsk690693 n1=cyclopeptide | n2=en:pan-akt kinase inhibitor gsk690693 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-fgfr tyrosine kinase inhibitor bay1163877 n1=cyclopeptide | n2=en:pan-fgfr tyrosine kinase inhibitor bay1163877 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-fgfr tyrosine kinase inhibitor jnj-42756493 n1=cyclopeptide | n2=en:pan-fgfr tyrosine kinase inhibitor jnj-42756493 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-her kinase inhibitor ac480 n1=cyclopeptide | n2=en:pan-her kinase inhibitor ac480 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-idh mutant inhibitor ag-881 n1=cyclopeptide | n2=en:pan-idh mutant inhibitor ag-881 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-pi3k inhibitor clr457 n1=cyclopeptide | n2=en:pan-pi3k inhibitor clr457 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-pi3k/mtor inhibitor pqr309 n1=cyclopeptide | n2=en:pan-pi3k/mtor inhibitor pqr309 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-pi3k/mtor inhibitor sf1126 n1=cyclopeptide | n2=en:pan-pi3k/mtor inhibitor sf1126 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-pim inhibitor incb053914 n1=cyclopeptide | n2=en:pan-pim inhibitor incb053914 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-pim kinase inhibitor azd1208 n1=cyclopeptide | n2=en:pan-pim kinase inhibitor azd1208 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-raf inhibitor lxh254 n1=cyclopeptide | n2=en:pan-raf inhibitor lxh254 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-raf inhibitor ly3009120 n1=cyclopeptide | n2=en:pan-raf inhibitor ly3009120 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-raf kinase inhibitor cct3833 n1=cyclopeptide | n2=en:pan-raf kinase inhibitor cct3833 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-raf kinase inhibitor tak-580 n1=cyclopeptide | n2=en:pan-raf kinase inhibitor tak-580 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-selectin antagonist gmi-1070 n1=cyclopeptide | n2=en:pan-selectin antagonist gmi-1070 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pan-vegfr/tie2 tyrosine kinase inhibitor cep-11981 n1=cyclopeptide | n2=en:pan-vegfr/tie2 tyrosine kinase inhibitor cep-11981 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pancrelipase n1=cyclopeptide | n2=en:pancrelipase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:panitumumab n1=cyclopeptide | n2=en:panitumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:panitumumab-irdye800 n1=cyclopeptide | n2=en:panitumumab-irdye800 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pannus formation n1=cyclopeptide | n2=en:pannus formation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:panobinostat n1=cyclopeptide | n2=en:panobinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pantoprazole sodium n1=cyclopeptide | n2=en:pantoprazole sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:panuveitis (rare) n1=cyclopeptide | n2=en:panuveitis (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:papaverine n1=cyclopeptide | n2=en:papaverine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:papillo-macular atrophic chorioretinopathy (1 report) n1=cyclopeptide | n2=en:papillo-macular atrophic chorioretinopathy (1 report) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:papillomacular detachment (rare) n1=cyclopeptide | n2=en:papillomacular detachment (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:papules along the eyebrows and palpebral fissures n1=cyclopeptide | n2=en:papules along the eyebrows and palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parakeratosis n1=cyclopeptide | n2=en:parakeratosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parathyroid hormone-related protein (1-36) n1=cyclopeptide | n2=en:parathyroid hormone-related protein (1-36) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parecoxib sodium n1=cyclopeptide | n2=en:parecoxib sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parenteral dosage form product n1=cyclopeptide | n2=en:parenteral dosage form product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paricalcitol n1=cyclopeptide | n2=en:paricalcitol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paromomycin sulfate n1=cyclopeptide | n2=en:paromomycin sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paroxetine hydrochloride n1=cyclopeptide | n2=en:paroxetine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:paroxysmal involuntary eye movements n1=cyclopeptide | n2=en:paroxysmal involuntary eye movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parp 1/2 inhibitor e7449 n1=cyclopeptide | n2=en:parp 1/2 inhibitor e7449 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parp inhibitor azd2461 n1=cyclopeptide | n2=en:parp inhibitor azd2461 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parp inhibitor bgb-290 n1=cyclopeptide | n2=en:parp inhibitor bgb-290 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parp inhibitor cep-9722 n1=cyclopeptide | n2=en:parp inhibitor cep-9722 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parp inhibitor e7016 n1=cyclopeptide | n2=en:parp inhibitor e7016 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parp-1/2 inhibitor abt-767 n1=cyclopeptide | n2=en:parp-1/2 inhibitor abt-767 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parsatuzumab n1=cyclopeptide | n2=en:parsatuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:partial blindness (in some) n1=cyclopeptide | n2=en:partial blindness (in some) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:partial hypoplasia of optic disc n1=cyclopeptide | n2=en:partial hypoplasia of optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:partial-total absence of lower eyelashes n1=cyclopeptide | n2=en:partial-total absence of lower eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:partial-total retinal detachment n1=cyclopeptide | n2=en:partial-total retinal detachment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:partially reduced visually acuity n1=cyclopeptide | n2=en:partially reduced visually acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:particulate debris in vitreous n1=cyclopeptide | n2=en:particulate debris in vitreous | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:parvovirus h-1 n1=cyclopeptide | n2=en:parvovirus h-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pasireotide n1=cyclopeptide | n2=en:pasireotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:patchy iris atrophy n1=cyclopeptide | n2=en:patchy iris atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:patco protocol n1=cyclopeptide | n2=en:patco protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:patent blue v dye n1=cyclopeptide | n2=en:patent blue v dye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:patent ductus arteriosus - persisting type n1=cyclopeptide | n2=en:patent ductus arteriosus - persisting type | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:patient-specific follicular lymphoma-derived anti-idiotype vaccine n1=cyclopeptide | n2=en:patient-specific follicular lymphoma-derived anti-idiotype vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:patritumab n1=cyclopeptide | n2=en:patritumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pattern dystrophy of macula n1=cyclopeptide | n2=en:pattern dystrophy of macula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pattern visual evoked potentials show reduced amplitude n1=cyclopeptide | n2=en:pattern visual evoked potentials show reduced amplitude | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:patupilone n1=cyclopeptide | n2=en:patupilone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pazopanib hydrochloride n1=cyclopeptide | n2=en:pazopanib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pbcar3 phosphopeptide-tetanus peptide vaccine n1=cyclopeptide | n2=en:pbcar3 phosphopeptide-tetanus peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pbcar3/pirs2-phosphopeptide-tetanus peptide vaccine n1=cyclopeptide | n2=en:pbcar3/pirs2-phosphopeptide-tetanus peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pbi-shrna stmn1 lipoplex n1=cyclopeptide | n2=en:pbi-shrna stmn1 lipoplex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pbn derivative okn-007 n1=cyclopeptide | n2=en:pbn derivative okn-007 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pbtl cd19car-28 zeta n1=cyclopeptide | n2=en:pbtl cd19car-28 zeta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pc regimen n1=cyclopeptide | n2=en:pc regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pc-spes n1=cyclopeptide | n2=en:pc-spes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pcav protocol n1=cyclopeptide | n2=en:pcav protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pcmf protocol n1=cyclopeptide | n2=en:pcmf protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pcnu n1=cyclopeptide | n2=en:pcnu | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pcr regimen n1=cyclopeptide | n2=en:pcr regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pcv regimen n1=cyclopeptide | n2=en:pcv regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pd l 506 n1=cyclopeptide | n2=en:pd l 506 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pd0325901 n1=cyclopeptide | n2=en:pd0325901 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pdcd-1 knockout autologous t-lymphocytes n1=cyclopeptide | n2=en:pdcd-1 knockout autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pdgfr alpha/kit mutant-specific inhibitor blu-285 n1=cyclopeptide | n2=en:pdgfr alpha/kit mutant-specific inhibitor blu-285 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pdk1 inhibitor ar-12 n1=cyclopeptide | n2=en:pdk1 inhibitor ar-12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pdm08 n1=cyclopeptide | n2=en:pdm08 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pe/hpv16 e7/kdel fusion protein tvgv-1 n1=cyclopeptide | n2=en:pe/hpv16 e7/kdel fusion protein tvgv-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peau d'orange retinal changes n1=cyclopeptide | n2=en:peau d'orange retinal changes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peau d'orange retinal changes (yellow-mottled retinal hyperpigmentation) n1=cyclopeptide | n2=en:peau d'orange retinal changes (yellow-mottled retinal hyperpigmentation) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pecc protocol n1=cyclopeptide | n2=en:pecc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pediatric nutritional supplement drink n1=cyclopeptide | n2=en:pediatric nutritional supplement drink | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pedunculated nodules on eyelid margins n1=cyclopeptide | n2=en:pedunculated nodules on eyelid margins | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pefloxacin n1=cyclopeptide | n2=en:pefloxacin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peg recombinant human megakaryocyte growth and development factor n1=cyclopeptide | n2=en:peg recombinant human megakaryocyte growth and development factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peg-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid-based laxative n1=cyclopeptide | n2=en:peg-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid-based laxative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peg-based laxative ner1006 n1=cyclopeptide | n2=en:peg-based laxative ner1006 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peg-interleukin-2 n1=cyclopeptide | n2=en:peg-interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peg-linked l-rna oligonucleotide hepcidin-targeting agent nox-h94 n1=cyclopeptide | n2=en:peg-linked l-rna oligonucleotide hepcidin-targeting agent nox-h94 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1 n1=cyclopeptide | n2=en:peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peg-proline-interferon alfa-2b n1=cyclopeptide | n2=en:peg-proline-interferon alfa-2b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegamotecan n1=cyclopeptide | n2=en:pegamotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegaspargase n1=cyclopeptide | n2=en:pegaspargase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegdinetanib n1=cyclopeptide | n2=en:pegdinetanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegfilgrastim n1=cyclopeptide | n2=en:pegfilgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegfilgrastim anti-neutropenic factor n1=cyclopeptide | n2=en:pegfilgrastim anti-neutropenic factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegfilgrastim biosimilar la-ep2006 n1=cyclopeptide | n2=en:pegfilgrastim biosimilar la-ep2006 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peginesatide n1=cyclopeptide | n2=en:peginesatide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peginterferon alfa-2a n1=cyclopeptide | n2=en:peginterferon alfa-2a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peginterferon alfa-2b n1=cyclopeptide | n2=en:peginterferon alfa-2b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegol sihematide n1=cyclopeptide | n2=en:pegol sihematide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegsunercept n1=cyclopeptide | n2=en:pegsunercept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegvisomant n1=cyclopeptide | n2=en:pegvisomant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated anti-gfr antibody fragment n1=cyclopeptide | n2=en:pegylated anti-gfr antibody fragment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated arginine deiminase n1=cyclopeptide | n2=en:pegylated arginine deiminase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated granulocyte colony stimulating factor maxy-g34 n1=cyclopeptide | n2=en:pegylated granulocyte colony stimulating factor maxy-g34 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated human recombinant arginase 1 aeb1102 n1=cyclopeptide | n2=en:pegylated human recombinant arginase 1 aeb1102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated interferon alfa n1=cyclopeptide | n2=en:pegylated interferon alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated irinotecan n1=cyclopeptide | n2=en:pegylated irinotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated liposomal belotecan n1=cyclopeptide | n2=en:pegylated liposomal belotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated liposomal doxorubicin hydrochloride n1=cyclopeptide | n2=en:pegylated liposomal doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated liposomal irinotecan n1=cyclopeptide | n2=en:pegylated liposomal irinotecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated liposomal mitomycin c lipid-based prodrug n1=cyclopeptide | n2=en:pegylated liposomal mitomycin c lipid-based prodrug | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated liposomal nanoparticle-based docetaxel prodrug mnk-010 n1=cyclopeptide | n2=en:pegylated liposomal nanoparticle-based docetaxel prodrug mnk-010 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated paclitaxel n1=cyclopeptide | n2=en:pegylated paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated recombinant human arginase i bct-100 n1=cyclopeptide | n2=en:pegylated recombinant human arginase i bct-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated recombinant human hyaluronidase ph20 n1=cyclopeptide | n2=en:pegylated recombinant human hyaluronidase ph20 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated recombinant human interleukin-10 am0010 n1=cyclopeptide | n2=en:pegylated recombinant human interleukin-10 am0010 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pegylated recombinant l-asparaginase erwinia chrysanthemi n1=cyclopeptide | n2=en:pegylated recombinant l-asparaginase erwinia chrysanthemi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peldesine n1=cyclopeptide | n2=en:peldesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pelitinib n1=cyclopeptide | n2=en:pelitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pelitrexol n1=cyclopeptide | n2=en:pelitrexol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pembrolizumab n1=cyclopeptide | n2=en:pembrolizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pemetrexed disodium n1=cyclopeptide | n2=en:pemetrexed disodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:penberol n1=cyclopeptide | n2=en:penberol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:penclomedine n1=cyclopeptide | n2=en:penclomedine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:penicillamine n1=cyclopeptide | n2=en:penicillamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:penicillin v potassium n1=cyclopeptide | n2=en:penicillin v potassium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentamethylmelamine n1=cyclopeptide | n2=en:pentamethylmelamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentamidine n1=cyclopeptide | n2=en:pentamidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentamidine isethionate n1=cyclopeptide | n2=en:pentamidine isethionate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentavalent klh conjugate vaccine n1=cyclopeptide | n2=en:pentavalent klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentetic acid n1=cyclopeptide | n2=en:pentetic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentetic acid calcium n1=cyclopeptide | n2=en:pentetic acid calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentosan polysulfate sodium n1=cyclopeptide | n2=en:pentosan polysulfate sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentostatin n1=cyclopeptide | n2=en:pentostatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pentoxifylline n1=cyclopeptide | n2=en:pentoxifylline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pep-3-klh conjugate vaccine n1=cyclopeptide | n2=en:pep-3-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pep-cmv vaccine n1=cyclopeptide | n2=en:pep-cmv vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peplomycin n1=cyclopeptide | n2=en:peplomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peppered pigmentary mottling of peripheral retinal pigment in carrier females n1=cyclopeptide | n2=en:peppered pigmentary mottling of peripheral retinal pigment in carrier females | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peptichemio n1=cyclopeptide | n2=en:peptichemio | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peptide 946 melanoma vaccine n1=cyclopeptide | n2=en:peptide 946 melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peptide 946-tetanus peptide conjugate melanoma vaccine n1=cyclopeptide | n2=en:peptide 946-tetanus peptide conjugate melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peptides hydrolases n1=cyclopeptide | n2=en:peptides hydrolases | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perampanel n1=cyclopeptide | n2=en:perampanel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peretinoin n1=cyclopeptide | n2=en:peretinoin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perflenapent emulsion n1=cyclopeptide | n2=en:perflenapent emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perflubron n1=cyclopeptide | n2=en:perflubron | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perflubutane n1=cyclopeptide | n2=en:perflubutane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perflutren n1=cyclopeptide | n2=en:perflutren | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perflutren lipid microspheres n1=cyclopeptide | n2=en:perflutren lipid microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perflutren protein-type a microspheres n1=cyclopeptide | n2=en:perflutren protein-type a microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perforation of cornea n1=cyclopeptide | n2=en:perforation of cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perfosfamide n1=cyclopeptide | n2=en:perfosfamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perifosine n1=cyclopeptide | n2=en:perifosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perillyl alcohol n1=cyclopeptide | n2=en:perillyl alcohol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perimacular grayness n1=cyclopeptide | n2=en:perimacular grayness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perimacular retinal surface wrinkling (rare) n1=cyclopeptide | n2=en:perimacular retinal surface wrinkling (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:perindopril erbumine n1=cyclopeptide | n2=en:perindopril erbumine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:periorbital cellulitis (in some patients) n1=cyclopeptide | n2=en:periorbital cellulitis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:periorbital ecchymoses (soft tissue involvement) n1=cyclopeptide | n2=en:periorbital ecchymoses (soft tissue involvement) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:periorbital edema n1=cyclopeptide | n2=en:periorbital edema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:periorbital fullness n1=cyclopeptide | n2=en:periorbital fullness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:periorbital heterogeneous thickening on ct scan n1=cyclopeptide | n2=en:periorbital heterogeneous thickening on ct scan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:periorbital hyperpigmentation n1=cyclopeptide | n2=en:periorbital hyperpigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:periorbital swelling n1=cyclopeptide | n2=en:periorbital swelling | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:periorbital wrinkles n1=cyclopeptide | n2=en:periorbital wrinkles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripapillary atrophy n1=cyclopeptide | n2=en:peripapillary atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripapillary atrophy (rare) n1=cyclopeptide | n2=en:peripapillary atrophy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripapillary chorioretinal atrophy, progressive n1=cyclopeptide | n2=en:peripapillary chorioretinal atrophy, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripapillary retinal pigment epithelium atrophy (in older patients) n1=cyclopeptide | n2=en:peripapillary retinal pigment epithelium atrophy (in older patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral pigment deposits n1=cyclopeptide | n2=en:peripheral pigment deposits | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral retinal atrophy n1=cyclopeptide | n2=en:peripheral retinal atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral retinal avascularization n1=cyclopeptide | n2=en:peripheral retinal avascularization | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral retinal cone degeneration n1=cyclopeptide | n2=en:peripheral retinal cone degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral retinal pigment epithelium atrophy n1=cyclopeptide | n2=en:peripheral retinal pigment epithelium atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral retinal telangiectasia, capillary closure, leakage, and microaneurysm formation n1=cyclopeptide | n2=en:peripheral retinal telangiectasia, capillary closure, leakage, and microaneurysm formation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral retinopathy n1=cyclopeptide | n2=en:peripheral retinopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral sensitivity loss, widespread, on photopic and dark-adapted perimetry testing n1=cyclopeptide | n2=en:peripheral sensitivity loss, widespread, on photopic and dark-adapted perimetry testing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral traction retinal detachment (middle age) n1=cyclopeptide | n2=en:peripheral traction retinal detachment (middle age) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peripheral vitreoretinal degeneration n1=cyclopeptide | n2=en:peripheral vitreoretinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:permanent loss of sight n1=cyclopeptide | n2=en:permanent loss of sight | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:persistent cloaca n1=cyclopeptide | n2=en:persistent cloaca | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:persistent fetal hyaloid vasculature n1=cyclopeptide | n2=en:persistent fetal hyaloid vasculature | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:persistent hyperplastic primary vitreous n1=cyclopeptide | n2=en:persistent hyperplastic primary vitreous | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:persistent primary vitreous (rare) n1=cyclopeptide | n2=en:persistent primary vitreous (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:persistent pupillary membrane (1 patient, wws) n1=cyclopeptide | n2=en:persistent pupillary membrane (1 patient, wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:persistent pupillary membrane (in some patients) n1=cyclopeptide | n2=en:persistent pupillary membrane (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:personalized polyepitope plasmid dna breast cancer vaccine n1=cyclopeptide | n2=en:personalized polyepitope plasmid dna breast cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:personalized synthetic long peptide breast cancer vaccine n1=cyclopeptide | n2=en:personalized synthetic long peptide breast cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pertuzumab n1=cyclopeptide | n2=en:pertuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pesticide n1=cyclopeptide | n2=en:pesticide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peter's anomaly (congenital anomaly of the anterior segment) n1=cyclopeptide | n2=en:peter's anomaly (congenital anomaly of the anterior segment) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peters anomaly (rare) n1=cyclopeptide | n2=en:peters anomaly (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:peters anomaly (wws) n1=cyclopeptide | n2=en:peters anomaly (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pethema all-3-97 protocol n1=cyclopeptide | n2=en:pethema all-3-97 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pethema all-96 protocol n1=cyclopeptide | n2=en:pethema all-96 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:petrolatum-mineral oil-lanolin-ceresin ointment n1=cyclopeptide | n2=en:petrolatum-mineral oil-lanolin-ceresin ointment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pevonedistat n1=cyclopeptide | n2=en:pevonedistat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pexastimogene-devacirepvec n1=cyclopeptide | n2=en:pexastimogene-devacirepvec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pexidartinib n1=cyclopeptide | n2=en:pexidartinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pg13-cd19-h3 (anti-cd19 car) retroviral vector-transduced peripheral blood lymphocytes n1=cyclopeptide | n2=en:pg13-cd19-h3 (anti-cd19 car) retroviral vector-transduced peripheral blood lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pgg beta-glucan n1=cyclopeptide | n2=en:pgg beta-glucan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pgla/peg copolymer-based paclitaxel n1=cyclopeptide | n2=en:pgla/peg copolymer-based paclitaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ph20 hyaluronidase-expressing adenovirus vcn-01 n1=cyclopeptide | n2=en:ph20 hyaluronidase-expressing adenovirus vcn-01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phaces syndrome n1=cyclopeptide | n2=en:phaces syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phacodonesis n1=cyclopeptide | n2=en:phacodonesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phakomatosis n1=cyclopeptide | n2=en:phakomatosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phaleria macrocarpa extract dlbs-1425 n1=cyclopeptide | n2=en:phaleria macrocarpa extract dlbs-1425 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pharmaceutic aids n1=cyclopeptide | n2=en:pharmaceutic aids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pharmaceutical base or inactive agent n1=cyclopeptide | n2=en:pharmaceutical base or inactive agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pharmaceutical dosage form n1=cyclopeptide | n2=en:pharmaceutical dosage form | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pharmaceutical fluid or solution agent n1=cyclopeptide | n2=en:pharmaceutical fluid or solution agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pharmaceutical preparations, dental n1=cyclopeptide | n2=en:pharmaceutical preparations, dental | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pharmacokinetic aspects n1=cyclopeptide | n2=en:pharmacokinetic aspects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phellodendron amurense bark extract n1=cyclopeptide | n2=en:phellodendron amurense bark extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenamet n1=cyclopeptide | n2=en:phenamet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenelzine sulfate n1=cyclopeptide | n2=en:phenelzine sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenesterin n1=cyclopeptide | n2=en:phenesterin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenethyl isothiocyanate n1=cyclopeptide | n2=en:phenethyl isothiocyanate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenethyl isothiocyanate-containing watercress juice n1=cyclopeptide | n2=en:phenethyl isothiocyanate-containing watercress juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenformin hydrochloride n1=cyclopeptide | n2=en:phenformin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenobarbital n1=cyclopeptide | n2=en:phenobarbital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenoxybenzamine hydrochloride n1=cyclopeptide | n2=en:phenoxybenzamine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenprocoumon n1=cyclopeptide | n2=en:phenprocoumon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phentolamine mesylate n1=cyclopeptide | n2=en:phentolamine mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenyl acetate n1=cyclopeptide | n2=en:phenyl acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phenylketophosphamide n1=cyclopeptide | n2=en:phenylketophosphamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phosphaplatin pt-112 n1=cyclopeptide | n2=en:phosphaplatin pt-112 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phosphatidylcholine-bound silybin n1=cyclopeptide | n2=en:phosphatidylcholine-bound silybin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phosphomannopentaose sulfate n1=cyclopeptide | n2=en:phosphomannopentaose sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phosphoramide n1=cyclopeptide | n2=en:phosphoramide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phosphoramide mustard n1=cyclopeptide | n2=en:phosphoramide mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phosphoramide mustards n1=cyclopeptide | n2=en:phosphoramide mustards | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phosphorodiamidate morpholino oligomer avi-4126 n1=cyclopeptide | n2=en:phosphorodiamidate morpholino oligomer avi-4126 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phosphorus p-32 n1=cyclopeptide | n2=en:phosphorus p-32 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photocyanine n1=cyclopeptide | n2=en:photocyanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia (early symptom) n1=cyclopeptide | n2=en:photophobia (early symptom) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia (in most patients) n1=cyclopeptide | n2=en:photophobia (in most patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia (in some patients) n1=cyclopeptide | n2=en:photophobia (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia (infancy) n1=cyclopeptide | n2=en:photophobia (infancy) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia (rare) n1=cyclopeptide | n2=en:photophobia (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia and epiphora in day light n1=cyclopeptide | n2=en:photophobia and epiphora in day light | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia, moderate n1=cyclopeptide | n2=en:photophobia, moderate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia, severe n1=cyclopeptide | n2=en:photophobia, severe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photophobia, severe (rare) n1=cyclopeptide | n2=en:photophobia, severe (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photopic responses reduced on electroretinography n1=cyclopeptide | n2=en:photopic responses reduced on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photopic visual field defects, asymptomatic, demonstrated by static perimetry in second decade of life n1=cyclopeptide | n2=en:photopic visual field defects, asymptomatic, demonstrated by static perimetry in second decade of life | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photoreceptor layer thinned on optical coherence tomography (oct) n1=cyclopeptide | n2=en:photoreceptor layer thinned on optical coherence tomography (oct) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photoreceptor loss, primarily in foveal region, on optical coherence tomography n1=cyclopeptide | n2=en:photoreceptor loss, primarily in foveal region, on optical coherence tomography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photosensitivity (in some patients) n1=cyclopeptide | n2=en:photosensitivity (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photosensitizer luz 11 n1=cyclopeptide | n2=en:photosensitizer luz 11 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:photosensitizing agent n1=cyclopeptide | n2=en:photosensitizing agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phthisical globe n1=cyclopeptide | n2=en:phthisical globe | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phthisis bulbi (rare) n1=cyclopeptide | n2=en:phthisis bulbi (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phytochemical n1=cyclopeptide | n2=en:phytochemical | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phytochlorin sodium-polyvinylpyrrolidone complex n1=cyclopeptide | n2=en:phytochlorin sodium-polyvinylpyrrolidone complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:phytonadione n1=cyclopeptide | n2=en:phytonadione | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k alpha inhibitor mln1117 n1=cyclopeptide | n2=en:pi3k alpha inhibitor mln1117 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k alpha/beta inhibitor bay1082439 n1=cyclopeptide | n2=en:pi3k alpha/beta inhibitor bay1082439 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k alpha/mtor inhibitor pwt33597 mesylate n1=cyclopeptide | n2=en:pi3k alpha/mtor inhibitor pwt33597 mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k delta/gamma inhibitor ipi-145 n1=cyclopeptide | n2=en:pi3k delta/gamma inhibitor ipi-145 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k delta/gamma inhibitor rp6530 n1=cyclopeptide | n2=en:pi3k delta/gamma inhibitor rp6530 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k family kinase inhibitor xl147 n1=cyclopeptide | n2=en:pi3k family kinase inhibitor xl147 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor acp-319 n1=cyclopeptide | n2=en:pi3k inhibitor acp-319 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor bgt226 n1=cyclopeptide | n2=en:pi3k inhibitor bgt226 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor ch5132799 n1=cyclopeptide | n2=en:pi3k inhibitor ch5132799 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor gdc-0084 n1=cyclopeptide | n2=en:pi3k inhibitor gdc-0084 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor gdc-0941 bismesylate n1=cyclopeptide | n2=en:pi3k inhibitor gdc-0941 bismesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor gsk1059615 n1=cyclopeptide | n2=en:pi3k inhibitor gsk1059615 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor gsk2126458 n1=cyclopeptide | n2=en:pi3k inhibitor gsk2126458 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor px-866 n1=cyclopeptide | n2=en:pi3k inhibitor px-866 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor wx-037 n1=cyclopeptide | n2=en:pi3k inhibitor wx-037 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k inhibitor zstk474 n1=cyclopeptide | n2=en:pi3k inhibitor zstk474 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k p110beta/delta inhibitor ka2237 n1=cyclopeptide | n2=en:pi3k p110beta/delta inhibitor ka2237 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k-beta inhibitor gsk2636771 n1=cyclopeptide | n2=en:pi3k-beta inhibitor gsk2636771 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k-beta inhibitor sar260301 n1=cyclopeptide | n2=en:pi3k-beta inhibitor sar260301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k-delta inhibitor amg 319 n1=cyclopeptide | n2=en:pi3k-delta inhibitor amg 319 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k-delta inhibitor incb050465 n1=cyclopeptide | n2=en:pi3k-delta inhibitor incb050465 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k-delta inhibitor pwt143 n1=cyclopeptide | n2=en:pi3k-delta inhibitor pwt143 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k-delta inhibitor tgr-1202 n1=cyclopeptide | n2=en:pi3k-delta inhibitor tgr-1202 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k-gamma inhibitor ipi-549 n1=cyclopeptide | n2=en:pi3k-gamma inhibitor ipi-549 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k/hdac inhibitor cudc-907 n1=cyclopeptide | n2=en:pi3k/hdac inhibitor cudc-907 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k/mtor inhibitor bez235 n1=cyclopeptide | n2=en:pi3k/mtor inhibitor bez235 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k/mtor inhibitor ly3023414 n1=cyclopeptide | n2=en:pi3k/mtor inhibitor ly3023414 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k/mtor kinase inhibitor ds-7423 n1=cyclopeptide | n2=en:pi3k/mtor kinase inhibitor ds-7423 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k/mtor kinase inhibitor pf-04691502 n1=cyclopeptide | n2=en:pi3k/mtor kinase inhibitor pf-04691502 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k/mtor kinase inhibitor vs-5584 n1=cyclopeptide | n2=en:pi3k/mtor kinase inhibitor vs-5584 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k/mtor/alk-1/dna-pk inhibitor p7170 n1=cyclopeptide | n2=en:pi3k/mtor/alk-1/dna-pk inhibitor p7170 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3k/mtorc1/mtorc2 inhibitor dcbci0901 n1=cyclopeptide | n2=en:pi3k/mtorc1/mtorc2 inhibitor dcbci0901 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3ka/mtor inhibitor pki-179 n1=cyclopeptide | n2=en:pi3ka/mtor inhibitor pki-179 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3kalpha inhibitor azd8835 n1=cyclopeptide | n2=en:pi3kalpha inhibitor azd8835 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3kbeta inhibitor azd8186 n1=cyclopeptide | n2=en:pi3kbeta inhibitor azd8186 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3kdelta inhibitor gs-9901 n1=cyclopeptide | n2=en:pi3kdelta inhibitor gs-9901 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pi3kdelta inhibitor incb040093 n1=cyclopeptide | n2=en:pi3kdelta inhibitor incb040093 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pibenzimol n1=cyclopeptide | n2=en:pibenzimol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pibrozelesin n1=cyclopeptide | n2=en:pibrozelesin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:picibanil n1=cyclopeptide | n2=en:picibanil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:picoplatin n1=cyclopeptide | n2=en:picoplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:picropodophyllin n1=cyclopeptide | n2=en:picropodophyllin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pidilizumab n1=cyclopeptide | n2=en:pidilizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pierre robin syndrome n1=cyclopeptide | n2=en:pierre robin syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:Pierre Robin's syndrome n1=cyclopeptide | n2=en:Pierre Robin's syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment abnormalities, both central and peripheral n1=cyclopeptide | n2=en:pigment abnormalities, both central and peripheral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment clumping n1=cyclopeptide | n2=en:pigment clumping | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment clumping (in some patients) n1=cyclopeptide | n2=en:pigment clumping (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment deposition in the trabecular meshwork n1=cyclopeptide | n2=en:pigment deposition in the trabecular meshwork | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment deposits in macular region n1=cyclopeptide | n2=en:pigment deposits in macular region | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment epithelial atrophy of macula n1=cyclopeptide | n2=en:pigment epithelial atrophy of macula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment epithelium of eye n1=cyclopeptide | n2=en:pigment epithelium of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment granule deposition from iris epithelium to other ocular structures n1=cyclopeptide | n2=en:pigment granule deposition from iris epithelium to other ocular structures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment migration n1=cyclopeptide | n2=en:pigment migration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment mottling in mid-periphery (in some patients) n1=cyclopeptide | n2=en:pigment mottling in mid-periphery (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment retinopathy (in all but youngest patients) n1=cyclopeptide | n2=en:pigment retinopathy (in all but youngest patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigment-dispersion type open-angle glaucoma n1=cyclopeptide | n2=en:pigment-dispersion type open-angle glaucoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary changes ('flecks') in the perimacular region n1=cyclopeptide | n2=en:pigmentary changes ('flecks') in the perimacular region | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary changes consistent with retinitis pigmentosa n1=cyclopeptide | n2=en:pigmentary changes consistent with retinitis pigmentosa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary changes in retina, including mottling and clumping n1=cyclopeptide | n2=en:pigmentary changes in retina, including mottling and clumping | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary changes in the peripheral retina n1=cyclopeptide | n2=en:pigmentary changes in the peripheral retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary changes of macula n1=cyclopeptide | n2=en:pigmentary changes of macula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary changes, retinal and/or subretinal (in some patients) n1=cyclopeptide | n2=en:pigmentary changes, retinal and/or subretinal (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary iris degeneration n1=cyclopeptide | n2=en:pigmentary iris degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinal changes (1 patient) n1=cyclopeptide | n2=en:pigmentary retinal changes (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinal degeneration n1=cyclopeptide | n2=en:pigmentary retinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinal deposits n1=cyclopeptide | n2=en:pigmentary retinal deposits | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinopathy (mixed nummular and spicular type in autosomal dominant cases) n1=cyclopeptide | n2=en:pigmentary retinopathy (mixed nummular and spicular type in autosomal dominant cases) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinopathy (more common in classic disease) n1=cyclopeptide | n2=en:pigmentary retinopathy (more common in classic disease) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinopathy (rare) n1=cyclopeptide | n2=en:pigmentary retinopathy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinopathy (reported in 1 patient) n1=cyclopeptide | n2=en:pigmentary retinopathy (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinopathy (round, irregular clumps of pigment with little or no evidence of bone spicule formation in autosomal recessive cases) n1=cyclopeptide | n2=en:pigmentary retinopathy (round, irregular clumps of pigment with little or no evidence of bone spicule formation in autosomal recessive cases) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinopathy (variable) n1=cyclopeptide | n2=en:pigmentary retinopathy (variable) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinopathy throughout the posterior pole and into the staphyloma in older individuals n1=cyclopeptide | n2=en:pigmentary retinopathy throughout the posterior pole and into the staphyloma in older individuals | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentary retinopathy with typical bone spicule appearance n1=cyclopeptide | n2=en:pigmentary retinopathy with typical bone spicule appearance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentation in retinal periphery n1=cyclopeptide | n2=en:pigmentation in retinal periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmentation of the sclera n1=cyclopeptide | n2=en:pigmentation of the sclera | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmented macular degeneration, adult-onset n1=cyclopeptide | n2=en:pigmented macular degeneration, adult-onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmented nevus (rare) n1=cyclopeptide | n2=en:pigmented nevus (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pigmenting agent n1=cyclopeptide | n2=en:pigmenting agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pilocarpine hydrochloride n1=cyclopeptide | n2=en:pilocarpine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pim kinase inhibitor lgh447 n1=cyclopeptide | n2=en:pim kinase inhibitor lgh447 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pim kinase inhibitor sgi-1776 n1=cyclopeptide | n2=en:pim kinase inhibitor sgi-1776 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pimasertib n1=cyclopeptide | n2=en:pimasertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pimecrolimus n1=cyclopeptide | n2=en:pimecrolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pimonidazole n1=cyclopeptide | n2=en:pimonidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pimonidazole hydrochloride n1=cyclopeptide | n2=en:pimonidazole hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pinaverium bromide n1=cyclopeptide | n2=en:pinaverium bromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pinguecula n1=cyclopeptide | n2=en:pinguecula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pink irides (childhood) n1=cyclopeptide | n2=en:pink irides (childhood) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pioglitazone hydrochloride n1=cyclopeptide | n2=en:pioglitazone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pipendoxifene n1=cyclopeptide | n2=en:pipendoxifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:piperacillin sodium n1=cyclopeptide | n2=en:piperacillin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:piperacillin-tazobactam n1=cyclopeptide | n2=en:piperacillin-tazobactam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:piperazinedione n1=cyclopeptide | n2=en:piperazinedione | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:piperine extract (standardized) n1=cyclopeptide | n2=en:piperine extract (standardized) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pipobroman n1=cyclopeptide | n2=en:pipobroman | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pirarubicin n1=cyclopeptide | n2=en:pirarubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pirfenidone n1=cyclopeptide | n2=en:pirfenidone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:piritramide n1=cyclopeptide | n2=en:piritramide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:piritrexim n1=cyclopeptide | n2=en:piritrexim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pirmagrel n1=cyclopeptide | n2=en:pirmagrel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pirotinib n1=cyclopeptide | n2=en:pirotinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:piroxantrone n1=cyclopeptide | n2=en:piroxantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:piroxicam n1=cyclopeptide | n2=en:piroxicam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pirs2 phosphopeptide-tetanus peptide vaccine n1=cyclopeptide | n2=en:pirs2 phosphopeptide-tetanus peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pivaloyloxymethylbutyrate n1=cyclopeptide | n2=en:pivaloyloxymethylbutyrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pixantrone n1=cyclopeptide | n2=en:pixantrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pixantrone dimaleate n1=cyclopeptide | n2=en:pixantrone dimaleate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:placebo administration n1=cyclopeptide | n2=en:placebo administration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pladienolide derivative e7107 n1=cyclopeptide | n2=en:pladienolide derivative e7107 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plagiocephaly (asymmetry of orbits) n1=cyclopeptide | n2=en:plagiocephaly (asymmetry of orbits) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plant extracts n1=cyclopeptide | n2=en:plant extracts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plant-derived hematopoiesis enhancer pg2 n1=cyclopeptide | n2=en:plant-derived hematopoiesis enhancer pg2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plasmacytoid dendritic cell vaccine n1=cyclopeptide | n2=en:plasmacytoid dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plasmid encoding antiangiogenic metargidin peptide n1=cyclopeptide | n2=en:plasmid encoding antiangiogenic metargidin peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plectin-1 targeting agent ptp-01 n1=cyclopeptide | n2=en:plectin-1 targeting agent ptp-01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pled-based mnsod mimetic n1=cyclopeptide | n2=en:pled-based mnsod mimetic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pleiotropic pathway modifier cc-122 hydrochloride n1=cyclopeptide | n2=en:pleiotropic pathway modifier cc-122 hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plerixafor n1=cyclopeptide | n2=en:plerixafor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plevitrexed n1=cyclopeptide | n2=en:plevitrexed | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plicamycin n1=cyclopeptide | n2=en:plicamycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plinabulin n1=cyclopeptide | n2=en:plinabulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plitidepsin n1=cyclopeptide | n2=en:plitidepsin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plk1 inhibitor tak-960 n1=cyclopeptide | n2=en:plk1 inhibitor tak-960 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plozalizumab n1=cyclopeptide | n2=en:plozalizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:plx73086 n1=cyclopeptide | n2=en:plx73086 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pm-fac protocol n1=cyclopeptide | n2=en:pm-fac protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pm00104 n1=cyclopeptide | n2=en:pm00104 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pmitcebo protocol n1=cyclopeptide | n2=en:pmitcebo protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pneumococcal 13-valent conjugate vaccine n1=cyclopeptide | n2=en:pneumococcal 13-valent conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pneumococcal 7-valent conjugate vaccine n1=cyclopeptide | n2=en:pneumococcal 7-valent conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pneumococcal polyvalent vaccine n1=cyclopeptide | n2=en:pneumococcal polyvalent vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pngvl3-hicd vaccine n1=cyclopeptide | n2=en:pngvl3-hicd vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pngvl4a-crt/e7(detox) dna vaccine n1=cyclopeptide | n2=en:pngvl4a-crt/e7(detox) dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pngvl4a-sig/e7(detox)/hsp70 dna vaccine n1=cyclopeptide | n2=en:pngvl4a-sig/e7(detox)/hsp70 dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pnp-expressing ovine atadenovirus fp253 n1=cyclopeptide | n2=en:pnp-expressing ovine atadenovirus fp253 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pog 8493 protocol n1=cyclopeptide | n2=en:pog 8493 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poisoning aspects n1=cyclopeptide | n2=en:poisoning aspects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poisoning by antineoplastic and/or immunosuppressive drug n1=cyclopeptide | n2=en:poisoning by antineoplastic and/or immunosuppressive drug | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pol i inhibitor cx5461 n1=cyclopeptide | n2=en:pol i inhibitor cx5461 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polaprezinc n1=cyclopeptide | n2=en:polaprezinc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polatuzumab vedotin n1=cyclopeptide | n2=en:polatuzumab vedotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:policosanol n1=cyclopeptide | n2=en:policosanol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polifeprosan 20 with carmustine implant n1=cyclopeptide | n2=en:polifeprosan 20 with carmustine implant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polihexanide solution n1=cyclopeptide | n2=en:polihexanide solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polo-like kinase 1 inhibitor gsk461364 n1=cyclopeptide | n2=en:polo-like kinase 1 inhibitor gsk461364 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polo-like kinase 1 inhibitor mk1496 n1=cyclopeptide | n2=en:polo-like kinase 1 inhibitor mk1496 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polo-like kinase 1 inhibitor nms-1286937 n1=cyclopeptide | n2=en:polo-like kinase 1 inhibitor nms-1286937 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polo-like kinase 4 inhibitor cfi-400945 fumarate n1=cyclopeptide | n2=en:polo-like kinase 4 inhibitor cfi-400945 fumarate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poly (adp-ribose) polymerase inhibitor n1=cyclopeptide | n2=en:poly (adp-ribose) polymerase inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poly au n1=cyclopeptide | n2=en:poly au | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poly ic n1=cyclopeptide | n2=en:poly ic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poly iclc n1=cyclopeptide | n2=en:poly iclc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poly-alendronate dextran-guanidine conjugate n1=cyclopeptide | n2=en:poly-alendronate dextran-guanidine conjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poly-gamma glutamic acid n1=cyclopeptide | n2=en:poly-gamma glutamic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyacrylamide hydrogel n1=cyclopeptide | n2=en:polyacrylamide hydrogel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyamine analogue n1=cyclopeptide | n2=en:polyamine analogue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyamine analogue pg11047 n1=cyclopeptide | n2=en:polyamine analogue pg11047 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyamine synthesis inhibitor n1=cyclopeptide | n2=en:polyamine synthesis inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polycarbophil/carbomer/glycerin/palm oil glyceride/mineral oil-containing vaginal moisturizer n1=cyclopeptide | n2=en:polycarbophil/carbomer/glycerin/palm oil glyceride/mineral oil-containing vaginal moisturizer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polycoria (rare) n1=cyclopeptide | n2=en:polycoria (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polycystic kidney disease n1=cyclopeptide | n2=en:polycystic kidney disease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polydextrose n1=cyclopeptide | n2=en:polydextrose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyethylene glycol n1=cyclopeptide | n2=en:polyethylene glycol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyethylene glycol 3350-containing enema ner1008 n1=cyclopeptide | n2=en:polyethylene glycol 3350-containing enema ner1008 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyethylene glycol polymer surgical sealant n1=cyclopeptide | n2=en:polyethylene glycol polymer surgical sealant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyethylene glycol recombinant endostatin n1=cyclopeptide | n2=en:polyethylene glycol recombinant endostatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyethyleneglycol-7-ethyl-10-hydroxycamptothecin dfp-13318 n1=cyclopeptide | n2=en:polyethyleneglycol-7-ethyl-10-hydroxycamptothecin dfp-13318 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyglutamate camptothecin n1=cyclopeptide | n2=en:polyglutamate camptothecin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polymeric camptothecin prodrug xmt-1001 n1=cyclopeptide | n2=en:polymeric camptothecin prodrug xmt-1001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polymorphic geographic deposits at bowman's layer n1=cyclopeptide | n2=en:polymorphic geographic deposits at bowman's layer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polymyxin b n1=cyclopeptide | n2=en:polymyxin b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polysaccharide-k n1=cyclopeptide | n2=en:polysaccharide-k | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polysyndactyly n1=cyclopeptide | n2=en:polysyndactyly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyunsaturated fatty acid n1=cyclopeptide | n2=en:polyunsaturated fatty acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyvalent antigen-klh conjugate vaccine n1=cyclopeptide | n2=en:polyvalent antigen-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyvalent melanoma vaccine n1=cyclopeptide | n2=en:polyvalent melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:polyvinylpyrrolidone-sodium hyaluronate gel n1=cyclopeptide | n2=en:polyvinylpyrrolidone-sodium hyaluronate gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pomace protocol n1=cyclopeptide | n2=en:pomace protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pomalidomide n1=cyclopeptide | n2=en:pomalidomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pomb-ace protocol n1=cyclopeptide | n2=en:pomb-ace protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pomb-ace-pav regimen n1=cyclopeptide | n2=en:pomb-ace-pav regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pomb/ace regimen n1=cyclopeptide | n2=en:pomb/ace regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pomegranate juice n1=cyclopeptide | n2=en:pomegranate juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pomegranate liquid extract n1=cyclopeptide | n2=en:pomegranate liquid extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pomegranate-extract pill n1=cyclopeptide | n2=en:pomegranate-extract pill | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ponatinib hydrochloride n1=cyclopeptide | n2=en:ponatinib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ponesimod n1=cyclopeptide | n2=en:ponesimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor central vision or blindness from birth n1=cyclopeptide | n2=en:poor central vision or blindness from birth | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor corneal tear film n1=cyclopeptide | n2=en:poor corneal tear film | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor eye contact n1=cyclopeptide | n2=en:poor eye contact | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor eye contact (in some patients) n1=cyclopeptide | n2=en:poor eye contact (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor fixation n1=cyclopeptide | n2=en:poor fixation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor fixation and following n1=cyclopeptide | n2=en:poor fixation and following | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor mydriasis n1=cyclopeptide | n2=en:poor mydriasis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor or lack of visual contact (in some patients) n1=cyclopeptide | n2=en:poor or lack of visual contact (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor pupillary reflexes n1=cyclopeptide | n2=en:poor pupillary reflexes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor response to light (in some patients) n1=cyclopeptide | n2=en:poor response to light (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor smooth pursuit n1=cyclopeptide | n2=en:poor smooth pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor vision (1 patient) n1=cyclopeptide | n2=en:poor vision (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor vision (1/4 patients) n1=cyclopeptide | n2=en:poor vision (1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor vision at birth n1=cyclopeptide | n2=en:poor vision at birth | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual acuity n1=cyclopeptide | n2=en:poor visual acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual attention n1=cyclopeptide | n2=en:poor visual attention | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual contact n1=cyclopeptide | n2=en:poor visual contact | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual contact (in 1 patient) n1=cyclopeptide | n2=en:poor visual contact (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual fixation n1=cyclopeptide | n2=en:poor visual fixation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual fixation (1 patient) n1=cyclopeptide | n2=en:poor visual fixation (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual pursuit n1=cyclopeptide | n2=en:poor visual pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual tracking n1=cyclopeptide | n2=en:poor visual tracking | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poor visual tracking (in some patients) n1=cyclopeptide | n2=en:poor visual tracking (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poorly reactive pupils n1=cyclopeptide | n2=en:poorly reactive pupils | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:porcupine inhibitor etc-1922159 n1=cyclopeptide | n2=en:porcupine inhibitor etc-1922159 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:porcupine inhibitor wnt974 n1=cyclopeptide | n2=en:porcupine inhibitor wnt974 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:porfimer sodium n1=cyclopeptide | n2=en:porfimer sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:porfiromycin n1=cyclopeptide | n2=en:porfiromycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posaconazole n1=cyclopeptide | n2=en:posaconazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:positive angle kappa (appearance of exotropia but no shift on cover test) n1=cyclopeptide | n2=en:positive angle kappa (appearance of exotropia but no shift on cover test) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior amorphous corneal dystrophy extending to the corneal limbus n1=cyclopeptide | n2=en:posterior amorphous corneal dystrophy extending to the corneal limbus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior chamber of the eye n1=cyclopeptide | n2=en:posterior chamber of the eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior embryotoxon n1=cyclopeptide | n2=en:posterior embryotoxon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior embryotoxon (in some patients) n1=cyclopeptide | n2=en:posterior embryotoxon (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior eyeball segment structure n1=cyclopeptide | n2=en:posterior eyeball segment structure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior lens luxation (rare) n1=cyclopeptide | n2=en:posterior lens luxation (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior lenticonus n1=cyclopeptide | n2=en:posterior lenticonus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior polar cataract n1=cyclopeptide | n2=en:posterior polar cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior staphyloma in most eyes n1=cyclopeptide | n2=en:posterior staphyloma in most eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior subcapsular cataract n1=cyclopeptide | n2=en:posterior subcapsular cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior subcapsular cataract (rare) n1=cyclopeptide | n2=en:posterior subcapsular cataract (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior subcapsular cataracts (onset in second or third decade) n1=cyclopeptide | n2=en:posterior subcapsular cataracts (onset in second or third decade) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior subcapsular cataracts, mild (rare) n1=cyclopeptide | n2=en:posterior subcapsular cataracts, mild (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior subcapsular lens opacities (in some patients) n1=cyclopeptide | n2=en:posterior subcapsular lens opacities (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior subcapsular opacities of the lens (in carrier females) n1=cyclopeptide | n2=en:posterior subcapsular opacities of the lens (in carrier females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior synechiae, diffuse n1=cyclopeptide | n2=en:posterior synechiae, diffuse | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior urethral valve n1=cyclopeptide | n2=en:posterior urethral valve | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:posterior y-sutural cataracts (females) n1=cyclopeptide | n2=en:posterior y-sutural cataracts (females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:povidone-iodine n1=cyclopeptide | n2=en:povidone-iodine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:poziotinib n1=cyclopeptide | n2=en:poziotinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ppe-expressing replication-defective hsv-1 vector np2 n1=cyclopeptide | n2=en:ppe-expressing replication-defective hsv-1 vector np2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ppi-2458 n1=cyclopeptide | n2=en:ppi-2458 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pr-104 n1=cyclopeptide | n2=en:pr-104 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pr1 leukemia peptide vaccine n1=cyclopeptide | n2=en:pr1 leukemia peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pracinostat n1=cyclopeptide | n2=en:pracinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pralatrexate n1=cyclopeptide | n2=en:pralatrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prame-targeting t-cell receptor/inducible caspase 9 bpx-701 n1=cyclopeptide | n2=en:prame-targeting t-cell receptor/inducible caspase 9 bpx-701 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pramipexole dihydrochloride n1=cyclopeptide | n2=en:pramipexole dihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prasterone n1=cyclopeptide | n2=en:prasterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pravastatin sodium n1=cyclopeptide | n2=en:pravastatin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:preauricular cyst n1=cyclopeptide | n2=en:preauricular cyst | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:precocious puberty n1=cyclopeptide | n2=en:precocious puberty | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prednimustine n1=cyclopeptide | n2=en:prednimustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prednisolone n1=cyclopeptide | n2=en:prednisolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prednisone n1=cyclopeptide | n2=en:prednisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pregabalin n1=cyclopeptide | n2=en:pregabalin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:preimplantation factor pif-1 n1=cyclopeptide | n2=en:preimplantation factor pif-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:premature epiphyseal fusion n1=cyclopeptide | n2=en:premature epiphyseal fusion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prescription drugs n1=cyclopeptide | n2=en:prescription drugs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:presenile cataract n1=cyclopeptide | n2=en:presenile cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:preservation of central vision into later adulthood (in some patients) n1=cyclopeptide | n2=en:preservation of central vision into later adulthood (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:preserved negative component (a-wave) on electroretinography n1=cyclopeptide | n2=en:preserved negative component (a-wave) on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:preserved rod function n1=cyclopeptide | n2=en:preserved rod function | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prexasertib n1=cyclopeptide | n2=en:prexasertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prilocaine hydrochloride n1=cyclopeptide | n2=en:prilocaine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prima-1 analog apr-246 n1=cyclopeptide | n2=en:prima-1 analog apr-246 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:primary prostate cancer tissue/htert/survivin mrna-loaded autologous dendritic cell vaccine n1=cyclopeptide | n2=en:primary prostate cancer tissue/htert/survivin mrna-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prinomastat n1=cyclopeptide | n2=en:prinomastat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pro-mace-c-mopp protocol n1=cyclopeptide | n2=en:pro-mace-c-mopp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:probenecid n1=cyclopeptide | n2=en:probenecid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:procarbazine n1=cyclopeptide | n2=en:procarbazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:procarbazine hydrochloride n1=cyclopeptide | n2=en:procarbazine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:procaspase activating compound-1 vo-100 n1=cyclopeptide | n2=en:procaspase activating compound-1 vo-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prochlorperazine n1=cyclopeptide | n2=en:prochlorperazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prodrugs n1=cyclopeptide | n2=en:prodrugs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:product bases and inactive substances n1=cyclopeptide | n2=en:product bases and inactive substances | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:proflavine n1=cyclopeptide | n2=en:proflavine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:proflavine hemisulfate n1=cyclopeptide | n2=en:proflavine hemisulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:profound atrophy in fovea (in some patients) n1=cyclopeptide | n2=en:profound atrophy in fovea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progenipoietin n1=cyclopeptide | n2=en:progenipoietin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progesterone vaginal insert n1=cyclopeptide | n2=en:progesterone vaginal insert | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progestin n1=cyclopeptide | n2=en:progestin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive central vision loss n1=cyclopeptide | n2=en:progressive central vision loss | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive central vision toss n1=cyclopeptide | n2=en:progressive central vision toss | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive chorioretinal degeneration n1=cyclopeptide | n2=en:progressive chorioretinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive cone degeneration (in some patients) n1=cyclopeptide | n2=en:progressive cone degeneration (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive external ophthalmoplegia (1 patient) n1=cyclopeptide | n2=en:progressive external ophthalmoplegia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive juvenile macular dystrophy (onset 3-21 years) n1=cyclopeptide | n2=en:progressive juvenile macular dystrophy (onset 3-21 years) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive loss of peripheral vision (onset in first decade) n1=cyclopeptide | n2=en:progressive loss of peripheral vision (onset in first decade) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive ptosis n1=cyclopeptide | n2=en:progressive ptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive retinal degeneration n1=cyclopeptide | n2=en:progressive retinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive retinitis pigmentosa n1=cyclopeptide | n2=en:progressive retinitis pigmentosa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive vision loss (in males and some carrier females) n1=cyclopeptide | n2=en:progressive vision loss (in males and some carrier females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive visual impairment, mild n1=cyclopeptide | n2=en:progressive visual impairment, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:progressive visual loss n1=cyclopeptide | n2=en:progressive visual loss | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prohibitin-targeting peptide 1 n1=cyclopeptide | n2=en:prohibitin-targeting peptide 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:proliferant agent n1=cyclopeptide | n2=en:proliferant agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:promace protocol n1=cyclopeptide | n2=en:promace protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:promace-cytabom regimen n1=cyclopeptide | n2=en:promace-cytabom regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:promece-cytabom protocol n1=cyclopeptide | n2=en:promece-cytabom protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:promegapoietin n1=cyclopeptide | n2=en:promegapoietin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:promestriene n1=cyclopeptide | n2=en:promestriene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:promethazine hydrochloride n1=cyclopeptide | n2=en:promethazine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent corneal nerves n1=cyclopeptide | n2=en:prominent corneal nerves | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent epicanthal folds n1=cyclopeptide | n2=en:prominent epicanthal folds | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent eyes n1=cyclopeptide | n2=en:prominent eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent eyes (14%) n1=cyclopeptide | n2=en:prominent eyes (14%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent eyes (37%) n1=cyclopeptide | n2=en:prominent eyes (37%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent eyes (in one patient) n1=cyclopeptide | n2=en:prominent eyes (in one patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent globes n1=cyclopeptide | n2=en:prominent globes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent optic disc with irregular capillaries (in some patients) n1=cyclopeptide | n2=en:prominent optic disc with irregular capillaries (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent schwalbe line (posterior embryotoxon) n1=cyclopeptide | n2=en:prominent schwalbe line (posterior embryotoxon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent scleral vessels (in some patients) n1=cyclopeptide | n2=en:prominent scleral vessels (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prominent supraorbital ridges n1=cyclopeptide | n2=en:prominent supraorbital ridges | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pronase oral solution n1=cyclopeptide | n2=en:pronase oral solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pronounced convex arch of eyebrows n1=cyclopeptide | n2=en:pronounced convex arch of eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pronounced eyebrows n1=cyclopeptide | n2=en:pronounced eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:propacetamol n1=cyclopeptide | n2=en:propacetamol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:propofol n1=cyclopeptide | n2=en:propofol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:propranolol hydrochloride n1=cyclopeptide | n2=en:propranolol hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:proptosis (1 patient) n1=cyclopeptide | n2=en:proptosis (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:propylbenzilylcholine mustard n1=cyclopeptide | n2=en:propylbenzilylcholine mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:propylthiouracil n1=cyclopeptide | n2=en:propylthiouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prosoposchisis n1=cyclopeptide | n2=en:prosoposchisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prospidium n1=cyclopeptide | n2=en:prospidium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prospidium chloride n1=cyclopeptide | n2=en:prospidium chloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prostate cancer vaccine ony-p1 n1=cyclopeptide | n2=en:prostate cancer vaccine ony-p1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prostate cancer vaccine pf-06755990 n1=cyclopeptide | n2=en:prostate cancer vaccine pf-06755990 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prostate cancer vaccine pf-06755992 n1=cyclopeptide | n2=en:prostate cancer vaccine pf-06755992 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prostate health cocktail dietary supplement n1=cyclopeptide | n2=en:prostate health cocktail dietary supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prostate tumor antigen-activated autologous dendritic cell vaccine n1=cyclopeptide | n2=en:prostate tumor antigen-activated autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:prostatic acid phosphatase-sargramostim fusion protein n1=cyclopeptide | n2=en:prostatic acid phosphatase-sargramostim fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protan defect on color vision testing (in some patients) n1=cyclopeptide | n2=en:protan defect on color vision testing (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:proteasome inhibitor n1=cyclopeptide | n2=en:proteasome inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protective agent n1=cyclopeptide | n2=en:protective agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protein e7, human papillomavirus type 16 n1=cyclopeptide | n2=en:protein e7, human papillomavirus type 16 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protein kinase c inhibitor lxs196 n1=cyclopeptide | n2=en:protein kinase c inhibitor lxs196 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protein phosphatase 2a inhibitor lb-100 n1=cyclopeptide | n2=en:protein phosphatase 2a inhibitor lb-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protein stabilized liposomal docetaxel nanoparticles n1=cyclopeptide | n2=en:protein stabilized liposomal docetaxel nanoparticles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protein tyrosine kinase 2 inhibitor bi 853520 n1=cyclopeptide | n2=en:protein tyrosine kinase 2 inhibitor bi 853520 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protocol 8001 n1=cyclopeptide | n2=en:protocol 8001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protruding eyes n1=cyclopeptide | n2=en:protruding eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:protuberant eyes n1=cyclopeptide | n2=en:protuberant eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psa rna-pulsed dendritic cell vaccine n1=cyclopeptide | n2=en:psa rna-pulsed dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psa-pap/klh-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:psa-pap/klh-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psa:154-163(155l) peptide vaccine n1=cyclopeptide | n2=en:psa:154-163(155l) peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psa/il-2/gm-csf vaccine n1=cyclopeptide | n2=en:psa/il-2/gm-csf vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psa/psma dna plasmid ino-5150 n1=cyclopeptide | n2=en:psa/psma dna plasmid ino-5150 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pseudo-ptosis n1=cyclopeptide | n2=en:pseudo-ptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pseudoexfoliation of lens (physical finding) n1=cyclopeptide | n2=en:pseudoexfoliation of lens (physical finding) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pseudoexophthalmos (rare) n1=cyclopeptide | n2=en:pseudoexophthalmos (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pseudoglioma n1=cyclopeptide | n2=en:pseudoglioma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pseudomonas aeruginosa preparation n1=cyclopeptide | n2=en:pseudomonas aeruginosa preparation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pseudouveitis due to breakdown of blood-aqueous barrier n1=cyclopeptide | n2=en:pseudouveitis due to breakdown of blood-aqueous barrier | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psicrip-mfg-s-tk1-67 n1=cyclopeptide | n2=en:psicrip-mfg-s-tk1-67 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psilocybine n1=cyclopeptide | n2=en:psilocybine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psma-targeted docetaxel nanoparticles bind-014 n1=cyclopeptide | n2=en:psma-targeted docetaxel nanoparticles bind-014 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psma-targeted tubulysin b-containing conjugate ec1169 n1=cyclopeptide | n2=en:psma-targeted tubulysin b-containing conjugate ec1169 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psma/tarp peptide vaccine n1=cyclopeptide | n2=en:psma/tarp peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psoralen n1=cyclopeptide | n2=en:psoralen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:psychopharmacologic agent n1=cyclopeptide | n2=en:psychopharmacologic agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptef-b/cdk9 inhibitor bay1251152 n1=cyclopeptide | n2=en:ptef-b/cdk9 inhibitor bay1251152 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pterygium colli n1=cyclopeptide | n2=en:pterygium colli | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (1 patient) n1=cyclopeptide | n2=en:ptosis (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (50%) n1=cyclopeptide | n2=en:ptosis (50%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (about half of patients) n1=cyclopeptide | n2=en:ptosis (about half of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (hcs) n1=cyclopeptide | n2=en:ptosis (hcs) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (in some patients) n1=cyclopeptide | n2=en:ptosis (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (less common) n1=cyclopeptide | n2=en:ptosis (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (patient a) n1=cyclopeptide | n2=en:ptosis (patient a) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (rare) n1=cyclopeptide | n2=en:ptosis (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (uncommon) n1=cyclopeptide | n2=en:ptosis (uncommon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis (with longer disease duration) n1=cyclopeptide | n2=en:ptosis (with longer disease duration) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis, bilateral (in some patients) n1=cyclopeptide | n2=en:ptosis, bilateral (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis, bilateral symmetric minimal levator function, bilaterally n1=cyclopeptide | n2=en:ptosis, bilateral symmetric minimal levator function, bilaterally | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis, ipsilateral n1=cyclopeptide | n2=en:ptosis, ipsilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis, mild n1=cyclopeptide | n2=en:ptosis, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis, mild (less common) n1=cyclopeptide | n2=en:ptosis, mild (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis, unilateral or more severe on one side n1=cyclopeptide | n2=en:ptosis, unilateral or more severe on one side | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptosis, variable (bilateral, unilateral, or absent) n1=cyclopeptide | n2=en:ptosis, variable (bilateral, unilateral, or absent) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ptvg-hp plasmid dna vaccine n1=cyclopeptide | n2=en:ptvg-hp plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:puckered skin about the eyes n1=cyclopeptide | n2=en:puckered skin about the eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:puffy and droopy eyelids n1=cyclopeptide | n2=en:puffy and droopy eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pulverulent cataract (in some patients) n1=cyclopeptide | n2=en:pulverulent cataract (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pumvc3-higfbp-2 multi-epitope plasmid dna vaccine n1=cyclopeptide | n2=en:pumvc3-higfbp-2 multi-epitope plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pumvc3-igfbp2-her2-igf1r plasmid dna vaccine n1=cyclopeptide | n2=en:pumvc3-igfbp2-her2-igf1r plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:punctal pits (in some patients) n1=cyclopeptide | n2=en:punctal pits (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:punctate corneal epithelial erosions n1=cyclopeptide | n2=en:punctate corneal epithelial erosions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:punctate keratitis n1=cyclopeptide | n2=en:punctate keratitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:punctate lenticular opacities n1=cyclopeptide | n2=en:punctate lenticular opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:punctate white opacities in the retina n1=cyclopeptide | n2=en:punctate white opacities in the retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:punctate yellow-white sub-retinal pigment epithelium (rpe) lesions n1=cyclopeptide | n2=en:punctate yellow-white sub-retinal pigment epithelium (rpe) lesions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pupil n1=cyclopeptide | n2=en:pupil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pupil diameter:len:pt:eye.left:qn:auto n1=cyclopeptide | n2=en:pupil diameter:len:pt:eye.left:qn:auto | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pupil diameter:len:pt:eye.left:qn:manual n1=cyclopeptide | n2=en:pupil diameter:len:pt:eye.left:qn:manual | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pupil diameter:len:pt:eye.right:qn:auto n1=cyclopeptide | n2=en:pupil diameter:len:pt:eye.right:qn:auto | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pupil diameter:len:pt:eye.right:qn:manual n1=cyclopeptide | n2=en:pupil diameter:len:pt:eye.right:qn:manual | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pupillary abnormalities (reported in 1 family) n1=cyclopeptide | n2=en:pupillary abnormalities (reported in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pupillary contraction in response to methacholine n1=cyclopeptide | n2=en:pupillary contraction in response to methacholine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pupillary reflex sluggish n1=cyclopeptide | n2=en:pupillary reflex sluggish | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:purple grape juice n1=cyclopeptide | n2=en:purple grape juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pv-10 n1=cyclopeptide | n2=en:pv-10 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pv701 n1=cyclopeptide | n2=en:pv701 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pva microporous hydrospheres n1=cyclopeptide | n2=en:pva microporous hydrospheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pva microporous hydrospheres/doxorubicin hydrochloride n1=cyclopeptide | n2=en:pva microporous hydrospheres/doxorubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pvaxrcpsav53l dna vaccine n1=cyclopeptide | n2=en:pvaxrcpsav53l dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyloric stenosis n1=cyclopeptide | n2=en:pyloric stenosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrazinamide n1=cyclopeptide | n2=en:pyrazinamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrazine diazohydroxide n1=cyclopeptide | n2=en:pyrazine diazohydroxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrazofurin n1=cyclopeptide | n2=en:pyrazofurin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrazole derivative n1=cyclopeptide | n2=en:pyrazole derivative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrazoloacridine n1=cyclopeptide | n2=en:pyrazoloacridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyridoxine hydrochloride n1=cyclopeptide | n2=en:pyridoxine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyridyl cyanoguanidine chs 828 n1=cyclopeptide | n2=en:pyridyl cyanoguanidine chs 828 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrimethamine n1=cyclopeptide | n2=en:pyrimethamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrimethamine-sulfadoxine n1=cyclopeptide | n2=en:pyrimethamine-sulfadoxine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrogen n1=cyclopeptide | n2=en:pyrogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyrotinib n1=cyclopeptide | n2=en:pyrotinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyroxamide n1=cyclopeptide | n2=en:pyroxamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:pyruvate kinase inhibitor tln-232 n1=cyclopeptide | n2=en:pyruvate kinase inhibitor tln-232 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:qs21 n1=cyclopeptide | n2=en:qs21 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine n1=cyclopeptide | n2=en:quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quarfloxin n1=cyclopeptide | n2=en:quarfloxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quaternary ammonium polyethylenimine nanoparticles n1=cyclopeptide | n2=en:quaternary ammonium polyethylenimine nanoparticles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quercetin n1=cyclopeptide | n2=en:quercetin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quinacrine hydrochloride n1=cyclopeptide | n2=en:quinacrine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quinacrine mustard n1=cyclopeptide | n2=en:quinacrine mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quinidine n1=cyclopeptide | n2=en:quinidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quinine n1=cyclopeptide | n2=en:quinine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quinoline n1=cyclopeptide | n2=en:quinoline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quisinostat n1=cyclopeptide | n2=en:quisinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:quizartinib n1=cyclopeptide | n2=en:quizartinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r 7160 n1=cyclopeptide | n2=en:r 7160 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r-(-)-gossypol acetic acid n1=cyclopeptide | n2=en:r-(-)-gossypol acetic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r-14 regimen n1=cyclopeptide | n2=en:r-14 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r-chop protocol n1=cyclopeptide | n2=en:r-chop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r-chop regimen n1=cyclopeptide | n2=en:r-chop regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r-cvp regimen n1=cyclopeptide | n2=en:r-cvp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r-epoch regimen n1=cyclopeptide | n2=en:r-epoch regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r-fcm regimen n1=cyclopeptide | n2=en:r-fcm regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r-ice regimen n1=cyclopeptide | n2=en:r-ice regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r(+)xk469 n1=cyclopeptide | n2=en:r(+)xk469 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:r1 cooling gel plus r2 moisturizing/sun protecting lotion n1=cyclopeptide | n2=en:r1 cooling gel plus r2 moisturizing/sun protecting lotion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rabeprazole sodium n1=cyclopeptide | n2=en:rabeprazole sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rabusertib n1=cyclopeptide | n2=en:rabusertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:racop protocol n1=cyclopeptide | n2=en:racop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:racotumomab n1=cyclopeptide | n2=en:racotumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radiation-induced disorder n1=cyclopeptide | n2=en:radiation-induced disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radiopharmaceutical agent n1=cyclopeptide | n2=en:radiopharmaceutical agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radiopharmaceutical bay1862864 n1=cyclopeptide | n2=en:radiopharmaceutical bay1862864 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radiopharmaceutical compound n1=cyclopeptide | n2=en:radiopharmaceutical compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radioprotective agent n1=cyclopeptide | n2=en:radioprotective agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radiosensitizer rrx-001 n1=cyclopeptide | n2=en:radiosensitizer rrx-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radiosensitizing agent n1=cyclopeptide | n2=en:radiosensitizing agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radium ra 223 dichloride n1=cyclopeptide | n2=en:radium ra 223 dichloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radix angelicae sinensis/radix astragali herbal supplement n1=cyclopeptide | n2=en:radix angelicae sinensis/radix astragali herbal supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:radotinib hydrochloride n1=cyclopeptide | n2=en:radotinib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:raf kinase inhibitor hm95573 n1=cyclopeptide | n2=en:raf kinase inhibitor hm95573 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:raf kinase inhibitor lgx818 n1=cyclopeptide | n2=en:raf kinase inhibitor lgx818 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:raf kinase inhibitor xl281 n1=cyclopeptide | n2=en:raf kinase inhibitor xl281 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:raf/mek serine/threonine kinase inhibitor ro5126766 n1=cyclopeptide | n2=en:raf/mek serine/threonine kinase inhibitor ro5126766 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:raised, yellowish-gray gelatinous masses (subepithelium and anterior stroma) n1=cyclopeptide | n2=en:raised, yellowish-gray gelatinous masses (subepithelium and anterior stroma) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:raloxifene n1=cyclopeptide | n2=en:raloxifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:raltegravir potassium n1=cyclopeptide | n2=en:raltegravir potassium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:raltitrexed n1=cyclopeptide | n2=en:raltitrexed | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ramelteon n1=cyclopeptide | n2=en:ramelteon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ramipril n1=cyclopeptide | n2=en:ramipril | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ramosetron hydrochloride n1=cyclopeptide | n2=en:ramosetron hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ramucirumab n1=cyclopeptide | n2=en:ramucirumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ranibizumab n1=cyclopeptide | n2=en:ranibizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ranimustine n1=cyclopeptide | n2=en:ranimustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ranitidine hydrochloride/bismuth potassium citrate/sucralfate hydrate formulation n1=cyclopeptide | n2=en:ranitidine hydrochloride/bismuth potassium citrate/sucralfate hydrate formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ranolazine n1=cyclopeptide | n2=en:ranolazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ranpirnase n1=cyclopeptide | n2=en:ranpirnase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rapamycin-polarized th1/tc1 autologous t lymphocytes n1=cyclopeptide | n2=en:rapamycin-polarized th1/tc1 autologous t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rar-alpha agonist vtp195183 n1=cyclopeptide | n2=en:rar-alpha agonist vtp195183 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rarefaction of retinal pigmentation n1=cyclopeptide | n2=en:rarefaction of retinal pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ras peptide cancer vaccine n1=cyclopeptide | n2=en:ras peptide cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rasburicase n1=cyclopeptide | n2=en:rasburicase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ravuconazole n1=cyclopeptide | n2=en:ravuconazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:razoxane n1=cyclopeptide | n2=en:razoxane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rbl001/rbl002 vaccine n1=cyclopeptide | n2=en:rbl001/rbl002 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:realgar-indigo naturalis formulation n1=cyclopeptide | n2=en:realgar-indigo naturalis formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rebamipide n1=cyclopeptide | n2=en:rebamipide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rebastinib tosylate n1=cyclopeptide | n2=en:rebastinib tosylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rebimastat n1=cyclopeptide | n2=en:rebimastat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:receptor tyrosine kinase inhibitor r1530 n1=cyclopeptide | n2=en:receptor tyrosine kinase inhibitor r1530 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant 70-kd heat-shock protein n1=cyclopeptide | n2=en:recombinant 70-kd heat-shock protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant adenovirus 5 encoding tumor necrosis factor-related apoptosis-inducing ligand n1=cyclopeptide | n2=en:recombinant adenovirus 5 encoding tumor necrosis factor-related apoptosis-inducing ligand | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant adenovirus encoding p53 n1=cyclopeptide | n2=en:recombinant adenovirus encoding p53 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant adenovirus-hifn-beta n1=cyclopeptide | n2=en:recombinant adenovirus-hifn-beta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant adenovirus-interferon sch 721015 n1=cyclopeptide | n2=en:recombinant adenovirus-interferon sch 721015 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant adenovirus-interferon/syn3 n1=cyclopeptide | n2=en:recombinant adenovirus-interferon/syn3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant adenovirus-l523s vaccine n1=cyclopeptide | n2=en:recombinant adenovirus-l523s vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant adenovirus-p53 sch-58500 n1=cyclopeptide | n2=en:recombinant adenovirus-p53 sch-58500 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant anti-wt1 immunotherapeutic gsk2302024a n1=cyclopeptide | n2=en:recombinant anti-wt1 immunotherapeutic gsk2302024a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant attenuated salmonella typhimurium expressing il-2 n1=cyclopeptide | n2=en:recombinant attenuated salmonella typhimurium expressing il-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant b. pertussis adenylate cyclase toxin-tyrosinase a2 epitope vaccine n1=cyclopeptide | n2=en:recombinant b. pertussis adenylate cyclase toxin-tyrosinase a2 epitope vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant bispecific single-chain antibody rm28 n1=cyclopeptide | n2=en:recombinant bispecific single-chain antibody rm28 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant cd40-ligand n1=cyclopeptide | n2=en:recombinant cd40-ligand | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant cell-surface anchored sialidase das181 n1=cyclopeptide | n2=en:recombinant cell-surface anchored sialidase das181 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant dher2 vaccine n1=cyclopeptide | n2=en:recombinant dher2 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant dna-l523s vaccine n1=cyclopeptide | n2=en:recombinant dna-l523s vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant ephb4-hsa fusion protein n1=cyclopeptide | n2=en:recombinant ephb4-hsa fusion protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant flt3 ligand n1=cyclopeptide | n2=en:recombinant flt3 ligand | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant fowlpox gm-csf vaccine adjuvant n1=cyclopeptide | n2=en:recombinant fowlpox gm-csf vaccine adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant fowlpox-b7.1 vaccine n1=cyclopeptide | n2=en:recombinant fowlpox-b7.1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant fowlpox-cea(6d)/tricom vaccine n1=cyclopeptide | n2=en:recombinant fowlpox-cea(6d)/tricom vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant fowlpox-prostate specific antigen vaccine n1=cyclopeptide | n2=en:recombinant fowlpox-prostate specific antigen vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant fowlpox-tricom vaccine n1=cyclopeptide | n2=en:recombinant fowlpox-tricom vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant fowlpox-tyrosinase vaccine n1=cyclopeptide | n2=en:recombinant fowlpox-tyrosinase vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant gonadorelin n1=cyclopeptide | n2=en:recombinant gonadorelin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant granulocyte-macrophage colony-stimulating factor n1=cyclopeptide | n2=en:recombinant granulocyte-macrophage colony-stimulating factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human 6ckine n1=cyclopeptide | n2=en:recombinant human 6ckine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human adenovirus type 5 h101 n1=cyclopeptide | n2=en:recombinant human adenovirus type 5 h101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human albumin-human granulocyte colony-stimulating factor n1=cyclopeptide | n2=en:recombinant human albumin-human granulocyte colony-stimulating factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human angiotensin converting enzyme 2 apn01 n1=cyclopeptide | n2=en:recombinant human angiotensin converting enzyme 2 apn01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human apolipoprotein(a) kringle v mg1102 n1=cyclopeptide | n2=en:recombinant human apolipoprotein(a) kringle v mg1102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human chorionic gonadotropin n1=cyclopeptide | n2=en:recombinant human chorionic gonadotropin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human egf-rp64k/montanide isa 51 vaccine n1=cyclopeptide | n2=en:recombinant human egf-rp64k/montanide isa 51 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human endostatin n1=cyclopeptide | n2=en:recombinant human endostatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human fusion protein l19tnfalpha n1=cyclopeptide | n2=en:recombinant human fusion protein l19tnfalpha | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human granulocyte colony stimulating factor n1=cyclopeptide | n2=en:recombinant human granulocyte colony stimulating factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human hsp110-gp100 chaperone complex vaccine n1=cyclopeptide | n2=en:recombinant human hsp110-gp100 chaperone complex vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human hyaluronidase n1=cyclopeptide | n2=en:recombinant human hyaluronidase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human interleukin-15 n1=cyclopeptide | n2=en:recombinant human interleukin-15 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human papillomavirus nonavalent vaccine n1=cyclopeptide | n2=en:recombinant human papillomavirus nonavalent vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant human serum amyloid p/pentraxin 2 n1=cyclopeptide | n2=en:recombinant human serum amyloid p/pentraxin 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interferon n1=cyclopeptide | n2=en:recombinant interferon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interferon alfa n1=cyclopeptide | n2=en:recombinant interferon alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interferon alfa-1b n1=cyclopeptide | n2=en:recombinant interferon alfa-1b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interferon alfa-2a n1=cyclopeptide | n2=en:recombinant interferon alfa-2a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interferon alfa-2b n1=cyclopeptide | n2=en:recombinant interferon alfa-2b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interferon alpha 2b-like protein n1=cyclopeptide | n2=en:recombinant interferon alpha 2b-like protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interferon beta n1=cyclopeptide | n2=en:recombinant interferon beta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interferon gamma n1=cyclopeptide | n2=en:recombinant interferon gamma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interleukin-1 receptor antagonist n1=cyclopeptide | n2=en:recombinant interleukin-1 receptor antagonist | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interleukin-1-alpha n1=cyclopeptide | n2=en:recombinant interleukin-1-alpha | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interleukin-1-beta n1=cyclopeptide | n2=en:recombinant interleukin-1-beta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interleukin-12 n1=cyclopeptide | n2=en:recombinant interleukin-12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interleukin-18 n1=cyclopeptide | n2=en:recombinant interleukin-18 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interleukin-3 n1=cyclopeptide | n2=en:recombinant interleukin-3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant interleukin-7 n1=cyclopeptide | n2=en:recombinant interleukin-7 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant leukocyte interleukin n1=cyclopeptide | n2=en:recombinant leukocyte interleukin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant macrophage colony-stimulating factor n1=cyclopeptide | n2=en:recombinant macrophage colony-stimulating factor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant mage-3.1 antigen n1=cyclopeptide | n2=en:recombinant mage-3.1 antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant mip1-alpha variant eci301 n1=cyclopeptide | n2=en:recombinant mip1-alpha variant eci301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant modified vaccinia ankara-5t4 vaccine n1=cyclopeptide | n2=en:recombinant modified vaccinia ankara-5t4 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant nematode anticoagulant protein c2 n1=cyclopeptide | n2=en:recombinant nematode anticoagulant protein c2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant oncolytic poliovirus pvs-ripo n1=cyclopeptide | n2=en:recombinant oncolytic poliovirus pvs-ripo | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant oxytocin n1=cyclopeptide | n2=en:recombinant oxytocin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant parathyroid hormone n1=cyclopeptide | n2=en:recombinant parathyroid hormone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant platelet factor 4 n1=cyclopeptide | n2=en:recombinant platelet factor 4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant prame protein plus as15 adjuvant gsk2302025a n1=cyclopeptide | n2=en:recombinant prame protein plus as15 adjuvant gsk2302025a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant saccharomyces cerevisia-cea(610d)-expressing vaccine gi-6207 n1=cyclopeptide | n2=en:recombinant saccharomyces cerevisia-cea(610d)-expressing vaccine gi-6207 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant soluble human cd4 protein n1=cyclopeptide | n2=en:recombinant soluble human cd4 protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant soluble t4 n1=cyclopeptide | n2=en:recombinant soluble t4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant super-compound interferon n1=cyclopeptide | n2=en:recombinant super-compound interferon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant thymosin n1=cyclopeptide | n2=en:recombinant thymosin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant thyroglobulin n1=cyclopeptide | n2=en:recombinant thyroglobulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant thyroid-stimulating hormone n1=cyclopeptide | n2=en:recombinant thyroid-stimulating hormone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant thyrotropin alfa n1=cyclopeptide | n2=en:recombinant thyrotropin alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant transforming growth factor-beta-2 n1=cyclopeptide | n2=en:recombinant transforming growth factor-beta-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant tumor necrosis factor family protein n1=cyclopeptide | n2=en:recombinant tumor necrosis factor family protein | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant tyrosinase-related protein-2 n1=cyclopeptide | n2=en:recombinant tyrosinase-related protein-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant urokinase n1=cyclopeptide | n2=en:recombinant urokinase | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia df3/muc1 vaccine n1=cyclopeptide | n2=en:recombinant vaccinia df3/muc1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia psa vaccine n1=cyclopeptide | n2=en:recombinant vaccinia psa vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia viral vector ro5217790 n1=cyclopeptide | n2=en:recombinant vaccinia viral vector ro5217790 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia-b7.1 vaccine n1=cyclopeptide | n2=en:recombinant vaccinia-b7.1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia-cea(6d)-tricom vaccine n1=cyclopeptide | n2=en:recombinant vaccinia-cea(6d)-tricom vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia-muc-1 vaccine n1=cyclopeptide | n2=en:recombinant vaccinia-muc-1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia-multiepitope melanoma peptides-b7.1-b7.2 vaccine n1=cyclopeptide | n2=en:recombinant vaccinia-multiepitope melanoma peptides-b7.1-b7.2 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia-ny-eso-1 vaccine n1=cyclopeptide | n2=en:recombinant vaccinia-ny-eso-1 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vaccinia-tricom vaccine n1=cyclopeptide | n2=en:recombinant vaccinia-tricom vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recombinant vesicular stomatitis virus-expressing interferon-beta n1=cyclopeptide | n2=en:recombinant vesicular stomatitis virus-expressing interferon-beta | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recovery of visual acuity occurs in 60% of patients n1=cyclopeptide | n2=en:recovery of visual acuity occurs in 60% of patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rectal dosage form product n1=cyclopeptide | n2=en:rectal dosage form product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recurrent erosion of cornea n1=cyclopeptide | n2=en:recurrent erosion of cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:recurrent erosions uncommon n1=cyclopeptide | n2=en:recurrent erosions uncommon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:red eye n1=cyclopeptide | n2=en:red eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:red reflex on transillumination of the iris n1=cyclopeptide | n2=en:red reflex on transillumination of the iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:red tomato juice n1=cyclopeptide | n2=en:red tomato juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:red-blind color blindness (reported in 1 patient) n1=cyclopeptide | n2=en:red-blind color blindness (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:red-green color defect in many patients with deletion downstream of exon 30 n1=cyclopeptide | n2=en:red-green color defect in many patients with deletion downstream of exon 30 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:red/green color vision defect n1=cyclopeptide | n2=en:red/green color vision defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:redness of the conjunctivae n1=cyclopeptide | n2=en:redness of the conjunctivae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced and delayed cone responses on electroretinography n1=cyclopeptide | n2=en:reduced and delayed cone responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced axial length (nanophthalmos) if no staphyloma n1=cyclopeptide | n2=en:reduced axial length (nanophthalmos) if no staphyloma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced central vision (occurs last) n1=cyclopeptide | n2=en:reduced central vision (occurs last) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced central vision, progressive n1=cyclopeptide | n2=en:reduced central vision, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced cone responses on electroretinography n1=cyclopeptide | n2=en:reduced cone responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced electroretinographic (erg) flicker n1=cyclopeptide | n2=en:reduced electroretinographic (erg) flicker | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced glutathione-l-cysteine-anthocyanins gel n1=cyclopeptide | n2=en:reduced glutathione-l-cysteine-anthocyanins gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced macular reflex n1=cyclopeptide | n2=en:reduced macular reflex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced night vision n1=cyclopeptide | n2=en:reduced night vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced or abolished electroretinogram (erg) n1=cyclopeptide | n2=en:reduced or abolished electroretinogram (erg) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced or extinguished electroretinography responses n1=cyclopeptide | n2=en:reduced or extinguished electroretinography responses | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced or nonrecordable cone responses on electroretinography n1=cyclopeptide | n2=en:reduced or nonrecordable cone responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced peripheral vision n1=cyclopeptide | n2=en:reduced peripheral vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced peripheral vision (early) n1=cyclopeptide | n2=en:reduced peripheral vision (early) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced photopic and scotopic responses on electroretinography n1=cyclopeptide | n2=en:reduced photopic and scotopic responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced positive component (b-wave) on electroretinography n1=cyclopeptide | n2=en:reduced positive component (b-wave) on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced red-green color vision, progressive n1=cyclopeptide | n2=en:reduced red-green color vision, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced retinal nerve fiber layer thickness n1=cyclopeptide | n2=en:reduced retinal nerve fiber layer thickness | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced scotopic responses on electroretinography n1=cyclopeptide | n2=en:reduced scotopic responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced upgaze n1=cyclopeptide | n2=en:reduced upgaze | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced visual acuity (less common) n1=cyclopeptide | n2=en:reduced visual acuity (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced visual acuity by age 3 years n1=cyclopeptide | n2=en:reduced visual acuity by age 3 years | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced visual acuity, bilateral n1=cyclopeptide | n2=en:reduced visual acuity, bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduced visual evoked potentials n1=cyclopeptide | n2=en:reduced visual evoked potentials | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reduction of capillary-free zone n1=cyclopeptide | n2=en:reduction of capillary-free zone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:refametinib n1=cyclopeptide | n2=en:refametinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:refractive error (usually combined hyperopic astigmatism) n1=cyclopeptide | n2=en:refractive error (usually combined hyperopic astigmatism) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:refractive errors (astigmatism, hyperopia, myopia) n1=cyclopeptide | n2=en:refractive errors (astigmatism, hyperopia, myopia) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:regadenoson n1=cyclopeptide | n2=en:regadenoson | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:regorafenib n1=cyclopeptide | n2=en:regorafenib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:relative central scotoma n1=cyclopeptide | n2=en:relative central scotoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:relative paracentral scotoma in 2/3 of patients n1=cyclopeptide | n2=en:relative paracentral scotoma in 2/3 of patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:relative sparing of fovea n1=cyclopeptide | n2=en:relative sparing of fovea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:relative sparing of fovea with surrounding atrophic ring (in some patients) n1=cyclopeptide | n2=en:relative sparing of fovea with surrounding atrophic ring (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:relative sparing of periphery n1=cyclopeptide | n2=en:relative sparing of periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:relatively large eyes n1=cyclopeptide | n2=en:relatively large eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:relcovaptan n1=cyclopeptide | n2=en:relcovaptan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:remestemcel-l n1=cyclopeptide | n2=en:remestemcel-l | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:remifentanil hydrochloride n1=cyclopeptide | n2=en:remifentanil hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:renal agents n1=cyclopeptide | n2=en:renal agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:renal cell carcinoma peptides vaccine ima901 n1=cyclopeptide | n2=en:renal cell carcinoma peptides vaccine ima901 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:renal cell carcinoma/cd40l rna-transfected autologous dendritic cell vaccine ags-003 n1=cyclopeptide | n2=en:renal cell carcinoma/cd40l rna-transfected autologous dendritic cell vaccine ags-003 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:repaglinide n1=cyclopeptide | n2=en:repaglinide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reparixin n1=cyclopeptide | n2=en:reparixin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:repetitive eye blinking accompanying visual hallucinations (in some patients) n1=cyclopeptide | n2=en:repetitive eye blinking accompanying visual hallucinations (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:replacement agent n1=cyclopeptide | n2=en:replacement agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reproductive system drug n1=cyclopeptide | n2=en:reproductive system drug | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:resiniferatoxin n1=cyclopeptide | n2=en:resiniferatoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:resiquimod n1=cyclopeptide | n2=en:resiquimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:resiquimod topical gel n1=cyclopeptide | n2=en:resiquimod topical gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:resistant starch n1=cyclopeptide | n2=en:resistant starch | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:resminostat n1=cyclopeptide | n2=en:resminostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:respiratory form lucinactant n1=cyclopeptide | n2=en:respiratory form lucinactant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:respiratory form tiotropium n1=cyclopeptide | n2=en:respiratory form tiotropium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:respiratory system agents n1=cyclopeptide | n2=en:respiratory system agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:restricted eye movement n1=cyclopeptide | n2=en:restricted eye movement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:restricted visual fields n1=cyclopeptide | n2=en:restricted visual fields | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:restrictive external ophthalmoplegia n1=cyclopeptide | n2=en:restrictive external ophthalmoplegia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:restrictive external ophthalmoplegia, bilateral n1=cyclopeptide | n2=en:restrictive external ophthalmoplegia, bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:restrictive partial ophthalmoplegia n1=cyclopeptide | n2=en:restrictive partial ophthalmoplegia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:resveratrol n1=cyclopeptide | n2=en:resveratrol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:resveratrol formulation srt501 n1=cyclopeptide | n2=en:resveratrol formulation srt501 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retaspimycin hydrochloride n1=cyclopeptide | n2=en:retaspimycin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:reticulate pigmentation (bulbar conjunctiva) n1=cyclopeptide | n2=en:reticulate pigmentation (bulbar conjunctiva) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retina n1=cyclopeptide | n2=en:retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retina abnormality n1=cyclopeptide | n2=en:retina abnormality | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retina-normal n1=cyclopeptide | n2=en:retina-normal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal 'bone corpuscle' pigmentation n1=cyclopeptide | n2=en:retinal 'bone corpuscle' pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal arterial beading along all 4 retinal arterial trunks n1=cyclopeptide | n2=en:retinal arterial beading along all 4 retinal arterial trunks | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal arterial macroaneurysms, multiple, developing at sites of beading n1=cyclopeptide | n2=en:retinal arterial macroaneurysms, multiple, developing at sites of beading | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal arteries attenuated n1=cyclopeptide | n2=en:retinal arteries attenuated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal arteriolar constriction n1=cyclopeptide | n2=en:retinal arteriolar constriction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal arteriolar tortuosity n1=cyclopeptide | n2=en:retinal arteriolar tortuosity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal astrocytoma n1=cyclopeptide | n2=en:retinal astrocytoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal calcification n1=cyclopeptide | n2=en:retinal calcification | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal cavernous hemangioma n1=cyclopeptide | n2=en:retinal cavernous hemangioma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal degeneration n1=cyclopeptide | n2=en:retinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal degeneration (in 1 patient) n1=cyclopeptide | n2=en:retinal degeneration (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal degeneration (in some patients) n1=cyclopeptide | n2=en:retinal degeneration (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal degeneration in adult patients, progressive n1=cyclopeptide | n2=en:retinal degeneration in adult patients, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal degeneration with macular involvement n1=cyclopeptide | n2=en:retinal degeneration with macular involvement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal degeneration, adult-onset n1=cyclopeptide | n2=en:retinal degeneration, adult-onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal depigmentation n1=cyclopeptide | n2=en:retinal depigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal detachment n1=cyclopeptide | n2=en:retinal detachment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal detachment (childhood) n1=cyclopeptide | n2=en:retinal detachment (childhood) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal detachment (in 1 patient) n1=cyclopeptide | n2=en:retinal detachment (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal detachment (in some patients) n1=cyclopeptide | n2=en:retinal detachment (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal detachment (rare) n1=cyclopeptide | n2=en:retinal detachment (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal detachment (wws) n1=cyclopeptide | n2=en:retinal detachment (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal detachment, postsurgical (in some patients) n1=cyclopeptide | n2=en:retinal detachment, postsurgical (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal disorders congenital n1=cyclopeptide | n2=en:retinal disorders congenital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dysfunction n1=cyclopeptide | n2=en:retinal dysfunction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dysplasia n1=cyclopeptide | n2=en:retinal dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dysplasia (1 patient) n1=cyclopeptide | n2=en:retinal dysplasia (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dysplasia (less common) n1=cyclopeptide | n2=en:retinal dysplasia (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dysplasia (wws) n1=cyclopeptide | n2=en:retinal dysplasia (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy n1=cyclopeptide | n2=en:retinal dystrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy (1 family) n1=cyclopeptide | n2=en:retinal dystrophy (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy (in most patients) n1=cyclopeptide | n2=en:retinal dystrophy (in most patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy (less common) n1=cyclopeptide | n2=en:retinal dystrophy (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy (rare) n1=cyclopeptide | n2=en:retinal dystrophy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy (reported in 1 patient) n1=cyclopeptide | n2=en:retinal dystrophy (reported in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy (rods and cones affected), early onset n1=cyclopeptide | n2=en:retinal dystrophy (rods and cones affected), early onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy (variable) n1=cyclopeptide | n2=en:retinal dystrophy (variable) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy, congenital, nonprogressive n1=cyclopeptide | n2=en:retinal dystrophy, congenital, nonprogressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal dystrophy, progressive n1=cyclopeptide | n2=en:retinal dystrophy, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal edema (rare) n1=cyclopeptide | n2=en:retinal edema (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal exudates n1=cyclopeptide | n2=en:retinal exudates | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal fibrosis n1=cyclopeptide | n2=en:retinal fibrosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal fold n1=cyclopeptide | n2=en:retinal fold | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal hamartoma n1=cyclopeptide | n2=en:retinal hamartoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal hemangioblastomatosis n1=cyclopeptide | n2=en:retinal hemangioblastomatosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal hemangioma n1=cyclopeptide | n2=en:retinal hemangioma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal hemorrhage n1=cyclopeptide | n2=en:retinal hemorrhage | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal ischemia n1=cyclopeptide | n2=en:retinal ischemia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal lesions with tortuous vessels n1=cyclopeptide | n2=en:retinal lesions with tortuous vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal malformations (wws) n1=cyclopeptide | n2=en:retinal malformations (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal microaneurysm n1=cyclopeptide | n2=en:retinal microaneurysm | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal neovascularization n1=cyclopeptide | n2=en:retinal neovascularization | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal nerve atrophy (in some patients) n1=cyclopeptide | n2=en:retinal nerve atrophy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pallor, generalized n1=cyclopeptide | n2=en:retinal pallor, generalized | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment abnormalities n1=cyclopeptide | n2=en:retinal pigment abnormalities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelial atrophy n1=cyclopeptide | n2=en:retinal pigment epithelial atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelial atrophy, widespread n1=cyclopeptide | n2=en:retinal pigment epithelial atrophy, widespread | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelial defects in the temporal nerve fiber bundle n1=cyclopeptide | n2=en:retinal pigment epithelial defects in the temporal nerve fiber bundle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelial migration and proliferation n1=cyclopeptide | n2=en:retinal pigment epithelial migration and proliferation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelial mottling n1=cyclopeptide | n2=en:retinal pigment epithelial mottling | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelium n1=cyclopeptide | n2=en:retinal pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelium (rpe) thinning and photoreceptor loss correlate with thickness of sub-rpe deposits of lipid, esterified- and non-esterified cholesterol n1=cyclopeptide | n2=en:retinal pigment epithelium (rpe) thinning and photoreceptor loss correlate with thickness of sub-rpe deposits of lipid, esterified- and non-esterified cholesterol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelium atrophy n1=cyclopeptide | n2=en:retinal pigment epithelium atrophy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelium atrophy peripherally n1=cyclopeptide | n2=en:retinal pigment epithelium atrophy peripherally | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment epithelium atrophy with pigment clumping and bone-spicule pigmentation (in some patients) n1=cyclopeptide | n2=en:retinal pigment epithelium atrophy with pigment clumping and bone-spicule pigmentation (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigment present n1=cyclopeptide | n2=en:retinal pigment present | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigmentary changes n1=cyclopeptide | n2=en:retinal pigmentary changes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigmentation n1=cyclopeptide | n2=en:retinal pigmentation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigmentation anterior to boundary of the staphyloma in younger patients n1=cyclopeptide | n2=en:retinal pigmentation anterior to boundary of the staphyloma in younger patients | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal pigmentation, peripheral n1=cyclopeptide | n2=en:retinal pigmentation, peripheral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal staphyloma (rare) n1=cyclopeptide | n2=en:retinal staphyloma (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal tears (in some patients) n1=cyclopeptide | n2=en:retinal tears (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal telangiectasia n1=cyclopeptide | n2=en:retinal telangiectasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal thinning n1=cyclopeptide | n2=en:retinal thinning | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal thrombosis n1=cyclopeptide | n2=en:retinal thrombosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal vascular malformation n1=cyclopeptide | n2=en:retinal vascular malformation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal vascular tortuosity n1=cyclopeptide | n2=en:retinal vascular tortuosity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal vasculopathy n1=cyclopeptide | n2=en:retinal vasculopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal vein occlusion n1=cyclopeptide | n2=en:retinal vein occlusion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal venous segmental beading n1=cyclopeptide | n2=en:retinal venous segmental beading | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal vessel attenuation (in all but youngest patients) n1=cyclopeptide | n2=en:retinal vessel attenuation (in all but youngest patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinal vessels severely attenuated n1=cyclopeptide | n2=en:retinal vessels severely attenuated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis n1=cyclopeptide | n2=en:retinitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa n1=cyclopeptide | n2=en:retinitis pigmentosa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa (1 patient) n1=cyclopeptide | n2=en:retinitis pigmentosa (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa (in some patients) n1=cyclopeptide | n2=en:retinitis pigmentosa (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa (late-onset) n1=cyclopeptide | n2=en:retinitis pigmentosa (late-onset) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa (onset in infancy to early childhood) n1=cyclopeptide | n2=en:retinitis pigmentosa (onset in infancy to early childhood) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa (rare) n1=cyclopeptide | n2=en:retinitis pigmentosa (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa with preserved central vision n1=cyclopeptide | n2=en:retinitis pigmentosa with preserved central vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa, late-onset form n1=cyclopeptide | n2=en:retinitis pigmentosa, late-onset form | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa, progressive (prepubertal onset) n1=cyclopeptide | n2=en:retinitis pigmentosa, progressive (prepubertal onset) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa, sector type (in some patients) n1=cyclopeptide | n2=en:retinitis pigmentosa, sector type (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis pigmentosa, severe, early-onset n1=cyclopeptide | n2=en:retinitis pigmentosa, severe, early-onset | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinitis punctata albescens (disorder) n1=cyclopeptide | n2=en:retinitis punctata albescens (disorder) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinoblastoma n1=cyclopeptide | n2=en:retinoblastoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinoblastoma (25% bilateral, 15% unilateral) n1=cyclopeptide | n2=en:retinoblastoma (25% bilateral, 15% unilateral) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinoic acid agent n1=cyclopeptide | n2=en:retinoic acid agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinoid 9cuab30 n1=cyclopeptide | n2=en:retinoid 9cuab30 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinoid analogue nrx 195183 n1=cyclopeptide | n2=en:retinoid analogue nrx 195183 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinomas (translucent, grayish retinal mass protruding into the vitreous) n1=cyclopeptide | n2=en:retinomas (translucent, grayish retinal mass protruding into the vitreous) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinopathy n1=cyclopeptide | n2=en:retinopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinopathy (1 patient) n1=cyclopeptide | n2=en:retinopathy (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinopathy (in some patients) n1=cyclopeptide | n2=en:retinopathy (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinopathy (rare) n1=cyclopeptide | n2=en:retinopathy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinopathy may resemble retinitis pigmentosa n1=cyclopeptide | n2=en:retinopathy may resemble retinitis pigmentosa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinoschisis n1=cyclopeptide | n2=en:retinoschisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retinyl acetate n1=cyclopeptide | n2=en:retinyl acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retraction of lower eyelid n1=cyclopeptide | n2=en:retraction of lower eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retrobulbar venous varix n1=cyclopeptide | n2=en:retrobulbar venous varix | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retrovector encoding mutant anti-cyclin g1 n1=cyclopeptide | n2=en:retrovector encoding mutant anti-cyclin g1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:retrovirus vector ln n1=cyclopeptide | n2=en:retrovirus vector ln | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:revm10 gene n1=cyclopeptide | n2=en:revm10 gene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:revm10 gene/polas gene n1=cyclopeptide | n2=en:revm10 gene/polas gene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rexinoid nrx 194204 n1=cyclopeptide | n2=en:rexinoid nrx 194204 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rft5-dga immunotoxin n1=cyclopeptide | n2=en:rft5-dga immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rg 12915 n1=cyclopeptide | n2=en:rg 12915 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rhenium re 188 bmeda-labeled liposomes n1=cyclopeptide | n2=en:rhenium re 188 bmeda-labeled liposomes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rhenium re 188 p2045 n1=cyclopeptide | n2=en:rhenium re 188 p2045 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rhenium re-186 hydroxyethylidene diphosphonate n1=cyclopeptide | n2=en:rhenium re-186 hydroxyethylidene diphosphonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rhenium re-188 ethiodized oil n1=cyclopeptide | n2=en:rhenium re-188 ethiodized oil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rhinocephaly n1=cyclopeptide | n2=en:rhinocephaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rhizoxin n1=cyclopeptide | n2=en:rhizoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rhubarb/licorice herbal supplement n1=cyclopeptide | n2=en:rhubarb/licorice herbal supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ribavirin n1=cyclopeptide | n2=en:ribavirin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ribociclib n1=cyclopeptide | n2=en:ribociclib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:riboflavin n1=cyclopeptide | n2=en:riboflavin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ribonuclease qbi-139 n1=cyclopeptide | n2=en:ribonuclease qbi-139 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ribosome-inactivating protein cy503 n1=cyclopeptide | n2=en:ribosome-inactivating protein cy503 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ribozyme rpi.4610 n1=cyclopeptide | n2=en:ribozyme rpi.4610 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rice bran n1=cyclopeptide | n2=en:rice bran | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ricin immunoconjugate n1=cyclopeptide | n2=en:ricin immunoconjugate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ricolinostat n1=cyclopeptide | n2=en:ricolinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ridaforolimus n1=cyclopeptide | n2=en:ridaforolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rieger anomaly (goniodysgenesis) n1=cyclopeptide | n2=en:rieger anomaly (goniodysgenesis) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rifabutin n1=cyclopeptide | n2=en:rifabutin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rifampin n1=cyclopeptide | n2=en:rifampin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rifaximin n1=cyclopeptide | n2=en:rifaximin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:right eye n1=cyclopeptide | n2=en:right eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:right eyeball n1=cyclopeptide | n2=en:right eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rigosertib sodium n1=cyclopeptide | n2=en:rigosertib sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rilimogene galvacirepvec n1=cyclopeptide | n2=en:rilimogene galvacirepvec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rilotumumab n1=cyclopeptide | n2=en:rilotumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:riluzole n1=cyclopeptide | n2=en:riluzole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rimiducid n1=cyclopeptide | n2=en:rimiducid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rindopepimut n1=cyclopeptide | n2=en:rindopepimut | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ring of moderately increased perifoveal autofluorescence n1=cyclopeptide | n2=en:ring of moderately increased perifoveal autofluorescence | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ring scotoma (early) n1=cyclopeptide | n2=en:ring scotoma (early) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rintatolimod n1=cyclopeptide | n2=en:rintatolimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:risedronate sodium n1=cyclopeptide | n2=en:risedronate sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ritonavir n1=cyclopeptide | n2=en:ritonavir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rituximab n1=cyclopeptide | n2=en:rituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rivaroxaban n1=cyclopeptide | n2=en:rivaroxaban | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rivastigmine tartrate n1=cyclopeptide | n2=en:rivastigmine tartrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rizatriptan benzoate n1=cyclopeptide | n2=en:rizatriptan benzoate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rk-0202 n1=cyclopeptide | n2=en:rk-0202 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rna electroporated cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes n1=cyclopeptide | n2=en:rna electroporated cd19car-cd3zeta-4-1bb-expressing autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rnr inhibitor coh29 n1=cyclopeptide | n2=en:rnr inhibitor coh29 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ro6874813 n1=cyclopeptide | n2=en:ro6874813 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ro6895882 n1=cyclopeptide | n2=en:ro6895882 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:robatumumab n1=cyclopeptide | n2=en:robatumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rocuronium bromide n1=cyclopeptide | n2=en:rocuronium bromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rod and cone responses reduced or nondetectable on electroretinography n1=cyclopeptide | n2=en:rod and cone responses reduced or nondetectable on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rod dystrophy (rare) n1=cyclopeptide | n2=en:rod dystrophy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rod responses extinguished on erg n1=cyclopeptide | n2=en:rod responses extinguished on erg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rod-cone dystrophy (rare) n1=cyclopeptide | n2=en:rod-cone dystrophy (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rod-cone dystrophy on erg (early) n1=cyclopeptide | n2=en:rod-cone dystrophy on erg (early) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rod-cone dystrophy, onset by end of 2nd decade (major) n1=cyclopeptide | n2=en:rod-cone dystrophy, onset by end of 2nd decade (major) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rod-cone perimetry showed normal rod sensitivity, but impaired peripheral cone sensitivity n1=cyclopeptide | n2=en:rod-cone perimetry showed normal rod sensitivity, but impaired peripheral cone sensitivity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rofecoxib n1=cyclopeptide | n2=en:rofecoxib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:roflumilast n1=cyclopeptide | n2=en:roflumilast | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rogletimide n1=cyclopeptide | n2=en:rogletimide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rolapitant hydrochloride n1=cyclopeptide | n2=en:rolapitant hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:romidepsin n1=cyclopeptide | n2=en:romidepsin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:romiplostim n1=cyclopeptide | n2=en:romiplostim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:roniciclib n1=cyclopeptide | n2=en:roniciclib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ropidoxuridine n1=cyclopeptide | n2=en:ropidoxuridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ropinirole hydrochloride n1=cyclopeptide | n2=en:ropinirole hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ropivacaine hydrochloride n1=cyclopeptide | n2=en:ropivacaine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:roquinimex n1=cyclopeptide | n2=en:roquinimex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ror1 car-specific autologous t-lymphocytes n1=cyclopeptide | n2=en:ror1 car-specific autologous t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rosabulin n1=cyclopeptide | n2=en:rosabulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rosen's t-10 protocol n1=cyclopeptide | n2=en:rosen's t-10 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rosiglitazone maleate n1=cyclopeptide | n2=en:rosiglitazone maleate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rosuvastatin calcium n1=cyclopeptide | n2=en:rosuvastatin calcium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rotary nystagmus (in 1 patient) n1=cyclopeptide | n2=en:rotary nystagmus (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rotavirus vaccine n1=cyclopeptide | n2=en:rotavirus vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rotigotine n1=cyclopeptide | n2=en:rotigotine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rounded palpebral fissures n1=cyclopeptide | n2=en:rounded palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:roxithromycin n1=cyclopeptide | n2=en:roxithromycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rsv fusion inhibitor gs-5806 n1=cyclopeptide | n2=en:rsv fusion inhibitor gs-5806 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rubidium rb-82 n1=cyclopeptide | n2=en:rubidium rb-82 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rubinstein-taybi syndrome n1=cyclopeptide | n2=en:rubinstein-taybi syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rubitecan n1=cyclopeptide | n2=en:rubitecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rucaparib phosphate n1=cyclopeptide | n2=en:rucaparib phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ruthenium ru-106 n1=cyclopeptide | n2=en:ruthenium ru-106 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ruthenium-based transferrin targeting agent nkp-1339 n1=cyclopeptide | n2=en:ruthenium-based transferrin targeting agent nkp-1339 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:rutin n1=cyclopeptide | n2=en:rutin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ruxolitinib n1=cyclopeptide | n2=en:ruxolitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ruxolitinib phosphate n1=cyclopeptide | n2=en:ruxolitinib phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:s-3304 n1=cyclopeptide | n2=en:s-3304 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:s-adenosyl-l-methionine disulfate p-toluene-sulfonate n1=cyclopeptide | n2=en:s-adenosyl-l-methionine disulfate p-toluene-sulfonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:s-adenosylmethionine n1=cyclopeptide | n2=en:s-adenosylmethionine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:s-curved lower eyelids n1=cyclopeptide | n2=en:s-curved lower eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:s-equol n1=cyclopeptide | n2=en:s-equol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:s-shaped blepharoptosis n1=cyclopeptide | n2=en:s-shaped blepharoptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:s-shaped eyelids n1=cyclopeptide | n2=en:s-shaped eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:s1p receptor agonist krp203 n1=cyclopeptide | n2=en:s1p receptor agonist krp203 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sabarubicin n1=cyclopeptide | n2=en:sabarubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccade initiation failure n1=cyclopeptide | n2=en:saccade initiation failure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccades n1=cyclopeptide | n2=en:saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic intrusions n1=cyclopeptide | n2=en:saccadic intrusions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic movements n1=cyclopeptide | n2=en:saccadic movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic ocular pursuit (in 1 of 3 families) n1=cyclopeptide | n2=en:saccadic ocular pursuit (in 1 of 3 families) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic pursuit (in some patients) n1=cyclopeptide | n2=en:saccadic pursuit (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic pursuit (less common) n1=cyclopeptide | n2=en:saccadic pursuit (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic pursuit (rare) n1=cyclopeptide | n2=en:saccadic pursuit (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic slowing (rare) n1=cyclopeptide | n2=en:saccadic slowing (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic smooth pursuit n1=cyclopeptide | n2=en:saccadic smooth pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccadic visual pursuit n1=cyclopeptide | n2=en:saccadic visual pursuit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccharomyces boulardii preparation n1=cyclopeptide | n2=en:saccharomyces boulardii preparation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccharomyces boulardii probiotic supplement n1=cyclopeptide | n2=en:saccharomyces boulardii probiotic supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saccular conjunctival aneurysms n1=cyclopeptide | n2=en:saccular conjunctival aneurysms | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sacituzumab govitecan n1=cyclopeptide | n2=en:sacituzumab govitecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sacral dimple n1=cyclopeptide | n2=en:sacral dimple | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:safingol n1=cyclopeptide | n2=en:safingol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sagopilone n1=cyclopeptide | n2=en:sagopilone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:salirasib n1=cyclopeptide | n2=en:salirasib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:salmon spots n1=cyclopeptide | n2=en:salmon spots | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:salmonella vnp20009 n1=cyclopeptide | n2=en:salmonella vnp20009 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:salt and pepper retinopathy, early n1=cyclopeptide | n2=en:salt and pepper retinopathy, early | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:salvia hispanica seed n1=cyclopeptide | n2=en:salvia hispanica seed | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:salvia officinalis extract tablet n1=cyclopeptide | n2=en:salvia officinalis extract tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sam68 modulator cwp232291 n1=cyclopeptide | n2=en:sam68 modulator cwp232291 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:samarium sm-153 lexidronam pentasodium n1=cyclopeptide | n2=en:samarium sm-153 lexidronam pentasodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saob-0401 n1=cyclopeptide | n2=en:saob-0401 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sapacitabine n1=cyclopeptide | n2=en:sapacitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sapanisertib n1=cyclopeptide | n2=en:sapanisertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saperconazole n1=cyclopeptide | n2=en:saperconazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sapitinib n1=cyclopeptide | n2=en:sapitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saponin-based immunoadjuvant obi-821 n1=cyclopeptide | n2=en:saponin-based immunoadjuvant obi-821 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saponin-cholesterol-phospholipid adjuvant n1=cyclopeptide | n2=en:saponin-cholesterol-phospholipid adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saquinavir mesylate n1=cyclopeptide | n2=en:saquinavir mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saracatinib n1=cyclopeptide | n2=en:saracatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sarcnu n1=cyclopeptide | n2=en:sarcnu | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sarcoid-associated optic neuropathy (1-5% of patients with neurosarcoidosis) n1=cyclopeptide | n2=en:sarcoid-associated optic neuropathy (1-5% of patients with neurosarcoidosis) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sarcolysin n1=cyclopeptide | n2=en:sarcolysin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sardomozide n1=cyclopeptide | n2=en:sardomozide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sargramostim plasmid dna hepatocellular carcinoma vaccine adjuvant n1=cyclopeptide | n2=en:sargramostim plasmid dna hepatocellular carcinoma vaccine adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sargramostim plasmid dna melanoma vaccine adjuvant n1=cyclopeptide | n2=en:sargramostim plasmid dna melanoma vaccine adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sargramostim plasmid dna pancreatic tumor cell vaccine n1=cyclopeptide | n2=en:sargramostim plasmid dna pancreatic tumor cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sargramostim plasmid dna sarcoma vaccine n1=cyclopeptide | n2=en:sargramostim plasmid dna sarcoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saridegib n1=cyclopeptide | n2=en:saridegib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:satraplatin n1=cyclopeptide | n2=en:satraplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saw palmetto berry extract n1=cyclopeptide | n2=en:saw palmetto berry extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:saxagliptin hydrochloride n1=cyclopeptide | n2=en:saxagliptin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sb as-2 n1=cyclopeptide | n2=en:sb as-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sb injection n1=cyclopeptide | n2=en:sb injection | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sb-743921 n1=cyclopeptide | n2=en:sb-743921 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sb-as02b adjuvant n1=cyclopeptide | n2=en:sb-as02b adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sb-as15 adjuvant n1=cyclopeptide | n2=en:sb-as15 adjuvant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scant bone-spicule pigment (rare) n1=cyclopeptide | n2=en:scant bone-spicule pigment (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scant eyebrows n1=cyclopeptide | n2=en:scant eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scant lateral eyebrows n1=cyclopeptide | n2=en:scant lateral eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scant-absent eyebrows n1=cyclopeptide | n2=en:scant-absent eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scant-absent eyelashes n1=cyclopeptide | n2=en:scant-absent eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scarred macula n1=cyclopeptide | n2=en:scarred macula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scattered bone-spicule pigmentation in midperiphery n1=cyclopeptide | n2=en:scattered bone-spicule pigmentation in midperiphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scb01a n1=cyclopeptide | n2=en:scb01a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:schwalbe line (posterior embryotoxon) n1=cyclopeptide | n2=en:schwalbe line (posterior embryotoxon) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sclera n1=cyclopeptide | n2=en:sclera | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scleral icterus (in some patients) n1=cyclopeptide | n2=en:scleral icterus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scleral thickening n1=cyclopeptide | n2=en:scleral thickening | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sclerocornea n1=cyclopeptide | n2=en:sclerocornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sclerocornea (in some patients) n1=cyclopeptide | n2=en:sclerocornea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scotomas, episodic n1=cyclopeptide | n2=en:scotomas, episodic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:scotopic responses reduced or nondetectable on electroretinography n1=cyclopeptide | n2=en:scotopic responses reduced or nondetectable on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sdf-1-targeted agent nox-a12 n1=cyclopeptide | n2=en:sdf-1-targeted agent nox-a12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:secondary glaucoma n1=cyclopeptide | n2=en:secondary glaucoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:secretin human n1=cyclopeptide | n2=en:secretin human | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:secukinumab n1=cyclopeptide | n2=en:secukinumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sedoxantrone trihydrochloride n1=cyclopeptide | n2=en:sedoxantrone trihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:see-saw eye winking n1=cyclopeptide | n2=en:see-saw eye winking | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sees haloes around lights n1=cyclopeptide | n2=en:sees haloes around lights | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selatinib ditosilate n1=cyclopeptide | n2=en:selatinib ditosilate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selective adhesion molecule inhibitor n1=cyclopeptide | n2=en:selective adhesion molecule inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selective androgen receptor modulator ly2452473 n1=cyclopeptide | n2=en:selective androgen receptor modulator ly2452473 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selective estrogen receptor degrader arn-810 n1=cyclopeptide | n2=en:selective estrogen receptor degrader arn-810 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selective estrogen receptor degrader azd9496 n1=cyclopeptide | n2=en:selective estrogen receptor degrader azd9496 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selective estrogen receptor degrader lsz102 n1=cyclopeptide | n2=en:selective estrogen receptor degrader lsz102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selective estrogen receptor degrader srn-927 n1=cyclopeptide | n2=en:selective estrogen receptor degrader srn-927 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selective estrogen receptor degrader/modulator rad1901 n1=cyclopeptide | n2=en:selective estrogen receptor degrader/modulator rad1901 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selective estrogen receptor modulator n1=cyclopeptide | n2=en:selective estrogen receptor modulator | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selenium n1=cyclopeptide | n2=en:selenium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:seliciclib n1=cyclopeptide | n2=en:seliciclib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selinexor n1=cyclopeptide | n2=en:selinexor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:selumetinib n1=cyclopeptide | n2=en:selumetinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:semaxanib n1=cyclopeptide | n2=en:semaxanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:semuloparin n1=cyclopeptide | n2=en:semuloparin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:semustine n1=cyclopeptide | n2=en:semustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:seneca valley virus-001 n1=cyclopeptide | n2=en:seneca valley virus-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:senna extract n1=cyclopeptide | n2=en:senna extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:senna fruit n1=cyclopeptide | n2=en:senna fruit | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sensorineural deafness, progressive n1=cyclopeptide | n2=en:sensorineural deafness, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sensorineural hearing loss n1=cyclopeptide | n2=en:sensorineural hearing loss | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:seocalcitol n1=cyclopeptide | n2=en:seocalcitol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sepantronium bromide n1=cyclopeptide | n2=en:sepantronium bromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:septo-optic dysplasia n1=cyclopeptide | n2=en:septo-optic dysplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:seribantumab n1=cyclopeptide | n2=en:seribantumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:serine n1=cyclopeptide | n2=en:serine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:serine protease inhibitor wx-671 n1=cyclopeptide | n2=en:serine protease inhibitor wx-671 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:serine/threonine kinase inhibitor xl418 n1=cyclopeptide | n2=en:serine/threonine kinase inhibitor xl418 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:serotonin 5-ht1 receptor agonists n1=cyclopeptide | n2=en:serotonin 5-ht1 receptor agonists | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:serous retinal detachment n1=cyclopeptide | n2=en:serous retinal detachment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sertraline hydrochloride n1=cyclopeptide | n2=en:sertraline hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:serum-derived bovine immunoglobulin protein isolate n1=cyclopeptide | n2=en:serum-derived bovine immunoglobulin protein isolate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sevacizumab n1=cyclopeptide | n2=en:sevacizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe ectropion n1=cyclopeptide | n2=en:severe ectropion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe hypertelorism n1=cyclopeptide | n2=en:severe hypertelorism | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe limitations of eye movements n1=cyclopeptide | n2=en:severe limitations of eye movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe loss of rod and cone function on electroretinography n1=cyclopeptide | n2=en:severe loss of rod and cone function on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe loss of vision n1=cyclopeptide | n2=en:severe loss of vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe myopia n1=cyclopeptide | n2=en:severe myopia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe photoreceptor dystrophy involving both rods and cones seen on electroretinography n1=cyclopeptide | n2=en:severe photoreceptor dystrophy involving both rods and cones seen on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe visual impairment n1=cyclopeptide | n2=en:severe visual impairment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severe, early-onset eye disease n1=cyclopeptide | n2=en:severe, early-onset eye disease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severely reduced central responses on multifocal erg n1=cyclopeptide | n2=en:severely reduced central responses on multifocal erg | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severely reduced cone and absent 30hz flicker responses on cone electroretinogram (in some patients) n1=cyclopeptide | n2=en:severely reduced cone and absent 30hz flicker responses on cone electroretinogram (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severely reduced focal macular electroretinogram n1=cyclopeptide | n2=en:severely reduced focal macular electroretinogram | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severely reduced or undetectable photopic and scotopic responses on electroretinography n1=cyclopeptide | n2=en:severely reduced or undetectable photopic and scotopic responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severely reduced peripheral visual field n1=cyclopeptide | n2=en:severely reduced peripheral visual field | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:severely reduced rod responses on electroretinography (in some patients) n1=cyclopeptide | n2=en:severely reduced rod responses on electroretinography (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sevoflurane n1=cyclopeptide | n2=en:sevoflurane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sex maturation female accelerated n1=cyclopeptide | n2=en:sex maturation female accelerated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sex maturation male accelerated n1=cyclopeptide | n2=en:sex maturation male accelerated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sh u04722 n1=cyclopeptide | n2=en:sh u04722 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:shallow anterior chamber (in some patients) n1=cyclopeptide | n2=en:shallow anterior chamber (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:shallow anterior chamber and angle (in some patients) n1=cyclopeptide | n2=en:shallow anterior chamber and angle (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:shallow anterior chamber of eye n1=cyclopeptide | n2=en:shallow anterior chamber of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:shallow orbits n1=cyclopeptide | n2=en:shallow orbits | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:shark cartilage n1=cyclopeptide | n2=en:shark cartilage | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:shark cartilage extract ae-941 n1=cyclopeptide | n2=en:shark cartilage extract ae-941 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sheddase inhibitor incb007839 n1=cyclopeptide | n2=en:sheddase inhibitor incb007839 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sheng-mai san n1=cyclopeptide | n2=en:sheng-mai san | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sheng-yu-tang n1=cyclopeptide | n2=en:sheng-yu-tang | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:shi pi yin herbal decoction n1=cyclopeptide | n2=en:shi pi yin herbal decoction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sho-saiko-to n1=cyclopeptide | n2=en:sho-saiko-to | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short and narrow palpebral fissures n1=cyclopeptide | n2=en:short and narrow palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short chain fatty acid hqk-1004 n1=cyclopeptide | n2=en:short chain fatty acid hqk-1004 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short eyelashes n1=cyclopeptide | n2=en:short eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short palpebral fissure n1=cyclopeptide | n2=en:short palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short palpebral fissure (male) n1=cyclopeptide | n2=en:short palpebral fissure (male) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short palpebral fissures (1 patient) n1=cyclopeptide | n2=en:short palpebral fissures (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short palpebral fissures (2 patients) n1=cyclopeptide | n2=en:short palpebral fissures (2 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short palpebral fissures (in 1/4 patients) n1=cyclopeptide | n2=en:short palpebral fissures (in 1/4 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short palpebral fissures (in some patients) n1=cyclopeptide | n2=en:short palpebral fissures (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:short/abnormal palpebral fissure n1=cyclopeptide | n2=en:short/abnormal palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:shu yu wan formula n1=cyclopeptide | n2=en:shu yu wan formula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sialyl lewis-keyhole limpet hemocyanin conjugate vaccine n1=cyclopeptide | n2=en:sialyl lewis-keyhole limpet hemocyanin conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sialyl tn antigen n1=cyclopeptide | n2=en:sialyl tn antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sig12d loder n1=cyclopeptide | n2=en:sig12d loder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:signal transduction inhibitor n1=cyclopeptide | n2=en:signal transduction inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:significantly decreased axial length n1=cyclopeptide | n2=en:significantly decreased axial length | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silatecan ar-67 n1=cyclopeptide | n2=en:silatecan ar-67 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sildenafil citrate n1=cyclopeptide | n2=en:sildenafil citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silicon phthalocyanine 4 n1=cyclopeptide | n2=en:silicon phthalocyanine 4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silmitasertib n1=cyclopeptide | n2=en:silmitasertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silodosin n1=cyclopeptide | n2=en:silodosin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:siltuximab n1=cyclopeptide | n2=en:siltuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:siltuximab 100mg powder for injection solution n1=cyclopeptide | n2=en:siltuximab 100mg powder for injection solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:siltuximab 400mg powder for injection solution n1=cyclopeptide | n2=en:siltuximab 400mg powder for injection solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silver nitrate n1=cyclopeptide | n2=en:silver nitrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silver sulfadiazine n1=cyclopeptide | n2=en:silver sulfadiazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silver-gray eyebrows n1=cyclopeptide | n2=en:silver-gray eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silver-gray eyelashes n1=cyclopeptide | n2=en:silver-gray eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:silymarin n1=cyclopeptide | n2=en:silymarin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:simethicone n1=cyclopeptide | n2=en:simethicone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:simmitecan hydrochloride n1=cyclopeptide | n2=en:simmitecan hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:simo decoction n1=cyclopeptide | n2=en:simo decoction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:simotinib hydrochloride n1=cyclopeptide | n2=en:simotinib hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:simple ectopia lentis n1=cyclopeptide | n2=en:simple ectopia lentis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:simtrazene n1=cyclopeptide | n2=en:simtrazene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:simtuzumab n1=cyclopeptide | n2=en:simtuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:simvastatin n1=cyclopeptide | n2=en:simvastatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:single congenital anomaly n1=cyclopeptide | n2=en:single congenital anomaly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sinus of branchial cleft (disorder) n1=cyclopeptide | n2=en:sinus of branchial cleft (disorder) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:siplizumab n1=cyclopeptide | n2=en:siplizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sipuleucel-t n1=cyclopeptide | n2=en:sipuleucel-t | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sirenomelia n1=cyclopeptide | n2=en:sirenomelia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sirna-expressing sv40 vector n1=cyclopeptide | n2=en:sirna-expressing sv40 vector | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sirna-transfected peripheral blood mononuclear cells apn401 n1=cyclopeptide | n2=en:sirna-transfected peripheral blood mononuclear cells apn401 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sirolimus n1=cyclopeptide | n2=en:sirolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sirolimus 0.5 mg oral tablet n1=cyclopeptide | n2=en:sirolimus 0.5 mg oral tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sirolimus 1mg tablet n1=cyclopeptide | n2=en:sirolimus 1mg tablet | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sirolimus 1mg/ml oral solution n1=cyclopeptide | n2=en:sirolimus 1mg/ml oral solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sirpa-fc fusion protein tti-621 n1=cyclopeptide | n2=en:sirpa-fc fusion protein tti-621 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sitagliptin phosphate n1=cyclopeptide | n2=en:sitagliptin phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:situs inversus n1=cyclopeptide | n2=en:situs inversus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sivifene n1=cyclopeptide | n2=en:sivifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sizofiran n1=cyclopeptide | n2=en:sizofiran | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:skeletal muscle relaxants n1=cyclopeptide | n2=en:skeletal muscle relaxants | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:skin photosensitivity n1=cyclopeptide | n2=en:skin photosensitivity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slanting of the palpebral fissure n1=cyclopeptide | n2=en:slanting of the palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slightly eccentric pupils (in some patients) n1=cyclopeptide | n2=en:slightly eccentric pupils (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slightly or moderately attenuated vessels n1=cyclopeptide | n2=en:slightly or moderately attenuated vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slow decrease in visual acuity n1=cyclopeptide | n2=en:slow decrease in visual acuity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slow eye movements (onset in second decade) n1=cyclopeptide | n2=en:slow eye movements (onset in second decade) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slow pupillary reaction with slow light convergence reflex n1=cyclopeptide | n2=en:slow pupillary reaction with slow light convergence reflex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slow pupillary reflexes n1=cyclopeptide | n2=en:slow pupillary reflexes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slow saccades (less common) n1=cyclopeptide | n2=en:slow saccades (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slow saccades (with longer disease duration) n1=cyclopeptide | n2=en:slow saccades (with longer disease duration) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slow, delayed pupillary light reflex n1=cyclopeptide | n2=en:slow, delayed pupillary light reflex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slowed horizontal saccades n1=cyclopeptide | n2=en:slowed horizontal saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slowed saccades n1=cyclopeptide | n2=en:slowed saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:slowing of vertical saccades n1=cyclopeptide | n2=en:slowing of vertical saccades | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sluggish pupils n1=cyclopeptide | n2=en:sluggish pupils | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smac mimetic gdc-0152 n1=cyclopeptide | n2=en:smac mimetic gdc-0152 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smac mimetic gdc-0917 n1=cyclopeptide | n2=en:smac mimetic gdc-0917 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smac mimetic lcl161 n1=cyclopeptide | n2=en:smac mimetic lcl161 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small atonic pupils n1=cyclopeptide | n2=en:small atonic pupils | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small cornea (in some patients) n1=cyclopeptide | n2=en:small cornea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small eyelashes n1=cyclopeptide | n2=en:small eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small eyes n1=cyclopeptide | n2=en:small eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small optic nerve, bilateral n1=cyclopeptide | n2=en:small optic nerve, bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small orbits n1=cyclopeptide | n2=en:small orbits | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small pale optic discs n1=cyclopeptide | n2=en:small pale optic discs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small palpebral fissure n1=cyclopeptide | n2=en:small palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small pupils (in some patients) n1=cyclopeptide | n2=en:small pupils (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small vessel retinal infarcts and aneurysms n1=cyclopeptide | n2=en:small vessel retinal infarcts and aneurysms | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small, deep-set eyes n1=cyclopeptide | n2=en:small, deep-set eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small, downslanting palpebral fissures n1=cyclopeptide | n2=en:small, downslanting palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:small, sunken eyes n1=cyclopeptide | n2=en:small, sunken eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smoked plum n1=cyclopeptide | n2=en:smoked plum | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smokeless tobacco n1=cyclopeptide | n2=en:smokeless tobacco | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smooth muscle relaxant n1=cyclopeptide | n2=en:smooth muscle relaxant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smooth pursuit abnormalities n1=cyclopeptide | n2=en:smooth pursuit abnormalities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smoothened antagonist bms-833923 n1=cyclopeptide | n2=en:smoothened antagonist bms-833923 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smoothened antagonist lde225 topical n1=cyclopeptide | n2=en:smoothened antagonist lde225 topical | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smoothened antagonist leq506 n1=cyclopeptide | n2=en:smoothened antagonist leq506 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:smoothened antagonist tak-441 n1=cyclopeptide | n2=en:smoothened antagonist tak-441 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sn-38-loaded polymeric micelles nk012 n1=cyclopeptide | n2=en:sn-38-loaded polymeric micelles nk012 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sns01-t nanoparticles n1=cyclopeptide | n2=en:sns01-t nanoparticles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:soblidotin n1=cyclopeptide | n2=en:soblidotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium alginate microspheres n1=cyclopeptide | n2=en:sodium alginate microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium bicarbonate n1=cyclopeptide | n2=en:sodium bicarbonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium bicarbonate solution n1=cyclopeptide | n2=en:sodium bicarbonate solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium bicarbonate/potassium bicarbonate/anhydrous citric acid n1=cyclopeptide | n2=en:sodium bicarbonate/potassium bicarbonate/anhydrous citric acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium borocaptate n1=cyclopeptide | n2=en:sodium borocaptate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium butyrate n1=cyclopeptide | n2=en:sodium butyrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium carboxymethylcellulose dressing n1=cyclopeptide | n2=en:sodium carboxymethylcellulose dressing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium citrate n1=cyclopeptide | n2=en:sodium citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium dibunate n1=cyclopeptide | n2=en:sodium dibunate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium dichloroacetate n1=cyclopeptide | n2=en:sodium dichloroacetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium ferric gluconate complex in sucrose n1=cyclopeptide | n2=en:sodium ferric gluconate complex in sucrose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium fluoride n1=cyclopeptide | n2=en:sodium fluoride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium glycididazole n1=cyclopeptide | n2=en:sodium glycididazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium hyaluronate topical hydrogel n1=cyclopeptide | n2=en:sodium hyaluronate topical hydrogel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium iodide i-131 n1=cyclopeptide | n2=en:sodium iodide i-131 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium metaarsenite n1=cyclopeptide | n2=en:sodium metaarsenite | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium phenylbutyrate n1=cyclopeptide | n2=en:sodium phenylbutyrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium phosphate n1=cyclopeptide | n2=en:sodium phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium phosphate/sodium biphosphate laxative n1=cyclopeptide | n2=en:sodium phosphate/sodium biphosphate laxative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium picosulfate/magnesium oxide/citric acid laxative n1=cyclopeptide | n2=en:sodium picosulfate/magnesium oxide/citric acid laxative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium salicylate n1=cyclopeptide | n2=en:sodium salicylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium selenite n1=cyclopeptide | n2=en:sodium selenite | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium stibogluconate n1=cyclopeptide | n2=en:sodium stibogluconate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium sulfate/potassium sulfate/magnesium sulfate-based laxative n1=cyclopeptide | n2=en:sodium sulfate/potassium sulfate/magnesium sulfate-based laxative | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sodium thiosulfate n1=cyclopeptide | n2=en:sodium thiosulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sofosbuvir n1=cyclopeptide | n2=en:sofosbuvir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:solifenacin succinate n1=cyclopeptide | n2=en:solifenacin succinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:solitomab n1=cyclopeptide | n2=en:solitomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:solution n1=cyclopeptide | n2=en:solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:somatropin n1=cyclopeptide | n2=en:somatropin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:some patients may be asymptomatic n1=cyclopeptide | n2=en:some patients may be asymptomatic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sonepcizumab n1=cyclopeptide | n2=en:sonepcizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sonidegib n1=cyclopeptide | n2=en:sonidegib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sorafenib tosylate n1=cyclopeptide | n2=en:sorafenib tosylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sorghum bicolor supplement n1=cyclopeptide | n2=en:sorghum bicolor supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sorivudine n1=cyclopeptide | n2=en:sorivudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sotagliflozin n1=cyclopeptide | n2=en:sotagliflozin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sotatercept n1=cyclopeptide | n2=en:sotatercept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sotrastaurin acetate n1=cyclopeptide | n2=en:sotrastaurin acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:soy isoflavones n1=cyclopeptide | n2=en:soy isoflavones | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:soy lecithin/glycerol dioleate-based oral spray n1=cyclopeptide | n2=en:soy lecithin/glycerol dioleate-based oral spray | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:soy protein isolate n1=cyclopeptide | n2=en:soy protein isolate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparfosic acid n1=cyclopeptide | n2=en:sparfosic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparing of far periphery n1=cyclopeptide | n2=en:sparing of far periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparing of macula n1=cyclopeptide | n2=en:sparing of macula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse and high-arched eyebrows (in some patients) n1=cyclopeptide | n2=en:sparse and high-arched eyebrows (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse eyebrows (in some patients) n1=cyclopeptide | n2=en:sparse eyebrows (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse eyebrows (rare) n1=cyclopeptide | n2=en:sparse eyebrows (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse eyebrows laterally (rare) n1=cyclopeptide | n2=en:sparse eyebrows laterally (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse eyebrows, especially laterally (in some patients) n1=cyclopeptide | n2=en:sparse eyebrows, especially laterally (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse eyelashes n1=cyclopeptide | n2=en:sparse eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse eyelashes (classic feature) n1=cyclopeptide | n2=en:sparse eyelashes (classic feature) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse eyelashes (in some patients) n1=cyclopeptide | n2=en:sparse eyelashes (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse eyelashes, more severe in lower lashes (in some patients) n1=cyclopeptide | n2=en:sparse eyelashes, more severe in lower lashes (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse lateral eyebrows n1=cyclopeptide | n2=en:sparse lateral eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse lower eyelashes n1=cyclopeptide | n2=en:sparse lower eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse medial eyebrows n1=cyclopeptide | n2=en:sparse medial eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse or absent eyebrows n1=cyclopeptide | n2=en:sparse or absent eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse or absent eyelashes n1=cyclopeptide | n2=en:sparse or absent eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse pigmentation of the peripheral ocular fundus n1=cyclopeptide | n2=en:sparse pigmentation of the peripheral ocular fundus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse to absent eyelashes n1=cyclopeptide | n2=en:sparse to absent eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sparse/absent eyebrows n1=cyclopeptide | n2=en:sparse/absent eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spasmodic eye blinking n1=cyclopeptide | n2=en:spasmodic eye blinking | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spebrutinib n1=cyclopeptide | n2=en:spebrutinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:speckled corneal dystrophy (white flecks in corneal stroma) n1=cyclopeptide | n2=en:speckled corneal dystrophy (white flecks in corneal stroma) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spheno-frontal dysostosis n1=cyclopeptide | n2=en:spheno-frontal dysostosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spherophakia n1=cyclopeptide | n2=en:spherophakia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sphingosine kinase-2 inhibitor abc294640 n1=cyclopeptide | n2=en:sphingosine kinase-2 inhibitor abc294640 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spina bifida n1=cyclopeptide | n2=en:spina bifida | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spiramycin n1=cyclopeptide | n2=en:spiramycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spirogermanium n1=cyclopeptide | n2=en:spirogermanium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spiromustine n1=cyclopeptide | n2=en:spiromustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spironolactone n1=cyclopeptide | n2=en:spironolactone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spiroplatin n1=cyclopeptide | n2=en:spiroplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spleen tyrosine kinase inhibitor tak-659 n1=cyclopeptide | n2=en:spleen tyrosine kinase inhibitor tak-659 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:splicing inhibitor h3b-8800 n1=cyclopeptide | n2=en:splicing inhibitor h3b-8800 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:spontaneous hyphema (rare) n1=cyclopeptide | n2=en:spontaneous hyphema (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:squalamine lactate n1=cyclopeptide | n2=en:squalamine lactate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:square wave jerks n1=cyclopeptide | n2=en:square wave jerks | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sr-t100 gel n1=cyclopeptide | n2=en:sr-t100 gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sr31747a n1=cyclopeptide | n2=en:sr31747a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:src kinase inhibitor kx2-391 n1=cyclopeptide | n2=en:src kinase inhibitor kx2-391 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:src kinase inhibitor kx2-391 ointment n1=cyclopeptide | n2=en:src kinase inhibitor kx2-391 ointment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:src/abl kinase inhibitor azd0424 n1=cyclopeptide | n2=en:src/abl kinase inhibitor azd0424 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:src/tubulin inhibitor kx02 n1=cyclopeptide | n2=en:src/tubulin inhibitor kx02 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ss1(dsfv)-pe38 immunotoxin n1=cyclopeptide | n2=en:ss1(dsfv)-pe38 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ssr411298 n1=cyclopeptide | n2=en:ssr411298 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:st jude's regimen n1=cyclopeptide | n2=en:st jude's regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:st-hd-86 regimen n1=cyclopeptide | n2=en:st-hd-86 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:st. john's wort n1=cyclopeptide | n2=en:st. john's wort | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stabilized sulphur hexafluoride microbubble-based contrast agent n1=cyclopeptide | n2=en:stabilized sulphur hexafluoride microbubble-based contrast agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stamp v regimen n1=cyclopeptide | n2=en:stamp v regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stamp-i protocol n1=cyclopeptide | n2=en:stamp-i protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:standardized freeze-dried table grape powder n1=cyclopeptide | n2=en:standardized freeze-dried table grape powder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:standards characteristics n1=cyclopeptide | n2=en:standards characteristics | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stanford university protocol n1=cyclopeptide | n2=en:stanford university protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stanford v regimen n1=cyclopeptide | n2=en:stanford v regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stanford-ncog protocol n1=cyclopeptide | n2=en:stanford-ncog protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stanozolol n1=cyclopeptide | n2=en:stanozolol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:staphage lysate n1=cyclopeptide | n2=en:staphage lysate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:staphylococcal enterotoxin a n1=cyclopeptide | n2=en:staphylococcal enterotoxin a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:staphylococcal enterotoxin b n1=cyclopeptide | n2=en:staphylococcal enterotoxin b | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:staphylococcus aureus protein a n1=cyclopeptide | n2=en:staphylococcus aureus protein a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stargardt disease n1=cyclopeptide | n2=en:stargardt disease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:staring n1=cyclopeptide | n2=en:staring | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:staring gaze n1=cyclopeptide | n2=en:staring gaze | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stat inhibitor opb-111077 n1=cyclopeptide | n2=en:stat inhibitor opb-111077 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stat3 antisense oligonucleotide isis 481464 n1=cyclopeptide | n2=en:stat3 antisense oligonucleotide isis 481464 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stat3 decoy oligonucleotide n1=cyclopeptide | n2=en:stat3 decoy oligonucleotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stat3 inhibitor opb-31121 n1=cyclopeptide | n2=en:stat3 inhibitor opb-31121 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stat3 inhibitor opb-51602 n1=cyclopeptide | n2=en:stat3 inhibitor opb-51602 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stavudine n1=cyclopeptide | n2=en:stavudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:steep corneas n1=cyclopeptide | n2=en:steep corneas | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stellate cataract n1=cyclopeptide | n2=en:stellate cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stellate pattern of iris n1=cyclopeptide | n2=en:stellate pattern of iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stellate retinal folds (rare) n1=cyclopeptide | n2=en:stellate retinal folds (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stenosis of nasolacrimal duct n1=cyclopeptide | n2=en:stenosis of nasolacrimal duct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stereopsis, limited to absent n1=cyclopeptide | n2=en:stereopsis, limited to absent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stimulant/agonist n1=cyclopeptide | n2=en:stimulant/agonist | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sting-activating cyclic dinucleotide agonist miw815 n1=cyclopeptide | n2=en:sting-activating cyclic dinucleotide agonist miw815 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stippled pigmentation (cat's paw) n1=cyclopeptide | n2=en:stippled pigmentation (cat's paw) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stomatognathic system abnormalities n1=cyclopeptide | n2=en:stomatognathic system abnormalities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus n1=cyclopeptide | n2=en:strabismus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (1 family) n1=cyclopeptide | n2=en:strabismus (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (1 patient) n1=cyclopeptide | n2=en:strabismus (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (10%) n1=cyclopeptide | n2=en:strabismus (10%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (13 to 30% of patients) n1=cyclopeptide | n2=en:strabismus (13 to 30% of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (15% of adults) n1=cyclopeptide | n2=en:strabismus (15% of adults) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (45%) n1=cyclopeptide | n2=en:strabismus (45%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (cvs+) n1=cyclopeptide | n2=en:strabismus (cvs+) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (females) n1=cyclopeptide | n2=en:strabismus (females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (in brother) n1=cyclopeptide | n2=en:strabismus (in brother) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (in some patients) n1=cyclopeptide | n2=en:strabismus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (less common) n1=cyclopeptide | n2=en:strabismus (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (rare) n1=cyclopeptide | n2=en:strabismus (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (reported in 1 family) n1=cyclopeptide | n2=en:strabismus (reported in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (specifically v-type esotropia) n1=cyclopeptide | n2=en:strabismus (specifically v-type esotropia) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus (type ii) n1=cyclopeptide | n2=en:strabismus (type ii) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus, alternating (in some patients) n1=cyclopeptide | n2=en:strabismus, alternating (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus, mild n1=cyclopeptide | n2=en:strabismus, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus, most frequently exotropia n1=cyclopeptide | n2=en:strabismus, most frequently exotropia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strabismus, transient (1 patient) n1=cyclopeptide | n2=en:strabismus, transient (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:straight eyebrows n1=cyclopeptide | n2=en:straight eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strawberry-blackberry-black raspberry-blueberry mixture n1=cyclopeptide | n2=en:strawberry-blackberry-black raspberry-blueberry mixture | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:street drugs n1=cyclopeptide | n2=en:street drugs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:streptavidin n1=cyclopeptide | n2=en:streptavidin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:streptonigrin n1=cyclopeptide | n2=en:streptonigrin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:streptozocin n1=cyclopeptide | n2=en:streptozocin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stromal corneal edema n1=cyclopeptide | n2=en:stromal corneal edema | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stromal inflammatory infiltrate n1=cyclopeptide | n2=en:stromal inflammatory infiltrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stromal scar tissue (in some patients) n1=cyclopeptide | n2=en:stromal scar tissue (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stromal thinning n1=cyclopeptide | n2=en:stromal thinning | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strong retention of foveal function n1=cyclopeptide | n2=en:strong retention of foveal function | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:strontium chloride sr-89 n1=cyclopeptide | n2=en:strontium chloride sr-89 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:structure of anterior pole of eye n1=cyclopeptide | n2=en:structure of anterior pole of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:structure of equator of eyeball n1=cyclopeptide | n2=en:structure of equator of eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:structure of external axis of eyeball n1=cyclopeptide | n2=en:structure of external axis of eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:structure of fascial sheath of eyeball n1=cyclopeptide | n2=en:structure of fascial sheath of eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:structure of internal axis of eyeball n1=cyclopeptide | n2=en:structure of internal axis of eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:structure of posterior pole of eye n1=cyclopeptide | n2=en:structure of posterior pole of eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:stye n1=cyclopeptide | n2=en:stye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:su014813 n1=cyclopeptide | n2=en:su014813 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subcapsular cataract n1=cyclopeptide | n2=en:subcapsular cataract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subconjunctival epithelial cysts n1=cyclopeptide | n2=en:subconjunctival epithelial cysts | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subepithelial and anterior stromal opacities on slit-lamp examination n1=cyclopeptide | n2=en:subepithelial and anterior stromal opacities on slit-lamp examination | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subepithelial corneal opacities n1=cyclopeptide | n2=en:subepithelial corneal opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subepithelial deposits of a combination of chondroitin-4-sulfate and dermatan sulfate n1=cyclopeptide | n2=en:subepithelial deposits of a combination of chondroitin-4-sulfate and dermatan sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subepithelial fibrosis n1=cyclopeptide | n2=en:subepithelial fibrosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subepithelial opacities and haze most dense centrally n1=cyclopeptide | n2=en:subepithelial opacities and haze most dense centrally | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subnormal focal erg corresponding to punctate yellow-white sub-rpe lesions n1=cyclopeptide | n2=en:subnormal focal erg corresponding to punctate yellow-white sub-rpe lesions | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:substance p-saporin n1=cyclopeptide | n2=en:substance p-saporin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:substance p/neurokinin 1 receptor antagonist n1=cyclopeptide | n2=en:substance p/neurokinin 1 receptor antagonist | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:subtle foveal changes n1=cyclopeptide | n2=en:subtle foveal changes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sucralfate n1=cyclopeptide | n2=en:sucralfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sufentanil citrate n1=cyclopeptide | n2=en:sufentanil citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sufentanil transdermal system n1=cyclopeptide | n2=en:sufentanil transdermal system | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sufosfamide n1=cyclopeptide | n2=en:sufosfamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sugammadex sodium n1=cyclopeptide | n2=en:sugammadex sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sulfasalazine n1=cyclopeptide | n2=en:sulfasalazine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sulfate-based laxative bli850 n1=cyclopeptide | n2=en:sulfate-based laxative bli850 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sulfatinib n1=cyclopeptide | n2=en:sulfatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sulforaphane n1=cyclopeptide | n2=en:sulforaphane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sulforaphane-cyclodextrin complex n1=cyclopeptide | n2=en:sulforaphane-cyclodextrin complex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sulfur hexafluoride n1=cyclopeptide | n2=en:sulfur hexafluoride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sulindac n1=cyclopeptide | n2=en:sulindac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sulofenur n1=cyclopeptide | n2=en:sulofenur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sumac/black cumin powder n1=cyclopeptide | n2=en:sumac/black cumin powder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sumatriptan succinate n1=cyclopeptide | n2=en:sumatriptan succinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sun protection agent md-3511356 n1=cyclopeptide | n2=en:sun protection agent md-3511356 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sun's soup n1=cyclopeptide | n2=en:sun's soup | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sunitinib malate n1=cyclopeptide | n2=en:sunitinib malate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sunken eyes n1=cyclopeptide | n2=en:sunken eyes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sunless tanning lotion n1=cyclopeptide | n2=en:sunless tanning lotion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sunscreen n1=cyclopeptide | n2=en:sunscreen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:superagonist interleukin-15:interleukin-15 receptor alphasu/fc fusion complex alt-803 n1=cyclopeptide | n2=en:superagonist interleukin-15:interleukin-15 receptor alphasu/fc fusion complex alt-803 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:superficial and deep corneal stromal vascularization with scarring n1=cyclopeptide | n2=en:superficial and deep corneal stromal vascularization with scarring | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:superior hemisphere field impairment (e.g. 180380.0004 and 180380.0025) n1=cyclopeptide | n2=en:superior hemisphere field impairment (e.g. 180380.0004 and 180380.0025) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:supernormal and delayed rod responses on electroretinography n1=cyclopeptide | n2=en:supernormal and delayed rod responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:supernormal and delayed scotopic rod electroretinogram (in some patients) n1=cyclopeptide | n2=en:supernormal and delayed scotopic rod electroretinogram (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:supernumerary structure n1=cyclopeptide | n2=en:supernumerary structure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:supersaturated calcium phosphate rinse n1=cyclopeptide | n2=en:supersaturated calcium phosphate rinse | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:suppression of vestibuloocular reflex n1=cyclopeptide | n2=en:suppression of vestibuloocular reflex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:supranuclear gaze palsy n1=cyclopeptide | n2=en:supranuclear gaze palsy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:supranuclear gaze palsy (less common) n1=cyclopeptide | n2=en:supranuclear gaze palsy (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:supranuclear gaze palsy, horizontal (type iiib) n1=cyclopeptide | n2=en:supranuclear gaze palsy, horizontal (type iiib) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:supranuclear ophthalmoplegia n1=cyclopeptide | n2=en:supranuclear ophthalmoplegia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:suramin n1=cyclopeptide | n2=en:suramin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:surface retinal neovascularization n1=cyclopeptide | n2=en:surface retinal neovascularization | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:surface-active agent n1=cyclopeptide | n2=en:surface-active agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:survivin antigen n1=cyclopeptide | n2=en:survivin antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:survivin antigen vaccine dpx-survivac n1=cyclopeptide | n2=en:survivin antigen vaccine dpx-survivac | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:survivin mrna antagonist ezn-3042 n1=cyclopeptide | n2=en:survivin mrna antagonist ezn-3042 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:survivin sur1m2 peptide vaccine n1=cyclopeptide | n2=en:survivin sur1m2 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:survivin/p53/her2 antigen-loaded autologous dendritic cell vaccine n1=cyclopeptide | n2=en:survivin/p53/her2 antigen-loaded autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:suspensory ligament of lens n1=cyclopeptide | n2=en:suspensory ligament of lens | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sustained-release lipid inhaled cisplatin n1=cyclopeptide | n2=en:sustained-release lipid inhaled cisplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:sustained-release mitomycin c hydrogel formulation n1=cyclopeptide | n2=en:sustained-release mitomycin c hydrogel formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:suvorexant n1=cyclopeptide | n2=en:suvorexant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:svn53-67/m57-klh peptide vaccine n1=cyclopeptide | n2=en:svn53-67/m57-klh peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:swelling of eyelid n1=cyclopeptide | n2=en:swelling of eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:swelling of retinal nerve fiber layer (acute phase) n1=cyclopeptide | n2=en:swelling of retinal nerve fiber layer (acute phase) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:swelling of the eyelids (in 1 patient) n1=cyclopeptide | n2=en:swelling of the eyelids (in 1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:syk inhibitor hmpl-523 n1=cyclopeptide | n2=en:syk inhibitor hmpl-523 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:syk-jak inhibitor prt062070 n1=cyclopeptide | n2=en:syk-jak inhibitor prt062070 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:symblepharon (adhesion of the eyelid to the eyeball) n1=cyclopeptide | n2=en:symblepharon (adhesion of the eyelid to the eyeball) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:symptom/complaint contact lens n1=cyclopeptide | n2=en:symptom/complaint contact lens | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:symptoms/complaints glasses n1=cyclopeptide | n2=en:symptoms/complaints glasses | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synbiotic supplement n1=cyclopeptide | n2=en:synbiotic supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synchrotope ta2m plasmid dna vaccine n1=cyclopeptide | n2=en:synchrotope ta2m plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synchrovax sem plasmid dna vaccine n1=cyclopeptide | n2=en:synchrovax sem plasmid dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:syndactyly n1=cyclopeptide | n2=en:syndactyly | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:syndrome, branchio-oculo-facial n1=cyclopeptide | n2=en:syndrome, branchio-oculo-facial | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:syneresis n1=cyclopeptide | n2=en:syneresis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synophrys n1=cyclopeptide | n2=en:synophrys | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synophrys, mild n1=cyclopeptide | n2=en:synophrys, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synophthalmia n1=cyclopeptide | n2=en:synophthalmia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthesis inhibitors, dna n1=cyclopeptide | n2=en:synthesis inhibitors, dna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic antiandrogen n1=cyclopeptide | n2=en:synthetic antiandrogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic antiestrogen n1=cyclopeptide | n2=en:synthetic antiestrogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic brain tumor peptides-pulsed autologous dendritic cell vaccine n1=cyclopeptide | n2=en:synthetic brain tumor peptides-pulsed autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic breast cancer peptides-tetanus toxoid-montanide isa-51 vaccine n1=cyclopeptide | n2=en:synthetic breast cancer peptides-tetanus toxoid-montanide isa-51 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic breast cancer peptides-tetanus toxoid-poly iclc vaccine n1=cyclopeptide | n2=en:synthetic breast cancer peptides-tetanus toxoid-poly iclc vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic glioblastoma mutated tumor-specific peptides vaccine therapy apvac2 n1=cyclopeptide | n2=en:synthetic glioblastoma mutated tumor-specific peptides vaccine therapy apvac2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic glioblastoma tumor-associated peptides vaccine therapy apvac1 n1=cyclopeptide | n2=en:synthetic glioblastoma tumor-associated peptides vaccine therapy apvac1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic htert dna vaccine ino-1400 n1=cyclopeptide | n2=en:synthetic htert dna vaccine ino-1400 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic human papillomavirus 16 e6 peptide n1=cyclopeptide | n2=en:synthetic human papillomavirus 16 e6 peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic hypericin n1=cyclopeptide | n2=en:synthetic hypericin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic long e6/e7 peptides vaccine hpv-01 n1=cyclopeptide | n2=en:synthetic long e6/e7 peptides vaccine hpv-01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic melanoma-associated antigens vaccine n1=cyclopeptide | n2=en:synthetic melanoma-associated antigens vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:synthetic peptides e-pra and e-psm vaccine n1=cyclopeptide | n2=en:synthetic peptides e-pra and e-psm vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:syp-0704a n1=cyclopeptide | n2=en:syp-0704a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:t-6 protocol n1=cyclopeptide | n2=en:t-6 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:t-type calcium channel blocker abt-639 n1=cyclopeptide | n2=en:t-type calcium channel blocker abt-639 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:t10 a protocol n1=cyclopeptide | n2=en:t10 a protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:t1e28z car-expressing autologous cd4-positive t lymphocytes n1=cyclopeptide | n2=en:t1e28z car-expressing autologous cd4-positive t lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:t4n5 liposomal lotion n1=cyclopeptide | n2=en:t4n5 liposomal lotion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:t7 protocol n1=cyclopeptide | n2=en:t7 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:t900607 n1=cyclopeptide | n2=en:t900607 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tabalumab n1=cyclopeptide | n2=en:tabalumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tac protocol n1=cyclopeptide | n2=en:tac protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tac regimen n1=cyclopeptide | n2=en:tac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tacc protocol n1=cyclopeptide | n2=en:tacc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tacedinaline n1=cyclopeptide | n2=en:tacedinaline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tacrolimus n1=cyclopeptide | n2=en:tacrolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tacrolimus 5 mg oral capsule [prograf] n1=cyclopeptide | n2=en:tacrolimus 5 mg oral capsule [prograf] | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tacrolimus 500micrograms capsule n1=cyclopeptide | n2=en:tacrolimus 500micrograms capsule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tacrolimus anhydrous n1=cyclopeptide | n2=en:tacrolimus anhydrous | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tadalafil n1=cyclopeptide | n2=en:tadalafil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tafamidis meglumine n1=cyclopeptide | n2=en:tafamidis meglumine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tak-448 n1=cyclopeptide | n2=en:tak-448 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talabostat mesylate n1=cyclopeptide | n2=en:talabostat mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talactoferrin alfa n1=cyclopeptide | n2=en:talactoferrin alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taladegib n1=cyclopeptide | n2=en:taladegib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talampanel n1=cyclopeptide | n2=en:talampanel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talaporfin sodium n1=cyclopeptide | n2=en:talaporfin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talazoparib n1=cyclopeptide | n2=en:talazoparib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talc n1=cyclopeptide | n2=en:talc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taliglucerase alfa n1=cyclopeptide | n2=en:taliglucerase alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talimogene laherparepvec n1=cyclopeptide | n2=en:talimogene laherparepvec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tallimustine n1=cyclopeptide | n2=en:tallimustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talmapimod n1=cyclopeptide | n2=en:talmapimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:talotrexin ammonium n1=cyclopeptide | n2=en:talotrexin ammonium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taltirelin hydrate n1=cyclopeptide | n2=en:taltirelin hydrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tamibarotene n1=cyclopeptide | n2=en:tamibarotene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tamoxifen citrate n1=cyclopeptide | n2=en:tamoxifen citrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tamsulosin hydrochloride n1=cyclopeptide | n2=en:tamsulosin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tandutinib n1=cyclopeptide | n2=en:tandutinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tanespimycin n1=cyclopeptide | n2=en:tanespimycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tanezumab n1=cyclopeptide | n2=en:tanezumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tangerine tomato juice n1=cyclopeptide | n2=en:tangerine tomato juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tanibirumab n1=cyclopeptide | n2=en:tanibirumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tanomastat n1=cyclopeptide | n2=en:tanomastat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tapentadol hydrochloride n1=cyclopeptide | n2=en:tapentadol hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tarenflurbil n1=cyclopeptide | n2=en:tarenflurbil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tarextumab n1=cyclopeptide | n2=en:tarextumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tariquidar n1=cyclopeptide | n2=en:tariquidar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tarp 27-35 peptide vaccine n1=cyclopeptide | n2=en:tarp 27-35 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tarp 29-37-9v peptide vaccine n1=cyclopeptide | n2=en:tarp 29-37-9v peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tarsal hypoplasia n1=cyclopeptide | n2=en:tarsal hypoplasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tas-108 n1=cyclopeptide | n2=en:tas-108 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taselisib n1=cyclopeptide | n2=en:taselisib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tasidotin n1=cyclopeptide | n2=en:tasidotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tasisulam n1=cyclopeptide | n2=en:tasisulam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tasisulam sodium n1=cyclopeptide | n2=en:tasisulam sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tasquinimod n1=cyclopeptide | n2=en:tasquinimod | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taurolidine n1=cyclopeptide | n2=en:taurolidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tauromustine n1=cyclopeptide | n2=en:tauromustine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taurultam n1=cyclopeptide | n2=en:taurultam | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taxane analogue mst-997 n1=cyclopeptide | n2=en:taxane analogue mst-997 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taxane analogue tpi 287 n1=cyclopeptide | n2=en:taxane analogue tpi 287 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taxol analogue sid 530 n1=cyclopeptide | n2=en:taxol analogue sid 530 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:taxonomic n1=cyclopeptide | n2=en:taxonomic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tazarotene n1=cyclopeptide | n2=en:tazarotene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tazemetostat n1=cyclopeptide | n2=en:tazemetostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tazobactam sodium n1=cyclopeptide | n2=en:tazobactam sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tazofelone n1=cyclopeptide | n2=en:tazofelone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tc 99m monoclonal antibody 170 n1=cyclopeptide | n2=en:tc 99m monoclonal antibody 170 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tcap protocol n1=cyclopeptide | n2=en:tcap protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tccsg b-8801 protocol n1=cyclopeptide | n2=en:tccsg b-8801 protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tcid protocol n1=cyclopeptide | n2=en:tcid protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tearing n1=cyclopeptide | n2=en:tearing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tec protocol n1=cyclopeptide | n2=en:tec protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 94m sestamibi n1=cyclopeptide | n2=en:technetium tc 94m sestamibi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 n1=cyclopeptide | n2=en:technetium tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99m epratuzumab n1=cyclopeptide | n2=en:technetium tc 99m epratuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99m galactosyl human serum albumin n1=cyclopeptide | n2=en:technetium tc 99m galactosyl human serum albumin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99m mip 1405 n1=cyclopeptide | n2=en:technetium tc 99m mip 1405 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99m trofolastat n1=cyclopeptide | n2=en:technetium tc 99m trofolastat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99m-3prgd2 n1=cyclopeptide | n2=en:technetium tc 99m-3prgd2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99m-labeled albumin microspheres n1=cyclopeptide | n2=en:technetium tc 99m-labeled albumin microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99m-labeled rhenium sulfide nanocolloid n1=cyclopeptide | n2=en:technetium tc 99m-labeled rhenium sulfide nanocolloid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc 99m-labeled tilmanocept n1=cyclopeptide | n2=en:technetium tc 99m-labeled tilmanocept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m n1=cyclopeptide | n2=en:technetium tc-99m | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m albumin aggregated n1=cyclopeptide | n2=en:technetium tc-99m albumin aggregated | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m demobesin-4 n1=cyclopeptide | n2=en:technetium tc-99m demobesin-4 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m dextran n1=cyclopeptide | n2=en:technetium tc-99m dextran | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m dtpa n1=cyclopeptide | n2=en:technetium tc-99m dtpa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m ethylenedicysteine-deoxyglucose n1=cyclopeptide | n2=en:technetium tc-99m ethylenedicysteine-deoxyglucose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m glycopeptide n1=cyclopeptide | n2=en:technetium tc-99m glycopeptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m human serum albumin colloid n1=cyclopeptide | n2=en:technetium tc-99m human serum albumin colloid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m hydroxydiphosphonate n1=cyclopeptide | n2=en:technetium tc-99m hydroxydiphosphonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m mebrofenin n1=cyclopeptide | n2=en:technetium tc-99m mebrofenin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m medronate n1=cyclopeptide | n2=en:technetium tc-99m medronate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m sestamibi n1=cyclopeptide | n2=en:technetium tc-99m sestamibi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m sodium pertechnetate n1=cyclopeptide | n2=en:technetium tc-99m sodium pertechnetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m sulfur colloid n1=cyclopeptide | n2=en:technetium tc-99m sulfur colloid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:technetium tc-99m-nc100692 n1=cyclopeptide | n2=en:technetium tc-99m-nc100692 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tecogalan sodium n1=cyclopeptide | n2=en:tecogalan sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teduglutide n1=cyclopeptide | n2=en:teduglutide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tegafur n1=cyclopeptide | n2=en:tegafur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tegafur-gimeracil-oteracil potassium n1=cyclopeptide | n2=en:tegafur-gimeracil-oteracil potassium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tegafur-gimeracil-oteracil potassium-leucovorin calcium oral formulation n1=cyclopeptide | n2=en:tegafur-gimeracil-oteracil potassium-leucovorin calcium oral formulation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tegafur-uracil n1=cyclopeptide | n2=en:tegafur-uracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teglarinad n1=cyclopeptide | n2=en:teglarinad | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teglarinad chloride n1=cyclopeptide | n2=en:teglarinad chloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teicoplanin n1=cyclopeptide | n2=en:teicoplanin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telaprevir n1=cyclopeptide | n2=en:telaprevir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telapristone acetate n1=cyclopeptide | n2=en:telapristone acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telatinib mesylate n1=cyclopeptide | n2=en:telatinib mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telavancin hydrochloride n1=cyclopeptide | n2=en:telavancin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telbivudine n1=cyclopeptide | n2=en:telbivudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telecanthus n1=cyclopeptide | n2=en:telecanthus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telecanthus (females) n1=cyclopeptide | n2=en:telecanthus (females) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telecanthus (in 1 family) n1=cyclopeptide | n2=en:telecanthus (in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telecanthus (in some patients) n1=cyclopeptide | n2=en:telecanthus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telomerase peptide vaccine gv1001 n1=cyclopeptide | n2=en:telomerase peptide vaccine gv1001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telomerase-specific type 5 adenovirus obp-301 n1=cyclopeptide | n2=en:telomerase-specific type 5 adenovirus obp-301 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telomerase: 540-548 peptide vaccine n1=cyclopeptide | n2=en:telomerase: 540-548 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:telotristat etiprate n1=cyclopeptide | n2=en:telotristat etiprate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teloxantrone hydrochloride n1=cyclopeptide | n2=en:teloxantrone hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:temoporfin n1=cyclopeptide | n2=en:temoporfin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:temozolomide n1=cyclopeptide | n2=en:temozolomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:temporal nerve fiber bundle defects hyperfluorescent on angiography n1=cyclopeptide | n2=en:temporal nerve fiber bundle defects hyperfluorescent on angiography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:temporal optic nerve pallor n1=cyclopeptide | n2=en:temporal optic nerve pallor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:temsirolimus n1=cyclopeptide | n2=en:temsirolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tenifatecan n1=cyclopeptide | n2=en:tenifatecan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teniposide n1=cyclopeptide | n2=en:teniposide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tenofovir n1=cyclopeptide | n2=en:tenofovir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tenofovir disoproxil fumarate n1=cyclopeptide | n2=en:tenofovir disoproxil fumarate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tepotinib n1=cyclopeptide | n2=en:tepotinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teprotumumab n1=cyclopeptide | n2=en:teprotumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:terameprocol n1=cyclopeptide | n2=en:terameprocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teratogen n1=cyclopeptide | n2=en:teratogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:terephthalamidine n1=cyclopeptide | n2=en:terephthalamidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:terfluranol n1=cyclopeptide | n2=en:terfluranol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tergenpumatucel-l n1=cyclopeptide | n2=en:tergenpumatucel-l | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:teroxirone n1=cyclopeptide | n2=en:teroxirone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tesetaxel n1=cyclopeptide | n2=en:tesetaxel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tesevatinib n1=cyclopeptide | n2=en:tesevatinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tesmilifene n1=cyclopeptide | n2=en:tesmilifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tesselated appearance of fundus (in some patients) n1=cyclopeptide | n2=en:tesselated appearance of fundus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:testolactone n1=cyclopeptide | n2=en:testolactone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:testosterone cypionate n1=cyclopeptide | n2=en:testosterone cypionate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:testosterone enanthate n1=cyclopeptide | n2=en:testosterone enanthate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:testosterone gel n1=cyclopeptide | n2=en:testosterone gel | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:testosterone undecanoate n1=cyclopeptide | n2=en:testosterone undecanoate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:testosterone vaginal cream n1=cyclopeptide | n2=en:testosterone vaginal cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetanus peptide melanoma vaccine n1=cyclopeptide | n2=en:tetanus peptide melanoma vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetanus toxoid helper peptide n1=cyclopeptide | n2=en:tetanus toxoid helper peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetanus toxoid vaccine n1=cyclopeptide | n2=en:tetanus toxoid vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetanus-cmv fusion peptide vaccine n1=cyclopeptide | n2=en:tetanus-cmv fusion peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetracycline antibiotic n1=cyclopeptide | n2=en:tetracycline antibiotic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetracycline hydrochloride n1=cyclopeptide | n2=en:tetracycline hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetradecanoylphorbol acetate n1=cyclopeptide | n2=en:tetradecanoylphorbol acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetrahydrouridine n1=cyclopeptide | n2=en:tetrahydrouridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetralogy of fallot n1=cyclopeptide | n2=en:tetralogy of fallot | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetrandrine n1=cyclopeptide | n2=en:tetrandrine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetraphenyl chlorin disulfonate n1=cyclopeptide | n2=en:tetraphenyl chlorin disulfonate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetravalent rna-lipoplex cancer vaccine n1=cyclopeptide | n2=en:tetravalent rna-lipoplex cancer vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tetrodotoxin n1=cyclopeptide | n2=en:tetrodotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tezacitabine n1=cyclopeptide | n2=en:tezacitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tf(c)-klh conjugate vaccine n1=cyclopeptide | n2=en:tf(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tgf-beta-resistant lmp-specific cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:tgf-beta-resistant lmp-specific cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tgfa-pe38 immunotoxin n1=cyclopeptide | n2=en:tgfa-pe38 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tgfbdnrii-transduced autologous tumor infiltrating lymphocytes n1=cyclopeptide | n2=en:tgfbdnrii-transduced autologous tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thalicarpine n1=cyclopeptide | n2=en:thalicarpine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thalidomide n1=cyclopeptide | n2=en:thalidomide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:theophylline n1=cyclopeptide | n2=en:theophylline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:theramide n1=cyclopeptide | n2=en:theramide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic allogeneic cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:therapeutic allogeneic cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic allogeneic lymphocytes n1=cyclopeptide | n2=en:therapeutic allogeneic lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic androstanolone n1=cyclopeptide | n2=en:therapeutic androstanolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic angiotensin-(1-7) n1=cyclopeptide | n2=en:therapeutic angiotensin-(1-7) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic autologous dendritic cells n1=cyclopeptide | n2=en:therapeutic autologous dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic autologous lymphocytes n1=cyclopeptide | n2=en:therapeutic autologous lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic breast/ovarian/prostate peptide cancer vaccine dpx-0907 n1=cyclopeptide | n2=en:therapeutic breast/ovarian/prostate peptide cancer vaccine dpx-0907 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic corticosteroid n1=cyclopeptide | n2=en:therapeutic corticosteroid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic cortisone n1=cyclopeptide | n2=en:therapeutic cortisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic dendritic cells/cytokine-induced killer cells n1=cyclopeptide | n2=en:therapeutic dendritic cells/cytokine-induced killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic epinephrine n1=cyclopeptide | n2=en:therapeutic epinephrine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic estetrol n1=cyclopeptide | n2=en:therapeutic estetrol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic estradiol n1=cyclopeptide | n2=en:therapeutic estradiol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic estrone n1=cyclopeptide | n2=en:therapeutic estrone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic function n1=cyclopeptide | n2=en:therapeutic function | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic gamma delta t-lymphocytes n1=cyclopeptide | n2=en:therapeutic gamma delta t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic hemin n1=cyclopeptide | n2=en:therapeutic hemin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic hepatitis c immune globulin n1=cyclopeptide | n2=en:therapeutic hepatitis c immune globulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic hydrocortisone n1=cyclopeptide | n2=en:therapeutic hydrocortisone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic immune globulin n1=cyclopeptide | n2=en:therapeutic immune globulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic insulin n1=cyclopeptide | n2=en:therapeutic insulin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic melatonin n1=cyclopeptide | n2=en:therapeutic melatonin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic progesterone n1=cyclopeptide | n2=en:therapeutic progesterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic testosterone n1=cyclopeptide | n2=en:therapeutic testosterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic tumor infiltrating lymphocytes n1=cyclopeptide | n2=en:therapeutic tumor infiltrating lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:therapeutic use - qualifier n1=cyclopeptide | n2=en:therapeutic use - qualifier | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thiabendazole n1=cyclopeptide | n2=en:thiabendazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thiamine n1=cyclopeptide | n2=en:thiamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thiarabine n1=cyclopeptide | n2=en:thiarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thick choroid n1=cyclopeptide | n2=en:thick choroid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thick eyebrows (in some patients) n1=cyclopeptide | n2=en:thick eyebrows (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thick eyelashes n1=cyclopeptide | n2=en:thick eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thick eyelids n1=cyclopeptide | n2=en:thick eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thick ropy lattice lines in the corneal stroma n1=cyclopeptide | n2=en:thick ropy lattice lines in the corneal stroma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thick sclera n1=cyclopeptide | n2=en:thick sclera | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thick, arched eyebrows n1=cyclopeptide | n2=en:thick, arched eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thickened and keratinized eyelids n1=cyclopeptide | n2=en:thickened and keratinized eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thickened sclera (in some patients) n1=cyclopeptide | n2=en:thickened sclera (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thickened upper eyelids n1=cyclopeptide | n2=en:thickened upper eyelids | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thickened, anteverted eyelid n1=cyclopeptide | n2=en:thickened, anteverted eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thickening and elevation of the outer retina-rpe-choroid complex on oct n1=cyclopeptide | n2=en:thickening and elevation of the outer retina-rpe-choroid complex on oct | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thin central cornea n1=cyclopeptide | n2=en:thin central cornea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thin eyebrows (laterally) n1=cyclopeptide | n2=en:thin eyebrows (laterally) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thin optic nerves n1=cyclopeptide | n2=en:thin optic nerves | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thin or notched neuroretinal rim n1=cyclopeptide | n2=en:thin or notched neuroretinal rim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thin, long eyebrows n1=cyclopeptide | n2=en:thin, long eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thin, sparse eyelashes n1=cyclopeptide | n2=en:thin, sparse eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thinning of central cornea (in some patients) n1=cyclopeptide | n2=en:thinning of central cornea (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thinning of outer retinal layer on optical coherence tomography n1=cyclopeptide | n2=en:thinning of outer retinal layer on optical coherence tomography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thinning of retinal nerve fiber layer seen on optical coherence tomography n1=cyclopeptide | n2=en:thinning of retinal nerve fiber layer seen on optical coherence tomography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thioguanine n1=cyclopeptide | n2=en:thioguanine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thioinosine n1=cyclopeptide | n2=en:thioinosine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thioredoxin-1 inhibitor px-12 n1=cyclopeptide | n2=en:thioredoxin-1 inhibitor px-12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thiotepa n1=cyclopeptide | n2=en:thiotepa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thioureidobutyronitrile n1=cyclopeptide | n2=en:thioureidobutyronitrile | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thl-p n1=cyclopeptide | n2=en:thl-p | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thomsen-friedenreich antigen n1=cyclopeptide | n2=en:thomsen-friedenreich antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thoracogastroschisis n1=cyclopeptide | n2=en:thoracogastroschisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thoracoschisis n1=cyclopeptide | n2=en:thoracoschisis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thp-copblm regimen n1=cyclopeptide | n2=en:thp-copblm regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:three concentric rings of hyperautofluorescence - around the fovea, along the vascular arcades, and in the far periphery n1=cyclopeptide | n2=en:three concentric rings of hyperautofluorescence - around the fovea, along the vascular arcades, and in the far periphery | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:threonine tyrosine kinase inhibitor cfi-402257 n1=cyclopeptide | n2=en:threonine tyrosine kinase inhibitor cfi-402257 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thrombopoietin receptor agonist lgd-4665 n1=cyclopeptide | n2=en:thrombopoietin receptor agonist lgd-4665 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thumb in palm deformity n1=cyclopeptide | n2=en:thumb in palm deformity | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thymergasia n1=cyclopeptide | n2=en:thymergasia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thymidine n1=cyclopeptide | n2=en:thymidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thymidylate synthase inhibitor dfp-11207 n1=cyclopeptide | n2=en:thymidylate synthase inhibitor dfp-11207 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thymopentin n1=cyclopeptide | n2=en:thymopentin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thyroid dysgenesis n1=cyclopeptide | n2=en:thyroid dysgenesis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thyroid extract n1=cyclopeptide | n2=en:thyroid extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thyroid gland malformation n1=cyclopeptide | n2=en:thyroid gland malformation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thyrotropin alfa n1=cyclopeptide | n2=en:thyrotropin alfa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:thyroxine n1=cyclopeptide | n2=en:thyroxine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tiazofurin n1=cyclopeptide | n2=en:tiazofurin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tibolone n1=cyclopeptide | n2=en:tibolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ticarcillin n1=cyclopeptide | n2=en:ticarcillin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tigapotide n1=cyclopeptide | n2=en:tigapotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tigatuzumab n1=cyclopeptide | n2=en:tigatuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tigecycline n1=cyclopeptide | n2=en:tigecycline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tigroid appearance of fundus (in some patients) n1=cyclopeptide | n2=en:tigroid appearance of fundus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tigroid fundus n1=cyclopeptide | n2=en:tigroid fundus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tigroid-appearing fundus (in some patients) n1=cyclopeptide | n2=en:tigroid-appearing fundus (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:til 1383i t cell receptor-transduced autologous t cells n1=cyclopeptide | n2=en:til 1383i t cell receptor-transduced autologous t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tilarginine n1=cyclopeptide | n2=en:tilarginine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tilorone n1=cyclopeptide | n2=en:tilorone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tilted optic discs (in some patients) n1=cyclopeptide | n2=en:tilted optic discs (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:timcodar dimesylate n1=cyclopeptide | n2=en:timcodar dimesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:timolol maleate gel forming solution n1=cyclopeptide | n2=en:timolol maleate gel forming solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:timonacic n1=cyclopeptide | n2=en:timonacic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tin ethyl etiopurpurin n1=cyclopeptide | n2=en:tin ethyl etiopurpurin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tin sn 117m dtpa n1=cyclopeptide | n2=en:tin sn 117m dtpa | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tinidazole n1=cyclopeptide | n2=en:tinidazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tinnitus (less common) n1=cyclopeptide | n2=en:tinnitus (less common) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tinzaparin sodium n1=cyclopeptide | n2=en:tinzaparin sodium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tiomolibdate diammonium n1=cyclopeptide | n2=en:tiomolibdate diammonium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tiotropium bromide monohydrate n1=cyclopeptide | n2=en:tiotropium bromide monohydrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tipifarnib n1=cyclopeptide | n2=en:tipifarnib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tirapazamine n1=cyclopeptide | n2=en:tirapazamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:titanium dioxide/zinc oxide sunscreen n1=cyclopeptide | n2=en:titanium dioxide/zinc oxide sunscreen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tivantinib n1=cyclopeptide | n2=en:tivantinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tivozanib n1=cyclopeptide | n2=en:tivozanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tizanidine hydrochloride n1=cyclopeptide | n2=en:tizanidine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr 7/8 agonist medi9197 n1=cyclopeptide | n2=en:tlr 7/8 agonist medi9197 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr agonist cadi-05 n1=cyclopeptide | n2=en:tlr agonist cadi-05 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr-directed cationic lipid-dna complex jvrs-100 n1=cyclopeptide | n2=en:tlr-directed cationic lipid-dna complex jvrs-100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr4 agonist gla-se n1=cyclopeptide | n2=en:tlr4 agonist gla-se | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr4 agonist gsk1795091 n1=cyclopeptide | n2=en:tlr4 agonist gsk1795091 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr7 agonist 852a n1=cyclopeptide | n2=en:tlr7 agonist 852a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr7 agonist ana773 tosylate n1=cyclopeptide | n2=en:tlr7 agonist ana773 tosylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr7/8/9 antagonist imo-8400 n1=cyclopeptide | n2=en:tlr7/8/9 antagonist imo-8400 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr8 agonist vtx-2337 n1=cyclopeptide | n2=en:tlr8 agonist vtx-2337 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr9 agonist duk-cpg-001 n1=cyclopeptide | n2=en:tlr9 agonist duk-cpg-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr9 agonist emd 1201081 n1=cyclopeptide | n2=en:tlr9 agonist emd 1201081 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr9 agonist mgn1703 n1=cyclopeptide | n2=en:tlr9 agonist mgn1703 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tlr9 agonist sd-101 n1=cyclopeptide | n2=en:tlr9 agonist sd-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tmc regimen n1=cyclopeptide | n2=en:tmc regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tn(c)-klh conjugate vaccine n1=cyclopeptide | n2=en:tn(c)-klh conjugate vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tncf regimen n1=cyclopeptide | n2=en:tncf regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tobramycin sulfate n1=cyclopeptide | n2=en:tobramycin sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tocilizumab n1=cyclopeptide | n2=en:tocilizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tocladesine n1=cyclopeptide | n2=en:tocladesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tocolytic agents n1=cyclopeptide | n2=en:tocolytic agents | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tocopherol n1=cyclopeptide | n2=en:tocopherol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tocophersolan n1=cyclopeptide | n2=en:tocophersolan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tocotrienol n1=cyclopeptide | n2=en:tocotrienol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tocotrienol-rich fraction n1=cyclopeptide | n2=en:tocotrienol-rich fraction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tofacitinib n1=cyclopeptide | n2=en:tofacitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tolazamide n1=cyclopeptide | n2=en:tolazamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tolbutamide n1=cyclopeptide | n2=en:tolbutamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tolfenamic acid n1=cyclopeptide | n2=en:tolfenamic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:toll-like receptor 9 agonist imo-2125 n1=cyclopeptide | n2=en:toll-like receptor 9 agonist imo-2125 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tolnidamine n1=cyclopeptide | n2=en:tolnidamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tolvaptan n1=cyclopeptide | n2=en:tolvaptan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tomato-soy juice n1=cyclopeptide | n2=en:tomato-soy juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tonic upgaze n1=cyclopeptide | n2=en:tonic upgaze | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tonically dilated pupils (in some patients) n1=cyclopeptide | n2=en:tonically dilated pupils (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical agent ad17137 n1=cyclopeptide | n2=en:topical agent ad17137 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical betulinic acid n1=cyclopeptide | n2=en:topical betulinic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical calcitriol n1=cyclopeptide | n2=en:topical calcitriol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical cocaine hydrochloride n1=cyclopeptide | n2=en:topical cocaine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical dosage form n1=cyclopeptide | n2=en:topical dosage form | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical fluorouracil n1=cyclopeptide | n2=en:topical fluorouracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical gemcitabine hydrochloride n1=cyclopeptide | n2=en:topical gemcitabine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical keratin n1=cyclopeptide | n2=en:topical keratin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical lfx453 n1=cyclopeptide | n2=en:topical lfx453 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical menthol cream n1=cyclopeptide | n2=en:topical menthol cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical myristyl nicotinate cream n1=cyclopeptide | n2=en:topical myristyl nicotinate cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical phenylephrine solution n1=cyclopeptide | n2=en:topical phenylephrine solution | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical piperidine nitroxide mts-01 n1=cyclopeptide | n2=en:topical piperidine nitroxide mts-01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical pvdf/sirolimus n1=cyclopeptide | n2=en:topical pvdf/sirolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical sirolimus n1=cyclopeptide | n2=en:topical sirolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical trichloroacetic acid n1=cyclopeptide | n2=en:topical trichloroacetic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical vitamin e n1=cyclopeptide | n2=en:topical vitamin e | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topical wound spray hp802-247 n1=cyclopeptide | n2=en:topical wound spray hp802-247 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topiramate n1=cyclopeptide | n2=en:topiramate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topoisomerase i inhibitor genz-644282 n1=cyclopeptide | n2=en:topoisomerase i inhibitor genz-644282 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topoisomerase i inhibitor lmp400 n1=cyclopeptide | n2=en:topoisomerase i inhibitor lmp400 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topoisomerase i inhibitor lmp776 n1=cyclopeptide | n2=en:topoisomerase i inhibitor lmp776 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topoisomerase i/ii inhibitor nev-801 n1=cyclopeptide | n2=en:topoisomerase i/ii inhibitor nev-801 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topoisomerase inhibitor n1=cyclopeptide | n2=en:topoisomerase inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topoisomerase-ii inhibitor n1=cyclopeptide | n2=en:topoisomerase-ii inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topotecan hydrochloride n1=cyclopeptide | n2=en:topotecan hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topotecan hydrochloride liposomes n1=cyclopeptide | n2=en:topotecan hydrochloride liposomes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:topsalysin n1=cyclopeptide | n2=en:topsalysin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:torc1/2 kinase inhibitor ds-3078a n1=cyclopeptide | n2=en:torc1/2 kinase inhibitor ds-3078a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:toremifene n1=cyclopeptide | n2=en:toremifene | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tortuosity of conjunctival vessels n1=cyclopeptide | n2=en:tortuosity of conjunctival vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tortuous conjunctival vessels (1 family) n1=cyclopeptide | n2=en:tortuous conjunctival vessels (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tortuous retinal vasculature n1=cyclopeptide | n2=en:tortuous retinal vasculature | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tosedostat n1=cyclopeptide | n2=en:tosedostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tositumomab n1=cyclopeptide | n2=en:tositumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tositumomab and iodine i 131 tositumomab n1=cyclopeptide | n2=en:tositumomab and iodine i 131 tositumomab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:total coloboma, involving the macula n1=cyclopeptide | n2=en:total coloboma, involving the macula | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:total tumor rna-loaded dendritic cell vaccine n1=cyclopeptide | n2=en:total tumor rna-loaded dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:toxicity aspects n1=cyclopeptide | n2=en:toxicity aspects | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tozasertib lactate n1=cyclopeptide | n2=en:tozasertib lactate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tp40 immunotoxin n1=cyclopeptide | n2=en:tp40 immunotoxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tpf regimen n1=cyclopeptide | n2=en:tpf regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tpo receptor agonist ono-7746 n1=cyclopeptide | n2=en:tpo receptor agonist ono-7746 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trabectedin n1=cyclopeptide | n2=en:trabectedin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trabeculodysgenesis, primary (in some patients) n1=cyclopeptide | n2=en:trabeculodysgenesis, primary (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trabedersen n1=cyclopeptide | n2=en:trabedersen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trachoma n1=cyclopeptide | n2=en:trachoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tractional retinal detachment n1=cyclopeptide | n2=en:tractional retinal detachment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tractional retinal detachment (in some patients) n1=cyclopeptide | n2=en:tractional retinal detachment (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trametinib n1=cyclopeptide | n2=en:trametinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trampco protocol n1=cyclopeptide | n2=en:trampco protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trampcol protocol n1=cyclopeptide | n2=en:trampcol protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tranexamic acid n1=cyclopeptide | n2=en:tranexamic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trans sodium crocetinate n1=cyclopeptide | n2=en:trans sodium crocetinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transdermal 17beta-estradiol gel bhr-200 n1=cyclopeptide | n2=en:transdermal 17beta-estradiol gel bhr-200 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transdermal 4-hydroxytestosterone n1=cyclopeptide | n2=en:transdermal 4-hydroxytestosterone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transdermal estrogen n1=cyclopeptide | n2=en:transdermal estrogen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 n1=cyclopeptide | n2=en:transferrin receptor-targeted anti-rrm2 sirna calaa-01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transferrin receptor-targeted liposomal p53 cdna n1=cyclopeptide | n2=en:transferrin receptor-targeted liposomal p53 cdna | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transferrin-crm107 n1=cyclopeptide | n2=en:transferrin-crm107 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transgenic lymphocyte immunization vaccine n1=cyclopeptide | n2=en:transgenic lymphocyte immunization vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transient blindness (elicited by light, sudden standing, or direct pressure on the eyelid) lasting 3 to 10 seconds n1=cyclopeptide | n2=en:transient blindness (elicited by light, sudden standing, or direct pressure on the eyelid) lasting 3 to 10 seconds | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transillumination of the iris (in some patients) n1=cyclopeptide | n2=en:transillumination of the iris (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:translucent iris n1=cyclopeptide | n2=en:translucent iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transparent iris n1=cyclopeptide | n2=en:transparent iris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transposition of great vessels n1=cyclopeptide | n2=en:transposition of great vessels | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:transthyretin antisense oligonucleotide isis-ttr rx n1=cyclopeptide | n2=en:transthyretin antisense oligonucleotide isis-ttr rx | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tranylcypromine sulfate n1=cyclopeptide | n2=en:tranylcypromine sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trastuzumab n1=cyclopeptide | n2=en:trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trastuzumab emtansine n1=cyclopeptide | n2=en:trastuzumab emtansine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trastuzumab vc-seco-duba n1=cyclopeptide | n2=en:trastuzumab vc-seco-duba | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:traumeel s n1=cyclopeptide | n2=en:traumeel s | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:treacher collins syndrome n1=cyclopeptide | n2=en:treacher collins syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trebananib n1=cyclopeptide | n2=en:trebananib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tremelimumab n1=cyclopeptide | n2=en:tremelimumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:treosulfan n1=cyclopeptide | n2=en:treosulfan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tresperimus n1=cyclopeptide | n2=en:tresperimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tretazicar n1=cyclopeptide | n2=en:tretazicar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tretinoin n1=cyclopeptide | n2=en:tretinoin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tretinoin liposome n1=cyclopeptide | n2=en:tretinoin liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tri-virus/gd2-specific allogeneic cytotoxic t-lymphocytes n1=cyclopeptide | n2=en:tri-virus/gd2-specific allogeneic cytotoxic t-lymphocytes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triamcinolone n1=cyclopeptide | n2=en:triamcinolone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triamcinolone acetonide n1=cyclopeptide | n2=en:triamcinolone acetonide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triangular medial eyebrows with distal tapering n1=cyclopeptide | n2=en:triangular medial eyebrows with distal tapering | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triapine n1=cyclopeptide | n2=en:triapine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triazene antineoplastic n1=cyclopeptide | n2=en:triazene antineoplastic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triazene derivative trin2755 n1=cyclopeptide | n2=en:triazene derivative trin2755 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triazinate n1=cyclopeptide | n2=en:triazinate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tributyrin n1=cyclopeptide | n2=en:tributyrin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trichiasis n1=cyclopeptide | n2=en:trichiasis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trichlormethine n1=cyclopeptide | n2=en:trichlormethine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triciribine phosphate n1=cyclopeptide | n2=en:triciribine phosphate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trientine hydrochloride n1=cyclopeptide | n2=en:trientine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triethylenemelamine n1=cyclopeptide | n2=en:triethylenemelamine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trifluoperazine hydrochloride n1=cyclopeptide | n2=en:trifluoperazine hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trifluridine n1=cyclopeptide | n2=en:trifluridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trifluridine/tipiracil hydrochloride combination agent tas-102 n1=cyclopeptide | n2=en:trifluridine/tipiracil hydrochloride combination agent tas-102 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trilostane n1=cyclopeptide | n2=en:trilostane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trimethoprim n1=cyclopeptide | n2=en:trimethoprim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trimethoprim-sulfamethoxazole n1=cyclopeptide | n2=en:trimethoprim-sulfamethoxazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trimethylcolchicinic acid n1=cyclopeptide | n2=en:trimethylcolchicinic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trimetrexate n1=cyclopeptide | n2=en:trimetrexate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trimetrexate glucuronate n1=cyclopeptide | n2=en:trimetrexate glucuronate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trioxifene mesylate n1=cyclopeptide | n2=en:trioxifene mesylate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triptolide analog n1=cyclopeptide | n2=en:triptolide analog | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triptorelin n1=cyclopeptide | n2=en:triptorelin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:triptorelin pamoate n1=cyclopeptide | n2=en:triptorelin pamoate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tris-acryl gelatin microspheres n1=cyclopeptide | n2=en:tris-acryl gelatin microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trisomy 22 n1=cyclopeptide | n2=en:trisomy 22 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tritan color vision defect, complete or partial (in some patients) n1=cyclopeptide | n2=en:tritan color vision defect, complete or partial (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tritan color vision deficits (in some patients) n1=cyclopeptide | n2=en:tritan color vision deficits (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tritan defect on color vision testing (in some patients) n1=cyclopeptide | n2=en:tritan defect on color vision testing (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trivalent influenza vaccine n1=cyclopeptide | n2=en:trivalent influenza vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trivalent live-attenuated influenza vaccine n1=cyclopeptide | n2=en:trivalent live-attenuated influenza vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trk inhibitor azd6918 n1=cyclopeptide | n2=en:trk inhibitor azd6918 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trk inhibitor loxo-101 n1=cyclopeptide | n2=en:trk inhibitor loxo-101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trodusquemine n1=cyclopeptide | n2=en:trodusquemine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trofosfamide n1=cyclopeptide | n2=en:trofosfamide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:troglitazone n1=cyclopeptide | n2=en:troglitazone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tropisetron n1=cyclopeptide | n2=en:tropisetron | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tropisetron hydrochloride n1=cyclopeptide | n2=en:tropisetron hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tropomyosin receptor kinase inhibitor azd7451 n1=cyclopeptide | n2=en:tropomyosin receptor kinase inhibitor azd7451 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:troxacitabine n1=cyclopeptide | n2=en:troxacitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trp2 mrna-electroporated autologous langerhans-type dendritic cell vaccine n1=cyclopeptide | n2=en:trp2 mrna-electroporated autologous langerhans-type dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:trpv6 calcium channel inhibitor sor-c13 n1=cyclopeptide | n2=en:trpv6 calcium channel inhibitor sor-c13 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:true anophthalmia n1=cyclopeptide | n2=en:true anophthalmia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tsop protocol n1=cyclopeptide | n2=en:tsop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tsp-1 mimetic fusion protein cvx-045 n1=cyclopeptide | n2=en:tsp-1 mimetic fusion protein cvx-045 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tti-237 n1=cyclopeptide | n2=en:tti-237 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tubercidin n1=cyclopeptide | n2=en:tubercidin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tuberous sclerosis n1=cyclopeptide | n2=en:tuberous sclerosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tubulin inhibitor alb 109564(a) n1=cyclopeptide | n2=en:tubulin inhibitor alb 109564(a) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tubulin polymerization inhibitor ckd-516 n1=cyclopeptide | n2=en:tubulin polymerization inhibitor ckd-516 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tubulin-binding agent ssr97225 n1=cyclopeptide | n2=en:tubulin-binding agent ssr97225 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tucotuzumab celmoleukin n1=cyclopeptide | n2=en:tucotuzumab celmoleukin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tumor cell-derived dribbles vaccine n1=cyclopeptide | n2=en:tumor cell-derived dribbles vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tumor peptide-loaded myeloid dendritic cells n1=cyclopeptide | n2=en:tumor peptide-loaded myeloid dendritic cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tumor-associated antigen peptide vaccine grn-1201 n1=cyclopeptide | n2=en:tumor-associated antigen peptide vaccine grn-1201 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tumor-cells apoptosis factor hormone-peptide n1=cyclopeptide | n2=en:tumor-cells apoptosis factor hormone-peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tumor-homing peptide irgd n1=cyclopeptide | n2=en:tumor-homing peptide irgd | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tw1025 supplement n1=cyclopeptide | n2=en:tw1025 supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:twin-twin transfusion syndrome n1=cyclopeptide | n2=en:twin-twin transfusion syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:twitching around the eyes, episodic n1=cyclopeptide | n2=en:twitching around the eyes, episodic | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tyloxapol n1=cyclopeptide | n2=en:tyloxapol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:type 2 vitreous phenotype (irregularly thickened fiber bundles throughout vitreous cavity) n1=cyclopeptide | n2=en:type 2 vitreous phenotype (irregularly thickened fiber bundles throughout vitreous cavity) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:type of chemotherapy:type:pt:^patient:nom:phenx n1=cyclopeptide | n2=en:type of chemotherapy:type:pt:^patient:nom:phenx | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:typhoid vaccine n1=cyclopeptide | n2=en:typhoid vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tyroserleutide n1=cyclopeptide | n2=en:tyroserleutide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tyrosinase peptide n1=cyclopeptide | n2=en:tyrosinase peptide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tyrosinase related protein-1 n1=cyclopeptide | n2=en:tyrosinase related protein-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tyrosinase-klh n1=cyclopeptide | n2=en:tyrosinase-klh | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tyrosine kinase inhibitor n1=cyclopeptide | n2=en:tyrosine kinase inhibitor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tyrosine kinase inhibitor osi-930 n1=cyclopeptide | n2=en:tyrosine kinase inhibitor osi-930 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:tyrosine kinase inhibitor xl228 n1=cyclopeptide | n2=en:tyrosine kinase inhibitor xl228 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uae inhibitor tak-243 n1=cyclopeptide | n2=en:uae inhibitor tak-243 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ubenimex n1=cyclopeptide | n2=en:ubenimex | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ubidecarenone injectable nanosuspension n1=cyclopeptide | n2=en:ubidecarenone injectable nanosuspension | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ublituximab n1=cyclopeptide | n2=en:ublituximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uch i protocol n1=cyclopeptide | n2=en:uch i protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:udenafil n1=cyclopeptide | n2=en:udenafil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ulcer of eyelid n1=cyclopeptide | n2=en:ulcer of eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ulimorelin hyrdrochloride n1=cyclopeptide | n2=en:ulimorelin hyrdrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ulinastatin n1=cyclopeptide | n2=en:ulinastatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ulipristal acetate n1=cyclopeptide | n2=en:ulipristal acetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ulixertinib n1=cyclopeptide | n2=en:ulixertinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ulocuplumab n1=cyclopeptide | n2=en:ulocuplumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ulvwf multimer-targeting agent arc1779 n1=cyclopeptide | n2=en:ulvwf multimer-targeting agent arc1779 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:umbilical cord blood-derived hematopoietic cd34-positive progenitor cells n1=cyclopeptide | n2=en:umbilical cord blood-derived hematopoietic cd34-positive progenitor cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:umbilical cord blood-derived mesenchymal stem cells n1=cyclopeptide | n2=en:umbilical cord blood-derived mesenchymal stem cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:umbilical cord blood-derived natural killer cells n1=cyclopeptide | n2=en:umbilical cord blood-derived natural killer cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:umeclidinium n1=cyclopeptide | n2=en:umeclidinium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uncaria tomentosa extract n1=cyclopeptide | n2=en:uncaria tomentosa extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uncontrolled eye movements n1=cyclopeptide | n2=en:uncontrolled eye movements | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:underdeveloped supraorbital ridges n1=cyclopeptide | n2=en:underdeveloped supraorbital ridges | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:undetectable electroretinogram n1=cyclopeptide | n2=en:undetectable electroretinogram | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:undetectable responses on electroretinography (by fourth decade of life) n1=cyclopeptide | n2=en:undetectable responses on electroretinography (by fourth decade of life) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:undetectable rod and cone responses on electroretinography n1=cyclopeptide | n2=en:undetectable rod and cone responses on electroretinography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:undetectable visual evoked potentials n1=cyclopeptide | n2=en:undetectable visual evoked potentials | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uniformly-labeled [u-13c]glucose n1=cyclopeptide | n2=en:uniformly-labeled [u-13c]glucose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:unilateral (right eye) involvement n1=cyclopeptide | n2=en:unilateral (right eye) involvement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:unilateral hypertropia n1=cyclopeptide | n2=en:unilateral hypertropia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:unilateral hypotropia n1=cyclopeptide | n2=en:unilateral hypotropia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:unilateral microphthalmia n1=cyclopeptide | n2=en:unilateral microphthalmia | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:unilateral narrow palpebral fissure n1=cyclopeptide | n2=en:unilateral narrow palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:unilateral ptosis n1=cyclopeptide | n2=en:unilateral ptosis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:unrecordable perg by 7th decade n1=cyclopeptide | n2=en:unrecordable perg by 7th decade | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:unusual eyebrow pattern n1=cyclopeptide | n2=en:unusual eyebrow pattern | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upper eyelid n1=cyclopeptide | n2=en:upper eyelid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upper eyelid coloboma n1=cyclopeptide | n2=en:upper eyelid coloboma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upper limb defect with eye and ear abnormalities syndrome n1=cyclopeptide | n2=en:upper limb defect with eye and ear abnormalities syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upslanting palpebral fissures (1 family) n1=cyclopeptide | n2=en:upslanting palpebral fissures (1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upslanting palpebral fissures (1 patient) n1=cyclopeptide | n2=en:upslanting palpebral fissures (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upslanting palpebral fissures (37%) n1=cyclopeptide | n2=en:upslanting palpebral fissures (37%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upslanting palpebral fissures (97%) n1=cyclopeptide | n2=en:upslanting palpebral fissures (97%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upslanting palpebral fissures (in some patients) n1=cyclopeptide | n2=en:upslanting palpebral fissures (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upslanting palpebral fissures, mild n1=cyclopeptide | n2=en:upslanting palpebral fissures, mild | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upward displacement of the globes n1=cyclopeptide | n2=en:upward displacement of the globes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upward eye deviation during episodes n1=cyclopeptide | n2=en:upward eye deviation during episodes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upward gaze paralysis n1=cyclopeptide | n2=en:upward gaze paralysis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upward gaze paresis n1=cyclopeptide | n2=en:upward gaze paresis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upward or downward slanting palpebral fissures n1=cyclopeptide | n2=en:upward or downward slanting palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upward slant of palpebral fissure n1=cyclopeptide | n2=en:upward slant of palpebral fissure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upward tented eyebrows n1=cyclopeptide | n2=en:upward tented eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:upward-slanted palpebral fissures (68%) n1=cyclopeptide | n2=en:upward-slanted palpebral fissures (68%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uracil n1=cyclopeptide | n2=en:uracil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uracil mustard n1=cyclopeptide | n2=en:uracil mustard | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uracil ointment n1=cyclopeptide | n2=en:uracil ointment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:urea n1=cyclopeptide | n2=en:urea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:urea/lactic acid-based topical cream n1=cyclopeptide | n2=en:urea/lactic acid-based topical cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:urelumab n1=cyclopeptide | n2=en:urelumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ureterocele n1=cyclopeptide | n2=en:ureterocele | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:urethane n1=cyclopeptide | n2=en:urethane | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uridine n1=cyclopeptide | n2=en:uridine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uridine triacetate n1=cyclopeptide | n2=en:uridine triacetate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:urlc10 peptide vaccine n1=cyclopeptide | n2=en:urlc10 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:urlc10-cdca1-koc1 multipeptide vaccine n1=cyclopeptide | n2=en:urlc10-cdca1-koc1 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:urlc10-ttk-koc1-vegfr1-vegfr2 multipeptide vaccine n1=cyclopeptide | n2=en:urlc10-ttk-koc1-vegfr1-vegfr2 multipeptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:urokinase-derived peptide a6 n1=cyclopeptide | n2=en:urokinase-derived peptide a6 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ursodiol n1=cyclopeptide | n2=en:ursodiol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:usp14/uchl5 inhibitor vlx1570 n1=cyclopeptide | n2=en:usp14/uchl5 inhibitor vlx1570 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ustekinumab n1=cyclopeptide | n2=en:ustekinumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uterine anomalies n1=cyclopeptide | n2=en:uterine anomalies | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uv1 telomerase peptide vaccine n1=cyclopeptide | n2=en:uv1 telomerase peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uvea n1=cyclopeptide | n2=en:uvea | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uveal coloboma n1=cyclopeptide | n2=en:uveal coloboma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uveal effusion (rare) n1=cyclopeptide | n2=en:uveal effusion (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uveal melanoma n1=cyclopeptide | n2=en:uveal melanoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:uveitis n1=cyclopeptide | n2=en:uveitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:v-cam protocol n1=cyclopeptide | n2=en:v-cam protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:v930 vaccine n1=cyclopeptide | n2=en:v930 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vab-6 regimen n1=cyclopeptide | n2=en:vab-6 regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vab-iv protocol n1=cyclopeptide | n2=en:vab-iv protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vac regimen n1=cyclopeptide | n2=en:vac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vac-m protocol n1=cyclopeptide | n2=en:vac-m protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vac-map protocol n1=cyclopeptide | n2=en:vac-map protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vacad protocol n1=cyclopeptide | n2=en:vacad protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vaccine-sensitized draining lymph node cells n1=cyclopeptide | n2=en:vaccine-sensitized draining lymph node cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vaccinia cea vaccine n1=cyclopeptide | n2=en:vaccinia cea vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vaccinia virus dd-cdsr n1=cyclopeptide | n2=en:vaccinia virus dd-cdsr | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vaccinia-gm-csf vaccine n1=cyclopeptide | n2=en:vaccinia-gm-csf vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vaccinia-tyrosinase vaccine n1=cyclopeptide | n2=en:vaccinia-tyrosinase vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vaccinium myrtillus/macleaya cordata/echinacea angustifolia extract granules n1=cyclopeptide | n2=en:vaccinium myrtillus/macleaya cordata/echinacea angustifolia extract granules | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vacime protocol n1=cyclopeptide | n2=en:vacime protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vaco-b protocol n1=cyclopeptide | n2=en:vaco-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vacop-b protocol n1=cyclopeptide | n2=en:vacop-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vadastuximab talirine n1=cyclopeptide | n2=en:vadastuximab talirine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vadimezan n1=cyclopeptide | n2=en:vadimezan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vadriac regimen n1=cyclopeptide | n2=en:vadriac regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vadriac-ie regimen n1=cyclopeptide | n2=en:vadriac-ie regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vaginal dosage form product n1=cyclopeptide | n2=en:vaginal dosage form product | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:valacyclovir n1=cyclopeptide | n2=en:valacyclovir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:valdecoxib n1=cyclopeptide | n2=en:valdecoxib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:valerian n1=cyclopeptide | n2=en:valerian | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:valganciclovir n1=cyclopeptide | n2=en:valganciclovir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:valproic acid n1=cyclopeptide | n2=en:valproic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:valrubicin n1=cyclopeptide | n2=en:valrubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:valsartan n1=cyclopeptide | n2=en:valsartan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:valspodar n1=cyclopeptide | n2=en:valspodar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vamp regimen n1=cyclopeptide | n2=en:vamp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vancomycin n1=cyclopeptide | n2=en:vancomycin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vandetanib n1=cyclopeptide | n2=en:vandetanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vandortuzumab vedotin n1=cyclopeptide | n2=en:vandortuzumab vedotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vantictumab n1=cyclopeptide | n2=en:vantictumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vapec-b protocol n1=cyclopeptide | n2=en:vapec-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vapreotide n1=cyclopeptide | n2=en:vapreotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vardenafil hydrochloride trihydrate n1=cyclopeptide | n2=en:vardenafil hydrochloride trihydrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:varenicline n1=cyclopeptide | n2=en:varenicline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:variable degree of angle closure n1=cyclopeptide | n2=en:variable degree of angle closure | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:variable degree of corneal opacities n1=cyclopeptide | n2=en:variable degree of corneal opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:variable rod and cone responses seen on electroretinogram n1=cyclopeptide | n2=en:variable rod and cone responses seen on electroretinogram | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:varicella-zoster virus strain oka/merck live antigen n1=cyclopeptide | n2=en:varicella-zoster virus strain oka/merck live antigen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:varlilumab n1=cyclopeptide | n2=en:varlilumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:varlitinib n1=cyclopeptide | n2=en:varlitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:varying degrees of doubling of intrinsic ocular structures n1=cyclopeptide | n2=en:varying degrees of doubling of intrinsic ocular structures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vascular disrupting agent bnc105p n1=cyclopeptide | n2=en:vascular disrupting agent bnc105p | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vascular disrupting agent zd6126 n1=cyclopeptide | n2=en:vascular disrupting agent zd6126 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vascular endothelial growth factor antisense oligonucleotide n1=cyclopeptide | n2=en:vascular endothelial growth factor antisense oligonucleotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vascular sheathing (in some patients) n1=cyclopeptide | n2=en:vascular sheathing (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vascularizing keratitis n1=cyclopeptide | n2=en:vascularizing keratitis | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vatalanib n1=cyclopeptide | n2=en:vatalanib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vbcfm protocol n1=cyclopeptide | n2=en:vbcfm protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vbcmf protocol n1=cyclopeptide | n2=en:vbcmf protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vbmcp regimen n1=cyclopeptide | n2=en:vbmcp regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcaa protocol n1=cyclopeptide | n2=en:vcaa protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcad regimen n1=cyclopeptide | n2=en:vcad regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcav protocol n1=cyclopeptide | n2=en:vcav protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vccp protocol n1=cyclopeptide | n2=en:vccp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcd protocol n1=cyclopeptide | n2=en:vcd protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcdp protocol n1=cyclopeptide | n2=en:vcdp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcl-cb01 vaccine n1=cyclopeptide | n2=en:vcl-cb01 vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcma protocol n1=cyclopeptide | n2=en:vcma protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcp protocol 2 n1=cyclopeptide | n2=en:vcp protocol 2 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcpc protocol n1=cyclopeptide | n2=en:vcpc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcrp protocol n1=cyclopeptide | n2=en:vcrp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vcsp protocol n1=cyclopeptide | n2=en:vcsp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vdbcp protocol n1=cyclopeptide | n2=en:vdbcp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vebep regimen n1=cyclopeptide | n2=en:vebep regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vecabop protocol n1=cyclopeptide | n2=en:vecabop protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vecuronium bromide n1=cyclopeptide | n2=en:vecuronium bromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vedolizumab n1=cyclopeptide | n2=en:vedolizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegf inhibitor ptc299 n1=cyclopeptide | n2=en:vegf inhibitor ptc299 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegf/hgf-targeting darpin mp0250 n1=cyclopeptide | n2=en:vegf/hgf-targeting darpin mp0250 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr inhibitor krn951 n1=cyclopeptide | n2=en:vegfr inhibitor krn951 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr-2 dna vaccine vxm01 n1=cyclopeptide | n2=en:vegfr-2 dna vaccine vxm01 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr/fgfr inhibitor odm-203 n1=cyclopeptide | n2=en:vegfr/fgfr inhibitor odm-203 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr/pdgfr dual kinase inhibitor x-82 n1=cyclopeptide | n2=en:vegfr/pdgfr dual kinase inhibitor x-82 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr/pdgfr tyrosine kinase inhibitor tak-593 n1=cyclopeptide | n2=en:vegfr/pdgfr tyrosine kinase inhibitor tak-593 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr1-1084 peptide vaccine n1=cyclopeptide | n2=en:vegfr1-1084 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr2 tyrosine kinase inhibitor pf-00337210 n1=cyclopeptide | n2=en:vegfr2 tyrosine kinase inhibitor pf-00337210 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr2-169 peptide vaccine n1=cyclopeptide | n2=en:vegfr2-169 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vegfr2-targeted contrast agent br55 n1=cyclopeptide | n2=en:vegfr2-targeted contrast agent br55 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:veip regimen n1=cyclopeptide | n2=en:veip regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:velafermin n1=cyclopeptide | n2=en:velafermin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:veliparib n1=cyclopeptide | n2=en:veliparib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:veltuzumab n1=cyclopeptide | n2=en:veltuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vemfah protocol n1=cyclopeptide | n2=en:vemfah protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vemp protocol 1 n1=cyclopeptide | n2=en:vemp protocol 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vemp protocol 3 n1=cyclopeptide | n2=en:vemp protocol 3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vemurafenib n1=cyclopeptide | n2=en:vemurafenib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:venetoclax n1=cyclopeptide | n2=en:venetoclax | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:venlafaxine n1=cyclopeptide | n2=en:venlafaxine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ventricular septal defect n1=cyclopeptide | n2=en:ventricular septal defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vep-thp protocol n1=cyclopeptide | n2=en:vep-thp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vepa-b protocol n1=cyclopeptide | n2=en:vepa-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vepa-l protocol n1=cyclopeptide | n2=en:vepa-l protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vepemb protocol n1=cyclopeptide | n2=en:vepemb protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vepoloxamer n1=cyclopeptide | n2=en:vepoloxamer | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:verapamil n1=cyclopeptide | n2=en:verapamil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:verpasep caltespen n1=cyclopeptide | n2=en:verpasep caltespen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:verteporfin n1=cyclopeptide | n2=en:verteporfin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vertical cup-to-disc ratio greater than or equal to 0.7 n1=cyclopeptide | n2=en:vertical cup-to-disc ratio greater than or equal to 0.7 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vertical gaze impairment n1=cyclopeptide | n2=en:vertical gaze impairment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vertical gaze limitation n1=cyclopeptide | n2=en:vertical gaze limitation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vertical gaze palsy n1=cyclopeptide | n2=en:vertical gaze palsy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vertical ocular movements are usually preserved n1=cyclopeptide | n2=en:vertical ocular movements are usually preserved | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vertical supranuclear gaze palsy n1=cyclopeptide | n2=en:vertical supranuclear gaze palsy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vertically inserted eyelashes n1=cyclopeptide | n2=en:vertically inserted eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:verubulin hydrochloride n1=cyclopeptide | n2=en:verubulin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:very poor corneal healing n1=cyclopeptide | n2=en:very poor corneal healing | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vestibular dysfunction, variable n1=cyclopeptide | n2=en:vestibular dysfunction, variable | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:veterinary drugs n1=cyclopeptide | n2=en:veterinary drugs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vhcp protocol n1=cyclopeptide | n2=en:vhcp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:viagenpumatucel-l n1=cyclopeptide | n2=en:viagenpumatucel-l | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:viced protocol n1=cyclopeptide | n2=en:viced protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vicop-b protocol n1=cyclopeptide | n2=en:vicop-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vidarabine n1=cyclopeptide | n2=en:vidarabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vigabatrin n1=cyclopeptide | n2=en:vigabatrin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vilazodone n1=cyclopeptide | n2=en:vilazodone | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vildagliptin n1=cyclopeptide | n2=en:vildagliptin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinblastine n1=cyclopeptide | n2=en:vinblastine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinblastine sulfate n1=cyclopeptide | n2=en:vinblastine sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinca alkaloid compound n1=cyclopeptide | n2=en:vinca alkaloid compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vincristine n1=cyclopeptide | n2=en:vincristine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vincristine sulfate n1=cyclopeptide | n2=en:vincristine sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vincristine sulfate liposome n1=cyclopeptide | n2=en:vincristine sulfate liposome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vindesine n1=cyclopeptide | n2=en:vindesine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinflunine n1=cyclopeptide | n2=en:vinflunine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinfosiltine n1=cyclopeptide | n2=en:vinfosiltine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinmcp protocol n1=cyclopeptide | n2=en:vinmcp protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinorelbine tartrate n1=cyclopeptide | n2=en:vinorelbine tartrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinorelbine tartrate emulsion n1=cyclopeptide | n2=en:vinorelbine tartrate emulsion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinorelbine tartrate oral n1=cyclopeptide | n2=en:vinorelbine tartrate oral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vintafolide n1=cyclopeptide | n2=en:vintafolide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vinzolidine n1=cyclopeptide | n2=en:vinzolidine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vip regimen n1=cyclopeptide | n2=en:vip regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:virulizin n1=cyclopeptide | n2=en:virulizin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visilizumab n1=cyclopeptide | n2=en:visilizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision impairment from infancy n1=cyclopeptide | n2=en:vision impairment from infancy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision impairment, progressive n1=cyclopeptide | n2=en:vision impairment, progressive | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision impairment, progressive (onset in late childhood or teens in some patients) n1=cyclopeptide | n2=en:vision impairment, progressive (onset in late childhood or teens in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision is usually not affected n1=cyclopeptide | n2=en:vision is usually not affected | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision limited to detection of hand motion n1=cyclopeptide | n2=en:vision limited to detection of hand motion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss (chronic phase) n1=cyclopeptide | n2=en:vision loss (chronic phase) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss with age (middle age) n1=cyclopeptide | n2=en:vision loss with age (middle age) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, monocular n1=cyclopeptide | n2=en:vision loss, monocular | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, peripheral n1=cyclopeptide | n2=en:vision loss, peripheral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, profound n1=cyclopeptide | n2=en:vision loss, profound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, profound (males) n1=cyclopeptide | n2=en:vision loss, profound (males) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, progressive (4 to 10 years) n1=cyclopeptide | n2=en:vision loss, progressive (4 to 10 years) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, progressive (type i) n1=cyclopeptide | n2=en:vision loss, progressive (type i) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, progressive, during childhood or adolescence n1=cyclopeptide | n2=en:vision loss, progressive, during childhood or adolescence | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, severe, beginning in childhood (12 of 62 patients) n1=cyclopeptide | n2=en:vision loss, severe, beginning in childhood (12 of 62 patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, severe, by the 8th decade n1=cyclopeptide | n2=en:vision loss, severe, by the 8th decade | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision loss, unilateral or bilateral n1=cyclopeptide | n2=en:vision loss, unilateral or bilateral | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vision usually normal n1=cyclopeptide | n2=en:vision usually normal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vismodegib n1=cyclopeptide | n2=en:vismodegib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vistusertib n1=cyclopeptide | n2=en:vistusertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual acuity for distant vision ranges from 1/10 to 2/10 as adult n1=cyclopeptide | n2=en:visual acuity for distant vision ranges from 1/10 to 2/10 as adult | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual acuity log mar.left:cmplx:pt:eye.left:qn n1=cyclopeptide | n2=en:visual acuity log mar.left:cmplx:pt:eye.left:qn | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual acuity log mar.right:cmplx:pt:eye.right:qn n1=cyclopeptide | n2=en:visual acuity log mar.right:cmplx:pt:eye.right:qn | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual acuity loss (none to moderate (20/16 to 20/100)) n1=cyclopeptide | n2=en:visual acuity loss (none to moderate (20/16 to 20/100)) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual acuity ranges from 20/20 to light perception only n1=cyclopeptide | n2=en:visual acuity ranges from 20/20 to light perception only | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual acuity ranging from perception of light to 20/100 n1=cyclopeptide | n2=en:visual acuity ranging from perception of light to 20/100 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual acuity, relatively preserved n1=cyclopeptide | n2=en:visual acuity, relatively preserved | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual blurring n1=cyclopeptide | n2=en:visual blurring | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual cortex disorder n1=cyclopeptide | n2=en:visual cortex disorder | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual disturbance n1=cyclopeptide | n2=en:visual disturbance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual field constriction n1=cyclopeptide | n2=en:visual field constriction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual field decrease n1=cyclopeptide | n2=en:visual field decrease | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual field defect n1=cyclopeptide | n2=en:visual field defect | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual field defects (in some patients) n1=cyclopeptide | n2=en:visual field defects (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual field defects (middle age) n1=cyclopeptide | n2=en:visual field defects (middle age) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual field defects (severe in some patients) n1=cyclopeptide | n2=en:visual field defects (severe in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual field restriction n1=cyclopeptide | n2=en:visual field restriction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual fields moderately to severely restricted n1=cyclopeptide | n2=en:visual fields moderately to severely restricted | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual fixation absent from birth or lost in first months of life n1=cyclopeptide | n2=en:visual fixation absent from birth or lost in first months of life | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual floaters/spots n1=cyclopeptide | n2=en:visual floaters/spots | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment n1=cyclopeptide | n2=en:visual impairment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment (1 patient) n1=cyclopeptide | n2=en:visual impairment (1 patient) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment (50-70% of patients) n1=cyclopeptide | n2=en:visual impairment (50-70% of patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment (55%) n1=cyclopeptide | n2=en:visual impairment (55%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment (childhood-onset) n1=cyclopeptide | n2=en:visual impairment (childhood-onset) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment (in some patients) n1=cyclopeptide | n2=en:visual impairment (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment (rare) n1=cyclopeptide | n2=en:visual impairment (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment, cortical (in severe cases) n1=cyclopeptide | n2=en:visual impairment, cortical (in severe cases) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual impairment, progressive, starting early childhood n1=cyclopeptide | n2=en:visual impairment, progressive, starting early childhood | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual inattention n1=cyclopeptide | n2=en:visual inattention | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual loss (in 1 family) n1=cyclopeptide | n2=en:visual loss (in 1 family) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual loss (in some patients) n1=cyclopeptide | n2=en:visual loss (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual loss, progressive (in most patients) n1=cyclopeptide | n2=en:visual loss, progressive (in most patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual loss, progressive painless n1=cyclopeptide | n2=en:visual loss, progressive painless | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual loss, variable n1=cyclopeptide | n2=en:visual loss, variable | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:visual problems (in some patients) n1=cyclopeptide | n2=en:visual problems (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitamin n1=cyclopeptide | n2=en:vitamin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitamin / trace element n1=cyclopeptide | n2=en:vitamin / trace element | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitamin a compound n1=cyclopeptide | n2=en:vitamin a compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitamin e compound n1=cyclopeptide | n2=en:vitamin e compound | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitamin k1-containing urea skin cream n1=cyclopeptide | n2=en:vitamin k1-containing urea skin cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitelliform ('egg-yolk') deposits, macular or multifocal n1=cyclopeptide | n2=en:vitelliform ('egg-yolk') deposits, macular or multifocal | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitelliform ('egg-yolk') deposits, macular or multifocal (in some patients) n1=cyclopeptide | n2=en:vitelliform ('egg-yolk') deposits, macular or multifocal (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitespen n1=cyclopeptide | n2=en:vitespen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreal opacities n1=cyclopeptide | n2=en:vitreal opacities | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreoretinal abnormalities, congenital (rare) n1=cyclopeptide | n2=en:vitreoretinal abnormalities, congenital (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreoretinal degeneration n1=cyclopeptide | n2=en:vitreoretinal degeneration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreoretinal dysgenesis (wws) n1=cyclopeptide | n2=en:vitreoretinal dysgenesis (wws) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreoretinal traction n1=cyclopeptide | n2=en:vitreoretinal traction | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreoretinochoroidopathy (disorder) n1=cyclopeptide | n2=en:vitreoretinochoroidopathy (disorder) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreoretinopathy n1=cyclopeptide | n2=en:vitreoretinopathy | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreous attachment at the disc n1=cyclopeptide | n2=en:vitreous attachment at the disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreous body n1=cyclopeptide | n2=en:vitreous body | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreous detachment n1=cyclopeptide | n2=en:vitreous detachment | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreous fibrillar condensation n1=cyclopeptide | n2=en:vitreous fibrillar condensation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreous hemorrhage n1=cyclopeptide | n2=en:vitreous hemorrhage | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreous hemorrhage (rare) n1=cyclopeptide | n2=en:vitreous hemorrhage (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitreous humor n1=cyclopeptide | n2=en:vitreous humor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vitritis (rare) n1=cyclopeptide | n2=en:vitritis (rare) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vlp-encapsulated tlr9 agonist cmp-001 n1=cyclopeptide | n2=en:vlp-encapsulated tlr9 agonist cmp-001 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vmcp-vbap regimen n1=cyclopeptide | n2=en:vmcp-vbap regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vncop-b protocol n1=cyclopeptide | n2=en:vncop-b protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vocimagene amiretrorepvec n1=cyclopeptide | n2=en:vocimagene amiretrorepvec | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:voglibose n1=cyclopeptide | n2=en:voglibose | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:volasertib n1=cyclopeptide | n2=en:volasertib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:volitinib n1=cyclopeptide | n2=en:volitinib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:volociximab n1=cyclopeptide | n2=en:volociximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:von hippel-lindau peptide vaccine n1=cyclopeptide | n2=en:von hippel-lindau peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:voriconazole n1=cyclopeptide | n2=en:voriconazole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vorinostat n1=cyclopeptide | n2=en:vorinostat | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vorozole n1=cyclopeptide | n2=en:vorozole | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vorsetuzumab-mafodotin n1=cyclopeptide | n2=en:vorsetuzumab-mafodotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vortioxetine hydrobromide n1=cyclopeptide | n2=en:vortioxetine hydrobromide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vosaroxin n1=cyclopeptide | n2=en:vosaroxin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:voxtalisib n1=cyclopeptide | n2=en:voxtalisib | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vpc protocol n1=cyclopeptide | n2=en:vpc protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vpcbae protocol n1=cyclopeptide | n2=en:vpcbae protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vqep protocol n1=cyclopeptide | n2=en:vqep protocol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:vx-803 n1=cyclopeptide | n2=en:vx-803 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:waardenburg anophthalmia syndrome n1=cyclopeptide | n2=en:waardenburg anophthalmia syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wall of eyeball n1=cyclopeptide | n2=en:wall of eyeball | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:warfarin n1=cyclopeptide | n2=en:warfarin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:water o-15 n1=cyclopeptide | n2=en:water o-15 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:water-based vaginal lubricant n1=cyclopeptide | n2=en:water-based vaginal lubricant | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:water, mineral or uric acid metabolism drug n1=cyclopeptide | n2=en:water, mineral or uric acid metabolism drug | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wave-shaped palpebral fissures n1=cyclopeptide | n2=en:wave-shaped palpebral fissures | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:waxy appearance of optic disc n1=cyclopeptide | n2=en:waxy appearance of optic disc | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:waxy optic disc (in some patients) n1=cyclopeptide | n2=en:waxy optic disc (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:waxy optic pallor n1=cyclopeptide | n2=en:waxy optic pallor | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:waxy pallor of optic discs n1=cyclopeptide | n2=en:waxy pallor of optic discs | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:waxy-appearing optic nerve head n1=cyclopeptide | n2=en:waxy-appearing optic nerve head | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:weak extraocular muscles n1=cyclopeptide | n2=en:weak extraocular muscles | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:weakness of orbicularis oculi muscle n1=cyclopeptide | n2=en:weakness of orbicularis oculi muscle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wee1 inhibitor azd1775 n1=cyclopeptide | n2=en:wee1 inhibitor azd1775 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:weight control agent n1=cyclopeptide | n2=en:weight control agent | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:well-defined eyebrows n1=cyclopeptide | n2=en:well-defined eyebrows | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:well-demarcated atrophy of central retina n1=cyclopeptide | n2=en:well-demarcated atrophy of central retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:well-demarcated atrophy of choriocapillaris n1=cyclopeptide | n2=en:well-demarcated atrophy of choriocapillaris | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:well-demarcated atrophy of pigment epithelium n1=cyclopeptide | n2=en:well-demarcated atrophy of pigment epithelium | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wheatgrass juice n1=cyclopeptide | n2=en:wheatgrass juice | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:whey protein isolate n1=cyclopeptide | n2=en:whey protein isolate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white button mushroom extract n1=cyclopeptide | n2=en:white button mushroom extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white carrot n1=cyclopeptide | n2=en:white carrot | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white deposits in corneal epithelium, anterior chamber angle, ciliary body, and pupillary margin n1=cyclopeptide | n2=en:white deposits in corneal epithelium, anterior chamber angle, ciliary body, and pupillary margin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white dots throughout retina n1=cyclopeptide | n2=en:white dots throughout retina | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white eyebrow n1=cyclopeptide | n2=en:white eyebrow | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white eyelashes n1=cyclopeptide | n2=en:white eyelashes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white painless eye n1=cyclopeptide | n2=en:white painless eye | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white sclera n1=cyclopeptide | n2=en:white sclera | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white to faintly blue sclera n1=cyclopeptide | n2=en:white to faintly blue sclera | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white to gray sclerae n1=cyclopeptide | n2=en:white to gray sclerae | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:white wine n1=cyclopeptide | n2=en:white wine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:whorl-like corneal dystrophy in carrier females n1=cyclopeptide | n2=en:whorl-like corneal dystrophy in carrier females | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wide palpebral fissures (34%) n1=cyclopeptide | n2=en:wide palpebral fissures (34%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wide palpebral fissures (50%) n1=cyclopeptide | n2=en:wide palpebral fissures (50%) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wide palpebral fissures (in some patients) n1=cyclopeptide | n2=en:wide palpebral fissures (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wide-eye appearance n1=cyclopeptide | n2=en:wide-eye appearance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:widely-spaced eyes (hypertelorism) n1=cyclopeptide | n2=en:widely-spaced eyes (hypertelorism) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:widened inner canthal distance n1=cyclopeptide | n2=en:widened inner canthal distance | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wild-type reovirus n1=cyclopeptide | n2=en:wild-type reovirus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wnt signaling inhibitor sm04755 n1=cyclopeptide | n2=en:wnt signaling inhibitor sm04755 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wnt-5a mimic hexapeptide foxy-5 n1=cyclopeptide | n2=en:wnt-5a mimic hexapeptide foxy-5 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wobe-mugos e n1=cyclopeptide | n2=en:wobe-mugos e | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wrinkled appearance of inner retina (in some patients) n1=cyclopeptide | n2=en:wrinkled appearance of inner retina (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 124-138 peptide vaccine n1=cyclopeptide | n2=en:wt1 124-138 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 126-134 peptide vaccine n1=cyclopeptide | n2=en:wt1 126-134 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 235-243 peptide vaccine n1=cyclopeptide | n2=en:wt1 235-243 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 247-261 peptide vaccine n1=cyclopeptide | n2=en:wt1 247-261 peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 analog peptide vaccine n1=cyclopeptide | n2=en:wt1 analog peptide vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 mrna-electroporated autologous dendritic cell vaccine n1=cyclopeptide | n2=en:wt1 mrna-electroporated autologous dendritic cell vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 peptide vaccine ocv-501 n1=cyclopeptide | n2=en:wt1 peptide vaccine ocv-501 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 peptide vaccine wt2725 n1=cyclopeptide | n2=en:wt1 peptide vaccine wt2725 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1 protein-derived peptide vaccine dsp-7888 n1=cyclopeptide | n2=en:wt1 protein-derived peptide vaccine dsp-7888 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1-a10/as01b immunotherapeutic gsk2130579a n1=cyclopeptide | n2=en:wt1-a10/as01b immunotherapeutic gsk2130579a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wt1-sensitized t cells n1=cyclopeptide | n2=en:wt1-sensitized t cells | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wu-ling-san n1=cyclopeptide | n2=en:wu-ling-san | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wx-uk1 n1=cyclopeptide | n2=en:wx-uk1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:wyburn mason's syndrome n1=cyclopeptide | n2=en:wyburn mason's syndrome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xaliproden hydrochloride n1=cyclopeptide | n2=en:xaliproden hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xanthohumol n1=cyclopeptide | n2=en:xanthohumol | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xanthoma n1=cyclopeptide | n2=en:xanthoma | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xbp1-us/xbp1-sp/cd138/cs1 multipeptide vaccine pvx-410 n1=cyclopeptide | n2=en:xbp1-us/xbp1-sp/cd138/cs1 multipeptide vaccine pvx-410 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xeliri regimen n1=cyclopeptide | n2=en:xeliri regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xelox regimen n1=cyclopeptide | n2=en:xelox regimen | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xenobiotics n1=cyclopeptide | n2=en:xenobiotics | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xenogeneic tyrosinase dna vaccine n1=cyclopeptide | n2=en:xenogeneic tyrosinase dna vaccine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xenon n1=cyclopeptide | n2=en:xenon | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xianling gubao n1=cyclopeptide | n2=en:xianling gubao | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xiap/ciap1 antagonist astx660 n1=cyclopeptide | n2=en:xiap/ciap1 antagonist astx660 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xl820 n1=cyclopeptide | n2=en:xl820 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xonrid cream n1=cyclopeptide | n2=en:xonrid cream | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xpo1 inhibitor kpt-8602 n1=cyclopeptide | n2=en:xpo1 inhibitor kpt-8602 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:xpo1 inhibitor sl-801 n1=cyclopeptide | n2=en:xpo1 inhibitor sl-801 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:y 90 monoclonal antibody cc49 n1=cyclopeptide | n2=en:y 90 monoclonal antibody cc49 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:y 90 monoclonal antibody hmfg1 n1=cyclopeptide | n2=en:y 90 monoclonal antibody hmfg1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:y 90 monoclonal antibody lym-1 n1=cyclopeptide | n2=en:y 90 monoclonal antibody lym-1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:y 90 monoclonal antibody m170 n1=cyclopeptide | n2=en:y 90 monoclonal antibody m170 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:y 90 monoclonal antibody m195 n1=cyclopeptide | n2=en:y 90 monoclonal antibody m195 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:y-shape branched pegylated filgrastim n1=cyclopeptide | n2=en:y-shape branched pegylated filgrastim | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:y-shaped sutural cataract (in some patients) n1=cyclopeptide | n2=en:y-shaped sutural cataract (in some patients) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yangzheng xiaoji extract n1=cyclopeptide | n2=en:yangzheng xiaoji extract | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yangzheng xiaoji supplement n1=cyclopeptide | n2=en:yangzheng xiaoji supplement | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yellow lesions hypofluorescent on angiography n1=cyclopeptide | n2=en:yellow lesions hypofluorescent on angiography | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yellow or grey discoloration of retina that disappears after prolonged dark adaptation n1=cyclopeptide | n2=en:yellow or grey discoloration of retina that disappears after prolonged dark adaptation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yellow pigmented material in butterfly-shaped configuration n1=cyclopeptide | n2=en:yellow pigmented material in butterfly-shaped configuration | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yellowish dots in fundi n1=cyclopeptide | n2=en:yellowish dots in fundi | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ym598 n1=cyclopeptide | n2=en:ym598 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yoshi-864 n1=cyclopeptide | n2=en:yoshi-864 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 anti-cd19 monoclonal antibody bu12 n1=cyclopeptide | n2=en:yttrium y 90 anti-cd19 monoclonal antibody bu12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 anti-cd45 monoclonal antibody ahn-12 n1=cyclopeptide | n2=en:yttrium y 90 anti-cd45 monoclonal antibody ahn-12 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 anti-cd45 monoclonal antibody bc8 n1=cyclopeptide | n2=en:yttrium y 90 anti-cd45 monoclonal antibody bc8 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 anti-cd66 monoclonal antibody bw 250/183 n1=cyclopeptide | n2=en:yttrium y 90 anti-cd66 monoclonal antibody bw 250/183 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 anti-cdh3 monoclonal antibody ff-21101 n1=cyclopeptide | n2=en:yttrium y 90 anti-cdh3 monoclonal antibody ff-21101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 anti-cea monoclonal antibody ct84.66 n1=cyclopeptide | n2=en:yttrium y 90 anti-cea monoclonal antibody ct84.66 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 basiliximab n1=cyclopeptide | n2=en:yttrium y 90 basiliximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 colloid n1=cyclopeptide | n2=en:yttrium y 90 colloid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 daclizumab n1=cyclopeptide | n2=en:yttrium y 90 daclizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 dota anti-cea monoclonal antibody m5a n1=cyclopeptide | n2=en:yttrium y 90 dota anti-cea monoclonal antibody m5a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 glass microspheres n1=cyclopeptide | n2=en:yttrium y 90 glass microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 monoclonal antibody b3 n1=cyclopeptide | n2=en:yttrium y 90 monoclonal antibody b3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 monoclonal antibody bre-3 n1=cyclopeptide | n2=en:yttrium y 90 monoclonal antibody bre-3 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 monoclonal antibody hu3s193 n1=cyclopeptide | n2=en:yttrium y 90 monoclonal antibody hu3s193 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 monoclonal antibody idec-159 n1=cyclopeptide | n2=en:yttrium y 90 monoclonal antibody idec-159 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 monoclonal antibody mn-14 n1=cyclopeptide | n2=en:yttrium y 90 monoclonal antibody mn-14 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90 resin microspheres n1=cyclopeptide | n2=en:yttrium y 90 resin microspheres | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90-dota-biotin n1=cyclopeptide | n2=en:yttrium y 90-dota-biotin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90-dota-di-hsg peptide imp-288 n1=cyclopeptide | n2=en:yttrium y 90-dota-di-hsg peptide imp-288 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90-edotreotide n1=cyclopeptide | n2=en:yttrium y 90-edotreotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101 n1=cyclopeptide | n2=en:yttrium y 90-labeled anti-fzd10 monoclonal antibody otsa101 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y-90 clivatuzumab tetraxetan n1=cyclopeptide | n2=en:yttrium y-90 clivatuzumab tetraxetan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y-90 epratuzumab tetraxetan n1=cyclopeptide | n2=en:yttrium y-90 epratuzumab tetraxetan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y-90 ibritumomab tiuxetan n1=cyclopeptide | n2=en:yttrium y-90 ibritumomab tiuxetan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y-90 tacatuzumab tetraxetan n1=cyclopeptide | n2=en:yttrium y-90 tacatuzumab tetraxetan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium y-90-dota-girentuximab n1=cyclopeptide | n2=en:yttrium y-90-dota-girentuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:yttrium-90 polycarbonate brachytherapy plaque n1=cyclopeptide | n2=en:yttrium-90 polycarbonate brachytherapy plaque | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:z-360 n1=cyclopeptide | n2=en:z-360 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:z-endoxifen hydrochloride n1=cyclopeptide | n2=en:z-endoxifen hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zalcitabine n1=cyclopeptide | n2=en:zalcitabine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zalutumumab n1=cyclopeptide | n2=en:zalutumumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zanamivir n1=cyclopeptide | n2=en:zanamivir | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zanolimumab n1=cyclopeptide | n2=en:zanolimumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zen003365 n1=cyclopeptide | n2=en:zen003365 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zeniplatin n1=cyclopeptide | n2=en:zeniplatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zhongyao fufang n1=cyclopeptide | n2=en:zhongyao fufang | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zibotentan n1=cyclopeptide | n2=en:zibotentan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ziconotide n1=cyclopeptide | n2=en:ziconotide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zidovudine n1=cyclopeptide | n2=en:zidovudine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zileuton n1=cyclopeptide | n2=en:zileuton | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zinc finger nuclease zfn-603 n1=cyclopeptide | n2=en:zinc finger nuclease zfn-603 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zinc finger nuclease zfn-758 n1=cyclopeptide | n2=en:zinc finger nuclease zfn-758 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zinc gluconate n1=cyclopeptide | n2=en:zinc gluconate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zinc oxide n1=cyclopeptide | n2=en:zinc oxide | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zinc oxide/aluminum starch octenylsuccinate/glycyrrhetinic phytosome/vitamin e/botanical extracts-based skin protectant paste n1=cyclopeptide | n2=en:zinc oxide/aluminum starch octenylsuccinate/glycyrrhetinic phytosome/vitamin e/botanical extracts-based skin protectant paste | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zinc sulfate n1=cyclopeptide | n2=en:zinc sulfate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zinostatin n1=cyclopeptide | n2=en:zinostatin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89 bevacizumab n1=cyclopeptide | n2=en:zirconium zr 89 bevacizumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89 cetuximab n1=cyclopeptide | n2=en:zirconium zr 89 cetuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89 desferrioxamine b monoclonal antibody huj591 n1=cyclopeptide | n2=en:zirconium zr 89 desferrioxamine b monoclonal antibody huj591 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89 df-iab2m n1=cyclopeptide | n2=en:zirconium zr 89 df-iab2m | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89 dfo-mstp2109a n1=cyclopeptide | n2=en:zirconium zr 89 dfo-mstp2109a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89 girentuximab n1=cyclopeptide | n2=en:zirconium zr 89 girentuximab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89 trastuzumab n1=cyclopeptide | n2=en:zirconium zr 89 trastuzumab | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1 n1=cyclopeptide | n2=en:zirconium zr 89-labeled anti-ca19-9 monoclonal antibody 5b1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89-labeled anti-pd-l1 monoclonal antibody mpdl3280a n1=cyclopeptide | n2=en:zirconium zr 89-labeled anti-pd-l1 monoclonal antibody mpdl3280a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89-labeled anti-pigf monoclonal antibody ro5323441 n1=cyclopeptide | n2=en:zirconium zr 89-labeled anti-pigf monoclonal antibody ro5323441 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89-labeled monoclonal antibody mmot0530a n1=cyclopeptide | n2=en:zirconium zr 89-labeled monoclonal antibody mmot0530a | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zirconium zr 89-labeled ro5479599 n1=cyclopeptide | n2=en:zirconium zr 89-labeled ro5479599 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:ziv-aflibercept n1=cyclopeptide | n2=en:ziv-aflibercept | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zoledronic acid n1=cyclopeptide | n2=en:zoledronic acid | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zolmitriptan n1=cyclopeptide | n2=en:zolmitriptan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zolpidem tartrate n1=cyclopeptide | n2=en:zolpidem tartrate | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zoptarelin doxorubicin n1=cyclopeptide | n2=en:zoptarelin doxorubicin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zorubicin hydrochloride n1=cyclopeptide | n2=en:zorubicin hydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zosuquidar trihydrochloride n1=cyclopeptide | n2=en:zosuquidar trihydrochloride | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zotarolimus n1=cyclopeptide | n2=en:zotarolimus | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> en:zyc300 n1=cyclopeptide | n2=en:zyc300 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> endoscopique n1=cyclopeptide | n2=endoscopique | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> endoxan n1=cyclopeptide | n2=endoxan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> Endoxan n1=cyclopeptide | n2=Endoxan | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> excyclophorie n1=cyclopeptide | n2=excyclophorie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> foie n1=cyclopeptide | n2=foie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> fusion n1=cyclopeptide | n2=fusion | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> glycine n1=cyclopeptide | n2=glycine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> glycine (acide aminé) n1=cyclopeptide | n2=glycine (acide aminé) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> groupement alkyle n1=cyclopeptide | n2=groupement alkyle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> hématologie n1=cyclopeptide | n2=hématologie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> holoproencéphalie n1=cyclopeptide | n2=holoproencéphalie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> holoprosencéphalie alobaire familiale n1=cyclopeptide | n2=holoprosencéphalie alobaire familiale | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> HPE n1=cyclopeptide | n2=HPE | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> imunophiline n1=cyclopeptide | n2=imunophiline | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> incyclophorie n1=cyclopeptide | n2=incyclophorie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> lymphome n1=cyclopeptide | n2=lymphome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> maladie bipolaire n1=cyclopeptide | n2=maladie bipolaire | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> maladie (médecine) n1=cyclopeptide | n2=maladie (médecine) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> maladie (médecine, être humain) n1=cyclopeptide | n2=maladie (médecine, être humain) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> malformations n1=cyclopeptide | n2=malformations | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> malformations congénitales des os du crâne et de la face n1=cyclopeptide | n2=malformations congénitales des os du crâne et de la face | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> médecine spécialisée n1=cyclopeptide | n2=médecine spécialisée | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> médecine (science) n1=cyclopeptide | n2=médecine (science) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> molécule n1=cyclopeptide | n2=molécule | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> molécule anticancéreuse n1=cyclopeptide | n2=molécule anticancéreuse | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> monopsie n1=cyclopeptide | n2=monopsie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> monstre cyclocéphalien n1=cyclopeptide | n2=monstre cyclocéphalien | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> neuroblastome n1=cyclopeptide | n2=neuroblastome | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> œil n1=cyclopeptide | n2=œil | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> oncologie n1=cyclopeptide | n2=oncologie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> ophtalmologie n1=cyclopeptide | n2=ophtalmologie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> orbite n1=cyclopeptide | n2=orbite | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> orbites n1=cyclopeptide | n2=orbites | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> paralysie n1=cyclopeptide | n2=paralysie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> paralysie de l'accommodation n1=cyclopeptide | n2=paralysie de l'accommodation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> paralysie de l'accommodation visuelle n1=cyclopeptide | n2=paralysie de l'accommodation visuelle | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> parésie de l'accommodation n1=cyclopeptide | n2=parésie de l'accommodation | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> persistance du canal thyréoglosse n1=cyclopeptide | n2=persistance du canal thyréoglosse | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> pharmacie (médicaments) n1=cyclopeptide | n2=pharmacie (médicaments) | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> pharmacologie n1=cyclopeptide | n2=pharmacologie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> photocoagulation endoscopique n1=cyclopeptide | n2=photocoagulation endoscopique | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> posologie n1=cyclopeptide | n2=posologie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> prodrogue n1=cyclopeptide | n2=prodrogue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> protéine n1=cyclopeptide | n2=protéine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> protéines fixant cyclosporine n1=cyclopeptide | n2=protéines fixant cyclosporine | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> psychose, maladie, trouble bipolaire n1=cyclopeptide | n2=psychose, maladie, trouble bipolaire | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> R-ACVBP n1=cyclopeptide | n2=R-ACVBP | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> spécialités médicales n1=cyclopeptide | n2=spécialités médicales | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> strabisme n1=cyclopeptide | n2=strabisme | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome cryptophtalmique n1=cyclopeptide | n2=syndrome cryptophtalmique | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome de Goldenhar n1=cyclopeptide | n2=syndrome de Goldenhar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome de goldenhar n1=cyclopeptide | n2=syndrome de goldenhar | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome de Moebius n1=cyclopeptide | n2=syndrome de Moebius | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome de moebius n1=cyclopeptide | n2=syndrome de moebius | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome de Papillon-Léage et Psaume n1=cyclopeptide | n2=syndrome de Papillon-Léage et Psaume | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome de papillon-léage et psaume n1=cyclopeptide | n2=syndrome de papillon-léage et psaume | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome de pierre robin n1=cyclopeptide | n2=syndrome de pierre robin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome de Pierre Robin n1=cyclopeptide | n2=syndrome de Pierre Robin | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome des fentes médianes n1=cyclopeptide | n2=syndrome des fentes médianes | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome oro-digito-facial n1=cyclopeptide | n2=syndrome oro-digito-facial | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome oro-digito-facial de type 1 n1=cyclopeptide | n2=syndrome oro-digito-facial de type 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome oro-facio-digital n1=cyclopeptide | n2=syndrome oro-facio-digital | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome oro-facio-digital de type 1 n1=cyclopeptide | n2=syndrome oro-facio-digital de type 1 | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome oro-facio-digital de type I n1=cyclopeptide | n2=syndrome oro-facio-digital de type I | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndrome orodigitofacial n1=cyclopeptide | n2=syndrome orodigitofacial | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndromes congénitaux malformatifs affectant l'aspect de la face n1=cyclopeptide | n2=syndromes congénitaux malformatifs affectant l'aspect de la face | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> syndromes congénitaux malformatifs atteignant principalement l'aspect de la face n1=cyclopeptide | n2=syndromes congénitaux malformatifs atteignant principalement l'aspect de la face | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> tératologie n1=cyclopeptide | n2=tératologie | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> troubles de la motilité oculaire n1=cyclopeptide | n2=troubles de la motilité oculaire | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> troubles de la vision n1=cyclopeptide | n2=troubles de la vision | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> tumeur n1=cyclopeptide | n2=tumeur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> visage de siffleur n1=cyclopeptide | n2=visage de siffleur | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> vue n1=cyclopeptide | n2=vue | rel=r_associated | relid=0 | w=5 cyclopeptide -- r_associated #0: 5 / 0.109 -> yeux n1=cyclopeptide | n2=yeux | rel=r_associated | relid=0 | w=5

≈ 40 relations entrantes en:cyclopeptide --- r_associated #0: 35 --> cyclopeptide n1=en:cyclopeptide | n2=cyclopeptide | rel=r_associated | relid=0 | w=35 peptides cycliques --- r_associated #0: 35 --> cyclopeptide n1=peptides cycliques | n2=cyclopeptide | rel=r_associated | relid=0 | w=35 en:cyclic peptides --- r_associated #0: 34 --> cyclopeptide n1=en:cyclic peptides | n2=cyclopeptide | rel=r_associated | relid=0 | w=34 peptide cyclique --- r_associated #0: 31 --> cyclopeptide n1=peptide cyclique | n2=cyclopeptide | rel=r_associated | relid=0 | w=31 en:cyclic peptide --- r_associated #0: 28 --> cyclopeptide n1=en:cyclic peptide | n2=cyclopeptide | rel=r_associated | relid=0 | w=28 en:cycloserine --- r_associated #0: 26 --> cyclopeptide n1=en:cycloserine | n2=cyclopeptide | rel=r_associated | relid=0 | w=26 cyclosérine --- r_associated #0: 22 --> cyclopeptide n1=cyclosérine | n2=cyclopeptide | rel=r_associated | relid=0 | w=22 médecine --- r_associated #0: 20 --> cyclopeptide n1=médecine | n2=cyclopeptide | rel=r_associated | relid=0 | w=20 pathologie --- r_associated #0: 20 --> cyclopeptide n1=pathologie | n2=cyclopeptide | rel=r_associated | relid=0 | w=20 pharmacie --- r_associated #0: 20 --> cyclopeptide n1=pharmacie | n2=cyclopeptide | rel=r_associated | relid=0 | w=20 cyclope (oeil) --- r_associated #0: 15 --> cyclopeptide n1=cyclope (oeil) | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cyclophiline --- r_associated #0: 15 --> cyclopeptide n1=cyclophiline | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cyclophorie --- r_associated #0: 15 --> cyclopeptide n1=cyclophorie | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cyclophosphamide --- r_associated #0: 15 --> cyclopeptide n1=cyclophosphamide | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cyclophotocoagulation endoscopique --- r_associated #0: 15 --> cyclopeptide n1=cyclophotocoagulation endoscopique | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cyclophrénie --- r_associated #0: 15 --> cyclopeptide n1=cyclophrénie | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cyclopie --- r_associated #0: 15 --> cyclopeptide n1=cyclopie | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cyclopie-arhinencéphalie --- r_associated #0: 15 --> cyclopeptide n1=cyclopie-arhinencéphalie | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cycloplégie --- r_associated #0: 15 --> cyclopeptide n1=cycloplégie | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cycloplégique --- r_associated #0: 15 --> cyclopeptide n1=cycloplégique | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 cyclorrhaphes --- r_associated #0: 15 --> cyclopeptide n1=cyclorrhaphes | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 en:cyclophosphamide --- r_associated #0: 15 --> cyclopeptide n1=en:cyclophosphamide | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 en:cyclopia --- r_associated #0: 15 --> cyclopeptide n1=en:cyclopia | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 en:cyclops eye --- r_associated #0: 15 --> cyclopeptide n1=en:cyclops eye | n2=cyclopeptide | rel=r_associated | relid=0 | w=15 Cyclophosphamide --- r_associated #0: 10 --> cyclopeptide n1=Cyclophosphamide | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 Cyclosérine --- r_associated #0: 10 --> cyclopeptide n1=Cyclosérine | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 Pepper (syndrome de) --- r_associated #0: 10 --> cyclopeptide n1=Pepper (syndrome de) | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 cyclophyllidés --- r_associated #0: 10 --> cyclopeptide n1=cyclophyllidés | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 cyclopia --- r_associated #0: 10 --> cyclopeptide n1=cyclopia | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:arhinencephalia-cyclopia --- r_associated #0: 10 --> cyclopeptide n1=en:arhinencephalia-cyclopia | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:cyclophilin --- r_associated #0: 10 --> cyclopeptide n1=en:cyclophilin | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:cyclophoria --- r_associated #0: 10 --> cyclopeptide n1=en:cyclophoria | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:cyclophrenia --- r_associated #0: 10 --> cyclopeptide n1=en:cyclophrenia | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:cycloplegia --- r_associated #0: 10 --> cyclopeptide n1=en:cycloplegia | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:cycloplegic --- r_associated #0: 10 --> cyclopeptide n1=en:cycloplegic | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:cyclorrhapha --- r_associated #0: 10 --> cyclopeptide n1=en:cyclorrhapha | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:endoscopic cyclophotocoagulation --- r_associated #0: 10 --> cyclopeptide n1=en:endoscopic cyclophotocoagulation | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 en:thymergasia --- r_associated #0: 10 --> cyclopeptide n1=en:thymergasia | n2=cyclopeptide | rel=r_associated | relid=0 | w=10 chimie --- r_associated #0: 5 --> cyclopeptide n1=chimie | n2=cyclopeptide | rel=r_associated | relid=0 | w=5 en:monopia --- r_associated #0: 5 --> cyclopeptide n1=en:monopia | n2=cyclopeptide | rel=r_associated | relid=0 | w=5